FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Piris, A Sanchez, D Canete, S Campagnoli, T Gonzalez, L Zarza, P Oneto, S Lezcano, C Rodriguez, I Mihm, M Cubilla, A AF Piris, Adriano Sanchez, Diego Canete, Sofia Campagnoli, Tania Gonzalez, Lorena Zarza, Patricia Oneto, Sabrina Lezcano, Cecilia Rodriguez, Ingrid Mihm, Martin Cubilla, Antonio TI Pathological Features of Penile Lichen Sclerosus (LS) According To a Topographical Method of Evaluation in 200 Patients SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Inst Patol & Invest, Asuncion, Paraguay. Fac Ciencias Med UNA, Asuncion, Paraguay. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. RI Sanchez, Diego/K-2398-2016 OI Sanchez, Diego/0000-0002-9503-1947 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 997 BP 251A EP 251A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201335 ER PT J AU Sanchez, D Rodriguez, I Piris, A Canete, S Lezcano, C Velazquez, E Hoang, M Cubilla, A AF Sanchez, Diego Rodriguez, Ingrid Piris, Adriano Canete, Sofia Lezcano, Cecilia Velazquez, Elsa Hoang, Mai Cubilla, Antonio TI Clear Cell Carcinoma of the Penis. An Unusual and Distinctive HPV-Related Variant of Squamous Cell Carcinoma. A Report of 3 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Inst Patol & Invest, Asuncion, Paraguay. Fac Ciencias Med UNA, Asuncion, Paraguay. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. Miraca Life Sci, Boston, MA USA. Tufts Univ, Boston, MA 02111 USA. RI Sanchez, Diego/K-2398-2016 OI Sanchez, Diego/0000-0002-9503-1947 NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1018 BP 256A EP 256A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201356 ER PT J AU Bennett, J Oliva, E AF Bennett, Jennifer Oliva, Esther TI Mismatch Repair Protein Defects in Clear Cell Carcinoma of the Ovary: Incidence and Morphologic Associations in 57 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Lahey Hosp & Med Ctr, Burlington, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1103 BP 276A EP 276A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201441 ER PT J AU Bennett, J Oliva, E Nardi, V Lindeman, N Ferry, J Louissaint, A AF Bennett, Jennifer Oliva, Esther Nardi, Valentina Lindeman, Neal Ferry, Judith Louissaint, Abner TI Primary Extranodal Marginal Zone Lymphoma (MALT)-Like Lymphoid Proliferations of the Endometrium SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1104 BP 276A EP 276A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201442 ER PT J AU Bennett, J Chiang, S Chen, YB Bialik, A Aryee, M Young, R Reuter, V Soslow, R Oliva, E AF Bennett, Jennifer Chiang, Sarah Chen, Ying-Bei Bialik, Ann Aryee, Martin Young, Robert Reuter, Victor Soslow, Robert Oliva, Esther TI Leiomyoma With Bizarre Nuclei: Correlation Between Morphology and Fumarate Hydratase/S-(2-Succino)-Cysteine Expression SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Lahey Hosp & Med Ctr, Burlington, MA USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1102 BP 276A EP 276A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201440 ER PT J AU Chuang, AY Young, R Lerwill, M AF Chuang, Ai-Ying Young, Robert Lerwill, Melinda TI Lobular Carcinoma of the Breast Metastatic To the Ovary SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Koo Fdn, Sun Yat Sen Canc Ctr, Taipei, Taiwan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1115 BP 279A EP 279A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201453 ER PT J AU Chuang, AY Young, R Lerwill, M AF Chuang, Ai-Ying Young, Robert Lerwill, Melinda TI Ductal Carcinoma of the Breast Metastatic To the Ovary SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Koo Fdn, Sun Yat Sen Canc Ctr, Taipei, Taiwan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1114 BP 279A EP 279A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201452 ER PT J AU Croce, S Ribeiro, A Perot, G Neuville, A MacGrogan, G Young, R Oliva, E Chibon, F AF Croce, Sabrina Ribeiro, Agnes Perot, Gaelle Neuville, Agnes MacGrogan, Gaetan Young, Robert Oliva, Esther Chibon, Frederic TI Leiomyoma With Bizarre Nuclei: Genomic Analysis By Comparative Genomic Hybridization SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Inst Bergonie, Bordeaux, France. Massachusetts Gen Hosp, Boston, MA 02114 USA. RI chibon, frederic/A-2651-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1121 BP 281A EP 281A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201459 ER PT J AU Howitt, B Lee, L Sun, H Viswanathan, A Horowitz, N Liao, XY Crum, C Freeman, G Rodig, S AF Howitt, Brooke Lee, Larissa Sun, Heather Viswanathan, Akila Horowitz, Neil Liao, Xiaoyun Crum, Christopher Freeman, Gordon Rodig, Scott TI Expression of a Therapeutic Target (PD-L1) in HPV+ and HPV-Vulvar Squamous Cell Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber & Brigham & Womens Canc Ctr, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1155 BP 289A EP 289A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201493 ER PT J AU Ip, P Lim, D Cheung, A Oliva, E AF Ip, Philip Lim, Diana Cheung, Annie Oliva, Esther TI Immunoexpression of p16 in Uterine Leiomyomas With Infarct Type Necrosis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. Natl Univ Singapore Hosp, Singapore, Singapore. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1162 BP 291A EP 291A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201500 ER PT J AU Kao, CS Idrees, M Young, R Ulbright, T AF Kao, Chia-Sui Idrees, Muhammad Young, Robert Ulbright, Thomas TI Dissecting Gonadoblastoma of Scully: A Morphologic Variant That Mimics Germinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Indiana Univ Sch Med, Indianapolis, IN 46202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1169 BP 292A EP 292A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201507 ER PT J AU Schoolmeester, J Oliva, E Keeney, G Carlson, J Fritchie, K Young, R Nucci, M AF Schoolmeester, John Oliva, Esther Keeney, Gary Carlson, Joseph Fritchie, Karen Young, Robert Nucci, Marisa TI Alveolar Soft Part Sarcoma of the Female Genital Tract: An Immunohistochemical and Molecular Cytogenetic Study SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Mayo Clin, Rochester, MN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Karolinska Inst, Stockholm, Sweden. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1226 BP 305A EP 305A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201564 ER PT J AU Schultheis, A Conlon, N Piscuoglio, S Silva, A Guerra, E Tornos, C Soslow, R Young, R Oliva, E Weigelt, B AF Schultheis, Anne Conlon, Niamh Piscuoglio, Salvatore Silva, Annacarolina Guerra, Esther Tornos, Carmen Soslow, Robert Young, Robert Oliva, Esther Weigelt, Britta TI A Survey of DICER1 Hotspot Mutations in a Range of Ovarian Sex Cord Stromal Tumor Subtypes SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Stony Brook Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1228 BP 306A EP 306A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201566 ER PT J AU Silva, A Ali, R Aryee, M Lee, CH Oliva, E AF Silva, Annacarolina Ali, Rola Aryee, Martin Lee, Cheng-Han Oliva, Esther TI Old Versus New FIGO Staging System for Predicting Outcome in Uterine Endometrial Stromal Sarcomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Alberta, Edmonton, AB, Canada. Kuwait Univ, Hlth Sci Ctr, Safat, Kuwait. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1231 BP 307A EP 307A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201569 ER PT J AU Stall, J Young, R AF Stall, Jennifer Young, Robert TI Granulosa Theca Cell Tumor of the Ovary: A Report of Twenty-Two Cases of an Entity That Should Be Distinguished From Diffuse Adult Granulosa Cell Tumor SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1240 BP 309A EP 309A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201578 ER PT J AU Watkins, J Hinchcliff, E del Carmen, M Rauh-Hain, A Esselen, K Muto, M Quade, B AF Watkins, Jaclyn Hinchcliff, Emily del Carmen, Marcelo Rauh-Hain, Alejandro Esselen, Katharine Muto, Michael Quade, Bradley TI Preoperative Detection of Uterine Leiomyosarcoma By Endometrial Biopsy: An Examination of Clinical and Histologic Features SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1256 BP 314A EP 314A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201594 ER PT J AU Arora, K Kerr, D Mahadevan, K Hornick, J Krane, J Rivera, M Ting, D Nose, V Sadow, P Deshpande, V Faquin, W AF Arora, Kshitij Kerr, Darcy Mahadevan, Krishnan Hornick, Jason Krane, Jeffrey Rivera, Miguel Ting, David Nose, Vania Sadow, Peter Deshpande, Vikram Faquin, William TI Performance of a Branch Chain RNA In-Situ Hybridization Assay for the Detection of High-Risk Human Papillomavirus in Head and Neck Squamous Cell Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1277 BP 319A EP 319A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502201615 ER PT J AU Carey, C Sun, H Stack, E Peterson, M Hoyt, C Johnson, K Freeman, G Loda, M Shipp, M Rodig, S Bowden, M AF Carey, Chris Sun, Heather Stack, Edward Peterson, Michael Hoyt, Clifford Johnson, Kent Freeman, Gordon Loda, Massimo Shipp, Margaret Rodig, Scott Bowden, Michaela TI A Novel Method for the Simultaneous Assessment of PDL1 Expression in the Tumor Cells and Tumor Associated Macrophages of Classical Hodgkin Lymphoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. PerkinElmer, Waltham, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1356 BP 339A EP 339A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202066 ER PT J AU Geyer, J Hasserjian, R Wang, S Orazi, A AF Geyer, Julia Hasserjian, Robert Wang, Sa Orazi, Attilio TI Oligomonocytic Chronic Myelomonocytic Leukemia: Can the Threshold for Peripheral Blood Monocytosis Be Lowered? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Weill Cornell Med Coll, New York, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1381 BP 345A EP 345A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202090 ER PT J AU Kluk, M Lindsley, RC Szeto, D Zepf, D Aster, J Lindeman, N Kuo, F AF Kluk, Michael Lindsley, R. Coleman Szeto, David Zepf, Dimity Aster, Jon Lindeman, Neal Kuo, Frank TI Validation and Implementation of a Custom Next Generation Sequencing Assay for Clinical Testing of Hematologic Neoplasms SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1419 BP 355A EP 356A PG 2 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202128 ER PT J AU Liu, H Medeiros, LJ Weisenburger, D Clemens, M Hunt, K Chai, S Amin, M Vadlamani, I Sohani, A Ferry, J Morgan, EA Parkash, V Bhagat, G Yang, LJ Thomazy, V Kanagal-Shamanna, R Vasef, M Herman, C Oyarzo, M Narbaitz, M Piccolini, J Lamar, W Porter, W Hughes, C Baptista, M Tritz, D Zhang, D Khoury, J Young, K Miranda, R AF Liu, Hui Medeiros, L. Jeffrey Weisenburger, Dennis Clemens, Mark Hunt, Kelly Chai, Siaw Amin, Mitual Vadlamani, Indira Sohani, Aliyah Ferry, Judith Morgan, Elizabeth A. Parkash, Vinita Bhagat, Govind Yang, Li-Jun Thomazy, Vilmos Kanagal-Shamanna, Rashmi Vasef, Mohammad Herman, Christopher Oyarzo, Mauricio Narbaitz, Marina Piccolini, Jorge Lamar, Walter Porter, William Hughes, Condon, III Baptista, Matt Tritz, Denise Zhang, Da Khoury, Joseph Young, Ken Miranda, Roberto TI Breast Implant-Associated Anaplastic Large Cell Lymphoma (BI-ALCL): A Comprehensive Histopathological Evaluation of 40 Cases With a Proposal for a Pathologic Staging System SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Xuzhou Med Coll, Xuzhou, Jiangsu, Peoples R China. City Hope Natl Med Ctr, Duarte, CA USA. Queen Elizabeth II, Nedlands, WA, Australia. William Beaumont Hosp, Royal Oak, MI 48072 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Yale Univ, Bridgeport, CT USA. Columbia Univ, Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 3 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1435 BP 360A EP 360A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202144 ER PT J AU O'Malley, D Andersen, E Paxton, C Louissaint, A Hornick, J Griffin, G Fedoriw, Y Kim, Y Weiss, L South, S AF O'Malley, Dennis Andersen, Erica Paxton, Christian Louissaint, Abner Hornick, Jason Griffin, Gabriel Fedoriw, Yuri Kim, Young Weiss, Lawrence South, Sarah TI Genetic Array Analysis of Follicular Dendritic Cell Sarcoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Clarient Pathol Serv, Aliso Viejo, CA USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Univ N Carolina, Sch Med, Chapel Hill, NC USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1468 BP 368A EP 368A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202177 ER PT J AU Pozdnyakova, O Hasserjian, R Fathi, A DeAngelo, D Morgan, E AF Pozdnyakova, Olga Hasserjian, Robert Fathi, Amir DeAngelo, Daniel Morgan, Elizabeth TI Lack of Detectable CD19 Expression By Flow Cytometry in B-Lineage Cells Following Administration of an Antibody-Drug Conjugate Targeting CD19 SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1482 BP 372A EP 372A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202191 ER PT J AU Rosenbaum, M Pozdnyakova, O Geyer, J Dal Cin, P Hassejian, R AF Rosenbaum, Matthew Pozdnyakova, Olga Geyer, Julia Dal Cin, Paola Hassejian, Robert TI Ring Chromosome in Myeloid Neoplasms Is Associated With Genetic Instability and Complex Hypodiploid Karyotype SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. New York Presbyterian Hosp, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1491 BP 374A EP 374A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202200 ER PT J AU Ryan, R Drier, Y Whitton, H Gillespie, S Epstein, C Hochberg, E Sohani, A Bernstein, B AF Ryan, Russell Drier, Yotam Whitton, Holly Gillespie, Shawn Epstein, Charles Hochberg, Ephraim Sohani, Aliyah Bernstein, Bradley TI Detection of Oncogenic Rearrangements By Enrichment of Regulatory DNA Elements SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Broad Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1497 BP 376A EP 376A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202206 ER PT J AU van Slambrouck, C Huh, J Suh, C Song, J Menon, M Sohani, A Hyjek, E Venkataraman, G AF van Slambrouck, Charles Huh, Jooryung Suh, Cheolwon Song, Joo Menon, Madhu Sohani, Aliyah Hyjek, Elizabeth Venkataraman, Girish TI Nuclear Staining for Stat6 With the YE361 Monoclonal Antibody Is Restricted To Classical Hodgkin Lymphoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Chicago, Chicago, IL 60637 USA. Henry Ford Hlth Syst, Detroit, MI USA. City Hope Med Ctr, Duarte, CA USA. Asan Univ, Seoul, South Korea. Massachusetts Gen Hosp, Boston, MA 02114 USA. Toronto Gen Hosp, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1522 BP 382A EP 383A PG 2 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202231 ER PT J AU Wang, SA Pozdnyakova, O Peng, J Hasserjian, R AF Wang, Sa A. Pozdnyakova, Olga Peng, Jie Hasserjian, Robert TI Acute Erythroleukemia and Refractory Anemia With Excess Blasts: One Single or Two Distinct Entities? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1528 BP 384A EP 384A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202237 ER PT J AU Weinberg, O Pozdnyakova, O Campigotto, F DeAngelo, D Stone, R Neuberg, D Hasserjian, R AF Weinberg, Olga Pozdnyakova, Olga Campigotto, Federico DeAngelo, Daniel Stone, Richard Neuberg, Donna Hasserjian, Robert TI Reproducibility and Prognostic Significance of Morphologic Dysplasia in De Novo AML SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Boston Childrens Hosp, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1534 BP 385A EP 386A PG 2 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202243 ER PT J AU Xu, J Sun, H Morgan, E Shipp, M Pinkus, G Freeman, G Rodig, S AF Xu, Jie Sun, Heather Morgan, Elizabeth Shipp, Margaret Pinkus, Geraldine Freeman, Gordon Rodig, Scott TI Differential Expression of PD-L2 in T-Cell Lymphomas Suggests Novel Candidates for PD-1 Directed Immunotherapy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1546 BP 388A EP 389A PG 2 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202255 ER PT J AU Xu, J Sun, H Morgan, E Pinkus, G Hornick, J Fletcher, C Freeman, G Rodig, S AF Xu, Jie Sun, Heather Morgan, Elizabeth Pinkus, Geraldine Hornick, Jason Fletcher, Christopher Freeman, Gordon Rodig, Scott TI Expression of the Immunosuppressive Molecules PD-L1 and PD-L2 By Histiocytic and Dendritic Cell Neoplasms: Novel Candidates for PD-1 Pathway Immunotherapy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1547 BP 389A EP 389A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202256 ER PT J AU Fox, S Vander Heide, R Law, C Faulkner-Jones, B AF Fox, Sharon Vander Heide, Richard Law, C. Faulkner-Jones, Beverly TI Gaze Pattern During Diagnostic Exploration of Whole-Slide Images and Glass Slides SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 BIDMC, Boston, MA USA. Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA. Kitware Inc, Clifton Pk, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1580 BP 396A EP 396A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202289 ER PT J AU Fulton, E Burns, K Ward, A Law, C Faulkner-Jones, B AF Fulton, Edward Burns, Kristin Ward, Ashley Law, C. Faulkner-Jones, Beverly TI Alopecia Diagnosis: 3D Analysis of Aligned Serial Whole Slide Images SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 BIDMC, Boston, MA USA. Kitware Inc, Clifton Pk, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1581 BP 397A EP 397A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202290 ER PT J AU Batal, I De Serres, S Onozato, M Najafian, N Chandraker, A AF Batal, Ibrahim De Serres, Sacha Onozato, Maristela Najafian, Nader Chandraker, Anil TI Dendritic Cells (DCs) in Kidney Transplant Biopsies Cluster With T Lymphocytes and Are Associated with Graft and Systemic Inflammatory Milieu and Poor Allograft Survival SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1609 BP 404A EP 405A PG 2 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202318 ER PT J AU Tuecking, M Sieber, J Mundel, P Weins, A AF Tuecking, Marcel Sieber, Jonas Mundel, Peter Weins, Astrid TI Hic-5 Protects Podocytes From Genotoxic Cell Death By Stabilizing p21 SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Mass Gen Hosp, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1648 BP 414A EP 414A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202357 ER PT J AU Shinagare, S Deshpande, V AF Shinagare, Shweta Deshpande, Vikram TI Role of Arginase-1 and Hep Par 1 in Distinguishing Hepatocellular Carcinoma From Intrahepatic Cholangiocarcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Tufts Med Ctr, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1691 BP 423A EP 424A PG 2 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202399 ER PT J AU Abedalthagafi, M Bi, WL Mei, Y Alexander, B Beroukhim, R Al-Mefty, O Dunn, I Ligon, A Santagata, S AF Abedalthagafi, Malak Bi, Wenya Linda Mei, Yu Alexander, Brian Beroukhim, Rameen Al-Mefty, Ossama Dunn, Ian Ligon, Azra Santagata, Sandro TI Genomic Alterations in Skull Base Meningiomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1706 BP 427A EP 427A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202414 ER PT J AU Miller, M Linda, W Ramkissoon, L Abedalthagafi, M Kang, YJ Knoff, D Dunn, I Wen, P Reardon, D Alexander, B Laws, E Beroukhim, R Ligon, K Ramkissoon, S AF Miller, Michael Linda, Wenya Ramkissoon, Lori Abedalthagafi, Malak Kang, Yun Jee Knoff, David Dunn, Ian Wen, Patrick Reardon, David Alexander, Brian Laws, Edward, Jr. Beroukhim, Rameen Ligon, Keith Ramkissoon, Shakti TI MAPK Activation and HRAS Mutations Identified in Pituitary Spindle Cell Oncocytoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1733 BP 434A EP 434A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202441 ER PT J AU Ramkissoon, S Bi, WY Schumacher, S Ramkissoon, L Haidar, S Knoff, D Dubuc, A Brown, L Abedalthagafi, M Reardon, D Dunn, I Santagata, S Folkerth, R Wen, P Ligon, A Alexander, B Beroukhim, R Ligon, K AF Ramkissoon, Shakti Bi, Wenya Schumacher, Steven Ramkissoon, Lori Haidar, Sam Knoff, David Dubuc, Adrian Brown, Loreal Abedalthagafi, Malak Reardon, David Dunn, Ian Santagata, Sandro Folkerth, Rebecca Wen, Patrick Ligon, Azra Alexander, Brian Beroukhim, Rameen Ligon, Keith TI Clinical Implementation of Integrated Whole Genome Copy-Number and Mutation Profiling for Glioblastoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1742 BP 435A EP 435A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202450 ER PT J AU Conner, J Garcia, E Marino-Enriquez, A Pitman, M Mino-Kenudson, M Sholl, L Srivastava, A Doyle, LA AF Conner, James Garcia, Elizabeth Marino-Enriquez, Adrian Pitman, Martha Mino-Kenudson, Mari Sholl, Lynette Srivastava, Amitabh Doyle, Leona A. TI Genomic Characterization of Neoplastic Progression in Pancreatic Mucinous Cystic Neoplasm SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1764 BP 440A EP 441A PG 2 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202472 ER PT J AU Dudley, J Zheng, ZL Le, L Batten, J Vernovsky, K Sweeney, B Arpin, R Brugge, W Pitman, M Iafrate, A AF Dudley, Jonathan Zheng, Zongli Le, Long Batten, Julie Vernovsky, Kathy Sweeney, Brenda Arpin, Ronald Brugge, William Pitman, Martha Iafrate, Anthony TI Next-Generation Sequencing and Fluorescence In Situ Hybridization in the Analysis of Bile Duct Brushings for Malignancy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Dudley, Jonathan; Zheng, Zongli; Le, Long; Batten, Julie; Vernovsky, Kathy; Sweeney, Brenda; Arpin, Ronald; Brugge, William; Pitman, Martha; Iafrate, Anthony] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1767 BP 441A EP 441A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202475 ER PT J AU Gupta, R Deshpande, V Patton, K Behrman, S Xie, B AF Gupta, Rajib Deshpande, Vikram Patton, Kurt Behrman, Stephen Xie, Bill TI Follicular Pancreatitis: A Mimic of Pancreatic Malignancy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Pathol Grp Midsouth, Germantown, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1773 BP 443A EP 443A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202481 ER PT J AU Jones, M Zheng, ZL Wang, J Albanese, E Kadayifci, A Dias-Santagata, D Le, L Brugge, W Castillo, CFD Mino-Kenudson, M Iafrate, AJ Pitman, M AF Jones, Martin Zheng, Zongli Wang, Jessica Albanese, Emily Kadayifci, Abdurrahman Dias-Santagata, Dora Le, Long Brugge, William Castillo, Carlos Fernandez-del Mino-Kenudson, Marl Iafrate, A. John Pitman, Martha TI Impact of Next-Generation Sequencing on the Clinical Impression of Pancreatic Cysts SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Jones, Martin; Zheng, Zongli; Wang, Jessica; Albanese, Emily; Kadayifci, Abdurrahman; Dias-Santagata, Dora; Le, Long; Brugge, William; Castillo, Carlos Fernandez-del; Mino-Kenudson, Marl; Iafrate, A. John; Pitman, Martha] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1777 BP 444A EP 444A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202485 ER PT J AU Scourtas, A Dudley, J Brugge, W Kadayifci, A Mino-Kenudson, M Pitman, M AF Scourtas, Aristana Dudley, Jonathan Brugge, William Kadayifci, Abdurrahman Mino-Kenudson, Mari Pitman, Martha TI Clinicopathologic Characteristics of 136 Mucinous Cystic Neoplasms SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Scourtas, Aristana; Dudley, Jonathan; Brugge, William; Kadayifci, Abdurrahman; Mino-Kenudson, Mari; Pitman, Martha] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1796 BP 448A EP 449A PG 2 WC Pathology SC Pathology GA CB3BF UT WOS:000349502202504 ER PT J AU Kuo, F Szeto, D Zepf, D Jia, YH Garcia, E Macconaill, L Aster, J AF Kuo, Frank Szeto, David Zepf, Dimity Jia, Yonghui Garcia, Elizabeth Macconaill, Laura Aster, Jon TI Spectrum of Notch Gene Mutations in Diverse Human Cancers SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1840 BP 459A EP 459A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502203037 ER PT J AU Lee, J Lindeman, N Chin, G Luke, J Ott, P Hodi, FS Granter, S Laga, A Yoon, C Haynes, H Werchniak, A Lin, J Liu, R Bailey, N Murphy, G Lian, C AF Lee, Jonathan Lindeman, Neal Chin, Gary Luke, Jason Ott, Patrick Hodi, F. Stephen Granter, Scott Laga, Alvaro Yoon, Charles Haynes, Harley Werchniak, Andrew Lin, Jennifer Liu, Robert Bailey, Nancy Murphy, George Lian, Christine TI Targeted Next Generation Sequencing of Treatment-Naive Metastatic Melanoma Specimens Reveals High Frequency of Epigenetic Alterations SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1841 BP 459A EP 460A PG 2 WC Pathology SC Pathology GA CB3BF UT WOS:000349502203038 ER PT J AU Lindeman, N Sholl, L Garcia, E Ducar, M Kuo, F Leslin, C MacConaill, L AF Lindeman, Neal Sholl, Lynette Garcia, Elizabeth Ducar, Matt Kuo, Frank Leslin, Chesley MacConaill, Laura TI Profile: Exome Sequencing of 4027 Cancer Samples in a Clinical Laboratory SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1842 BP 460A EP 460A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502203039 ER PT J AU Bozkurtlar, E Uruga, H Huynh, T Lanuti, M Mark, E Mino-Kenudson, M AF Bozkurtlar, Emine Uruga, Hironori Huynh, Tiffany Lanuti, Michael Mark, Eugene Mino-Kenudson, Mari TI SOX-2 Expression and Its Prognostic Value in Stage II and III Lung Adenocarcinomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Bozkurtlar, Emine; Uruga, Hironori; Huynh, Tiffany; Lanuti, Michael; Mark, Eugene; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1899 BP 474A EP 474A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502203096 ER PT J AU Bozkurtlar, E Uruga, H Huynh, T Lanuti, M Mark, E Mino-Kenudson, M AF Bozkurtlar, Emine Uruga, Hironori Huynh, Tiffany Lanuti, Michael Mark, Eugene Mino-Kenudson, Mari TI Comparison of Programmed Cell Death Ligand 1 (PD-L1) Expression in Main Tumor and Lymph Node Metastasis of Stage II and III Lung Adenocarcinomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Bozkurtlar, Emine; Uruga, Hironori; Huynh, Tiffany; Lanuti, Michael; Mark, Eugene; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1897 BP 474A EP 474A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502203094 ER PT J AU Bozkurtlar, E Uruga, H Hariri, L Mino-Kenudson, M Mark, E AF Bozkurtlar, Emine Uruga, Hironori Hariri, Lida Mino-Kenudson, Mart Mark, Eugene TI Idiopathic Tracheal Stenosis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Marmara Univ, Istanbul, Turkey. Toranomon Gen Hosp, Tokyo, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1898 BP 474A EP 474A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502203095 ER PT J AU Brachtel, E Huynh, T Mino-Kenudson, M AF Brachtel, Elena Huynh, Tiffany Mino-Kenudson, Mari TI P40 and GATA-3 Are Useful To Distinguish Between Lung Squamous Cell Carcinoma and Triple Negative Breast Cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Brachtel, Elena; Huynh, Tiffany; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1900 BP 474A EP 474A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502203097 ER PT J AU Huynh, T Chi, A Uruga, H Bozkurtlar, E Mark, E Mino-Kenudson, M AF Huynh, Tiffany Chi, Anthony Uruga, Hironori Bozkurtlar, Emine Mark, Eugene Mino-Kenudson, Mari TI Clinicopatholgical and Molecular Features Associated With Programmed Cell Death Ligand 1 (PD-L1) Expression in Resected Lung Squamous Cell Carcinomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Huynh, Tiffany; Chi, Anthony; Uruga, Hironori; Bozkurtlar, Emine; Mark, Eugene; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1916 BP 478A EP 478A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502203112 ER PT J AU Huynh, T Uruga, H Bozkurtlar, E Mark, E Mino-Kenudson, M AF Huynh, Tiffany Uruga, Hironori Bozkurtlar, Emine Mark, Eugene Mino-Kenudson, Mari TI Clinicopathological and Molecular Features Associated With Programmed Cell Death Ligand 1 (PD-L1) Expression in Resected Lung Adenocarcinomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Huynh, Tiffany; Uruga, Hironori; Bozkurtlar, Emine; Mark, Eugene; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1917 BP 478A EP 478A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502203113 ER PT J AU Matsubara, O Ishikawa, Y Nakatani, Y Mark, E AF Matsubara, Osamu Ishikawa, Yuichi Nakatani, Yukio Mark, Eugene TI Pathological Role of Fibroblastic Foci and Bronchiolar Epithelial Proliferation in Idiopathic Pulmonary Fibrosis (IPF)/Usual Interstitial Pneumonia (UIP) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Japanese Fdn Canc Res, Inst Canc, Tokyo 170, Japan. Hiratsuka Kyosai Hosp, Hiratsuka, Kanagawa, Japan. Chiba Univ, Chiba, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1941 BP 484A EP 484A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502203137 ER PT J AU Aisagbonhi, O Ly, A AF Aisagbonhi, Omonigho Ly, Amy TI Utility of Flow Cytometry in the Pathologic Evaluation of Tonsils and Adenoids SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Aisagbonhi, Omonigho; Ly, Amy] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 1987 BP 494A EP 495A PG 2 WC Pathology SC Pathology GA CB3BF UT WOS:000349502203183 ER PT J AU Mahadevan, K Bhan, A Deshpande, V Brachtel, E AF Mahadevan, Krishnan Bhan, Atul Deshpande, Vikram Brachtel, Elena TI Triple Negative Breast Cancers Evaluated By Amplified mRNA In-Situ Hybridization for Estrogen Receptor-Alpha SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Mahadevan, Krishnan; Bhan, Atul; Deshpande, Vikram; Brachtel, Elena] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 2083 BP 519A EP 519A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502203279 ER PT J AU Yoshimizu, T Pan, JQ Mungenast, AE Madison, JM Su, S Ketterman, J Ongur, D McPhie, D Cohen, B Perlis, R Tsai, LH AF Yoshimizu, T. Pan, J. Q. Mungenast, A. E. Madison, J. M. Su, S. Ketterman, J. Ongur, D. McPhie, D. Cohen, B. Perlis, R. Tsai, L-H TI Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons SO MOLECULAR PSYCHIATRY LA English DT Article ID BIPOLAR DISORDER; CALCIUM-CHANNEL; DIRECT CONVERSION; GENETIC-VARIATION; CA2+ CHANNELS; CELLS; SCHIZOPHRENIA; TRANSCRIPTION; ASSOCIATION; FIBROBLASTS AB Psychiatric disorders have clear heritable risk. Several large-scale genome-wide association studies have revealed a strong association between susceptibility for psychiatric disorders, including bipolar disease, schizophrenia and major depression, and a haplotype located in an intronic region of the L-type voltage-gated calcium channel (VGCC) subunit gene CACNA1C (peak associated SNP rs1006737), making it one of the most replicable and consistent associations in psychiatric genetics. In the current study, we used induced human neurons to reveal a functional phenotype associated with this psychiatric risk variant. We generated induced human neurons, or iN cells, from more than 20 individuals harboring homozygous risk genotypes, heterozygous or homozygous non-risk genotypes at the rs1006737 locus. Using these iNs, we performed electrophysiology and quantitative PCR experiments that demonstrated increased L-type VGCC current density as well as increased mRNA expression of CACNA1C in iNs homozygous for the risk genotype, compared with non-risk genotypes. These studies demonstrate that the risk genotype at rs1006737 is associated with significant functional alterations in human iNs, and may direct future efforts at developing novel therapeutics for the treatment of psychiatric disease. C1 [Yoshimizu, T.; Mungenast, A. E.; Su, S.; Tsai, L-H] MIT, Picower Inst Learning & Memory, Cambridge, MA 02139 USA. [Yoshimizu, T.; Mungenast, A. E.; Su, S.; Tsai, L-H] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [Pan, J. Q.; Madison, J. M.; Ketterman, J.; Perlis, R.] Broad Inst, Stanley Ctr Psychiat Res, Cambridge, MA USA. [Ongur, D.; McPhie, D.; Cohen, B.] McLean Hosp, Boston, MA USA. [Ongur, D.; McPhie, D.; Cohen, B.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Perlis, R.] Massachusetts Gen Hosp, Bipolar Clin, Boston, MA 02114 USA. [Perlis, R.] Massachusetts Gen Hosp, Res Program, Boston, MA 02114 USA. [Perlis, R.] Harvard Univ, Sch Med, Boston, MA USA. [Tsai, L-H] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA. RP Pan, JQ (reprint author), Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, 75 Ames 9016, Cambridge, MA 02142 USA. EM jpan@broadinstitute.org; lhtsai@mit.edu RI Yoshimizu, Takao/A-1339-2011 OI Yoshimizu, Takao/0000-0002-2553-8195 FU National Institutes of Health [R01-MH091115, RF1-AG042978, R01-NS051874, R01-NS078839, MH09395, MH10028, R21MH099448-01]; Stanley Medical Research Institute FX This work was supported by grants from the National Institutes of Health (R01-MH091115, RF1-AG042978, R01-NS051874 and R01-NS078839 to LHT; MH09395 and MH10028 to RP; R21MH099448-01 to JQP), and the Stanley Medical Research Institute (to LHT, JQP and JMM). NR 41 TC 27 Z9 27 U1 3 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD FEB PY 2015 VL 20 IS 2 BP 162 EP 169 DI 10.1038/mp.2014.143 PG 8 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA CB9XE UT WOS:000349986700004 PM 25403839 ER PT J AU Andreassen, OA Harbo, HF Wang, Y Thompson, WK Schork, AJ Mattingsdal, M Zuber, V Bettella, F Ripke, S Kelsoe, JR Kendler, KS O'Donovan, MC Sklar, P McEvoy, LK Desikan, RS Lie, BA Djurovic, S Dale, AM AF Andreassen, O. A. Harbo, H. F. Wang, Y. Thompson, W. K. Schork, A. J. Mattingsdal, M. Zuber, V. Bettella, F. Ripke, S. Kelsoe, J. R. Kendler, K. S. O'Donovan, M. C. Sklar, P. McEvoy, L. K. Desikan, R. S. Lie, B. A. Djurovic, S. Dale, A. M. CA PGC Bipolar Disorder Schizophrenia IMSGC TI Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci SO MOLECULAR PSYCHIATRY LA English DT Article DE false discovery rate; HLA region; multiple sclerosis; polygenic pleiotropy; schizophrenia ID GENOME-WIDE ASSOCIATION; COMMON VARIANTS; RISK LOCI; PSYCHIATRIC-DISORDERS; SUSCEPTIBILITY LOCI; METAANALYSIS; MECHANISMS; DISEASES; AGENTS AB Converging evidence implicates immune abnormalities in schizophrenia (SCZ), and recent genome-wide association studies (GWAS) have identified immune-related single-nucleotide polymorphisms (SNPs) associated with SCZ. Using the conditional false discovery rate (FDR) approach, we evaluated pleiotropy in SNPs associated with SCZ (n = 21 856) and multiple sclerosis (MS) (n = 43 879), an inflammatory, demyelinating disease of the central nervous system. Because SCZ and bipolar disorder (BD) show substantial clinical and genetic overlap, we also investigated pleiotropy between BD (n = 16 731) and MS. We found significant genetic overlap between SCZ and MS and identified 21 independent loci associated with SCZ, conditioned on association with MS. This enrichment was driven by the major histocompatibility complex (MHC). Importantly, we detected the involvement of the same human leukocyte antigen (HLA) alleles in both SCZ and MS, but with an opposite directionality of effect of associated HLA alleles (that is, MS risk alleles were associated with decreased SCZ risk). In contrast, we found no genetic overlap between BD and MS. Considered together, our findings demonstrate genetic pleiotropy between SCZ and MS and suggest that the MHC signals may differentiate SCZ from BD susceptibility. C1 [Andreassen, O. A.; Wang, Y.; Mattingsdal, M.; Zuber, V.; Bettella, F.; Djurovic, S.] Univ Oslo, Inst Clin Med, NORMENT, KG Jebsen Ctr Psychosis Res, Oslo, Norway. [Andreassen, O. A.; Wang, Y.; Zuber, V.; Bettella, F.; Djurovic, S.] Oslo Univ Hosp, Div Mental Hlth & Addict, N-0424 Oslo, Norway. [Andreassen, O. A.; Thompson, W. K.; Kelsoe, J. R.; Dale, A. M.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Harbo, H. F.] Oslo Univ Hosp, Dept Neurol, Ulleval, Norway. [Harbo, H. F.] Univ Oslo, Inst Clin Med, Oslo, Norway. [Wang, Y.; Schork, A. J.; McEvoy, L. K.; Desikan, R. S.; Dale, A. M.] Univ Calif San Diego, Multimodal Imaging Lab, La Jolla, CA 92093 USA. [Wang, Y.; Dale, A. M.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Schork, A. J.] Univ Calif San Diego, Cognit Sci Grad Program, La Jolla, CA 92093 USA. [Schork, A. J.] Univ Calif San Diego, Ctr Human Dev, La Jolla, CA 92093 USA. [Mattingsdal, M.] Sorlandet Hosp, Kristiansand, Norway. [Zuber, V.] Univ Oslo, Nord EMBL Partnership, Ctr Mol Med Norway, Oslo, Norway. [Zuber, V.] Oslo Univ Hosp, N-0424 Oslo, Norway. [Ripke, S.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA. [Ripke, S.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA. [Kendler, K. S.] Virginia Commonwealth Univ, Dept Psychiat, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA. [O'Donovan, M. C.] Cardiff Univ, Sch Med, MRC Ctr Neuropsychiat Genet & Genom, Cardiff CF10 3AX, S Glam, Wales. [Sklar, P.] Mt Sinai Sch Med, Div Psychiat Genet & Genom, New York, NY USA. [McEvoy, L. K.; Desikan, R. S.; Dale, A. M.] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA. [Djurovic, S.] Oslo Univ Hosp, Dept Med Genet, N-0424 Oslo, Norway. [Lie, B. A.; Djurovic, S.] Univ Oslo, Oslo, Norway. RP Andreassen, OA (reprint author), Oslo Univ Hosp, NORMENT, KG Jebsen Ctr Psychosis Res, Bldg 49,Kirkeveien 166,POB 4956 Nydalen, N-0424 Oslo, Norway. EM o.a.andreassen@medisin.uio.no; amdale@ucsd.edu RI Hansen, Thomas/O-5965-2014; Schalling, Martin/F-1518-2015; OI Hansen, Thomas/0000-0001-6703-7762; Schalling, Martin/0000-0001-5011-2922; Saarela, Janna/0000-0002-0853-6219; O'Donovan, Michael/0000-0001-7073-2379; Andreassen, Ole A./0000-0002-4461-3568; Zuber, Verena/0000-0001-9827-1877 FU Wellcome Trust [085475/B/08/Z, 085475/Z/08/Z] FX We thank all study participants for their contributions, the researchers involved in Psychiatric Genomics Consortium (PGC) Bipolar disorder and Schizophrenia Work Groups, the PGC ADHD, Autism, and MDD Groups, and the SURFsara Computer Cluster (www.surfsara.nl). The International Multiple Sclerosis Genetics Consortium and the Wellcome Trust Case Control Consortium2 is acknowledged for providing data from their MS genome-wide study, supported by the Wellcome Trust (project 085475/B/08/Z and 085475/Z/08/Z). NR 39 TC 44 Z9 44 U1 0 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD FEB PY 2015 VL 20 IS 2 BP 207 EP 214 DI 10.1038/mp.2013.195 PG 8 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA CB9XE UT WOS:000349986700010 PM 24468824 ER PT J AU Raghavan, K Healy, BC Carruthers, RL Chitnis, T AF Raghavan, Kesav Healy, Brian C. Carruthers, Robert L. Chitnis, Tanuja TI Progression rates and sample size estimates for PPMS based on the CLIMB study population SO MULTIPLE SCLEROSIS JOURNAL LA English DT Article DE Epidemiology; primary progressive multiple sclerosis ID INTERVAL CENSORED-DATA; MULTIPLE-SCLEROSIS; NATURAL-HISTORY; PROGNOSTIC-FACTORS; DOUBLE-BLIND; DISABILITY; MULTICENTER; INTERRATER; DISEASE; TRIALS AB Background: The clinical trial design for primary progressive multiple sclerosis (PPMS) requires understanding of disability progression in modern patient cohorts. Objective: The objective of this paper is to characterize demographic and clinical characteristics of PPMS and assess rate of disability progression. Methods: We studied PPMS (n = 73) and relapsing-onset MS (ROMS) patients (n = 1541) enrolled in CLIMB, a longitudinal study of MS patients at the Brigham and Women's Hospital (Boston, MA). Disability progression for each group was compared using interval-censored survival analysis and time to six-month sustained progression. Results: The PP group had a 1.09:1 male:female ratio compared to 1:2.89 for the RO group and greater mean age of onset (PP: 44.49.6; RO: 32.7 +/- 9.9; p < 0.0001). Motor symptoms at onset and first symptoms localized to spinal cord were each strongly associated with PPMS (p < 0.001). Median time from onset to EDSS 6.0 was faster in PPMS (p < 0.001). PPMS patients progressed faster to EDSS 3 (p < 0.001) and from EDSS 3 to 6 (p < 0.001). Median time to sustained progression in the PP group was 4.85 years (95% CI 2.83-8.35), significantly faster than the RO group (p < 0.001). Conclusions: Our modern PPMS cohort is demographically similar to previously studied cohorts. PPMS is associated with faster disability accrual than ROMS. Current real-world observations of time to sustained progression will inform design of new clinical trials for PPMS. C1 [Raghavan, Kesav; Healy, Brian C.; Carruthers, Robert L.; Chitnis, Tanuja] Brigham & Womens Hosp, Partners MS Ctr, Brookline, MA 02445 USA. [Healy, Brian C.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. RP Chitnis, T (reprint author), Brigham & Womens Hosp, Partners MS Ctr, 1 Brookline Pl,Suite 602, Brookline, MA 02445 USA. EM tchitnis@partners.org FU National Multiple Sclerosis Society (NMSS) [RG-4256A4/2]; Nancy Davis Foundation; Merck Serono; Foundation of the Consortium of Multiple Sclerosis Centers (FCMSC); NMSS FX This work was supported by the National Multiple Sclerosis Society (NMSS) RG-4256A4/2 (T.C.). The CLIMB study is funded in part by the Nancy Davis Foundation and Merck Serono S.A. KR received a medical student summer research scholarship from the Foundation of the Consortium of Multiple Sclerosis Centers (FCMSC). RC received a Clinical Fellowship Training Grant from the NMSS. NR 30 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD FEB PY 2015 VL 21 IS 2 BP 180 EP 188 DI 10.1177/1352458514541976 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CB6VL UT WOS:000349764700011 PM 25070676 ER PT J AU Nguyen, PL AF Nguyen, Paul L. TI Radiation Therapy for Node-Positive Prostate Cancer: It's Time for a Randomized Trial SO ONCOLOGY-NEW YORK LA English DT Editorial Material ID RADICAL PROSTATECTOMY; RADIOTHERAPY; IMPACT C1 Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Canc Ctr,Brigham & Womens Hosp, Boston, MA 02115 USA. RP Nguyen, PL (reprint author), Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Canc Ctr,Brigham & Womens Hosp, Boston, MA 02115 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD FEB PY 2015 VL 29 IS 2 BP 116 EP 117 PG 2 WC Oncology SC Oncology GA CB9IJ UT WOS:000349944900006 PM 25683832 ER PT J AU Sullivan, RJ AF Sullivan, Ryan J. TI Optimal Treatment Selection for Patients With Metastatic Melanoma SO ONCOLOGY-NEW YORK LA English DT Editorial Material ID MEK INHIBITION; COMBINED BRAF; IPILIMUMAB; VEMURAFENIB; SURVIVAL; DABRAFENIB; TRAMETINIB; COBIMETINIB; NIVOLUMAB; COHORT C1 Massachusetts Gen Hosp, Ctr Canc, Ctr Melanoma, Boston, MA 02114 USA. RP Sullivan, RJ (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Melanoma, Boston, MA 02114 USA. NR 25 TC 0 Z9 0 U1 0 U2 1 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD FEB PY 2015 VL 29 IS 2 BP 139 EP 141 PG 3 WC Oncology SC Oncology GA CB9IJ UT WOS:000349944900010 PM 25683836 ER PT J AU Malec, M Weiner, DK Shega, JW AF Malec, Monica Weiner, Debra K. Shega, Joseph W. TI Optimal Pharmacologic Pain Management in the Older Adult: An Ongoing Quagmire SO PAIN MEDICINE LA English DT Editorial Material C1 [Malec, Monica] Univ Chicago, Dept Med, Sect Geriatr & Palliat Med, Chicago, IL 60637 USA. [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Shega, Joseph W.] Vitas Healthcare, Miami, FL USA. RP Malec, M (reprint author), Univ Chicago, Dept Med, Sect Geriatr & Palliat Med, 5841 S Maryland Ave, Chicago, IL 60637 USA. NR 3 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD FEB PY 2015 VL 16 IS 2 BP 217 EP 218 DI 10.1111/pme.12653 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CB9UU UT WOS:000349979600001 PM 25521331 ER PT J AU King, W Ahmed, SU Baisden, J Patel, N Kennedy, DJ MacVicar, J Duszynski, B AF King, Wade Ahmed, Shihab U. Baisden, Jamie Patel, Nileshkumar Kennedy, David J. MacVicar, John Duszynski, Belinda TI Diagnosis and Treatment of Posterior Sacroiliac Complex Pain: A Systematic Review with Comprehensive Analysis of the Published Data SO PAIN MEDICINE LA English DT Article DE Posterior Sacroiliac Complex Pain; Lateral Branch Block; Radiofrequency Lateral Branch Neurotomy; Sacroiliac Joint ID LATERAL BRANCH BLOCKS; INJECTION ARTHROGRAPHY TECHNIQUE; LOW-BACK-PAIN; JOINT PAIN; RADIOFREQUENCY DENERVATION; REFERRAL MAPS; NEUROTOMY; ANESTHETIZE; OUTCOMES; ABILITY AB ObjectiveTo assess the evidence on the validity of sacral lateral branch blocks and the effectiveness of sacral lateral branch thermal radiofrequency neurotomy in managing sacroiliac complex pain. DesignSystematic review with comprehensive analysis of all published data. InterventionsSix reviewers searched the literature on sacral lateral branch interventions. Each assessed the methodologies of studies found and the quality of the evidence presented. Outcome MeasuresThe outcomes assessed were diagnostic validity and effectiveness of treatment for sacroiliac complex pain. The evidence found was appraised in accordance with the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system of evaluating scientific evidence. ResultsThe searches yielded two primary publications on sacral lateral branch blocks and 15 studies of the effectiveness of sacral lateral branch thermal radiofrequency neurotomy. One study showed multisite, multidepth sacral lateral branch blocks can anesthetize the posterior sacroiliac ligaments. Therapeutic studies show sacral lateral branch thermal radiofrequency neurotomy can relieve sacroiliac complex pain to some extent. The evidence of the validity of these blocks and the effectiveness of this treatment were rated as moderate in accordance with the GRADE system. ConclusionsThe literature on sacral lateral branch interventions is sparse. One study demonstrates the face validity of multisite, multidepth sacral lateral branch blocks for diagnosis of posterior sacroiliac complex pain. Some evidence of moderate quality exists on therapeutic procedures, but it is insufficient to determine the indications and effectiveness of sacral lateral branch thermal radiofrequency neurotomy, and more research is required. C1 [King, Wade] Lingard Hosp, Merewether, NSW 2291, Australia. [Ahmed, Shihab U.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Baisden, Jamie] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA. [Patel, Nileshkumar] Adv Pain Management, Green Bay, WI USA. [Kennedy, David J.] Stanford Univ, Redwood City, CA USA. [Duszynski, Belinda] Int Spine Intervent Soc, Crystal Lake, IL USA. [MacVicar, John] St Georges Med Ctr, Southern Rehabil Inst, Christchurch, New Zealand. RP King, W (reprint author), Lingard Hosp, 23 Merewether St, Merewether, NSW 2291, Australia. EM wmbaking@bigpond.com FU Bayliss Medical FX Conflicts of interest: Nileshkumar Patel MD has a consulting agreement with Kimberly Clark, and the study on sacroiliac neurotomy was sponsored by Bayliss Medical, which was subsequently acquired by Kimberly Clark. None of the other authors have any financial conflicts of interest to disclose. NR 28 TC 6 Z9 6 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD FEB PY 2015 VL 16 IS 2 BP 257 EP 265 DI 10.1111/pme.12630 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CB9UU UT WOS:000349979600009 PM 25677327 ER PT J AU Steinman, MA Komaiko, KDR Fung, KZ Ritchie, CS AF Steinman, Michael A. Komaiko, Kiya D. R. Fung, Kathy Z. Ritchie, Christine S. TI Use of Opioids and Other Analgesics by Older Adults in the United States, 1999-2010 SO PAIN MEDICINE LA English DT Article DE Opioid Analgesics; Aged; Physician's Practice Patterns; Pharmacoepidemiology; Analgesics; United States ID EMERGENCY-DEPARTMENTS; COMPARATIVE SAFETY; NONMALIGNANT PAIN; NONCANCER PAIN; TRENDS; PRESCRIPTION; WORKERS; RISK; CARE; AGE AB Background and ObjectiveThere has been concern over rising use of prescription opioids in young and middle-aged adults. Much less is known about opioid prescribing in older adults, for whom clinical recommendations and the balance of risks and benefits differ from younger adults. We evaluated changes in use of opioids and other analgesics in a national sample of clinic visits made by older adults between 1999 and 2010. Design, Setting, and SubjectsObservational study of adults aged 65 and older from the 1999-2010 National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, serial cross-sectional surveys of outpatient visits in the United States. MethodsMedication use was assessed at each study visit and included medications in use prior to the visit and medications newly prescribed at the visit. Results were adjusted for survey weights and design factors to provide nationally representative estimates. ResultsMean age was 757 years, and 45% of visits occurred in primary care settings. Between 1999-2000 and 2009-2010, the percent of clinic visits at which an opioid was used rose from 4.1% to 9.0% (P<0.001). Although use of all major opioid classes increased, the largest contributor to increased use was hydrocodone-containing combination opioids, which rose from 1.1% to 3.5% of visits over the study period (P<0.001). Growth in opioid use was observed across a wide range of patient and clinic characteristics, including in visits for musculoskeletal problems (10.7% of visits in 1999-2000 to 17.0% in 2009-2010, P<0.001) and in visits for other reasons (2.8% to 7.3%, P<0.001). ConclusionsOpioid use by older adults visiting clinics more than doubled between 1999 and 2010, and occurred across a wide range of patient characteristics and clinic settings. C1 [Steinman, Michael A.; Komaiko, Kiya D. R.; Fung, Kathy Z.; Ritchie, Christine S.] Univ Calif San Francisco, San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94141 USA. RP Steinman, MA (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,VA Box 181G, San Francisco, CA 94141 USA. EM mike.steinman@ucsf.edu FU National Institute of Aging; American Federation for Aging Research [1K23-AG030999, 1K07AG31779] FX Funding sources: This study was supported by the National Institute of Aging and by the American Federation for Aging Research (1K23-AG030999 [MAS] and 1K07AG31779 [CSR]). The sponsors had no role in the design, analysis, authorship, or decision to publish this work. NR 26 TC 12 Z9 12 U1 3 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD FEB PY 2015 VL 16 IS 2 BP 319 EP 327 DI 10.1111/pme.12613 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CB9UU UT WOS:000349979600016 PM 25352175 ER PT J AU Ganzini, L Rakoski, A Cohn, S Mularski, RA AF Ganzini, Linda Rakoski, Alexa Cohn, Sharilyn Mularski, Richard A. TI Family members' views on the benefits of harp music vigils for terminally-ill or dying loved ones SO PALLIATIVE & SUPPORTIVE CARE LA English DT Article DE Music; palliative care; family; dyspnea; spirituality AB Objectives: Music-thanatology is a palliative modality that uses harp and voice to provide bedside vigils, particularly for terminally ill or actively dying. We sought to determine the benefits of music vigils for terminally ill patients. Methods: Survey of 55 family members, whose terminally ill loved one experienced a music vigil during hospitalization, regarding effects on the patient's breathing, relaxation, comfort, pain and ability to sleep. Written comments on negative and positive results of the vigils were coded using content analysis. Results: Family members perceived that the vigils resulted in modest improvement in the patients' breathing, relaxation, comfort, and ability to sleep, with fewer positive effects on pain, and almost no negative effects. Open ended comments focused on the positive benefit in increasing calm, relaxation, comfort. Comments on the positive effects for the family were almost as common as comments on the positive results for the patient. Significance of Results: The use of music-vigils in palliative care should be investigated more extensively as our study supports that this intervention has benefits, almost no risk, minimal cost, and may improve patient-family experience of the dying process. C1 [Ganzini, Linda] Portland VA Med Ctr, Hlth Serv Res & Dev, Portland, OR USA. [Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Rakoski, Alexa] Univ Notre Dame, Notre Dame, IN 46556 USA. [Cohn, Sharilyn] SacredFlight, Portland, OR USA. [Mularski, Richard A.] Kaiser Permanente, Portland, OR USA. RP Ganzini, L (reprint author), Portland VA Med Ctr, R&D 66, POB 1034, Portland, OR 97207 USA. EM Linda.Ganzini@va.gov NR 6 TC 0 Z9 0 U1 4 U2 8 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1478-9515 EI 1478-9523 J9 PALLIAT SUPPORT CARE JI Palliat. Support Care PD FEB PY 2015 VL 13 IS 1 BP 41 EP 44 DI 10.1017/S1478951513000564 PG 4 WC Health Policy & Services SC Health Care Sciences & Services GA CB6TA UT WOS:000349758400006 PM 24128665 ER PT J AU Colombero, C Catano, G Rocco, CA Mecikovsky, D Bologna, R Aulicino, PC Sen, LS Mangano, A AF Colombero, Cecilia Catano, Gabriel Rocco, Carlos A. Mecikovsky, Debora Bologna, Rosa Aulicino, Paula C. Sen, Luisa Mangano, Andrea TI Role of 3 Lipoprotein Lipase Variants in Triglycerides in Children Receiving Highly Active Antiretroviral Therapy SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE lipoprotein lipase; triglycerides; highly active antiretroviral therapy; children; human immunodeficiency virus-1 infection ID HUMAN-IMMUNODEFICIENCY-VIRUS; CORONARY-ARTERY-DISEASE; CARDIOVASCULAR RISK-FACTORS; HIV PROTEASE INHIBITORS; MIDDLE-AGED MEN; GENE POLYMORPHISMS; INFECTED CHILDREN; HEART-DISEASE; YOUNG-ADULTS; LIPID-LEVELS AB Background: Lipoprotein lipase is a key enzyme in lipid metabolism, especially for plasma triglycerides (TGs). Genetic variants have been associated with lipid levels in healthy individuals, cardiovascular disease, obesity and diabetes. Our aim was to evaluate the influence of 3 polymorphisms: Hind III, Pvu II and S447X in plasma TG levels in human immunodeficiency virus-1-infected children under highly active antiretroviral therapy (HAART). Methods: Fifty-two children diagnosed with human immunodeficiency virus-1 between 2005 and 2009 were retrospectively selected with at least 1 plasma TG level assessment. TG levels were examined before and after 1 year of HAART. Hypertriglyceridemia was defined as TG > 150 mg/dL. Hind III (H+/H-), Pvu II (P+/P-) and S447X (S/X) were determined by polymerase chain reaction and restricted fragment length polymorphism. The Wilcoxon sum-rank test was used to compare median plasma TG among groups. Also, allelic frequencies were estimated for these variants in an Argentinean population. Results: Allelic frequencies for human immunodeficiency virus-1-infected children were: H-, 0.21; P-, 0.53; and X, 0.05 with no significant differences to controls. After 1 year of HAART, median TG levels were significantly lower in P-/P-(98.5 mg/dL) when compared with P+/P+ (180 mg/dL) (P = 0.039). The presence of the P-allele was associated with an 11-fold lower risk of hypertriglyceridemia. Hind III and S447X were not associated with TG at the selected time points. Conclusions: Our findings suggest a protective effect of lipoprotein lipase polymorphisms against hypertriglyceridemia in children after 1 year of HAART. These results could endorse a prompt nutritional or pharmacological intervention in patients lacking the P-allele. C1 [Colombero, Cecilia; Rocco, Carlos A.; Aulicino, Paula C.; Sen, Luisa; Mangano, Andrea] Hosp Pediat Dr JP Garrahan, Lab Biol Celular & Retrovirus, RA-1245 Buenos Aires, DF, Argentina. [Catano, Gabriel] South Texas Vet Hlth Care Syst, Vet Affairs Res Ctr AIDS & HIV Infect 1, San Antonio, TX USA. [Catano, Gabriel] South Texas Vet Hlth Care Syst, Ctr Personalized Med, San Antonio, TX USA. [Catano, Gabriel] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Mecikovsky, Debora; Bologna, Rosa; Mangano, Andrea] Hosp Pediat Dr JP Garrahan, Serv Epidemiol & Infectol, Buenos Aires, DF, Argentina. [Aulicino, Paula C.; Sen, Luisa; Mangano, Andrea] Consejo Nacl Invest Cient & Tecn CONICET, Buenos Aires, DF, Argentina. RP Mangano, A (reprint author), Hosp Pediat Dr JP Garrahan, Lab Biol Celular & Retrovirus, Combate Pozos 1881, RA-1245 Buenos Aires, DF, Argentina. EM amangano@garrahan.gov.ar FU Fogarty AITRP [D43TW001037]; Fondo Nacional para Ciencia y Tecnologia (FONCYT-ANPCyT, PICT) [1235] FX This work was supported, in part, by Fogarty AITRP grant #D43TW001037 and by Fondo Nacional para Ciencia y Tecnologia (FONCYT-ANPCyT, PICT 2006 No. 1235). NR 72 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD FEB PY 2015 VL 34 IS 2 BP 155 EP 161 DI 10.1097/INF.0000000000000474 PG 7 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA CB8VE UT WOS:000349908800011 PM 24988117 ER PT J AU Crytzer, TM Dicianno, BE Robertson, RJ Cheng, YT AF Crytzer, T. M. Dicianno, B. E. Robertson, R. J. Cheng, Yu-Ting TI VALIDITY OF A WHEELCHAIR PERCEIVED EXERTION SCALE (WHEEL SCALE) FOR ARM ERGOMETRY EXERCISE IN PEOPLE WITH SPINA BIFIDA SO PERCEPTUAL AND MOTOR SKILLS LA English DT Article ID CHILDRENS OMNI SCALE; PHYSICAL-ACTIVITY; YOUNG-ADULTS; RESISTANCE EXERCISE; HEART-RATE; STEPPING EXERCISE; AEROBIC FITNESS; RPE SCALE; VALIDATION; ADOLESCENTS AB This study assessed the concurrent and construct validity of the Borg 6-20 Scale and WHEEL Scale during arm ergometry exercise stress testing in (n = 24) adolescents and adults with spina bifida. Significant, moderate, positive correlations were observed between power output and relative heart rate and power output to relative VO(2)peak. Further, a moderate, significant correlation between physiologic criterion variables and the rating of perceived exertion derived from the Borg Scale and the WHEEL Scale was found. Concurrent validity was supported by the following findings: (1) relative heart rate was significantly correlated with the Borg (Kendall's tau =.41) and WHEEL Scales (tau =.44), and relative VO2 was significantly correlated with the Borg (tau =.46) and WHEEL Scales (tau =.47); (2) content validity was supported by the finding that the Borg and WHEEL Scales shared significant variance (tau =.70), demonstrating internal consistency. The WHEEL Scale shows strong potential for use in this cohort subsequent to further testing and validation. C1 [Crytzer, T. M.] Vet Affairs Pittsburgh Healthcare Syst, Sch Hlth & Rehabil Sci, Human Engn Res Labs, Pittsburgh, PA USA. [Crytzer, T. M.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Crytzer, T. M.] Univ Pittsburgh, Med Ctr, Ctr Assist Technol, Pittsburgh, PA USA. [Dicianno, B. E.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Dicianno, B. E.] Univ Pittsburgh, Med Ctr, UPMC Mercy Hosp, Adult Outpatient Spina Bifida Clin, Pittsburgh, PA USA. [Dicianno, B. E.] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Pittsburgh, PA USA. [Robertson, R. J.] Univ Pittsburgh, Sch Educ, Ctr Exercise & Hlth Fitness Res, Pittsburgh, PA 15260 USA. [Cheng, Yu-Ting] Chung Shan Med Univ, Sch Phys Therapy, Taichung, Taiwan. RP Crytzer, TM (reprint author), 6425 Bakery Sq,Suite 400, Pittsburgh, PA 15206 USA. EM tmc38@pitt.edu FU Spina Bifida Association; Ashley Rose Foundation through the Spina Bifida Association Young Investigators Award FX This study was funded by the Spina Bifida Association and Ashley Rose Foundation through the Spina Bifida Association 2011 Young Investigators Award. The authors wish to thank our participants, without whom this study would not have been possible. We thank the exercise physiologists who conducted the exercise testing, Mr. Steve Anthony and Ms. Shannon Speight, Division of Endocrinology and Metabolism, University of Pittsburgh. We thank Mr. and Mrs. Pitek who provided funding for this project through the Ashley Rose Foundation with love and honor of their daughter Ashley Rose. Without their generous support and the support of the Spina Bifida Association, we would not have been able to conduct this study. NR 49 TC 0 Z9 0 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0031-5125 EI 1558-688X J9 PERCEPT MOTOR SKILL JI Percept. Mot. Skills PD FEB PY 2015 VL 120 IS 1 BP 304 EP 322 DI 10.2466/15.08.PMS.120v12x8 PG 19 WC Psychology, Experimental SC Psychology GA CC4RP UT WOS:000350341200023 PM 25650508 ER PT J AU Ruiz, C Li, JL Luttgen, MS Kolatkar, A Kendall, JT Flores, E Topp, Z Samlowski, WE McClay, E Bethel, K Ferrone, S Hicks, J Kuhn, P AF Ruiz, Carmen Li, Julia Luttgen, Madelyn S. Kolatkar, Anand Kendall, Jude T. Flores, Edna Topp, Zheng Samlowski, Wolfram E. McClay, Edward Bethel, Kelly Ferrone, Soldano Hicks, James Kuhn, Peter TI Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients SO PHYSICAL BIOLOGY LA English DT Article DE CSPG4; nuclear morphometry; circulating melanoma cells; DNA copy number variation; metastatic melanoma ID HIGH-MOLECULAR-WEIGHT; TUMOR-CELLS; PERIPHERAL-BLOOD; GENETIC-HETEROGENEITY; METASTATIC MELANOMA; CUTANEOUS MELANOMA; CANCER; BRAF; ANTIGEN; MARKERS AB Purpose. Circulating melanoma cells (CMCs) constitute a potentially important representation of time-resolved tumor biology in patients. To date, genomic characterization of CMCs has been limited due to the lack of a robust methodology capable of identifying them in a format suitable for downstream characterization. Here, we have developed a methodology to detect intact CMCs that enables phenotypic, morphometric and genomic analysis at the single cell level. Experimental design. Blood samples from 40 metastatic melanoma patients and 10 normal blood donors were prospectively collected. A panel of 7 chondroitin sulfate proteoglycan 4 (CSPG4)-specific monoclonal antibodies (mAbs) was used to immunocytochemically label CMCs. Detection was performed by automated digital fluorescence microscopy and multi-parametric computational analysis. Individual CMCs were captured by micromanipulation for whole genome amplification and copy number variation (CNV) analysis. Results. Based on CSPG4 expression and nuclear size, 1-250 CMCs were detected in 22 (55%) of 40 metastatic melanoma patients (0.5-371.5 CMCs ml(-1)). Morphometric analysis revealed that CMCs have a broad spectrum of morphologies and sizes but exhibit a relatively homogeneous nuclear size that was on average 1.5-fold larger than that of surrounding PBMCs. CNV analysis of single CMCs identified deletions of CDKN2A and PTEN, and amplification(s) of TERT, BRAF, KRAS and MDM2. Furthermore, novel chromosomal amplifications in chr12, 17 and 19 were also found. Conclusions. Our findings show that CSPG4 expressing CMCs can be found in the majority of advanced melanoma patients. High content analysis of this cell population may contribute to the design of effective personalized therapies in patients with melanoma. C1 [Ruiz, Carmen; Li, Julia; Luttgen, Madelyn S.; Kolatkar, Anand] Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA. [Flores, Edna; Topp, Zheng; Bethel, Kelly] Scripps Clin, Med Grp, La Jolla, CA 92037 USA. [Samlowski, Wolfram E.] Comprehens Canc Ctr Nevada, Las Vegas, NV 89148 USA. [McClay, Edward] San Diego Pacific Oncol & Hematol, Encinitas, CA USA. [Ferrone, Soldano] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA. [Kendall, Jude T.; Hicks, James] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA. [Kuhn, Peter] Univ So Calif, Dornsife Coll Letters Arts & Sci, Los Angeles, CA USA. RP Ruiz, C (reprint author), Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA. EM pkuhn@usc.edu FU Carol Vassiliadis Fellowship; National Cancer Institute [U54CA143906]; PHS grants - National Cancer Institute [RO1CA138188, P50CA121973] FX This work was supported by the Carol Vassiliadis Fellowship and by Award Number U54CA143906 from the National Cancer Institute. Soldano Ferrone was supported in part by PHS grants RO1CA138188, and P50CA121973 awarded by the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. NR 45 TC 8 Z9 8 U1 0 U2 4 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 1478-3967 EI 1478-3975 J9 PHYS BIOL JI Phys. Biol. PD FEB PY 2015 VL 12 IS 1 AR 016008 DI 10.1088/1478-3975/12/1/016008 PG 12 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA CB9JN UT WOS:000349948000008 PM 25574741 ER PT J AU Freeman, EW Ensrud, KE Larson, JC Guthrie, KA Carpenter, JS Joffe, H Newton, KM Sternfeld, B LaCroix, AZ AF Freeman, Ellen W. Ensrud, Kristine E. Larson, Joseph C. Guthrie, Katherine A. Carpenter, Janet S. Joffe, Hadine Newton, Katherine M. Sternfeld, Barbara LaCroix, Andrea Z. TI Placebo Improvement in Pharmacologic Treatment of Menopausal Hot Flashes: Time Course, Duration, and Predictors SO PSYCHOSOMATIC MEDICINE LA English DT Article DE placebo response; placebo improvement; hot flash treatment; menopause ID RANDOMIZED CONTROLLED-TRIAL; VASOMOTOR SYMPTOMS; MIDLIFE WOMEN; DEPRESSION SEVERITY; CLINICAL-TRIALS; SMOKING; ANTIDEPRESSANTS; ASSOCIATION; METABOLISM; MANAGEMENT AB Objectives To characterize the time course, duration of improvement, and clinical predictors of placebo response in treatment of menopausal hot flashes. Methods Data were pooled from two trials conducted in the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health network, providing a combined placebo group (n = 247) and a combined active treatment group (n = 297). Participants recorded hot flash frequency in diaries twice daily during treatment (Weeks 0-8) and subsequent follow-up (Weeks 9-11). The primary outcome variable was clinically significant improvement, defined as a 50% or greater decrease in hot flash frequency from baseline and calculated for each week in the study. Subgroups were defined a priori using standard clinical definitions for significant improvement and partial improvement. Clinical and demographic characteristics of the participants were evaluated as predictors of improvement. Results Clinically significant improvement with placebo accrued each treatment week, with 33% significantly improved at Week 8. Of placebo responders who were improved at both Weeks 4 and 8, 77% remained clinically improved at Week 11 after treatment ended. Independent predictors of significant placebo improvement in the final multivariable model were African American race (odds ratio [OR] = 5.61, 95% confidence interval [CI] = 2.41-13.07, p < .001), current smokers (OR = 2.30, 95% CI = 1.05-5.06, p = .038), and hot flash severity in screening (OR = 1.45, 95% CI = 1.00-2.10, p = .047). Conclusions Clinically significant improvement with placebo accrued throughout treatment with a time course similar to improvement with active drug. A meaningful number of participants in the placebo group sustained a clinically significant response after stopping placebo pills. The results suggest that nonspecific effects are important components of treatment and warrant further studies to optimize their contributions in clinical care. C1 [Freeman, Ellen W.] Univ Penn, Dept Obstet Gynecol & Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Ensrud, Kristine E.] Vet Affairs Hlth Syst, Dept Med, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Ensrud, Kristine E.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Larson, Joseph C.; Guthrie, Katherine A.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, MsFlash Data Coordinating Ctr, Seattle, WA 98104 USA. [Carpenter, Janet S.] Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA. [Joffe, Hadine] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. [Joffe, Hadine] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Joffe, Hadine] Harvard Univ, Sch Med, Dana Farber Inst, Dept Psychosocial, Boston, MA USA. [Newton, Katherine M.] Grp Hlth Res Inst, Seattle, WA USA. [Sternfeld, Barbara] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [LaCroix, Andrea Z.] Univ Calif San Diego, Womens Hlth Ctr, La Jolla, CA 92093 USA. RP Freeman, EW (reprint author), Univ Penn, Dept Obstet Gynecol & Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. EM freemane@mail.med.upenn.edu FU National Institutes of Health, under National Institute of Aging [UO1AG032656, UO1AG032659, UO1AG032669, UO1AG032682, UO1AG 032699, UO1AG032700]; National Institutes of Health; Forest Laboratories, Inc.; Bionovo; Merck Sharpe Dohme; Teva/Cephalon; National Institute of Aging FX All authors received funding for this study from the National Institutes of Health, under a cooperative agreement issued by the National Institute of Aging to each participating site in the MsFlash network: Grant Nos. UO1AG032656, UO1AG032659, UO1AG032669, UO1AG032682, UO1AG 032699, and UO1AG032700. Dr. Freeman reports receiving research support from the National Institutes of Health, Forest Laboratories, Inc. and Bionovo. Dr. Ensrud reports receiving research support from the National Institutes of Health and financial compensation for serving as a consultant on the data monitoring committee for Merck Sharpe & Dohme. Dr. Joffe reports receiving research support from the National Institutes of Health and Teva/Cephalon and serving as a consultant for Noven. Dr. LaCroix reports receiving research support from the National Institute of Aging and the National Institutes of Health. Dr. Carpenter, Dr. Guthrie, Dr. Newton, and Dr. Sternfeld report receiving research support from the National Institute of Aging. No other disclosures were reported. NR 32 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0033-3174 EI 1534-7796 J9 PSYCHOSOM MED JI Psychosom. Med. PD FEB-MAR PY 2015 VL 77 IS 2 BP 167 EP 175 DI 10.1097/PSY.0000000000000143 PG 9 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA CC0UC UT WOS:000350051500007 PM 25647753 ER PT J AU Abers, MS Uy, N Musher, DM AF Abers, M. S. Uy, N. Musher, D. M. TI Response: Predicting poor outcomes in community-acquired pneumonia SO QJM-AN INTERNATIONAL JOURNAL OF MEDICINE LA English DT Letter C1 [Abers, M. S.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Uy, N.; Musher, D. M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Musher, D. M.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX USA. RP Abers, MS (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. EM mabers@partners.org NR 4 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1460-2725 EI 1460-2393 J9 QJM-INT J MED JI QJM-An Int. J. Med. PD FEB 1 PY 2015 VL 108 IS 2 BP 174 EP 174 DI 10.1093/qjmed/hcu152 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CC1RB UT WOS:000350118700023 PM 25078412 ER PT J AU Wouters, BG Skarsgard, LD Gerweck, LE Carabe-Fernandez, A Wong, M Durand, RE Nielson, D Bussiere, MR Wagner, M Biggs, P Paganetti, H Suit, HD AF Wouters, Bradly G. Skarsgard, Lloyd D. Gerweck, Leo E. Carabe-Fernandez, Alejandro Wong, Michelle Durand, Ralph E. Nielson, Deanna Bussiere, Marc R. Wagner, Miles Biggs, Peter Paganetti, Harald Suit, Herman D. TI Radiobiological Intercomparison of the 160 MeV and 230 MeV Proton Therapy Beams at the Harvard Cyclotron Laboratory and at Massachusetts General Hospital SO RADIATION RESEARCH LA English DT Article ID RELATIVE BIOLOGICAL EFFECTIVENESS; RADIATION SURVIVAL RESPONSE; HEAVY CHARGED-PARTICLES; HAMSTER V79 CELLS; HUMAN TUMOR-CELLS; ENHANCED SENSITIVITY; EFFECTIVENESS RBE; MAMMALIAN-CELLS; ENERGY PROTONS; MODEL AB The purpose of this study was to determine the relative biological effectiveness (RBE) along the axis of two range-modulated proton beams (160 and 230 MeV). Both the depth and the dose dependence of RBE were investigated. Chinese hamster V79-WNRE cells, suspended in medium containing gelatin and cooled to 2 degrees C, were used to obtain complete survival curves at multiple positions throughout the entrance and 10 cm spread-out Bragg peak (SOBP). Simultaneous measurements of the survival response to Co-60 gamma rays served as the reference data for the proton RBE determinations. For both beams the RBE increased significantly with depth in the 10 cm SOBP, particularly in the distal half of the SOBP, then rose even more sharply at the distal edge, the most distal position measured. At a 4 Gy dose of gamma radiation (S = 0.34) the average RBE values for the entrance, proximal half, distal half and distal edge were 1.07 +/- 0.01, 1.10 +/- 0.01, 1.17 +/- 0.01 and 1.21 +/- 0.01, respectively, and essentially the same for both beams. At a 2 Gy dose of gamma radiation (S = 0.71) the average RBE values rose to 1.13 +/- 0.03, 1.15 +/- 0.02, 1.26 +/- 0.02 and 1.30 +/- 0.02, respectively, for the same four regions of the SOBP. The difference between the 4 Gy and 2 Gy RBE values reflects the dose dependence of RBE as measured in these V79-WNRE cells, which have a low alpha/beta value, as do other widely used cell lines that also show dose-dependent RBE values. Late-responding tissues are also characterized by low alpha/beta values, so it is possible that these cell lines may be predictive for the response of such tissues (e.g., spinal cord, optic nerve, kidney, liver, lung). However, in the very small number of studies of late-responding tissues performed to date there appears to be no evidence of an increased RBE for protons at low doses. Similarly, RBE measurements using early responding in vivo systems (mostly mouse jejunum, an early-responding tissue which has a large alpha/beta similar to 10 Gy) have generally shown little or no detectable dose dependence. It is useful to compare the RBE values reported here to the commonly used generic clinical RBE of 1.1, which assumes no dependence on depth or on dose. Our proximal RBEs obviously avoid the depth-related increase in RBE and for doses of 4 Gy or more, the low-dose increase in RBE is also minimized, as shown in this article. Thus the proximal RBE at a 4 Gy dose of 1.10 +/- 0.01, quoted above, represents an interesting point of congruence with the clinical RBE for conditions where it could reasonably be expected in the measurements reported here. The depth dependence of RBE reported here is consistent with the majority of measurements, both in vitro and in vivo, by other investigators. The dose dependence of RBE, on the other hand, is tissue specific but has not yet been demonstrated for protons by RBE values in late-responding normal tissue systems. This indicates a need for additional RBE determination as function of dose, especially in late-responding tissues. (C) 2015 by Radiation Research Society C1 [Wouters, Bradly G.] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Radiat Oncol & Med Biophys, Toronto, ON, Canada. [Skarsgard, Lloyd D.; Wong, Michelle; Durand, Ralph E.; Nielson, Deanna] British Columbia Canc Res Ctr, Dept Med Biophys, Vancouver, BC V5Z 1L3, Canada. [Gerweck, Leo E.; Bussiere, Marc R.; Biggs, Peter; Paganetti, Harald; Suit, Herman D.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Gerweck, Leo E.; Bussiere, Marc R.; Biggs, Peter; Paganetti, Harald; Suit, Herman D.] Harvard Univ, Sch Med, Boston, MA USA. [Carabe-Fernandez, Alejandro] Univ Penn, Roberts Proton Therapy Ctr, Dept Radiat Oncol, Philadelphia, PA 19104 USA. [Wagner, Miles] Harvard Univ, Dept Phys, Boston, MA 02115 USA. RP Wouters, BG (reprint author), MaRS Discovery Dist, Toronto Med Discovery Tower MaRS,12th Floor, Toronto, ON M5G 1L7, Canada. EM bradwouters@gmail.com FU National Cancer Institute of Canada; Canadian Cancer Society; Ontario Ministry of Health and Long Term Care (OMOHLTC); Ontario Institute for Cancer Research FX The skillful technical assistance of Denise McDougal and Adriana Vinczan is gratefully acknowledged. This work was supported by the National Cancer Institute of Canada with funds from the Canadian Cancer Society, the Ontario Ministry of Health and Long Term Care (OMOHLTC) and the Ontario Institute for Cancer Research. The views expressed do not necessarily reflect those of the OMOHLTC. NR 65 TC 9 Z9 9 U1 0 U2 7 PU RADIATION RESEARCH SOC PI LAWRENCE PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA SN 0033-7587 EI 1938-5404 J9 RADIAT RES JI Radiat. Res. PD FEB PY 2015 VL 183 IS 2 BP 174 EP 187 DI 10.1667/RR13795.1 PG 14 WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology, Nuclear Medicine & Medical Imaging GA CC0KL UT WOS:000350024200004 PM 25587741 ER PT J AU Bush, NE Dobscha, SK Crumpton, R Denneson, LM Hoffman, JE Crain, A Cromer, R Kinn, JT AF Bush, Nigel E. Dobscha, Steven K. Crumpton, Rosa Denneson, Lauren M. Hoffman, Julia E. Crain, Aysha Cromer, Risa Kinn, Julie T. TI A Virtual Hope Box Smartphone App as an Accessory to Therapy: Proof-of-Concept in a Clinical Sample of Veterans SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID COGNITIVE THERAPY; SUICIDE ATTEMPTS; INTERVENTION; PREVENTION; INJURY AB A Hope Box is a therapeutic tool employed by clinicians with patients who are having difficulty coping with negative thoughts and stress, including patients who may be at risk of suicide or nonsuicidal self-harm. We conducted a proof-of-concept test of a Virtual Hope Box (VHB)a smartphone app that delivers patient-tailored coping tools. Compared with a conventional hope box integrated into VA behavioral health treatment, high-risk patients and their clinicians used the VHB more regularly and found the VHB beneficial, useful, easy to set up, and said they were likely to use the VHB in the future and recommend the VHB to peers. C1 [Bush, Nigel E.; Crumpton, Rosa; Kinn, Julie T.] US Dept Def, Natl Ctr Telehlth & Technol T2, Tacoma, WA USA. [Dobscha, Steven K.; Denneson, Lauren M.; Crain, Aysha; Cromer, Risa] Portland VA Med Ctr, Portland Ctr Improve Vet Involvement Care CIVIC, Portland, OR USA. [Dobscha, Steven K.; Denneson, Lauren M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Hoffman, Julia E.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Palo Alto, CA USA. RP Bush, NE (reprint author), Natl Ctr Telehlth & Technol T2, OMAMC, Joint Base Lewis McChord, 9933 West Hayes St, Tacoma, WA 98431 USA. EM nigel.e.bush.civ@mail.mil FU Military Suicide Research Consortium (MSRC); Office of the Assistant Secretary of Defense for Health Affairs [W81XWH-10-2-0178] FX The views expressed are those of the authors and do not reflect the official policy of the Department of Defense or the U.S. Government. This work was in part supported by the Military Suicide Research Consortium (MSRC), an effort supported by the Office of the Assistant Secretary of Defense for Health Affairs under Award No. W81XWH-10-2-0178. Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the MSRC or the Department of Defense. NR 18 TC 4 Z9 5 U1 3 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD FEB PY 2015 VL 45 IS 1 BP 1 EP 9 DI 10.1111/sltb.12103 PG 9 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA CC0BA UT WOS:000349998700001 PM 24828126 ER PT J AU Sidhwa, F Itani, KMF AF Sidhwa, Feroze Itani, Kamal M. F. TI Skin Preparation Before Surgery: Options and Evidence SO SURGICAL INFECTIONS LA English DT Review ID SURGICAL SITE INFECTIONS; PROSPECTIVE RANDOMIZED-TRIAL; CARE-ASSOCIATED INFECTIONS; POVIDONE-IODINE; CHLORHEXIDINE-ALCOHOL; WOUND CONTAMINATION; ANTISEPSIS; PREVENTION; HEALTH; IMPACT AB Background: Despite many advances in surgical asepsis, surgical site infection (SSI) remains a challenging and costly problem. Decontamination of the skin with an antiseptic agent is standard practice before any trans-cutaneous invasive procedure, but the antiseptic agent of choice to best reduce the risk of SSI remains controversial. Methods: Review of relevant literature. Results: Many randomized controlled trials (RCTs) have evaluated chlorhexidine-based and iodine-based preparation solutions, with and without an alcohol component. Most of these trials are underpowered to detect differences in SSI rates. The largest modern RCT showed that a chlorhexidine-isopropyl alcohol preparation reduced the risk of SSI substantially compared with a povidone-iodine preparation without alcohol in clean-contaminated surgery. Many smaller RCTs have shown that chlorhexidine-isopropyl alcohol is superior to povidone-iodine plus isopropyl alcohol or iodine povacrylex plus isopropyl alcohol in pre-operative skin decontamination; whether or not this translates into lower SSI rates is unknown. A mixed treatment comparison of 10 RCTs concluded that alcohol-based preparations have a 98% probability of reducing the risk of SSI more effectively than aqueous-based preparations. Non-randomized observational studies have generally found no difference in SSI rates among various skin antiseptic preparations. Conclusions: Alcohol-based agents are likely superior to aqueous agents. Chlorhexidine may decrease SSI rates compared with povidone-iodine, and chlorhexidine-isopropyl alcohol likely offers better skin decontamination before clean surgery than povidone-iodine plus isopropyl alcohol or iodine povacrylex plus isopropyl alcohol. The quality of the available data is moderate. Rigorous, well-powered RCTs with appropriate treatment comparisons are needed to establish the optimal and most cost-effective pre-operative skin preparation in various operations and wound classifications. C1 [Sidhwa, Feroze; Itani, Kamal M. F.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Itani, Kamal M. F.] VA Boston Healthcare Syst, Dept Surg, West Roxbury, MA 02132 USA. [Itani, Kamal M. F.] Harvard Univ, Sch Med, Boston, MA USA. RP Itani, KMF (reprint author), VA Boston Healthcare Syst, Dept Surg, 1400 VFW Pkwy, West Roxbury, MA 02132 USA. EM kitani@va.gov FU Merck; Sanofi; Dr. Reddy's laboratories FX Dr. Feroze Sidhwa has no conflicts of interest. Dr. Kamal M.F. Itani has received research funds to his institution from Merck, Sanofi, and Dr. Reddy's laboratories. He was a research consultant for Irrimax. NR 51 TC 6 Z9 7 U1 3 U2 13 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-2964 EI 1557-8674 J9 SURG INFECT JI Surg. Infect. PD FEB 1 PY 2015 VL 16 IS 1 BP 14 EP 23 DI 10.1089/sur.2015.010 PG 10 WC Infectious Diseases; Surgery SC Infectious Diseases; Surgery GA CD0GN UT WOS:000350748800002 PM 25761076 ER PT J AU Canavan, M Smyth, A Bosch, J Jensen, M McGrath, ER Mulkerrin, EC O'Donnell, MJ AF Canavan, Michelle Smyth, Andrew Bosch, Jackie Jensen, Mette McGrath, Emer R. Mulkerrin, Eamon C. O'Donnell, Martin J. TI Does Lowering Blood Pressure With Antihypertensive Therapy Preserve Independence in Activities of Daily Living? A Systematic Review SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE activities of daily living; antihypertensive therapy; blood pressure; functional impairment; hypertension; older adults ID QUALITY-OF-LIFE; ISOLATED SYSTOLIC HYPERTENSION; SUBCLINICAL CARDIOVASCULAR-DISEASE; SECONDARY PREVENTION; OLDER PERSONS; RISK-FACTORS; ORTHOSTATIC HYPOTENSION; FUNCTIONAL OUTCOMES; ELDERLY PROGRAM; CLINICAL-TRIALS AB BACKGROUND Hypertension is a major risk factor for functional impairment. Dependence is an important related outcome for older adults, but outcomes in hypertension trials appear to focus primarily on major vascular events. This systematic review had 2 objectives: (i) to determine the proportion of randomized controlled trials (RCTs) evaluating antihypertensive therapies that reported a measure of a person's ability to carry out activities of daily living (ADL) and (ii) to evaluate the effect of blood pressure (BP)-lowering therapies on ability to carry out ADL compared with control therapy. METHODS We searched electronic databases, reference lists of relevant meta-analyses, and hypertension guidelines for clinical trials of adults with hypertension/prehypertension that were randomized to antihypertensive therapy or control for >= 1 year. RESULTS Of 2,924 citations screened, there were 93 eligible RCTs. One (1%) reported ADL as a primary outcome measure. Nine (10%) reported ADL as a secondary outcome. Of these, 6 used validated ADL scales, whereas 4 measured ADL within quality-of-life scales. Six trials with duration of > 1 year (n = 12,663) were amenable to meta-analysis, despite use of different ADL scales. The odds of having difficulty with ADL was reduced by BP-lowering therapy compared with control therapy (odds ratio = 0.84; 95% confidence interval = 0.77-0.92; I-2 = 0%). CONCLUSIONS We identified few trials of antihypertensive therapy that reported ADL as an outcome measure, with heterogeneity in scales used. Antihypertensive therapy was associated with a lower risk of ADL impairment compared with control therapy. RCTs evaluating the effect of antihypertensive drugs on ADL in older adults with mild hypertension are required. C1 [Canavan, Michelle; Mulkerrin, Eamon C.; O'Donnell, Martin J.] Univ Hosp Galway, Dept Med Elderly, Galway, Ireland. [Canavan, Michelle; Smyth, Andrew; McGrath, Emer R.; O'Donnell, Martin J.] Natl Univ Ireland, HRB Clin Res Facil, Galway, Ireland. [Smyth, Andrew; Bosch, Jackie; O'Donnell, Martin J.] Populat Hlth Res Inst, Hamilton, ON, Canada. [Bosch, Jackie] McMaster Univ, Sch Rehabil Sci, Hamilton, ON, Canada. [Jensen, Mette] Sligo Reg Hosp, Sligo, Ireland. [McGrath, Emer R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Canavan, M (reprint author), Univ Hosp Galway, Dept Med Elderly, Galway, Ireland. EM canavanmichelle@gmail.com OI O'Donnell, Martin/0000-0002-7347-7761; McGrath, Emer/0000-0002-3589-2964 NR 43 TC 1 Z9 1 U1 2 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0895-7061 EI 1941-7225 J9 AM J HYPERTENS JI Am. J. Hypertens. PD FEB PY 2015 VL 28 IS 2 BP 273 EP 279 DI 10.1093/ajh/hpu131 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CB3WF UT WOS:000349559300016 PM 25156624 ER PT J AU Phillips, ML Chase, HW Sheline, YI Etkin, A Almeida, JRC Deckersbach, T Trivedi, MH AF Phillips, Mary L. Chase, Henry W. Sheline, Yvette I. Etkin, Amit Almeida, Jorge R. C. Deckersbach, Thilo Trivedi, Madhukar H. TI Identifying Predictors, Moderators, and Mediators of Antidepressant Response in Major Depressive Disorder: Neuroimaging Approaches SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Review ID FUNCTIONAL MAGNETIC-RESONANCE; CATECHOL-O-METHYLTRANSFERASE; SEROTONIN TRANSPORTER GENES; PREFRONTAL CORTEX ACTIVITY; ANTERIOR CINGULATE CORTEX; MOOD REGULATING CIRCUIT; WHITE-MATTER INTEGRITY; SAD FACIAL EXPRESSIONS; BIPOLAR-DISORDER; REWARD ANTICIPATION AB Objective: Despite significant advances in neuroscience and treatment development, no widely accepted biomarkers are available to inform diagnostics or identify preferred treatments for individuals with major depressive disorder. Method: In this critical review, the authors examine the extent to which multimodal neuroimaging techniques can identify biomarkers reflecting key pathophysiologic processes in depression and whether such biomarkers may act as predictors, moderators, and mediators of treatment response that might facilitate development of personalized treatments based on a better understanding of these processes. Results: The authors first highlight the most consistent findings from neuroimaging studies using different techniques in depression, including structural and functional abnormalities in two parallel neural circuits: serotonergically modulated implicit emotion regulation circuitry, centered on the amygdala and different regions in the medial prefrontal cortex; and dopaminergically modulated reward neural circuitry, centered on the ventral striatum and medial prefrontal Cortex. They then describe key findings from the relatively small number of studies indicating that specific measures of regional function and; to a lesser extent, structure in these neural circuits predict treatment response in depression. Conclusions: Limitations of existing studies include small sample sizes, use of only one neuroimaging modality, and a focus on identifying predictors rather than moderators and mediators of differential treatment response. By addressing these limitations and, most importantly, capitalizing on the benefits of multimodal neuroimaging, future studies can yield moderators and mediators of treatment response in depression to facilitate significant improvements in shorter- and longer-term clinical and functional outcomes. C1 [Phillips, Mary L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. UT Southwestern Med Ctr, Dept Psychiat, Dallas, TX USA. RP Phillips, ML (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. EM phillipsml@upmc.edu FU NIMH [U01MH092221, U01MH092250]; Neosynch; Brain Resource; Depressive and Bipolar Disorder Alternative Treatment Foundation; International OCD Foundation; NARSAD; NIMH; Transportation Security Administration; Tufts University; Boston University; BrainCells; Catalan Agency for Health Technology Assessment and Research; Clintara; Massachusetts Medical Society; MGH Psychiatry Academy; National Association of Social Workers Massachusetts; NIDA; Oxford University Press; Systems Research and Applications Corporation; Agency for Healthcare Research and Quality; Cyberonics; Forest; Janssen; Medtronic; NIH; Northstar; Patient-Centered Outcomes Research Institute; Shire; Takeda; Corcept Therapeutics; Novartis; Pharmacia Upjohn; Predix Pharmaceuticals (Epix); Solvay FX Supported by NIMH grants U01MH092221 and U01MH092250.; Dr Sheline has received research support from Neosynch. Dr. Etkin has received research funding from Brain Resource. Dr. Deckersbach has received research support from the Depressive and Bipolar Disorder Alternative Treatment Foundation, the International OCD Foundation, NARSAD, NIMH, the Transportation Security Administration, and Tufts University; he has received honoraria, consultation fees, or royalties from Boston University, BrainCells, the Catalan Agency for Health Technology Assessment and Research, Clintara, the Massachusetts Medical Society, the MGH Psychiatry Academy, the National Association of Social Workers Massachusetts, NIDA, NIMH, Oxford University Press, Systems Research and Applications Corporation, and Tufts University; and he has participated in research funded by the Agency for Healthcare Research and Quality, Cyberonics, Forest, Janssen, Medtronic, NIDA, NIH, Northstar, the Patient-Centered Outcomes Research Institute, Shire, and Takeda. Dr. Trivedi has served as an adviser or consultant to Abbott, Abdi Ibrahim, Akzo (Organon), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb, Cephaton, Cerecor, Concert Pharmaceuticals, Eli Lilly, Evotec, Fabre Kramer Pharmaceuticals, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, Janssen Pharmaceutica Products, Johnson Er Johnson PRD, Libby, Lundbeck, Mead Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Naurex, Neuronetics, Otsuka, Pamlab, Parke-Davis, Pfizer, PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products, Sepracor, Shire Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus, and Wyeth-Ayerst Laboratories; he has received research support from the Agency for Healthcare Research and Quality, Corcept Therapeutics, Cyberonics, NARSAD, NIMH, NIDA, Novartis, Pharmacia & Upjohn, Predix Pharmaceuticals (Epix), and Solvay. The other authors report no financial relationships with commercial interests. NR 184 TC 36 Z9 39 U1 7 U2 34 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD FEB PY 2015 VL 172 IS 2 BP 124 EP 138 DI 10.1176/appi.ajp.2014.14010076 PG 15 WC Psychiatry SC Psychiatry GA CA5VG UT WOS:000348975300006 PM 25640931 ER PT J AU Amri, R Bordeianou, LG Sylla, P Berger, DL AF Amri, Ramzi Bordeianou, Liliana G. Sylla, Patricia Berger, David L. TI Colon cancer surgery following emergency presentation: effects on admission and stage-adjusted outcomes SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE Emergency surgery; Colon cancer; Survival; Disease-free survival; Pathology; Perioperative outcomes ID COLORECTAL-CANCER; SOCIOECONOMIC-STATUS; RECTAL-CANCER; HEALTH-CARE; SURVIVAL; DISPARITIES; IMPACT; CARCINOMA; PATHOLOGY; SMOKING AB BACKGROUND: Emergency presentation with colon cancer is intuitively related to advanced disease. We measured its effect on outcomes of surgically treated colon cancer. METHODS: A retrospective cohort of 1,071 surgical colon cancer patients (2004 to 2011), with 102 emergency cases requiring surgery within the index admission, was analyzed. RESULTS: Emergency patients required longer surgeries (median 141 vs 124 minutes; P = .04), longer median admissions (8% vs 5%; P < .001), more readmissions (12.7% vs 7.1%; P = .040), and perioperative mortality (7.8% vs.8%; P < .001). Surgical pathology displayed higher rates of node-positive disease (56.6% vs 38.6%; P < .001), extramural vascular invasion (39.6% vs 29.1%; P = .021), and metastatic disease (19.6% vs 8%; P < .001). Consequently, adjusting for staging, emergency presentations had considerably higher mortality (odds ratio = 2.07; P = .003) and shorter disease-free survival (hazard ratio = 1.39; P = .042). CONCLUSIONS: Emergency presentation is a stage-independent poor prognostic factor associated with aggressive tumor biology, resulting in longer surgeries and admissions, frequent readmissions, worsening outcomes, and increasing healthcare costs. (C) 2015 Elsevier Inc. All rights reserved. C1 [Berger, David L.] Massachusetts Gen Hosp, Div Gen & Gastrointestinal Surg, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Berger, DL (reprint author), Massachusetts Gen Hosp, Div Gen & Gastrointestinal Surg, Boston, MA 02114 USA. EM dberger@mgh.harvard.edu OI Amri, Ramzi/0000-0001-7416-6650 FU Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Research Resources); Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) [8UL1TR000170-05]; Harvard Catalyst, The Harvard Clinical and Translational Science Center (Harvard University); Dutch Cancer Society; Dutch Digestive Society; Amsterdam University Funds; Royal Netherlands Academy of Arts and Sciences; Fulbright Foundation FX This work was conducted with support from Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award 8UL1TR000170-05, and financial contributions from Harvard University and its affiliated academic healthcare centers). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University, and its affiliated academic healthcare centers, or the National Institutes of Health. This work was also supported in part by the Dutch Cancer Society, the Dutch Digestive Society, the Amsterdam University Funds, the Royal Netherlands Academy of Arts and Sciences, and the Fulbright Foundation. NR 32 TC 3 Z9 4 U1 1 U2 7 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 EI 1879-1883 J9 AM J SURG JI Am. J. Surg. PD FEB PY 2015 VL 209 IS 2 BP 246 EP 253 DI 10.1016/j.amjsurg.2014.07.014 PG 8 WC Surgery SC Surgery GA CB6EU UT WOS:000349720500005 PM 25457246 ER PT J AU Keuthen, NJ Tung, ES Reese, HE Raikes, J Lee, L Mansueto, CS AF Keuthen, Nancy J. Tung, Esther S. Reese, Hannah E. Raikes, Jennifer Lee, Leslie Mansueto, Charles S. TI Getting the word out: Cognitive-behavioral therapy for trichotillomania (hair-pulling disorder) and excoriation (skin-picking) disorder SO ANNALS OF CLINICAL PSYCHIATRY LA English DT Article AB BACKGROUND: To date, there has been no investigation of dissemination outcomes for cognitive-behavioral training programs for body-focused repetitive behaviors (BFRBs). METHODS: Sixty-three past participants of the Trichotillomania Learning Center (TLC) intensive professional training institutes completed an online survey assessing referral sources, skills utilization, and treatment outcomes before and after training. The intensive training focused on the treatment of trichotillomania (hair-pulling) disorder and excoriation (skin-picking) disorder using in-person or videotaped didactics, role playing, and case presentations with supervision upon request. RESULTS: Participants endorsed a greater number of referral sources and BFRB patients after attending training. Paired t tests indicated significant pre- to post-training increases in self-reported utilization of all individual cognitive-behavioral therapy (CBT) skills as well as overall mean skills usage (both P < .001). Changes after training in the reported percent of abstinent patients and mean reduction in symptom severity were also noted. CONCLUSIONS: The TLC intensive professional training institutes may be useful for disseminating CBT skills for the treatment of BFRBs, but additional research is warranted. C1 [Keuthen, Nancy J.; Tung, Esther S.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Reese, Hannah E.] Bowdoin Coll, Dept Psychol, Brunswick, ME 04011 USA. [Raikes, Jennifer; Lee, Leslie] Trichotillomania Learning Ctr Inc, Santa Cruz, CA USA. [Mansueto, Charles S.] Behav Therapy Ctr Greater Washington, Washington, DC USA. RP Keuthen, NJ (reprint author), Massachusetts Gen Hosp, OCD, 185 Cambridge St,Suite 2200, Boston, MA 02114 USA. EM nkeuthen@partners.org FU Trichotillomania Learning Center FX Ms. Tung and Dr. Reese report no financial or other relationship with any company whose products are mentioned in this article or with manufacturers of competing products. Ms. Raikes is the Executive Director and Ms. Lee is the Program Coordinator of the TLC. Dr. Keuthen currently receives research support from the Trichotillomania Learning Center. She has equity ownership in Johnson & Johnson, Merck & Co. Inc., and Pfizer, Inc. She receives royalties from New Harbinger Publications. She and Dr. Mansueto are members of the Scientific Advisory Boards of the Trichotillomania Learning Center and the International Obsessive-Compulsive Disorder Foundation. NR 4 TC 4 Z9 4 U1 3 U2 18 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 1040-1237 EI 1547-3325 J9 ANN CLIN PSYCHIATRY JI Ann. Clin. Psychiatry PD FEB PY 2015 VL 27 IS 1 BP 10 EP 15 PG 6 WC Psychiatry SC Psychiatry GA CB3FJ UT WOS:000349513300003 PM 25696776 ER PT J AU Salgado, R Denkert, C Demaria, S Sirtaine, N Klauschen, F Pruneri, G Wienert, S Van den Eynden, G Baehner, FL Penault-Llorca, F Perez, EA Thompson, EA Symmans, WF Richardson, AL Brock, J Criscitiello, C Bailey, H Ignatiadis, M Floris, G Sparano, J Kos, Z Nielsen, T Rimm, DL Allison, KH Reis, JS Loibl, S Sotiriou, C Viale, G Badve, S Adams, S Willard-Gallo, K Loi, S AF Salgado, R. Denkert, C. Demaria, S. Sirtaine, N. Klauschen, F. Pruneri, G. Wienert, S. Van den Eynden, G. Baehner, F. L. Penault-Llorca, F. Perez, E. A. Thompson, E. A. Symmans, W. F. Richardson, A. L. Brock, J. Criscitiello, C. Bailey, H. Ignatiadis, M. Floris, G. Sparano, J. Kos, Z. Nielsen, T. Rimm, D. L. Allison, K. H. Reis-Filho, J. S. Loibl, S. Sotiriou, C. Viale, G. Badve, S. Adams, S. Willard-Gallo, K. Loi, S. TI The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 SO ANNALS OF ONCOLOGY LA English DT Review DE tumor-infiltrating lymphocytes (TILs); breast cancer (BC); prognosis; prediction; clinical validity ID T-CELL INFILTRATION; NEOADJUVANT CHEMOTHERAPY; ESTROGEN-RECEPTOR; PREDICT RESPONSE; PROGNOSTIC-SIGNIFICANCE; IMMUNE CELLS; EXPRESSION; CARCINOMA; THERAPY; MICROENVIRONMENT AB Background: The morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of hematoxylin and eosin (H&E)-stained tumor sections. TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC. Design: A standardized methodology for evaluating TILs is now needed as a prerequisite for integrating this parameter in standard histopathological practice, in a research setting as well as in clinical trials. This article reviews current data on the clinical validity and utility of TILs in BC in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections, acknowledging the future potential of molecular/multiplexed approaches. Conclusions: The methodology provided is sufficiently detailed to offer a uniformly applied, pragmatic starting point and improve consistency and reproducibility in the measurement of TILs for future studies. C1 [Salgado, R.] Inst Jules Bordet, Breast Int Grp, Breast Canc Translat Res Lab, B-1000 Brussels, Belgium. [Salgado, R.] GZA, Dept Pathol, Antwerp, Belgium. [Salgado, R.] GZA, TCRU, Antwerp, Belgium. [Denkert, C.; Klauschen, F.; Wienert, S.] Charite, Inst Pathol, D-13353 Berlin, Germany. [Demaria, S.; Adams, S.] NYU, Sch Med, Perlmutter Canc Ctr, New York, NY USA. [Sirtaine, N.] Univ Libre Bruxelles, Inst Jules Bordet, Dept Pathol, Brussels, Belgium. [Pruneri, G.] IEO, Milan, Italy. [Pruneri, G.] Univ Milan, Milan, Italy. [Van den Eynden, G.] TCRU Hosp, Dept Pathol GZA, Antwerp, Belgium. [Van den Eynden, G.] CORE Antwerp Univ, Antwerp, Belgium. [Baehner, F. L.; Bailey, H.] Genom Hlth Inc, Redwood City, CA USA. [Baehner, F. L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Penault-Llorca, F.] Univ Auvergne, Jean Perrin Comprehens Canc Ctr, Clermont Ferrand Biopathol, Clermont Ferrand, France. [Perez, E. A.] Mayo Clin, Div Haematol Med Oncol, Jacksonville, FL USA. [Thompson, E. A.] Mayo Clin, Mayo Clin Comprehens Canc Ctr, Dept Canc Biol, Jacksonville, FL USA. [Symmans, W. F.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Boston, MA USA. [Richardson, A. L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Richardson, A. L.; Brock, J.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Brock, J.] Harvard Univ, Sch Med, Dept Canc Biol, Boston, MA USA. [Criscitiello, C.] Ist Europeo Oncol, Milan, Italy. [Ignatiadis, M.; Sotiriou, C.] Univ Libre Bruxelles, Inst Jules Bordet, Dept Med Oncol, Brussels, Belgium. [Floris, G.] Univ Hosp Leuven, Dept Pathol, Leuven, Belgium. [Sparano, J.] Albert Einstein Med Ctr, Dept Obstet & Gynecol & Womens Hlth, Dept Med, Bronx, NY USA. [Kos, Z.] Univ Toronto, Univ Hlth Network, Lab Med Program, Toronto, ON, Canada. [Nielsen, T.] Univ British Columbia, Genet Pathol Evaluat Ctr, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada. [Rimm, D. L.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA. [Allison, K. H.] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA. [Reis-Filho, J. S.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA. [Loibl, S.] German Breast Grp, Neu Isenburg, Germany. [Viale, G.] Univ Milan, Ist Europeo Oncol, Dept Pathol, Milan, Italy. [Badve, S.] Indiana Univ, Dept Pathol & Lab Med, Indianapolis, IN 46204 USA. [Willard-Gallo, K.] Univ Libre Bruxelles, Inst Jules Bordet, Mol Immunol Unit, Brussels, Belgium. [Loi, S.] Univ Melbourne, Peter MacCallum Canc Ctr, Div Res & Canc Med, Melbourne, Vic 8006, Australia. RP Loi, S (reprint author), Univ Melbourne, Peter MacCallum Canc Ctr, Div Res & Canc Med, Locked Bag 1,ABeckett St VIC, Melbourne, Vic 8006, Australia. EM sherene.loi@petermac.org RI Loi, Sherene/H-1979-2016; OI Denkert, Carsten/0000-0002-2249-0982 FU NCI NIH HHS [P30 CA016672] NR 51 TC 170 Z9 177 U1 17 U2 52 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2015 VL 26 IS 2 BP 259 EP 271 DI 10.1093/annonc/mdu450 PG 13 WC Oncology SC Oncology GA CB4PH UT WOS:000349609600003 PM 25214542 ER PT J AU Smith, MR Coleman, RE Klotz, L Pittman, K Milecki, P Ng, S Chi, KN Balakumaran, A Wei, R Wang, H Braun, A Fizazi, K AF Smith, M. R. Coleman, R. E. Klotz, L. Pittman, K. Milecki, P. Ng, S. Chi, K. N. Balakumaran, A. Wei, R. Wang, H. Braun, A. Fizazi, K. TI Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events SO ANNALS OF ONCOLOGY LA English DT Article DE denosumab; zoledronic acid; symptomatic skeletal events; skeletal-related events; prostate cancer; phase III ID QUALITY-OF-LIFE; BONE METASTASES; ZOLEDRONIC ACID; SOLID TUMORS; DOUBLE-BLIND; PHASE-3; RADIUM-223; TRIAL AB Background: In a phase III trial in patients with castration-resistant prostate cancer (CRPC) and bone metastases, denosumab was superior to zoledronic acid in reducing skeletal-related events (SREs; radiation to bone, pathologic fracture, surgery to bone, or spinal cord compression). This study reassessed the efficacy of denosumab using symptomatic skeletal events (SSEs) as a prespecified exploratory end point. Patients and methods: Patients with CRPC, no previous bisphosphonate exposure, and radiographic evidence of bone metastasis were randomized to subcutaneous denosumab 120 mg plus i. v. placebo every 4 weeks (Q4W), or i. v. zoledronic acid 4 mg plus subcutaneous placebo Q4W during the blinded treatment phase. SSEs were defined as radiation to bone, symptomatic pathologic fracture, surgery to bone, or symptomatic spinal cord compression. The relationship between SSE or SRE and time to moderate/severe pain was assessed using the Brief Pain Inventory Short Form. Results: Treatment with denosumab significantly reduced the risk of developing first SSE [HR, 0.78; 95% confidence interval (CI) 0.66-0.93; P = 0.005] and first and subsequent SSEs (rate ratio, 0.78; 95% CI 0.65-0.92; P = 0.004) compared with zoledronic acid. The treatment differences in the number of patients with SSEs or SREs were similar (n = 48 and n = 45, respectively). Among patients with no/mild pain at baseline, both SSEs and SREs were associated with moderate/ severe pain development (P < 0.0001). Fewer patients had skeletal complications, particularly fractures, when defined as SSE versus SRE. Conclusion: In patients with CRPC and bone metastases, denosumab reduced the risk of skeletal complications versus zoledronic acid regardless of whether the end point was defined as SSE or SRE. C1 [Smith, M. R.] Massachusetts Gen Hosp, Ctr Canc, Dept Hematol Oncol, Boston, MA 02114 USA. [Coleman, R. E.] Sheffield Canc Res Ctr, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England. [Klotz, L.] Sunnybrook & Womens Coll Hlth Sci Ctr, Div Urol, Toronto, ON, Canada. [Pittman, K.] Queen Elizabeth Hosp, Dept Med Oncol, Woodville, SA 5011, Australia. [Milecki, P.] Poznan Univ Med Sci, Dept Electroradiol, Poznan, Poland. [Milecki, P.] Wielkopolskie Ctr Onkol, Dept Radiotherapy, Poznan, Poland. [Ng, S.] St John God Hosp, Subiaco, WA, Australia. [Chi, K. N.] BC Canc Agcy, Dept Med Oncol, Vancouver, BC, Canada. [Balakumaran, A.; Braun, A.] Amgen Inc, Dept Hematol Oncol, Thousand Oaks, CA 91320 USA. [Wei, R.; Wang, H.] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA 91320 USA. [Fizazi, K.] Univ Paris 11, Inst Gustave Roussy, Dept Med Oncol, Paris, France. RP Smith, MR (reprint author), Massachusetts Gen Hosp, Ctr Canc, Dept Hematol Oncol, Yawkey 7030,55 Fruit St, Boston, MA 02114 USA. EM smith.matthew@mgh.harvard.edu FU NCI NIH HHS [K24 CA121990] NR 20 TC 30 Z9 30 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2015 VL 26 IS 2 BP 368 EP 374 DI 10.1093/annonc/mdu519 PG 8 WC Oncology SC Oncology GA CB4PH UT WOS:000349609600017 PM 25425475 ER PT J AU Mahal, BA Inverso, G Aizer, AA Ziehr, DR Hyatt, AS Choueiri, TK Hoffman, KE Hu, JC Beard, CJ D'Amico, AV Martin, NE Orio, PF Trinh, QD Nguyen, PL AF Mahal, B. A. Inverso, G. Aizer, A. A. Ziehr, D. R. Hyatt, A. S. Choueiri, T. K. Hoffman, K. E. Hu, J. C. Beard, C. J. D'Amico, A. V. Martin, N. E. Orio, P. F., III Trinh, Q. -D. Nguyen, P. L. TI Incidence and determinants of 1-month mortality after cancer-directed surgery SO ANNALS OF ONCOLOGY LA English DT Article DE surgery; mortality rate; outcomes research; health policy; socioeconomic disparities; SEER program ID SURGICAL MORTALITY; UNITED-STATES; RACIAL DISPARITIES; OUTCOMES; QUALITY; VOLUME; RATES AB Background: Death within 1 month of surgery is considered treatment related and serves as an important health care quality metric. We sought to identify the incidence of and factors associated with 1-month mortality after cancer-directed surgery. Patients and methods: We used the Surveillance, Epidemiology and End Results Program to study a cohort of 1 110 236 patients diagnosed from 2004 to 2011 with cancers that are among the 10 most common or most fatal who received cancer-directed surgery. Multivariable logistic regression analyses were used to identify factors associated with 1-month mortality after cancer-directed surgery. Results: A total of 53 498 patients (4.8%) died within 1 month of cancer-directed surgery. Patients who were married, insured, or who had a top 50th percentile income or educational status had lower odds of 1-month mortality from cancer-directed surgery {[adjusted odds ratio (AOR) 0.80; 95% confidence interval (CI) 0.79-0.82; P < 0.001], (AOR 0.88; 95% CI 0.82-0.94; P < 0.001), (AOR 0.95; 95% CI 0.93-0.97; P < 0.001), and (AOR 0.98; 95% CI 0.96-0.99; P = 0.043), respectively}. Patients who were non-white minority, male, or older (per year increase), or who had advanced tumor stage 4 disease all had a higher risk of 1-month mortality after cancer-directed surgery, with AORs of 1.13 (95% CI 1.11-1.15), P < 0.001; 1.11 (95% CI 1.08-1.13), P < 0.001; 1.02 (95% 1.02-1.03), P < 0.001; and 1.89 (95% CI 1.82-1.95), P < 0.001 respectively. Conclusions: Unmarried, uninsured, non-white, male, older, less educated, and poorer patients were all at a significantly higher risk for death within 1 month of cancer-directed surgery. Efforts to reduce 1-month surgical mortality and eliminate sociodemographic disparities in this adverse outcome could significantly improve survival among patients with cancer. C1 [Mahal, B. A.; Ziehr, D. R.] Harvard Univ, Sch Med, Dept Med Oncol, Boston, MA 02115 USA. [Inverso, G.] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. [Aizer, A. A.; Hyatt, A. S.; Beard, C. J.; D'Amico, A. V.; Martin, N. E.; Orio, P. F., III; Nguyen, P. L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Choueiri, T. K.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Choueiri, T. K.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. [Hoffman, K. E.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA. [Hu, J. C.] Univ Calif Los Angeles, Med Ctr, Dept Urol, Los Angeles, CA 90024 USA. [Trinh, Q. -D.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Urol, Boston, MA 02115 USA. RP Nguyen, PL (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. EM pnguyen@lroc.harvard.edu RI Martin, Neil/E-2193-2014 OI Martin, Neil/0000-0002-8164-8516 FU NCI NIH HHS [P30 CA016672] NR 21 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2015 VL 26 IS 2 BP 399 EP 406 DI 10.1093/annonc/mdu534 PG 9 WC Oncology SC Oncology GA CB4PH UT WOS:000349609600022 PM 25430935 ER PT J AU Whelan, JS Bielack, SS Marina, N Smeland, S Jovic, G Hook, JM Krailo, M Anninga, J Butterfass-Bahloul, T Bohling, T Calaminus, G Capra, M Deffenbaugh, C Dhooge, C Eriksson, M Flanagan, AM Gelderblom, H Goorin, A Gorlick, R Gosheger, G Grimer, RJ Hall, KS Helmke, K Hogendoorn, PCW Jundt, G Kager, L Kuehne, T Lau, CC Letson, GD Meyer, J Meyers, PA Morris, C Mottl, H Nadel, H Nagarajan, R Randall, RL Schomberg, P Schwarz, R Teot, LA Sydes, MR Bernstein, M AF Whelan, J. S. Bielack, S. S. Marina, N. Smeland, S. Jovic, G. Hook, J. M. Krailo, M. Anninga, J. Butterfass-Bahloul, T. Bohling, T. Calaminus, G. Capra, M. Deffenbaugh, C. Dhooge, C. Eriksson, M. Flanagan, A. M. Gelderblom, H. Goorin, A. Gorlick, R. Gosheger, G. Grimer, R. J. Hall, K. S. Helmke, K. Hogendoorn, P. C. W. Jundt, G. Kager, L. Kuehne, T. Lau, C. C. Letson, G. D. Meyer, J. Meyers, P. A. Morris, C. Mottl, H. Nadel, H. Nagarajan, R. Randall, R. L. Schomberg, P. Schwarz, R. Teot, L. A. Sydes, M. R. Bernstein, M. CA EURAMOS Collaborators TI EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment SO ANNALS OF ONCOLOGY LA English DT Article DE osteosarcoma; randomised controlled trial; trial conduct; international collaboration ID HIGH-DOSE METHOTREXATE; QUALITY-OF-LIFE; SCANDINAVIAN-SARCOMA-GROUP; NEOADJUVANT CHEMOTHERAPY; PEDIATRIC-ONCOLOGY; PROGNOSTIC-FACTORS; CLINICAL-TRIALS; YOUNG-ADULTS; IFOSFAMIDE; CANCER AB Background: Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response. Patients and methods: Patients with resectable osteosarcoma aged <= 40 years were treated with the MAP regimen, comprising pre-operatively of two 5-week cycles of cisplatin 120 mg/m(2), doxorubicin 75mg/m(2), methotrexate 12 g/m(2) x 2 (MAP) and post-operatively two further cycles of MAP and two cycles of just MA. Patients were randomised after surgery. Those with >= 10% viable tumour in the resected specimen received MAP or MAP with ifosfamide and etoposide. Those with < 10% viable tumour were allocated to MAP or MAP followed by pegylated interferon. Longitudinal evaluation of quality of life was undertaken. Results: Recruitment was completed to the largest osteosarcoma study to date in 75 months. Commencing March 2005, 2260 patients were registered from 326 centres across 17 countries. About 1334 of 2260 registered patients (59%) were randomised. Pre-operative chemotherapy was completed according to protocol in 94%. Grade 3-4 neutropenia affected 83% of cycles and 59% were complicated by infection. There were three (0.13%) deaths related to pre-operative chemotherapy. At definitive surgery, 50% of patients had at least 90% necrosis in the resected specimen. Conclusions: New models of collaboration are required to successfully conduct trials to improve outcomes of patients with rare cancers; EURAMOS-1 demonstrates achievability. Considerable regulatory, financial and operational challenges must be overcome to develop similar studies in the future. The trial is registered as NCT00134030 and ISRCTN 67613327. C1 [Whelan, J. S.] Univ Coll London Hosp, Dept Oncol, London, England. [Bielack, S. S.] Olga Hosp, Klinikum Stuttgart, Cooperat Osteosarcoma Study Grp COSS, Stuttgart, Germany. [Marina, N.] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA. [Smeland, S.] Oslo Univ Hosp, Div Canc Surg & Transplantat, Oslo, Norway. [Smeland, S.] Oslo Univ Hosp, Scandinavian Sarcoma Grp, Oslo, Norway. [Smeland, S.] Univ Oslo, Inst Clin Med, Oslo, Norway. [Jovic, G.; Hook, J. M.; Sydes, M. R.] UCL, MRC, Clin Trials Unit, London, England. [Krailo, M.] Childrens Oncol Grp, Arcadia, CA USA. [Anninga, J.; Gelderblom, H.; Hogendoorn, P. C. W.] Leiden Univ, Med Ctr, Dept Pediat & Med Oncol, Leiden, Netherlands. [Butterfass-Bahloul, T.] Univ Hosp Munster, Ctr Clin Trials, Munster, Germany. [Bohling, T.] Univ Helsinki, Helsinki, Finland. [Bohling, T.] HUSLAB, Helsinki, Finland. [Calaminus, G.] Univ Hosp Muenster, Munster, Germany. [Capra, M.] Our Ladys Childrens Hosp, Dublin, Ireland. [Deffenbaugh, C.] Lucile Salter Packard Childrens Hosp Stanford, Palo Alto, CA USA. [Dhooge, C.] Univ Hosp Ghent, Ghent, Belgium. [Eriksson, M.] Lund Univ, Skane Univ Hosp, Lund, Sweden. [Flanagan, A. M.] Royal Natl Orthopaed Hosp, Stanmore HA7 4LP, Middx, England. [Flanagan, A. M.] UCL, Canc Inst, London, England. [Goorin, A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Gorlick, R.] Montefiore Med Ctr, Sect Pediat Hematol Oncol, Bronx, NY 10467 USA. [Gosheger, G.] Univ Hosp Munster, Dept Gen Orthoped & Tumor Orthoped, Munster, Germany. [Grimer, R. J.] Royal Orthopaed Hosp, Birmingham B31 2AP, W Midlands, England. [Hall, K. S.] Norwegian Radium Hosp, Oslo Univ Hosp, Scandinavian Sarcoma Grp, Dept Oncol, Oslo, Norway. [Helmke, K.] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Radiol, Hamburg, Germany. [Jundt, G.] Univ Basel Hosp, Inst Pathol, Bone Tumor Reference Ctr, CH-4031 Basel, Switzerland. [Kager, L.] St Anna Childrens Hosp, A-1090 Vienna, Austria. [Kuehne, T.] Univ Childrens Hosp Basel, Basel, Switzerland. [Lau, C. C.] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA. [Letson, G. D.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Meyer, J.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA. [Meyers, P. A.; Morris, C.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Morris, C.] Johns Hopkins, Orthoped Surg, Baltimore, MD USA. [Mottl, H.] Univ Hosp, Dept Pediat Hematol Oncol, Prague, Czech Republic. [Nadel, H.] Univ British Columbia, British Columbia Childrens Hosp, Vancouver, BC V5Z 1M9, Canada. [Nagarajan, R.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Randall, R. L.] Univ Utah, Primary Childrens Hosp, Salt Lake City, UT USA. [Randall, R. L.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Schomberg, P.] Mayo Clin, Rochester, MN USA. [Schwarz, R.] Med Ctr Hamburg Eppendorf, Dept Radiat Oncol, Hamburg, Germany. [Teot, L. A.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA. [Bernstein, M.] Dalhousie Univ, IWK Hlth Ctr, Halifax, NS, Canada. RP Sydes, MR (reprint author), UCL, MRC, Clin Trials Unit, London, England. EM m.sydes@ucl.ac.uk RI Hogendoorn, Pancras/H-5859-2015; OI Meyers, Paul/0000-0001-6146-6101; Hogendoorn, Pancras/0000-0002-1513-8104; Sydes, Matthew/0000-0002-9323-1371 FU Medical Research Council [MC_EX_G0400248, MC_EX_UU_G0400248, MC_UU_12023/11]; NCI NIH HHS [U10 CA098543, U10 CA180899] NR 28 TC 43 Z9 43 U1 0 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2015 VL 26 IS 2 BP 407 EP 414 DI 10.1093/annonc/mdu526 PG 8 WC Oncology SC Oncology GA CB4PH UT WOS:000349609600023 PM 25421877 ER PT J AU Menzies, AM Ashworth, MT Swann, S Kefford, RF Flaherty, K Weber, J Infante, JR Kim, KB Gonzalez, R Hamid, O Schuchter, L Cebon, J Sosman, JA Little, S Sun, P Aktan, G Ouellet, D Jin, F Long, GV Daud, A AF Menzies, A. M. Ashworth, M. T. Swann, S. Kefford, R. F. Flaherty, K. Weber, J. Infante, J. R. Kim, K. B. Gonzalez, R. Hamid, O. Schuchter, L. Cebon, J. Sosman, J. A. Little, S. Sun, P. Aktan, G. Ouellet, D. Jin, F. Long, G. V. Daud, A. TI Characteristics of pyrexia in BRAF(V600E/K) metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial SO ANNALS OF ONCOLOGY LA English DT Article DE melanoma; BRAF; dabrafenib; trametinib; pyrexia; fever ID DOSE-ESCALATION TRIAL; MEK INHIBITION; IMPROVED SURVIVAL; COMBINED BRAF; SOLID TUMORS; OPEN-LABEL; MULTICENTER; VEMURAFENIB AB Background: Pyrexia is a frequent adverse event with combined dabrafenib and trametinib therapy (CombiDT), but little is known of its clinical associations, etiology, or appropriate management. Patients and methods: All patients on the BRF133220 phase I/II trial of CombiDT treated at the standard dose (150/2) were included for assessment of pyrexia (n = 201). BRAF and MEK inhibitor-naive patients (n = 117) were included for efficacy analyses. Pyrexia was defined as temperature >= 38 degrees C (>= 100.4 degrees F) or related symptoms. Results: Fifty-nine percent of patients developed pyrexia during treatment, 24% of which had pyrexia symptoms without a recorded elevation in body temperature. Pyrexia was grade 2+ in 60% of pyrexia patients. Median time to onset of first pyrexia was 19 days, with a median duration of 9 days. Pyrexia patients had a median of two pyrexia events, but 21% had three or more events. Various pyrexia management approaches were conducted in this study. A trend was observed between dabrafenib and hydroxy-dabrafenib exposure and pyrexia. No baseline clinical characteristics predicted pyrexia, and pyrexia was not statistically significantly associated with treatment outcome. Conclusions: Pyrexia is a frequent and recurrent toxicity with CombiDT treatment. No baseline features predict pyrexia, and it is not associated with clinical outcome. Dabrafenib and metabolite exposure may contribute to the etiology of pyrexia. The optimal secondary prophylaxis for pyrexia is best studied in a prospective trial. C1 [Menzies, A. M.; Kefford, R. F.; Long, G. V.] Melanoma Inst Australia, Sydney, NSW, Australia. [Menzies, A. M.; Kefford, R. F.; Long, G. V.] Univ Sydney, Sydney, NSW 2006, Australia. [Ashworth, M. T.; Daud, A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Swann, S.; Little, S.; Sun, P.; Aktan, G.; Ouellet, D.; Jin, F.] GlaxoSmithKline, Clin Stat, Collegeville, PA USA. [Kefford, R. F.] Univ Sydney, Westmead Hosp, Sydney, NSW 2006, Australia. [Kefford, R. F.; Long, G. V.] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia. [Flaherty, K.] Massachusetts Gen Hosp Ctr, Boston, MA USA. [Weber, J.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Cutaneous Oncol, Tampa, FL 33682 USA. [Infante, J. R.] Sarah Cannon Res Inst Tennessee Oncol PLLC, Nashville, TN USA. [Kim, K. B.] Calif Pacific Med Ctr, San Francisco, CA USA. [Gonzalez, R.] Univ Colorado, Ctr Canc, Dept Med Oncol, Aurora, CO USA. [Hamid, O.] Angeles Clin & Res Inst, Dept Oncol, Santa Monica, CA USA. [Schuchter, L.] Univ Penn, Penn Med, Philadelphia, PA 19104 USA. [Cebon, J.] Ludwig Inst Canc Res, Oncol Unit, Heidelberg, Vic, Australia. [Sosman, J. A.] Vanderbilt Univ, Med Ctr, Dept Oncol, Nashville, TN USA. RP Menzies, AM (reprint author), Melanoma Inst Australia, 40 Rocklands Rd, Sydney, NSW 2060, Australia. EM alexander.menzies@sydney.edu.au NR 20 TC 14 Z9 14 U1 0 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2015 VL 26 IS 2 BP 415 EP 421 DI 10.1093/annonc/mdu529 PG 7 WC Oncology SC Oncology GA CB4PH UT WOS:000349609600024 PM 25411413 ER PT J AU Lee, P Murphy, B Miller, R Menon, V Banik, NL Giglio, P Lindhorst, SM Varma, AK Vandergrift, WA Patel, SJ Das, A AF Lee, Philip Murphy, Ben Miller, Rickey Menon, Vivek Banik, Naren L. Giglio, Pierre Lindhorst, Scott M. Varma, Abhay K. Vandergrift, William A., III Patel, Sunil J. Das, Arabinda TI Mechanisms and Clinical Significance of Histone Deacetylase Inhibitors: Epigenetic Glioblastoma Therapy SO ANTICANCER RESEARCH LA English DT Review DE Clinical trials; epigenetics; glioblastoma; histone deacetylase inhibitor; preclinical trials; review ID CEREBROSPINAL-FLUID PHARMACOKINETICS; HUMAN GLIOMA-CELLS; PHASE-II TRIAL; HDAC INHIBITORS; VALPROIC ACID; IN-VIVO; QUISINOSTAT JNJ-26481585; NONHUMAN-PRIMATES; CANCER-TREATMENT; UP-REGULATION AB Glioblastoma is the most common and deadliest of malignant primary brain tumors (Grade IV astrocytoma) in adults. Current standard treatments have been improving but patient prognosis still remains unacceptably devastating. Glioblastoma recurrence is linked to epigenetic mechanisms and cellular pathways. Thus, greater knowledge of the cellular, genetic and epigenetic origin of glioblastoma is the key for advancing glioblastoma treatment. One rapidly growing field of treatment, epigenetic modifiers; histone deacetylase inhibitors (HDACis), has now shown much promise for improving patient outcomes through regulation of the acetylation states of histone proteins (a form of epigenetic modulation) and other non-histone protein targets. HDAC inhibitors have been shown, in a pre-clinical setting, to be effective anticancer agents via multiple mechanisms, by up-regulating expression of tumor suppressor genes, inhibiting oncogenes, inhibiting tumor angiogenesis and up-regulating the immune system. There are many HDAC inhibitors that are currently in pre-clinical and clinical stages of investigation for various types of cancers. This review will explain the theory of epigenetic cancer therapy, identify HDAC inhibitors that are being investigated for glioblastoma therapy, explain the mechanisms of therapeutic effects as demonstrated by pre-clinical and clinical studies and describe the current status of development of these drugs as they pertain to glioblastoma therapy. C1 [Lee, Philip; Murphy, Ben; Miller, Rickey; Menon, Vivek; Banik, Naren L.; Giglio, Pierre; Lindhorst, Scott M.; Varma, Abhay K.; Vandergrift, William A., III; Patel, Sunil J.; Das, Arabinda] Med Univ S Carolina, Dept Neurol & Neurosurg, Charleston, SC 29425 USA. [Lee, Philip; Murphy, Ben; Miller, Rickey; Menon, Vivek; Banik, Naren L.; Giglio, Pierre; Lindhorst, Scott M.; Varma, Abhay K.; Vandergrift, William A., III; Patel, Sunil J.; Das, Arabinda] Med Univ S Carolina, MUSC Brain & Spine Tumor Program, Charleston, SC 29425 USA. [Banik, Naren L.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Giglio, Pierre] Ohio State Univ, Wexner Med Coll, Dept Neurol Surg, Columbus, OH 43210 USA. RP Das, A (reprint author), Med Univ S Carolina, Dept Neurol & Neurosurg, Charleston, SC 29425 USA. EM dasa@musc.edu FU Office of Research and Development; Department of Veterans Affairs [101BX001262, SC SCIRF-11-002]; Jerry Zucker Fund for Brain Tumor Research at the MUSC Foundation; American Brain Tumor Association Medical Student Summer Fellowship in Honor of Paul Fabri; [NS-38146]; [NS-41088] FX Completion of this investigation was made possible in part by the grants NS-38146, NS-41088. This work in part was supported by a merit award from the Office of Research and Development, Department of Veterans Affairs (101BX001262) and SC SCIRF-11-002), the Jerry Zucker Fund for Brain Tumor Research at the MUSC Foundation and the American Brain Tumor Association Medical Student Summer Fellowship in Honor of Paul Fabri. We thank the Medical University of South Carolina, Department of Neurosurgery and College of Medicine, for assistance. We appreciate consultation for illustration by Lane Brown. NR 77 TC 10 Z9 10 U1 2 U2 13 PU INT INST ANTICANCER RESEARCH PI ATHENS PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE SN 0250-7005 EI 1791-7530 J9 ANTICANCER RES JI Anticancer Res. PD FEB PY 2015 VL 35 IS 2 BP 615 EP 625 PG 11 WC Oncology SC Oncology GA CB4LG UT WOS:000349598600002 PM 25667438 ER PT J AU Kamphorst, JJ Nofal, M Commisso, C Hackett, SR Lu, WY Grabocka, E Vander Heiden, MG Miller, G Drebin, JA Bar-Sagi, D Thompson, CB Rabinowitz, JD AF Kamphorst, Jurre J. Nofal, Michel Commisso, Cosimo Hackett, Sean R. Lu, Wenyun Grabocka, Elda Vander Heiden, Matthew G. Miller, George Drebin, Jeffrey A. Bar-Sagi, Dafna Thompson, Craig B. Rabinowitz, Joshua D. TI Human Pancreatic Cancer Tumors Are Nutrient Poor and Tumor Cells Actively Scavenge Extracellular Protein SO CANCER RESEARCH LA English DT Article ID RAS-TRANSFORMED CELLS; METABOLOMIC ANALYSIS; MASS-SPECTROMETRY; PATHWAY; GROWTH; PHASE; GLUCOSE; METABOLITES; HYPOXIA; ACIDS AB Glucose and amino acids are key nutrients supporting cell growth. Amino acids are imported as monomers, but an alternative route induced by oncogenic KRAS involves uptake of extracellular proteins via macropinocytosis and subsequent lysosomal degradation of these proteins as a source of amino acids. In this study, we examined the metabolism of pancreatic ductal adenocarcinoma (PDAC), a poorly vascularized lethal KRAS-driven malignancy. Metabolomic comparisons of human PDAC and benign adjacent tissue revealed that tumor tissue was low in glucose, upper glycolytic intermediates, creatine phosphate, and the amino acids glutamine and serine, two major metabolic substrates. Surprisingly, PDAC accumulated essential amino acids. Such accumulation could arise from extracellular proteins being degraded through macropinocytosis in quantities necessary to meet glutamine requirements, which in turn produces excess of most other amino acids. Consistent with this hypothesis, active macropinocytosis is observed in primary human PDAC specimens. Moreover, in the presence of physiologic albumin, we found that cultured murine PDAC cells grow indefinitely in media lacking single essential amino acids and replicate once in the absence of free amino acids. Growth under these conditions was characterized by simultaneous glutamine depletion and essential amino acid accumulation. Overall, our findings argue that the scavenging of extracellular proteins is an important mode of nutrient uptake in PDAC. (C) 2014 AACR. C1 [Kamphorst, Jurre J.; Nofal, Michel; Hackett, Sean R.; Lu, Wenyun; Rabinowitz, Joshua D.] Princeton Univ, Carl Icahn Lab, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA. [Commisso, Cosimo; Grabocka, Elda; Bar-Sagi, Dafna] NYU, Sch Med, Dept Mol Pharmacol & Biochem, New York, NY USA. [Vander Heiden, Matthew G.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Vander Heiden, Matthew G.] MIT, Dept Biol, Cambridge, MA USA. [Vander Heiden, Matthew G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Miller, George] NYU, Dept Surg, Sch Med, New York, NY 10016 USA. [Miller, George] NYU, Dept Cell Biol, Sch Med, New York, NY 10016 USA. [Drebin, Jeffrey A.] Hosp Univ Penn, Dept Surg, Philadelphia, PA 19104 USA. [Thompson, Craig B.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA. RP Rabinowitz, JD (reprint author), Princeton Univ, Carl Icahn Lab, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA. EM joshr@princeton.edu OI Kamphorst, Jurre/0000-0002-2042-5474 FU NIH [P50GM071508, 1R01CA16359-01A1, 1R01CA055360]; Stand Up To Cancer Dream Team Translational Research Grant [SU2C-AACR-DT0509]; Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research; Hope Funds for Cancer Research Fellow [HFCR-11-03-01]; NYU School of Medicine Biorepository Center; Cancer Center Support Grant at the Laura and Isaac Perlmutter Cancer Center [P30CA016087]; National Center for the Advancement of Translational Science (NCATS), NIH [UL 1 TR000038]; Histopathology Core of NYU School of Medicine [5 P30CA016087-32] FX This work was supported by the NIH grants P50GM071508 (J.D. Rabinowitz), 1R01CA16359-01A1 (J.D. Rabinowitz), and 1R01CA055360 (D. Bar-Sagi), and by a Stand Up To Cancer Dream Team Translational Research Grant, Grant Number SU2C-AACR-DT0509. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. J.J. Kamphorst is a Hope Funds for Cancer Research Fellow (HFCR-11-03-01). The authors thank the NYU School of Medicine Biorepository Center, which is partially supported by the Cancer Center Support Grant, P30CA016087, at the Laura and Isaac Perlmutter Cancer Center. It is also supported, in part, by grant UL 1 TR000038 from the National Center for the Advancement of Translational Science (NCATS), NIH. The Histopathology Core of NYU School of Medicine is partially supported by the NIH (grant 5 P30CA016087-32). NR 33 TC 71 Z9 72 U1 7 U2 26 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD FEB 1 PY 2015 VL 75 IS 3 BP 544 EP 553 DI 10.1158/0008-5472.CAN-14-2211 PG 10 WC Oncology SC Oncology GA CB7XE UT WOS:000349841200008 PM 25644265 ER PT J AU Bauer, C Yazzolino, L Hirsch, G Cattaneo, Z Vecchi, T Merabet, LB AF Bauer, Corinna Yazzolino, Lindsay Hirsch, Gabriella Cattaneo, Zaira Vecchi, Tomaso Merabet, Lotfi B. TI Neural correlates associated with superior tactile symmetry perception in the early blind SO CORTEX LA English DT Article DE Blind; Lateral occipital cortex; Symmetry; Striate cortex; Extrastriate cortex; Haptic; Tactile; Crossmodal; Plasticity ID LATERAL OCCIPITAL COMPLEX; CROSS-MODAL PLASTICITY; VISUAL-CORTEX; SPATIAL ACUITY; WORKING-MEMORY; HAPTIC DISCRIMINATION; UNFAMILIAR DISPLAYS; CORTICAL ACTIVITY; SHAPE PERCEPTION; BRAILLE READERS AB Symmetry is an organizational principle that is ubiquitous throughout the visual world. However, this property can also be detected through non-visual modalities such as touch. The role of prior visual experience on detecting tactile patterns containing symmetry remains unclear. We compared the behavioral performance of early blind and sighted (blindfolded) controls on a tactile symmetry detection task. The tactile patterns used were similar in design and complexity as in previous visual perceptual studies. The neural correlates associated with this behavioral task were identified with functional magnetic resonance imaging (fMRI). In line with growing evidence demonstrating enhanced tactile processing abilities in the blind, we found that early blind individuals showed significantly superior performance in detecting tactile symmetric patterns compared to sighted controls. Furthermore, comparing patterns of activation between these two groups identified common areas of activation (e.g. superior parietal cortex) but key differences also emerged. In particular, tactile symmetry detection in the early blind was also associated with activation that included peri-calcarine cortex, lateral occipital (LO), and middle temporal (MT) cortex, as well as inferior temporal and fusiform cortex. These results contribute to the growing evidence supporting superior behavioral abilities in the blind, and the neural correlates associated with crossmodal neuroplasticity following visual deprivation. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Bauer, Corinna; Yazzolino, Lindsay; Hirsch, Gabriella; Merabet, Lotfi B.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Lab Visual Neuroplast,Dept Ophthalmol, Boston, MA 02114 USA. [Cattaneo, Zaira] Univ Milano Bicocca, Dept Psychol, Milan, Italy. [Cattaneo, Zaira; Vecchi, Tomaso] Natl Neurol Inst C Mondino, Brain Connect Ctr, Pavia, Italy. [Vecchi, Tomaso] Univ Pavia, Dept Brain & Behav Sci, I-27100 Pavia, Italy. RP Merabet, LB (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, 20 Staniford St, Boston, MA 02114 USA. EM lotfi_merabet@meei.harvard.edu FU NIH/NEI RO1 [EY019924] FX This work was supported by an NIH/NEI RO1 GRANT EY019924 (L.B.M.). NR 82 TC 4 Z9 4 U1 3 U2 8 PU ELSEVIER MASSON PI MILANO PA VIA PALEOCAPA 7, 20121 MILANO, ITALY SN 0010-9452 EI 1973-8102 J9 CORTEX JI Cortex PD FEB PY 2015 VL 63 BP 104 EP 117 DI 10.1016/j.cortex.2014.08.003 PG 14 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA CB4BN UT WOS:000349573300011 PM 25243993 ER PT J AU Race, E Keane, MM Verfaellie, M AF Race, Elizabeth Keane, Margaret M. Verfaellie, Mieke TI Sharing mental simulations and stories: Hippocampal contributions to discourse integration SO CORTEX LA English DT Article DE Amnesia; Hippocampus; Binding; Language; Memory ID MEDIAL TEMPORAL-LOBE; WORKING-MEMORY; TIME-TRAVEL; EPISODIC MEMORY; RELATIONAL MEMORY; COGNITIVE-PROCESSES; HUMAN MIND; LANGUAGE; AMNESIA; ORDER AB Accumulating evidence suggests that mental simulation of the future and past relies on common processes supported by the hippocampus. However, it is currently unknown whether the hippocampus also supports the ability to share these mental simulations with others. Recently, it has been proposed that language and language-related structures in the brain are particularly important for communicating information not tied to the immediate environment, and indeed specifically evolved so that humans could share their mental time travels into the future and the past with others. The current study investigated whether processes supported by the hippocampus are necessary for effectively communicating the contents of one's mental simulations by examining the discourse of amnesic patients with medial temporal lobe damage. In Experiment 1 we tested whether patients can produce integrated discourse about future and past events by measuring lower-level discourse cohesion and higher-lever discourse coherence. Striking reductions in both measures were observed in amnesic patients' narratives about novel future events and experienced past events. To investigate whether these deficits simply reflected concurrent reductions in narrative content, in Experiment 2 we examined the status of discourse integration in patients' verbal narratives about pictures, which contained an equivalent amount of narrative content as controls'. Discourse cohesion and coherence deficits were also present when patients generated narratives based on pictures, and these deficits did not depend on the presence of neural damage outside the hippocampus. Together, these results reveal a pervasive linguistic integration deficit in amnesia that is not limited to discourse about the past or the future and is not simply secondary to reductions in narrative content. More broadly, this study demonstrates that the hippocampus supports the integration of individual narrative elements into coherent and cohesive discourse when constructing complex verbal accounts, and plays a critical role in the effective communication of information to others. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Race, Elizabeth; Keane, Margaret M.; Verfaellie, Mieke] Boston VA Healthcare Syst, Memory Disorders Res Ctr, Boston, MA 02130 USA. [Race, Elizabeth; Keane, Margaret M.; Verfaellie, Mieke] Boston Univ, Sch Med, Boston, MA 02130 USA. [Keane, Margaret M.] Wellesley Coll, Dept Psychol, Wellesley, MA 02181 USA. RP Race, E (reprint author), Boston VA Healthcare Syst, Memory Disorders Res Ctr, 150 S Huntington Ave 151-A, Boston, MA 02130 USA. EM race@bu.edu OI Verfaellie, Mieke/0000-0001-5535-4584 FU NIH [RO1MH093431, F32NS073212]; Department of Veterans Affairs Clinical Science Research and Development Service FX This research was supported by NIH grants RO1MH093431 and F32NS073212 and by the Department of Veterans Affairs Clinical Science Research and Development Service. NR 68 TC 6 Z9 6 U1 1 U2 10 PU ELSEVIER MASSON PI MILANO PA VIA PALEOCAPA 7, 20121 MILANO, ITALY SN 0010-9452 EI 1973-8102 J9 CORTEX JI Cortex PD FEB PY 2015 VL 63 BP 271 EP 281 DI 10.1016/j.cortex.2014.09.004 PG 11 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA CB4BN UT WOS:000349573300027 PM 25303274 ER PT J AU Kristensen, SL Jhund, PS Kober, L Preiss, D Kjekshus, J McKelvie, RS Zile, MR Anand, IS Wikstrand, J Wedel, H Komajda, M Carson, PE Cleland, JGF McMurray, JJV AF Kristensen, Soren L. Jhund, Pardeep S. Kober, Lars Preiss, David Kjekshus, John McKelvie, Robert S. Zile, Michael R. Anand, Inder S. Wikstrand, John Wedel, Hans Komajda, Michel Carson, Peter E. Cleland, John G. F. McMurray, John J. V. TI Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Heart failure; Clinical trials; HF-PEF; HF-REF; Mortality ID ROSUVASTATIN; TRIAL; PROGRESSION; IRBESARTAN; DESIGN; CORONA AB AimsTo investigate the prognostic significance of hospitalization for worsening heart failure (WHF), myocardial infarction (MI), and stroke in patients with chronic heart failure (HF). Methods and resultsWe studied 5011 patients with HF and reduced EF (HF-REF) in the CORONA trial and 4128 patients with HF and preserved EF (HF-PEF) in the I-Preserve trial. Adjusted hazard ratios (HRs) for death were estimated for 0-30 days and 31 days after first post-randomization WHF, MI, or stroke used as a time-dependent variable, compared with patients with none of these events. In CORONA, 1616 patients (32%) had post-randomization first events (1223 WHF, 216 MI, 177 stroke), and the adjusted HR for mortality 30 days after an event was: WHF 7.21 [95% confidence interval (CI) 2.05-25.40], MI 23.08 (95% CI 6.44-82.71), and stroke 32.15 (95% CI 8.93-115.83). The HR for mortality at >30 days was: WHF 3.62 (95% CI 3.11-4.21), MI 4.41 (95% CI 3.23-6.02), and stroke 3.19 (95% CI 2.21-4.61). In I-Preserve, 896 patients (22%) experienced a post-randomization event (638 WHF, 111 MI, 147 stroke). The HR for mortality 30 days was WHF 31.77 (95% CI 7.60-132.81), MI 154.77 (95% CI 34.21-700.17), and stroke 223.30 (95% CI 51.42-969.78); for >30 days it was WHF 3.36 (95% CI 2.79-4.05), MI 3.29 (95% CI 2.14-5.06), and stroke 5.13 (95% CI 3.61-7.29). ConclusionsIn patients with both HF-REF and HF-PEF, hospitalization for WHF was associated with high early and late mortality. The early relative risk of death was not as great as following MI or stroke, but the longer term relative risk of death was similar following all three types of event. Numerically, more deaths occurred following WHF because it was a much more common event. C1 [Kristensen, Soren L.; Jhund, Pardeep S.; Preiss, David; McMurray, John J. V.] Univ Glasgow, BHF Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland. [Kristensen, Soren L.] Gentofte Univ Hosp, Dept Cardiol, Copenhagen, Denmark. [Kober, Lars] Univ Copenhagen, Rigshosp, Dept Cardiol, DK-2100 Copenhagen, Denmark. [Kjekshus, John] Univ Oslo, Rikshosp, Dept Cardiol, N-0027 Oslo, Norway. [McKelvie, Robert S.] McMaster Univ, Hamilton Hlth Sci, Hamilton, ON, Canada. [Zile, Michael R.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Anand, Inder S.] Vet Affairs Med Ctr, Minneapolis, MN USA. [Anand, Inder S.] Univ Minnesota, Minneapolis, MN USA. [Wikstrand, John] Gothenburg Univ, Wallenberg Lab Cardiovasc Res, Sahlgrenska Acad, Gothenburg, Sweden. [Wedel, Hans] Nord Sch Publ Hlth, Gothenburg, Sweden. [Komajda, Michel] Univ Paris 06, Hosp Pitie Salpetriere, Paris, France. [Komajda, Michel] Inst ICAN, Paris, France. [Carson, Peter E.] Georgetown Univ, Washington, DC USA. [Carson, Peter E.] Washington DC Vet Affairs Med Ctr, Washington, DC USA. [Cleland, John G. F.] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Natl Heart & Lung Inst, London, England. [Cleland, John G. F.] Univ London Imperial Coll Sci Technol & Med, Harefield Hosp, Natl Heart & Lung Inst, London, England. RP McMurray, JJV (reprint author), Univ Glasgow, BHF Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow G12 8TA, Lanark, Scotland. EM john.mcmurray@glasgow.ac.uk OI Cleland, John/0000-0002-1471-7016; Preiss, David/0000-0003-3139-1836; mcmurray, john/0000-0002-6317-3975; Jhund, Pardeep/0000-0003-4306-5317 NR 17 TC 3 Z9 3 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD FEB PY 2015 VL 17 IS 2 BP 169 EP 176 DI 10.1002/ejhf.211 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CB5NT UT WOS:000349675200010 PM 25756844 ER PT J AU Goedecke, JH Chorell, E Livingstone, DEW Stimson, RH Hayes, P Adams, K Dave, JA Victor, H Levitt, NS Kahn, SE Seckl, JR Walker, BR Olsson, T AF Goedecke, J. H. Chorell, E. Livingstone, D. E. W. Stimson, R. H. Hayes, P. Adams, K. Dave, J. A. Victor, H. Levitt, N. S. Kahn, S. E. Seckl, J. R. Walker, B. R. Olsson, T. TI Glucocorticoid receptor gene expression in adipose tissue and associated metabolic risk in black and white South African women SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article ID 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; INSULIN-RESISTANCE; VISCERAL OBESITY; MESSENGER-RNA; INFLAMMATION; SENSITIVITY; FAT; BETA; ADIPOGENESIS; REGULATOR AB BACKGROUND: Black women have lower visceral adipose tissue (VAT) but are less insulin sensitive than white women; the mechanisms responsible are unknown. OBJECTIVE: The study aimed to test the hypothesis that variation in subcutaneous adipose tissue (SAT) sensitivity to glucocorticoids might underlie these differences. METHODS: Body fatness (dual energy X-ray absorptiometry) and distribution (computerized tomography), insulin sensitivity (SI, intravenous and oral glucose tolerance tests), and expression of 11 beta-hydroxysteroid dehydrogenase-1 (11HSD1), hexose-6-phosphate dehydrogenase and glucocorticoid receptor-alpha (GR alpha), as well as genes involved in adipogenesis and inflammation were measured in abdominal deep SAT, superficial SAT and gluteal SAT (GLUT) depots of 56 normal-weight or obese black and white premenopausal South African (SA) women. We used a combination of univariate and multivariate statistics to evaluate ethnic-specific patterns in adipose gene expression and related body composition and insulin sensitivity measures. RESULTS: Although 11HSD1 activity and mRNA did not differ by ethnicity, GRa mRNA levels were significantly lower in SAT of black compared with white women, particularly in the GLUT depot (0.52 +/- 0.21 vs 0.91 +/- 0.26 AU, respectively, P < 0.01). In black women, lower SAT GRa mRNA levels were associated with increased inflammatory gene transcript levels and abdominal SAT area, and reduced adipogenic gene transcript levels, VAT/SAT ratio and SI. Abdominal SAT 11HSD1 activity associated with increased VAT area and decreased SI in white, but not in black women. CONCLUSIONS: In black SA women, downregulation of GRa mRNA levels with obesity and reduced insulin sensitivity, possibly via increased SAT inflammation, is associated with reduced VAT accumulation. C1 [Goedecke, J. H.] S African MRC, Noncommunicable Dis Res Unit, ZA-7505 Cape Town, South Africa. [Goedecke, J. H.; Victor, H.] UCT MRC Res Unit Exercise Sci & Sports Med, Dept Human Biol, Cape Town, South Africa. [Chorell, E.; Olsson, T.] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden. [Livingstone, D. E. W.; Stimson, R. H.; Seckl, J. R.; Walker, B. R.] Univ Edinburgh, Univ British Heart Fdn Ctr Cardiovasc Sci, Endocrinol Unit, Edinburgh, Midlothian, Scotland. [Hayes, P.; Adams, K.] Univ Cape Town, Dept Plast Surg, Div Surg, ZA-7925 Cape Town, South Africa. [Dave, J. A.; Levitt, N. S.] Univ Cape Town, Dept Med, Div Diabet & Endocrinol, ZA-7925 Cape Town, South Africa. [Kahn, S. E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, S. E.] Univ Washington, Seattle, WA 98195 USA. RP Goedecke, JH (reprint author), S African MRC, Noncommunicable Dis Res Unit, POB 19070, ZA-7505 Cape Town, South Africa. EM julia.goedecke@mrc.ac.za RI Goedecke, Julia/E-1820-2016; OI Goedecke, Julia/0000-0001-6795-4771; Kahn, Steven/0000-0001-7307-9002 FU South African Medical Research Council; International Atomic Energy Agency; National Research Foundation of South Africa; Royal Society SA-UK Science Networks Program; University of Cape Town; British Heart Foundation; Welcome Trust; United States Department of Veterans Affairs; Swedish Heart and Lung Foundation FX We thank the research volunteers for their participation in this study. J Bergman and N Fenton of Symington Radiology are thanked for performing the computerized tomography scans and L Bewerunge is thanked for performing the dual-energy X-ray absorptiometry scans. S West is acknowledged for her clinical support. This study was funded by the South African Medical Research Council, the International Atomic Energy Agency, the National Research Foundation of South Africa and Royal Society SA-UK Science Networks Program, the University of Cape Town, the British Heart Foundation, the Welcome Trust, the United States Department of Veterans Affairs and the Swedish Heart and Lung Foundation. NR 41 TC 1 Z9 1 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 EI 1476-5497 J9 INT J OBESITY JI Int. J. Obes. PD FEB PY 2015 VL 39 IS 2 BP 303 EP 311 DI 10.1038/ijo.2014.94 PG 9 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA CB3UA UT WOS:000349553200016 PM 24854429 ER PT J AU Nizamuddin, SL Broderick, DK Minehart, RD Kamdar, BB AF Nizamuddin, S. L. Broderick, D. K. Minehart, R. D. Kamdar, B. B. TI Spontaneous coronary artery dissection in a parturient with Nail-Patella syndrome SO INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA LA English DT Article DE Acute coronary syndrome; Coronary artery dissection; Nail-Patella syndrome ID ACUTE MYOCARDIAL-INFARCTION; HEART-DISEASE; PREGNANCY; OXYTOCIN; WOMAN AB Spontaneous coronary artery dissection is an uncommon cause of acute coronary syndrome, occurring predominantly in women during and immediately after pregnancy; it carries a mortality rate of greater than 50%. While the exact etiology is unknown, possible contributing factors include pregnancy-related hormonal, connective tissue and hemodynamic changes. We present a case of a 35-year-old multigravid woman with Nail-Patella syndrome who developed an acute myocardial infarction secondary to spontaneous coronary artery dissection during labor which was not diagnosed until after delivery. We hypothesize that abnormal collagen fiber formation found in Nail-Patella syndrome may have put her at an increased risk of coronary dissection and myocardial infarction. Regardless of etiology, a delay in diagnosis of myocardial ischemia can lead to significant morbidity and mortality. In light of the increasing burden of cardiac disease in the obstetric population, clinicians should remain vigilant for signs of myocardial infarction and prepare for definitive diagnosis and treatment. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Nizamuddin, S. L.; Broderick, D. K.; Minehart, R. D.; Kamdar, B. B.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. RP Nizamuddin, SL (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. EM snizamuddin@partners.org NR 30 TC 1 Z9 1 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0959-289X EI 1532-3374 J9 INT J OBSTET ANESTH JI Int. J. Obstet. Anesth. PD FEB PY 2015 VL 24 IS 1 BP 69 EP 73 DI 10.1016/j.ijoa.2014.07.010 PG 5 WC Anesthesiology; Obstetrics & Gynecology SC Anesthesiology; Obstetrics & Gynecology GA CB6GP UT WOS:000349725800013 PM 25433575 ER PT J AU Gradl, G Knobe, M Pape, HC Neuhaus, PV Ring, D Guitton, T AF Gradl, Gertraud Knobe, Matthias Pape, Hans-Christoph Neuhaus, Paul Valentin Ring, David Guitton, Thierry TI Decision making in displaced fractures of the proximal humerus: fracture or surgeon based? SO INTERNATIONAL ORTHOPAEDICS LA English DT Article DE Proximal humerus fracture; Treatment; Decision-making; Arthroplasty ID OPEN REDUCTION; FIXATION; CLASSIFICATION; OUTCOMES; PLATE AB The aim of this study was to analyse the factors that influence surgeon decision-making in the treatment of proximal humerus fractures that might be considered for arthroplasty or open reduction and internal fixation. A total of 217 surgeons evaluated radiographs and clinical vignettes of ten patients with fractures of the proximal humerus. In addition to radiographs, we provided patient age, sex, trauma mechanism, activity level (sedentary-vigorously active), and physical status (normal healthy-moribund). Observers were asked to: (1) choose open reduction and internal fixation or hemiarthroplasty (closed question, one option) and (2) to briefly describe the factors that led to their decision (open-ended question). We assessed interobserver reliability using the Fleiss generalized kappa and analysed factors that influenced decision-making according to treatment choice. Internal fixation was the preferred treatment for the majority of fractures. The overall multirater agreement was fair (kappa = 0.30), with a 75 % proportion of agreement. When asked to describe the factors that influenced decision-making, surgeons favouring internal fixation described patient-based factors in 52 %, fracture morphology in 51 %, surgeon factors in 42 %, and bone quality in 11 %. In contrast, fracture morphology was the most common factor (67 %) described by surgeons recommending replacement. Patient age, sex, activity level, physical status and the presence of angular displacement were associated with a recommendation for internal fixation. There is substantial variation in recommendations for internal fixation vs. arthroplasty for fractures of the proximal humerus that arises in large part from patient and surgeon factors. C1 [Gradl, Gertraud; Knobe, Matthias; Pape, Hans-Christoph] Univ Aachen, Med Ctr, Aachen, Germany. [Neuhaus, Paul Valentin; Ring, David] Massachusetts Gen Hosp, Dept Orthopaed Surg, Hand & Upper Extrem Serv, Boston, MA 02114 USA. [Guitton, Thierry] Acad Med Ctr Amsterdam, Dept Orthopaed Surg, Amsterdam, Netherlands. RP Gradl, G (reprint author), Univ Aachen, Med Ctr, Aachen, Germany. EM ggradl@ukaachen.de OI Guitton, Thierry/0000-0002-2599-1985; Neuhaus, Valentin/0000-0003-4012-5628 NR 24 TC 7 Z9 7 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0341-2695 EI 1432-5195 J9 INT ORTHOP JI Int. Orthop. PD FEB PY 2015 VL 39 IS 2 BP 329 EP 334 DI 10.1007/s00264-014-2630-5 PG 6 WC Orthopedics SC Orthopedics GA CB4XM UT WOS:000349631700017 PM 25500958 ER PT J AU Emami, H Singh, P MacNabb, M Vucic, E Lavender, Z Rudd, JHF Fayad, ZA Lehrer-Graiwer, J Korsgren, M Figueroa, AL Fredrickson, J Rubin, B Hoffmann, U Truong, QA Min, JK Baruch, A Nasir, K Nahrendorf, M Tawakol, A AF Emami, Hamed Singh, Parmanand MacNabb, Megan Vucic, Esad Lavender, Zachary Rudd, James H. F. Fayad, Zahi A. Lehrer-Graiwer, Joshua Korsgren, Magnus Figueroa, Amparo L. Fredrickson, Jill Rubin, Barry Hoffmann, Udo Truong, Quynh A. Min, James K. Baruch, Amos Nasir, Khurram Nahrendorf, Matthias Tawakol, Ahmed TI Splenic Metabolic Activity Predicts Risk of Future Cardiovascular Events SO JACC-CARDIOVASCULAR IMAGING LA English DT Article DE acute coronary syndrome; atherosclerosis; events; FDG; inflammation; spleen ID POSITRON-EMISSION-TOMOGRAPHY; ACUTE CORONARY SYNDROMES; CELL LUNG-CANCER; MYOCARDIAL-INFARCTION; ACTIVATED MACROPHAGES; STATIN THERAPY; HEART-FAILURE; INFLAMMATION; ATHEROSCLEROSIS; PLAQUE AB OBJECTIVES This study sought to determine whether splenic activation after acute coronary syndrome (ACS) is linked to leukocyte proinflammatory remodeling and whether splenic activity independently predicts the risk of cardiovascular disease (CVD) events. BACKGROUND Pre-clinical data suggest the existence of a cardiosplenic axis, wherein activation of hematopoietic tissues (notably in the spleen) results in Liberation of proinflammatory leukocytes and accelerated atherosclerotic inflammation. However, it is presently unknown whether a cardiosplenic axis exists in humans and whether splenic activation relates to CVD risk. METHODS F-18-fluorodeoxyglucose ((18)FDG)-positron emission tomography (PET) imaging was performed in 508 individuals across 2 studies. In the first study, we performed FDG-PET imaging in 22 patients with recent ACS and 22 control subjects. FDG uptake was measured in spleen and arterial wall, whereas proinflammatory gene expression of circulating leukocytes was assessed by quantitative real-time polymerase chain reaction. In a second study, we examined the relationship between splenic tissue FDG uptake with subsequent CVD events during follow-up (median 4 years) in 464 patients who previously had undergone FDG-PET imaging. RESULTS Splenic activity increased after ACS and was significantly associated with multiple indices of inflammation: 1) up-regulated gene expression of proinflammatory leukocytes; 2) increased C-reactive protein; and 3) increased arterial wall inflammation (FDG uptake). Moreover, in the second study, splenic activity (greater than or equal to the median) was associated with an increased risk of CVD events (hazard ratio [HR]: 3.3; 95% confidence interval [CI]: 1.5 to 7.3; p = 0.003), which remained significant after adjustment for CVD risk factors (HR: 2.26; 95% CI: 1.01 to 5.06; p = 0.04) and for arterial FDG uptake (HR: 2.68; 95% CI: 1.5 to 7.4; p = 0.02). CONCLUSIONS Our findings demonstrate increased splenic metabolic activity after ACS and its association with proinflammatory remodeling of circulating leukocytes. Moreover, we observed that metabolic activity of the spleen independently predicted risk of subsequent CVD events. Collectively, these findings provide evidence of a cardiosplenic axis in humans similar to that shown in pre-clinical studies. (C) 2015 by the American College of Cardiology Foundation. C1 [Emami, Hamed; Singh, Parmanand; MacNabb, Megan; Vucic, Esad; Lavender, Zachary; Figueroa, Amparo L.; Hoffmann, Udo; Truong, Quynh A.; Tawakol, Ahmed] Massachusetts Gen Hosp, Div Cardiac Imaging, Cardiac MR PET CT Program, Boston, MA 02114 USA. [Emami, Hamed; Singh, Parmanand; MacNabb, Megan; Vucic, Esad; Lavender, Zachary; Figueroa, Amparo L.; Hoffmann, Udo; Truong, Quynh A.; Nahrendorf, Matthias; Tawakol, Ahmed] Harvard Univ, Sch Med, Boston, MA USA. [Rudd, James H. F.] Univ Cambridge, Div Cardiovasc Med, Cambridge, England. [Fayad, Zahi A.] Icahn Sch Med Mt Sinai, Translat & Mol Imaging Inst, New York, NY 10029 USA. [Lehrer-Graiwer, Joshua; Fredrickson, Jill; Baruch, Amos] Genentech Inc, San Francisco, CA 94080 USA. [Korsgren, Magnus] BioInvent Int AB, Lund, Sweden. [Rubin, Barry] Univ Toronto, Toronto Gen Hosp, Div Vasc Surg, Peter Munk Cardiac Ctr, Toronto, ON M5G 1L7, Canada. [Min, James K.] Weill Cornell Med Coll, Dept Radiol, New York, NY USA. [Min, James K.] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Min, James K.] New York Presbyterian Hosp, New York, NY USA. [Nasir, Khurram] Baptist Hlth South Florida, Miami, FL USA. [Nahrendorf, Matthias] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Tawakol, Ahmed] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. RP Tawakol, A (reprint author), Massachusetts Gen Hosp, MR PET CT Program, 165 Cambridge St,Suite 400, Boston, MA 02114 USA. EM atawakol@partners.org FU Genentech, Inc.; BioInvent International AB; Genentech FX Funding for the first study (ACS Study) was provided by Genentech, Inc., and BioInvent International AB. No funding from any source was provided for the second study (Clinical Outcomes Study). Dr. Lehrer-Graiwer is an employee of and owns stock in Global Blood Therapeutics. At the time this study was conducted, Dr. Korsgren was employed by BioInvent International AB, Sweden. Dr. Fredrickson is an employee of and a shareholder in Genentech/Roche. Dr. Baruch is an employee of Genentech/Roche. Dr. Tawakol has received grant support from Genentech. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Emami and Singh are joint first authors. George Beller, MD, has served as Guest Editor for this paper. NR 28 TC 36 Z9 37 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X EI 1876-7591 J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD FEB PY 2015 VL 8 IS 2 BP 121 EP 130 DI 10.1016/j.jcmg.2014.10.009 PG 10 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA CB5HZ UT WOS:000349659400001 PM 25577441 ER PT J AU Hedden, T Growdon, JH AF Hedden, Trey Growdon, John H. TI Challenges and Opportunities in Linking Brain-Based Biomarkers to Person-Specific Variation in Cognition Pumping Up the Volume SO JAMA NEUROLOGY LA English DT Editorial Material ID METAANALYSIS; CORTEX; ADULTS C1 [Hedden, Trey] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA. [Hedden, Trey] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Growdon, John H.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA. RP Hedden, T (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, 149 13th St,Ste 2301, Charlestown, MA 02129 USA. EM hedden@nmr.mgh.harvard.edu FU NIA NIH HHS [P50 AG005134, K01 AG040197] NR 16 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD FEB PY 2015 VL 72 IS 2 BP 149 EP 151 DI 10.1001/jamaneurol.2014.3832 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA CB4SU UT WOS:000349619200005 PM 25485512 ER PT J AU Rotstein, DL Healy, BC Malik, MT Chitnis, T Weiner, HL AF Rotstein, Dalia L. Healy, Brian C. Malik, Muhammad T. Chitnis, Tanuja Weiner, Howard L. TI Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort SO JAMA NEUROLOGY LA English DT Article ID DISABILITY STATUS SCALE; LONG-TERM DISABILITY; TIMED 25-FOOT WALK; MRI LESIONS; FOLLOW-UP; PREDICTORS; MS; PROGRESSION; RELAPSES; PARADOX AB IMPORTANCE With multiple and increasingly effective therapies for relapsing forms of multiple sclerosis (MS), disease-free status or no evidence of disease activity (NEDA) has become a treatment goal and a new outcome measure. However, the persistence of NEDA over time and its predictive power for long-term prognosis are unknown. OBJECTIVE To investigate NEDA during 7 years as measured by relapses, disability progression, and yearly magnetic resonance imaging (MRI). DESIGN, SETTING, AND PARTICIPANTS Patients were selected from the 2200-patient Comprehensive Longitudinal Investigation of Multiple Sclerosis at Brigham and Women's Hospital (CLIMB) cohort study. Patients were required to have an initial diagnosis of clinically isolated syndrome or relapsing-remittingMS and a minimum of 7 years of prospective follow-up that included yearly brain MRI and biannual clinical visits (n = 219). Patients were analyzed independent of disease-modifying therapy. Patients were classified as having early (recent-onset) MS if they were 5 years or less from their first MS symptom at enrollment or otherwise considered to have established MS (>5 years from onset). MAIN OUTCOMES AND MEASURES NEDA was defined as a composite that consisted of absence of relapses, no sustained Expanded Disability Status Scale score progression, and no new or enlarging T2 or T1 gadolinium-enhancing lesions on annual MRI. Relapses, progression, and MRI changes were also investigated as individual outcomes. RESULTS A total of 99 of 215 patients (46.0%) had NEDA for clinical and MRI measures at 1 year, but only 17 of 216 (7.9%) maintained NEDA status after 7 years. No differences were found in NEDA status between patients with early vs established MS. A dissociation was found between clinical and MRI disease activity. Each year, 30.6%(64 of 209) to 42.9% (93 of 217) of the cohort had evidence of either clinical or MRI disease activity but not both. NEDA at 2 years had a positive predictive value of 78.3% for no progression (Expanded Disability Status Scale score change <= 0.5) at 7 years. Only minor improvement was found in the positive predictive values with additional follow-up of 1 to 3 years. CONCLUSIONS AND RELEVANCE NEDA is difficult to sustain long term even with treatment. NEDA status at 2 years may be optimal in terms of prognostic value in the longer term. Our results provide a basis for investigating NEDA as an outcome measure and treatment goal and for evaluating the effect of new MS drugs on NEDA. C1 [Rotstein, Dalia L.; Healy, Brian C.; Malik, Muhammad T.; Chitnis, Tanuja; Weiner, Howard L.] Brigham & Womens Hosp, Partners Multiple Sclerosis Ctr, Boston, MA 02115 USA. [Healy, Brian C.] Massachusetts Gen Hosp, Biostat Ctr, Brookline, MA USA. RP Weiner, HL (reprint author), Brigham & Womens Hosp, Partners Multiple Sclerosis Ctr, 1 Brookline Pl,Ste 227, Brookline, MA 02445 USA. EM hweiner@rics.bwh.harvard.edu FU Merck Serono FX Merck Serono provided partial financial support for data collection and reviewed the manuscript. NR 39 TC 59 Z9 60 U1 5 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD FEB PY 2015 VL 72 IS 2 BP 152 EP 158 DI 10.1001/jamaneurol.2014.3537 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA CB4SU UT WOS:000349619200006 PM 25531931 ER PT J AU Weiss, RB Stange, JP Boland, EM Black, SK LaBelle, DR Abramson, LY Alloy, LB AF Weiss, Rachel B. Stange, Jonathan P. Boland, Elaine M. Black, Shimrit K. LaBelle, Denise R. Abramson, Lyn Y. Alloy, Lauren B. TI Kindling of Life Stress in Bipolar Disorder: Comparison of Sensitization and Autonomy Models SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE kindling; stress sensitization; bipolar disorder; life events; course ID BEHAVIORAL-APPROACH SYSTEM; SPECTRUM DISORDERS; MOOD DISORDERS; RISK-FACTORS; DEPRESSION; EVENTS; RECURRENCE; HYPOTHESIS; INVENTORY; ONSET AB Research on life stress in bipolar disorder largely fails to account for the possibility of a dynamic relationship between psychosocial stress and episode initiation. The kindling hypothesis (Post, 1992) states that over the course of recurrent affective disorders, there is a weakening temporal relationship between major life stress and episode initiation that could reflect either a progressive sensitization or progressive autonomy to life stress. The present study involved a comprehensive and precise examination of the kindling hypothesis in 102 participants with bipolar II disorder that allowed for a direct comparison of sensitization and autonomy models. Polarity-specific tests were conducted across the continuum of event severity with respect to impact and frequency of life events. Hypotheses were polarity-and event-valence specific and were based on the stress sensitization model. Results were only partially consistent with the sensitization model: Individuals with more prior mood episodes had an increased frequency of minor negative events before depression and of minor positive events before hypomania. However, the number of past episodes did not moderate relationships between life events and time until prospective onset of mood episodes. These results are more consistent with a sensitization than an autonomy model, but several predictions of the sensitization model were not supported. Methodological strengths, limitations, and implications are discussed regarding putative changes in stress reactivity that may occur with repeated exposure to mood episodes in bipolar II disorder. C1 [Weiss, Rachel B.] Harvard Univ, McLean Hosp, Sch Med, Dept Psychiat, Belmont, MA 02478 USA. [Stange, Jonathan P.; Boland, Elaine M.; LaBelle, Denise R.; Alloy, Lauren B.] Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA. [Black, Shimrit K.] VA Boston Healthcare Syst, Boston, MA USA. [Black, Shimrit K.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Abramson, Lyn Y.] Univ Wisconsin Madison, Dept Psychol, Madison, WI USA. RP Weiss, RB (reprint author), Harvard Univ, McLean Hosp, Sch Med, 115 Mill St, Belmont, MA 02478 USA. EM rbweiss@mclean.harvard.edu FU National Institute of Mental Health (NIMH) [MH52617, MH77908, MH52662]; Society for the Science of Clinical Psychology; NIMH [F31MH099761] FX This research was supported by National Institute of Mental Health (NIMH) Grants MH52617 and MH77908 to Lauren B. Alloy and MH52662 to Lyn Y. Abramson and by a dissertation grant awarded to Rachel B. Weiss by the Society for the Science of Clinical Psychology. Jonathan P. Stange was supported by National Research Service Award F31MH099761 from NIMH. NR 45 TC 10 Z9 10 U1 1 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X EI 1939-1846 J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD FEB PY 2015 VL 124 IS 1 BP 4 EP 16 DI 10.1037/abn0000014 PG 13 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA CB6QY UT WOS:000349752800002 PM 25688428 ER PT J AU Cook, JW Piper, ME Leventhal, AM Schlam, TR Fiore, MC Baker, TB AF Cook, Jessica W. Piper, Megan E. Leventhal, Adam M. Schlam, Tanya R. Fiore, Michael C. Baker, Timothy B. TI Anhedonia as a Component of the Tobacco Withdrawal Syndrome SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE anhedonia; tobacco withdrawal; tobacco dependence; smoking cessation ID SMOKING-CESSATION PHARMACOTHERAPIES; BRAIN REWARD FUNCTION; NICOTINE DEPENDENCE; NEGATIVE AFFECT; BEHAVIORAL ACTIVATION; DEPRESSIVE SYMPTOMS; RESPONSE-INHIBITION; WISCONSIN INVENTORY; HEDONIC CAPACITY; OPPONENT-PROCESS AB Animal research suggests that anhedonia is a tobacco withdrawal symptom, but this topic has not been addressed definitively in research with humans. This research sought to determine whether anhedonia is (a) an element of the tobacco withdrawal syndrome in humans and (b) an impediment to successful tobacco cessation. Data were from 1,175 smokers (58.3% women; 85.5% White) participating in a randomized double-blind, placebo-controlled trial of smoking cessation pharmacotherapies. Ecological momentary assessments for 5 days before and 10 days after the target quit day were used to assess anhedonia and other established withdrawal symptoms. Consistent with drug withdrawal, anhedonia showed an inverted-U pattern of change in response to tobacco cessation and was associated with the severity of other withdrawal symptoms and tobacco dependence. Postquit anhedonia was associated with decreased latency to relapse (hazard ratio = 1.09, 95% confidence interval [CI] [1.02, 1.17]) and with lower 8-week point-prevalence abstinence (odds ratio = .91, 95% CI [.86, .97])-relations that remained significant when other withdrawal symptoms were included as predictors. Finally, nicotine replacement therapy nearly fully suppressed the increase in abstinence-related anhedonia (beta = -.66, p < .001), suggesting agonist suppression of withdrawal. Results suggest that anhedonia is a unique and motivationally significant element of the tobacco withdrawal syndrome in humans. These results have implications for defining and assessing tobacco use disorder and for understanding and treating tobacco addiction. C1 [Cook, Jessica W.; Piper, Megan E.; Schlam, Tanya R.; Fiore, Michael C.; Baker, Timothy B.] Ctr Tobacco Res & Intervent, Madison, WI 53711 USA. [Cook, Jessica W.; Piper, Megan E.; Schlam, Tanya R.; Fiore, Michael C.; Baker, Timothy B.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA. [Cook, Jessica W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Leventhal, Adam M.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Leventhal, Adam M.] Univ So Calif, Keck Sch Med, Dept Psychol, Los Angeles, CA 90033 USA. RP Cook, JW (reprint author), Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. EM jwcook@ctri.medicine.wisc.edu FU National Cancer Institute [9P50CA143188]; General Clinical Research Centers Program of the National Center for Research Resources, National Institutes of Health (NIH) [M01 RR03186]; NIH [K08DA02131, K08DA025041, K05CA139871]; Health Resources and Services Administration [T32HP10010]; Wisconsin Partnership Program FX This research was supported in part by Grant 9P50CA143188 from the National Cancer Institute to the University of Wisconsin Center for Tobacco Research and Intervention; Grant M01 RR03186 from the General Clinical Research Centers Program of the National Center for Research Resources, National Institutes of Health (NIH); Grants K08DA02131, K08DA025041, and K05CA139871 from NIH; a National Research Service Award (T32HP10010) from the Health Resources and Services Administration to the University of Wisconsin Department of Family Medicine; and by the Wisconsin Partnership Program. Medication was provided to participants at no cost under a research agreement with GlaxoSmithKline; no part of this article was written or edited by anyone employed by GlaxoSmithKline. The authors have no conflicts of interest to declare. NR 77 TC 12 Z9 12 U1 14 U2 20 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X EI 1939-1846 J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD FEB PY 2015 VL 124 IS 1 BP 215 EP 225 DI 10.1037/abn0000016 PG 11 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA CB6QY UT WOS:000349752800020 PM 25384069 ER PT J AU Engels, EB Vegh, EM Van Deursen, CJM Vernooy, K Singh, JP Prinzen, FW AF Engels, Elien B. Vegh, Eszter M. Van Deursen, Caroline J. M. Vernooy, Kevin Singh, Jagmeet P. Prinzen, Frits W. TI T-Wave Area Predicts Response to Cardiac Resynchronization Therapy in Patients with Left Bundle Branch Block SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article DE biventricular pacing; cardiac resynchronization therapy; electrocardiography; heart failure; left bundle branch block; T wave ID DEFIBRILLATOR IMPLANTATION TRIAL; HEART-FAILURE PATIENTS; MADIT-CRT; VECTORCARDIOGRAM; DURATION; WOMEN; MEN AB T-Wave Predicts CRT Response in LBBB Patients IntroductionChronic heart failure patients with a left ventricular (LV) conduction delay, mostly due to left bundle branch block (LBBB), generally derive benefit from cardiac resynchronization therapy (CRT). However, 30-50% of patients do not show a clear response to CRT. We investigated whether T-wave analysis of the ECG can improve patient selection. Methods and ResultsThe study population comprised 244 CRT recipients with baseline 12-lead electrocardiogram recordings. Echocardiographic response after 6-month CRT was defined as a 5% increase in LV ejection fraction (LVEF). Vectorcardiograms (VCGs) were constructed from the measured 12-lead ECGs using an adapted Kors algorithm on digitized ECGs. Logistic regression models indicated repolarization variables as good predictors of CRT response. The VCG-derived T-wave area predicted CRT response (odds ratio [OR] per 10 Vs increase 1.172 [P < 0.001]) even better than QRS-wave area (OR = 1.116 [P = 0.001]). T-wave area had especially predictive value in the LBBB patient group (OR = 2.77 in LBBB vs. 1.09 in non-LBBB). This predictive value persisted after adjustment of multiple covariates, such as gender, ischemia, age, hypertension, coronary artery bypass graft, and the usage of diuretics and -blockers. In LBBB patients, the increase in LVEF was 6.1 9.7% and 11.3 +/- 9.1% in patients with T-wave area below and above the median value, respectively (P < 0.01). ConclusionIn patients with LBBB morphology of the QRS complex, a larger baseline T-wave area is an important independent predictor of LVEF increase following CRT. C1 [Engels, Elien B.; Van Deursen, Caroline J. M.; Prinzen, Frits W.] Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Physiol, NL-6200 MD Maastricht, Netherlands. [Vernooy, Kevin] Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Cardiol, NL-6200 MD Maastricht, Netherlands. [Vegh, Eszter M.; Singh, Jagmeet P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Arrhythmia Serv, Boston, MA USA. RP Prinzen, FW (reprint author), Maastricht Univ, Deptartment Physiol, POB 616, NL-6200 MD Maastricht, Netherlands. EM frits.prinzen@maastrichtuniversity.nl OI Engels, Elien/0000-0002-6300-0564 FU Biological Delivery Systems (Johnson Johnson); EBR Systems; Medtronic; MSD; Proteus Biomedical; Biotronik; Boston Scientific; SJM; Sorin Group FX F.W.P. has received research grants from Biological Delivery Systems (Johnson & Johnson), EBR Systems, Medtronic, MSD, and Proteus Biomedical and is advisor to St. Jude Medical. J.P.S. receives research grants and consults for Biotronik, Boston Scientific, SJM, Medtronic, and Sorin Group. K.V. received research grants and consults for Medtronic. Other authors: No disclosures. NR 28 TC 9 Z9 9 U1 5 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1045-3873 EI 1540-8167 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD FEB PY 2015 VL 26 IS 2 BP 176 EP 183 DI 10.1111/jce.12549 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CB4VO UT WOS:000349626600011 PM 25230363 ER PT J AU Keo-Meier, CL Herman, LI Reisner, SL Pardo, ST Sharp, C Babcock, JC AF Keo-Meier, Colton L. Herman, Levi I. Reisner, Sari L. Pardo, Seth T. Sharp, Carla Babcock, Julia C. TI Testosterone Treatment and MMPI-2 Improvement in Transgender Men: A Prospective Controlled Study SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE transgender; psychopathology; hormonal sex-reassignment therapy; female-to-male; testosterone ID GENDER IDENTITY DISORDER; TO-MALE TRANSSEXUALS; CROSS-SEX HORMONES; PSYCHIATRIC COMORBIDITY; REPLACEMENT THERAPY; ENDOCRINE TREATMENT; HEALTH; DEPRESSION; STRESS; ADULT AB Objective: Most transgender men desire to receive testosterone treatment in order to masculinize their bodies. In this study, we aimed to investigate the short-term effects of testosterone treatment on psychological functioning in transgender men. This is the 1st controlled prospective follow-up study to examine such effects. Method: We examined a sample of transgender men (n = 48) and nontransgender male (n = 53) and female (n = 62) matched controls (mean age = 26.6 years; 74% White). We asked participants to complete the Minnesota Multiphasic Personality Inventory (2nd ed., or MMPI-2; Butcher, Graham, Tellegen, Dahlstrom, & Kaemmer, 2001) to assess psychological functioning at baseline and at the acute posttreatment follow-up (3 months after testosterone initiation). Regression models tested (a) Gender x Time interaction effects comparing divergent mean response profiles across measurements by gender identity; (b) changes in psychological functioning scores for acute postintervention measurements, adjusting for baseline measures, comparing transgender men with their matched nontransgender male and female controls and adjusting for baseline scores; and (c) changes in meeting clinical psychopathological thresholds. Results: Statistically significant changes in MMPI-2 scale scores were found at 3-month follow-up after initiating testosterone treatment relative to baseline for transgender men compared with female controls (female template): reductions in Hypochondria (p = .05), Depression (p = .05), Hysteria (p = .05), and Paranoia (p = .01); and increases in Masculinity-Femininity scores (p = .01). Gender = Time interaction effects were found for Hysteria (p = .05) and Paranoia (p = .01) relative to female controls (female template) and for Hypochondria (p = .05), Depression (p = .01), Hysteria (p = .01), Psychopathic Deviate (p = .05), Paranoia (p = .01), Psychasthenia (p = .01), and Schizophrenia (p = .01) compared with male controls (male template). In addition, the proportion of transgender men presenting with co-occurring psychopathology significantly decreased from baseline compared with 3-month follow-up relative to controls (p = .05). Conclusions: Findings suggest that testosterone treatment resulted in increased levels of psychological functioning on multiple domains in transgender men relative to nontransgender controls. These findings differed in comparisons of transgender men with female controls using the female template and with male controls using the male template. No iatrogenic effects of testosterone were found. These findings suggest a direct positive effect of 3 months of testosterone treatment on psychological functioning in transgender men. C1 [Keo-Meier, Colton L.] Univ Houston, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77204 USA. [Keo-Meier, Colton L.] Baylor Coll Med, Houston, TX 77030 USA. [Herman, Levi I.; Sharp, Carla; Babcock, Julia C.] Univ Houston, Houston, TX 77204 USA. [Herman, Levi I.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Reisner, Sari L.] Harvard Sch Publ Hlth & Fenway Hlth, Boston, MA USA. [Pardo, Seth T.] Alliant Int Univ, San Diego, CA USA. RP Keo-Meier, CL (reprint author), Univ Houston, Dept Psychol, 126 Heyne Bldg, Houston, TX 77204 USA. EM ckeo-meier@uh.edu OI Babcock, Julia/0000-0001-6049-8988; Sharp, Carla/0000-0001-8349-4701 FU American Psychological Association Division 44 Matthew W. Scholarship Award; University of Houston Women, Gender, & Sexuality Studies Blanche Espy Chenoweth Graduate Fellowship award; University of Houston Small Grants Program; University of Houston; University of Houston College of Liberal Arts and Sciences Graduate Scholarship; Parents, Families, and Friends of Lesbians and Gays (PFLAG) HATCH Scholarship; Houston Transgender Unity Committee Peggy Rudd Scholarship; National Institutes of Mental Health [1R01MH094323-01] FX Funding for this study was provided by the American Psychological Association Division 44 Matthew W. Scholarship Award for Female to Male Transgender Research; the University of Houston Women, Gender, & Sexuality Studies Blanche Espy Chenoweth Graduate Fellowship award; the University of Houston Small Grants Program awarded to Julia C. Babcock; the University of Houston Start-Up Funding awarded to Carla Sharp; the University of Houston College of Liberal Arts and Sciences Graduate Scholarship; the Parents, Families, and Friends of Lesbians and Gays (PFLAG) HATCH Scholarship; and the Houston Transgender Unity Committee Peggy Rudd Scholarship. Sari L. Reisner was supported by National Institutes of Mental Health Grant 1R01MH094323-01. NR 69 TC 10 Z9 10 U1 4 U2 18 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD FEB PY 2015 VL 83 IS 1 BP 143 EP 156 DI 10.1037/a0037599 PG 14 WC Psychology, Clinical SC Psychology GA CB4PY UT WOS:000349611500013 PM 25111431 ER PT J AU Franklin, A Franklin, A Swanson, JB Shui, A Voigt, RG AF Franklin, Adiaha Franklin, Adiaha Swanson, Jennifer B. Shui, Amy Voigt, Robert G. TI Effect of Parent Education on Autistic Regression in Preschool-Aged Children SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS LA English DT Meeting Abstract C1 [Franklin, Adiaha; Franklin, Adiaha; Swanson, Jennifer B.; Voigt, Robert G.] Baylor Coll Med, Houston, TX 77030 USA. [Shui, Amy] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0196-206X EI 1536-7312 J9 J DEV BEHAV PEDIATR JI J. Dev. Behav. Pediatr. PD FEB-MAR PY 2015 VL 36 IS 2 MA 72 BP S16 EP S16 PG 1 WC Behavioral Sciences; Psychology, Developmental; Pediatrics SC Behavioral Sciences; Psychology; Pediatrics GA CB2HO UT WOS:000349448000057 ER PT J AU Meadows, EA Vannatta, K Gerhardt, CA Barrera, M Patenaude, A Fairclough, D Kupst, MJ AF Meadows, Emily A. Vannatta, Kathryn Gerhardt, Cynthia A. Barrera, Maru Patenaude, Andrea Fairclough, Diane Kupst, Mary Jo TI Peer Experiences and Emotional Distress Among Pediatric Brain Tumor Survivors SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS LA English DT Meeting Abstract C1 [Meadows, Emily A.; Vannatta, Kathryn; Gerhardt, Cynthia A.] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA. [Barrera, Maru] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Patenaude, Andrea] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Fairclough, Diane] Univ Colorado, Aurora, CO USA. [Kupst, Mary Jo] Med Coll Wisconsin, Milwaukee, WI 53226 USA. RI Vannatta, Kathryn/E-4237-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0196-206X EI 1536-7312 J9 J DEV BEHAV PEDIATR JI J. Dev. Behav. Pediatr. PD FEB-MAR PY 2015 VL 36 IS 2 MA 47 BP S12 EP S12 PG 1 WC Behavioral Sciences; Psychology, Developmental; Pediatrics SC Behavioral Sciences; Psychology; Pediatrics GA CB2HO UT WOS:000349448000042 ER PT J AU Eaton, JL Mohr, DC Mohammad, A Kirkhorn, S Gerstel-Santucci, C McPhaul, K Hodgson, MJ AF Eaton, Jennifer L. Mohr, David C. Mohammad, Amir Kirkhorn, Steven Gerstel-Santucci, Christina McPhaul, Kathleen Hodgson, Michael J. TI Implementation of a Novel Occupational and Environmental Medicine Specialty Teleconsultation Service The VHA Experience SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID HEALTH-CARE; PROVIDER SATISFACTION; WORKERS-COMPENSATION; CONSULTATION; TELEPHONE; TELEMEDICINE; CLINICIAN; PATIENT AB Objective: Occupational and environmental medicine (OEM) physician specialty practices continue to grow in scope and intensity across the Veterans Health Administration. This study characterizes the implementation of a novel, nationwide telemedicine program that provides OEM specialty consultation to providers across the Veterans Health Administration. Methods: We examined provider requests and specialist responses for a 6-month pilot from May to October 2013. Characteristics of consult users, determinants of case complexity, and specific applications of OEM specialty expertise were identified. Results: Over a 6-month period, employee occupational health providers consulted the OEM telemedicine pilot a total of 65 times. Employee occupational health providers without formal training repeatedly identified complex cases related to work and disability. Conclusions: The program has created a new system management solution to deliver expert, in-depth consultation and real-time provider education in OEM. C1 [Eaton, Jennifer L.; Mohammad, Amir; Kirkhorn, Steven; Gerstel-Santucci, Christina; McPhaul, Kathleen] VHA, Occupat Hlth Grp, Off Publ Hlth, Washington, DC 20006 USA. [Eaton, Jennifer L.] VA Med Ctr, War Related Illness & Injury Study Ctr, Washington, DC USA. [Mohr, David C.] VA Boston Healthcare Syst, Dept Vet Affairs, Ctr Healthcare Org & Implementat Res, Jamaica Plain, MA USA. [Mohr, David C.] Boston Univ, Dept Hlth Policy & Management, Sch Publ Hlth, Boston, MA 02215 USA. [Mohammad, Amir] Yale Univ, Yale Occupat & Environm Med Program, Dept Internal Med, VA Connecticut Healthcare Syst,Sch Med, New Haven, CT 06510 USA. [Hodgson, Michael J.] Occupat Safety & Hlth Adm, Off Occupat Med, Washington, DC USA. RP Eaton, JL (reprint author), VHA, Occupat Hlth Grp, 1717 H St NW Rm 504, Washington, DC 20006 USA. EM Jennifer.Lipkowitz-Eaton@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development [CIN 13-403]; VA Office of Public Health FX This material is based upon work supported by the VA Office of Public Health. Dr Mohr's work on this project was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, for Center for Healthcare Organization and Implementation Research (CIN 13-403). NR 29 TC 0 Z9 0 U1 3 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD FEB PY 2015 VL 57 IS 2 BP 173 EP 177 DI 10.1097/JOM.0000000000000330 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CB2VO UT WOS:000349486700012 PM 25654518 ER PT J AU Cicero, DC Docherty, AR Becker, TM Martin, EA Kerns, JG AF Cicero, David C. Docherty, Anna R. Becker, Theresa M. Martin, Elizabeth A. Kerns, John G. TI ABERRANT SALIENCE, SELF-CONCEPT CLARITY, AND INTERVIEW-RATED PSYCHOTIC-LIKE EXPERIENCES SO JOURNAL OF PERSONALITY DISORDERS LA English DT Article ID HIGH-RISK; 1ST-EPISODE PSYCHOSIS; PERSONALITY-DISORDERS; STRUCTURED INTERVIEW; MAGICAL IDEATION; 5-FACTOR MODEL; SCHIZOPHRENIA; SCHIZOTYPY; SYMPTOMS; ESTEEM AB Many social-cognitive models of psychotic-like symptoms posit a role for self-concept and aberrant salience. Previous work has shown that the interaction between aberrant salience and self-concept clarity is associated with self-reported psychotic-like experiences. In the current research with two structured interviews, the interaction between aberrant salience and self-concept clarity was found to be associated with interview-rated psychotic-like experiences. The interaction was associated with psychotic-like experiences composite scores, delusional ideation, grandiosity, and perceptual anomalies. In all cases, self-concept clarity was negatively associated with psychotic-like experiences at high levels of aberrant salience, but unassociated with psychotic-like experiences at low levels of aberrant salience. The interaction was specific to positive psychotic-like experiences and not present for negative or disorganized ratings. The interaction was not mediated by self-esteem levels. These results provide further evidence that aberrant salience and self-concept clarity play an important role in the generation of psychotic-like experiences. C1 [Cicero, David C.] Univ Hawaii Manoa, Honolulu, HI 96822 USA. [Docherty, Anna R.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. [Becker, Theresa M.] Univ Washington, Seattle, WA 98195 USA. [Martin, Elizabeth A.] Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Kerns, John G.] Univ Missouri, Columbia, MO 65211 USA. RP Cicero, DC (reprint author), Univ Hawaii Manoa, Dept Psychol, Sakamaki Hall,D406,2530 Dole St, Honolulu, HI 96822 USA. EM dcicero@hawaii.edu RI Cicero, David/E-2046-2016; OI Cicero, David/0000-0002-5666-9139; Docherty, Anna/0000-0001-7139-7007 FU National Research Service Award from the National Institute of Mental Health FX Work on this article was supported by a National Research Service Award from the National Institute of Mental Health. NR 75 TC 3 Z9 3 U1 3 U2 9 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0885-579X EI 1943-2763 J9 J PERS DISORD JI J. Pers. Disord. PD FEB PY 2015 VL 29 IS 1 BP 79 EP 99 PG 21 WC Psychiatry SC Psychiatry GA CB6MS UT WOS:000349741700006 PM 25102085 ER PT J AU Xu, K Krystal, JH Ning, YP Chen, DC He, HB Wang, DP Ke, XY Zhang, XF Ding, Y Liu, YP Gueorguieva, R Wang, ZH Limoncelli, D Pietrzak, RH Petrakis, IL Zhang, XY Fan, N AF Xu, Ke Krystal, John H. Ning, Yuping Chen, Da Chun He, Hongbo Wang, Daping Ke, Xiaoyin Zhang, Xifan Ding, Yi Liu, Yuping Gueorguieva, Ralitza Wang, Zuoheng Limoncelli, Diana Pietrzak, Robert H. Petrakis, Ismene L. Zhang, Xiangyang Fan, Ni TI Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Ketamine psychosis; Schizophrenia; Positive and Negative Syndrome Scale (PANSS); Factor analysis; Symptom severity ID GENDER-DIFFERENCES; WORKING-MEMORY; SUBANESTHETIC KETAMINE; RECEPTOR HYPOFUNCTION; COGNITIVE IMPAIRMENT; HEALTHY-VOLUNTEERS; THOUGHT-DISORDER; NMDA ANTAGONIST; 5-FACTOR MODEL; ANIMAL-MODEL AB Objective: Studies of the effects of the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, ketamine, have suggested similarities to the symptoms of schizophrenia. Our primary goal was to evaluate the dimensions of the Positive and Negative Syndrome Scale (PANSS) in ketamine users (acute and chronic) compared to schizophrenia patients (early and chronic stages). Method: We conducted exploratory factor analysis for the PANSS from four groups: 135 healthy subject administrated ketamine or saline, 187 inpatients of ketamine abuse; 154 inpatients of early course schizophrenia and 522 inpatients of chronic schizophrenia. Principal component factor analyses were conducted to identify the factor structure of the PANSS. Results: Factor analysis yielded five factors for each group: positive, negative, cognitive, depressed, excitement or dissociation symptoms. The symptom dimensions in two schizophrenia groups were consistent with the established five-factor model (Wallwork et al., 2012). The factor structures across four groups were similar, with 19 of 30 symptoms loading on the same factor in at least 3 of 4 groups. The factors in the chronic ketamine group were more similar to the factors in the two schizophrenia groups rather than to the factors in the acute ketamine group. Symptom seventies were significantly different across the groups (Kruskal Wallis chi(2)(4) = 540.6, p < 0.0001). Symptoms in the two ketamine groups were milder than in the two schizophrenia groups (Cohen's d = 0.7). Conclusion: Our results provide the evidence of similarity in symptom dimensions between ketamine psychosis and schizophrenia psychosis. The interpretations should be cautious because of potential confounding factors. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Xu, Ke; Krystal, John H.; Gueorguieva, Ralitza; Pietrzak, Robert H.; Petrakis, Ismene L.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Ning, Yuping; He, Hongbo; Wang, Daping; Ke, Xiaoyin; Ding, Yi; Liu, Yuping; Fan, Ni] Guangzhou Med Univ, Guangzhou Brain Hosp, Affiliated Brain Hosp, Guangzhou 510370, Guangdong, Peoples R China. [Xu, Ke; Krystal, John H.; Limoncelli, Diana; Pietrzak, Robert H.; Petrakis, Ismene L.] US Dept Vet Affairs, VA Connecticut Healthcare Syst, West Haven, CT USA. [Zhang, Xifan] Guangzhou Baiyun Mental Hlth Hosp, Guangzhou, Guangdong, Peoples R China. [Gueorguieva, Ralitza; Wang, Zuoheng] Yale Univ, Dept Biostat, Sch Publ Hlth, New Haven, CT USA. [Chen, Da Chun; Zhang, Xiangyang] Peking Univ, Beijing Hui Long Guan Hosp, Biol Psychiat Ctr, Beijing 100096, Peoples R China. RP Fan, N (reprint author), Guangzhou Brain Hosp, 36 Mingxin Rd, Guangzhou 510370, Guangdong, Peoples R China. EM fanni2005@126.com OI Gueorguieva, Ralitza/0000-0003-0944-5973 FU Chinese National Key Clinical Program in Psychiatry to Guangzhou Brain Hospital; Health Bureau of Guangzhou, China [20131A011091]; National Institute on Drug Abuse, US [K12 DA000167]; APA/Merck Early Academic Career Award, US FX This work is supported by grants from Chinese National Key Clinical Program in Psychiatry to Guangzhou Brain Hospital and from Health Bureau of Guangzhou (No: 20131A011091), China, the grant K12 DA000167 from National Institute on Drug Abuse, US, and APA/Merck Early Academic Career Award, US. NR 55 TC 7 Z9 7 U1 2 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD FEB PY 2015 VL 61 BP 64 EP 72 DI 10.1016/j.jpsychires.2014.12.012 PG 9 WC Psychiatry SC Psychiatry GA CB6IP UT WOS:000349731000010 PM 25560772 ER PT J AU Zvolensky, MJ Kotov, R Schechter, CB Gonzalez, A Vujanovic, A Pietrzak, RH Crane, M Kaplan, J Moline, J Southwick, SM Feder, A Udasin, I Reissman, DB Luft, BJ AF Zvolensky, Michael J. Kotov, Roman Schechter, Clyde B. Gonzalez, Adam Vujanovic, Anka Pietrzak, Robert H. Crane, Michael Kaplan, Julia Moline, Jacqueline Southwick, Steven M. Feder, Adriana Udasin, Iris Reissman, Dori B. Luft, Benjamin J. TI Post-disaster stressful life events and WTC-related posttraumatic stress, depressive symptoms, and overall functioning among responders to the World Trade Center disaster SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Stress exposure; Stress generation; Depression; Disaster; Trauma ID PTSD CHECKLIST PCL; RISK-FACTORS; PSYCHOMETRIC PROPERTIES; RECOVERY WORKERS; VICTIMS SPEAK; CENTER RESCUE; FIT INDEXES; DISORDER; EXPOSURE; RESILIENCE AB Background: The current study examined contributions of post-disaster stressful life events in relation to the maintenance of WTC-related posttraumatic stress, depressive symptoms, and overall functioning among rescue, recovery, and clean-up workers who responded to the September 11, 2001 World Trade Center (WTC) terrorist attacks. Methods: Participants were 18,896 WTC responders, including 8466 police officers and 10,430 non-traditional responders (85.8% male; 86.4% Caucasian; M-age = 39.5, SD = 8.8) participating in the WTC Health Program who completed an initial examination between July, 2002 and April, 2010 and who were reassessed, on average, 2.5 years later. Results: Path analyses were conducted to evaluate contributions of life events to the maintenance of WTC-related posttraumatic stress, depressive symptoms, and overall functioning. These analyses were stratified by police and non-traditional responder groups and adjusted for age, sex, time from 9/11 to initial visit, WTC exposures (three WTC contextual exposures: co-worker, friend, or a relative died in the disaster; co-worker, friend, or a relative injured in the disaster; and responder was exposed to the dust cloud on 9/11), and interval from initial to first follow-up visit. In both groups, WTC-related posttraumatic stress, depressive symptoms, and overall functioning were stable over the follow-up period. WTC exposures were related to these three outcomes at the initial assessment. WTC-related posttraumatic stress, depressive symptoms, and overall functioning, at the initial assessment each predicted the occurrence of post-disaster stressful life events, as measured by Disaster Supplement of the Diagnostic Interview Schedule. Post-disaster stressful life events, in turn, were associated with subsequent mental health, indicating partial mediation of the stability of observed mental health. Conclusions: The present findings suggest a dynamic interplay between exposure, post-disaster stressful life events, and WTC-related posttraumatic stress, depressive symptoms, and overall functioning among WTC disaster responders. Published by Elsevier Ltd. C1 [Zvolensky, Michael J.] Univ Houston, Dept Psychol, Houston, TX 77204 USA. [Zvolensky, Michael J.] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA. [Kotov, Roman; Gonzalez, Adam] SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA. [Schechter, Clyde B.] Albert Einstein Coll Med, Dept Family & Social Med, Bronx, NY 10467 USA. [Vujanovic, Anka] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Pietrzak, Robert H.; Southwick, Steven M.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, VA Connecticut Healthcare Syst, West Haven, CT USA. [Pietrzak, Robert H.; Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Crane, Michael; Kaplan, Julia] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA. [Moline, Jacqueline] North Shore LIJ Hlth Syst, Dept Populat Hlth, Great Neck, NY USA. [Feder, Adriana] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Udasin, Iris] Univ Med & Dent New Jersey, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA. [Reissman, Dori B.] NIOSH, WTC Hlth Program, Washington, DC USA. [Luft, Benjamin J.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA. RP Zvolensky, MJ (reprint author), Univ Houston, 126 Heyne Bldg,Suite 104, Houston, TX 77204 USA. EM mjzvolen@central.uh.edu OI Luft, Benjamin/0000-0001-9008-7004 FU National Institute of Occupational Safety and Health [200-2011-42057, 200-201139410] FX This project was supported by National Institute of Occupational Safety and Health awards (200-2011-42057 and 200-201139410). NIOSH had no direct role in the study design, collection, analysis, or interpretation of the data, writing of the manuscript, or the decision to submit the paper for publication. NR 59 TC 3 Z9 3 U1 5 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD FEB PY 2015 VL 61 BP 97 EP 105 DI 10.1016/j.jpsychires.2014.11.010 PG 9 WC Psychiatry SC Psychiatry GA CB6IP UT WOS:000349731000014 PM 25499737 ER PT J AU Armour, C Tsai, J Durham, TA Charak, R Biehn, TL Elhai, JD Pietrzak, RH AF Armour, Cherie Tsai, Jack Durham, Tory A. Charak, Ruby Biehn, Tracey L. Elhai, Jon D. Pietrzak, Robert H. TI Dimensional structure of DSM-5 posttraumatic stress symptoms: Support for a hybrid Anhedonia and Externalizing Behaviors model SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Posttraumatic stress disorder; DSM-5; 7-Factor hybrid model; Confirmatory factor analysis; Latent structure ID CONFIRMATORY FACTOR-ANALYSIS; DYSPHORIC AROUSAL MODEL; TRAUMA HISTORY; ANXIETY DISORDERS; PTSD SYMPTOMS; SAMPLE; VETERANS; EXPOSURE; SYMPTOMATOLOGY; ADOLESCENTS AB Several revisions to the symptom clusters of posttraumatic stress disorder (PTSD) have been made in the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Central to the focus of this study was the revision of PTSD's tripartite structure in DSM-IV into four symptom clusters in DSM-5. Emerging confirmatory factor analytic (CFA) studies have suggested that DSM-5 PTSD symptoms may be best represented by one of two 6-factor models: (1) an Externalizing Behaviors model characterized by a factor which combines the irritability/anger and self-destructive/reckless behavior items; and (2) an Anhedonia model characterized by items of loss of interest, detachment, and restricted affect. The current study conducted CFAs of DSM-5 PTSD symptoms assessed using the PTSD Checklist for DSM-5 (PCL-5) in two independent and diverse trauma-exposed samples of a nationally representative sample of 1484 U.S. veterans and a sample of 497 Midwestern U.S. university undergraduate students. Relative fits of the DSM-5 model, the DSM-5 Dysphoria model, the DSM-5 Dysphoric Arousal model, the two 6-factor models, and a newly proposed 7-factor Hybrid model, which consolidates the two 6-factor models, were evaluated. Results revealed that, in both samples, both 6-factor models provided significantly better fit than the 4-factor DSM-5 model, the DSM-5 Dysphoria model and the DSM-5 Dysphoric Arousal model. Further, the 7-factor Hybrid model, which incorporates key features of both 6-factor models and is comprised of re-experiencing, avoidance, negative affect, anhedonia, externalizing behaviors, and anxious and dysphoric arousal symptom clusters, provided superior fit to the data in both samples. Results are discussed in light of theoretical and empirical support for the latent structure of DSM-5 PTSD symptoms. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Armour, Cherie] Univ Ulster, Psychol Res Inst, Coleraine BT52 1SA, Londonderry, North Ireland. [Tsai, Jack] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA. [Tsai, Jack; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Durham, Tory A.; Biehn, Tracey L.] Univ Toledo, Dept Psychol, Toledo, OH USA. [Charak, Ruby] Univ Nebraska, Dept Psychol, Lincoln, NE 68588 USA. [Elhai, Jon D.] Univ Toledo, Dept Psychiat, Toledo, OH USA. [Pietrzak, Robert H.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, VA Connecticut Healthcare Syst, West Haven, CT USA. RP Armour, C (reprint author), Univ Ulster, Psychol Res Inst, Coleraine Campus,Cromore Rd, Coleraine BT52 1SA, Londonderry, North Ireland. EM armour.cherie@gmail.com OI Armour, Cherie/0000-0001-7649-3874 FU U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder (PTSD); Clinical Neurosciences Division of the National Center for PTSD FX The National Health and Resilience in Veterans Study was funded by the U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder (PTSD). Preparation of this report was supported in part by the Clinical Neurosciences Division of the National Center for PTSD and a private donation. The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of sponsoring organizations, agencies, or the U.S. government. NR 56 TC 40 Z9 41 U1 5 U2 30 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD FEB PY 2015 VL 61 BP 106 EP 113 DI 10.1016/j.jpsychires.2014.10.012 PG 8 WC Psychiatry SC Psychiatry GA CB6IP UT WOS:000349731000015 PM 25479765 ER PT J AU Jung, M Parrinello, CM Xue, XN Mack, WJ Anastos, K Lazar, JM Selzer, RH Shircore, AM Plankey, M Tien, P Cohen, M Gange, SJ Hodis, HN Kaplan, RC AF Jung, Molly Parrinello, Christina M. Xue, Xiaonan Mack, Wendy J. Anastos, Kathryn Lazar, Jason M. Selzer, Robert H. Shircore, Anne M. Plankey, Michael Tien, Phyllis Cohen, Mardge Gange, Stephen J. Hodis, Howard N. Kaplan, Robert C. TI Echolucency of the Carotid Artery Intima-Media Complex and Intima-Media Thickness Have Different Cardiovascular Risk Factor Relationships: The Women's Interagency HIV Study SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE carotid arteries; epidemiology; immune system; risk factors; ultrasonics ID ACTIVE ANTIRETROVIRAL THERAPY; UPPSALA SENIORS PIVUS; OXIDATIVE STRESS; INFECTED WOMEN; LIPID-RICH; ATHEROSCLEROSIS; ULTRASOUND; PLAQUES; COHORT; LIPOPROTEINS AB Background-Adults infected with HIV have increased atherosclerosis potentially associated with both HIV and non-HIV associated factors. We characterized risk factors for atherosclerosis as measured by noninvasive vascular imaging. Methods and Results-We used B-mode ultrasound to examine levels and correlates of echogenicity and vessel wall thickness of the carotid artery intima-media complex in 1282 HIV-infected and 510 HIV-uninfected women of the Women's Interagency HIV Study. Levels of gray scale median (GSM, a measure of echogenicity) did not vary between HIV infection groups. In both groups, smokers had increased GSM, whereas age, diabetes, elevated blood pressure, and high BMI were associated with lower (rather than higher) GSM. Each of these non-lipid CVD risk factors, especially age and blood pressure, was also associated with higher levels of carotid artery intima-media thickness (cIMT). Higher serum triglyceride levels were associated with lower GSM in both HIV-infected and HIV-uninfected groups. Additional lipid risk factors for low GSM including high LDL cholesterol and low HDL cholesterol levels were identified in HIV uninfected but not in HIV infected women. In contrast to findings for GSM, among the lipid parameters only LDL cholesterol level had an association with cIMT, which was observed only in the HIV uninfected group. Conclusions-Lipid and non-lipid risk factor associations with echolucency of the carotid artery and the thickness of the common carotid artery intima-media layer suggest that these measures capture different aspects of atherosclerosis. C1 [Jung, Molly; Xue, Xiaonan; Anastos, Kathryn; Kaplan, Robert C.] Albert Einstein Coll Med, Dept Epidemiol, Bronx, NY 10461 USA. [Parrinello, Christina M.; Gange, Stephen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Mack, Wendy J.; Selzer, Robert H.; Shircore, Anne M.; Hodis, Howard N.] Univ So Calif, Dept Med, Atherosclerosis Res Unit, Los Angeles, CA USA. [Lazar, Jason M.] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA. [Plankey, Michael] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA. [Tien, Phyllis] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Tien, Phyllis] San Francisco VA Med Ctr, San Francisco, CA USA. [Cohen, Mardge] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge] Rush Univ, Chicago, IL 60612 USA. RP Kaplan, RC (reprint author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, 1300 Morris Pk Ave,Room 1315, Bronx, NY 10461 USA. EM robert.kaplan@einstein.yu.edu FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI grant) [UL1 RR024131]; National Heart, Lung and Blood Institute [1R01HL095140, 1R01HL083760, R21HL120394, R01HL126543] FX The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is co-funded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI grant number UL1 RR024131). Additional co-funding is provided by the National Heart, Lung and Blood Institute (1R01HL095140, 1R01HL083760, R21HL120394 and R01HL126543 to Kaplan). NR 22 TC 1 Z9 1 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD FEB PY 2015 VL 4 IS 2 AR e001405 DI 10.1161/JAHA.114.001405 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CB5LG UT WOS:000349668000009 ER PT J AU Tuzova, M Richmond, J Wolpowitz, D Curiel-Lewandrowski, C Chaney, K Kupper, T Cruikshank, W AF Tuzova, Marina Richmond, Jillian Wolpowitz, Deon Curiel-Lewandrowski, Clara Chaney, Keri Kupper, Thomas Cruikshank, William TI CCR4+T cell recruitment to the skin in mycosis fungoides: potential contributions by thymic stromal lymphopoietin and interleukin-16 SO LEUKEMIA & LYMPHOMA LA English DT Article DE Thymic stromal lymphopoietin (TSLP); interleukin-16 (IL-16); mycosis fungoides (MF); cutaneous T cell lymphoma (CTCL) ID MACROPHAGE-DERIVED CHEMOKINE; EOSINOPHIL CATIONIC PROTEIN; T-REGULATORY CELLS; ATOPIC-DERMATITIS; DISEASE-ACTIVITY; DENDRITIC CELLS; SEZARY-SYNDROME; EXPRESSION; LYMPHOMA; IL-16 AB Mycosis fungoides (MF) is characterized by skin accumulation of CCR4+CCR7- effector memory T cells; however the mechanism for their recruitment is not clearly identified. Thymic Stromal Lymphopoietin (TSLP) is a keratinocyte-derived cytokine that triggers Th2 immunity and is associated with T cell recruitment to the skin in atopic dermatitis. Interleukin-16 (IL-16) is a chemoattractant and growth factor for CD4+ T cells. We hypothesized that TSLP and IL-16 could contribute to recruitment of malignant T cells in MF. We found elevated TSLP and IL-16 in very early stage patients' plasma and skin biopsies, prior to elevation in CCL22. Both TSLP and IL-16 induced migratory responses of CCR4+TSLPR+CD4+CCR7-CD31+ cells, characteristic of malignant T cells in the skin. Co-stimulation also resulted in signifi cant proliferative responses. We conclude that TSLP and IL-16, expressed at early stages of disease, function to recruit malignant T cells to the skin and contribute to their enhanced proliferation. C1 [Tuzova, Marina; Richmond, Jillian; Cruikshank, William] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA. [Wolpowitz, Deon] Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA. [Curiel-Lewandrowski, Clara] Arizona State Univ, Arizona Canc Ctr, Tucson, AZ USA. [Chaney, Keri; Kupper, Thomas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Cruikshank, W (reprint author), Boston Univ, Sch Med, Ctr Pulm, 72 East Concord St,R-304, Boston, MA 02118 USA. EM bcruiksh@bu.edu FU NIH [1R01CA122737] FX This work was supported by NIH grant 1R01CA122737. NR 46 TC 2 Z9 3 U1 1 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 EI 1029-2403 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PD FEB PY 2015 VL 56 IS 2 BP 440 EP 449 DI 10.3109/10428194.2014.919634 PG 10 WC Oncology; Hematology SC Oncology; Hematology GA CB5IZ UT WOS:000349662000028 PM 24794807 ER PT J AU Singer, SJ Nieva, HR Brede, N Ling, J Leydon, N Weissman, JS Goldmann, D Griswold, P Yoon, C Orav, EJ Bates, DW Biondolillo, M Schiff, GD AF Singer, Sara J. Nieva, Harry Reyes Brede, Namara Ling, Judy Leydon, Nicholas Weissman, Joel S. Goldmann, Don Griswold, Paula Yoon, Catherine Orav, E. John Bates, David W. Biondolillo, Madeleine Schiff, Gordon D. TI Evaluating Ambulatory Practice Safety The PROMISES Project Administrators and Practice Staff Surveys SO MEDICAL CARE LA English DT Article DE primary care; care improvement; patient safety; survey research ID HOSPITALIZED-PATIENTS; ADVERSE EVENTS; PRIMARY-CARE; TEAMWORK; PHYSICIANS; ATTITUDES; NURSES; CLAIMS AB Background: Ambulatory practices deliver most health care services and contribute to malpractice risk. Yet, policymakers and practitioners often lack information about safety and malpractice risk needed to guide improvement. Objective: To assess staff and administrator perceptions of safety and malpractice risk in ambulatory settings. Research Design: We administered surveys in small-sized to medium-sized primary care practices in Massachusetts as part of a randomized controlled trial to reduce ambulatory malpractice risk. Subjects: Twenty-five office practice managers/administrators and 482 staff, including [physicians, physician assistants, and nurse practitioners (MD/PA/NPs)], nurses, other clinicians, managers, and administrators. Measures: Surveys included structured questions about 3 high-risk clinical domains: referral, test result, and medication management, plus communication with patients and among staff. The 30-item administrator survey evaluated the presence of organizational safety structures and processes; the 63-item staff survey queried safety and communication concerns. Results: Twenty-two administrators (88%) and 292 staff (61%) responded. Administrators frequently reported important safety systems and processes were absent. Suboptimal or incomplete implementation of referral and test result management systems related to staff perceptions of their quality (P < 0.05). Staff perceptions of suboptimal processes correlated with their concern about practice vulnerability to malpractice suits (P < 0.05). Staff was least positive about referral management system safety, talking openly about safety problems, willingness to report mistakes, and feeling rushed. MD/PA/NPs viewed high-risk system reliability more negatively (P < 0.0001) and teamwork more positively (P < 0.03) than others. Conclusions: Results show opportunities for improvement in closing informational loops and establishing more reliable systems and environments where staff feels respected and safe speaking up. Initiatives to transform primary care should emphasize improving communication among facilities and practitioners. C1 [Singer, Sara J.; Goldmann, Don; Orav, E. John; Bates, David W.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Singer, Sara J.; Nieva, Harry Reyes; Weissman, Joel S.; Goldmann, Don; Orav, E. John; Bates, David W.; Schiff, Gordon D.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Singer, Sara J.; Weissman, Joel S.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Nieva, Harry Reyes; Brede, Namara; Yoon, Catherine; Orav, E. John; Bates, David W.; Schiff, Gordon D.] Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA. [Ling, Judy; Leydon, Nicholas; Biondolillo, Madeleine] Massachusetts Dept Publ Hlth, Bur Hlth Care Safety & Qual, Boston, MA USA. [Leydon, Nicholas] North Shore Med Ctr, Salem, MA USA. [Weissman, Joel S.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA. [Goldmann, Don] Inst Healthcare Improvement, Cambridge, MA USA. [Griswold, Paula] Massachusetts Coalit Prevent Med Errors, Burlington, MA USA. RP Singer, SJ (reprint author), Harvard Univ, Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02115 USA. EM ssinger@hsph.harvard.edu OI Reyes Nieva, Harry/0000-0001-7774-2561 FU Agency for Healthcare Research and Quality [R18HS019508] FX Supported by Grant Number R18HS019508 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. NR 22 TC 2 Z9 2 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD FEB PY 2015 VL 53 IS 2 BP 141 EP 152 PG 12 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CB6ZG UT WOS:000349775000008 PM 25464161 ER PT J AU Keane, MM Cruz, ME Verfaellie, M AF Keane, Margaret M. Cruz, Matt E. Verfaellie, Mieke TI Attention and implicit memory: priming-induced benefits and costs have distinct attentional requirements SO MEMORY & COGNITION LA English DT Article DE Implicit memory; Attention; Amnesia ID DIVIDED ATTENTION; EXPLICIT MEMORY; PERCEPTUAL IDENTIFICATION; CATEGORY-VERIFICATION; EXEMPLAR GENERATION; TERM-MEMORY; AMNESIA; TESTS; TASK; BIAS AB Attention at encoding plays a critical and ubiquitous role in explicit memory performance, but its role in implicit memory performance (i.e., priming) is more variable: some, but not all, priming effects are reduced by division of attention at encoding. A wealth of empirical and theoretical work has aimed to define the critical features of priming effects that do or do not require attention at encoding. This work, however, has focused exclusively on priming effects that are beneficial in nature (wherein performance is enhanced by prior exposure to task stimuli), and has overlooked priming effects that are costly in nature (wherein performance is harmed by prior exposure to task stimuli). The present study takes up this question by examining the effect of divided attention on priming-induced costs and benefits in a speeded picture-naming task. Experiment 1 shows that the costs, but not the benefits, are eliminated by division of attention at encoding. Experiment 2 shows that the costs (as well as the benefits) in this task are intact in amnesic participants, demonstrating that the elimination of the cost in the divided attention condition in Experiment 1 was not an artifact of the reduced availability of explicit memory in that condition. We suggest that the differential role of attention in priming-induced performance costs and benefits is linked to differences in response competition associated with these effects. This interpretation situates the present findings within a theoretical framework that has been applied to a broad range of facilitatory priming effects. C1 [Keane, Margaret M.] Wellesley Coll, Dept Psychol, Wellesley, MA 02481 USA. [Keane, Margaret M.] VA Boston Healthcare Syst, Memory Disorders Res Ctr, Wellesley, MA 02481 USA. [Cruz, Matt E.; Verfaellie, Mieke] VA Boston Healthcare Syst, Memory Disorders Res Ctr, Boston, MA USA. [Cruz, Matt E.; Verfaellie, Mieke] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Keane, MM (reprint author), Wellesley Coll, Dept Psychol, Wellesley, MA 02481 USA. EM mkeane@wellesley.edu FU NIMH NIH HHS [MH70830, R01 MH070830] NR 44 TC 0 Z9 0 U1 1 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0090-502X EI 1532-5946 J9 MEM COGNITION JI Mem. Cogn. PD FEB PY 2015 VL 43 IS 2 BP 216 EP 225 DI 10.3758/s13421-014-0464-4 PG 10 WC Psychology, Experimental SC Psychology GA CB6TL UT WOS:000349759500006 PM 25257650 ER PT J AU Hu, YX Huang, XW Lu, S Hamblin, MR Mylonakis, E Zhang, JM Xi, LY AF Hu, Yongxuan Huang, Xiaowen Lu, Sha Hamblin, Michael R. Mylonakis, Eleftherios Zhang, Junmin Xi, Liyan TI Photodynamic Therapy Combined with Terbinafine Against Chromoblastomycosis and the Effect of PDT on Fonsecaea monophora In Vitro SO MYCOPATHOLOGIA LA English DT Article DE Photodynamic Therapy; Terbinafine; Chromoblastomycosis ID CANDIDA-ALBICANS; PEDROSOI; ITRACONAZOLE AB Chromoblastomycosis, a chronic fungal infection of skin and subcutaneous tissue caused by dematiaceous fungi, is associated with low cure and high relapse rates. Among all factors affecting clinical outcome, etiological agents have an important position. In southern China, Fonsecaea pedrosoi and Fonsecaea monophora are main causative agents causing Chromoblastomycosis. We treated one case of chromoblastomycosis by photodynamic therapy (PDT) of 5-aminolevulinic acid (ALA) irradiation combined with terbinafine 250 mg a day. The lesions were improved after two sessions of ALA-PDT treatment, each including nine times, at an interval of 1 week, combined with terbinafine 250 mg/day oral, and clinical improvement could be observed. In the following study, based on the clinical treatment, the effect of PDT and antifungal drugs on this isolate was detected in vitro. It showed sensitivity to terbinafine, itraconazole or voriconazole, and PDT inhibited the growth. Both the clinic and experiments in vitro confirm the good outcome of ALA-PDT applied in the inhibition of F. monophora. It demonstrated that combination of antifungal drugs with ALA-PDT arises as a promising alternative method for the treatment of these refractory cases of chromoblastomycosis. C1 [Hu, Yongxuan; Huang, Xiaowen; Lu, Sha; Zhang, Junmin; Xi, Liyan] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Dermatol, Guangzhou 510120, Peoples R China. [Hu, Yongxuan] Southern Med Univ, Affiliated Hosp 3, Dept Dermatol & Venerol, Guangzhou 510630, Guangdong, Peoples R China. [Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Mylonakis, Eleftherios] Brown Univ, Dept Med, Warren Alpert Med Sch, Providence, RI 02903 USA. RP Xi, LY (reprint author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Dermatol, 107 West Yanjiang Rd, Guangzhou 510120, Peoples R China. EM xiliyan@mail.sysu.edu.cn OI Hamblin, Michael/0000-0001-6431-4605 FU National Natural Science Foundation of China [81371747] FX This work was kindly supported by the National Natural Science Foundation of China (81371747). NR 23 TC 3 Z9 4 U1 2 U2 8 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0301-486X EI 1573-0832 J9 MYCOPATHOLOGIA JI Mycopathologia PD FEB PY 2015 VL 179 IS 1-2 BP 103 EP 109 DI 10.1007/s11046-014-9828-3 PG 7 WC Mycology SC Mycology GA CB3LG UT WOS:000349528700012 PM 25366276 ER PT J AU Gaudin, R Barteneva, NS AF Gaudin, Raphael Barteneva, Natasha S. TI Sorting of small infectious virus particles by flow virometry reveals distinct infectivity profiles SO NATURE COMMUNICATIONS LA English DT Article ID TETRASPANIN-ENRICHED MICRODOMAINS; PLASMA-MEMBRANE; HEMORRHAGIC-FEVER; ARENAVIRUSES; CYTOMETRY; ORGANIZATION; CHOLESTEROL; MACROPHAGES; RESOLUTION; CELLS AB The nature and concentration of lipids and proteins at the surface of viruses are essential parameters for determining particle infectiveness. Historically, averaged bulk analysis of viral particles has been the primary method to quantitatively investigate these parameters, though this neglects heterogeneity within populations. Here we analyse the properties of Junin virus particles using a sensitive flow virometry assay and further sort virions while conserving their infectiveness. This method allows us to characterize the relationship between infectivity, virus size and RNA content and to compare particles secreted by Vero cells with those from physiologically relevant human primary macrophages. Our study highlights significant differences in particle infectivity according to its nature, the type of producer cells and the lipid membrane composition at the budding site. Together, our results present the flow virometry assay as a powerful and versatile tool to define virus particle profiles. C1 [Gaudin, Raphael; Barteneva, Natasha S.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. [Gaudin, Raphael] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. [Barteneva, Natasha S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. RP Gaudin, R (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, 200 Longwood Ave, Boston, MA 02115 USA. EM raphael.gaudin@childrens.harvard.edu; natasha.barteneva@childrens.harvard.edu FU Harvard Pilot Grant; PCMM/Boston Children's Hospital; National Institutes of Health (New England Regional Center of Excellence in Biodefense and Emerging Infectious Diseases [NERCE BEID]) [GM-075252, U54 AI057159] FX We are thankful to Larry Duckett, David Matsuyama and Paul Melanson, BD Biosciences Inc. (San Jose, CA) for their help with the cytometer's upgrade and functionality. We are grateful to Dr Michael W. Olszowy (Life Technologies) for providing the 40- and 100-nm fluorescent beads. We thank Lloyd Bahlmann for giving us access to Izon technology. We also thank Tom Kirchhausen for letting us use his laboratory and microscopes and Ivan Vorobjev for his helpful advice. We thank Frances Evesson for her comments and critical reading of the manuscript. We greatly acknowledge the Harvard Medical School Electron Microscopy facility. N.S.B. was supported by the Harvard Pilot Grant and PCMM/Boston Children's Hospital. R.G. was supported by the National Institutes of Health Grants GM-075252 and U54 AI057159 (New England Regional Center of Excellence in Biodefense and Emerging Infectious Diseases [NERCE BEID]). NR 39 TC 10 Z9 10 U1 2 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD FEB PY 2015 VL 6 AR 6022 DI 10.1038/ncomms7022 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CC0OL UT WOS:000350035200001 PM 25641385 ER PT J AU Goldman, A Majumder, B Dhawan, A Ravi, S Goldman, D Kohandel, M Majumder, PK Sengupta, S AF Goldman, Aaron Majumder, Biswanath Dhawan, Andrew Ravi, Sudharshan Goldman, David Kohandel, Mohammad Majumder, Pradip K. Sengupta, Shiladitya TI Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition SO NATURE COMMUNICATIONS LA English DT Article ID METASTATIC BREAST-CANCER; TUMOR HETEROGENEITY; POOR-PROGNOSIS; CELLS; MECHANISMS; EXPRESSION; CAVEOLIN-1; DASATINIB; PHASE-2; P73 AB Understanding the emerging models of adaptive resistance is key to overcoming cancer chemotherapy failure. Using human breast cancer explants, in vitro cell lines, mouse in vivo studies and mathematical modelling, here we show that exposure to a taxane induces phenotypic cell state transition towards a favoured transient CD44(Hi)CD24(Hi) chemotherapy-tolerant state. This state is associated with a clustering of CD44 and CD24 in membrane lipid rafts, leading to the activation of Src Family Kinase (SFK)/hemopoietic cell kinase (Hck) and suppression of apoptosis. The use of pharmacological inhibitors of SFK/Hck in combination with taxanes in a temporally constrained manner, where the kinase inhibitor is administered post taxane treatment, but not when co-administered, markedly sensitizes the chemotolerant cells to the chemotherapy. This approach of harnessing chemotherapy-induced phenotypic cell state transition for improving antitumour outcome could emerge as a translational strategy for the management of cancer. C1 [Goldman, Aaron; Sengupta, Shiladitya] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Goldman, Aaron; Sengupta, Shiladitya] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Goldman, Aaron; Ravi, Sudharshan; Sengupta, Shiladitya] Brigham & Womens Hosp, Dept Med, Div Biomed Engn, Boston, MA 02115 USA. [Majumder, Biswanath] India Innovat Res Ctr, Bangalore 560099, Karnataka, India. [Majumder, Biswanath; Majumder, Pradip K.] Narayana Nethrayala, Mitra Biotech Pvt Ltd, Bangalore 560099, Karnataka, India. [Dhawan, Andrew] Queens Univ, Sch Med, Kingston, ON K7L 3N6, Canada. [Kohandel, Mohammad] Univ Waterloo, Dept Appl Math, Waterloo, ON N2L 3G1, Canada. [Sengupta, Shiladitya] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Goldman, A (reprint author), Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. EM goldman1@mit.edu; shiladit@mit.edu FU DoD BCRP Collaborative Innovator Grant [W81XWH-09-1-0700]; NIH [RO1 (1R01CA135242)]; DoD Breakthrough Award [BC132168]; American Lung Association Innovation Award [LCD-259932-N]; Indo-US Joint Center Grant from IUSSTF; American Cancer Society Postdoctoral Fellowship [122854-PF-12-226-01-CDD]; NSERC, Canada FX We would like to thank the Dana Farber Cancer Institute Flow Cytometry Core Facility for their expertise, consulting and assistance with cell sorting experiments. We would like to also thank Dr P. Mukhopadhyay, MD for analysis and interpretation of explant IHC, Dr. Andriy Marusyk for assistance implanting orthotopic tumors and Dr Ashish Kulkarni, PhD for performing blinded measurement of tumour volume. Medical art was obtained from servier.com S.S is supported by a DoD BCRP Collaborative Innovator Grant (W81XWH-09-1-0700), a NIH RO1 (1R01CA135242), a DoD Breakthrough Award (BC132168), an American Lung Association Innovation Award (LCD-259932-N), and an Indo-US Joint Center Grant from IUSSTF. A.G is supported by an American Cancer Society Postdoctoral Fellowship (122854-PF-12-226-01-CDD). M. K is supported by the NSERC, Canada. NR 48 TC 31 Z9 31 U1 2 U2 11 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD FEB PY 2015 VL 6 AR 6139 DI 10.1038/ncomms7139 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CC2TT UT WOS:000350198200001 PM 25669750 ER PT J AU Seidman, MD Gurgel, RK Lin, SY Schwartz, SR Baroody, FM Bonner, JR Dawson, DE Dykewicz, MS Hackell, JM Han, JK Ishman, SL Krouse, HJ Malekzadeh, S Mims, JW Omole, FS Reddy, WD Wallace, DV Walsh, SA Warren, BE Wilson, MN Nnacheta, LC AF Seidman, Michael D. Gurgel, Richard K. Lin, Sandra Y. Schwartz, Seth R. Baroody, Fuad M. Bonner, James R. Dawson, Douglas E. Dykewicz, Mark S. Hackell, Jesse M. Han, Joseph K. Ishman, Stacey L. Krouse, Helene J. Malekzadeh, Sonya Mims, James (Whit) W. Omole, Folashade S. Reddy, William D. Wallace, Dana V. Walsh, Sandra A. Warren, Barbara E. Wilson, Meghan N. Nnacheta, Lorraine C. TI Clinical Practice Guideline: Allergic Rhinitis Executive Summary SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE allergic rhinitis; runny nose; nasal congestion; rhinitis; allergies ID DIAGNOSIS; IMPACT AB The American Academy of OtolaryngologyHead and Neck Surgery Foundation (AAO-HNSF) has published a supplement to this issue featuring the new Clinical Practice Guideline: Allergic Rhinitis. To assist in implementing the guideline recommendations, this article summarizes the rationale, purpose, and key action statements. The 14 recommendations developed address the evaluation of patients with allergic rhinitis, including performing and interpretation of diagnostic testing and assessment and documentation of chronic conditions and comorbidities. It will then focus on the recommendations to guide the evaluation and treatment of patients with allergic rhinitis, to determine the most appropriate interventions to improve symptoms and quality of life for patients with allergic rhinitis. C1 [Seidman, Michael D.] Henry Ford West Bloomfield Hosp, Dept Otolaryngol Head & Neck Surg, West Bloomfield, MI 48322 USA. [Gurgel, Richard K.] Univ Utah, Dept Surg Otolaryngol Head & Neck Surg, Salt Lake City, UT USA. [Lin, Sandra Y.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA. [Schwartz, Seth R.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Baroody, Fuad M.] Univ Chicago, Med Ctr, Dept Otolaryngol, Chicago, IL 60637 USA. [Bonner, James R.] Birmingham VA Med Ctr, Birmingham, AL USA. [Dykewicz, Mark S.] St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO USA. [Hackell, Jesse M.] Pomona Pediat, Pomona, NY USA. [Han, Joseph K.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA. [Ishman, Stacey L.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Krouse, Helene J.] Wayne State Univ, Philadelphia, PA USA. [Malekzadeh, Sonya] Georgetown Univ Hosp, Washington, DC 20007 USA. [Mims, James (Whit) W.] Wake Forest Baptist Hlth, Winston Salem, NC USA. [Omole, Folashade S.] Morehouse Sch Med, East Point, GA USA. [Reddy, William D.] Acupuncture & Oriental Med AAAOM, Annandale, VA USA. [Wallace, Dana V.] Florida Atlantic Univ, Boca Raton, FL 33431 USA. [Wallace, Dana V.] Nova SE Univ, Davie, FL USA. [Walsh, Sandra A.; Warren, Barbara E.] Consumers United Evidence Based Healthcare, Fredericton, NB, Canada. [Wilson, Meghan N.] Louisiana State Univ, Sch Med, New Orleans, LA USA. [Nnacheta, Lorraine C.] Amer Acad Otolaryngol Head & Neck Surg, Dept Res & Qual, Alexandria, VA USA. RP Seidman, MD (reprint author), Henry Ford West Bloomfield Hosp, 6777 West Maple Rd, West Bloomfield, MI 48322 USA. EM mseidma1@hfhs.org FU American Academy of Otolaryngology-Head and Neck Surgery Foundation FX Funding Source: American Academy of Otolaryngology-Head and Neck Surgery Foundation. NR 10 TC 14 Z9 17 U1 4 U2 20 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2015 VL 152 IS 2 BP 197 EP 206 DI 10.1177/0194599814562166 PG 10 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CB2OU UT WOS:000349468100003 PM 25645524 ER PT J AU Willson, TJ Lospinoso, J Weitzel, E McMains, K AF Willson, Thomas J. Lospinoso, Joshua Weitzel, Erik McMains, Kevin TI Correlating Regional Aeroallergen Effects on Internet Search Activity SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE aeroallergen; allergen; allergic rhinitis ID ALLERGIC RHINITIS AB Objective To investigate the correlation between the change in regional aeroallergen levels and Internet search activity related to allergies. Study Design A retrospective time series analysis using a graphical analytical approach and statistical modeling was used. Setting Tertiary academic hospital setting. Subjects and Methods There were no specific enrolled subjects. Data from Google Trends were obtained (google.com/trends) for the following search terms: allergy, allergies, pollen, runny nose, congestion, and post nasal drainage. Daily pollen and mold spore count data were obtained for the same period from throughout Texas. Graphical analysis, correlation, and autoregressive integrated moving average (ARIMA) were employed to assess the relationship between aeroallergens on Google search activity. Results A strong positive correlation was observed between observed pollen counts and search activity for the terms allergies (r(pollen) = 0.798), allergy (r(pollen) = 0.781), and pollen (r(pollen) = 0.849). Symptom term searches were weakly correlated with pollen and mold counts. Also, ARIMA modeling supported the relationships indicated by the correlations. Conclusion Search activities for surrogate terms such as allergy, allergies, and pollen correlate strongly with observed pollen counts but not mold counts. These data demonstrate the usefulness of Google Trends search data in assessing regional disease burdens and offer insight into how the public seeks information about their own illness. C1 [Willson, Thomas J.; Weitzel, Erik] San Antonio Mil Med Ctr, Dept Otolaryngol Head & Neck Surg, San Antonio, TX 78234 USA. [Lospinoso, Joshua] Portia Stat Consulting LLC, San Antonio, TX USA. [McMains, Kevin] South Texas Vet Hlth Care Syst, Otolaryngol Sect, San Antonio, TX USA. RP Willson, TJ (reprint author), San Antonio Mil Med Ctr, Dept Otolaryngol Head & Neck Surg, 3551 Roger Brooke Dr, San Antonio, TX 78234 USA. EM S10twillson@gmail.com NR 12 TC 4 Z9 4 U1 0 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2015 VL 152 IS 2 BP 228 EP 232 DI 10.1177/0194599814560149 PG 5 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CB2OU UT WOS:000349468100007 PM 25505261 ER PT J AU Huynh, J Dawson, D Roberts, D Bentley-Lewis, R AF Huynh, J. Dawson, D. Roberts, D. Bentley-Lewis, R. TI A systematic review of placental pathology in maternal diabetes mellitus SO PLACENTA LA English DT Article DE Placenta; Pathology; Histology; Diabetes mellitus; Type 1; Type 2; Gestational ID TERMINAL VILLI; FETOPLACENTAL ANGIOGENESIS; INTERVILLOUS PORES; VASCULAR PATHOLOGY; RISK-FACTORS; WOMEN; PREGNANCIES; HISTOMORPHOMETRY; TYPE-1; FETAL AB Introduction: During a pregnancy complicated by diabetes, the human placenta undergoes a number of functional and structural pathologic changes, such as increased placental weight and increased incidence of placental lesions including villous maturational defects and fibrinoid necrosis. The pathologic findings reported have differed among studies, potentially reflecting differences in type of diabetes, study methodology, or glycemic control of study participants. Alternatively, these discrepancies may represent different biologic adaptations to distinct metabolic diseases. Methods: We conducted a comprehensive review of English language citations in Pubmed and Embase using the keywords "diabetes", "placenta", AND "pathology". Abstracts were reviewed for relevance then full-text articles were reviewed in order to extract a comprehensive summary of current pathological findings associated with pregestational and gestational diabetes mellitus, as well as an understanding of the impact of glycemic control on placental pathology. Results: Placental abnormalities most consistently associated with maternal diabetes are an increased incidence of villous immaturity, increased measures of angiogenesis, and increased placental weight. Conclusions: The literature suggests that, despite similarities in placental abnormalities, differences in placental pathology may reflect differences in pathophysiology among different types of diabetes. Consequently, standardization of terminology used to define placental lesions is warranted. Moreover, further research is needed to investigate the impact of pathophysiology, glycemic control and clinical factors, such as infant sex, weight and race, on placental structure and function. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Huynh, J.; Dawson, D.; Bentley-Lewis, R.] Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA 02114 USA. [Roberts, D.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Bentley-Lewis, R (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Bulfinch 4-415, Boston, MA 02114 USA. EM rbentleylewis@mgh.harvard.edu FU NIH [1R03DK096152]; Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Program [68133]; Harvard Summer Clinical and Translational Research Program, Harvard Catalyst, Harvard Clinical and Translational Research Center FX The authors would like to thank Rebecca Walmer, BA of the Diabetes Research Center at the Massachusetts General Hospital for her assistance in manuscript review. This work was funded in part by the NIH 1R03DK096152 and the Robert Wood Johnson Foundation Harold Amos Medical Faculty Development (Grant ID# 68133) Program awarded to R.B.-L and the Harvard Summer Clinical and Translational Research Program, Harvard Catalyst, Harvard Clinical and Translational Research Center awarded to D.D. NR 67 TC 18 Z9 18 U1 1 U2 11 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0143-4004 EI 1532-3102 J9 PLACENTA JI Placenta PD FEB PY 2015 VL 36 IS 2 BP 101 EP 114 DI 10.1016/j.placenta.2014.11.021 PG 14 WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology GA CB4FH UT WOS:000349583100001 PM 25524060 ER PT J AU Bromley, EG May, FP Federer, L Spiegel, BMR van Oijen, MGH AF Bromley, Erica G. May, Folasade P. Federer, Lisa Spiegel, Brennan M. R. van Oijen, Martijn G. H. TI Explaining persistent under-use of colonoscopic cancer screening in African Americans: A systematic review SO PREVENTIVE MEDICINE LA English DT Review DE Barriers; Colorectal cancer; Screening; Colonoscopy; Race; Ethnicity; African-American ID DIGITAL RECTAL EXAMINATION; COLORECTAL-CANCER; PRACTICE GUIDELINES; PREVENTIVE SERVICES; BARRIERS; DISPARITIES; COLON; MEN; FACILITATORS; PHYSICIANS AB Introduction. Although African Americans have the highest incidence and mortality from colorectal cancer (CRC), they are less likely than other racial groups to undergo CRC screening. Previous research has identified barriers to CRC screening among African Americans. However we lack a systematic review that synthesizes contributing factors and informs interventions to address persistent disparities. Methods. We conducted a systematic review to evaluate barriers to colonoscopic CRC screening in African Americans. We developed a conceptual model to summarize the patient-, provider-, and system-level barriers and suggest strategies to address these barriers. Results. Nineteen studies met inclusion criteria. Patient barriers to colonoscopy included fear, poor knowledge of CRC risk, and low perceived benefit of colonoscopy. Provider-level factors included failure to recommend screening and knowledge deficits about guidelines and barriers to screening. System barriers included financial obstacles, lack of insurance and access to care, and intermittent primary care visits. Conclusions. There are modifiable barriers to colonoscopic CRC screening among African Americans. Future interventions should confront patient fear, patient and physician knowledge about barriers, and access to healthcare services. As the Affordable Care Act aims to improve uptake of preventive services, focused interventions to increase CRC screening in African Americans are essential and timely. (C) 2014 Elsevier Inc. All rights reserved. C1 [Bromley, Erica G.; May, Folasade P.; Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. [May, Folasade P.; Spiegel, Brennan M. R.; van Oijen, Martijn G. H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90073 USA. [May, Folasade P.; Spiegel, Brennan M. R.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [May, Folasade P.; Spiegel, Brennan M. R.] UCLA VA Ctr Outcomes Res & Educ CORE, Los Angeles, CA USA. [van Oijen, Martijn G. H.] Univ Utrecht, NL-3508 TC Utrecht, Netherlands. [Federer, Lisa] Univ Calif Los Angeles, Los Angeles, CA 90073 USA. RP May, FP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Ctr Outcomes Res & Educ, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM fmay@mednet.ucla.edu FU NIDDK NIH HHS [P30 DK041301, T32 DK007180] NR 51 TC 12 Z9 13 U1 2 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD FEB PY 2015 VL 71 BP 40 EP 48 DI 10.1016/j.ypmed.2014.11.022 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CB6NL UT WOS:000349743600009 PM 25481094 ER PT J AU Davidson, TM Soltis, K Albia, CM de Arellano, M Ruggiero, KJ AF Davidson, Tatiana M. Soltis, Kathryn Albia, Christina MinHee de Arellano, Michael Ruggiero, Kenneth J. TI Providers' Perspectives Regarding the Development of a Web-Based Depression Intervention for Latina/o Youth SO PSYCHOLOGICAL SERVICES LA English DT Article DE Latina/o adolescents; depression; cultural adaptation; Internet-based intervention ID COGNITIVE-BEHAVIORAL THERAPY; CHILD INTERACTION THERAPY; PUERTO-RICAN ADOLESCENTS; ETHNIC-MINORITY YOUTH; MENTAL-HEALTH-CARE; MEXICAN-AMERICANS; CULTURAL-ADAPTATION; CONTROLLED-TRIAL; LOW-INCOME; ACTIVATION AB Latina/o youth appear to be at significant risk for depression and, of concern, is the high underutilization of mental health services observed in this population. There is a tremendous need for novel intervention methods to better serve the unique needs of this population. This article describes the development of Rise Above (Siempre Sale el Sol), a Web-based, self-help, depression intervention for Latina/o adolescents funded by the National Institute of Mental Health. We applied a cultural adaptation model to an evidence-based depression treatment to reduce potential service barriers and increase the relevance and potential efficacy of the intervention for Latina/o youth. We conducted thematic interviews with 32 national experts to obtain feedback that would inform our application of the cultural adaptation model, the potential efficacy of the intervention, and the feasibility of implementation. Future directions for the evaluation of Rise Above (Siempre Sale el Sol) are described. C1 [Davidson, Tatiana M.; Soltis, Kathryn; de Arellano, Michael; Ruggiero, Kenneth J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Albia, Christina MinHee] Coll Charleston, Charleston, SC USA. [Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Davidson, TM (reprint author), Med Univ S Carolina, Mental Hlth Dispar & Divers Program, 67 President St IOP 4 South,MSC 861, Charleston, SC 29425 USA. EM davidst@musc.edu FU NIMH NIH HHS [R34 MH077149, R01 MH81056, R34 MH77149, R01 MH081056-03S2, R01 MH081056, P60 MH082598] NR 69 TC 1 Z9 1 U1 4 U2 10 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2015 VL 12 IS 1 BP 37 EP 48 DI 10.1037/a0037686 PG 12 WC Psychology, Clinical SC Psychology GA CB3TK UT WOS:000349551400006 PM 25133417 ER PT J AU Fox, AB Meyer, EC Vogt, D AF Fox, Annie B. Meyer, Eric C. Vogt, Dawne TI Attitudes About the VA Health-Care Setting, Mental Illness, and Mental Health Treatment and Their Relationship With VA Mental Health Service Use Among Female and Male OEF/OIF Veterans SO PSYCHOLOGICAL SERVICES LA English DT Article DE barriers to care; gender differences; mental health beliefs; perceptions of care; VA mental health care ID POSTTRAUMATIC-STRESS-DISORDER; PROFESSIONAL PSYCHOLOGICAL HELP; SUBSTANCE USE DISORDERS; TREATMENT-SEEKING; ALCOHOL MISUSE; AFGHANISTAN VETERANS; ANTICIPATED STIGMA; CAGE QUESTIONNAIRE; WOMEN VETERANS; IRAQ AB In the present study, the authors explored gender differences in attitudinal barriers to and facilitators of care for Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) veterans and examined the relationship of those factors with VA mental health service use among female and male veterans with probable mental health conditions. Data were collected as part of a national cross-sectional survey of OEF/OIF veterans; the current sample was limited to participants with a probable diagnosis of post-traumatic stress disorder, depression, or alcohol abuse (N = 278). Although negligible gender differences were observed in attitudes about VA care and perceived fit in the VA setting, men reported slightly more negative beliefs about mental illness and mental health treatment than women. In addition, logistic regressions revealed different associations with VA mental health service use for women and men. For women only, positive perceptions of VA care were associated with increased likelihood of seeking mental health treatment. For men only, perceived similarity to other VA care users and negative beliefs about mental health treatment were associated with increased likelihood of service use, whereas negative beliefs about mental illness were associated with lower likelihood of service use. For both women and men, perceived entitlement to VA care was associated with increased likelihood of service use and negative beliefs about treatment-seeking were associated with a reduced likelihood of seeking mental health care in the past 6 months. Results support the need for tailored outreach to address unique barriers to mental health treatment for female and male OEF/OIF veterans. C1 [Fox, Annie B.; Vogt, Dawne] VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Womens Hlth Sci Div, Boston, MA 02130 USA. [Meyer, Eric C.] VISN 17 Ctr Excellence Res Returning War Vet, Waco, TX USA. [Meyer, Eric C.] Cent Texas Vet Healthcare Syst, Temple, TX USA. [Vogt, Dawne] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA. RP Fox, AB (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B3, 150 South Huntington Ave, Boston, MA 02130 USA. EM annie.fox-galalis@va.gov NR 68 TC 5 Z9 5 U1 1 U2 8 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2015 VL 12 IS 1 BP 49 EP 58 DI 10.1037/a0038269 PG 10 WC Psychology, Clinical SC Psychology GA CB3TK UT WOS:000349551400007 PM 25365245 ER PT J AU Finley, EP Garcia, HA Ketchum, NS McGeary, DD McGeary, CA Stirman, SW Peterson, AL AF Finley, Erin P. Garcia, Hector A. Ketchum, Norma S. McGeary, Donald D. McGeary, Cindy A. Stirman, Shannon Wiltsey Peterson, Alan L. TI Utilization of Evidence-Based Psychotherapies in Veterans Affairs Posttraumatic Stress Disorder Outpatient Clinics SO PSYCHOLOGICAL SERVICES LA English DT Article DE posttraumatic stress disorder; prolonged exposure; cognitive processing therapy; implementation; veterans ID COGNITIVE PROCESSING THERAPY; PROLONGED EXPOSURE THERAPY; MENTAL-HEALTH PROVIDERS; RESIDENTIAL-TREATMENT PROGRAMS; PSYCHOLOGISTS ATTITUDES; JOB BURNOUT; IMPLEMENTATION; DISSEMINATION; PTSD; CARE AB In response to the growing numbers of veterans with posttraumatic stress disorder (PTSD), the Department of Veterans Affairs (VA) has sought to make evidence-based psychotherapies for PTSD available at every VA facility. We conducted a national survey of providers within VA PTSD clinical teams (PCTs) to describe utilization of prolonged exposure (PE) and cognitive processing therapy (CPT) and to identify individual and organizational factors associated with treatment uptake and adherence. Participants (N = 128) completed an electronic survey assessing reported utilization of PE and CPT treatments, adherence to treatment manuals, and characteristics of the provider and workplace environment. Participants reported conducting a weekly mean of 4.5 hours of PE, 3.9 hours of CPT (individual format), 1.3 hours of CPT (group format), and 13.4 hours of supportive care. Perceived effectiveness of PE and CPT were significantly associated with utilization of and adherence to those treatments. Reported number of hours conducting supportive care was positively associated with feeling the clinic was not sufficiently staffed (p = .05). Adherence to the PE treatment manual was positively associated with receiving emotional support from coworkers (p = .01). Provider attitudes and organizational factors such as staffing and work relationships may have an important impact on treatment selection and the quality of PTSD care provided in VA PCTs. C1 [Finley, Erin P.; Garcia, Hector A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hosp Med, San Antonio, TX 78229 USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, Div Hosp Med, San Antonio, TX 78229 USA. [Garcia, Hector A.; McGeary, Donald D.; McGeary, Cindy A.; Peterson, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Ketchum, Norma S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Stirman, Shannon Wiltsey] VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr PTSD, Boston, MA USA. [Stirman, Shannon Wiltsey] Boston Univ, Dept Psychiat, Boston, MA 02215 USA. RP Finley, EP (reprint author), Audie L Murphy Mem Vet Hosp Div 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM finleye@uthscsa.edu OI Finley, Erin/0000-0003-4497-7721 FU NIMH NIH HHS [R25 MH080916, R25 MH080916-01A2] NR 52 TC 17 Z9 17 U1 3 U2 13 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2015 VL 12 IS 1 BP 73 EP 82 DI 10.1037/ser0000014 PG 10 WC Psychology, Clinical SC Psychology GA CB3TK UT WOS:000349551400010 PM 25419915 ER PT J AU Dismuke, CE Egede, LE Saunders, L Krause, JS AF Dismuke, C. E. Egede, L. E. Saunders, L. Krause, J. S. TI Diabetes increases financial burden of individuals with traumatic spinal cord injury (TSCI) SO SPINAL CORD LA English DT Article ID RACE AB Study design: Secondary analysis of existing data. Objective: To estimate the association of diabetes with family income in a pooled 15-year cohort of individuals with TSCI. Setting: A large specialty hospital in the southeastern United States. Methods: A total number of 1408 individuals identified with TSCI were surveyed regarding family income as well as clinical and demographic factors. Due to income being reported in censored intervals rather than individual dollar values, interval regression was used to estimate models of the association of family income with diabetes. Results: Approximately 12% of individuals with TSCI reported being diagnosed with diabetes. The most frequent family income interval in our sample was <$10 000, lower than the poverty threshold. The family income interval with the highest rate of diabetes was $15000-$20 000. In an unadjusted model, diabetes was associated with a significant reduction of $8749 and in a fully adjusted model, diabetes was significantly associated with a reduction of $8560 in family income. Being a minority was also significantly associated with a reduction whereas educational attainment was associated with increased family income. TSCI severity was not significantly related to family income. Conclusion: Diabetes imposes an additional financial burden on individuals with TSCI an already vulnerable population with high health care costs. The burden is more pronounced in minorities with TSCI. Providers should be aware of the higher prevalence of diabetes among patients with TSCI and pursue a policy of testing early and vigilant management. Further studies are needed regarding special interventions for managing diabetes in the TSCI population. C1 [Dismuke, C. E.; Egede, L. E.] Ralph H Johnson Vet Affairs Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. [Dismuke, C. E.; Egede, L. E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Div Gen Internal Med, Charleston, SC 29425 USA. [Saunders, L.; Krause, J. S.] Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,MSC 593, Charleston, SC 29425 USA. EM egedel@musc.edu FU Department of Education, NIDRR [H133G050165, H133A080064]; National Institutes of Health [1R01 NS 48117] FX The contents of this presentation were developed under grants from the Department of Education, NIDRR Grant numbers H133G050165 and H133A080064 and a Grant from the National Institutes of Health, 1R01 NS 48117. However, those contents do not necessarily represent the policy of the Department of Education or the NIH, and one should not assume endorsement by the Federal Government. We thank the following persons who contributed to the work reported in the manuscript: Richard Aust, Jennifer Coker, Melinda Jarnecke and D'Andra Roper. NR 11 TC 0 Z9 0 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 EI 1476-5624 J9 SPINAL CORD JI Spinal Cord PD FEB PY 2015 VL 53 IS 2 BP 135 EP 138 DI 10.1038/sc.2014.200 PG 4 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CB3WW UT WOS:000349561100011 PM 25403503 ER PT J AU Sankari, A Martin, JL Bascom, AT Mitchell, MN Badr, MS AF Sankari, A. Martin, J. L. Bascom, A. T. Mitchell, M. N. Badr, M. S. TI Identification and treatment of sleep-disordered breathing in chronic spinal cord injury SO SPINAL CORD LA English DT Article ID POSITIVE AIRWAY PRESSURE; HIGH BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; APNEA SYNDROME; RISK-FACTOR; QUALITY INDEX; PREVALENCE; QUESTIONNAIRE; DISTURBANCES; TETRAPLEGIA AB Study design: A follow up on an ongoing prospective cohort study. Objective: Spinal cord injury or disorder (SCI/D) patients have higher rates of sleep-disordered breathing (SDB) than the general population. The objectives of this study were to examine predictors of SDB diagnosis and to estimate rates of SDB treatment in SCI/D patients. Setting: A SCI clinical sleep research laboratory. Methods: Twenty-eight SCI/D patients (7 women, age 42.8 +/- 15.8 years; 16 cervical and 12 thoracic level injuries) completed a battery of questionnaires (Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), Berlin questionnaire (BQ) and fatigue severity scale (FSS)) and had one night of attended laboratory polysomnography (PSG). Participants were then notified of the results of their PSG and were interviewed approximately 1 year later to assess clinical outcomes. Results: The majority of patients reported poor sleep quality on all questionnaires. On the basis of PSG, 22 (79%) patients had SDB (apnea-hypopnea index (AHI)>= 5 events per hour), and 17 (61%) had moderate/severe SDB (AHI >= 15 events per hour). Higher ESS scores were associated with a higher risk of AHI >= 5; however, other questionnaires did not distinguish between those with and without SDB using either AHI cutoff. In follow-up interviews, only 50% of patients had spoken to a health-care provider about SDB and only six patients with SDB were prescribed treatment, four of whom were using the treatment at follow-up. Conclusion: SDB is common and severe among SCI/D patients. Screening questionnaires do not appear to differentiate between those with and without SDB. Even when SDB was recognized, many patients remained untreated. The increased prevalence of cardiovascular disease in SCI/D patients could represent a consequence of untreated SDB, and improving diagnosis and management of SDB has the potential to improve outcomes for these patients. C1 [Sankari, A.; Badr, M. S.] Dingell VA Med Ctr, Detroit, MI USA. [Sankari, A.; Bascom, A. T.; Badr, M. S.] Wayne State Univ, Dept Med, Detroit, MI 48202 USA. [Martin, J. L.; Mitchell, M. N.] VA Greater Los Angeles Healthcare Syst, North Hills, CA USA. [Martin, J. L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Sankari, A (reprint author), Div Pulm Crit Care & Sleep Med, 3990 John R,3 Hudson, Detroit, MI 48201 USA. EM atarbich@med.wayne.edu FU United States Department of Veterans Affairs Merit Review [1I01CX001040]; Clinical Science Research & Development Service of the VA Office of Research and Development [1IK2CX000547] FX The research was supported by the United States Department of Veterans Affairs Merit Review # 1I01CX001040 and Career Development Award # 1IK2CX000547 from the Clinical Science Research & Development Service of the VA Office of Research and Development. NR 36 TC 5 Z9 5 U1 2 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 EI 1476-5624 J9 SPINAL CORD JI Spinal Cord PD FEB PY 2015 VL 53 IS 2 BP 145 EP 149 DI 10.1038/sc.2014.216 PG 5 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CB3WW UT WOS:000349561100013 PM 25510191 ER PT J AU Mekkaoui, C Pereira, FRS Macri, F Jackowski, MP Beregi, JP Gris, JC AF Mekkaoui, C. Pereira, F. R. S. Macri, F. Jackowski, M. Parolin Beregi, J. -P. Gris, J. -C. TI Microstructure white matter is altered in antiphospholipid syndrome: evidence from asymptomatic neurological patients SO THROMBOSIS RESEARCH LA English DT Meeting Abstract CT 6th International Symposium on Women's Health Issues in Thrombosis and Haemostasis CY FEB 13-15, 2015 CL Berlin, GERMANY C1 [Mekkaoui, C.; Pereira, F. R. S.; Macri, F.; Beregi, J. -P.] Univ Nimes Hosp, Dept Radiol, F-30006 Nimes, France. [Mekkaoui, C.; Pereira, F. R. S.; Macri, F.; Beregi, J. -P.] Univ Montpellier, Res Team, EA2415, Montpellier, France. [Mekkaoui, C.] Massachusetts Gen Hosp, Dept Radiol, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Mekkaoui, C.] Harvard Univ, Sch Med, Boston, MA USA. [Pereira, F. R. S.; Jackowski, M. Parolin] Univ Sao Paulo, Inst Math & Stat, BR-05508 Sao Paulo, Brazil. [Gris, J. -C.] Univ Nimes Hosp, Dept & Lab Haematol, F-30006 Nimes, France. [Gris, J. -C.] Univ Montpellier, Res Team, EA2992, Montpellier, France. EM jean.christophe.gris@chu-nimes.fr RI Cesar-Jr, Roberto/I-8222-2015; Jackowski, Marcel/G-7602-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0049-3848 J9 THROMB RES JI Thromb. Res. PD FEB PY 2015 VL 135 SU 1 MA OC-4b BP S67 EP S67 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CB4XS UT WOS:000349632300027 ER PT J AU Green, M Covington, S Taranto, S Wolfe, C Bell, W Biggins, SW Conti, D DeStefano, GD Dominguez, E Ennis, D Gross, T Klassen-Fischer, M Kotton, C LaPointe-Rudow, D Law, Y Ludrosky, K Menegus, M Morris, MI Nalesnik, MA Pavlakis, M Pruett, T Sifri, C Kaul, D AF Green, Michael Covington, Shandie Taranto, Sarah Wolfe, Cameron Bell, Walter Biggins, Scott W. Conti, David DeStefano, G. David Dominguez, Edward Ennis, Donna Gross, Thomas Klassen-Fischer, Mary Kotton, Camille LaPointe-Rudow, Dianne Law, Yuk Ludrosky, Kristen Menegus, Marilyn Morris, Michele I. Nalesnik, Michael A. Pavlakis, Martha Pruett, Timothy Sifri, Costi Kaul, Daniel TI Donor-Derived Transmission Events in 2013: A Report of the Organ Procurement Transplant Network Ad Hoc Disease Transmission Advisory Committee SO TRANSPLANTATION LA English DT Article AB Background. The Organ Procurement Transplant Network Disease Transmission Advisory Committee (DTAC), a multidisciplinary committee, evaluates potential donor-derived transmission events (PDDTE), including infections andmalignancies, to assess for donor transmitted events. Methods. Reports of unexpected PDDTE to Organ Procurement Transplant Network in 2013 were fully reviewed by DTAC. A standardized algorithm was used to assess each PDDTE from a given donor and to classify each individual recipient from that donor. Results. Of 443 total PDDTE submitted, 159 were triaged and not sent out to the full DTAC. Of 284 fully evaluated reports, 32 (11.3%) resulted in a proven/probable (P/P) transmission of infection, malignancy or other conditions to 42 recipients. Of 204 infection events, 24 were classified as P/P affecting 30 recipients, with four deaths. Bacteria were the most frequently reported type of infection, accounting for 99 reports but only 12 recipients from 11 donors experienced P/P transmission. There were 65 donors reported with potential malignancy events and 5 were classified as P/P transmissions with 8 affected recipients and 2 deaths. Additionally, there were 16 noninfection, nonmalignancy reports resulting in 3 P/P transmissions to 4 recipients and 1 death. Conclusions. There was a 43% increase in the number of PDDTE reported and reviewed in 2013 over 2012. However, the percent with P/P transmission remains low, affecting recipients from 32 donors especially when compared with the more than 14,000 donors recovered annually in the United States. The continued use of the new standard algorithm and triaging process will enhance the reproducibility of DTAC assessments and allow more robust analysis of our aggregate DTAC experience. C1 [Green, Michael] Univ Pittsburgh, Med Ctr, Div Pediat Infect Dis, Pittsburgh, PA USA. [Covington, Shandie; Taranto, Sarah] United Network Organ Sharing, Richmond, VA USA. [Wolfe, Cameron] Duke Univ, Med Ctr, Div Transplant Infect Dis, Durham, NC USA. [Bell, Walter] Univ Alabama Birmingham, Div Anat Pathol, Birmingham, AL USA. [Biggins, Scott W.] Univ Colorado, Div Gastroenterol, Aurora, CO USA. [Conti, David] Albany Med Coll, Dept Transplant Surg, Albany, NY 12208 USA. [DeStefano, G. David] Lifesharing, San Diego, CA USA. [Dominguez, Edward] Methodist Dallas Med Ctr, Div Infect Dis, Dallas, TX USA. [Ennis, Donna] Indiana Univ Hosp, Indianapolis, IN 46202 USA. [Gross, Thomas] NCI, Ctr Global Hlth, Rockville, MD USA. [Klassen-Fischer, Mary] Joint Pathol Ctr, Silver Spring, MD USA. [Kotton, Camille] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [LaPointe-Rudow, Dianne] Mt Sinai Med Ctr, New York, NY 10029 USA. [Law, Yuk] Seattle Childrens Hosp, Div Cardiac Transplant, Seattle, WA USA. [Ludrosky, Kristen] Cleveland Clin, Cleveland, OH 44106 USA. [Menegus, Marilyn] Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA. [Morris, Michele I.] Univ Miami Hosp, Div Internal Med, Miami, FL USA. [Nalesnik, Michael A.] Univ Pittsburgh, Med Ctr, Div Transplant Pathol, Pittsburgh, PA USA. [Pavlakis, Martha] Beth Israel Deaconess Med Ctr, Div Nephrol, Boston, MA 02215 USA. [Pruett, Timothy] Univ Minnesota, Med Ctr, Div Transplantat, Minneapolis, MN 55455 USA. [Sifri, Costi] Univ Virginia Hlth Syst, Div Infect Dis, Charlottesville, VA USA. [Kaul, Daniel] Univ Michigan, Med Ctr, Div Infect Dis, Ann Arbor, MI USA. RP Green, M (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. EM Michael.green@chp.edu FU Health Resources and Services Administration [234-2005-370011C] FX This analysis of DTAC data was supported wholly or in part by Health Resources and Services Administration contract 234-2005-370011C. NR 2 TC 8 Z9 8 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD FEB PY 2015 VL 99 IS 2 BP 282 EP 287 DI 10.1097/TP.0000000000000584 PG 6 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA CB2YH UT WOS:000349493900016 PM 25594557 ER PT J AU Taber, DJ Palanisamy, AP Srinivas, TR Gebregziabher, M Odeghe, J Chavin, KD Egede, LE Baliga, PK AF Taber, David J. Palanisamy, Arun P. Srinivas, Titte R. Gebregziabher, Mulugeta Odeghe, John Chavin, Kenneth D. Egede, Leonard E. Baliga, Prabhakar K. TI Inclusion of Dynamic Clinical Data Improves the Predictive Performance of a 30-Day Readmission Risk Model in Kidney Transplantation SO TRANSPLANTATION LA English DT Article ID EARLY HOSPITAL READMISSION; ELECTRONIC HEALTH RECORDS; BIG-DATA; UNITED-STATES; CARE; RECIPIENTS; QUALITY; PATIENT; REHOSPITALIZATIONS; CHALLENGES AB Background. Thirty-day readmissions (30DRA) are a highly scrutinized measure of healthcare quality and relatively frequent among kidney transplants (KTX). Development of predictive risk models is critical to reducing 30DRA and improving outcomes. Current approaches rely on fixed variables derived from administrative data. These models may not capture clinical evolution that is critical to predicting outcomes. Methods. We directed a retrospective analysis toward: (1) developing parsimonious risk models for 30DRA and (2) comparing efficiency of models based on the use of immutable versus dynamic data. Baseline and in-hospital clinical and outcomes data were collected from adult KTX recipients between 2005 and 2012. Risk models were developed using backward logistic regression and compared for predictive efficacy using receiver operating characteristic curves. Results. Of 1147 KTX patients, 123 had 30DRA. Risk factors for 30DRA included recipient comorbidities, transplant factors, and index hospitalization patient level clinical data. The initial fixed variable model included 9 risk factors and was modestly predictive (area under the curve, 0.64; 95% confidence interval [95% CI], 0.58-0.69). The model was parsimoniously reduced to 6 risks, which remained modestly predictive (area under the curve, 0.63; 95% CI, 0.58-0.69). The initial predictive model using 13 fixed and dynamic variables was significantly predictive (AUC, 0.73; 95% CI, 0.67-0.80), with parsimonious reduction to 9 variables maintaining predictive efficacy (AUC, 0.73; 95% CI, 0.67-0.79). The final model using dynamically evolving clinical data outperformed the model using static variables (P = 0.009). Internal validation demonstrated that the final model was stable with minimal bias. Conclusions. We demonstrate that modeling dynamic clinical data outperformed models using immutable data in predicting 30DRA. C1 [Taber, David J.; Palanisamy, Arun P.; Chavin, Kenneth D.; Baliga, Prabhakar K.] Med Univ S Carolina, Div Transplant Surg, Charleston, SC 29425 USA. [Taber, David J.] Ralph H Johnson VAMC, Dept Pharm, Charleston, SC USA. [Srinivas, Titte R.] Med Univ S Carolina, Div Transplant Nephrol, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Odeghe, John] Med Univ S Carolina, Coll Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VAMC, Ctr Innovat COIN, Charleston, SC USA. RP Taber, DJ (reprint author), Med Univ S Carolina, Div Transplant Surg, 96 Jonathan Lucas St,CSB 409, Charleston, SC 29425 USA. EM taberd@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [K23DK099440, T35 DK007431] FX D.J.T.'s efforts preparing this study were supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number K23DK099440. J.O.'s efforts conducting this analysis were supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number T35 DK007431. L.E.'s efforts conducting this analysis were supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number T35 DK007431. NR 34 TC 6 Z9 6 U1 3 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD FEB PY 2015 VL 99 IS 2 BP 324 EP 330 DI 10.1097/TP.0000000000000565 PG 7 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA CB2YH UT WOS:000349493900021 PM 25594549 ER PT J AU Cuckle, H Platt, LD Thornburg, LL Bromley, B Fuchs, K Abuhamad, A Benacerraf, B Copel, JA Depp, R D'Alton, M Goldberg, J O'Keeffe, D Spitz, J Toland, G Wapner, R AF Cuckle, H. Platt, L. D. Thornburg, L. L. Bromley, B. Fuchs, K. Abuhamad, A. Benacerraf, B. Copel, J. A. Depp, R. D'Alton, M. Goldberg, J. O'Keeffe, D. Spitz, J. Toland, G. Wapner, R. CA Perinatal Quality Fdn TI Nuchal Translucency Quality Review (NTQR) program: first one and half million results SO ULTRASOUND IN OBSTETRICS & GYNECOLOGY LA English DT Review DE epidemiologic monitoring; median NT-MoM; NT accuracy; NTQR ID DOWN-SYNDROME; 1ST-TRIMESTER; THICKNESS; ASSURANCE; CORRECT AB ObjectiveTo evaluate the performance of first-trimester nuchal translucency (NT) measurement by providers (physician-sonologists and sonographers) within the Nuchal Translucency Quality Review (NTQR) program. MethodsAfter training and credentialing providers, the NTQR monitored performance of NT measurement by the extent to which an individual's median multiple of the normal median (MoM) for crown-rump length (CRL) was within the range 0.9-1.1 MoM of a published normal median curve. The SD of log(10) MoM and regression slope of NT on CRL were also evaluated. We report the distribution between providers of these performance indicators and evaluate potential sources of variation. ResultsAmong the first 1.5 million scans in the NTQR program, performed between 2005 and 2011, there were 1485944 with CRL in the range 41-84 mm, from 4710 providers at 2150 ultrasound units. Among the 3463 providers with at least 30 scans in total, the median of the providers' median NT-MoMs was 0.913. Only 1901 (55%) had a median NT-MoM within the expected range; there were 89 above 1.1 MoM, 1046 at 0.8-0.9 MoM, 344 at 0.7-0.8 MoM and 83 below 0.7 MoM. There was a small increase in the median NT-MoM according to providers' length of time in the NTQR program and number of scans entered annually. On average, physician-sonologists had a higher median NT-MoM than did sonographers, as did those already credentialed before joining the program. The median provider SD was 0.093 and the median slope was 13.5%. SD correlated negatively with the median NT-MoM (r=-0.34) and positively with the slope (r = 0.22). ConclusionEven with extensive training, credentialing and monitoring, there remains considerable variability between NT providers. There was a general tendency towards under-measurement of NT compared with expected values, although more experienced providers had performance closer to that expected. Copyright (c) 2014 ISUOG. Published by John Wiley & Sons Ltd. C1 [Cuckle, H.; Fuchs, K.; D'Alton, M.; Wapner, R.] Columbia Univ, Med Ctr, Dept Obstet & Gynecol, New York, NY 10032 USA. [Platt, L. D.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Fetal Med & Womens Ultrasound, Los Angeles, CA 90095 USA. [Platt, L. D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA. [Thornburg, L. L.] Univ Rochester, Med Ctr, Div Maternal Fetal Med, Rochester, NY 14642 USA. [Bromley, B.; Benacerraf, B.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Bromley, B.; Benacerraf, B.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA. [Bromley, B.; Benacerraf, B.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. [Abuhamad, A.] Eastern Virginia Med Sch, Dept Obstet & Gynecol, Norfolk, VA 23501 USA. [Copel, J. A.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA. [Depp, R.] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA. [Goldberg, J.] San Francisco Perinatal Associates, San Francisco, CA USA. [O'Keeffe, D.] Soc Maternal Fetal Med, Washington, DC USA. [Spitz, J.] Univ Oklahoma, Oklahoma City, OK USA. [Spitz, J.; Toland, G.] Perinatal Qual Fdn, Oklahoma City, OK USA. RP Wapner, R (reprint author), Columbia Univ, Med Ctr, Dept Obstet & Gynecol, 622 W 168th St,PH1666, New York, NY 10032 USA. EM rw2191@columbia.edu NR 18 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0960-7692 EI 1469-0705 J9 ULTRASOUND OBST GYN JI Ultrasound Obstet. Gynecol. PD FEB PY 2015 VL 45 IS 2 BP 199 EP 204 DI 10.1002/uog.13390 PG 6 WC Acoustics; Obstetrics & Gynecology; Radiology, Nuclear Medicine & Medical Imaging SC Acoustics; Obstetrics & Gynecology; Radiology, Nuclear Medicine & Medical Imaging GA CB1EF UT WOS:000349368900013 PM 24753079 ER PT J AU Phillips, NA Vargas, CR Chuang, DJ Lee, BT AF Phillips, Nicole A. Vargas, Christina R. Chuang, Danielle J. Lee, Bernard T. TI Readability Assessment of Online Patient Abdominoplasty Resources SO AESTHETIC PLASTIC SURGERY LA English DT Article DE Abdominoplasty; Readability; Online resources; Patient literacy ID HEALTH-CARE; BREAST RECONSTRUCTION; SURGERY; INTERNET; INFORMATION; LITERACY; QUALITY; DECISION; RISK; WEB AB Limited functional health literacy is recognized as an important contributor to health disparities in the United States. As internet access becomes more universal, there is increasing concern about whether patients with poor or marginal literacy can access understandable healthcare information. As such, the National Institutes of Health and American Medical Association recommend that patient information be written at a sixth grade level. This study identifies the most popular online resources for patient information about abdominoplasty and evaluates their readability in the context of average American literacy. The two largest internet search engines were queried for "tummy tuck surgery" to simulate a patient search in lay terms. The ten most popular sites common to both search engines were identified, and all relevant articles from the main sites were downloaded. Sponsored results were excluded. Readability analysis of the articles was performed using ten established tests. Online information about abdominoplasty from the ten most popular publically available websites had an overall average readability of 12th grade. Mean reading grade level scores among tests were: Coleman-Liau 11.9, Flesch-Kincaid 11.4, FORCAST 11.1, Fry 13, Gunning Fog 13.5, New Dale-Chall 11.8, New Fog Count 9.9, Raygor Estimate 12, and SMOG 13.4; Flesch Reading Ease index score was 46. Online patient resources about abdominoplasty are uniformly above the recommended target readability level and are likely too difficult for many patients to understand. A range of readability identified among websites could allow surgeons to guide patients to more appropriate resources for their literacy skills. This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266. C1 [Phillips, Nicole A.; Vargas, Christina R.; Chuang, Danielle J.; Lee, Bernard T.] Harvard Univ, Div Plast & Reconstruct Surg, Dept Surg, Beth Israel Deaconess Med Ctr,Med Sch, Boston, MA 02215 USA. RP Lee, BT (reprint author), Harvard Univ, Div Plast & Reconstruct Surg, Dept Surg, Beth Israel Deaconess Med Ctr,Med Sch, 110 Francis St,Suite 5A, Boston, MA 02215 USA. EM blee3@bidmc.harvard.edu RI Lee, Bernard/K-1106-2016 OI Lee, Bernard/0000-0002-5533-3166 NR 32 TC 3 Z9 3 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-216X EI 1432-5241 J9 AESTHET PLAST SURG JI Aesthet. Plast. Surg. PD FEB PY 2015 VL 39 IS 1 BP 147 EP 153 DI 10.1007/s00266-014-0425-0 PG 7 WC Surgery SC Surgery GA CA2XW UT WOS:000348770400022 PM 25476602 ER PT J AU Banwait, R Aljawai, Y Cappuccio, J McDiarmid, S Morgan, EA Leblebjian, H Roccaro, AM Laubach, J Castillo, JJ Paba-Prada, C Treon, S Redd, R Weller, E Ghobrial, IM AF Banwait, Ranjit Aljawai, Yosra Cappuccio, Joseph McDiarmid, Serena Morgan, Elizabeth A. Leblebjian, Houry Roccaro, Aldo M. Laubach, Jacob Castillo, Jorge J. Paba-Prada, Claudia Treon, Steven Redd, Robert Weller, Edie Ghobrial, Irene M. TI Extramedullary Waldenstrom macroglobulinemia SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Article ID CONSENSUS PANEL RECOMMENDATIONS; 2ND INTERNATIONAL WORKSHOP; MULTIPLE-MYELOMA; MYD88 L265P; CXCR4; MUTATIONS; LYMPHOMA; FEATURES AB Disease assessment in Waldenstrom Macroglobulinemia (WM) is dependent on the percent involvement of B-cell neoplasm in the bone marrow and IgM paraprotein in the serum. A subset of patients also demonstrates extramedullary involvement, which is infrequently examined. The role of extramedullary involvement in the diagnosis and prognosis of WM is poorly understood. The purpose of this study is to report the characteristics of WM patients with extramedullary disease (EMD). Nine hundred and eight-five patients with WM were evaluated at one academic center and the presence of EMD was assessed in these patients. Forty-three (4.4%) patients were identified to have EMD. Nine (21%) patients presented with involvement at WM diagnosis, while 34 (79%) developed EMD post-therapy for WM. Most frequent EMD sites involved were pulmonary (30%), soft tissue (21%), cerebrospinal fluid (23%), renal (8%), and bone (9%). The median overall survival at 10 years was 79% (95% CI: 57-90%). This is the first study to describe the clinical characteristics, response and overall survival in patients with extramedullary WM. Further studies to define the molecular characteristics of this entity and mechanisms of its development are warranted. Am. J. Hematol. 90:100-104, 2015. (c) 2014 Wiley Periodicals, Inc. C1 [Banwait, Ranjit; Aljawai, Yosra; Cappuccio, Joseph; McDiarmid, Serena; Leblebjian, Houry; Roccaro, Aldo M.; Laubach, Jacob; Castillo, Jorge J.; Paba-Prada, Claudia; Treon, Steven; Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Banwait, Ranjit; Aljawai, Yosra; Cappuccio, Joseph; McDiarmid, Serena; Morgan, Elizabeth A.; Leblebjian, Houry; Roccaro, Aldo M.; Laubach, Jacob; Castillo, Jorge J.; Paba-Prada, Claudia; Treon, Steven; Redd, Robert; Weller, Edie; Ghobrial, Irene M.] Harvard Univ, Sch Med, Boston, MA USA. [Morgan, Elizabeth A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Redd, Robert; Weller, Edie] Dana Farber Canc Inst, Dept Biostat & Computat, Boston, MA 02115 USA. RP Ghobrial, IM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA. EM irene_ghobrial@dfci.harvard.edu OI Roccaro, Aldo/0000-0002-1872-5128; Morgan, Elizabeth/0000-0001-5880-9337; Castillo, Jorge/0000-0001-9490-7532 FU International Waldenstrom Macroglobulinemia Foundation; Kirsch Fund; Heje fellowship FX Supported in part by the International Waldenstrom Macroglobulinemia Foundation, Kirsch Fund and Heje fellowship. NR 28 TC 3 Z9 5 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 EI 1096-8652 J9 AM J HEMATOL JI Am. J. Hematol. PD FEB PY 2015 VL 90 IS 2 BP 100 EP 104 DI 10.1002/ajh.23880 PG 5 WC Hematology SC Hematology GA CA4AL UT WOS:000348846600008 PM 25349134 ER PT J AU Mannis, G Wu, D Dea, T Mauro, T Hsu, G AF Mannis, Gabriel Wu, Davina Dea, Tiffany Mauro, Theodora Hsu, Gerald TI Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Editorial Material ID TARGETING BTK; LYMPHOMA C1 [Mannis, Gabriel; Hsu, Gerald] San Francisco VA Med Ctr, Dept Med, Div Hematol Oncol, San Francisco, CA 94121 USA. [Wu, Davina; Mauro, Theodora] San Francisco VA Med Ctr, Dept Dermatol, San Francisco, CA USA. [Dea, Tiffany] San Francisco VA Med Ctr, Dept Clin Pharm, San Francisco, CA USA. RP Mannis, G (reprint author), San Francisco VA Med Ctr, Dept Med, Div Hematol Oncol, San Francisco, CA 94121 USA. EM gabriel.mannis@ucsf.edu FU NIA NIH HHS [R01 AG028492]; NIAMS NIH HHS [R01 AR051930] NR 3 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 EI 1096-8652 J9 AM J HEMATOL JI Am. J. Hematol. PD FEB PY 2015 VL 90 IS 2 BP 179 EP 179 DI 10.1002/ajh.23775 PG 1 WC Hematology SC Hematology GA CA4AL UT WOS:000348846600022 PM 24890909 ER PT J AU Zellmer, C Zimdars, P Parker, S Safdar, N AF Zellmer, Caroline Zimdars, Peggy Parker, Sarah Safdar, Nasia TI Evaluating the usefulness of patient education materials on surgical site infection: A systematic assessment SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Patient education; Surgical site infection ID HEALTH-CARE; INFORMATION AB Patient education is important for the prevention of surgical site infections (SSIs). The usefulness of available patient education materials is unclear. Using a validated evaluation tool, the Patient Education Materials Assessment Tool, we systematically assessed patient education materials for SSI. We found that available materials performed poorly, and further research is needed in this area. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Zellmer, Caroline; Zimdars, Peggy; Parker, Sarah; Safdar, Nasia] Univ Wisconsin, Dept Med, Infect Dis Sect, Madison, WI 53792 USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Safdar, N (reprint author), Univ Wisconsin, Dept Med, Madison, WI 53792 USA. EM ns2@medicine.wisc.edu NR 10 TC 2 Z9 2 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD FEB 1 PY 2015 VL 43 IS 2 BP 167 EP 168 DI 10.1016/j.ajic.2014.10.020 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CA2KK UT WOS:000348737200015 PM 25541334 ER PT J AU Larson, AM Shinnick, JE Shaaya, EA Thiele, EA Thibert, RL AF Larson, Anna M. Shinnick, Julianna E. Shaaya, Elias A. Thiele, Elizabeth A. Thibert, Ronald L. TI Angelman Syndrome in Adulthood SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE Angelman syndrome; adults; seizures; behavior; self-injury ID HAPPY PUPPET SYNDROME; GENETIC-ASPECTS; EPILEPSY; DELETION; EVOLUTION; COMMUNICATION; QUESTIONNAIRE; INDIVIDUALS; MUTATIONS; PHENOTYPE AB Angelman syndrome (AS) is a neurogenetic disorder. The goal of this study was to investigate the primary health issues affecting adults with AS and to further characterize the natural history and genotype-phenotype correlations. Standardized phone interviews with caregivers for 110 adolescents and adults with AS were conducted. The impact of age, sex, and genotype on specific outcomes in neurology, orthopedics, internal medicine, and psychiatry were investigated. The mean age of individuals with AS was 24 years (range 16-50y). Active seizures were present in 41% of individuals, and 72% had sleep dysfunction. Significant constipation was present in 85%, and 32% were overweight or obese, with obesity disproportionately affecting women. Scoliosis affected 50% with a mean age at diagnosis of 12 years, and 24% of those diagnosed with scoliosis required surgery, an intervention disproportionately affecting men. Sixty-eight percent were able to walk independently, and 13% were able to speak 5 or more words. Self-injurious behavior was exhibited in 52% of individuals. The results of this study indicate that epilepsy severity may assume a bimodal age distribution: seizures are typically most severe in early childhood but may recur in adulthood. While late-adolescent and adult sleep patterns were improved when compared to the degree of sleep dysfunction present during infancy and childhood, the prevalence of poor sleep in adults remained quite high. Primary areas of clinical management identified include the following: seizures, sleep, aspiration risk, GERD, constipation, dental care, vision, obesity, scoliosis, bone density, mobility, communication, behavior, and anxiety. (c) 2014 Wiley Periodicals, Inc. C1 [Larson, Anna M.; Shinnick, Julianna E.; Shaaya, Elias A.; Thiele, Elizabeth A.; Thibert, Ronald L.] Massachusetts Gen Hosp, Pediat Epilepsy Program, Dept Neurol, Boston, MA 02114 USA. RP Thibert, RL (reprint author), Massachusetts Gen Hosp, Pediat Epilepsy Program, 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM rthibert@partners.org FU Harvard Clinical and Translational Science Center [UL1 RR 025758]; Harvard University FX Grant sponsor: The Harvard Clinical and Translational Science Center; Grant number: UL1 RR 025758; Grant sponsor: Harvard University. NR 53 TC 5 Z9 5 U1 5 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 EI 1552-4833 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD FEB PY 2015 VL 167 IS 2 BP 331 EP 344 DI 10.1002/ajmg.a.36864 PG 14 WC Genetics & Heredity SC Genetics & Heredity GA CA3ZJ UT WOS:000348843600010 PM 25428759 ER PT J AU Hyman, BT Holtzman, DM AF Hyman, Bradley T. Holtzman, David M. TI Apolipoprotein E Levels and Alzheimer Risk SO ANNALS OF NEUROLOGY LA English DT Editorial Material ID CEREBROSPINAL-FLUID; DISEASE; CSF C1 [Hyman, Bradley T.] Massachusetts Gen Hosp, Neurol Serv, Boston, MA 02114 USA. [Holtzman, David M.] Washington Univ, Dept Neurol, St Louis, MO USA. RP Hyman, BT (reprint author), Massachusetts Gen Hosp, Neurol Serv, Boston, MA 02114 USA. NR 11 TC 2 Z9 2 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD FEB PY 2015 VL 77 IS 2 BP 204 EP 205 DI 10.1002/ana.24355 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CB1KF UT WOS:000349385400004 PM 25583643 ER PT J AU Mimiaga, MJ Closson, EF Safren, SA Mabude, Z Mosery, N Taylor, SW Perez-Brumer, A Matthews, LT Psaros, C Harrison, A Grelotti, DJ Bangsberg, DR Smit, JA AF Mimiaga, Matthew J. Closson, Elizabeth F. Safren, Steven A. Mabude, Zonke Mosery, Nzwakie Taylor, Scott W. Perez-Brumer, Amaya Matthews, Lynn T. Psaros, Christina Harrison, Abigail Grelotti, David J. Bangsberg, David R. Smit, Jennifer A. TI Inkwari: An Emerging High-Risk Place Potentiating HIV Spread Among Young Adults in a Hyper-Endemic South African Setting SO ARCHIVES OF SEXUAL BEHAVIOR LA English DT Article DE HIV; Inkwari; South Africa; Place; Youth ID SUB-SAHARAN AFRICA; ALCOHOL-USE; SEXUAL-BEHAVIOR; CAPE-TOWN; DRUG-USE; INFECTION; ADOLESCENTS; PREVENTION; WOMEN; VIOLENCE AB Young adults in South Africa are at the epicenter of the HIV epidemic. The prevalence of HIV among young people in the province of KwaZulu-Natal (KZN) is particularly high. This study characterizes inkwari (Zulu word for raves or weekend-long parties) in eThekwini District, KZN and explored how these place-based dynamics shape the risk environment for the young adult attendees. In 2011, 13 qualitative interviews were conducted with men and women between 18 and 30 years-old who reported unprotected sex with at least one casual partner in the prior 3 months and attended an inkwari in the same time period. Interviews were analyzed using qualitative content analysis. Nine key informant interviews helped to triangulate these data. Five women and eight men were interviewed and the mean age was 25 years (SD 3.24). Ten reported meeting a sexual partner at an inkwari. Inkwari were characterized as sexualized settings with limited adult supervision. Participants attended inkwari to socialize with peers, use drugs and alcohol, and meet sexual partners. Sexual and physical violence also occurred at inkwari. Given the convergence of social, sexual, and substance-using networks at inkwari, further inquiry is needed to determine how this place may potentiate HIV transmission risk in an endemic setting. C1 [Mimiaga, Matthew J.; Safren, Steven A.; Psaros, Christina] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA. [Mimiaga, Matthew J.; Perez-Brumer, Amaya; Grelotti, David J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02114 USA. [Mimiaga, Matthew J.; Closson, Elizabeth F.; Safren, Steven A.; Taylor, Scott W.; Perez-Brumer, Amaya] Fenway Hlth, Fenway Inst, Boston, MA USA. [Mabude, Zonke; Mosery, Nzwakie; Smit, Jennifer A.] Univ Witwatersrand, Maternal Adolescent & Child Hlth Div, Dept Obstet & Gynecol, Durban, South Africa. [Matthews, Lynn T.; Bangsberg, David R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Global Hlth, Boston, MA 02114 USA. [Matthews, Lynn T.; Bangsberg, David R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA. [Harrison, Abigail] Brown Univ, Dept Behav & Social Sci, Program Publ Hlth, Providence, RI 02912 USA. [Bangsberg, David R.] Ragon Inst MGH MIT & Harvard, Boston, MA USA. [Smit, Jennifer A.] Univ KwaZulu Natal, Sch Pharm & Pharmacol, Fac Hlth Sci, Durban, South Africa. RP Mimiaga, MJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, 1 Bowdoin Sq,7th Floor, Boston, MA 02114 USA. EM mmimiaga@partners.org FU NIAID NIH HHS [5P30AI060354-09, P30 AI060354]; NICHD NIH HHS [R24 HD041020]; NIMH NIH HHS [R25 MH083620, K24 MH094214, K24 MH087227, K23 MH096651, 5K24MH094214, 1K23MH096651]; PHS HHS [10K24087227] NR 46 TC 1 Z9 1 U1 2 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0004-0002 EI 1573-2800 J9 ARCH SEX BEHAV JI Arch. Sex. Behav. PD FEB PY 2015 VL 44 IS 2 BP 307 EP 315 DI 10.1007/s10508-014-0330-2 PG 9 WC Psychology, Clinical; Social Sciences, Interdisciplinary SC Psychology; Social Sciences - Other Topics GA CB3SB UT WOS:000349547500004 PM 25091214 ER PT J AU Wilhelm, S Berman, NC Keshaviah, A Schwartz, RA Steketee, G AF Wilhelm, Sabine Berman, Noah C. Keshaviah, Aparna Schwartz, Rachel A. Steketee, Gail TI Mechanisms of change in cognitive therapy for obsessive compulsive disorder: Role of maladaptive beliefs and schemas SO BEHAVIOUR RESEARCH AND THERAPY LA English DT Article DE Obsessive beliefs; Cognitive therapy; Mechanism of change; Early maladaptive schema; OCD ID PANIC DISORDER; PSYCHOMETRIC VALIDATION; INTRUSIONS INVENTORY; SELF-EFFICACY; QUESTIONNAIRE; RESPONSIBILITY; PERFECTIONISM; PREVENTION; MEDIATORS; EXPOSURE AB The present study aimed to identify mechanisms of change in individuals with moderately severe obsessive-compulsive disorder (OCD) receiving cognitive therapy (CT). Thirty-six adults with OCD received CT over 24 weeks. At weeks 0, 4/6, 12, 16/18, and 24, independent evaluators assessed OCD severity, along with obsessive beliefs and maladaptive schemas. To examine mechanisms of change, we utilized a time-varying lagged regression model with a random intercept and slope. Results indicated that perfectionism and certainty obsessive beliefs and maladaptive schemas related to dependency and incompetence significantly mediated (improved) treatment response. In conclusion, cognitive changes in perfectionism/certainty beliefs and maladaptive schemas related to dependency/incompetence precede behavioral symptom reduction for OCD patients. Targeting these mechanisms in future OCD treatment trials will emphasize the most relevant processes and facilitate maximum improvement. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Wilhelm, Sabine; Berman, Noah C.; Keshaviah, Aparna; Schwartz, Rachel A.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Steketee, Gail] Boston Univ, Sch Social Work, Boston, MA 02215 USA. RP Wilhelm, S (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, 185 Cambridge St,Suite 2000, Boston, MA 02115 USA. EM swilhelm@mgh.harvard.edu FU NIMH grant [R21 MH058804] FX This study was supported by an NIMH grant (R21 MH058804) awarded to the first author. NR 38 TC 10 Z9 11 U1 7 U2 29 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0005-7967 EI 1873-622X J9 BEHAV RES THER JI Behav. Res. Ther. PD FEB PY 2015 VL 65 BP 5 EP 10 DI 10.1016/j.brat.2014.12.006 PG 6 WC Psychology, Clinical SC Psychology GA CB2AK UT WOS:000349428900002 PM 25544403 ER PT J AU Abel, GA Albelda, R Coronado, DYS Marcellot, L Hahn, T Khera, N Tucker-Seeley, RD Bona, K Odejide, OO Soiffer, RJ AF Abel, Gregory A. Albelda, Randy Coronado, Diana Y. Solos Marcellot, Lyden Hahn, Theresa Khera, Nandita Tucker-Seeley, Reginald D. Bona, Kira Odejide, Oreofe O. Soiffer, Robert J. TI Prospective Assessment of Familial Financial Hardship after Hematopoietic Cell Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Abel, Gregory A.; Coronado, Diana Y. Solos; Marcellot, Lyden; Tucker-Seeley, Reginald D.; Bona, Kira; Odejide, Oreofe O.; Soiffer, Robert J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Albelda, Randy] Univ Massachusetts, Boston, MA 02125 USA. [Hahn, Theresa] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Khera, Nandita] Mayo Clin, Phoenix, AZ USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 58 BP S72 EP S72 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000063 ER PT J AU Arora, M Cutler, CS Jagasia, MH Pidala, J Chai, XY Martin, PJ Flowers, MED Inamoto, Y Chen, GL Wood, B Khera, N Palmer, J Duong, HK Arai, S Lee, SJ AF Arora, Mukta Cutler, Corey S. Jagasia, Madan H. Pidala, Joseph Chai, Xiaoyu Martin, Paul J. Flowers, Mary E. D. Inamoto, Yoshihiro Chen, George L. Wood, Bill Khera, Nandita Palmer, Jeanne Duong, Hien K. Arai, Sally Lee, Stephanie J. TI Incidence, Risk Factors, and Prognosis of Late Immune-Mediated Disorders after Allogeneic Hematopoietic Cell Transplantation (HCT) SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Arora, Mukta] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Jagasia, Madan H.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. [Pidala, Joseph] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Chai, Xiaoyu; Martin, Paul J.; Flowers, Mary E. D.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Inamoto, Yoshihiro] Natl Canc Ctr, Stem Cell Transplantat Div, Tokyo, Japan. [Chen, George L.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA. [Wood, Bill] Univ N Carolina, Chapel Hill, NC USA. [Khera, Nandita] Mayo Clin, Phoenix, AZ USA. [Palmer, Jeanne] Mayo Clin Arizona, Phoenix, AZ USA. [Duong, Hien K.] Cleveland Clin, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA. [Arai, Sally] Stanford Univ, Med Ctr, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 36 BP S54 EP S54 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000041 ER PT J AU Cheng, GS Pusic, I Jagasia, MH Burns, LJ Ho, VT Pidala, J Palmer, J Johnston, L Mayer, S Chai, XY Lee, SJ Williams, KM AF Cheng, Guang-Shing Pusic, Iskra Jagasia, Madan H. Burns, Linda J. Ho, Vincent T. Pidala, Joseph Palmer, Jeanne Johnston, Laura Mayer, Sebastian Chai, Xiaoyu Lee, Stephanie J. Williams, Kirsten M. TI BOS after HCT: Preceding Events, Diagnostic Characteristics, and Natural History of Patients Treated on a Prospective Trial SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Cheng, Guang-Shing; Chai, Xiaoyu; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Cheng, Guang-Shing] Univ Washington, Sch Med, Div Pulm & Crit Care Med, Seattle, WA USA. [Pusic, Iskra] Washington Univ, Med Ctr, St Louis, MO USA. [Jagasia, Madan H.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. [Burns, Linda J.] Natl Marrow Donor Program Be Match, Minneapolis, MN USA. [Ho, Vincent T.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pidala, Joseph] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Palmer, Jeanne] Mayo Clin Arizona, Phoenix, AZ USA. [Johnston, Laura] Stanford Univ, Med Ctr, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA. [Mayer, Sebastian] Weill Cornell Med Ctr, Dept Med, New York, NY USA. [Williams, Kirsten M.] NCI, CNMC, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 215 BP S172 EP S173 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000220 ER PT J AU Corbacioglu, S Carreras, E Mohty, M Pagliuca, A Ballabio, M Hume, R Bandiera, V Finetto, G Richardson, PG AF Corbacioglu, Selim Carreras, Enric Mohty, Mohamad Pagliuca, Antonio Ballabio, Maria Hume, Robin Bandiera, Valeria Finetto, Giorgia Richardson, Paul G. TI Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: An Update from the International Compassionate Use Program in 710 Patients SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Corbacioglu, Selim] Univ Regensburg, D-93053 Regensburg, Germany. [Carreras, Enric] Josep Carreras Fdn & Res Inst, Barcelona, Spain. [Mohty, Mohamad] Hop St Antoine, F-75571 Paris, France. [Pagliuca, Antonio] Kings Coll Hosp London, London, England. [Ballabio, Maria; Bandiera, Valeria; Finetto, Giorgia] Gentium SpA, Villa Guardia, Italy. [Hume, Robin] Jazz Pharmaceut Inc, Palo Alto, CA USA. [Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 109 BP S108 EP S108 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000114 ER PT J AU DePalo, J Chai, XY Lee, SJ Cutler, CS Treister, N AF DePalo, Joseph Chai, Xiaoyu Lee, Stephanie J. Cutler, Corey S. Treister, Nathaniel TI The Impact of Oral Chronic Graft-Versus-Host Disease on Global Measures of Quality of Life SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [DePalo, Joseph] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. [Chai, Xiaoyu; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Treister, Nathaniel] Brigham & Womens Hosp, Div Oral Med & Dent, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 68 BP S77 EP S78 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000073 ER PT J AU Dioguardi, J Bryson, E Ahmed-Winston, S Vaughn, G Slater, S Driscoll, J Perez-Albuerne, E Williams, KM AF Dioguardi, Jackie Bryson, Elyse Ahmed-Winston, Sameeya Vaughn, Gretchen Slater, Susan Driscoll, Jessica Perez-Albuerne, Evelio Williams, Kirsten M. TI A Multi-Institutional Retrospective Study Suggests That Optimal Enteral Nutrition (EN) Influences Outcomes after Hematopoietic Stem Cell Transplantation in Children and Adults SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Dioguardi, Jackie] Childrens Natl Med Ctr, Div Blood & Marrow Transplantat, Washington, DC 20010 USA. [Bryson, Elyse] Childrens Healthcare Atlanta, Hematol Oncol, Atlanta, GA USA. [Ahmed-Winston, Sameeya; Perez-Albuerne, Evelio] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Vaughn, Gretchen] All Childrens Hosp, Tampa, FL USA. [Slater, Susan] Oregon Hlth & Sci Univ, Ctr Hematol Malignancies, Portland, OR USA. [Driscoll, Jessica] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA. [Williams, Kirsten M.] NCI, CNMC, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 343 BP S248 EP S249 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000345 ER PT J AU Duong, HK Akhtari, M Ahn, KW Hu, ZH Popat, UR Alyea, EP Maziarz, RT Kalaycio, ME Saber, W AF Duong, Hien K. Akhtari, Mojtaba Ahn, Kwang Woo Hu, Zhen-Huan Popat, Uday R. Alyea, Edwin P., III Maziarz, Richard T. Kalaycio, Matt E. Saber, Wael TI Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Duong, Hien K.; Kalaycio, Matt E.] Cleveland Clin, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA. [Akhtari, Mojtaba] Univ Nebraska Med Ctr, Omaha, NE USA. [Ahn, Kwang Woo; Hu, Zhen-Huan; Saber, Wael] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Ahn, Kwang Woo] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA. [Popat, Uday R.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Alyea, Edwin P., III] Dana Farber Canc Inst, Boston, MA 02115 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR 97201 USA. NR 1 TC 5 Z9 5 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 8 BP S30 EP S31 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000013 ER PT J AU El-Jawahri, A Traeger, L Kuzmuk, K Eusebio, J Vandusen, H Keenan, T Shin, J Gallagher, E Greer, J Pirl, W Jackson, V Ballen, KK Spitzer, TR Graubert, T McAfee, SL Dey, BR Chen, YB Temel, J AF El-Jawahri, Areej Traeger, Lara Kuzmuk, Kailyn Eusebio, Justin Vandusen, Harry Keenan, Tanya Shin, Jennifer Gallagher, Emily Greer, Joseph Pirl, William Jackson, Vicki Ballen, Karen K. Spitzer, Thomas R. Graubert, Timothy McAfee, Steven L. Dey, Bimalangshu R. Chen, Yi-Bin Temel, Jennifer TI Prognostic Understanding, Quality of Life, and Mood in Patients Undergoing Hematopoietic Stem Cell Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [El-Jawahri, Areej; Traeger, Lara; Kuzmuk, Kailyn; Eusebio, Justin; Vandusen, Harry; Keenan, Tanya; Shin, Jennifer; Gallagher, Emily; Greer, Joseph; Pirl, William; Jackson, Vicki; Ballen, Karen K.; Graubert, Timothy; Chen, Yi-Bin; Temel, Jennifer] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Spitzer, Thomas R.] Massachusetts Gen Hosp, Bone Marrow Transplantat Unit, Boston, MA 02114 USA. [McAfee, Steven L.] Massachusetts Gen Hosp, Dept Med, BMT Program, Boston, MA 02114 USA. [Dey, Bimalangshu R.] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 219 BP S175 EP S175 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000224 ER PT J AU Forcade, E Paula, S Cowens, K Bento, ML Nikiforow, S Koreth, J Cutler, CS Ho, VT Armand, P Alyea, EP Soiffer, RJ Antin, JH Blazar, BR Ritz, J AF Forcade, Edouard Paula, Steven Cowens, Kristen Bento, Marta Leal Nikiforow, Sarah Koreth, John Cutler, Corey S. Ho, Vincent T. Armand, Philippe Alyea, Edwin P., III Soiffer, Robert J. Antin, Joseph H. Blazar, Bruce R. Ritz, Jerome TI Recovery of Circulating T-Follicular Helper Cells after Hematopoietic Stem Cell Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Forcade, Edouard; Paula, Steven; Cowens, Kristen; Bento, Marta Leal; Nikiforow, Sarah; Koreth, John; Cutler, Corey S.; Ho, Vincent T.; Armand, Philippe; Alyea, Edwin P., III; Soiffer, Robert J.; Antin, Joseph H.; Ritz, Jerome] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Blazar, Bruce R.] Univ Minnesota, Minneapolis, MN USA. [Ritz, Jerome] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 203 BP S164 EP S165 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000208 ER PT J AU Guallart, PA Zitsman, J Sondermeijer, H Buhler, L Ovanez, C McMurchy, A Levings, M Sykes, M Duran-Struuck, R AF Guallart, Paula Alonso Zitsman, Jonah Sondermeijer, Hugo Buehler, Leo Ovanez, Christopher McMurchy, Alicia Levings, Megan Sykes, Megan Duran-Struuck, Raimon TI Phenotype, Function and Expansion of Regulatory T Cells in the Cynomolgus Macaque (Macaca fascicularis) SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Guallart, Paula Alonso; Zitsman, Jonah; Sondermeijer, Hugo; Ovanez, Christopher; Sykes, Megan; Duran-Struuck, Raimon] Columbia Univ, CCTI, New York, NY USA. [Buehler, Leo] Massachusetts Gen Hosp, Boston, MA 02114 USA. [McMurchy, Alicia] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Levings, Megan] Univ British Columbia, Dept Surg, Child & Family Res Inst, Vancouver, BC V6T 1W5, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 399 BP S280 EP S281 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000401 ER PT J AU Guallart, PA Zitsman, J Sondermeijer, H Woodland, D Kato, Y Weiner, J Griesemer, A Buhler, L McMurchy, A Levings, M Sykes, M Duran-Struuck, R AF Guallart, Paula Alonso Zitsman, Jonah Sondermeijer, Hugo Woodland, David Kato, Yojiro Weiner, Joshua Griesemer, Adam Buehler, Leo McMurchy, Alicia Levings, Megan Sykes, Megan Duran-Struuck, Raimon TI Induction of Durable Mixed Hematopoietic Chimerism and Immune Tolerance in Monkeys SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Guallart, Paula Alonso; Zitsman, Jonah; Sondermeijer, Hugo; Woodland, David; Kato, Yojiro; Weiner, Joshua; Griesemer, Adam; Sykes, Megan; Duran-Struuck, Raimon] Columbia Univ, CCTI, New York, NY USA. [Buehler, Leo] Massachusetts Gen Hosp, Boston, MA 02114 USA. [McMurchy, Alicia] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Levings, Megan] Univ British Columbia, Dept Surg, Child & Family Res Inst, Vancouver, BC V6T 1W5, Canada. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 26 BP S46 EP S47 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000031 ER PT J AU Hanley, PJ Melenhorst, J Nikiforow, S Scheinberg, P Cruz, R Krance, RA Leung, K Martinez, C Heslop, HE Rooney, CM Barrett, AJ Shpall, EJ Bollard, CM AF Hanley, Patrick J. Melenhorst, Jan Nikiforow, Sarah Scheinberg, Phillip Cruz, Russell Krance, Robert A. Leung, Kathryn Martinez, Caridad Heslop, Helen E. Rooney, Cliona M. Barrett, A. John Shpall, Elizabeth J. Bollard, Catherine M. TI CMVpp65-Specific T Cells Generated from Naive T Cell Populations Recognize Atypical but Not Canonical Epitopes and May Be Protective In Vivo SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Hanley, Patrick J.] Childrens Natl Med Ctr, CETI, Washington, DC 20010 USA. [Melenhorst, Jan] NHLBI, NIH, Bethesda, MD 20892 USA. [Nikiforow, Sarah] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Scheinberg, Phillip] Hosp Beneficencia Portuguesa Sao Paulo, Antonio Ermirio de Moraes Oncol Ctr, Sao Paulo, Brazil. [Cruz, Russell] Childrens Natl Med Ctr, Sheikh Zayad Inst, Washington, DC 20010 USA. [Krance, Robert A.] Houston Methodist Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX USA. [Krance, Robert A.] Texas Childrens Hosp, Houston, TX 77030 USA. [Leung, Kathryn; Martinez, Caridad] Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. [Heslop, Helen E.; Rooney, Cliona M.] Houston Methodist Hosp, Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX USA. [Barrett, A. John] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Bollard, Catherine M.] Childrens Natl Med Ctr, Ctr Canc & Immunol Res, Washington, DC 20010 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 33 BP S51 EP S52 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000038 ER PT J AU Kekre, N Mak, K Stopsack, K Ishii, K Binder, M Branvall, E Cutler, CS AF Kekre, Natasha Mak, Kimberley Stopsack, Konrad Ishii, Kazusa Binder, Moritz Branvall, Elsa Cutler, Corey S. TI Impact of HLA-Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Comprehensive Meta-Analysis SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Kekre, Natasha; Cutler, Corey S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mak, Kimberley] Harvard Radiat Oncol Program, Boston, MA USA. [Stopsack, Konrad; Binder, Moritz] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Ishii, Kazusa] NIH, Bethesda, MD 20892 USA. [Branvall, Elsa] Karolinska Univ Hosp, Stockholm, Sweden. RI Binder, Moritz/D-3279-2016 OI Binder, Moritz/0000-0001-9014-9658 NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 52 BP S66 EP S67 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000057 ER PT J AU Khera, N Chai, XY Duong, HK Inamoto, Y Chen, GL Mayer, S Arora, M Palmer, J Flowers, MED Cutler, CS Lukezw, A Arai, S Lazaryan, A Jagasia, MH Pusic, I Wood, W Lee, SJ Pidala, J AF Khera, Nandita Chai, Xiaoyu Duong, Hien K. Inamoto, Yoshihiro Chen, George L. Mayer, Sebastian Arora, Mukta Palmer, Jeanne Flowers, Mary E. D. Cutler, Corey S. Lukezw, Alexander Arai, Sally Lazaryan, Aleksandr Jagasia, Madan H. Pusic, Iskra Wood, William Lee, Stephanie J. Pidala, Joseph TI Prospective Longitudinal Study of Late Acute Graft Versus Host Disease after Hematopoietic Cell Transplantation: A Report from Chronic GVHD Consortium SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Khera, Nandita] Mayo Clin, Phoenix, AZ USA. [Chai, Xiaoyu; Flowers, Mary E. D.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Duong, Hien K.] Cleveland Clin, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA. [Inamoto, Yoshihiro] Natl Canc Ctr, Stem Cell Transplantat Div, Tokyo, Japan. [Chen, George L.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA. [Mayer, Sebastian] Weill Cornell Med Ctr, Dept Med, New York, NY USA. [Arora, Mukta; Lazaryan, Aleksandr] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Palmer, Jeanne] Mayo Clin Arizona, Phoenix, AZ USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Lukezw, Alexander] Dana Farber Canc Inst, Boston, MA 02115 USA. [Arai, Sally] Stanford Univ, Med Ctr, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA. [Jagasia, Madan H.] Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Nashville, TN USA. [Pusic, Iskra] Washington Univ, Med Ctr, St Louis, MO USA. [Wood, William] Univ North Carolina Healthcare, Chapel Hill, NC USA. [Pidala, Joseph] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 489 BP S336 EP S337 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000491 ER PT J AU Luon, DK Gushiken, F Zigmond, M AF Luon, Darren K. Gushiken, Francisca Zigmond, Megan TI Contributing Factors to Renal Dysfunction during Engraftment Syndrome SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Luon, Darren K.] South Texas VA Hlth Care Syst, Pharm, San Antonio, TX USA. [Gushiken, Francisca] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Zigmond, Megan] South Texas Vet Hlth Care Syst, Pharm, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 161 BP S141 EP S141 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000166 ER PT J AU Mehta, PA Davies, SM Myers, KC Leemhuis, T Williams, DA Lehmann, LE Guinan, E Margolis, DA Baker, KS Klein, E Boulad, F AF Mehta, Parinda A. Davies, Stella M. Myers, Kasiani C. Leemhuis, Tom Williams, David A. Lehmann, Leslie E. Guinan, Eva Margolis, David Arthur Baker, K. Scott Klein, Elizabeth Boulad, Farid TI Chemotherapy-Only Preparative Regimen for Alternative Donor Hematopoietic Cell Transplantation for Patients with Fanconi Anemia (FA): Results of a Multi-Institutional Study SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Mehta, Parinda A.; Davies, Stella M.; Myers, Kasiani C.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Leemhuis, Tom] Hoxworth Blood Ctr, Cincinnati, OH USA. [Williams, David A.] Boston Childrens Hosp, Boston, MA USA. [Williams, David A.; Lehmann, Leslie E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Guinan, Eva] Dana Farber Canc Inst, Ctr Clin & Translat Res, Boston, MA 02115 USA. [Margolis, David Arthur] Med Coll Wisconsin, Childrens Hosp, Milwaukee, WI 53226 USA. [Baker, K. Scott] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Klein, Elizabeth; Boulad, Farid] Mem Sloan Kettering Canc Ctr, Bone Marrow Transplant Serv, Dept Pediat, New York, NY 10021 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 103 BP S104 EP S105 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000108 ER PT J AU Miklos, DB Coutre, S O'Brien, S Byrd, JC Hillmen, P Brown, JR Dyer, M Mato, AR Keating, M Zhou, C Fardis, M Styles, L Jaglowski, S AF Miklos, David B. Coutre, Steven O'Brien, Susan Byrd, John C. Hillmen, Peter Brown, Jennifer R. Dyer, Martin Mato, Anthony R. Keating, Michael Zhou, Cathy Fardis, Maria Styles, Lori Jaglowski, Samantha TI Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have. Undergone Prior Allogeneic Stem Cell Transplant SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Miklos, David B.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Coutre, Steven] Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA. [O'Brien, Susan; Keating, Michael] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Byrd, John C.; Jaglowski, Samantha] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Hillmen, Peter] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England. [Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Dyer, Martin] Univ Leicester, Leicester, Leics, England. [Mato, Anthony R.] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Zhou, Cathy; Fardis, Maria; Styles, Lori] Pharmacyclics Inc, Sunnyvale, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 76 BP S82 EP S83 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000081 ER PT J AU Palmer, J Chai, XY Martin, PJ Pidala, J Lazaryan, A Arora, M Cutler, CS Pavletic, SZ Pusic, I Jagasia, MH Inamoto, Y Flowers, MED Vogelsang, G Lee, SJ AF Palmer, Jeanne Chai, Xiaoyu Martin, Paul J. Pidala, Joseph Lazaryan, Aleksandr Arora, Mukta Cutler, Corey S. Pavletic, Steven Z. Pusic, Iskra Jagasia, Madan H. Inamoto, Yoshihiro Flowers, Mary E. D. Vogelsang, Georgia Lee, Stephanie J. TI Physician-Reported CR+PR at 6 Months Predicts Subsequent Survival in Patients with Chronic GVHD SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Palmer, Jeanne] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA. [Chai, Xiaoyu; Martin, Paul J.; Flowers, Mary E. D.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Pidala, Joseph] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Lazaryan, Aleksandr; Arora, Mukta] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Pavletic, Steven Z.] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA. [Pusic, Iskra] Washington Univ, Med Ctr, St Louis, MO USA. [Jagasia, Madan H.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. [Inamoto, Yoshihiro] Natl Canc Ctr, Stem Cell Transplantat Div, Tokyo, Japan. [Vogelsang, Georgia] Johns Hopkins Med Ctr, Lutherville Timonium, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 43 BP S59 EP S60 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000048 ER PT J AU Politikos, I Kim, HT Nikiforow, S Li, LQ Ballen, KK Antin, JH Ritz, J Cutler, CS Boussiotis, VA AF Politikos, Ioannis Kim, Haesook T. Nikiforow, Sarah Li, Lequn Ballen, Karen K. Antin, Joseph H. Ritz, Jerome Cutler, Corey S. Boussiotis, Vassiliki A. TI Prognostic Value of IL-7 and SCF Levels on Thymic Reconstitution and Clinical Outcomes after Double Umbilical Cord Transplantation in Adults SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Politikos, Ioannis; Li, Lequn; Boussiotis, Vassiliki A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol, Boston, MA 02215 USA. [Kim, Haesook T.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Nikiforow, Sarah; Antin, Joseph H.; Ritz, Jerome; Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 208 BP S168 EP S168 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000213 ER PT J AU Richardson, PG Kernan, NA Grupp, SA Martin, PL Soiffer, RJ Martin, R Hannah, A Villa, KF AF Richardson, Paul G. Kernan, Nancy A. Grupp, Stephan A. Martin, Paul L. Soiffer, Robert J. Martin, Richard Hannah, Alison Villa, Kathleen F. TI Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Richardson, Paul G.; Soiffer, Robert J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kernan, Nancy A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Grupp, Stephan A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Martin, Paul L.] Duke Univ, Med Ctr, Durham, NC USA. [Martin, Richard] EUSA Pharma, Oxford, England. [Hannah, Alison; Villa, Kathleen F.] Jazz Pharmaceut Inc, Palo Alto, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 112 BP S110 EP S110 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000117 ER PT J AU Richardson, PG Smith, AR Triplett, BM Kernan, NA Grupp, SA Arai, S Antin, JH Lehmann, LE Bandiera, V Hume, R Hannah, A Nejadnik, B Soiffer, RJ AF Richardson, Paul G. Smith, Angela R. Triplett, Brandon M. Kernan, Nancy A. Grupp, Stephan A. Arai, Sally Antin, Joseph H. Lehmann, Leslie E. Bandiera, Valeria Hume, Robin Hannah, Alison Nejadnik, Bijan Soiffer, Robert J. CA Defibrotide Study Grp TI Updated Results from the Ongoing US Treatment IND Study Using Defibrotide for Patients with Hepatic Veno-Occlusive Disease SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr,Div Hematol Ma, Boston, MA 02115 USA. [Smith, Angela R.] Univ Minnesota, Div Blood & Marrow Transplantat, Minneapolis, MN USA. [Triplett, Brandon M.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. [Kernan, Nancy A.] Mem Sloan Kettering Canc Ctr, Bone Marrow Transplant Serv, Dept Pediat, New York, NY 10021 USA. [Grupp, Stephan A.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA. [Arai, Sally] Stanford Univ, Med Ctr, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA. [Antin, Joseph H.; Soiffer, Robert J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Stem Cell Bone Marrow Transplantat Program,Div He, Boston, MA 02115 USA. [Lehmann, Leslie E.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Dept Med Oncol, Ctr Stem Cell Transplantat,Div Hematol Malignancy, Boston, MA 02115 USA. [Bandiera, Valeria; Defibrotide Study Grp] Gentium SpA, Villa Guardia, Italy. [Hume, Robin; Hannah, Alison; Nejadnik, Bijan] Jazz Pharmaceut Inc, Palo Alto, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 111 BP S109 EP S110 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000116 ER PT J AU Rowe, RG Duncan, C Margossian, S Lee, M Lehmann, LE AF Rowe, Robert Grant Duncan, Christine Margossian, Steven Lee, Michelle Lehmann, Leslie E. TI Factors Associated with CMV Disease in Pediatric Hematopoietic Stem Cell Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Rowe, Robert Grant; Duncan, Christine; Margossian, Steven; Lee, Michelle; Lehmann, Leslie E.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 321 BP S237 EP S237 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000324 ER PT J AU Sarantopoulos, S Blazar, BR Cutler, C Ritz, J AF Sarantopoulos, Stefanie Blazar, Bruce R. Cutler, Corey Ritz, Jerome TI B Cells in Chronic Graft-versus-Host Disease (Reprinted from Biol Blood Marrow Transplant, vol 21, pg 16-23, 2015) SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Reprint DE Stem cell transplantation; Chronic graft-versus-host disease; B cell ID MINOR HISTOCOMPATIBILITY ANTIGEN; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CD4(+) T-CELLS; CHRONIC GVHD; BRONCHIOLITIS OBLITERANS; TYROSINE KINASE; ANTIBODY-RESPONSE; ACTIVATING FACTOR; DENDRITIC CELLS; EXCESS BAFF AB Chronic graft-versus-host disease (cGVHD) continues to be a common complication of allogeneic hematopoietic stem cell transplantation. Unlike acute graft-versus-host disease, which is mediated almost entirely by donor T cells, the immune pathology of cGVHD is more complex and donor B cells have also been found to play an important role. Recent studies from several laboratories have enhanced our understanding of how donor B cells contribute to this clinical syndrome and this has led to new therapeutic opportunities. Here, Dr Sarantopoulos reviews some of the important mechanisms responsible for persistent B cell activation and loss of B cell tolerance in patients with cGVHD. Dr Blazar describes recent studies in preclinical models that have identified novel B cell directed agents that may be effective for prevention or treatment of cGVHD. Some B cell directed therapies have already been tested in patients with cGVHD and Dr Cutler reviews the results of these studies documenting the potential efficacy of this approach. Supported by mechanistic studies in patients and preclinical models, new B cell directed therapies for cGVHD will now be evaluated in clinical trials. (C) 2015 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation. C1 [Sarantopoulos, Stefanie] Duke Univ, Dept Med, Duke Canc Inst, Div Cell Therapy & Hematol Malignancies, Durham, NC USA. [Blazar, Bruce R.] Univ Minnesota, Dept Pediat, Masonic Canc Ctr, Div Blood & Marrow Transplantat, Minneapolis, MN 55455 USA. [Cutler, Corey; Ritz, Jerome] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02215 USA. RP Ritz, J (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Malignancies, 450 Brookline Ave, Boston, MA 02215 USA. EM jerome_ritz@dfci.harvard.edu NR 88 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 BP S11 EP S18 DI 10.1016/j.bbmt.2014.12.033 PG 8 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000003 PM 25620647 ER PT J AU Toro, JJ Cadena, JA Meinzen, S Shaw, S McKee, M Neumon, B Gushiken, F Haile, DJ Freytes, CO AF Toro, Juan J. Cadena, Jose A. Meinzen, Sarah Shaw, Sandra McKee, Megan Neumon, Bonita Gushiken, Francisca Haile, David J. Freytes, Cesar O. TI A Quality Improvement Project to Decrease Clostridium Difficile Associated Infection in a Bone Marrow Transplant Unit: A Multidisciplinary Approach SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Toro, Juan J.; Cadena, Jose A.; Meinzen, Sarah; Shaw, Sandra; McKee, Megan; Neumon, Bonita; Gushiken, Francisca; Haile, David J.; Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 366 BP S259 EP S260 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000368 ER PT J AU Williams, KM Cheng, GS Pusic, I Jagasia, MH Burns, LJ Ho, VT Pidala, J Palmer, J Johnston, L Mayer, S Jacobsohn, DA Martin, PJ Storer, BE Inamoto, Y Chai, XY Flowers, MED Lee, SJ AF Williams, Kirsten M. Cheng, Guang-Shing Pusic, Iskra Jagasia, Madan H. Burns, Linda J. Ho, Vincent T. Pidala, Joseph Palmer, Jeanne Johnston, Laura Mayer, Sebastian Jacobsohn, David A. Martin, Paul J. Storer, Barry E. Inamoto, Yoshihiro Chai, Xiaoyu Flowers, Mary E. D. Lee, Stephanie J. TI Encouraging Results of a Phase II Trial of Inhaled Fluticasone Propionate, Azithromycin, and Montelukast (FAM) May Maintain Lung Function in Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Williams, Kirsten M.] NCI, CNMC, NIH, Bethesda, MD 20892 USA. [Cheng, Guang-Shing] Univ Washington, Sch Med, Div Pulm & Crit Care Med, Seattle, WA USA. [Pusic, Iskra] Washington Univ, Med Ctr, St Louis, MO USA. [Jagasia, Madan H.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. [Burns, Linda J.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Ho, Vincent T.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pidala, Joseph] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Palmer, Jeanne] Mayo Clin Arizona, Phoenix, AZ USA. [Johnston, Laura] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Mayer, Sebastian] Weill Cornell Med Ctr, Dept Med, New York, NY USA. [Jacobsohn, David A.] Childrens Natl Med Ctr, Div Blood & Marrow Transplantat, Washington, DC 20010 USA. [Martin, Paul J.; Storer, Barry E.; Chai, Xiaoyu; Flowers, Mary E. D.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Inamoto, Yoshihiro] Natl Canc Ctr, Stem Cell Transplantat Div, Tokyo, Japan. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 46 BP S61 EP S62 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000051 ER PT J AU Wood, WA Lee, SJ Chai, XY Flowers, MED Cutler, CS Inamoto, Y Lazaryan, A Pidala, J Palmer, J Martin, PJ AF Wood, William A. Lee, Stephanie J. Chai, Xiaoyu Flowers, Mary E. D. Cutler, Corey S. Inamoto, Yoshihiro Lazaryan, Aleksandr Pidala, Joseph Palmer, Jeanne Martin, Paul J. TI Survival without Progressive Impairment As a Novel Endpoint in Chronic Graft-Versus-Host Disease SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Wood, William A.] Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC USA. [Lee, Stephanie J.; Chai, Xiaoyu; Flowers, Mary E. D.; Inamoto, Yoshihiro; Martin, Paul J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Cutler, Corey S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Lazaryan, Aleksandr] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Pidala, Joseph] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Palmer, Jeanne] Mayo Clin Arizona, Phoenix, AZ USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 513 BP S352 EP S353 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000514 ER PT J AU Low, JCM Ober, TJ McKinley, GH Stankovic, KM AF Low, Jacob C. M. Ober, Thomas J. McKinley, Gareth H. Stankovic, Konstantina M. TI Quantitative polarized light microscopy of human cochlear sections SO BIOMEDICAL OPTICS EXPRESS LA English DT Article ID OPTICAL COHERENCE TOMOGRAPHY; HUMAN VOCAL FOLD; SPIRAL LIGAMENT; MOUSE COCHLEA; TEMPORAL BONE; RAT COCHLEA; TENDONS; REPAIR AB Dysfunction of the inner ear is the most common cause of sensorineural hearing loss, which is the most common sensory deficit worldwide. Conventional imaging modalities are unable to depict the microanatomy of the human inner ear, hence the need to explore novel imaging modalities. We provide the first characterization of the polarization dependent optical properties of human cochlear sections using quantitative polarized light microscopy (qPLM). Eight pediatric cadaveric cochlear sections, aged 0 (term) to 24 months, were selected from the US National Temporal Bone Registry, imaged with qPLM and analyzed using Image J. Retardance of the bony otic capsule and basilar membrane were substantially higher than that of the stria vascularis, spiral ganglion neurons, organ of Corti and spiral ligament across the half turns of the spiraling cochlea. qPLM provides quantitative information about the human inner ear, and awaits future exploration in vivo. (C) 2015 Optical Society of America C1 [Low, Jacob C. M.] Univ Manchester, Manchester M13 9PL, Lancs, England. [Ober, Thomas J.; McKinley, Gareth H.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA. [Stankovic, Konstantina M.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Stankovic, Konstantina M.] Eaton Peabody Labs, Boston, MA 02114 USA. [Stankovic, Konstantina M.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Low, JCM (reprint author), Univ Manchester, Oxford Rd, Manchester M13 9PL, Lancs, England. EM Konstantina_stankovic@meei.harvard.edu FU NIDCD [K08DC010419]; Bertarelli Foundation; Curing Kids Foundation at Massachusetts Eye and Ear Infirmary FX We are grateful for support by NIDCD grant K08DC010419 (K.M.S.), the Bertarelli Foundation (K.M.S.), and Curing Kids Foundation at Massachusetts Eye and Ear Infirmary (K.M.S.). NR 29 TC 0 Z9 0 U1 1 U2 4 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 2156-7085 J9 BIOMED OPT EXPRESS JI Biomed. Opt. Express PD FEB 1 PY 2015 VL 6 IS 2 BP 599 EP 606 DI 10.1364/BOE.6.000599 PG 8 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA CB2KI UT WOS:000349455700026 PM 25780749 ER PT J AU Bachanova, V Burns, LJ Wang, T Carreras, J Gale, RP Wiernik, PH Ballen, KK Wirk, B Munker, R Rizzieri, DA Chen, YB Gibson, J Akpek, G Costa, LJ Kamble, RT Aljurf, MD Hsu, JW Cairo, MS Schouten, HC Bacher, U Savani, BN Wingard, JR Lazarus, HM Laport, GG Montoto, S Maloney, DG Smith, SM Brunstein, C Saber, W AF Bachanova, V. Burns, L. J. Wang, T. Carreras, J. Gale, R. P. Wiernik, P. H. Ballen, K. K. Wirk, B. Munker, R. Rizzieri, D. A. Chen, Y-B Gibson, J. Akpek, G. Costa, L. J. Kamble, R. T. Aljurf, M. D. Hsu, J. W. Cairo, M. S. Schouten, H. C. Bacher, U. Savani, B. N. Wingard, J. R. Lazarus, H. M. Laport, G. G. Montoto, S. Maloney, D. G. Smith, S. M. Brunstein, C. Saber, W. TI Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor SO BONE MARROW TRANSPLANTATION LA English DT Article ID STEM-CELL TRANSPLANTATION; UMBILICAL-CORD BLOOD; BONE-MARROW-TRANSPLANTATION; RELAPSED FOLLICULAR LYMPHOMA; UNRELATED DONOR; HODGKIN-LYMPHOMA; ALLOGENEIC TRANSPLANTATION; WORKING PARTY; ACUTE GVHD; CLASS-I AB Alternative donor transplantation is increasingly used for high-risk lymphoma patients. We analyzed 1593 transplant recipients (2000-2010) and compared transplant outcomes in recipients of 8/8 allele HLA-A, -B, -C and DRB1 matched unrelated donors (MUDs; n = 1176), 7/8 allele HLA mismatched unrelated donors (MMUDs; n = 275) and umbilical cord blood donors (1 or 2 units UCB; n = 142). Adjusted 3-year non-relapse mortality of MMUD (44%) was higher as compared with MUD (35%; P = 0.004), but similar to UCB recipients (37%; P = 0.19), although UCB had lower rates of neutrophil and platelet recovery compared with unrelated donor groups. With a median follow-up of 55 months, 3-year adjusted cumulative incidence of relapse was lower after MMUD compared with MUD (25% vs 33%, P = 0.003) but similar between UCB and MUD (30% vs 33%; P = 0.48). In multivariate analysis, UCB recipients had lower risks of acute and chronic GVHD compared with adult donor groups (UCB vs MUD: hazard ratio (HR) = 0.68, P = 0.05; HR = 0.35; P=0.001). Adjusted 3-year OS was comparable (43% MUD, 37% MMUD and 41% UCB). These data highlight the observation that patients with lymphoma have acceptable survival after alternative donor transplantation. MMUD and UCB can extend the curative potential of allotransplant to patients who lack suitable HLA matched sibling or MUD. C1 [Bachanova, V.; Burns, L. J.; Brunstein, C.] Univ Minnesota, Blood & Marrow Transplant Program, Minneapolis, MN USA. [Wang, T.; Carreras, J.; Saber, W.] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Wang, T.] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. [Gale, R. P.] Univ London Imperial Coll Sci Technol & Med, Hematol Res Ctr, Dept Med, Div Expt Med, London, England. [Wiernik, P. H.] Our Lady Mercy Med Ctr, Bronx, NY USA. [Ballen, K. K.; Chen, Y-B] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA. [Wirk, B.] SUNY Stony Brook, Med Ctr, BMT Program, Stony Brook, NY 11794 USA. [Munker, R.] Louisiana State Univ, Hlth Sci Ctr, Dept Hematol Oncol, Shreveport, LA 71105 USA. [Rizzieri, D. A.] Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA. [Gibson, J.] Royal Prince Alfred Hosp, Dept Hematol, Camperdown, NSW 2050, Australia. [Akpek, G.] Banner MD Anderson Canc Ctr, Gilbert, AZ USA. [Costa, L. J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Kamble, R. T.] Baylor Coll Med, Dept Hematol Oncol, Houston, TX 77030 USA. [Aljurf, M. D.] King Faisal Specialist Hosp & Res Ctr, Dept Oncol, Riyadh, Saudi Arabia. [Hsu, J. W.; Wingard, J. R.] Shands HealthCare, Gainesville, FL USA. [Hsu, J. W.; Wingard, J. R.] Univ Florida, Gainesville, FL USA. [Cairo, M. S.] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA. [Schouten, H. C.] Acad Ziekenhuis Maastricht, Maastricht, Netherlands. [Bacher, U.] Univ Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany. [Bacher, U.] Munich Leukemia Lab, Munich, Germany. [Savani, B. N.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Wingard, J. R.] LifeSouth Community Blood Ctr, Gainesville, FL USA. [Lazarus, H. M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. [Laport, G. G.] Stanford Hosp & Clin, Div BMT, Stanford, CA USA. [Montoto, S.] Barts Hlth NHS Trust, St Bartholomews Hosp, Dept Haematooncol, London, England. [Maloney, D. G.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Smith, S. M.] Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA. RP Bachanova, V (reprint author), Univ Minnesota, Blood & Marrow Transplant Program, Mayo Mail Code 480,420 Delaware St SE, Milwaukee, WI USA. EM bach0173@umn.edu FU Public Health Service Grant/Cooperative Agreement [U24-CA076518]; National Cancer Institute (NCI); National Heart, Lung and Blood Institute (NHLBI); National Institute of Allergy and Infectious Diseases (NIAID); NHLBI [5U10HL069294]; NCI [HHSH250201200016C]; Health Resources and Services Administration (HRSA/DHHS); Office of Naval Research [N00014-12-1-0142, N00014-13-1-0039]; Actinium Pharmaceuticals; Allos Therapeutics Inc.; Amgen Inc. FX The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-12-1-0142 and N00014-13-1-0039 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics Inc.; *Amgen Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; FreseniusBiotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech Inc.; *Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research Inc. Roswell Park Cancer Institute; HistoGenetics Inc.; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma- Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS, Inc.; University of Minnesota; University of Utah; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration ( HRSA) or any other agency of the U. S. Government. NR 32 TC 9 Z9 9 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD FEB PY 2015 VL 50 IS 2 BP 197 EP 203 DI 10.1038/bmt.2014.259 PG 7 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA CB1QM UT WOS:000349402900007 PM 25402415 ER PT J AU Konstantinopoulos, PA Matulonis, UA AF Konstantinopoulos, Panagiotis A. Matulonis, Ursula A. TI POLE Mutations as an Alternative Pathway for Microsatellite Instability in Endometrial Cancer: Implications for Lynch Syndrome Testing SO CANCER LA English DT Editorial Material ID DNA-POLYMERASE EPSILON; CARCINOMA C1 [Konstantinopoulos, Panagiotis A.; Matulonis, Ursula A.] Dana Farber Canc Inst, Gynecol Oncol Program, Boston, MA 02215 USA. RP Matulonis, UA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM ursula_matulonis@dfci.harvard.edu NR 11 TC 5 Z9 5 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD FEB 1 PY 2015 VL 121 IS 3 BP 331 EP 334 DI 10.1002/cncr.29057 PG 4 WC Oncology SC Oncology GA CB1NP UT WOS:000349394900005 PM 25224324 ER PT J AU Hirschberg, AM Chan-Smutko, G Pirl, WF AF Hirschberg, April Malia Chan-Smutko, Gayun Pirl, William F. TI Psychiatric Implications of Cancer Genetic Testing SO CANCER LA English DT Review DE BRCA1; BRCA2; HNPCC; Lynch syndrome; genetic testing; unaffected carrier; carrier; hereditary cancer syndrome; risk-reducing surgeries; psychosocial ID NONPOLYPOSIS COLORECTAL-CANCER; PROPHYLACTIC SALPINGO-OOPHORECTOMY; QUALITY-OF-LIFE; FAMILIAL ADENOMATOUS POLYPOSIS; RANDOMIZED CONTROLLED-TRIAL; TERM PSYCHOLOGICAL IMPACT; RISK-REDUCING MASTECTOMY; HEREDITARY COLON-CANCER; BRCA2 MUTATION CARRIERS; OVARIAN-CANCER AB As genetic testing for hereditary cancer syndromes has transitioned from research to clinical settings, research regarding its accompanying psychosocial effects has grown. Men and women being tested for hereditary cancer syndromes may experience some psychological distress while going through the process of testing or after carrier status is identified. Psychological distress appears to decrease over the course of the first year and it is typically not clinically significant. Longer term studies show mixed results with some mutation carriers continuing to experience elevated distress. Baseline distress is the greatest risk factor for both immediate (weeks-12 months) and long-term psychological distress (18 mo-8 years post genetic testing). In addition to baseline psychological distress, other risk factors can be identified to help identify individuals who may need psychosocial interventions during the genetic testing process. The challenges of providing clinical care to the growing population of individuals identified to be at increased risk for heritable cancers present opportunities for research and new models of care. (C) 2014 American Cancer Society. C1 [Hirschberg, April Malia; Pirl, William F.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Chan-Smutko, Gayun] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. RP Hirschberg, AM (reprint author), Massachusetts Gen Hosp, MGH Canc Ctr, Dept Psychiat, Yawkey 10B, Boston, MA 02114 USA. EM ahirschberg@partners.org NR 135 TC 5 Z9 5 U1 3 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD FEB 1 PY 2015 VL 121 IS 3 BP 341 EP 360 DI 10.1002/cncr.28879 PG 20 WC Oncology SC Oncology GA CB1NP UT WOS:000349394900008 PM 25234846 ER PT J AU Castillo, JJ Bower, M Bruhlmann, J Novak, U Furrer, H Tanaka, PY Besson, C Montoto, S Cwynarski, K Abramson, JS Dalia, S Bibas, M Connors, JM Furman, M Nguyen, ML Cooley, TP Beltran, BE Collins, JA Vose, JM Xicoy, B Ribera, JM AF Castillo, Jorge J. Bower, Mark Bruehlmann, Jeremy Novak, Urban Furrer, Hansjakob Tanaka, Paula Y. Besson, Caroline Montoto, Silvia Cwynarski, Kate Abramson, Jeremy S. Dalia, Samir Bibas, Michele Connors, Joseph M. Furman, Michael Minh-Ly Nguyen Cooley, Timothy P. Beltran, Brady E. Collins, Jaime A. Vose, Julie M. Xicoy, Blanca Ribera, Josep-Maria CA HIV-Associated Hodgkin Lymphoma cA TI Prognostic Factors for Advanced-Stage Human Immunodeficiency Virus-Associated Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Combined Antiretroviral Therapy A Multi-Institutional Retrospective Study SO CANCER LA English DT Article DE human immunodeficiency virus; Hodgkin lymphoma; doxorubicin; bleomycin; vinblastine; and dacarbazine; antiretroviral therapy; CD4 count ID MULTIPLE IMPUTATION; HIV-INFECTION; MISSING DATA; STANFORD-V; DISEASE; HAART; SURVIVAL; REGIMEN; MODELS; SCORE AB BACKGROUND: The treatment and outcomes of patients with human immunodeficiency virus (HIV)-associated Hodgkin lymphoma (HL) continue to evolve. The International Prognostic Score (IPS) is used to predict the survival of patients with advanced-stage HL, but it has not been validated in patients with HIV infection. METHODS: This was a multi-institutional, retrospective study of 229 patients with HIV-associated, advanced-stage, classical HL who received doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) plus combination antiretroviral therapy. Their clinical characteristics were presented descriptively, and multivariate analyses were performed to identify the factors that were predictive of response and prognostic of progression-free survival (PFS) and overall survival (OS). RESULTS: The overall and complete response rates to ABVD in patients with HIV-associated HL were 91% and 83%, respectively. After a median follow-up of 5 years, the 5-year PFS and OS rates were 69% and 78%, respectively. In multivariate analyses, there was a trend toward an IPS score >3 as an adverse factor for PFS (hazard ratio [HR], 1.49; P=.15) and OS (HR, 1.84; P=.06). A cluster of differentiation 4 (CD4)-positive (T-helper) cell count <200 cells/lL was associated independently with both PFS (HR, 2.60; P=.002) and OS (HR, 2.04; P=.04). The CD4-positive cell count was associated with an increased incidence of death from other causes (HR, 2.64; P=.04) but not with death from HL-related causes (HR, 1.55; P=.32). CONCLUSIONS: The current results indicate excellent response and survival rates in patients with HIV-associated, advanced-stage, classical HL who receive ABVD and combination antiretroviral therapy as well as the prognostic value of the CD4-positive cell count at the time of lymphoma diagnosis for PFS and OS. (C) 2014 American Cancer Society. C1 [Castillo, Jorge J.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02215 USA. [Bower, Mark] Chelsea & Westminster Hosp, Dept Med Oncol, London, England. [Bruehlmann, Jeremy; Novak, Urban; Furrer, Hansjakob] Univ Hosp Bern, Dept Med Oncol & Infect Dis, CH-3010 Bern, Switzerland. [Bruehlmann, Jeremy; Novak, Urban; Furrer, Hansjakob] Univ Bern, Bern, Switzerland. [Tanaka, Paula Y.] Emilio Ribas Inst Infectol, Sect Hematol, Sao Paulo, Brazil. [Besson, Caroline] Univ Paris Sud, Bicetre Hosp, INSERM, Clin Hematol Unit,U1012, F-94275 Le Kremlin Bicetre, France. [Montoto, Silvia] Barts Canc Inst, Ctr Hematooncol, London, England. [Cwynarski, Kate] Royal Free Hosp, Dept Hematol, London NW3 2QG, England. [Abramson, Jeremy S.] Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA. [Dalia, Samir] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Div Malignant Hematol, Tampa, FL 33612 USA. [Bibas, Michele] Lazzaro Spallanzani Natl Inst Infect Dis, Dept Clin Res, Rome, Italy. [Connors, Joseph M.] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 4E6, Canada. [Furman, Michael] Miriam Hosp, Dept Med, Rhode Isl Hosp, Providence, RI 02906 USA. [Minh-Ly Nguyen] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. [Cooley, Timothy P.] Boston Med Ctr, Div Hematol & Oncol, Boston, MA USA. [Beltran, Brady E.; Collins, Jaime A.] Edgardo Rebagliati Martins Natl Hosp, Dept Radiotherapy & Oncol, Lima, Peru. [Vose, Julie M.] Guillermo Almenara Irigoyen Natl Hosp, Dept Infect Dis, Lima, Peru. [Xicoy, Blanca] Univ Nebraska Med Ctr, Div Hematol & Oncol, Omaha, NE USA. [Ribera, Josep-Maria] Germans Trias & Pujol Hosp, Dept Clin Hematol, Catalan Inst Oncol, Jose Carreras Res Inst, Badalona, Spain. RP Castillo, JJ (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,M221, Boston, MA 02215 USA. EM jorgej_castillo@dfci.harvard.edu RI SHCS, all/G-4072-2011; SHCS, int. coll. A/G-4083-2011; Furrer, Hansjakob/G-6768-2013; OI Furrer, Hansjakob/0000-0002-1375-3146; Besson, Caroline/0000-0003-4364-7173; Beltran, Brady/0000-0003-4469-3817; Bower, Mark/0000-0002-4077-6351; Castillo, Jorge/0000-0001-9490-7532 FU Swiss National Science Foundation [148522]; Swiss National Science Foundation (SHCS) [713] FX This study has been cofinanced within the framework of the Swiss HIV Cohort Study, which is supported by the Swiss National Science Foundation (grant 148522 and SHCS project 713). NR 25 TC 9 Z9 9 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD FEB 1 PY 2015 VL 121 IS 3 BP 423 EP 431 DI 10.1002/cncr.29066 PG 9 WC Oncology SC Oncology GA CB1NP UT WOS:000349394900016 PM 25251326 ER PT J AU Villaruz, LC Socinski, MA Abberbock, S Berry, LD Johnson, BE Kwiatkowski, DJ Iafrate, AJ Varella-Garcia, M Franklin, WA Camidge, DR Sequist, LV Haura, EB Ladanyi, M Kurland, BF Kugler, K Minna, JD Bunn, PA Kris, MG AF Villaruz, Liza C. Socinski, Mark A. Abberbock, Shira Berry, Lynne D. Johnson, Bruce E. Kwiatkowski, David J. Iafrate, A. John Varella-Garcia, Marileila Franklin, Wilbur A. Camidge, D. Ross Sequist, Lecia V. Haura, Eric B. Ladanyi, Mark Kurland, Brenda F. Kugler, Kelly Minna, John D. Bunn, Paul A. Kris, Mark G. TI Clinicopathologic Features and Outcomes of Patients With Lung Adenocarcinomas Harboring BRAF Mutations in the Lung Cancer Mutation Consortium SO CANCER LA English DT Article DE BRAF; clinicopathologic features; genomic profiling; lung adenocarcinomas; Lung Cancer Mutation Consortium ID ACTIVATING MUTATIONS; KRAS MUTATIONS; NEVER SMOKERS; VEMURAFENIB; GEFITINIB; THERAPY; GENE; FREQUENCY; SPECTRUM; MODELS AB BACKGROUND: The advent of effective targeted therapy for BRAF(V600E)-mutant lung adenocarcinomas necessitates further exploration of the unique clinical features and behavior of advanced-stage BRAF-mutant lung adenocarcinomas. METHODS: Data were reviewed for patients with advanced lung adenocarcinomas enrolled in the Lung Cancer Mutation Consortium whose tumors underwent testing for mutations in epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), human epidermal growth factor receptor 2 (HER2), AKT1, BRAF, dual-specificity mitogen-activated protein kinase kinase 1 (MEK1), neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a (PIK3CA); for anaplastic lymphoma kinase (ALK) translocations; and for MET amplification. RESULTS: Twenty-one BRAF mutations were identified in 951 patients with adenocarcinomas (2.2%; 95% confidence interval [CI], 1.4%-3.4%): 17 (81%; 95% CI, 60%-92%) were BRAF(V600E) mutations, and 4 were non-BRAF(V600E) mutations. Among the 733 cases tested for all 10 genes, BRAF mutations were more likely to occur than most other genotypic abnormalities in current or former smokers (BRAF vs sensitizing EGFR, 82% vs 36%, mid-P<.001; BRAF vs ALK, 39%, mid-P=.003; BRAF vs other mutations, 49%, mid-P=.02; BRAF vs patients with more than 1 oncogenic driver [doubleton], 46%, mid-P=.04.) The double-mutation rate was 16% among patients with BRAF mutations but 5% among patients with other genomic abnormalities (mid-P=.045). Differences were not found in survival between patients with BRAF mutations and those with other genomic abnormalities (P>.20). CONCLUSIONS: BRAF mutations occurred in 2.2% of advanced-stage lung adenocarcinomas, were most commonly V600E, and were associated with distinct clinicopathologic features in comparison with other genomic subtypes and with a high mutation rate in more than 1 gene. These findings underscore the importance of comprehensive genomic profiling in assessing patients with advanced lung adenocarcinomas. (C) 2014 American Cancer Society. C1 [Villaruz, Liza C.; Socinski, Mark A.; Abberbock, Shira; Kurland, Brenda F.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15232 USA. [Berry, Lynne D.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Johnson, Bruce E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kwiatkowski, David J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Iafrate, A. John; Sequist, Lecia V.] Massachusettes Gen Hosp, Boston, MA USA. [Varella-Garcia, Marileila; Franklin, Wilbur A.; Camidge, D. Ross; Kugler, Kelly; Bunn, Paul A.] Univ Colorado, Canc Ctr Denver, Aurora, CO USA. [Haura, Eric B.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Ladanyi, Mark; Kris, Mark G.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Minna, John D.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. RP Villaruz, LC (reprint author), Univ Pittsburgh, Inst Canc, 5150 Ctr Ave,Room 567, Pittsburgh, PA 15232 USA. EM villaruzl@upmc.edu OI Kris, Mark/0000-0002-7317-5341; Kurland, Brenda/0000-0002-5669-0595 FU National Institutes of Health through the National Cancer Institute [HSS NIH NCI 1RC2CA148394-010]; [P30CA047904] FX This study was supported by a grant from the National Institutes of Health through the National Cancer Institute (HSS NIH NCI 1RC2CA148394-010). This project used the University of Pittsburgh Cancer Institute Biostatistics Facility, which is supported in part by award P30CA047904. NR 30 TC 20 Z9 20 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD FEB 1 PY 2015 VL 121 IS 3 BP 448 EP 456 DI 10.1002/cncr.29042 PG 9 WC Oncology SC Oncology GA CB1NP UT WOS:000349394900019 PM 25273224 ER PT J AU DuBois, SG Krailo, MD Gebhardt, MC Donaldson, SS Marcus, KJ Dormans, J Shamberger, RC Sailer, S Nicholas, RW Healey, JH Tarbell, NJ Randall, RL Devidas, M Meyer, JS Granowetter, L Womer, RB Bernstein, M Marina, N Grier, HE AF DuBois, Steven G. Krailo, Mark D. Gebhardt, Mark C. Donaldson, Sarah S. Marcus, Karen J. Dormans, John Shamberger, Robert C. Sailer, Scott Nicholas, Richard W. Healey, John H. Tarbell, Nancy J. Randall, R. Lor Devidas, Meenakshi Meyer, James S. Granowetter, Linda Womer, Richard B. Bernstein, Mark Marina, Neyssa Grier, Holcombe E. TI Comparative Evaluation of Local Control Strategies in Localized Ewing Sarcoma of Bone A Report From the Children's Oncology Group SO CANCER LA English DT Article DE Ewing sarcoma; local control; surgery; radiation; propensity score ID STANDARD CHEMOTHERAPY; PROGNOSTIC-FACTORS; RADIATION-THERAPY; TUMORS; ADJUVANT; CESS-86; EXPERIENCE; RIZZOLI; VOLUME; FAMILY AB BACKGROUND: Patients with Ewing sarcoma require local primary tumor control with surgery, radiation, or both. The optimal choice of local control for overall and local disease control remains unclear. METHODS: Patients with localized Ewing sarcoma of bone who were treated on 3 consecutive protocols with standard-dose, 5-drug chemotherapy every 3 weeks were included (n=465). Propensity scores were used to control for differences between local control groups by constructing multivariate models to assess the impact of local control type on clinical endpoints (event-free survival [EFS], overall survival, local failure, and distant failure) independent of differences in their propensity to receive each local control type. RESULTS: Patients who underwent surgery were younger (P=.02) and had more appendicular tumors (P<.001). Compared with surgery, radiation had higher unadjusted risks of any event (hazard ratio [HR], 1.70; 95% confidence interval [CI], 1.18-2.44), death (HR, 1.84; 95% CI, 1.18-2.85), and local failure (HR, 2.57; 95% CI, 1.37-4.83). On multivariate analysis, compared with surgery, radiation had a higher risk of local failure (HR, 2.41; 95% CI, 1.24-4.68), although there were no significant differences in EFS (HR, 1.42; 95% CI, 0.94-2.14), overall survival (HR, 1.37; 95% CI, 0.83-2.26), or distant failure (HR, 1.13; 95% CI, 0.70-1.84) between local control groups. CONCLUSIONS: In this large group of similarly treated patients, choice of the mode of local control was not related significantly to EFS, overall survival, or distant failure, although the risk of local failure was greater for radiation compared with surgery. These data support surgical resection when appropriate, whereas radiotherapy remains a reasonable alternative in selected patients. (C) 2014 American Cancer Society. C1 [DuBois, Steven G.] Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA. [DuBois, Steven G.] UCSF Benioff Childrens Hosp, San Francisco, CA USA. [Krailo, Mark D.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Gebhardt, Mark C.] Childrens Hosp, Dana Farber Canc Inst, Dept Orthoped Surg, Boston, MA 02115 USA. [Gebhardt, Mark C.; Marcus, Karen J.; Shamberger, Robert C.; Randall, R. Lor; Grier, Holcombe E.] Harvard Univ, Sch Med, Boston, MA USA. [Donaldson, Sarah S.] Stanford Univ, Sch Med, Dept Radiat Oncol, Palo Alto, CA 94304 USA. [Donaldson, Sarah S.; Marina, Neyssa] Lucille Packard Childrens Hosp, Palo Alto, CA USA. [Marcus, Karen J.] Childrens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Dormans, John] Univ Penn, Perelman Sch Med, Dept Orthoped Surg, Philadelphia, PA 19104 USA. [Dormans, John; Meyer, James S.; Womer, Richard B.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Shamberger, Robert C.] Childrens Hosp, Dana Farber Canc Inst, Dept Surg, Boston, MA 02115 USA. [Sailer, Scott] Wake Radiat Oncol, Cary, NC USA. [Nicholas, Richard W.] Univ Arkansas Med Sci, Dept Orthoped Surg, Little Rock, AR 72205 USA. [Healey, John H.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA. [Tarbell, Nancy J.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Randall, R. Lor] Univ Utah, Sch Med, Dept Orthoped, Salt Lake City, UT USA. [Devidas, Meenakshi] Childrens Oncol Grp, Ctr Data, Gainesville, FL USA. [Meyer, James S.] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Granowetter, Linda] NYU, Dept Pediat, Sch Med, New York, NY 10016 USA. [Granowetter, Linda] NYU, Langone Med Ctr, New York, NY USA. [Womer, Richard B.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Bernstein, Mark] IWK Hlth Ctr, Div Pediat Hematol Oncol, Halifax, NS, Canada. [Marina, Neyssa] Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA. [Grier, Holcombe E.] Childrens Hosp, Dept Pediat, Dana Farber Canc Inst, Boston, MA 02115 USA. RP DuBois, SG (reprint author), UCSF Sch Med, Dept Pediat, 505 Parnassus Ave,M646, San Francisco, CA 94143 USA. EM duboiss@peds.ucsf.edu OI Granowetter MD, Linda/0000-0002-2399-9107 FU Frank A. Campini Foundation; Nick Currey Fund; American Society of Clinical Oncology Young Investigator Grant; WWWW Foundation; Daniel P. Sullivan Fund; National Institutes of Health/National Cancer Institute [1K23CA154530, U10 CA98543] FX This work was supported by the Frank A. Campini Foundation, the Nick Currey Fund, an American Society of Clinical Oncology Young Investigator Grant, the WWWW Foundation, the Daniel P. Sullivan Fund, and National Institutes of Health/National Cancer Institute grants 1K23CA154530 and U10 CA98543. NR 19 TC 16 Z9 16 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD FEB 1 PY 2015 VL 121 IS 3 BP 467 EP 475 DI 10.1002/cncr.29065 PG 9 WC Oncology SC Oncology GA CB1NP UT WOS:000349394900021 PM 25251206 ER PT J AU Sawyer, SL Tian, L Kahkonen, M Schwartzentruber, J Kircher, M Majewski, J Dyment, DA Innes, AM Boycott, KM Moreau, LA Moilanen, JS Greenberg, RA AF Sawyer, Sarah L. Tian, Lei Kaehkoenen, Marketta Schwartzentruber, Jeremy Kircher, Martin Majewski, Jacek Dyment, David A. Innes, A. Micheil Boycott, Kym M. Moreau, Lisa A. Moilanen, Jukka S. Greenberg, Roger A. TI Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype SO CANCER DISCOVERY LA English DT Article ID CROSS-LINK REPAIR; OVARIAN-CANCER; DNA-REPAIR; RAD51C; BREAST; SUSCEPTIBILITY; MECHANISM; DEFECT; CELLS; PALB2 AB Deficiency in BRCA-dependent DNA interstrand crosslink (ICL) repair is intimately connected to breast cancer susceptibility and to the rare developmental syndrome Fanconi anemia. Bona fide Fanconi anemia proteins, BRCA2 (FANCD1), PALB2 (FANCN), and BRIP1 (FANCJ), interact with BRCA1 during ICL repair. However, the lack of detailed phenotypic and cellular characterization of a patient with biallelic BRCA1 mutations has precluded assignment of BRCA1 as a definitive Fanconi anemia susceptibility gene. Here, we report the presence of biallelic BRCA1 mutations in a woman with multiple congenital anomalies consistent with a Fanconi anemia-like disorder and breast cancer at age 23. Patient cells exhibited deficiency in BRCA1 and RAD51 localization to DNA-damage sites, combined with radial chromosome formation and hypersensitivity to ICL-inducing agents. Restoration of these functions was achieved by ectopic introduction of a BRCA1 transgene. These observations provide evidence in support of BRCA1 as a new Fanconi anemia gene (FANCS). SIGNIFICANCE: We establish that biallelic BRCA1 mutations cause a distinct FA-S, which has implications for risk counselling in families where both parents harbor BRCA1 mutations. The genetic basis of hereditary cancer susceptibility syndromes provides diagnostic information, insights into treatment strategies, and more accurate recurrence risk counseling to families. (C) 2014 AACR. C1 [Sawyer, Sarah L.] Univ Ottawa, Childrens Hosp Eastern Ontario Res Inst, Ottawa, ON, Canada. [Tian, Lei; Moilanen, Jukka S.; Greenberg, Roger A.] Univ Penn, Perelman Sch Med, Abramson Family Canc Res Inst, Basser Res Ctr BRCA,Dept Canc Biol, Philadelphia, PA 19104 USA. [Tian, Lei; Greenberg, Roger A.] Univ Penn, Perelman Sch Med, Abramson Family Canc Res Inst, Basser Res Ctr,Dept Pathol, Philadelphia, PA 19104 USA. [Kaehkoenen, Marketta] Pirkanmaa Hosp Dist, Fimlab Labs, Lab Clin Genet, Tampere, Finland. [Schwartzentruber, Jeremy] Wellcome Trust Sanger Inst, Hinxton, Cambs, England. [Kircher, Martin] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Majewski, Jacek] McGill Univ, Dept Human Genet, Montreal, PQ, Canada. [Majewski, Jacek] McGill Univ, Montreal, PQ, Canada. [Majewski, Jacek] Genome Quebec Innovat Ctr, Montreal, PQ, Canada. [Innes, A. Micheil] Univ Calgary, Dept Med Genet, Calgary, AB, Canada. [Innes, A. Micheil] Univ Calgary, Alberta Childrens Hosp Res Inst Child & Maternal, Calgary, AB, Canada. [Moreau, Lisa A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Moreau, Lisa A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat, Boston, MA 02115 USA. [Moilanen, Jukka S.] Oulu Univ Hosp, Dept Clin Genet, Oulu, Finland. [Moilanen, Jukka S.] Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland. [Moilanen, Jukka S.] Univ Oulu, Oulu, Finland. RP Greenberg, RA (reprint author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Canc Biol, 421 Curie Blvd,BRB 2-3 Room 513, Philadelphia, PA 19104 USA. EM rogergr@mail.med.upenn.edu RI Scherer, Stephen /B-3785-2013; Moilanen, Jukka/G-2604-2012; innes, allan micheil/A-9955-2017; OI Scherer, Stephen /0000-0002-8326-1999; Moilanen, Jukka/0000-0002-8041-3205; Schwartzentruber, Jeremy/0000-0002-6183-2092; Kircher, Martin/0000-0001-9278-5471 FU NIH [GM101149, CA138835, CA17494]; DOD Breast Cancer Idea Award; Harrington Discovery Institute Scholar-Innovator Award; Abramson Family Cancer Research Institute; Basser Research Center for BRCA; CIHR Institute of Genetics Clinical Investigatorship Award; Genome Canada; Canadian Institutes of Health Research (CIHR); Ontario Genomics Institute [OGI-049]; Genome Quebec; Genome British Columbia FX This work was supported by NIH grants GM101149, CA138835, and CA17494 to R.A. Greenberg, who is also supported by a DOD Breast Cancer Idea Award, a Harrington Discovery Institute Scholar-Innovator Award, and funds from the Abramson Family Cancer Research Institute and Basser Research Center for BRCA. D.A. Dyment and K.M. Boycott are supported by the CIHR Institute of Genetics Clinical Investigatorship Award. This patient was selected for study by the FORGE Canada Steering Committee, consisting of K. Boycott (University of Ottawa), J. Friedman (University of British Columbia), J. Michaud (University of Montreal), F. Bernier (University of Calgary), M. Brudno (University of Toronto), B. Fernandez (Memorial University), B. Knoppers (McGill University), M. Samuels (Universite de Montreal) and S. Scherer (University of Toronto). This work was also funded in part by Genome Canada, the Canadian Institutes of Health Research (CIHR), the Ontario Genomics Institute (OGI-049), Genome Quebec, and Genome British Columbia. NR 26 TC 67 Z9 67 U1 2 U2 18 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2159-8274 EI 2159-8290 J9 CANCER DISCOV JI Cancer Discov. PD FEB PY 2015 VL 5 IS 2 BP 135 EP 142 DI 10.1158/2159-8290.CD-14-1156 PG 8 WC Oncology SC Oncology GA CB1NC UT WOS:000349393600022 PM 25472942 ER PT J AU Glanz, K Volpicelli, K Jepson, C Ming, ME Schuchter, LM Armstrong, K AF Glanz, Karen Volpicelli, Kathryn Jepson, Christopher Ming, Michael E. Schuchter, Lynn M. Armstrong, Katrina TI Effects of Tailored Risk Communications for Skin Cancer Prevention and Detection: The PennSCAPE Randomized Trial SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID MELANOMA PATIENTS; SUN PROTECTION; PROJECT SCAPE; SUNSCREEN USE; INTERVENTIONS; EXPOSURE; CHILDREN; POPULATION; BEHAVIORS; EDUCATION AB Background: Prevention and early detection measures for melanoma, such as sun avoidance and skin examinations, are important, but are practiced inconsistently. In this replication of the Project SCAPE trial, we sought to determine whether tailored print materials were more effective at improving adherence than generic print materials for patients at increased risk of skin cancer. Methods: Participants were randomized to receive personalized mailed communications about their skin cancer risk and recommended sun protection, or generic mailings. Participants were Caucasian adults, at moderate or high risk for skin cancer, recruited in outpatient primary care. The main outcomes were overall sun protection behaviors and specific protective behaviors including use of sunscreen, shirt, hat, sunglasses, shade, and sun avoidance; recent sunburns; and skin self-examination and provider skin examination. Results: One hundred ninety-two (93.2%) subjects completed the study. Six outcome variables showed significant intervention condition effects in mixed effects models: overall sun protection behavior (P = 0.025); sunscreen use (P = 0.026); use of sunglasses (P = 0.011); sunburns in the past three months (P = 0.033); recency of last skin self-exam (P = 0.017); and frequency of skin exams by health care provider (P = 0.016). Conclusions: Relative to generic communications, tailored risk communications resulted in improved adherence to six skin cancer protective behaviors, including a composite sun protection behavior measure, sunburns, and health care provider skin examinations. Impact: Tailored interventions can be more effective in improving patient prevention behaviors than nontailored, generic information for patients at moderate to high risk of skin cancer. (C)2014 AACR. C1 [Glanz, Karen; Volpicelli, Kathryn; Jepson, Christopher; Ming, Michael E.; Schuchter, Lynn M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Glanz, Karen] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Armstrong, Katrina] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Glanz, K (reprint author), Univ Penn, 801 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM kglanz@upenn.edu FU NIH [5UC2 CA148310] FX This work was supported by NIH grant #5UC2 CA148310 (to K. Armstrong, principal investigator; K. Glanz, sub-principal investigator). NR 31 TC 3 Z9 3 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD FEB PY 2015 VL 24 IS 2 BP 415 EP 421 DI 10.1158/1055-9965.EPI-14-0926 PG 7 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CB1XY UT WOS:000349422500013 PM 25432953 ER PT J AU Partin, MR Burgess, DJ Burgess, JF Gravely, A Haggstrom, D Lillie, SE Nugent, S Powell, AA Shaukat, A Walter, LC Nelson, DB AF Partin, Melissa R. Burgess, Diana J. Burgess, James F., Jr. Gravely, Amy Haggstrom, David Lillie, Sarah E. Nugent, Sean Powell, Adam A. Shaukat, Aasma Walter, Louise C. Nelson, David B. TI Organizational Predictors of Colonoscopy Follow-up for Positive Fecal Occult Blood Test Results: An Observational Study SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID AMERICAN-CANCER-SOCIETY; ON-COLORECTAL-CANCER; HEALTH-CARE-SYSTEMS; SCREENING COLONOSCOPY; WAIT TIMES; PATIENT; GASTROENTEROLOGY; PROGRAM; INTERVENTION; SURVEILLANCE AB Background: This study assessed the contribution of organizational structures and processes identified from facility surveys to follow-up for positive fecal occult blood tests [FOBT-positive (FOBT+)]. Methods: We identified 74,104 patients with FOBT+ results from 98 Veterans Health Administration (VHA) facilities between August 16, 2009 and March 20, 2011, and followed them until September 30, 2011, for completion of colonoscopy. We identified patient characteristics from VHA administrative records, and organizational factors from facility surveys completed by primary care and gastroenterology chiefs. We estimated predictors of colonoscopy completion within 60 days and six months using hierarchical logistic regression models. Results: Thirty percent of patients with FOBT+ results received colonoscopy within 60 days and 49% within six months. Having gastroenterology or laboratory staff notify gastroenterology providers directly about FOBT+ cases was a significant predictor of 60-day [odds ratio (OR), 1.85; P = 0.01] and six-month follow-up (OR, 1.25; P = 0.008). Additional predictors of 60-day follow-up included adequacy of colonoscopy appointment availability (OR, 1.43; P = 0.01) and frequent individual feedback to primary care providers about FOBT+ referral timeliness (OR, 1.79; P = 0.04). Additional predictors of six-month follow-up included using guideline-concordant surveillance intervals for low-risk adenomas (OR, 1.57; P = 0.01) and using group appointments and combined verbal-written methods for colonoscopy preparation instruction (OR, 1.48; P = 0.0001). Conclusion: Directly notifying gastroenterology providers about FOBT+ results, using guideline-concordant adenoma surveillance intervals, and using colonoscopy preparations instruction methods that provide both verbal and written information may increase overall follow-up rates. Enhancing follow-up within 60 days may require increased colonoscopy capacity and feedback to primary care providers. Impact: These findings may inform organizational-level interventions to improve FOBT+ follow-up. (C)2014 AACR. C1 [Partin, Melissa R.; Burgess, Diana J.; Gravely, Amy; Lillie, Sarah E.; Nugent, Sean; Powell, Adam A.; Shaukat, Aasma; Nelson, David B.] Minneapolis Vet Affairs Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Partin, Melissa R.; Burgess, Diana J.; Lillie, Sarah E.; Shaukat, Aasma; Nelson, David B.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Burgess, James F., Jr.] Boston Vet Affairs Hlth Care Syst, Ctr Healthcare Org & Implementat Res, Boston, MA USA. [Burgess, James F., Jr.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Haggstrom, David] Roudebush VAMC, VA Hlth Serv Res & Dev Ctr Hlth Informat & Commun, Indianapolis, IN USA. [Haggstrom, David] Indiana Univ Sch Med, Dept Med, Div Gen Internal Med & Geriatr, Indianapolis, IN 46202 USA. [Walter, Louise C.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Walter, Louise C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Partin, MR (reprint author), Minneapolis Vet Affairs Med Ctr, 1 Vet Dr, Minneapolis, MN 55417 USA. EM Melissa.partin@va.gov RI Burgess, Diana/A-1946-2016; OI Lillie, Sarah/0000-0001-9854-7191 FU Department of Veterans Affairs Health Services Research and Development (VA HSRD) [IIR 08-334-2]; VA HSR&D Research Career Scientist award [RCS 10-185]; VA HSR&D Career Development Award (CDA) [CDA 07-016]; VA HSRD CDA [CDA 08-024]; VA Clinical Science Research and Development Career Development Award [CDA-2]; National Institute on Aging at the NIH [K24AG041180] FX This research was funded by the Department of Veterans Affairs Health Services Research and Development (VA HSR&D) grant IIR 08-334-2 (to M.R. Partin), VA HSR&D Research Career Scientist award RCS 10-185 (to M.R. Partin), VA HSR&D Career Development Award (CDA) #CDA 07-016 (to D. Haggstrom), VA HSR&D CDA #CDA 08-024 (to A.A. Powell), VA Clinical Science Research and Development Career Development Award CDA-2 (to A. Shaukat), and National Institute on Aging at the NIH grant K24AG041180 (to L.C. Walter). NR 47 TC 8 Z9 8 U1 1 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD FEB PY 2015 VL 24 IS 2 BP 422 EP 434 DI 10.1158/1055-9965.EPI-14-1170 PG 13 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CB1XY UT WOS:000349422500014 PM 25471345 ER PT J AU Guell, X Hoche, F Schmahmann, JD AF Guell, Xavier Hoche, Franziska Schmahmann, Jeremy D. TI Metalinguistic Deficits in Patients with Cerebellar Dysfunction: Empirical Support for the Dysmetria of Thought Theory SO CEREBELLUM LA English DT Article; Proceedings Paper CT SIXTH INTERNATIONAL SYMPOSIUM OF SRC CY JUL 03-04, 2014 CL Rome, ITALY DE Cerebellum; Language; Metalinguistic; Dysmetria of thought; Cerebellar cognitive affective syndrome; Universal cerebellar transform ID LANGUAGE; HYPOTHESIS; LESIONS; TASK AB The cerebellar cognitive affective syndrome (CCAS) includes disruption of linguistic processing such as verbal fluency, verbal working memory, grammar, and speech perception. We set out to examine linguistic capabilities in patients with cerebellar lesions to determine which domains are spared and which impaired and to evaluate the underlying cognitive structure of these deficits. Forty-four patients with cerebellar disease were compared to 40 healthy controls on the Oral Sentence Production Test (OSPT) which assesses production of sentences with correct syntactic structure and semantic quality. Twenty-five of these cerebellar patients and 25 controls received the Test of Language Competence-Expanded (TLC-E) that assesses metalinguistic ability. The OSPT failed to reveal differences between patients and controls. In contrast, all cerebellar patients were impaired on each of the four TLC-E subtests. Differences between isolated cerebellar and complex cerebrocerebellar patients were nonsignificant. These results confirm and extend prior observations of the TLC-E in patients with cerebellar lesions and suggest three separate but related language impairments following cerebellar dysfunction: (1) disruption in automatic adjustment of intact grammatical and semantic abilities to a linguistic context in sentence production, (2) disruption in automatic adjustment to a linguistic context in sentence interpretation, and (3) disruption of cognitive processes essential for linguistic skills, such as analysis and sequential logical reasoning. These findings are consistent with the unifying framework of the universal cerebellar transform and the dysmetria of thought theory and provide new insights into the nature of the cognitive impairments in patients with the CCAS. C1 [Guell, Xavier; Hoche, Franziska; Schmahmann, Jeremy D.] Harvard Univ, Lab Neuroanat & Cerebellar Neurobiol, Massachusetts Gen Hosp,Med Sch, Ataxia Unit,Cognit Behav Neurol Unit,Dept Neurol, Boston, MA 02114 USA. RP Schmahmann, JD (reprint author), Harvard Univ, Lab Neuroanat & Cerebellar Neurobiol, Massachusetts Gen Hosp,Med Sch, Ataxia Unit,Cognit Behav Neurol Unit,Dept Neurol, Suite 340,Charles River Plaza South,175 Cambridge, Boston, MA 02114 USA. EM jschmahmann@partners.org FU National Ataxia Foundation; Birmingham Foundation; MINDlink Foundation; [RO1-MH067980] FX The authors gratefully acknowledge Casey Evans, BA for her blinded scoring of subject performance, and Mark Vangel, PhD, for statistical assistance. The assistance of Jason MacMore, BA and Marygrace Neal, MEd is also gratefully acknowledged. This work was supported in part by RO1-MH067980,the National Ataxia Foundation, and the Birmingham and MINDlink Foundations. NR 16 TC 2 Z9 3 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1473-4222 EI 1473-4230 J9 CEREBELLUM JI Cerebellum PD FEB PY 2015 VL 14 IS 1 BP 50 EP 58 DI 10.1007/s12311-014-0630-z PG 9 WC Neurosciences SC Neurosciences & Neurology GA CB1SN UT WOS:000349408400014 PM 25503825 ER PT J AU Honda, JR Bernhard, JN Chan, ED AF Honda, Jennifer R. Bernhard, Jon N. Chan, Edward D. TI Natural Disasters and Nontuberculous Mycobacteria A Recipe for Increased Disease? SO CHEST LA English DT Article ID SOFT-TISSUE INFECTIONS; UNITED-STATES; ACANTHAMOEBA-KERATITIS; GROWING MYCOBACTERIA; TSUNAMI SURVIVORS; PUBLIC-HEALTH; EPIDEMIOLOGY; TRENDS; LUNG AB Infectious diseases acquired by survivors of large-scale natural disasters complicate the recovery process. During events such as tsunamis, hurricanes, earthquakes, and tornados and well into the recovery period, victims often are exposed to water-soil mixtures that have relocated with indigenous microbes. Because nontuberculous mycobacteria (NTM) are ubiquitous in water and soil, there is potential for increased exposure to these organisms during natural disasters. In this hypothesis-driven commentary, we discuss the rise in NTM lung disease and natural disasters and examine the geographic overlap of NTM infections and disaster frequencies in the United States. Moreover, we show an increased number of positive NTM cultures from Louisiana residents in the years following three of the relatively recent epic hurricanes and posit that such natural disasters may help to drive the increased number of NTM infections. Finally, we advocate for increased environmental studies and surveillance of NTM infections before and after natural disasters. C1 [Honda, Jennifer R.; Chan, Edward D.] Univ Colorado, Div Pulm Sci & Crit Care Med, Aurora, CO 80045 USA. [Honda, Jennifer R.; Chan, Edward D.] Denver Vet Affairs Med Ctr, Natl Jewish Hlth, Denver, CO USA. RP Honda, JR (reprint author), Univ Colorado, Div Pulm Sci & Crit Care Med, Anschutz Med Campus,RC2,Box C272, Aurora, CO 80045 USA. EM Jennifer.Honda@ucdenver.edu FU National Institutes of Health National Research Service Award for Pulmonary and Critical Care Medicine Training [T32 HL 7085-83]; Potts Memorial Foundation FX Dr Honda is supported by a National Institutes of Health National Research Service Award for Pulmonary and Critical Care Medicine Training [T32 HL 7085-83] and by the Potts Memorial Foundation. NR 36 TC 1 Z9 1 U1 1 U2 6 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD FEB PY 2015 VL 147 IS 2 BP 304 EP 308 DI 10.1378/chest.14-0974 PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CB1YF UT WOS:000349423200009 PM 25644904 ER PT J AU Hasegawa, K Cydulka, RK Sullivan, AF Langdorf, MI Nonas, SA Nowak, RM Wang, NE Camargo, CA AF Hasegawa, Kohei Cydulka, Rita K. Sullivan, Ashley F. Langdorf, Mark I. Nonas, Stephanie A. Nowak, Richard M. Wang, Nancy E. Camargo, Carlos A., Jr. TI Improved Management of Acute Asthma Among Pregnant Women Presenting to the ED SO CHEST LA English DT Article ID EMERGENCY-DEPARTMENT; PERINATAL OUTCOMES; MATERNAL ASTHMA; EXACERBATIONS; CARE; ADULTS AB BACKGROUND: A multicenter study in the late 1990s demonstrated suboptimal emergency asthma care for pregnant women in US EDs. Aft er a decade, follow-up data are lacking. We aimed to examine changes in emergency asthma care of pregnant women since the 1990s. METHODS: We combined data from four multicenter observational studies of ED patients with acute asthma performed in 1996 to 2001 (three studies) and 2011 to 2012 (one study). We restricted the data so that comparisons were based on the same 48 EDs in both time periods. We identified all pregnant patients aged 18 to 44 years with acute asthma. Primary outcomes were treatment with systemic corticosteroids in the ED and, among those sent home, at ED discharge. RESULTS: Of 4,895 ED patients with acute asthma, the analytic cohort comprised 125 pregnant women. Between the two time periods, there were no significant changes in patient demographics, chronic asthma severity, or initial peak expiratory flow. In contrast, ED systemic corticosteroid treatment increased significantly from 51% to 78% across the time periods (OR, 3.11; 95% CI, 1.27-7.60; P 5.01); systemic corticosteroids at discharge increased from 42% to 63% (OR, 2.49; 95% CI, 0.97-6.37; P 5.054). In the adjusted analyses, pregnant women in recent years were more likely to receive systemic corticosteroids, both in the ED (OR, 4.76; 95% CI, 1.63-13.9; P 5.004) and at discharge (OR, 3.18; 95% CI, 1.05-9.61; P 5.04). CONCLUSIONS: Between the two time periods, emergency asthma care in pregnant women significantly improved. However, with one in three pregnant women being discharged home without systemic corticosteroids, further improvement is warranted. C1 [Hasegawa, Kohei; Sullivan, Ashley F.; Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. [Cydulka, Rita K.] Case Western Reserve Univ, Sch Med, MetroHealth Med Ctr, Dept Emergency Med, Cleveland, OH USA. [Langdorf, Mark I.] Univ Calif Irvine, Med Ctr, Dept Emergency Med, Orange, CA USA. [Nonas, Stephanie A.] Oregon Hlth & Sci Univ Hosp, Div Pulm & Crit Care Med, Portland, OR USA. [Nowak, Richard M.] Henry Ford Hosp, Dept Emergency Med, Detroit, MI 48202 USA. [Wang, Nancy E.] Stanford Univ, Med Ctr, Dept Emergency Med, Stanford, CA 94305 USA. RP Hasegawa, K (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 326 Cambridge St,Ste 410, Boston, MA 02114 USA. EM khasegawa1@partners.org FU Novartis FX This study was funded by a grant from Novartis to Massachusetts General Hospital. NR 34 TC 4 Z9 4 U1 1 U2 2 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD FEB PY 2015 VL 147 IS 2 BP 406 EP 414 DI 10.1378/chest.14-1874 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CB1YF UT WOS:000349423200021 PM 25358070 ER PT J AU Bakal, K Danckers, M Denson, JL Sauthoff, H AF Bakal, Keren Danckers, Mauricio Denson, Joshua L. Sauthoff, Harald TI Therapeutic Hypothermia After Cardiac Arrest in a Patient With Systemic Sclerosis and Raynaud Phenomenon SO CHEST LA English DT Editorial Material ID LEFT-VENTRICULAR DYSFUNCTION; DIGITAL ULCERS; SCLERODERMA; HEART AB Therapeutic hypothermia favorably impacts neurologic outcomes in patients after cardiopulmonary arrest, although the appropriate target temperature is less clear. Its safety profile in patients with systemic sclerosis (SSc) and Raynaud phenomenon (RP), who may be at increased risk for ischemic complications, has not been addressed in the literature, to our knowledge. Digital lesions are commonly seen in patients with SSc, and cold-induced myocardial ischemia has also been reported. We describe a case of a man with SSc, RP, and digital ulcers who underwent therapeutic hypothermia after cardiopulmonary arrest. He regained full neurologic function, and except for digital necrosis, no hypothermia-associated adverse events were observed. Other risk factors for ischemia, such as cocaine use, may have contributed to the development of the digital necrosis. However, clinicians should be aware of the risk for ischemic complications in patients with SSc and RP when considering the appropriate target temperature after cardiopulmonary arrest. C1 [Bakal, Keren; Danckers, Mauricio; Denson, Joshua L.; Sauthoff, Harald] NYU, Sch Med, Dept Med, New York, NY 10010 USA. [Sauthoff, Harald] US Dept Vet Affairs, VA NY Harbor Healthcare Syst, New York, NY USA. RP Sauthoff, H (reprint author), NYU, Sch Med, Dept Med, 423 E 23rd St, New York, NY 10010 USA. EM Harald.sauthoff@nyumc.org OI Sauthoff, Harald/0000-0001-9258-4135 NR 16 TC 0 Z9 0 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD FEB PY 2015 VL 147 IS 2 BP E27 EP E30 DI 10.1378/chest.14-1184 PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CB1YF UT WOS:000349423200040 PM 25644911 ER PT J AU Cooke, CR Wiener, RS Slatore, CG AF Cooke, Colin R. Wiener, Renda Soylemez Slatore, Christopher G. TI Critical Care Use in Patients With Lung Cancer Response SO CHEST LA English DT Letter ID INTENSIVE-CARE; END C1 [Cooke, Colin R.] Univ Michigan, Div Pulm & Crit Care Med, Ctr Healthcare Outcomes & Policy, Inst Healthcare Policy & Innovat,Michigan Ctr Int, Ann Arbor, MI 48109 USA. [Wiener, Renda Soylemez] Edith Nourse Rogers Mem VA Hosp, Ctr Healthcare Org & Implementat Res, Boston, MA USA. [Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA. [Slatore, Christopher G.] Portland VA Med Ctr, Hlth Serv Res & Dev, Portland, VA USA. [Slatore, Christopher G.] Portland VA Med Ctr, Sect Pulm & Crit Care Med, Portland, VA USA. [Slatore, Christopher G.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA. RP Cooke, CR (reprint author), Univ Michigan, Ctr Healthcare Outcomes & Policy, 2800 Plymouth Rd,Bldg 16,Rm 127W, Ann Arbor, MI 48109 USA. EM cookecr@umich.edu FU AHRQ HHS [K08 HS020672]; NCI NIH HHS [K07 CA138772] NR 4 TC 0 Z9 0 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD FEB PY 2015 VL 147 IS 2 BP E57 EP E57 DI 10.1378/chest.14-2507 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CB1YF UT WOS:000349423200048 PM 25644919 ER PT J AU Gomeni, R Goyal, N Bressolle, F Fava, M AF Gomeni, R. Goyal, N. Bressolle, F. Fava, M. TI NOVEL METHODOLOGY FOR ESTIMATING THE TREATMENT EFFECT IN PRESENCE OF HIGHLY VARIABLE PLACEBO RESPONSE. SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics (ASCPT) CY MAR 03-07, 2015 CL New Orleans, LA SP Amer Soc Clin Pharmacol & Therapeut C1 [Gomeni, R.; Bressolle, F.] Pharmacometrica, La Fouillade, France. [Goyal, N.] GlaxoSmithKline, King Of Prussia, PA USA. [Fava, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9236 EI 1532-6535 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD FEB PY 2015 VL 97 SU 1 MA PII-040 BP S71 EP S71 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CA2HW UT WOS:000348730500218 ER PT J AU Ho, M Wang, L Ingle, J Goss, P Mushiroda, T Kubo, M Nakamura, Y Shepherd, L Weinshilboum, R Bongartz, T AF Ho, M. Wang, L. Ingle, J. Goss, P. Mushiroda, T. Kubo, M. Nakamura, Y. Shepherd, L. Weinshilboum, R. Bongartz, T. TI AROMATASE INHIBITOR-INDUCED ARTHRALGIA ASSOCIATED WITH TCL1A SNP AND ESTROGEN-DEPENDENT VARIATION IN CYTOKINE EXPRESSION: POSSIBLE LINKS BETWEEN ESTROGEN AND ARTHRITIS. SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics (ASCPT) CY MAR 03-07, 2015 CL New Orleans, LA SP Amer Soc Clin Pharmacol & Therapeut C1 [Ho, M.; Wang, L.; Ingle, J.; Weinshilboum, R.; Bongartz, T.] Mayo Clin, Rochester, MN USA. [Goss, P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mushiroda, T.; Kubo, M.] Riken Ctr, Yokohama, Kanagawa, Japan. [Nakamura, Y.] Univ Chicago, Knapp Ctr Biomed Discovery, Chicago, IL 60637 USA. [Shepherd, L.] NCIC Clin Trials Grp, Kingston, ON, Canada. RI Mushiroda, Taisei/E-3022-2010; Kubo, Michiaki/N-7947-2015 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9236 EI 1532-6535 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD FEB PY 2015 VL 97 SU 1 MA PT-08 BP S13 EP S13 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CA2HW UT WOS:000348730500035 ER PT J AU Xu, J Zhang, R Saad, O Liu, JF Moore, KN Burris, HA Humke, E Poon, KA Girish, S AF Xu, J. Zhang, R. Saad, O. Liu, J. F. Moore, K. N. Burris, H. A., III Humke, E. Poon, K. Achilles Girish, S. TI PHARMACOKINETICS OF AN ANTIBODY-DRUG CONJUGATE ( ADC) DMUC5754A IN A PHASE I STUDY WITH PLATINUM-RESISTANT OVARIAN CANCER (PROC) OR UNRESECTABLE PANCREATIC CANCER (PANC) SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics (ASCPT) CY MAR 03-07, 2015 CL New Orleans, LA SP Amer Soc Clin Pharmacol & Therapeut C1 [Xu, J.; Zhang, R.; Saad, O.; Humke, E.; Poon, K. Achilles; Girish, S.] Genentech Inc, San Francisco, CA 94080 USA. [Liu, J. F.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Moore, K. N.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Burris, H. A., III] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9236 EI 1532-6535 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD FEB PY 2015 VL 97 SU 1 MA PI-048 BP S34 EP S35 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CA2HW UT WOS:000348730500101 ER PT J AU Yu, T Sinha, M Hillard, M Sherwin, C Russell, S Spigarelli, M AF Yu, T. Sinha, M. Hillard, M. Sherwin, C. Russell, S. Spigarelli, M. TI POPULATION PHARMACOKINETICS OF INTRADERMAL VS. SUBCUTANEOUS INSULIN DELIVERY IN PATIENTS WITH TYPE 1 DIABETES. SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics (ASCPT) CY MAR 03-07, 2015 CL New Orleans, LA SP Amer Soc Clin Pharmacol & Therapeut C1 [Yu, T.; Sherwin, C.; Spigarelli, M.] Univ Utah, Salt Lake City, UT USA. [Sinha, M.; Hillard, M.; Russell, S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Yu, Tian/L-9383-2016 OI Yu, Tian/0000-0002-4044-7902 NR 0 TC 0 Z9 0 U1 3 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9236 EI 1532-6535 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD FEB PY 2015 VL 97 SU 1 MA PI-096 BP S48 EP S49 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CA2HW UT WOS:000348730500149 ER PT J AU Grissom, CK Hirshberg, EL Dickerson, JB Brown, SM Lanspa, MJ Liu, KD Schoenfeld, D Tidswell, M Hite, RD Rock, P Miller, RR Morris, AH AF Grissom, Colin K. Hirshberg, Eliotte L. Dickerson, Justin B. Brown, Samuel M. Lanspa, Michael J. Liu, Kathleen D. Schoenfeld, David Tidswell, Mark Hite, R. Duncan Rock, Peter Miller, Russell R., III Morris, Alan H. CA NHLBI TI Fluid Management With a Simplified Conservative Protocol for the Acute Respiratory Distress Syndrome SO CRITICAL CARE MEDICINE LA English DT Article DE acute kidney injury; adult respiratory distress syndrome; clinical protocols; critical illness; fluid therapy; shock ID ACUTE LUNG INJURY; ACUTE KIDNEY INJURY; SEPTIC SHOCK; RANDOMIZED-TRIAL; ACCUMULATION; OUTCOMES AB Objectives: In the Fluid and Catheter Treatment Trial (FACTT) of the National Institutes of Health Acute Respiratory Distress Syndrome Network, a conservative fluid protocol (FACTT Conservative) resulted in a lower cumulative fluid balance and better outcomes than a liberal fluid protocol (FACTT Liberal). Subsequent Acute Respiratory Distress Syndrome Network studies used a simplified conservative fluid protocol (FACTT Lite). The objective of this study was to compare the performance of FACTT Lite, FACTT Conservative, and FACTT Liberal protocols. Design: Retrospective comparison of FACTT Lite, FACTT Conservative, and FACTT Liberal. Primary outcome was cumulative fluid balance over 7 days. Secondary outcomes were 60-day adjusted mortality and ventilator-free days through day 28. Safety outcomes were prevalence of acute kidney injury and new shock. Setting: ICUs of Acute Respiratory Distress Syndrome Network participating hospitals. Patients: Five hundred three subjects managed with FACTT Conservative, 497 subjects managed with FACTT Liberal, and 1,124 subjects managed with FACTT Lite. Interventions: Fluid management by protocol. Measurements and Main Results: Cumulative fluid balance was 1,918 +/- 323 mL in FACTT Lite, 136 +/- 491 mL in FACTT Conservative, and 6,992 502 mL in FACTT Liberal (p < 0.001). Mortality was not different between groups (240% in FACTT Lite, 25% in FACTT Conservative and Liberal, p = 0.84). Ventilator-free days in FACTT Lite (14.9 +/- 0.3) were equivalent to FACTT Conservative (14.6 +/- 0.5) (p = 0.61) and greater than in FACTT Liberal (12.1 +/- 0.5, p < 0.001 vs Lite). Acute kidney injury prevalence was 58% in FACTT Lite and 57% in FACTT Conservative (p = 0.72) Prevalence of new shock in FACTT Lite (9%) was lower than in FACTT Conservative (13%) (p = 0.007 vs Lite) and similar to FACTT Liberal (11%) (p = 0.18 vs Lite). Conclusions: FACTT Lite had a greater cumulative fluid balance than FACTT Conservative but had equivalent clinical and safety outcomes. FACTT Lite is an alternative to FACTT Conservative for fluid management in Acute Respiratory Distress Syndrome. C1 [Grissom, Colin K.; Hirshberg, Eliotte L.; Dickerson, Justin B.; Brown, Samuel M.; Lanspa, Michael J.; Miller, Russell R., III; Morris, Alan H.] Intermt Med Ctr, Div Crit Care Med, Murray, UT 84157 USA. [Grissom, Colin K.; Hirshberg, Eliotte L.; Brown, Samuel M.; Lanspa, Michael J.; Miller, Russell R., III; Morris, Alan H.] Univ Utah, Dept Med, Div Pulm & Crit Care, Salt Lake City, UT 84112 USA. [Hirshberg, Eliotte L.] Univ Utah, Div Pediat Crit Care, Salt Lake City, UT USA. [Dickerson, Justin B.] Univ Utah, Coll Pharm, Salt Lake City, UT 84112 USA. [Liu, Kathleen D.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Liu, Kathleen D.] Univ Calif San Francisco, Div Crit Care Med, San Francisco, CA 94143 USA. [Schoenfeld, David] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA. [Tidswell, Mark] Baystate Med Ctr, Div Pulm & Crit Care Med, Springfield, MA USA. [Hite, R. Duncan] Cleveland Clin, Resp Inst, Cleveland, OH 44106 USA. [Rock, Peter] Univ Maryland, Dept Anesthesiol, Baltimore, MD 21201 USA. RP Grissom, CK (reprint author), Intermt Med Ctr, Div Crit Care Med, Murray, UT 84157 USA. EM colin.grissom@imail.org RI Brown, Samuel/E-6846-2015; OI Brown, Samuel/0000-0003-1206-6261; Shanholtz, Carl/0000-0003-3938-178X FU National Institutes of Health, National Heart Lung and Blood Institute, Acute Respiratory Distress Syndrome Network [HHSN268200536171C, HHSN268200536165C, HHSN268200536179C]; National Institutes of Health (NIH); NIH National Heart Lung and Blood Institute (NHLBI) Acute Respiratory Distress Syndrome (ARDS) Network and Prevention and Early Treatment of Acute Lung Injury Network; NIH; SBP World Technologies; National Institutes of General Medical Sciences (K23 award) [K23GM094465]; Intermountain Research and Medical Foundation; NHLBI; NIH ARDS Network contract FX Supported, in part, by the National Institutes of Health, National Heart Lung and Blood Institute, Acute Respiratory Distress Syndrome Network contracts (HHSN268200536171C, HHSN268200536165C, and HHSN268200536179C).; Dr. Grissom lectured for the Society of Critical Care Medicine (honorarium for lecturing at Fundamentals of Critical Care Ultrasound Courses) and received support for article research from the National Institutes of Health (NIH). His institution received grant support from the NIH National Heart Lung and Blood Institute (NHLBI) Acute Respiratory Distress Syndrome (ARDS) Network and Prevention and Early Treatment of Acute Lung Injury Network. Dr. Brown received support for article research from the NIH; served as board member for Vecna Technologies (medical advisor to robotics/informatics company); lectured for the Society of Critical Care Medicine (Critical Care Ultrasound courses as faculty/co-chair); received support from SBP World Technologies (Dr. Brown is cofounder of an air pollution mitigation company); and received royalties from Oxford University Press (academic history book). His institution has a patent with Intermountain Healthcare (Dr. Brown assigned a patent-pending airway device to Intermountain) and received grant support from National Institutes of General Medical Sciences (K23 award; K23GM094465) and from the Intermountain Research and Medical Foundation (various investigator-initiated research studies). Dr. Liu served as board member for Astute Biomedical (Clinical Events Adjudication Committee), Complexe (Scientific Advisory Board), and Cytopheryx (Data Safety Monitoring Board); consulted for Chemocentryx and Abbvie; provided expert testimony for the Law Offices of Randy Moore; has stock options with Amgen; received support for travel from the American Thoracic Society and the American Society of Nephrology; received support from Abbott and CMIC (gifts of reagents for biomarker assays); and received support for article research from the NIH. Dr. Liu and her institution received grant support from the NIH. Dr. Schoenfeld received support for article research from the NIH. His institution received grant support from the NHLBI. Dr. Tidswell received support for travel from the NHLBI, received royalties from University California, San Francisco and received support for article research from the NIH. His institution received grant support from the NHLBI. Dr. Hite consulted for the NIH and Cumberland Pharmaceuticals (Safety Monitoring Boards), received grant support from the NIH (studies focused on ARDS, sepsis, and pneumonia), and received support for article research from the NIH. His institution received grant support from the NIH. Dr. Rock received support from Hospira (supplied dexmedetomidine for the Delirium clinical trial), Covidean (supplied bispectral index monitors for the Dexlirium trial), and CAS Medical Systems (supplied tissue oximeter monitors for the Dexlirium trial) and received support for article research from the NIH. His institution received grant support from the NIH (support for ARDS Network trials: Fluid and Catheter Treatment Trial, Statins for Acutely Injured Lungs from Sepsis [SAILS], Early Versus Delayed Enteral Feeding, Albuterol for Treatment of Acute Lung Injury and for support for NIH-sponsored clinical trials: Modifying the Impact of ICU-Induced Neurologic Dysfunction-USA; Dexlirium; and Red Cell Storage Duration Study), support for travel from the NIH, and provision of materials/assistance (for the NIH-sponsored ARDS Network trial called "SAILS," AstraZeneca supplied study drugs and the resources to measure blood levels of rosuvastatin). Dr. Miller received support for travel. Dr. Morris received support for article research from the NIH.; His institution received grant support, support for travel, and provision of assistance/materials from the NIH ARDS Network contract. The remaining authors have disclosed that they do not have any potential conflicts of interest. NR 15 TC 27 Z9 29 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD FEB PY 2015 VL 43 IS 2 BP 288 EP 295 DI 10.1097/CCM.0000000000000715 PG 8 WC Critical Care Medicine SC General & Internal Medicine GA AZ2YX UT WOS:000348096200005 PM 25599463 ER PT J AU Villar, J Fernandez, RL Ambros, A Parra, L Blanco, J Dominguez-Berrot, AM Gutierrez, JM Blanch, L Anon, JM Martin, C Prieto, F Collado, J Perez-Mendez, L Kacmarek, RM AF Villar, Jesus Fernandez, Rosa L. Ambros, Alfonso Parra, Laura Blanco, Jesus Dominguez-Berrot, Ana M. Gutierrez, Jose M. Blanch, Lluis Anon, Jose M. Martin, Carmen Prieto, Francisca Collado, Javier Perez-Mendez, Lina Kacmarek, Robert M. CA Acute Lung Injury Epidemiology Nat TI A Clinical Classification of the Acute Respiratory Distress Syndrome for Predicting Outcome and Guiding Medical Therapy SO CRITICAL CARE MEDICINE LA English DT Article DE acute respiratory distress syndrome; classification; Pao(2)/Fio(2) ratio; positive end-expiratory pressure; risk stratification; outcome ID ACUTE LUNG INJURY; ARDS; MORTALITY; DEFINITIONS; VENTILATION; MANEUVERS; PRESSURE; STRATEGY; ONSET; RATIO AB Objective: Current in-hospital mortality of the acute respiratory distress syndrome (ARDS) is above 40%. ARDS outcome depends on the lung injury severity within the first 24 hours of ARDS onset. We investigated whether two widely accepted cutoff values of Pao(2)/Ro(2) and positive end-expiratory pressure (PEEP) would identify subsets of patients with ARDS for predicting outcome and guiding therapy. Design: A 16-month (September 2008 to January 2010) prospective, multicenter, observational study. Setting: Seventeen multidisciplinary ICUs in Spain. Patients: We studied 300 consecutive, mechanically ventilated patients meeting American-European Consensus Conference criteria for ARDS (Pao(2)/Ro(2) 5 200 mm Hg) on PEEP greater than or equal to 5 cm H2O, and followed up until hospital discharge. Interventions: None. Measurements and Main Results: Based on threshold values for Pao2/Fio2 (150mm Hg) and PEEP (10 cm H20) at ARDS onset and at 24 hours, we assigned patients to four categories: group I (Pao(2)/Fio(2) 150 on PEEP < 10), group ll (Pao(2)/Ro(2) >= 150 on PEEP 10), group III (Pao(2)/Fio(2)< 150 on PEEP < 10), and group IV (Pao(2)/Fio(2) < 150 on PEEP 10). The primary outcome was all-cause in-hospital mortality. Overall hospital mortality was 46.3%. Although at study entry, patients with Pao(2)/Ro(2) less than 150 had a higher mortality than patients with a Pao(2)/Fio(2) greater than or equal to 150 (p = 0.044), there was minimal variability in mortality among the four groups (p = 0.186). However, classification of patients in each group changed markedly after. 24 hours of usual care. Group categorization at 24 hours provided a strong association with in-hospital mortality (p < 0.00001): group I had the lowest mortality (23.1%), whereas group IV had the highest mortality (60.3%). Conclusions: The degree of lung dysfunction established by a Pao2/Ro2 of 150 mm Hg and a PEEP of 10 cm H2O demonstrated that ARDS is not a homogeneous disorder. Rather, it is a series of four subsets that should be considered for enrollment in clinical trials and for guiding therapy. A major contribution of our study is the distinction between survival after 24 hours of care versus survival at the time of ARDS onset. C1 [Villar, Jesus; Fernandez, Rosa L.; Blanco, Jesus; Blanch, Lluis; Perez-Mendez, Lina] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain. [Villar, Jesus; Fernandez, Rosa L.] Hosp Univ Dr Negrin, Res Unit, Multidisciplinary Organ Dysfunct Evaluat Res Netw, Las Palmas Gran Canaria, Spain. [Ambros, Alfonso] Hosp Gen Ciudad Real, Intens Care Unit, Ciudad Real, Spain. [Parra, Laura] Hosp Clin Univ Valladolid, Intens Care Unit, Valladolid, Spain. [Blanco, Jesus] Hosp Univ Rio Hortega, Intens Care Unit, Valladolid, Spain. [Dominguez-Berrot, Ana M.] Hosp Gen Leon, Intens Care Unit, Leon, Spain. [Gutierrez, Jose M.] Hosp Gen Univ Albacete, Intens Care Unit, Albacete, Spain. [Blanch, Lluis] Corp Sanitaria Parc Tauli, Crit Care Ctr, Sabadell, Spain. [Anon, Jose M.] Hosp Virgen de la Luz, Intens Care Unit, Cuenca, Spain. [Martin, Carmen] Hosp La Mancha Ctr, Intens Care Unit, Ciudad Real, Spain. [Prieto, Francisca] Hosp Santa Barbara, Intens Care Unit, Ciudad Real, Spain. [Collado, Javier] Hosp Gen Rio Carrion, Intens Care Unit, Palencia, Spain. [Perez-Mendez, Lina] Hosp Univ NS Candelaria, Res Unit, Santa Cruz De Tenerife, Spain. [Kacmarek, Robert M.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA. [Kacmarek, Robert M.] Harvard Univ, Dept Anesthesiol, Boston, MA 02115 USA. RP Villar, J (reprint author), Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain. EM jesus.villar54@gmail.com FU Instituto de Salud Carlos III, Spain [CB06/06/1088, PI10/0393, PI13/0119]; Asociacion Cientifica Pulmon y Ventilacion Mecanica; Maquet FX Supported, in part, by grants from Instituto de Salud Carlos III, Spain (CB06/06/1088, PI10/0393, PI13/0119), and Asociacion Cientifica Pulmon y Ventilacion Mecanica.; Dr. Kacmarek is a consultant for Covidien and has received honorarium from Maquet for lecturing. Dr. Villar has received a research grant from Maquet. Dr. Villar disclosed having received a grant from Maquet for research on mechanical ventilation (Money is not paid to Dr. Villar or to his institution). Dr. Kacmarek consulted and received support for development of educational presentations. The remaining authors have disclosed that they do not have any potential conflicts of interest. NR 30 TC 14 Z9 17 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD FEB PY 2015 VL 43 IS 2 BP 346 EP 353 DI 10.1097/CCM.0000000000000703 PG 8 WC Critical Care Medicine SC General & Internal Medicine GA AZ2YX UT WOS:000348096200011 PM 25393701 ER PT J AU Horkan, CM Purtle, SW Mendu, ML Moromizato, T Gibbons, FK Christopher, KB AF Horkan, Clare M. Purtle, Steven W. Mendu, Mallika L. Moromizato, Takuhiro Gibbons, Fiona K. Christopher, Kenneth B. TI The Association of Acute Kidney Injury in the Critically III and Postdischarge Outcomes: A Cohort Study SO CRITICAL CARE MEDICINE LA English DT Article DE acute kidney injury; critical care; hospital readmission; outcomes; risk; injury; failure; loss of kidney function; and end-stage kidney disease ID ACUTE-RENAL-FAILURE; QUALITY-OF-LIFE; INTENSIVE-CARE-UNIT; RANDOMIZED CONTROLLED-TRIAL; ILL PATIENTS; HOSPITAL READMISSION; RIFLE CRITERIA; REPLACEMENT THERAPY; 30-DAY READMISSION; MEDICAL PATIENTS AB Objective: Hospital readmissions contribute significantly to the cost of inpatient care and are targeted as a marker for quality of care. Little is known about risk factors associated with hospital readmission in survivors of critical illness. We hypothesized that acute kidney injury in patients who survived critical care would be associated with increased risk of 30-day postdischarge hospital readmission, postdischarge mortality, and progression to end-stage renal disease. Design: Two center observational cohort study. Setting: Medical and surgical ICUs at the Brigham and Women's Hospital and the Massachusetts General Hospital in Boston, Massachusetts. Patients: We studied 62,096 patients, 18 years old and older, who received critical care between 1997 and 2012 and survived hospitalization. Interventions: None Measurements and Main Results: All data was obtained from the Research Patient Data Registry at Partners HealthCare. The exposure of interest was acute kidney injury defined as meeting Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease Risk, Injury or Failure Criteria occurring 3 days prior to 7 days after critical care initiation. The primary outcome was hospital readmission in the 30 days following hospital discharge. The secondary outcome was mortality in the 30 days following hospital discharge. Adjusted odds ratios were estimated by multivariable logistic regression models with inclusion of covariate terms thought to plausibly interact with both acute kidney injury and readmission status. Adjustment included age, race (white vs nonwhite), gender, Deyo-Charlson Index, patient type (medical vs surgical) and sepsis. Additionally, long-term progression to End Stage Renal Disease in patients with acute kidney injury was analyzed with a risk-adjusted Cox proportional hazards regression model. The absolute risk of 30-day readmission was 12.3%, 19.0%, 21.2%, and 21.1% in patients with No Acute Kidney Injury, Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease class Risk, Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease class Injury, and Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease class Failure, respectively. In patients who received critical care and survived hospitalization, acute kidney injury was a robust predictor of hospital readmission and post-discharge mortality and remained so following multivariable adjustment. The odds of 30-day post-discharge hospital readmission in patients with Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease class Risk, Injury, or Failure fully adjusted were 1.44 (95% CI, 1.25-1.66), 1.98 (95% CI, 1.66-2.36), and 1.55 (95% CI, 1.26-1.91) respectively, relative to patients without acute kidney injury. Further, the odds of 30-day post-discharge mortality in patients with Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease class Risk, Injury, or Failure fully adjusted per our primary analysis were 1.39 (95% Cl, 1.28-1.51), 1.46 (95% CI, 1.30-1.64), and 1..42 (95% CI, 1.26-1.61) respectively, relative to patients without acute kidney injury. The addition of the propensity score to the multivariable model did not change the point estimates significantly. Finally, taking into account age, gender, race, Deyo-Charlson Index, and patient type, we observed a relationship between acute kidney injury and development of end-stage renal disease. Patients with Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease class Risk, Injury, Failure experienced a significantly higher risk of end-stage renal disease during follow-up than patients without acute kidney injury (hazard ratio, 2.03; 95% CI, 1.56-2.65; hazard ratio, 3.99; 95% CI, 3.04-5.23; hazard ratio, 10.40; 950/o CI, 8.54-12.69, respectively). Conclusions: Patients who suffer acute kidney injury are among a high-risk group of ICU survivors for adverse outcomes. In patients treated with critical care who survive hospitalization, acute kidney injury is a robust Predictor of subsequent unplanned hospital readmission. In critical illness survivors, acute kidney injury is also associated with the odds of 30-day postdischarge mortality and the risk of subsequent end-stage renal disease. C1 [Horkan, Clare M.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Purtle, Steven W.] Univ Colorado, Div Pulm Sci & Crit Care Med, Boulder, CO 80309 USA. [Mendu, Mallika L.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA. [Moromizato, Takuhiro] Hokubu Prefectural Hosp, Dept Med, Okinawa, Okinawa, Japan. [Gibbons, Fiona K.] Massachusetts Gen Hosp, Div Pulm, Boston, MA 02114 USA. [Christopher, Kenneth B.] Brigham & Womens Hosp, Div Renal, Nathan E Hellman Mem Lab, Boston, MA 02115 USA. RP Christopher, KB (reprint author), Brigham & Womens Hosp, Div Renal, Nathan E Hellman Mem Lab, Boston, MA 02115 USA. EM kbchristopher@partners.org NR 76 TC 20 Z9 20 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD FEB PY 2015 VL 43 IS 2 BP 354 EP 364 DI 10.1097/CCM.0000000000000706 PG 11 WC Critical Care Medicine SC General & Internal Medicine GA AZ2YX UT WOS:000348096200012 PM 25474534 ER PT J AU Kumar, G Ahmad, S Taneja, A Patel, J Guddati, AK Nanchal, R AF Kumar, Gagan Ahmad, Shahryar Taneja, Amit Patel, Jayshil Guddati, Achuta Kumar Nanchal, Rahul CA Milwaukee Initiative Critical Care TI Severe Sepsis in Hematopoietic Stem Cell Transplant Recipients SO CRITICAL CARE MEDICINE LA English DT Article DE administrative data; allogeneic hematopoietic stem cell transplant; autologous hematopoietic stem cell transplants; graft-versus-host disease; hematopoietic stem cell transplant; mortality; outcomes; severe sepsis ID INTENSIVE-CARE-UNIT; REQUIRING MECHANICAL VENTILATION; BONE-MARROW-TRANSPLANTATION; PROGNOSTIC-FACTORS; SEPTIC SHOCK; THERAPY; MORTALITY; OUTCOMES; FAILURE AB Objective: Severe sepsis requires timely management and has high mortality if care is delayed. Hematopoietic stem cell transplant recipients are more likely to be imnnunocompromised and are predisposed to serious infections. Reports of outcomes of severe sepsis in this population are limited to data from single, tertiary care centers, and national outcomes data are missing. Design: Retrospective analysis of an administrative database. Setting: Twenty percent of community hospitals in United States, excluding federal hospitals. Subject: Patients with severe sepsis. Intervention: None. Measurements and Main Results: We used International Classification of Diseases, 9th Edition, Clinical Modification codes indicating the presence of sepsis and organ system failure to identify hospitalizations for severe sepsis between 2000 and 2008. We also used International Classification of Diseases, 9th Edition, Clinical Modification codes to identify hematopoietic stem cell transplant recipients. We compared outcomes of hematopoietic stem cell transplant recipients with severe sepsis during engraftnnent and subsequent admissions with a non hematopoietic stem cell transplant cohort and excluded solid-organ transplantation from this cohort. We used mixed effect, multivariate logistic regression modeling with propensity score adjustment to examine factors associated with mortality of severe sepsis in hennatopoietic stem cell transplant recipients. A total of 21,898 hematopoietic stem cell transplant recipients with severe sepsis were identified. The frequency of severe sepsis in hematopoietic stem cell transplant recipients was five times higher when compared with the non hematopoietic stem cell transplant cohort. The unadjusted mortality was 32.9% in non hematopoietic stem cell transplant cohort, which was similar to autologous hennatopoietic stem cell transplant recipients (30.1%) and those who did not develop graft-versus-host disease (35%). Mortality was significantly higher in allogeneic transplants (55.1%, p < 0.001) and in those who developed graft-versus-host disease (47.9%, p < 0.001). After adjustment, during engraftment admission, the odds of in-hospital mortality in allogeneic hematopoietic stem cell transplant (odds ratio, 3.81; 95% Cl, 2.39-6.07) and autologous hematopoietic stem cell transplant (odds ratio, 1.28; 95% Cl, 1.06-1.53) recipients was significantly higher than non hematopoietic stem cell transplant patients. Similarly, in subsequent admissions, hematopoietic stem cell transplant recipients with graft-versus-host disease (odds ratio, 2.14; 95% Cl, 1.88-2.45) and without graft-versus-host disease (odds ratio, 1.35; 95% Cl, 1.19-1.54) had significantly higher odds of mortality than non hematopoietic stem cell transplant patients. Among patients with hematopoietic stem cell transplant, persons with autologous hematopoietic stem cell transplant and those without graft-versus-host disease fared better as compared with their allogeneic and graft-versus-host disease counterparts. Conclusions: Hematopoietic stem cell transplant recipients are more likely to develop severe sepsis and die following a severe sepsis episode than nontransplant patients. Autologous hematopoietic stem cell transplant recipients and those who do not develop graft-versus-host disease have significantly better outcomes than allogeneic and graft-versus-host disease patients. C1 [Kumar, Gagan; Taneja, Amit; Patel, Jayshil; Nanchal, Rahul] Med Coll Wisconsin, Dept Med, Div Pulm & Crit Care Med, Milwaukee, WI 53226 USA. [Ahmad, Shahryar] Med Coll Wisconsin, Dept Med, Div Hosp Med, Milwaukee, WI 53226 USA. [Guddati, Achuta Kumar] Massachusetts Gen Hosp, Dept Med, Div Hosp Med, Boston, MA 02114 USA. RP Kumar, G (reprint author), Med Coll Wisconsin, Dept Med, Div Pulm & Crit Care Med, Milwaukee, WI 53226 USA. EM gagankumar@gmail.com NR 25 TC 4 Z9 4 U1 0 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD FEB PY 2015 VL 43 IS 2 BP 411 EP 421 DI 10.1097/CCM.0000000000000714 PG 11 WC Critical Care Medicine SC General & Internal Medicine GA AZ2YX UT WOS:000348096200018 PM 25599465 ER PT J AU Rennekamp, AJ Peterson, RT AF Rennekamp, Andrew J. Peterson, Randall T. TI 15 years of zebrafish chemical screening SO CURRENT OPINION IN CHEMICAL BIOLOGY LA English DT Review ID ZINC-FINGER NUCLEASES; TAGGED TRIAZINE LIBRARY; BLOOD-BRAIN-BARRIER; GENETIC SCREEN; ANTIANGIOGENIC COMPOUNDS; TRANSGENIC ZEBRAFISH; TARGETED MUTAGENESIS; PATHWAYS; DRUGS; IDENTIFICATION AB In 2000, the first chemical screen using living zebrafish in a multi-well plate was reported. Since then, more than 60 additional screens have been published describing whole-organism drug and pathway discovery projects in zebrafish. To investigate the scope of the work reported in the last 14 years and to identify trends in the field, we analyzed the discovery strategies of 64 primary research articles from the literature. We found that zebrafish screens have expanded beyond the use of developmental phenotypes to include behavioral, cardiac, metabolic, proliferative and regenerative endpoints. Additionally, many creative strategies have been used to uncover the mechanisms of action of new small molecules including chemical phenocopy, genetic phenocopy, mutant rescue, and spatial localization strategies. C1 [Rennekamp, Andrew J.; Peterson, Randall T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA. [Rennekamp, Andrew J.; Peterson, Randall T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol,Dept Med, Charlestown, MA 02129 USA. [Rennekamp, Andrew J.; Peterson, Randall T.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. [Rennekamp, Andrew J.; Peterson, Randall T.] Broad Inst, Cambridge, MA 02142 USA. RP Peterson, RT (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA. EM peterson@cvrc.mgh.harvard.edu OI Rennekamp , Andrew /0000-0001-6174-7253 FU US National Institutes of Health grant [R01 MH 086867]; Charles and Ann Sanders MGH Research Scholar Award; NIH [T32 HL 007208] FX This work was supported by US National Institutes of Health grant R01 MH 086867 (RTP), by the Charles and Ann Sanders MGH Research Scholar Award (RTP), and NIH training grant T32 HL 007208 (AJR). We would like to acknowledge the support of our former colleague, mentor and friend the late Dr. Kenneth D. Bloch, who played important roles in the administration of the T32 grant and in the preclinical development of dorsomorphin/LDN-193189, which we have described in this review. NR 75 TC 38 Z9 39 U1 1 U2 18 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1367-5931 EI 1879-0402 J9 CURR OPIN CHEM BIOL JI Curr. Opin. Chem. Biol. PD FEB PY 2015 VL 24 BP 58 EP 70 DI 10.1016/j.cbpa.2014.10.025 PG 13 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA CB4CB UT WOS:000349574700008 PM 25461724 ER PT J AU Faje, AT Klibanski, A AF Faje, Alexander T. Klibanski, Anne TI The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: Cons SO ENDOCRINE LA English DT Editorial Material ID CARDIAC-VALVE REGURGITATION; BREAST-CANCER; PLASMA PROLACTIN; DOPAMINE AGONISTS; NATURAL-HISTORY; PLATELET-AGGREGATION; PREMENOPAUSAL WOMEN; CABERGOLINE THERAPY; PITUITARY-ADENOMAS; COMBINED ESTROGEN C1 [Faje, Alexander T.; Klibanski, Anne] Massachusetts Gen Hosp, Neuroendocrine Unit, BUL 457, Boston, MA 02114 USA. [Faje, Alexander T.; Klibanski, Anne] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Klibanski, A (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, BUL 457, 55 Fruit St, Boston, MA 02114 USA. EM aklibanski@partners.org NR 50 TC 3 Z9 3 U1 1 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1355-008X EI 1559-0100 J9 ENDOCRINE JI Endocrine PD FEB PY 2015 VL 48 IS 1 BP 79 EP 82 DI 10.1007/s12020-014-0308-9 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CB0RQ UT WOS:000349334800013 PM 24888765 ER PT J AU Ellis, CN Traverse, CC Mayo-Smith, L Buskirk, SW Cooper, VS AF Ellis, Crystal N. Traverse, Charles C. Mayo-Smith, Leslie Buskirk, Sean W. Cooper, Vaughn S. TI Character displacement and the evolution of niche complementarity in a model biofilm community SO EVOLUTION LA English DT Article DE Diversity; experimental evolution; productivity; resource limitation ID SMALL-COLONY VARIANTS; BURKHOLDERIA-CEPACIA COMPLEX; CYSTIC-FIBROSIS LUNG; C-DI-GMP; ADAPTIVE RADIATION; PSEUDOMONAS-AERUGINOSA; FACILITATION; INFECTIONS; DIVERSITY; DIVERSIFICATION AB Colonization of vacant environments may catalyze adaptive diversification and be followed by competition within the nascent community. How these interactions ultimately stabilize and affect productivity are central problems in evolutionary ecology. Diversity can emerge by character displacement, in which selection favors phenotypes that exploit an alternative resource and reduce competition, or by facilitation, in which organisms change the environment and enable different genotypes or species to become established. We previously developed a model of long-term experimental evolution in which bacteria attach to a plastic bead, form a biofilm, and disperse to a new bead. Here, we focus on the evolution of coexisting mutants within a population of Burkholderia cenocepacia and how their interactions affected productivity. Adaptive mutants initially competed for space, but later competition declined, consistent with character displacement and the predicted effects of the evolved mutations. The community reached a stable equilibrium as each ecotype evolved to inhabit distinct, complementary regions of the biofilm. Interactions among ecotypes ultimately became facilitative and enhanced mixed productivity. Observing the succession of genotypes within niches illuminated changing selective forces within the community, including a fundamental role for genotypes producing small colony variants that underpin chronic infections caused by B. cenocepacia. C1 [Ellis, Crystal N.; Traverse, Charles C.; Mayo-Smith, Leslie; Buskirk, Sean W.; Cooper, Vaughn S.] Univ New Hampshire, Dept Mol Cellular & Biomed Sci, Durham, NH 03824 USA. RP Ellis, CN (reprint author), Massachusetts Gen Hosp, Dept Med, Div Infect Dis, 55 Fruit St, Boston, MA 02114 USA. EM cnellis@partners.org OI Cooper, Vaughn/0000-0001-7726-0765 FU National Science Foundation CAREER [DEB-0845851] FX We thank S. Poltak, M. Dillon, and K. Flynn for useful feedback and two anonymous reviewers for the comments on constructive recommendations. This work was supported by National Science Foundation CAREER award DEB-0845851 to VSC. CE, CT, and LMS together performed culture-based experiments, data analysis, and statistics. CE completed the confocal microscopy and image analysis. All authors wrote the manuscript. NR 51 TC 6 Z9 6 U1 4 U2 59 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0014-3820 EI 1558-5646 J9 EVOLUTION JI Evolution PD FEB PY 2015 VL 69 IS 2 BP 283 EP 293 DI 10.1111/evo.12581 PG 11 WC Ecology; Evolutionary Biology; Genetics & Heredity SC Environmental Sciences & Ecology; Evolutionary Biology; Genetics & Heredity GA CA4ZL UT WOS:000348916200001 PM 25494960 ER PT J AU Liu, CY Dupuis, J Larson, MG Cupples, LA Ordovas, JM Vasan, RS Meigs, JB Jacques, PF Levy, D AF Liu, Chunyu Dupuis, Josee Larson, Martin G. Cupples, L. Adrienne Ordovas, Jose M. Vasan, Ramachandran S. Meigs, James B. Jacques, Paul F. Levy, Daniel TI Revisiting heritability accounting for shared environmental effects and maternal inheritance SO HUMAN GENETICS LA English DT Article ID HAN CHINESE FAMILY; MITOCHONDRIAL-DNA; VARIANCE-COMPONENTS; ESSENTIAL-HYPERTENSION; BLOOD-PRESSURE; HUMAN-DISEASE; MUTATION; ASSOCIATION; TRAITS; PEDIGREE AB Heritability measures the proportion of phenotypic variation attributable to genetic factors. In addition to a shared nuclear genetic component, a number of additional variance components, such as spousal correlation, sibship, household and maternal effects, may have strong contributions to inter-individual phenotype variation. In humans, the confounding effects of these components on heritability have not been studied thoroughly. We sought to obtain unbiased heritability estimates for complex traits in the presence of multiple variance components and also to estimate the contributions of these variance components to complex traits. We compared regression and variance component methods to estimate heritability in simulations when additional variance components existed. We then revisited heritability for several traits in Framingham Heart Study (FHS) participants. Using simulations, we found that failure to account for or misclassification of necessary variance components yielded biased heritability estimates. The direction and magnitude of the bias varied depending on a variance structure and an estimation method. Using the best fitted models to account for necessary variance components, we found that heritability estimates for most FHS traits were overestimated, ranging from 4 to 47 %, when we compared models that considered necessary variance components to models that only considered familial relationships. Spousal correlation explained 14-36 % of phenotypic variation in several anthropometric and lifestyle traits. Maternal and sibling effects also contributed to phenotypic variation, ranging from 3 to 5 % and 4 to 7 %, respectively, in several anthropometric and metabolic traits. Our findings may explain, in part, the missing heritability for some traits. C1 [Liu, Chunyu; Dupuis, Josee; Larson, Martin G.; Cupples, L. Adrienne; Vasan, Ramachandran S.; Levy, Daniel] Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA. [Liu, Chunyu; Levy, Daniel] NHLBI, Populat Sci Branch, Div Intramural Res, NIH, Bethesda, MD 20892 USA. [Dupuis, Josee; Larson, Martin G.; Cupples, L. Adrienne] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA. [Larson, Martin G.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA. [Ordovas, Jose M.] Tufts Univ, Jean Mayer USDA HNRCA, Nutr & Genom Lab, Boston, MA 02111 USA. [Vasan, Ramachandran S.] Boston Univ, Dept Med, Boston, MA 02118 USA. [Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Meigs, James B.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Jacques, Paul F.] Tufts Univ, Jean Mayer USDA HNRCA, Nutr Epidemiol Program, Boston, MA 02111 USA. RP Liu, CY (reprint author), Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA. EM liuchunyu2002@yahoo.com OI Ramachandran, Vasan/0000-0001-7357-5970 FU NHLBI, Framingham Heart Study, (NHLBI/NIH) [N01-HC-25195]; NIH NIDDK [R01 DK078616, K24 DK080140]; Boston University School of Medicine; US Department of Agriculture, Agriculture Research Service [53-K06-5-10, 58-1950-9-001] FX We acknowledge support from NHLBI, Framingham Heart Study, (NHLBI/NIH Contract #N01-HC-25195), from NIH NIDDK R01 DK078616 and K24 DK080140, from the Boston University School of Medicine, and from contracts 53-K06-5-10 and 58-1950-9-001 from the US Department of Agriculture, Agriculture Research Service. We thank Dr. Qiong Yang of Biostatistics, School of Public Health at Boston University for helpful discussions and Dr. Kathryn Lunetta of Biostatistics, School of Public Health at Boston University for providing R codes for incorporating additional variance components in lmekin () function. NR 41 TC 2 Z9 2 U1 2 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-6717 EI 1432-1203 J9 HUM GENET JI Hum. Genet. PD FEB PY 2015 VL 134 IS 2 BP 169 EP 179 DI 10.1007/s00439-014-1505-6 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA AZ3TM UT WOS:000348149500004 PM 25381465 ER PT J AU Luz, PM Morris, BL Grinsztejn, B Freedberg, KA Veloso, VG Walensky, RP Losina, E Nakamura, YM Girouard, MP Sax, PE Struchiner, CJ Paltiel, AD AF Luz, Paula M. Morris, Bethany L. Grinsztejn, Beatriz Freedberg, Kenneth A. Veloso, Valdilea G. Walensky, Rochelle P. Losina, Elena Nakamura, Yoriko M. Girouard, Michael P. Sax, Paul E. Struchiner, Claudio J. Paltiel, A. David TI Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE genotype; cost-effectiveness; Brazil; HIV; drug resistance ID HIV-INFECTED PATIENTS; HIV-1-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; CONTROLLED-TRIAL; EFFICACY; SAFETY; ETRAVIRINE; BENEFITS; IMPACT AB Objective:HIV genotype-resistance testing can help identify more effective antiretroviral treatment (ART) regimens for patients, substantially increasing the likelihood of viral suppression and immune recovery. We sought to evaluate the cost-effectiveness of genotype-resistance testing before first-line ART initiation in Brazil.Design:We used a previously published microsimulation model of HIV disease (CEPAC-International) and data from Brazil to compare the clinical impact, costs, and cost-effectiveness of initial genotype testing (Genotype) with no initial genotype testing (No genotype).Methods:Model parameters were derived from the HIV Clinical Cohort at the Evandro Chagas Clinical Research Institute and from published data, using Brazilian sources whenever possible. Baseline patient characteristics included 69% male, mean age of 36 years (SD, 10 years), mean CD4 count of 347 per microliter (SD, 300/mu L) at ART initiation, annual ART costs from 2012 US $1400 to US $13,400, genotype test cost of US $230, and primary resistance prevalence of 4.4%. Life expectancy and costs were discounted 3% per year. Genotype was defined as cost-effective compared with No Genotype if its incremental cost-effectiveness ratio was less than 3 times the 2012 Brazilian per capita GDP of US $12,300.Results:Compared with No genotype, Genotype increased life expectancy from 18.45 to 18.47 years and reduced lifetime cost from US $45,000 to $44,770; thus, in the base case, Genotype was cost saving. Genotype was cost-effective at primary resistance prevalence as low as 1.4% and remained cost-effective when subsequent-line ART costs decreased to 30% of baseline value. Cost-inefficient results were observed only when simultaneously holding multiple parameters to extremes of their plausible ranges.Conclusions:Genotype-resistance testing in ART-naive individuals in Brazil will improve survival and decrease costs and should be incorporated into HIV treatment guidelines in Brazil. C1 [Luz, Paula M.; Grinsztejn, Beatriz; Veloso, Valdilea G.; Struchiner, Claudio J.] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, BR-21040360 Rio De Janeiro, Brazil. [Morris, Bethany L.; Freedberg, Kenneth A.; Walensky, Rochelle P.; Nakamura, Yoriko M.; Girouard, Michael P.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Morris, Bethany L.; Freedberg, Kenneth A.; Walensky, Rochelle P.; Losina, Elena; Nakamura, Yoriko M.; Girouard, Michael P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA. [Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Freedberg, Kenneth A.; Walensky, Rochelle P.; Sax, Paul E.] Harvard Univ, Ctr AIDS Res, Sch Med, Boston, MA 02115 USA. [Freedberg, Kenneth A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA. [Freedberg, Kenneth A.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Walensky, Rochelle P.; Sax, Paul E.] Brigham & Womens Hosp, Div Infect Dis, Dept Med, Boston, MA 02115 USA. [Losina, Elena] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA. [Losina, Elena] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA. [Paltiel, A. David] Yale Univ, Sch Publ Hlth, New Haven, CT USA. RP Luz, PM (reprint author), Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil. EM paula.luz@ipec.fiocruz.br FU National Institute of Allergy and Infectious Diseases [UM1 AI068636, R01 AI058736]; National Council of Technological and Scientific Development (CNPq); Research Funding Agency of the State of Rio de Janeiro (FAPERJ); BMS; Gilead; GSK FX Supported by the National Institute of Allergy and Infectious Diseases (UM1 AI068636 and R01 AI058736).; P.M.L., B.G., and C.J.S. acknowledge funding from the National Council of Technological and Scientific Development (CNPq) and the Research Funding Agency of the State of Rio de Janeiro (FAPERJ). P.E.S. is a consultant to Abbott, BMS, Gilead, GSK, Merck, and Janssen and receives grant support from BMS, Gilead, and GSK. The remaining authors have no conflicts of interest to disclose. NR 36 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD FEB 1 PY 2015 VL 68 IS 2 BP 152 EP 161 DI 10.1097/QAI.0000000000000426 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AZ8IF UT WOS:000348458200011 PM 25415289 ER PT J AU Paisible, AL Chang, CCH So-Armah, KA Butt, AA Leaf, DA Budoff, M Rimland, D Bedimo, R Goetz, MB Rodriguez-Barradas, MC Crane, HM Gibert, CL Brown, ST Tindle, HA Warner, AL Alcorn, C Skanderson, M Justice, AC Freiberg, MS AF Paisible, Anne-Lise Chang, Chung-Chou H. So-Armah, Kaku A. Butt, Adeel A. Leaf, David A. Budoff, Matthew Rimland, David Bedimo, Roger Goetz, Matthew B. Rodriguez-Barradas, Maria C. Crane, Heidi M. Gibert, Cynthia L. Brown, Sheldon T. Tindle, Hilary A. Warner, Alberta L. Alcorn, Charles Skanderson, Melissa Justice, Amy C. Freiberg, Matthew S. CA VACS Project Team TI HIV Infection, Cardiovascular Disease Risk Factor Profile, and Risk for Acute Myocardial Infarction SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; optimal cardiovascular health; myocardial infarction ID CORONARY-HEART-DISEASE; ANTIRETROVIRAL THERAPY; HYPERTENSIVE PATIENTS; LIFETIME RISK; VETERANS; COHORT; INDIVIDUALS; POPULATION; PREVALENCE; MORTALITY AB Background:Traditional cardiovascular disease risk factors (CVDRFs) increase the risk of acute myocardial infarction (AMI) among HIV-infected (HIV+) participants. We assessed the association between HIV and incident AMI within CVDRF strata.Methods:Cohort81,322 participants (33% HIV+) without prevalent CVD from the Veterans Aging Cohort Study Virtual Cohort (prospective study of HIV+ and matched HIV- veterans) participated in this study. Veterans were followed from first clinical encounter on/after April 1, 2003, until AMI/death/last follow-up date (December 31, 2009). PredictorsHIV, CVDRFs (total cholesterol, cholesterol-lowering agents, blood pressure, blood pressure medication, smoking, diabetes) used to create 6 mutually exclusive profiles: all CVDRFs optimal, 1+ nonoptimal CVDRFs, 1+ elevated CVDRFs, and 1, 2, 3+ major CVDRFs. OutcomeIncident AMI [defined using enzyme, electrocardiogram (EKG) clinical data, 410 inpatient ICD-9 (Medicare), and/or death certificates]. StatisticsCox models adjusted for demographics, comorbidity, and substance use.Results:Of note, 858 AMIs (42% HIV+) occurred over 5.9 years (median). Prevalence of optimal cardiac health was <2%. Optimal CVDRF profile was associated with the lowest adjusted AMI rates. Compared with HIV- veterans, AMI rates among HIV+ veterans with similar CVDRF profiles were higher. Compared with HIV- veterans without major CVDRFs, HIV+ veterans without major CVDRFs had a 2-fold increased risk of AMI (HR: 2.0; 95% confidence interval: 1.0 to 3.9; P = 0.044).Conclusions:The prevalence of optimal cardiac health is low in this cohort. Among those without major CVDRFs, HIV+ veterans have twice the AMI risk. Compared with HIV- veterans with high CVDRF burden, AMI rates were still higher in HIV+ veterans. Preventing/reducing CVDRF burden may reduce excess AMI risk among HIV+ people. C1 [Paisible, Anne-Lise; Butt, Adeel A.; Tindle, Hilary A.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Chang, Chung-Chou H.; Alcorn, Charles] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [So-Armah, Kaku A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Butt, Adeel A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Leaf, David A.; Goetz, Matthew B.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Leaf, David A.; Goetz, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Budoff, Matthew] Harbor UCLA Med Ctr, Los Angeles, CA USA. [Budoff, Matthew] Los Angeles Biomed Res Inst, Los Angeles, CA USA. [Rimland, David] VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. [Bedimo, Roger] UT Southwestern Med Ctr, VA North Texas Hlth Care Syst, Dept Med, Infect Dis Sect, Dallas, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. [Crane, Heidi M.] Univ Washington, Dept Med, Seattle, WA USA. [Gibert, Cynthia L.] VA Med Ctr, Washington, DC USA. [Gibert, Cynthia L.] George Washington Univ, Med Ctr, Washington, DC 20037 USA. [Brown, Sheldon T.] Mt Sinai Med Ctr, Dept Internal Med, New York, NY USA. [Brown, Sheldon T.] Bronx Vet Affairs Med Ctr, Bronx, NY USA. [Warner, Alberta L.] Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90024 USA. [Skanderson, Melissa; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Justice, Amy C.] Yale Univ, Sch Med, Sect Gen Med, New Haven, CT USA. [Freiberg, Matthew S.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Freiberg, Matthew S.] Nashville Vet Affairs Med Ctr, Nashville, TN USA. RP Freiberg, MS (reprint author), Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, 2525 West End,Suite 300-A, Nashville, TN 37203 USA. EM matthew.s.freiberg@vanderbilt.edu OI Butt, Adeel/0000-0002-1118-1826; Goetz, Matthew/0000-0003-4542-992X; Justice, Amy/0000-0003-0139-5502 FU National Heart, Lung, and Blood Institute [HL095136-04]; National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health [AA013566-10, AA020790, AA020794]; National Institutes of Health; Merck; Pfizer; Merck Co, Inc; Janssen Therapeutics; Bristol-Myers Squibb FX Supported by grant HL095136-04 from the National Heart, Lung, and Blood Institute and grant Nos. AA013566-10, AA020790, and AA020794 from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health. M.B., H.C., S.B., A.J., and M.F. received funding from the National Institutes of Health related to this work; A.B. has received Investigator Initiated Research Support from Merck and Pfizer; and R.B. has received grants and research support awarded to the VA North TX Healthcare System from Merck & Co, Inc, Janssen Therapeutics, and Bristol-Myers Squibb. NR 34 TC 24 Z9 25 U1 0 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD FEB 1 PY 2015 VL 68 IS 2 BP 209 EP 216 DI 10.1097/QAI.0000000000000419 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AZ8IF UT WOS:000348458200018 PM 25588033 ER PT J AU Banks, GP Mikell, CB Youngerman, BE Henriques, B Kelly, KM Chan, AK Herrera, D Dougherty, DD Eskandar, EN Sheth, SA AF Banks, Garrett P. Mikell, Charles B. Youngerman, Brett E. Henriques, Bryan Kelly, Kathleen M. Chan, Andrew K. Herrera, Diana Dougherty, Darin D. Eskandar, Emad N. Sheth, Sameer A. TI Neuroanatomical Characteristics Associated With Response to Dorsal Anterior Cingulotomy for Obsessive-Compulsive Disorder SO JAMA PSYCHIATRY LA English DT Article ID TERM-FOLLOW-UP; DEEP BRAIN-STIMULATION; WHITE-MATTER ABNORMALITIES; GAMMA VENTRAL CAPSULOTOMY; VOXEL-BASED MORPHOMETRY; CINGULATE CORTEX; PSYCHIATRIC-DISORDERS; LESION TOPOGRAPHY; NUCLEUS-ACCUMBENS; BEHAVIOR-THERAPY AB IMPORTANCE Approximately 10% of patients with obsessive-compulsive disorder (OCD) have symptoms that are refractory to pharmacologic and cognitive-behavioral therapies. Neurosurgical interventions can be effective therapeutic options in these patients, but not all individuals respond. The mechanisms underlying this response variability are poorly understood. OBJECTIVE To identify neuroanatomical characteristics on preoperative imaging that differentiate responders from nonresponders to dorsal anterior cingulotomy, a neurosurgical lesion procedure used to treat refractory OCD. DESIGN, SETTING, AND PARTICIPANTS We retrospectively analyzed preoperative T1 and diffusion magnetic resonance imaging sequences from 15 patients (9 men and 6 women) who underwent dorsal anterior cingulotomy. Eight of the 15 patients (53%) responded to the procedure. MAIN OUTCOMES AND MEASURES We used voxel-based morphometry (VBM) and diffusion tensor imaging to identify structural and connectivity variations that could differentiate eventual responders from nonresponders. The VBM and probabilistic tractography metrics were correlated with clinical response to the cingulotomy procedure as measured by changes in the Yale-Brown Obsessive Compulsive Scale score. RESULTS Voxel-based morphometry analysis revealed a gray matter cluster in the right anterior cingulate cortex, anterior to the eventual lesion, for which signal strength correlated with poor response (P = .017). Decreased gray matter in this region of the dorsal anterior cingulate cortex predicted improved response (mean [SD] gray matter partial volume for responders vs nonresponders, 0.47 [0.03] vs 0.66 [0.03]; corresponding to mean Yale-Brown Obsessive Compulsive Scale score change, -60%[19] vs -11% [9], respectively). Hemispheric asymmetry in connectivity between the eventual lesion and the caudate (for responders vs nonresponders, mean [SD] group laterality for individual lesion seeds, -0.79 [0.18] vs -0.08 [0.65]; P = .04), putamen (-0.55 [0.35] vs 0.50 [0.33]; P = .001), thalamus (-0.82 [0.19] vs 0.41 [0.24]; P = .001), pallidum (-0.78 [0.18] vs 0.43 [0.48]; P = .001), and hippocampus (-0.66 [0.33] vs 0.33 [0.18]; P = .001) also correlated significantly with clinical response, with increased right-sided connectivity predicting greater response. CONCLUSIONS AND RELEVANCE We identified features of anterior cingulate cortex structure and connectivity that predict clinical response to dorsal anterior cingulotomy for refractory OCD. These results suggest that the variability seen in individual responses to a highly consistent, stereotyped procedure may be due to neuroanatomical variation in the patients. Furthermore, these variations may allow us to predict which patients are most likely to respond to cingulotomy, thereby refining our ability to individualize this treatment for refractory psychiatric disorders. C1 [Banks, Garrett P.; Mikell, Charles B.; Youngerman, Brett E.; Kelly, Kathleen M.; Chan, Andrew K.; Herrera, Diana; Sheth, Sameer A.] Columbia Univ, Neurol Inst, Dept Neurol Surg, New York, NY 10032 USA. [Henriques, Bryan] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Dougherty, Darin D.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Eskandar, Emad N.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. RP Sheth, SA (reprint author), Columbia Univ, Neurol Inst, Dept Neurol Surg, 710 W168th St, New York, NY 10032 USA. EM ss4451@cumc.columbia.edu NR 60 TC 6 Z9 6 U1 3 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD FEB PY 2015 VL 72 IS 2 BP 127 EP 135 DI 10.1001/jamapsychiatry.2014.2216 PG 9 WC Psychiatry SC Psychiatry GA CB2JH UT WOS:000349452800008 PM 25536384 ER PT J AU Simonetti, JA Mackelprang, JL Rowhani-Rahbar, A Zatzick, D Rivara, FR AF Simonetti, Joseph A. Mackelprang, Jessica L. Rowhani-Rahbar, Ali Zatzick, Douglas Rivara, Frederick R. TI Psychiatric Comorbidity, Suicidality, and In-Home Firearm Access Among a Nationally Representative Sample of Adolescents SO JAMA PSYCHIATRY LA English DT Article ID SUPPLEMENT NCS-A; STORAGE PRACTICES; UNITED-STATES; DEPRESSIVE SYMPTOMS; CONTROLLED-TRIAL; CLINICAL-TRIAL; SUBSTANCE USE; RISK; CHILDREN; GUN AB IMPORTANCE Suicide is the second leading cause of death among US adolescents, and in-home firearm access is an independent risk factor for suicide. Given recommendations to limit firearm access by those with mental health risk factors for suicide, we hypothesized that adolescents with such risk factors would be less likely to report in-home firearm access. OBJECTIVES To estimate the prevalence of self-reported in-home firearm access among US adolescents, to quantify the lifetime prevalence of mental illness and suicidality (ie, suicidal ideation, planning, or attempt) among adolescents living with a firearm in the home, and to compare the prevalence of in-home firearm access between adolescents with and without specific mental health risk factors for suicide. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional analysis of data from the National Comorbidity Survey-Adolescent Supplement, a nationally representative survey of 10 123 US adolescents (age range, 13-18 years) who were interviewed between February 2001 and January 2004 (response rate 82.9%). EXPOSURES Risk factors for suicide, including a history of any mental health disorder, suicidality, or any combination of the 2. MAIN OUTCOMES AND MEASURES Self-reported access to a firearm in the home. RESULTS One in three respondents (2778 [29.1%]) of the weighted survey sample reported living in a home with a firearm and responded to a question about firearm access; 1089 (40.9%) of those adolescents reported easy access to and the ability to shoot that firearm. Among adolescents with a firearm in home, those with access were significantly more likely to be older (15.6 vs 15.1 years), male (70.1% vs 50.9%), of non-Hispanic white race/ethnicity (86.6% vs 78.3%), and living in high-income households (40.0% vs 31.8%), and in rural areas (28.1% vs 22.6%) (P < .05 for all). Adolescents with firearm access also had a higher lifetime prevalence of alcohol abuse (10.1% vs 3.8%, P < .001) and drug abuse (11.4% vs 6.9%, P < .01) compared with those without firearm access. In multivariable analyses, adolescents with a history of mental illness without a history of suicidality (prevalence ratio [PR], 1.13; 95% CI, 0.98-1.29) and adolescents with a history of suicidality with or without a history of mental illness (PR, 1.20; 95% CI, 0.96-1.51) were as likely to report in-home firearm access as those without such histories. CONCLUSIONS AND RELEVANCE Adolescents with risk factors for suicide were just as likely to report in-home firearm access as those without such risk factors. Given that firearms are the second most common means of suicide among adolescents, further attention to developing and implementing evidence-based strategies to decrease firearm access in this age group is warranted. C1 [Simonetti, Joseph A.] Univ Washington, Div Gen Internal Med, Dept Med, Seattle, WA 98195 USA. [Simonetti, Joseph A.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Simonetti, Joseph A.; Mackelprang, Jessica L.; Rowhani-Rahbar, Ali; Zatzick, Douglas; Rivara, Frederick R.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA. RP Simonetti, JA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1100 OliveWay,Ste 1400, Seattle, WA 98101 USA. EM simonja@uw.edu OI Mackelprang, Jessica/0000-0001-9135-7811 FU Ruth L. Kirschstein National Research Service Award [T32HP10002]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [T32HD057822]; National Institute of Mental Health [R01 MH/DA46376, R01 MH49098]; National Institute on Drug Abuse [R01 MH/DA46376]; William T. Grant Foundation [90135190] FX During the preparation of the manuscript, Dr Simonetti received fellowship support by grant T32HP10002 from the Ruth L. Kirschstein National Research Service Award, administered by the Health Resources and Services Administration, and Dr Mackelprang received fellowship support by grant T32HD057822 from The Eunice Kennedy Shriver National Institute of Child Health and Human Development. The National Comorbidity Survey is funded by grants R01 MH/DA46376 and R01 MH49098 from the National Institute of Mental Health, by a supplement to grant R01 MH/DA46376 from the National Institute on Drug Abuse, and by grant 90135190 from the William T. Grant Foundation. NR 63 TC 9 Z9 9 U1 6 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD FEB PY 2015 VL 72 IS 2 BP 152 EP 159 DI 10.1001/jamapsychiatry.2014.1760 PG 8 WC Psychiatry SC Psychiatry GA CB2JH UT WOS:000349452800011 PM 25548879 ER PT J AU Solomon, DH Diem, SJ Ruppert, K Lian, YJ Liu, CC Wohlfart, A Greendale, GA Finkelstein, JS AF Solomon, Daniel H. Diem, Susan J. Ruppert, Kristine Lian, Yin Juan Liu, Chih-Chin Wohlfart, Alyssa Greendale, Gail A. Finkelstein, Joel S. TI Bone Mineral Density Changes Among Women Initiating Proton Pump Inhibitors or H2 Receptor Antagonists: A SWAN Cohort Study SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE BONE MINERAL DENSITY; PROTON PUMP INHIBITORS; HORMONE-REPLACEMENT THERAPY; HISTAMINE 2 RECEPTOR ANTAGONISTS ID POSTMENOPAUSAL OSTEOPOROSIS; MULTIETHNIC COHORT; PHYSICAL-ACTIVITY; HIP FRACTURE; RISK; THERAPY; MEDICATIONS; POPULATION; TRANSITION; HEALTH AB Proton pump inhibitors (PPIs) have been associated with diminished bone mineral density (BMD) and an increased risk of fracture; however, prior studies have not yielded consistent results, and many have suboptimal ascertainment of both PPI use and BMD. We used data from the Study of Women's Health Across the Nation (SWAN), a multicenter, multi-ethnic, community-based longitudinal cohort study of women across the menopause transition to examine the association between annualized BMD changes and new use of PPIs. We compared changes in BMD in new PPI users with changes in BMD in new users of histamine 2 receptor antagonists (H2RAs) and with changes in BMD in subjects who did not use either class of medications. Mixed linear regression models included recognized risk factors for osteoporosis, including demographics, menopausal transition stage, body mass index (BMI), lifestyle factors, as well as comorbidities and concomitant medications. To provide further evidence for the validity of our analytic approach, we also examined the effects of hormone-replacement therapy (HT), a class of medications that should reduce bone loss, on changes in BMD as an internal positive control group. We identified 207 new users of PPIs, 185 new users of H2RAs, and 1,676 non-users. Study subjects had a mean age of 50 years and were followed for a median of 9.9 years. Adjusted models found no difference in the annualized BMD change at the lumbar spine, femoral neck, or total hip in PPI users compared with H2RA users or non-users. These results were robust to sensitivity analyses. BMD increased as expected in HT users, supporting the validity of our study design. These longitudinal analyses plus similar prior studies argue against an association between PPI use and BMD loss. (c) 2014 American Society for Bone and Mineral Research. C1 [Solomon, Daniel H.; Liu, Chih-Chin; Wohlfart, Alyssa] Brigham & Womens Hosp, Div Rheumatol, Boston, MA 02115 USA. [Solomon, Daniel H.] Brigham & Womens Hosp, Div Pharmacoepidemiol, Boston, MA 02115 USA. [Diem, Susan J.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Diem, Susan J.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Ruppert, Kristine; Lian, Yin Juan] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Greendale, Gail A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Finkelstein, Joel S.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. RP Solomon, DH (reprint author), Brigham & Womens Hosp, Div Rheumatol, 75 Francis St, Boston, MA 02115 USA. EM dsolomon@partners.org RI Ruppert, Kristine/C-2555-2016 OI Ruppert, Kristine/0000-0002-3008-6584 FU National Institutes of Health (NIH), DHHS, through the National Institute on Aging (NIA) [NR004061, AG012505, AG012535, AG012531, AG012539, AG012546, AG012553, AG012554, AG012495]; National Institutes of Health (NIH), DHHS, through the National Institute of Nursing Research (NINR) [NR004061, AG012505, AG012535, AG012531, AG012539, AG012546, AG012553, AG012554, AG012495]; National Institutes of Health (NIH), DHHS, through the NIH Office of Research on Women's Health (ORWH) FX The Study of Women's Health Across the Nation (SWAN) has grant support from the National Institutes of Health (NIH), DHHS, through the National Institute on Aging (NIA), the National Institute of Nursing Research (NINR), and the NIH Office of Research on Women's Health (ORWH) (grants NR004061; AG012505, AG012535, AG012531, AG012539, AG012546, AG012553, AG012554, AG012495). The funding agencies had no direct role in the design or conduct of the study; the collection, management, analyses, and interpretation of the data; or preparation or approval of the manuscript. NR 25 TC 14 Z9 15 U1 0 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD FEB PY 2015 VL 30 IS 2 BP 232 EP 239 DI 10.1002/jbmr.2344 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CA4CM UT WOS:000348851900005 PM 25156141 ER PT J AU Reppe, S Noer, A Grimholt, RM Halldorsson, BV Medina-Gomez, C Gautvik, VT Olstad, OK Berg, JP Datta, H Estrada, K Hofman, A Uitterlinden, AG Rivadeneira, F Lyle, R Collas, P Gautvik, KM AF Reppe, Sjur Noer, Agate Grimholt, Runa M. Halldorsson, Bjarni V. Medina-Gomez, Carolina Gautvik, Vigdis T. Olstad, Ole Kristoffer Berg, Jens Petter Datta, Harish Estrada, Karol Hofman, Albert Uitterlinden, Andre G. Rivadeneira, Fernando Lyle, Robert Collas, Philippe Gautvik, Kaare M. TI Methylation of Bone SOST, Its mRNA, and Serum Sclerostin Levels Correlate Strongly With Fracture Risk in Postmenopausal Women SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE DISEASES AND DISORDERS OF; RELATED TO BONE; OSTEOPOROSIS; EPIGENETICS; GENETIC RESEARCH; HUMAN ASSOCIATION STUDIES ID VAN-BUCHEM-DISEASE; MINERAL CONTENT; OSTEOPOROSIS; GENE; EXPRESSION; DELETION; DENSITY; PROTEIN; DEFICIENCY; OSTEOCYTES AB Inhibition of sclerostin, a glycoprotein secreted by osteocytes, offers a new therapeutic paradigm for treatment of osteoporosis (OP) through its critical role as Wnt/catenin signaling regulator. This study describes the epigenetic regulation of SOST expression in bone biopsies of postmenopausal women. We correlated serum sclerostin to bone mineral density (BMD), fractures, and bone remodeling parameters, and related these findings to epigenetic and genetic disease mechanisms. Serum sclerostin and bone remodeling biomarkers were measured in two postmenopausal groups: healthy (BMD T-score>-1) and established OP (BMD T-score<-2.5, with at least one low-energy fracture). Bone specimens were used to analyze SOST mRNAs, single nucleotide polymorphisms (SNPs), and DNA methylation changes. The SOST gene promoter region showed increased CpG methylation in OP patients (n=4) compared to age and body mass index (BMI) balanced controls (n=4) (80.5% versus 63.2%, p=0.0001) with replication in independent cohorts (n=27 and n=36, respectively). Serum sclerostin and bone SOST mRNA expression correlated positively with age-adjusted and BMI-adjusted total hip BMD (r=0.47 and r=0.43, respectively; both p<0.0005), and inversely to serum bone turnover markers. Five SNPs, one of which replicates in an independent population-based genomewide association study (GWAS), showed association with serum sclerostin or SOST mRNA levels under an additive model (p=0.0016 to 0.0079). Genetic and epigenetic changes in SOST influence its bone mRNA expression and serum sclerostin levels in postmenopausal women. The observations suggest that increased SOST promoter methylation seen in OP is a compensatory counteracting mechanism, which lowers serum sclerostin concentrations and reduces inhibition of Wnt signaling in an attempt to promote bone formation. (c) 2014 American Society for Bone and Mineral Research. C1 [Reppe, Sjur; Noer, Agate; Grimholt, Runa M.; Olstad, Ole Kristoffer; Berg, Jens Petter; Gautvik, Kaare M.] Oslo Univ Hosp, Dept Med Biochem, NO-0424 Oslo, Norway. [Reppe, Sjur; Gautvik, Kaare M.] Lovisenberg Diakonale Hosp, Oslo, Norway. [Reppe, Sjur; Gautvik, Vigdis T.; Collas, Philippe; Gautvik, Kaare M.] Univ Oslo, Inst Basic Med Sci, Oslo, Norway. [Halldorsson, Bjarni V.] Reykjavik Univ, Dept Biomed Engn, Reykjavik, Iceland. [Medina-Gomez, Carolina; Rivadeneira, Fernando] Erasmus Univ, Med Ctr, Dept Internal Med, Rotterdam, Netherlands. [Berg, Jens Petter] Univ Oslo, Dept Med Biochem, Oslo, Norway. [Datta, Harish] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Estrada, Karol] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Hofman, Albert; Uitterlinden, Andre G.] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands. [Lyle, Robert] Oslo Univ Hosp, Dept Med Genet, NO-0424 Oslo, Norway. [Lyle, Robert] Univ Oslo, Dept Med Genet, Oslo, Norway. RP Reppe, S (reprint author), Oslo Univ Hosp, Dept Med Biochem, NO-0424 Oslo, Norway. EM sjur.reppe@medisin.uio.no RI Rivadeneira, Fernando/O-5385-2015; OI Rivadeneira, Fernando/0000-0001-9435-9441; Halldorsson, Bjarni/0000-0003-0756-0767; Medina-Gomez, Carolina/0000-0001-7999-5538; Berg, Jens P/0000-0003-0157-5888 NR 40 TC 10 Z9 11 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD FEB PY 2015 VL 30 IS 2 BP 249 EP 256 DI 10.1002/jbmr.2342 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CA4CM UT WOS:000348851900007 PM 25155887 ER PT J AU Chang, KK Frankovich, J Cooperstock, M Cunningham, MW Latimer, ME Murphy, TK Pasternack, M Thienemann, M Williams, K Walter, J Swedo, SE AF Chang, Kiki Frankovich, Jennifer Cooperstock, Michael Cunningham, Madeleine W. Latimer, M. Elizabeth Murphy, Tanya K. Pasternack, Mark Thienemann, Margo Williams, Kyle Walter, Jolan Swedo, Susan E. CA PANS Collaborative Consortium TI Clinical Evaluation of Youth with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): Recommendations from the 2013 PANS Consensus Conference SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY LA English DT Article ID MYCOPLASMA-PNEUMONIAE INFECTION; OBSESSIVE-COMPULSIVE DISORDER; STREPTOCOCCAL INFECTIONS; SYDENHAMS CHOREA; ANTINUCLEAR ANTIBODIES; TOURETTES-SYNDROME; CHILDREN; DISEASE; PANDAS; PATHOGENESIS AB On May 23 and 24, 2013, the First PANS Consensus Conference was convened at Stanford University, calling together a geographically diverse group of clinicians and researchers from complementary fields of pediatrics: General and developmental pediatrics, infectious diseases, immunology, rheumatology, neurology, and child psychiatry. Participants were academicians with clinical and research interests in pediatric autoimmune neuropsychiatric disorder associated with streptococcus (PANDAS) in youth, and the larger category of pediatric acute-onset neuropsychiatric syndrome (PANS). The goals were to clarify the diagnostic boundaries of PANS, to develop systematic strategies for evaluation of suspected PANS cases, and to set forth the most urgently needed studies in this field. Presented here is a consensus statement proposing recommendations for the diagnostic evaluation of youth presenting with PANS. C1 [Chang, Kiki] Stanford Univ, Sch Med, Pediat Bipolar Disorders Program, Stanford, CA 94305 USA. [Frankovich, Jennifer] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Cooperstock, Michael] Univ Missouri, Sch Med, Div Infect Dis & Rheumatol, Columbia, MO USA. [Cunningham, Madeleine W.] Univ Oklahoma, Coll Med, Norman, OK 73019 USA. [Latimer, M. Elizabeth] Latimer Neurol Ctr, Bethesda, MD USA. [Murphy, Tanya K.] Univ S Florida, St Petersburg, FL 33701 USA. [Pasternack, Mark] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thienemann, Margo] Stanford Univ, Sch Med, Adjunct Clin Fac, Stanford, CA 94305 USA. [Williams, Kyle] Massachusetts Gen Hosp, Behav & Immunol Clin OCD, Boston, MA 02114 USA. [Williams, Kyle] Massachusetts Gen Hosp, Related Disorders Program, Boston, MA 02114 USA. [Walter, Jolan] Massachusetts Gen Hosp, Pediat Immunodeficiency Program, Boston, MA 02114 USA. [Swedo, Susan E.] NIMH, Pediat & Dev Neurosci Branch, Rockville, MD 20857 USA. RP Chang, KK (reprint author), Stanford Univ, Sch Med, Div Child & Adolescent Psychiat, 401 Quarry Rd, Stanford, CA 94305 USA. EM kchang88@stanford.edu RI Murphy, Tanya/J-7079-2013 FU GlaxoSmithKline; Merck FX Dr. Chang is an unpaid consultant for GlaxoSmithKline, Lilly, and Bristol-Myers Squibb. He is on the DSMB for Sunovion. In the past two years he has received research support from GlaxoSmithKline and Merck. Dr. Walter is on the Advisory Board of Baxter regarding IGHy, a new formulation of subcutaneous immunoglobulin. NR 48 TC 13 Z9 13 U1 6 U2 16 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1044-5463 EI 1557-8992 J9 J CHILD ADOL PSYCHOP JI J. Child Adolesc. Psychopharmacol. PD FEB 1 PY 2015 VL 25 IS 1 SI SI BP 3 EP 13 DI 10.1089/cap.2014.0084 PG 11 WC Pediatrics; Pharmacology & Pharmacy; Psychiatry SC Pediatrics; Pharmacology & Pharmacy; Psychiatry GA CB4RF UT WOS:000349614900002 PM 25325534 ER PT J AU Toufexis, MD Hommer, R Gerardi, DM Grant, P Rothschild, L D'Souza, P Williams, K Leckman, J Swedo, SE Murphy, TK AF Toufexis, Megan D. Hommer, Rebecca Gerardi, Diana M. Grant, Paul Rothschild, Leah D'Souza, Precilla Williams, Kyle Leckman, James Swedo, Susan E. Murphy, Tanya K. TI Disordered Eating and Food Restrictions in Children with PANDAS/PANS SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY LA English DT Article ID OBSESSIVE-COMPULSIVE DISORDER; MYCOPLASMA-PNEUMONIAE INFECTION; ANOREXIA-NERVOSA; NEUROPSYCHIATRIC DISORDERS; STREPTOCOCCAL INFECTIONS; CLINICAL DESCRIPTION; TOURETTES-SYNDROME; BULIMIA-NERVOSA; ADOLESCENTS; CHILDHOOD AB Objective: Sudden onset clinically significant eating restrictions are a defining feature of the clinical presentation of some of the cases of pediatric acute-onset neuropsychiatric syndrome (PANS). Restrictions in food intake are typically fueled by contamination fears; fears of choking, vomiting, or swallowing; and/or sensory issues, such as texture, taste, or olfactory concerns. However, body image distortions may also be present. We investigate the clinical presentation of PANS disordered eating and compare it with that of other eating disorders. Methods: We describe 29 patients who met diagnostic criteria for PANS. Most also exhibited evidence that the symptoms might be sequelae of infections with Group A streptococcal bacteria (the pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections [PANDAS] subgroup of PANS). Results: The clinical presentations are remarkable for a male predominance (2:1 M:F), young age of the affected children (mean=9 years; range 5-12 years), acuity of symptom onset, and comorbid neuropsychiatric symptoms. Conclusions: The food refusal associated with PANS is compared with symptoms listed for the new Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-V) diagnosis of avoidant/restrictive food intake disorder (ARFID). Treatment implications are discussed, as well as directions for further research. C1 [Toufexis, Megan D.; Gerardi, Diana M.; Murphy, Tanya K.] Univ S Florida, Dept Pediat, Rothman Ctr, Div Pediat Neuropsychiat, St Petersburg, FL 33701 USA. [Hommer, Rebecca; Grant, Paul; Rothschild, Leah; D'Souza, Precilla; Swedo, Susan E.] NIMH, Pediat & Dev Neurosci Branch, Bethesda, MD 20892 USA. [Williams, Kyle] Massachusetts Gen Hosp, Pediat Neuropsychiat & Immunol Clin, Boston, MA 02114 USA. [Williams, Kyle] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Leckman, James] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA. [Murphy, Tanya K.] Univ S Florida, Dept Psychiat, Tampa, FL USA. RP Toufexis, MD (reprint author), USF Dept Pediat, Rothman Ctr Pediat Neuropsychiat, 880 6th St South,Suite 460,Box 7523, St Petersburg, FL 33701 USA. EM mtoufexi@health.usf.edu RI Murphy, Tanya/J-7079-2013 FU Intramural Research Program of the NIMH [11-M-0058 (NCT01281969)] FX This research was supported (in part) by the Intramural Research Program of the NIMH, including protocol 11-M-0058 (NCT01281969). NR 50 TC 3 Z9 3 U1 3 U2 13 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1044-5463 EI 1557-8992 J9 J CHILD ADOL PSYCHOP JI J. Child Adolesc. Psychopharmacol. PD FEB 1 PY 2015 VL 25 IS 1 SI SI BP 48 EP 56 DI 10.1089/cap.2014.0063 PG 9 WC Pediatrics; Pharmacology & Pharmacy; Psychiatry SC Pediatrics; Pharmacology & Pharmacy; Psychiatry GA CB4RF UT WOS:000349614900007 PM 25329522 ER PT J AU Freed, RD Tompson, MC Wang, CH Otto, MW Hirshfeld-Becker, DR Nierenberg, AA Henin, A AF Freed, Rachel D. Tompson, Martha C. Wang, Christine H. Otto, Michael W. Hirshfeld-Becker, Dina R. Nierenberg, Andrew A. Henin, Aude TI Family Functioning in the Context of Parental Bipolar Disorder: Associations With Offspring Age, Sex, and Psychopathology SO JOURNAL OF FAMILY PSYCHOLOGY LA English DT Article DE family functioning; conflict; cohesion; bipolar disorder; high-risk offspring ID MAJOR DEPRESSIVE DISORDER; COMORBID ANXIETY DISORDERS; I DISORDER; GENDER-DIFFERENCES; HIGH-RISK; CHILDRENS PSYCHOPATHOLOGY; INTERPARENTAL CONFLICT; ADOLESCENT ADJUSTMENT; EXPRESSED EMOTION; BEHAVIOR PROBLEMS AB Previous research has shown that families with a parent who has bipolar disorder (BD) may experience family functioning difficulties. However, the association between family functioning and psychopathology among offspring of parents with BD, and offspring characteristics that may moderate this association, remains poorly understood. This study examined the cross-sectional associations between family functioning (cohesion, expressiveness, and conflict) and psychopathology in 117 offspring (ages 5-18) of 75 parents with BD. We also examined whether age and sex differences moderated these associations. We measured offspring psychopathology by examining current dimensional symptoms and DSM-IV emotional and behavioral disorders. Correlational analyses indicated that higher family conflict and lower cohesion were associated with higher internalizing and externalizing symptoms in offspring. Lower family cohesion was also associated with current offspring mood disorders. Moderation analyses indicated, first, that the link between lower family cohesion and internalizing symptoms was stronger for younger offspring compared to older offspring. Second, higher family conflict and current mood disorder were associated in younger males but not in older males or in females. Results remained the same after controlling for parental anxiety or substance use disorder comorbidity. Our study highlights the importance of accounting for family functioning when working with offspring at risk for BD, while also recognizing that the connections between family functioning and offspring outcomes are complex and differ based on offspring sex and developmental stage. C1 [Freed, Rachel D.; Tompson, Martha C.; Otto, Michael W.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Wang, Christine H.] Univ Maryland, Dept Psychol, Baltimore, MD USA. [Hirshfeld-Becker, Dina R.; Nierenberg, Andrew A.; Henin, Aude] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Freed, RD (reprint author), Boston Univ, Dept Psychol, 648 Beacon St,4th Floor, Boston, MA 02215 USA. EM rfreed@bu.edu OI Tompson, Martha /0000-0003-0557-7856 FU Brain & Behavior Research Foundation; Brain and Behavior Research Foundation Young Investigator Award; SHINE Initiative; MGH Claflin Award FX This study was funded by two Brain & Behavior Research Foundation (formerly NARSAD) Independent Investigator Awards (Andrew A. Nierenberg), a Brain and Behavior Research Foundation Young Investigator Award (Aude Henin) generously supported in part by the SHINE Initiative, and an MGH Claflin Award (Aude Henin). NR 81 TC 0 Z9 0 U1 1 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0893-3200 EI 1939-1293 J9 J FAM PSYCHOL JI J. Fam. Psychol. PD FEB PY 2015 VL 29 IS 1 BP 108 EP 118 DI 10.1037/fam0000048 PG 11 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA CB4QN UT WOS:000349613000015 PM 25528073 ER PT J AU Taylor, JW Dietrich, J Gerstner, ER Norden, AD Rinne, ML Cahill, DP Stemmer-Rachamimov, A Wen, PY Betensky, RA Giorgio, DH Snodgrass, K Randall, AE Batchelor, TT Chi, AS AF Taylor, Jennie W. Dietrich, Jorg Gerstner, Elizabeth R. Norden, Andrew D. Rinne, Mikael L. Cahill, Daniel P. Stemmer-Rachamimov, Anat Wen, Patrick Y. Betensky, Rebecca A. Giorgio, Diana H. Snodgrass, Kellis Randall, Alison E. Batchelor, Tracy T. Chi, Andrew S. TI Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Glioblastoma; Bosutinib; Src inhibitor; Invasion ID II CLINICAL-TRIALS; ADJUVANT TEMOZOLOMIDE; MALIGNANT GLIOMA; KINASE INHIBITOR; COLON-CANCER; CELLS; DASATINIB; IMATINIB; SKI-606; MICE AB Tumor cell infiltration is a major mechanism of treatment escape in glioblastoma. Src is an intracellular tyrosine kinase that mediates tumor cell motility and invasiveness. We evaluated the efficacy and safety of bosutinib, a tyrosine kinase inhibitor that potently inhibits Src and Abl, in patients with recurrent glioblastoma. In this two-arm study, patients with histologically confirmed recurrent glioblastoma and a parts per thousand currency sign2 relapses, not previously treated with anti-vascular endothelial growth factor (VEGF) therapy, were administered oral bosutinib 400 mg daily. Arm A planned for 6 patients who were candidates for surgical resection to be given bosutinib for 7-9 days prior to resection. Arm B was a two-stage design phase 2 trial targeting 30 patients. The primary endpoint was progression-free survival at 6 months (PFS6) in Arm B. After 9 patients enrolled onto stage 1 of Arm B, 9 (100 %) patients progressed within 6 months. Therefore, the study met the pre-specified criteria for early closure and both Arms were closed. In Arm B, Median PFS was 7.71 weeks and median OS was 50 weeks. Best objective response was stable disease in one patient (11.1 %). Seven patients (77.8 %) had treatment-related AEs of any grade and 2 (22.2 %) were grade a parts per thousand yen3. Arm A was closed after 2 patients enrolled. Src activation was evident in all archival tumor samples. Bosutinib monotherapy does not appear to be effective in recurrent glioblastoma. However, Src remains a potential target based on its upregulation in tumor samples and role in glioma invasion. C1 [Taylor, Jennie W.; Dietrich, Jorg; Gerstner, Elizabeth R.; Batchelor, Tracy T.; Chi, Andrew S.] Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Div Hematol Oncol, Dept Neurol,Canc Ctr, Boston, MA 02114 USA. [Taylor, Jennie W.; Dietrich, Jorg; Gerstner, Elizabeth R.; Norden, Andrew D.; Rinne, Mikael L.; Cahill, Daniel P.; Stemmer-Rachamimov, Anat; Wen, Patrick Y.; Batchelor, Tracy T.; Chi, Andrew S.] Harvard Univ, Sch Med, Boston, MA USA. [Norden, Andrew D.; Rinne, Mikael L.; Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA. [Cahill, Daniel P.] Massachusetts Gen Hosp, Dept Neurosurg, Stephen E & Catherine Pappas Ctr Neurooncol, Ctr Canc, Boston, MA 02114 USA. [Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Betensky, Rebecca A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Sch Med, Boston, MA 02115 USA. [Giorgio, Diana H.; Snodgrass, Kellis; Randall, Alison E.] Pfizer Inc, New York, NY USA. [Batchelor, Tracy T.; Chi, Andrew S.] Massachusetts Gen Hosp, Translat Neurooncol Lab, Boston, MA 02114 USA. RP Chi, AS (reprint author), Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Div Hematol Oncol, Dept Neurol,Canc Ctr, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA. EM Jennie.Taylor@ucsf.edu; chi.andrew@mgh.harvard.edu OI Cahill, Daniel/0000-0003-2552-6546 FU U.S. National Cancer Institute of the National Institutes of Health [K12CA090354]; Richard B. Simches Scholars Award from The Ben and Catherine Ivy Foundation; Early Career Research Award from The Ben and Catherine Ivy Foundation FX J.W.T is supported by U.S. National Cancer Institute of the National Institutes of Health under Award Number K12CA090354. A.S.C. is supported by a Richard B. Simches Scholars Award and an Early Career Research Award from The Ben and Catherine Ivy Foundation. We thank Gino Ferraro and Carolyn Smith for assistance with immunohistochemistry. NR 27 TC 4 Z9 4 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD FEB PY 2015 VL 121 IS 3 BP 557 EP 563 DI 10.1007/s11060-014-1667-z PG 7 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA CB3KU UT WOS:000349527500016 PM 25411098 ER PT J AU Chheda, MG Wen, PY Hochberg, FH Chi, AS Drappatz, J Eichler, AF Yang, D Beroukhim, R Norden, AD Gerstner, ER Betensky, RA Batchelor, TT AF Chheda, Milan G. Wen, Patrick Y. Hochberg, Fred H. Chi, Andrew S. Drappatz, Jan Eichler, April F. Yang, Daniel Beroukhim, Rameen Norden, Andrew D. Gerstner, Elizabeth R. Betensky, Rebecca A. Batchelor, Tracy T. TI Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Clinical trial; Chemotherapy; Glioblastoma ID CELL LUNG-CANCER; MALIGNANT GLIOMA; RECEPTOR; ZD6474; TRIAL; PHARMACOKINETICS; TEMOZOLOMIDE; MULTIFORME; INHIBITOR; TUMORS AB Targeting specific molecular alterations in glioblastoma (GBM) might more effectively kill tumor cells and increase survival. Vandetanib inhibits epidermal growth factor receptor and vascular endothelial growth factor receptor 2. Sirolimus inhibits mammalian target of rapamycin (mTOR), a member the phosphoinositide 3-Kinase signaling pathway. We sought to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of vandetanib combined with sirolimus. Twenty-two patients (14 men; 8 women) with recurrent GBM enrolled. Median age and KPS were 52.5 years and 90 %, respectively. Patients were naive to anti-VEGF and anti-EGF therapy and mTOR inhibitors, and not on CYP3A4-inducing drugs. Vandetanib and sirolimus were orally administered on a continuous daily dosing schedule in escalating dose cohorts. Ten patients enrolled in the dose escalation phase. Twelve more enrolled at the MTD to explore progression-free survival at 6 months (PFS6) in a single arm, single stage phase II-type design. In total, 19 patients received at least one dose at the MTD, and 15 completed at least 1 cycle at MTD. MTD was 200 mg vandetanib plus 2 mg sirolimus. The DLT was elevated AST/SGOT. The most common toxicities were lymphopenia, fatigue, rash, and hypophosphatemia. For 19 patients who received at least one dose at the MTD, including seven from the phase I group, two had a partial response [10.5 %; 95 % CI (1, 33 %)] and PFS6 was 15.8 % [95 % CI (3.9, 34.9 %)]. Vandetanib and sirolimus can be safely co-administered on a continuous, daily dosing schedule. C1 [Chheda, Milan G.; Hochberg, Fred H.; Chi, Andrew S.; Eichler, April F.; Yang, Daniel; Gerstner, Elizabeth R.; Batchelor, Tracy T.] Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Boston, MA 02114 USA. [Wen, Patrick Y.; Beroukhim, Rameen; Norden, Andrew D.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA 02215 USA. [Hochberg, Fred H.] Univ Calif San Diego, Div Neurosurg, San Diego, CA 92103 USA. [Drappatz, Jan] Univ Pittsburg, Med Ctr, Hillman Canc Ctr, Div Hematol & Oncol,Dept Neurol, Pittsburgh, PA 15232 USA. [Drappatz, Jan] Univ Pittsburg, Med Ctr, Hillman Canc Ctr, Div Hematol & Oncol,Dept Med, Pittsburgh, PA 15232 USA. [Drappatz, Jan] Univ Pittsburg, Med Ctr, Hillman Canc Ctr, Neurooncol Program, Pittsburgh, PA 15232 USA. [Eichler, April F.] Wolters Kluwer Hlth, UpToDate, Waltham, MA 02453 USA. [Beroukhim, Rameen] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. [Beroukhim, Rameen] Dana Farber Canc Inst, Ctr Canc Genome Characterizat, Boston, MA 02215 USA. [Betensky, Rebecca A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Batchelor, TT (reprint author), Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Yawkey 9 East,55 Fruit St, Boston, MA 02114 USA. EM tbatchelor@mgh.harvard.edu FU Investigator-Sponsored Study Program of AstraZeneca; NIH [K08 NS062907, K12 CA090354, K24 CA125440]; Brain Tumor Center of Memorial Sloan-Kettering Cancer Center; American Brain Tumor Association Fellowship; American Association for Cancer Research/National Brain Tumor Foundation Fellowship; Richard Floor Bequest FX We gratefully acknowledge Faye Safavi and Karly Griffin for aiding with data collection. This research was conducted with support from the Investigator-Sponsored Study Program of AstraZeneca. Authors received grant support from the NIH (K08 NS062907 and K12 CA090354 Career Development Awards to MGC; K24 CA125440 and K12 CA090354 to TTB), Brain Tumor Center of Memorial Sloan-Kettering Cancer Center, American Brain Tumor Association Fellowship, and American Association for Cancer Research/National Brain Tumor Foundation Fellowship to MGC; and Richard Floor Bequest (FHH). These data were presented in part at the annual meeting of the American Academy of Neurology (2012). NR 28 TC 6 Z9 6 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD FEB PY 2015 VL 121 IS 3 BP 627 EP 634 DI 10.1007/s11060-014-1680-2 PG 8 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA CB3KU UT WOS:000349527500024 PM 25503302 ER PT J AU AlJaroudi, WA Hage, FG AF AlJaroudi, Wael A. Hage, Fadi G. TI Review of Cardiovascular Literature SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article ID CORONARY-ARTERY-DISEASE; RISK C1 [AlJaroudi, Wael A.] Amer Univ Beirut, Med Ctr, Div Cardiovasc Med, Beirut, Lebanon. [Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 314,1900 Univ BLVD, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 6 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2015 VL 22 IS 1 BP 6 EP 8 DI 10.1007/s12350-014-0043-x PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA CA3EZ UT WOS:000348790400003 PM 25515422 ER PT J AU Chatterjee, A Hage, FG AF Chatterjee, Arka Hage, Fadi G. TI Guidelines in review: 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article C1 [Chatterjee, Arka; Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Med, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Chatterjee, A (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Med, Lyons Harrison Res Bldg 314,1900 Univ BLVD, Birmingham, AL 35294 USA. EM arkachatterjee2608@gmail.com NR 2 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2015 VL 22 IS 1 BP 158 EP 161 DI 10.1007/s12350-014-9992-3 PG 4 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA CA3EZ UT WOS:000348790400021 PM 25208531 ER PT J AU Pierre, JF Heneghan, AF Wang, XY Roenneburg, DA Groblewski, GE Kudsk, KA AF Pierre, Joseph F. Heneghan, Aaron F. Wang, Xinying Roenneburg, Drew A. Groblewski, Guy E. Kudsk, Kenneth A. TI Bombesin Improves Adaptive Immunity of the Salivary Gland During Parenteral Nutrition SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article DE parenteral nutrition; salivary glands; parotid; submandibular; sIgA; amylase ID POLYMERIC IMMUNOGLOBULIN RECEPTOR; ENTERIC NERVOUS-SYSTEM; MUCOSAL IMMUNITY; LYMPHOID-TISSUE; FED MICE; BACTERIAL PNEUMONIA; IGA LEVELS; CELLS; IMPAIRMENT; TRANSPORT AB Background: The parotid and submandibular salivary glands are gut-associated lymphoid tissues (GALTs) that secrete immune compounds into the oral cavity. Parenteral nutrition (PN) without enteral stimulation decreases GALT function, including intestinal lymphocyte counts and secretory immunoglobulin A (sIgA) levels. Since the neuropeptide bombesin (BBS), a gastrin-releasing peptide analogue, stimulates intestinal function and restores GALT parameters, we hypothesized that PN + BBS would stimulate parotid and salivary gland IgA levels, T lymphocytes, and IgA plasma cell counts compared with PN alone. Methods: Male (Institute of Cancer Research) ICR mice received intravenous catheters and were randomized to chow with saline, PN, or PN + BBS (15 mu g/tid/mouse) for 5 days (8/group), 2 days after cannulation. Salivary glands were weighed and either frozen for IgA and amylase analysis or fixed for histological analysis of acinar cells, IgA+ plasma cells, and T lymphocytes. Small intestinal wash fluid was collected for IgA regression analysis with salivary glands. Results: PN reduced organ weight, acinar cell size, and amylase activity compared with chow; BBS had no significant effects on these parameters. Compared with chow, PN significantly reduced salivary gland IgA levels, IgA+ plasma cells, and T lymphocytes. PN + BBS significantly elevated IgA and restored cellularity compared with PN. Salivary gland tissue homogenate IgA levels significantly correlated with intestinal fluid IgA levels. Conclusions: Compared with chow, PN results in atrophy of the salivary glands characterized by reduced amylase, IgA, and immune cellularity. BBS has no effect on acinar cells or amylase activity compared with PN but maintains tissue IgA and plasma cells and T-lymphocyte numbers compared with chow. C1 [Pierre, Joseph F.; Heneghan, Aaron F.; Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. [Pierre, Joseph F.; Heneghan, Aaron F.; Wang, Xinying; Roenneburg, Drew A.; Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA. [Wang, Xinying] Nanjing Univ, Sch Med, Jinling Hosp, Dept Surg, Nanjing 210008, Jiangsu, Peoples R China. [Groblewski, Guy E.] Univ Wisconsin, Dept Nutr Sci, Madison, WI 53792 USA. RP Kudsk, KA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, G5-341 Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU Biomedical Laboratory Research & Development Service of the VA Office of Research and Development [I01BX001672] FX This study was supported by Award Number I01BX001672 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development. The contents of this article do not represent the views of the Veterans Affairs or the US government. NR 43 TC 6 Z9 6 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 EI 1941-2444 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD FEB PY 2015 VL 39 IS 2 BP 190 EP 199 DI 10.1177/0148607113507080 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CA7HK UT WOS:000349088200010 PM 24121183 ER PT J AU McCormack, C Lo Gull, R Kalra, M Louissaint, A Stone, J AF McCormack, Carmen Lo Gull, Roberto Kalra, Mannudeep Louissaint, Abner Stone, James TI Reliability of Body Size Measurements Obtained at Autopsy: Impact on the Pathologic Assessment of the Heart SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [McCormack, Carmen; Lo Gull, Roberto; Kalra, Mannudeep; Louissaint, Abner; Stone, James] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 17 BP 8A EP 8A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948000018 ER PT J AU Sajed, D Stone, J AF Sajed, Dipti Stone, James TI An Autopsy Study of Renal Fat Embolization Associated With Extracorporeal Membrane Oxygenation Placement SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Sajed, Dipti; Stone, James] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 24 BP 10A EP 10A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948000025 ER PT J AU Al-Ibraheemi, A Kurek, K Dentino, K Padwa, B Woo, S AF Al-Ibraheemi, Alyaa Kurek, Kyle Dentino, Kelley Padwa, Bonnie Woo, Sook TI Histopathologic Features of Chronic Nonbacterial Sclerosing Osteomyelitis: A Retrospective Review SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Boston Childrens Hosp, Boston, MA USA. Mass Gen Hosp, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 38 BP 14A EP 14A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948000039 ER PT J AU Inyang, A Inwards, C Folpe, A Nielsen, GP Rosenberg, A AF Inyang, Alero Inwards, Carrie Folpe, Andrew Nielsen, G. Petur Rosenberg, Andrew TI Primary Pseudomyogenic Hemangioendothelioma of Bone SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Miami, Miami, FL USA. Mayo Clin, Rochester, MN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 64 BP 19A EP 19A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948000065 ER PT J AU Wojcik, J Mahadevan, K Nielsen, GP Deshpande, V AF Wojcik, John Mahadevan, Krishnan Nielsen, G. Petur Deshpande, Vikrum TI In-Situ Hybridization of MDM2 RNA Is a Useful Adjunct To Immunohistochemistry in the Diagnosis of Atypical Lipomatous Neoplasm/Well-Differentiated Liposarcoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Hosp Univ Penn, Philadelphia, PA 19104 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 102 BP 29A EP 29A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948000103 ER PT J AU Torous, VF Schnitt, S Garber, J Hacker, M Poles, E Alexander, B Lee, L Collins, L Tung, N AF Torous, Vanda Farahmand Schnitt, Stuart Garber, Judy Hacker, Michele Poles, Emily Alexander, Brian Lee, Larissa Collins, Laura Tung, Nadine TI Prevalence of Androgen Receptor Expression in Triple Negative Breast Cancers According To BRCA1 Mutation Status SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 164 BP 44A EP 44A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948000165 ER PT J AU Eng, G Halushka, M Judge, D Semigran, M Stone, J AF Eng, George Halushka, Marc Judge, Daniel Semigran, Marc Stone, James TI Optimization of Serum Free Light Chain Analysis for Rapid and Reliable Subclassification of Cardiac Amyloidosis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 300 BP 78A EP 78A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948000301 ER PT J AU Farhat, N Pei, ZT Krane, J Sadow, P Faquin, W AF Farhat, Nada Pei, Zhengtong Krane, Jeffrey Sadow, Peter Faquin, William TI Cytologic, Histologic and Molecular Features of Primary Thyroid Neoplasms With Signet-Ring Cells SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Barnabas Hlth, Livingston, NJ USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 343 BP 88A EP 88A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948000344 ER PT J AU Holmes, B Brauner, E Krane, J Parangi, S Faquin, W AF Holmes, Brittany Brauner, Eran Krane, Jeffrey Parangi, Sareh Faquin, William TI Performance of the Afirma Gene Expression Classifier in Hurthle Cell Thyroid Nodules SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 363 BP 93A EP 93A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948000364 ER PT J AU Lee, T Phan, R Nham, P Moatamed, N AF Lee, Thomas Phan, Ryan Nham, Phillipp Moatamed, Neda TI Post Hoc Assessment of B-Cell and T-Cell Gene Rearrangements From Cytology Smears SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 375 BP 96A EP 96A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948000376 ER PT J AU Vaickus, L Tambouret, R AF Vaickus, Louis Tambouret, Rosemary TI N:C Ratio Estimation: Just How Accurate Are We? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Vaickus, Louis; Tambouret, Rosemary] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 424 BP 109A EP 109A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948000424 ER PT J AU Kerr, D Busarla, S Sohani, A Nazarian, R AF Kerr, Darcy Busarla, Satya Sohani, Aliyah Nazarian, Rosalynn TI mTOR, PDGFR, and C-Kit Signaling Pathway Activation in Kaposi Sarcoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Aga Khan Hosp, Kisumu, Kenya. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 475 BP 122A EP 122A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948000475 ER PT J AU Mochel, M Piris, A Nose, V Hoang, M AF Mochel, Mark Piris, Adriano Nose, Vania Hoang, Mai TI Loss of Bap1 Expression in Non-Melanoma Skin Cancer in Patients With Germline BAP1 Mutations SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Mochel, Mark; Piris, Adriano; Nose, Vania; Hoang, Mai] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 481 BP 124A EP 124A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948000481 ER PT J AU Fox, S Heide, RV Law, C Faulkner-Jones, B AF Fox, Sharon Heide, Richard Vander Law, C. Faulkner-Jones, Beverly TI Whole-Slide Images Versus Glass Slides for Pathology Resident Education SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 BIDMC, Boston, MA USA. Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA. Kitware Inc, Clifton Pk, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 505 BP 129A EP 129A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001012 ER PT J AU Cipriani, N Dias-Santagata, D Faquin, W Sadow, P AF Cipriani, Nicole Dias-Santagata, Dora Faquin, William Sadow, Peter TI Clear Cell Thyroid Carcinoma: A Clinicopathologic and Molecular Study SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Chicago, Chicago, IL 60637 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 519 BP 133A EP 133A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001026 ER PT J AU Cornejo, K Hutchinson, L St Cyr, M Nose, V Iafrate, AJ Sadow, P AF Cornejo, Kristine Hutchinson, Lloyd St Cyr, Maryann Nose, Vania Iafrate, A. John Sadow, Peter TI MYC Analysis By Fluorescent In Situ Hybridization and Immunohistochemistry in Primary Adrenal Angiosarcoma (PAA) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Massachusetts, Sch Med, Worcester, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 520 BP 133A EP 133A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001027 ER PT J AU Turk, A Asa, S Baloch, Z Du, E Faquin, W Ghossein, R Giordano, T LiVolsi, V Lloyd, R Mete, O Su, H Suster, S Thompson, L Wenig, B AF Turk, Andrew Asa, Sylvia Baloch, Zubair Du, Eugenie Faquin, William Ghossein, Ronald Giordano, Thomas LiVolsi, Virginia Lloyd, Ricardo Mete, Ozgur Su, Henry Suster, Saul Thompson, Lester Wenig, Bruce TI Minimal Extrathyroidal Extension (ETE) and Extranodal Extension (ENE) in Papillary Thyroid Carcinoma: A Consensus Evaluation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Mt Sinai Beth Israel, New York, NY USA. Columbia Univ, New York, NY USA. Univ Penn, Philadelphia, PA 19104 USA. Toronto Gen Hosp, Toronto, ON, Canada. Univ Michigan, Ann Arbor, MI 48109 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Wisconsin, Madison, WI USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. So Calif Permanente Med Grp, Woodland Hills, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 557 BP 142A EP 142A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001064 ER PT J AU Bledsoe, J Huynh, T Mino-Kenudson, M AF Bledsoe, Jacob Huynh, Tiffany Mino-Kenudson, Mari TI Yap1, a Hippo-Pathway Transcriptional Coactivator, Is Overexpressed in Microsatellite-Stable BRAF Mutant Colorectal Adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Bledsoe, Jacob; Huynh, Tiffany; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 587 BP 149A EP 149A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001094 ER PT J AU Borowsky, J Setia, N Lauwers, G Brown, I Rosty, C Conrad, R Susman, R AF Borowsky, Jennifer Setia, Namrata Lauwers, Gregory Brown, Ion Rosty, Christophe Conrad, Rod Susman, Rachel TI Gastrointestinal Tract Pathology in PTEN Hamartoma Tumour Syndrome: A Review of 43 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Pathol Queensland, Brisbane, Qld, Australia. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Envoi Specialist Pathologists, Brisbane, Qld, Australia. Sullivan Nicolaides Pathol, Brisbane, Qld, Australia. Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 589 BP 149A EP 150A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001096 ER PT J AU Cottreau, J Lauwers, G Arnason, T AF Cottreau, Jonathan Lauwers, Gregory Arnason, Thomas TI The Incidence of Epidermoid Metaplasia in 1048 Consecutive Esophageal Tissue Samples and 58 Cases of Esophageal Squamous Neoplasia SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 609 BP 155A EP 155A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001116 ER PT J AU Khor, T Ooi, E Srivastava, A Park, DY Lauwers, G Kumarasinghe, M AF Khor, Tze Ooi, Esther Srivastava, Amitabh Park, Do-Youn Lauwers, Gregory Kumarasinghe, Marian TI HER2 Expression in Dysplasia-Carcinoma Sequence of Barrett Esophagus and Its Role in the Different Pathways of Carcinogenesis in Barrett Esophagus SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. PathWest Lab, Nedlands, WA, Australia. Univ Western Australia, Nedlands, WA 6009, Australia. Brigham & Womens Hosp, Boston, MA 02115 USA. Pusan Natl Univ Hosp, Med Res Inst, Pusan, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 662 BP 168A EP 168A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001169 ER PT J AU Kojima, M Puppa, G Richard, K Basturk, O Frankel, W Vieth, M Lugli, A Sheahan, K Yeh, M Lauwers, G Risio, M Shimazaki, H Iwaya, K Kage, M Akiba, J Ohkura, Y Horiguchi, S Shomori, K Kushima, R Nomura, S Ajioka, Y Adsay, V Ochiai, A AF Kojima, Motohiro Puppa, Giacomo Richard, Kirsch Basturk, Olca Frankel, Wendy Vieth, Michael Lugli, Alessandro Sheahan, Kieran Yeh, Matthew Lauwers, Greg Risio, Mauro Shimazaki, Hideyuki Iwaya, Keiichi Kage, Masayoshi Akiba, Jun Ohkura, Yasuo Horiguchi, Shitzichiro Shomori, Kohei Kushima, Ryoji Nomura, Shogo Ajioka, Yoichi Adsay, Volkan Ochiai, Atsushi TI Construction of an Objective Pathological Diagnostic System of Blood and Lymphatic Vessel Invasion SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Natl Canc Ctr Hosp East, Chiba, Japan. Hop Univ Geneve, Geneva, Switzerland. Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. Klinikum Bayreuth, Bayreuth, Germany. Univ Bern, Bern, Switzerland. St Vincents Univ Hosp, Dublin 4, Ireland. Univ Washington, Sch Med, Seattle, WA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Inst Canc Res & Treatment, Turin, Italy. Natl Def Med Coll, Saitama, Japan. Kurume Univ, Scool Med, Fukuoka, Japan. Kyorin Univ, Grad Sch Med, Tokyo, Japan. Tokyo Metropolitan Komagome Hosp, Tokyo, Japan. Sanin Rosai Hosp, Tottori, Japan. Shiga Univ Med Sci Hosp, Otsu, Shiga, Japan. Niigata Univ, Niigata, Japan. Emory Univ, Sch Med, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 673 BP 171A EP 171A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001180 ER PT J AU Mahadevan, K Ting, D Arora, K Mattia, A Zukerberg, L Lauwers, G Deshpande, V AF Mahadevan, Krishnan Ting, David Arora, Kshitij Mattia, Anthony Zukerberg, Lawrence Lauwers, Gregory Deshpande, Vikram TI LINE-1 Overexpression Is a Hallmark of Gastrointestinal Cancers and Pre-Neoplastic Diseases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Mahadevan, Krishnan; Ting, David; Arora, Kshitij; Mattia, Anthony; Zukerberg, Lawrence; Lauwers, Gregory; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 699 BP 177A EP 178A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001206 ER PT J AU Mahadevan, K Arora, K Rivera, M Ting, D Deshpande, V AF Mahadevan, Krishnan Arora, Kshitij Rivera, Miguel Ting, David Deshpande, Vikram TI Human Papilloma Virus in Rectal Adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Mahadevan, Krishnan; Arora, Kshitij; Rivera, Miguel; Ting, David; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 698 BP 177A EP 177A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001205 ER PT J AU Rosenbaum, M Bledsoe, J Huynh, T Mino-Kenudson, M AF Rosenbaum, Matthew Bledsoe, Jacob Tiffany Huynh Mino-Kenudson, Mari TI Programmed Cell Death Ligand 1 Expression Is Associated With BRAF Mutation, Microsatellite Instability, Medullary Morphology, and Helps To Characterize Tumor Behavior in Colorectal Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Rosenbaum, Matthew; Bledsoe, Jacob; Tiffany Huynh; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 743 BP 188A EP 188A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001250 ER PT J AU Sajed, D MacKenzie, O Arora, K Aryee, M Ting, D Deshpande, V AF Sajed, Dipti MacKenzie, Olivia Arora, Kshitij Aryee, Martin Ting, David Deshpande, Vikram TI LINE-1 RNA In Situ Hybridization: A Novel Application for Assessing Global Methylation Status SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Sajed, Dipti; MacKenzie, Olivia; Arora, Kshitij; Aryee, Martin; Ting, David; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 749 BP 189A EP 189A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001256 ER PT J AU Setia, N Lennerz, J Mullen, J Kwak, E Hong, T Park, DY Lauwers, G AF Setia, Namrata Lennerz, Jochen Mullen, John Kwak, Eunice Hong, Theodore Park, Do Youn Lauwers, Gregory TI Western Series of Early Gastric Cancer: Comparison With Eastern Series and Evaluation of Risk Factors for Lymph Node Metastasis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Pusan Natl Univ Hosp, Pusan, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 762 BP 192A EP 192A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001269 ER PT J AU Setia, N Lennerz, J Srivastava, A Mino-Kenudson, M Lauwers, G AF Setia, Namrata Lennerz, Jochen Srivastava, Amitabh Mino-Kenudson, Mari Lauwers, Gregory TI Test Algorithm for Protein-Expression Based Classification of Gastric Adenocarcinoma Encompassing TCGA and "Mesenchymal" Subtype SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 761 BP 192A EP 192A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001268 ER PT J AU Setia, N Agoston, A Lauwers, G Srivastava, A AF Setia, Namrata Agoston, Agoston Lauwers, Gregory Srivastava, Amitabh TI ARID1A in Gastric Adenocarcinoma: Clincopathologic Features and Association With Expression of p53 and MMR Proteins SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 760 BP 192A EP 192A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001267 ER PT J AU Tse, J Chan, M Zukerberg, L Nazarian, R AF Tse, Julie Chan, May Zukerberg, Lawrence Nazarian, Rosalynn TI Assessment of Melanocyte Density in Anal Mucosa for the Evaluation of Surgical Margins in Primary Anal Melanoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 777 BP 196A EP 196A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001284 ER PT J AU Yang, M Li, ZS Lauwers, G AF Yang, Michelle Li, Zengshan Lauwers, Gregory TI Clinical Significance of Duodenal Mucosa With Normal Villous Architecture and Slightly Increased Intraepithelial Lymphocytes in Pediatric and Adult Populations SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Yang, Michelle; Li, Zengshan; Lauwers, Gregory] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 795 BP 200A EP 200A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001302 ER PT J AU Canete, S Sanchez, D Piris, A Zarza, P Oneto, S Lezcano, C Ayala, G Hoang, M Mihm, M Cubilla, A AF Canete, Sofia Sanchez, Diego Piris, Adriano Zarza, Patricia Oneto, Sabrina Lezcano, Cecilia Ayala, Gustavo Hoang, Mai Mihm, Martin Cubilla, Antonio TI Continuous Spatial Sequences of Lichen Sclerosus (LS), Penile Intraepithelial Neoplasia (PeIN) and Invasive Carcinomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Inst Patol & Invest, Asuncion, Paraguay. UNA, Fac Ciencias Med, Asuncion, Paraguay. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. Univ Texas Houston, Houston, TX USA. RI Sanchez, Diego/K-2398-2016 OI Sanchez, Diego/0000-0002-9503-1947 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 833 BP 210A EP 210A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001340 ER PT J AU Coulson, H Loda, M O'Donnell, E Sweeney, C Hirsch, M AF Coulson, Hannah Loda, Massimo O'Donnell, Elizabeth Sweeney, Christopher Hirsch, Michelle TI Targeted Next Generation Sequencing of Testicular Germ Cell Tumors SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 848 BP 213A EP 213A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001355 ER PT J AU Coulson, H Dal Cin, P Choueiri, T Hirsch, M AF Coulson, Hannah Dal Cin, Paola Choueiri, Toni Hirsch, Michelle TI Chromophobe Renal Cell Carcinoma - A Simplified and Reproducible Two Tier Approach to Tumor Grading SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 847 BP 213A EP 213A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001354 ER PT J AU Fontugne, J Sanda, M Tomlins, S Wei, J Patil, D Ye, HH Park, K Chipman, J Regan, M Scherr, D Siddiqui, J Chinnaiyan, A Rubin, M Mosquera, JM AF Fontugne, Jacqueline Sanda, Martin Tomlins, Scott Wei, John Patil, Dattatraya Ye, Huihui Park, Kyung Chipman, Jonathan Regan, Meredith Scherr, Douglas Siddiqui, Javed Chinnaiyan, Arul Rubin, Mark Mosquera, Juan Miguel TI Correlation of Urinary T2:ERG Fusion Detection and Tissue ERG Expression: Comprehensive Evaluation of Prostatectomy Specimens From the EDRN Study SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Weill Cornell Med Coll, New York, NY USA. Emory Univ, Sch Med, Atlanta, GA USA. Univ Michigan, Sch Med, Ann Arbor, MI USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RI Patil , Dattatraya /H-5682-2015; Sanda, Martin/B-2023-2015 OI Patil , Dattatraya /0000-0002-8242-9825; NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 876 BP 220A EP 220A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001383 ER PT J AU Huang, Y Bowden, M Loda, M AF Huang, Ying Bowden, Michaela Loda, Massimo TI Multiplex TSA-Plus Fluorescence IHC Combined With Spectral Image Analysis for PI3K Pathway Dysregulation in Prostate Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Huang, Ying; Bowden, Michaela; Loda, Massimo] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 917 BP 230A EP 230A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001424 ER PT J AU Kao, CS Cornejo, K Ulbright, T Young, R AF Kao, Chia-Sui Cornejo, Kristine Ulbright, Thomas Young, Robert TI Juvenile Granulosa Cell Tumors (JGCT) of the Testis: A Clinicopathologic Study of 68 Cases With Emphasis on Its Wide Morphologic Spectrum SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Indiana Univ Sch Med, Indianapolis, IN 46202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 925 BP 232A EP 232A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001432 ER PT J AU Kao, CS Cheng, L Ulbright, T Idrees, M AF Kao, Chia-Sui Cheng, Liang Ulbright, Thomas Idrees, Muhammad TI The Utility of SOX9, FOXL2, and SF1 Immunohistochemical (IHC) Stains in the Diagnosis of Testicular Sex Cord-Stromal Tumors (SCST) Compared To Other Commonly Used Markers SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Indiana Univ Sch Med, Indianapolis, IN 46202 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 926 BP 233A EP 233A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001433 ER PT J AU Kehr, E Loda, M Drapkin, R Dal Cin, P Choueiri, T Hirsch, M AF Kehr, Elizabeth Loda, Massimo Drapkin, Ronny Dal Cin, Paola Choueiri, Toni Hirsch, Michelle TI Targeted Next Generation Sequencing of Renal Epithelial Tumors SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RI Drapkin, Ronny/E-9944-2016 OI Drapkin, Ronny/0000-0002-6912-6977 NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 931 BP 234A EP 234A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948001438 ER PT J AU Piris, A Sanchez, D Canete, S Campagnoli, T Gonzalez, L Zarza, P Oneto, S Lezcano, C Rodriguez, I Mihm, M Cubilla, A AF Piris, Adriano Sanchez, Diego Canete, Sofia Campagnoli, Tania Gonzalez, Lorena Zarza, Patricia Oneto, Sabrina Lezcano, Cecilia Rodriguez, Ingrid Mihm, Martin Cubilla, Antonio TI Pathological Features of Penile Lichen Sclerosus (LS) According To a Topographical Method of Evaluation in 200 Patients SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Inst Patol & Invest, Asuncion, Paraguay. Fac Ciencias Med UNA, Asuncion, Paraguay. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. RI Sanchez, Diego/K-2398-2016 OI Sanchez, Diego/0000-0002-9503-1947 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 997 BP 251A EP 251A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002016 ER PT J AU Sanchez, D Rodriguez, I Piris, A Canete, S Lezcano, C Velazquez, E Hoang, M Cubilla, A AF Sanchez, Diego Rodriguez, Ingrid Piris, Adriano Canete, Sofia Lezcano, Cecilia Velazquez, Elsa Hoang, Mai Cubilla, Antonio TI Clear Cell Carcinoma of the Penis. An Unusual and Distinctive HPV-Related Variant of Squamous Cell Carcinoma. A Report of 3 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Inst Patol & Invest, Asuncion, Paraguay. Fac Ciencias Med UNA, Asuncion, Paraguay. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. Miraca Life Sci, Boston, MA USA. Tufts Univ, Boston, MA 02111 USA. RI Sanchez, Diego/K-2398-2016 OI Sanchez, Diego/0000-0002-9503-1947 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1018 BP 256A EP 256A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002037 ER PT J AU Bennett, J Oliva, E Nardi, V Lindeman, N Ferry, J Louissaint, A AF Bennett, Jennifer Oliva, Esther Nardi, Valentina Lindeman, Neal Ferry, Judith Louissaint, Abner TI Primary Extranodal Marginal Zone Lymphoma (MALT)-Like Lymphoid Proliferations of the Endometrium SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1104 BP 276A EP 276A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002123 ER PT J AU Bennett, J Chiang, S Chen, YB Bialik, A Aryee, M Young, R Reuter, V Soslow, R Oliva, E AF Bennett, Jennifer Chiang, Sarah Chen, Ying-Bei Bialik, Ann Aryee, Martin Young, Robert Reuter, Victor Soslow, Robert Oliva, Esther TI Leiomyoma With Bizarre Nuclei: Correlation Between Morphology and Fumarate Hydratase/S-(2-Succino)-Cysteine Expression SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Lahey Hosp & Med Ctr, Burlington, MA USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1102 BP 276A EP 276A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002121 ER PT J AU Bennett, J Oliva, E AF Bennett, Jennifer Oliva, Esther TI Mismatch Repair Protein Defects in Clear Cell Carcinoma of the Ovary: Incidence and Morphologic Associations in 57 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Lahey Hosp & Med Ctr, Burlington, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1103 BP 276A EP 276A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002122 ER PT J AU Chuang, AY Young, R Lerwill, M AF Chuang, Ai-Ying Young, Robert Lerwill, Melinda TI Lobular Carcinoma of the Breast Metastatic To the Ovary SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Koo Fdn Sun Yat Sen Canc Ctr, Taipei, Taiwan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1115 BP 279A EP 279A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002134 ER PT J AU Chuang, AY Young, R Lerwill, M AF Chuang, Ai-Ying Young, Robert Lerwill, Melinda TI Ductal Carcinoma of the Breast Metastatic To the Ovary SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Koo Fdn Sun Yat Sen Canc Ctr, Taipei, Taiwan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1114 BP 279A EP 279A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002133 ER PT J AU Croce, S Ribeiro, A Perot, G Neuville, A MacGrogan, G Young, R Oliva, E Chibon, F AF Croce, Sabrina Ribeiro, Agnes Perot, Gaelle Neuville, Agnes MacGrogan, Gaetan Young, Robert Oliva, Esther Chibon, Frederic TI Leiomyoma With Bizarre Nuclei: Genomic Analysis By Comparative Genomic Hybridization SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Inst Bergonie, Bordeaux, France. Massachusetts Gen Hosp, Boston, MA 02114 USA. RI chibon, frederic/A-2651-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1121 BP 281A EP 281A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002140 ER PT J AU Howitt, B Lee, L Sun, H Viswanathan, A Horowitz, N Liao, XY Crum, C Freeman, G Rodig, S AF Howitt, Brooke Lee, Larissa Sun, Heather Viswanathan, Akila Horowitz, Neil Liao, Xiaoyun Crum, Christopher Freeman, Gordon Rodig, Scott TI Expression of a Therapeutic Target (PD-L1) in HPV+ and HPV-Vulvar Squamous Cell Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber & Brigham & Womens Canc Ctr, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1155 BP 289A EP 289A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002174 ER PT J AU Ip, P Lim, D Cheung, A Oliva, E AF Ip, Philip Lim, Diana Cheung, Annie Oliva, Esther TI lmmunoexpression of p16 in Uterine Leiomyomas With InfarctType Necrosis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. Natl Univ Singapore Hosp, Singapore 117548, Singapore. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1162 BP 291A EP 291A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002181 ER PT J AU Kao, CS Idrees, M Young, R Ulbright, T AF Kao, Chia-Sui Idrees, Muhammad Young, Robert Ulbright, Thomas TI Dissecting Gonadoblastoma of Scully: A Morphologic Variant That Mimics Germinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Indiana Univ Sch Med, Indianapolis, IN 46202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1169 BP 292A EP 292A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002188 ER PT J AU Schoolmeester, J Oliva, E Keeney, G Carlson, J Fritchie, K Young, R Nucci, M AF Schoolmeester, John Oliva, Esther Keeney, Gary Carlson, Joseph Fritchie, Karen Young, Robert Nucci, Marisa TI Alveolar Soft Part Sarcoma of the Female Genital Tract: An Immunohistochemical and Molecular Cytogenetic Study SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Mayo Clin, Rochester, MN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Karolinska Inst, Stockholm, Sweden. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1226 BP 305A EP 305A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002245 ER PT J AU Schultheis, A Conlon, N Piscuoglio, S Silva, A Guerra, E Tornos, C Soslow, R Young, R Oliva, E Weigelt, B AF Schultheis, Anne Conlon, Niamh Piscuoglio, Salvatore Silva, Annacarolina Guerra, Esther Tornos, Carmen Soslow, Robert Young, Robert Oliva, Esther Weigelt, Britta TI A Survey of DICER1 Hotspot Mutations in a Range of Ovarian Sex Cord Stromal Tumor Subtypes SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Stony Brook Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1228 BP 306A EP 306A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002247 ER PT J AU Silva, A Ali, R Aryee, M Lee, CH Oliva, E AF Silva, Annacarolina Ali, Rola Aryee, Martin Lee, Cheng-Han Oliva, Esther TI Old Versus New FIGO Staging System for Predicting Outcome in Uterine Endometrial Stromal Sarcomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Alberta, Edmonton, AB, Canada. Kuwait Univ, Hlth Sci Ctr, Safat, Kuwait. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1231 BP 307A EP 307A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002250 ER PT J AU Stall, J Young, R AF Stall, Jennifer Young, Robert TI Granulosa Theca Cell Tumor of the Ovary: A Report of Twenty-Two Cases of an Entity That Should Be Distinguished From Diffuse Adult Granulosa Cell Tumor SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1240 BP 309A EP 309A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002259 ER PT J AU Watkins, J Hinchclijf, E del Carmen, M Rauh-Hain, A Esselen, K Muto, M Quade, B AF Watkins, Jaclyn Hinchclijf, Emily del Carmen, Marcela Rauh-Hain, Alejandro Esselen, Katharine Muto, Michael Quade, Bradley TI Preoperative Detection of Uterine Leiomyosarcoma By Endometrial Biopsy: An Examination of Clinical and Histologic Features SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1256 BP 314A EP 314A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002275 ER PT J AU Arora, K Kerr, D Mahadevan, K Hornick, J Krane, J Rivera, M Ting, D Nose, V Sadow, P Deshpande, V Faquin, W AF Arora, Kshitij Kerr, Darcy Mahadevan, Krishnan Hornick, Jason Krane, Jeffrey Rivera, Miguel Ting, David Nose, Vania Sadow, Peter Deshpande, Vikram Faquin, William TI Performance of a Branch Chain RNA In-Situ Hybridization Assay for the Detection of High-Risk Human Papillomavirus in Head and Neck Squamous Cell Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1277 BP 319A EP 319A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002296 ER PT J AU Carey, C Sun, H Stack, E Peterson, M Hoyt, C Johnson, K Freeman, G Loda, M Shipp, M Rodig, S Bowden, M AF Carey, Chris Sun, Heather Stack, Edward Peterson, Michael Hoyt, Clifford Johnson, Kent Freeman, Gordon Loda, Massimo Shipp, Margaret Rodig, Scott Bowden, Michaela TI A Novel Method for the Simultaneous Assessment of PDL1 Expression in the Tumor Cells and Tumor Associated Macrophages of Classical Hodgkin Lymphoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. PerkinElmer, Waltham, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1356 BP 339A EP 339A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002375 ER PT J AU Geyer, J Hasserjian, R Wang, S Orazi, A AF Geyer, Julia Hasserjian, Robert Wang, Sa Orazi, Attilio TI Oligomonocytic Chronic Myelomonocytic Leukemia: Can the Threshold for Peripheral Blood Monocytosis Be Lowered? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Weill Cornell Med Coll, New York, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1381 BP 345A EP 345A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002399 ER PT J AU Kluk, M Lindsley, RC Szeto, D Zepf, D Aster, J Lindeman, N Kuo, F AF Kluk, Michael Lindsley, R. Coleman Szeto, David Zepf, Dimity Aster, Jon Lindeman, Neal Kuo, Frank TI Validation and Implementation of a Custom Next Generation Sequencing Assay for Clinical Testing of Hematologic Neoplasms SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1419 BP 355A EP 356A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002437 ER PT J AU Liu, H Medeiros, LJ Weisenburger, D Clemens, M Hunt, K Chai, S Amin, M Vadlamani, I Sohani, A Ferry, J Morgan, EA Parkash, V Bhagat, G Yang, LJ Thomazy, V Kanagal-Shamanna, R Vasef, M Herman, C Oyarzo, M Narbaitz, M Piccolini, J Lamar, W Porter, W Hughes, C Baptista, M Tritz, D Zhang, D Khoury, J Young, K Miranda, R AF Liu, Hui Medeiros, L. Jeffrey Weisenburger, Dennis Clemens, Mark Hunt, Kelly Chai, Slaw Amin, Mitual Vadlamani, Indira Sohani, Aliyah Ferry, Judith Morgan, Elizabeth A. Parkash, Vinita Bhagat, Govind Yang, Li-Jun Thomazy, Vilmos Kanagal-Shamanna, Rashmi Vasef, Mohammad Herman, Christopher Oyarzo, Mauricio Narbaitz, Marina Piccolini, Jorge Lamar, Walter Porter, William Hughes, Condon, III Baptista, Matt Tritz, Denise Zhang, Da Khoury, Joseph Young, Ken Miranda, Roberto TI Breast Implant-Associated Anaplastic Large Cell Lymphoma (BI-ALCL): A Comprehensive Histopathological Evaluation of 40 Cases With a Proposal for a Pathologic Staging System SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Xuzhou Med Coll, Xuzhou, Jiangsu, Peoples R China. City Hope Natl Med Ctr, Duarte, CA USA. William Beaumont Hosp, Royal Oak, MI 48072 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Yale Univ, Bridgeport, CT USA. Columbia Univ, Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1435 BP 360A EP 360A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002453 ER PT J AU O'Malley, D Andersen, E Paxton, C Louissaint, A Hornick, J Griffin, G Fedoriw, Y Kim, Y Weiss, L South, S AF O'Malley, Dennis Andersen, Erica Paxton, Christian Louissaint, Abner Hornick, Jason Griffin, Gabriel Fedoriw, Yuri Kim, Young Weiss, Lawrence South, Sarah TI Genetic Array Analysis of Follicular Dendritic Cell Sarcoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Clarient Pathol Serv, Aliso Viejo, CA USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Univ N Carolina, Sch Med, Chapel Hill, NC USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1468 BP 368A EP 368A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002486 ER PT J AU Pozdnyakova, O Hasserjian, R Fathi, A DeAngelo, D Morgan, E AF Pozdnyakova, Olga Hasserjian, Robert Fathi, Amir DeAngelo, Daniel Morgan, Elizabeth TI Lack of Detectable CD19 Expression By Flow Cytometry in B-Lineage Cells Following Administration of an Antibody-Drug Conjugate Targeting CD19 SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1482 BP 372A EP 372A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002500 ER PT J AU Rosenbaum, M Pozdnyakova, O Geyer, J Dal Cin, P Hasserjian, R AF Rosenbaum, Matthew Pozdnyakova, Olga Geyer, Julia Dal Cin, Paola Hasserjian, Robert TI Ring Chromosome in Myeloid Neoplasms Is Associated With Genetic Instability and Complex Hypodiploid Karyotype SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. New York Presbyterian Hosp, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1491 BP 374A EP 374A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002509 ER PT J AU Ryan, R Drier, Y Whitton, H Gillespie, S Epstein, C Hochberg, E Sohni, A Bernstein, B AF Ryan, Russell Drier, Yotam Whitton, Holly Gillespie, Shawn Epstein, Charles Hochberg, Ephraim Sohni, Aliyah Bernstein, Bradley TI Detection of Oncogenic Rearrangements By Enrichment of Regulatory DNA Elements SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Broad Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1497 BP 376A EP 376A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948002515 ER PT J AU van Slambrouck, C Huh, J Sub, C Song, J Menon, M Sohani, A Hyjek, E Venkataraman, G AF van Slambrouck, Charles Huh, Jooryung Sub, Cheolwon Song, Joo Menon, Madhu Sohani, Aliyah Hyjek, Elizabeth Venkataraman, Girish TI Nuclear Staining for Stat6 With the YE361 Monoclonal Antibody Is Restricted To Classical Hodgkin Lymphoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Chicago, Chicago, IL 60637 USA. Henry Ford Hlth Syst, Detroit, MI USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Asan Univ, Seoul, South Korea. Massachusetts Gen Hosp, Boston, MA 02114 USA. Toronto Gen Hosp, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1522 BP 382A EP 383A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003023 ER PT J AU Wang, SA Pozdnyakova, O Peng, J Hasserjian, R AF Wang, Sa A. Pozdnyakova, Olga Peng, Jie Hasserjian, Robert TI Acute Erythroleukemia and Refractory Anemia With Excess Blasts: One Single or Two Distinct Entities? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1528 BP 384A EP 384A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003029 ER PT J AU Weinberg, O Pozdnyakova, O Campigotto, F DeAngelo, D Stone, R Neuberg, D Hasserjian, R AF Weinberg, Olga Pozdnyakova, Olga Campigotto, Federico DeAngelo, Daniel Stone, Richard Neuberg, Donna Hasserjian, Robert TI Reproducibility and Prognostic Significance of Morphologic Dysplasia in De Novo AML SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Boston Childrens Hosp, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1534 BP 385A EP 386A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003035 ER PT J AU Xu, J Sun, H Morgan, E Shipp, M Pinkus, G Freeman, G Rodig, S AF Xu, Jie Sun, Heather Morgan, Elizabeth Shipp, Margaret Pinkus, Geraldine Freeman, Gordon Rodig, Scott TI Differential Expression of PD-L2 in T-Cell Lymphomas Suggests Novel Candidates for PD-1 Directed Immunotherapy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1546 BP 388A EP 389A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003047 ER PT J AU Xu, J Sun, H Morgan, E Pinkus, G Hornick, J Fletcher, C Freeman, G Rodig, S AF Xu, Jie Sun, Heather Morgan, Elizabeth Pinkus, Geraldine Hornick, Jason Fletcher, Christopher Freeman, Gordon Rodig, Scott TI Expression of the Immunosuppressive Molecules PD-L1 and PD-L2 By Histiocytic and Dendritic Cell Neoplasms: Novel Candidates for PD-1 Pathway Immunotherapy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1547 BP 389A EP 389A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003048 ER PT J AU Fox, S Vander Heide, R Law, C Faulkner-Jones, B AF Fox, Sharon Vander Heide, Richard Law, C. Faulkner-Jones, Beverly TI Gaze Pattern During Diagnostic Exploration of Whole-Slide Images and Glass Slides SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 BIDMC, Boston, MA USA. Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA. Kitware Inc, Clifton Pk, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1580 BP 396A EP 396A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003081 ER PT J AU Fulton, E Burns, K Ward, A Law, C Faulkner-Jones, B AF Fulton, Edward Burns, Kristin Ward, Ashley Law, C. Faulkner-Jones, Beverly TI Alopecia Diagnosis: 3D Analysis of Aligned Serial Whole Slide Images SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 BIDMC, Boston, MA USA. Kitware Inc, Clifton Pk, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1581 BP 397A EP 397A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003082 ER PT J AU Batal, I De Serres, S Onozato, M Najafian, N Chandraker, A AF Batal, Ibrahim De Serres, Sacha Onozato, Maristela Najafian, Nader Chandraker, Anil TI Dendritic Cells (DCs) in Kidney Transplant Biopsies Cluster With T Lymphocytes and Are Associated with Graft and Systemic Inflammatory Milieu and Poor Allograft Survival SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1609 BP 404A EP 405A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003110 ER PT J AU Tuecking, M Sieber, J Mundel, P Weins, A AF Tuecking, Marcel Sieber, Jonas Mundel, Peter Weins, Astrid TI Hic-5 Protects Podocytes From Genotoxic Cell Death By Stabilizing p21 SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1648 BP 414A EP 414A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003149 ER PT J AU Shinagare, S Deshpande, V AF Shinagare, Shweta Deshpande, Vikram TI Role of Arginase-1 and Hep Par 1 in Distinguishing Hepatocellular Carcinoma From lntrahepatic Cholangiocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Tufts Med Ctr, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1691 BP 423A EP 424A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003191 ER PT J AU Abedalthagafi, M Bi, WL Mei, Y Alexander, B Beroukhim, R Al-Mefty, O Dunn, I Ligon, A Santagata, S AF Abedalthagafi, Malak Bi, Wenya Linda Mei, Yu Alexander, Brian Beroukhim, Rameen Al-Mefty, Ossama Dunn, Ian Ligon, Azra Santagata, Sandro TI Genomic Alterations in Skull Base Meningiomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1706 BP 427A EP 427A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003206 ER PT J AU Miller, M Bi, WL Ramkissoon, L Abedalthagafi, M Kang, YJ Knoff, D Dunn, I Wen, P Reardon, D Alexander, B Laws, E Beroukhim, R Ligon, K Ramkissoon, S AF Miller, Michael Bi, Wenya Linda Ramkissoon, Lori Abedalthagafi, Malak Kang, Yun Jee Knoff, David Dunn, Ian Wen, Patrick Reardon, David Alexander, Brian Laws, Edward, Jr. Beroukhim, Rameen Ligon, Keith Ramkissoon, Shakti TI MAPK Activation and HRAS Mutations Identified in Pituitary Spindle Cell Oncocytoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1733 BP 434A EP 434A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003233 ER PT J AU Ramkissoon, S Bi, WY Schumacher, S Ramkissoon, L Haidar, S Knoff, D Dubuc, A Brown, L Abedalthagafi, M Reardon, D Dunn, I Santagata, S Folkerth, R Wen, P Ligon, A Alexander, B Beroukhim, R Ligon, K AF Ramkissoon, Shakti Bi, Wenya Schumacher, Steven Ramkissoon, Lori Haidar, Sam Knoff, David Dubuc, Adrian Brown, Loreal Abedalthagafi, Malak Reardon, David Dunn, Ian Santagata, Sandra Folkerth, Rebecca Wen, Patrick Ligon, Azra Alexander, Brian Beroukhim, Rameen Ligon, Keith TI Clinical Implementation of Integrated Whole Genome Copy-Number and Mutation Profiling for Glioblastoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1742 BP 435A EP 435A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003242 ER PT J AU Conner, J Garcia, E Marino-Enriquez, A Pitman, M Mino-Kenudson, M Sholl, L Srivastava, A Doyle, LA AF Conner, James Garcia, Elizabeth Marino-Enriquez, Adrian Pitman, Martha Mino-Kenudson, Mari Sholl, Lynette Srivastava, Amitabh Doyle, Leona A. TI Genomic Characterization of Neoplastic Progression in Pancreatic Mucinous Cystic Neoplasm SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1764 BP 440A EP 441A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003264 ER PT J AU Dudley, J Zheng, ZL Le, L Batten, J Vernovslry, K Sweeney, B Arpin, R Brugge, W Pitman, M Lafrate, A AF Dudley, Jonathan Zheng, Zongli Le, Long Batten, Julie Vernovslry, Kathy Sweeney, Brenda Arpin, Ronald Brugge, William Pitman, Martha Lafrate, Anthony TI Next-Generation Sequencing and Fluorescence In Situ Hybridization in the Analysis of Bile Duct Brushings for Malignancy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Dudley, Jonathan; Zheng, Zongli; Le, Long; Batten, Julie; Vernovslry, Kathy; Sweeney, Brenda; Arpin, Ronald; Brugge, William; Pitman, Martha; Lafrate, Anthony] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1767 BP 441A EP 441A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003267 ER PT J AU Gupta, R Deshpande, V Patton, K Behrman, S Xie, B AF Gupta, Rajib Deshpande, Vikram Patton, Kurt Behrman, Stephen Xie, Bill TI Follicular Pancreatitis: A Mimic of Pancreatic Malignancy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Pathol Grp Midsouth, Germantown, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1773 BP 443A EP 443A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003273 ER PT J AU Jones, M Zheng, ZL Wang, J Albanese, E Kadayifci, A Dias-Santagata, D Le, L Brugge, W Fernandez-del Castillo, C Mino-Kenudson, M Lafrate, AJ Pitman, M AF Jones, Martin Zheng, Zongli Wang, Jessica Albanese, Emily Kadayifci, Abdurrahman Dias-Santagata, Dora Le, Long Brugge, William Fernandez-del Castillo, Carlos Mino-Kenudson, Mari Lafrate, A. John Pitman, Martha TI Impact of Next-Generation Sequencing on the Clinical Impression of Pancreatic Cysts SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Jones, Martin; Zheng, Zongli; Wang, Jessica; Albanese, Emily; Kadayifci, Abdurrahman; Dias-Santagata, Dora; Le, Long; Brugge, William; Fernandez-del Castillo, Carlos; Mino-Kenudson, Mari; Lafrate, A. John; Pitman, Martha] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1777 BP 444A EP 444A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003277 ER PT J AU Scourtas, A Dudley, J Brugge, W Kadayifci, A Mino-Kenudson, M Pitman, M AF Scourtas, Aristana Dudley, Jonathan Brugge, William Kadayifci, Abdurrahman Mino-Kenudson, Mari Pitman, Martha TI Clinicopathologic Characteristics of 136 Mucinous Cystic Neoplasms SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Scourtas, Aristana; Dudley, Jonathan; Brugge, William; Kadayifci, Abdurrahman; Mino-Kenudson, Mari; Pitman, Martha] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1796 BP 448A EP 449A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003296 ER PT J AU Kuo, F Szeto, D Zepf, D Jia, YH Garcia, E Macconaill, L Aster, J AF Kuo, Frank Szeto, David Zepf, Dimity Jia, Yonghui Garcia, Elizabeth Macconaill, Laura Aster, Jon TI Spectrum of Notch Gene Mutations in Diverse Human Cancers SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1840 BP 459A EP 459A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003340 ER PT J AU Lee, J Lindeman, N Chin, G Luke, J Ott, P Hodi, FS Granter, S Laga, A Yoon, C Haynes, H Werchniak, A Lin, J Liu, R Bailey, N Murphy, G Lian, C AF Lee, Jonathan Lindeman, Neal Chin, Gary Luke, Jason Ott, Patrick Hodi, F. Stephen Granter, Scott Laga, Alvaro Yoon, Charles Haynes, Harley Werchniak, Andrew Lin, Jennifer Liu, Robert Bailey, Nancy Murphy, George Lian, Christine TI Targeted Next Generation Sequencing of Treatment-Naive Metastatic Melanoma Specimens Reveals High Frequency of Epigenetic Alterations SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1841 BP 459A EP 460A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003341 ER PT J AU Lindeman, N Sholl, L Garcia, E Ducar, M Kuo, F Leslin, C MacConaill, L AF Lindeman, Neal Sholl, Lynette Garcia, Elizabeth Ducar, Matt Kuo, Frank Leslin, Chesley MacConaill, Laura TI Profile: Exome Sequencing of 4027 Cancer Samples in a Clinical Laboratory SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1842 BP 460A EP 460A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003342 ER PT J AU Bozkurtlar, E Uruga, H Hariri, L Mino-Kenudson, M Mark, E AF Bozkurtlar, Emine Uruga, Hironori Hariri, Lida Mino-Kenudson, Mari Mark, Eugene TI Idiopathic Tracheal Stenosis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Marmara Univ, Istanbul, Turkey. Toranomon Gen Hosp, Tokyo, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1898 BP 474A EP 474A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003398 ER PT J AU Bozkurtlar, E Uruga, H Huynh, T Lanuti, M Mark, E Mino-Kenudson, M AF Bozkurtlar, Emine Uruga, Hironori Huynh, Tiffany Lanuti, Michael Mark, Eugene Mino-Kenudson, Mari TI Comparison of Programmed Cell Death Ligand 1 (PD-L1) Expression in Main Tumor and Lymph Node Metastasis of Stage II and III Lung Adenocarcinomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Bozkurtlar, Emine; Uruga, Hironori; Huynh, Tiffany; Lanuti, Michael; Mark, Eugene; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1897 BP 474A EP 474A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003397 ER PT J AU Bozkurtlar, E Uruga, H Huynh, T Lanuti, M Mark, E Mino-Kenudson, M AF Bozkurtlar, Emine Uruga, Hironori Huynh, Tiffany Lanuti, Michael Mark, Eugene Mino-Kenudson, Mari TI SOX-2 Expression and Its Prognostic Value in Stage II and III Lung Adenocarcinomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Bozkurtlar, Emine; Uruga, Hironori; Huynh, Tiffany; Lanuti, Michael; Mark, Eugene; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1899 BP 474A EP 474A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003399 ER PT J AU Brachtel, E Huynh, T Mino-Kenudson, M AF Brachtel, Elena Huynh, Tiffany Mino-Kenudson, Mari TI P40 and GATA-3 Are Useful To Distinguish Between Lung Squamous Cell Carcinoma and Triple Negative Breast Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Brachtel, Elena; Huynh, Tiffany; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1900 BP 474A EP 474A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003400 ER PT J AU Huynh, T Uruga, H Bozkurtlar, E Mark, E Mino-Kenudson, M AF Huynh, Tiffany Uruga, Hironori Bozkurtlar, Emine Mark, Eugene Mino-Kenudson, Mari TI Clinicopathological and Molecular Features Associated With Programmed Cell Death Ligand 1 (PD-L1) Expression in Resected Lung Adenocarcinomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Huynh, Tiffany; Uruga, Hironori; Bozkurtlar, Emine; Mark, Eugene; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1917 BP 478A EP 478A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003416 ER PT J AU Huynh, T Chi, A Uruga, H Bozkurtlar, E Mark, E Mino-Kenudson, M AF Huynh, Tiffany Chi, Anthony Uruga, Hironori Bozkurtlar, Emine Mark, Eugene Mino-Kenudson, Mari TI Clinicopatholgical and Molecular Features Associated With Programmed Cell Death Ligand 1 (PD-L1) Expression in Resected Lung Squamous Cell Carcinomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Huynh, Tiffany; Chi, Anthony; Uruga, Hironori; Bozkurtlar, Emine; Mark, Eugene; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1916 BP 478A EP 478A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003415 ER PT J AU Matsubara, O Ishikawa, Y Nakatani, Y Mark, E AF Matsubara, Osamu Ishikawa, Yuichi Nakatani, Yukio Mark, Eugene TI Pathological Role of Fibroblastic Foci and Bronchiolar Epithelial Proliferation in Idiopathic Pulmonary Fibrosis (IPF)/Usual Interstitial Pneumonia (UIP) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Japanese Fdn Canc Res, Inst Canc, Tokyo 170, Japan. Hiratsuka Kyosai Hosp, Hiratsuka, Kanagawa, Japan. Chiba Univ, Chiba, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1941 BP 484A EP 484A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003440 ER PT J AU Aisagbonhi, O Ly, A AF Aisagbonhi, Omonigho Ly, Amy TI Utility of Flow Cytometry in the Pathologic Evaluation of Tonsils and Adenoids SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Aisagbonhi, Omonigho; Ly, Amy] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 1987 BP 494A EP 495A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003486 ER PT J AU Mahadevan, K Bhan, A Deshpande, V Brachtel, E AF Mahadevan, Krishnan Bhan, Atul Deshpande, Vikram Brachtel, Elena TI Triple Negative Breast Cancers Evaluated By Amplified mRNA In-Situ Hybridization for Estrogen Receptor-Alpha SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 [Mahadevan, Krishnan; Bhan, Atul; Deshpande, Vikram; Brachtel, Elena] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 2083 BP 519A EP 519A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948003582 ER PT J AU Hu, Y Song, W Cirstea, D Lu, D Munshi, NC Anderson, KC AF Hu, Y. Song, W. Cirstea, D. Lu, D. Munshi, N. C. Anderson, K. C. TI CSNK1 alpha 1 mediates malignant plasma cell survival SO LEUKEMIA LA English DT Article ID CASEIN KINASE-I; GROWTH-FACTOR RECEPTOR-3; MULTIPLE-MYELOMA; MOLECULAR PATHOGENESIS; EXPRESSION SIGNATURE; THERAPEUTIC TARGETS; INDUCED APOPTOSIS; C-MYC; PHOSPHORYLATION; CANCER AB Here we report that targeting casein kinase 1-alpha 1 (CSNK1 alpha 1) is a potential novel treatment strategy in multiple myeloma (MM) therapy distinct from proteasome inhibition. CSNK1 alpha 1 is expressed in all the tested MM cell lines and patient MM cells, and is not altered during bortezomib-triggered cytotoxicity. Inhibition of CSNK1 alpha 1 kinase activity in MM cells with targeted therapy D4476 or small hairpin RNAs triggers cell G0/G1-phase arrest, prolonged G2/M phase and apoptosis. D4476 also induced cytotoxicity in bortezomib-resistant MM cells and enhanced bortezomib-triggered cytotoxicity. CSNK1 alpha 1 signaling pathways include CDKN1B, P53 and FADD; gene signatures involved included interferon-alpha, tumor necrosis factor-alpha and LIN9. In addition, reduction of Csnk1 alpha 1 prevents cMYC/KRAS12V transformation of BaF3 cells independent of interleukin-3. Impartially, reducing Csnk1 alpha 1 prevented development of cMYC/KRAS12V-induced plasmacytomas in mice, suggesting that CSNK1 alpha 1 may be involved in MM initiation and progression. Our data suggest that targeting CSNK1 alpha 1, alone or combined with bortezomib, is a potential novel therapeutic strategy in MM. Moreover, inhibition of CSNK1 alpha 1 may prevent the progression of monoclonal gammopathy of undetermined significance to MM. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res,Dept Med O, Boston, MA 02115 USA. RP Anderson, KC (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA. EM kenneth_anderson@dfci.harvard.edu FU National Institutes of Health [P50-100707, P01-78378, RO1-50947] FX We thank Mei Zheng for performing the histological sections; Reddy Gali, who is part of Harvard Catalyst grant member, for his conduction in microarray analysis; the Microarray and the Flow Cytometry Core Facilities at Dana-Farber Cancer Institute for technical support. This study was supported in part by National Institutes of Health Grants P50-100707, P01-78378 and RO1-50947. KCA is an American Cancer Society Clinical Research Professor. NR 41 TC 6 Z9 8 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 EI 1476-5551 J9 LEUKEMIA JI Leukemia PD FEB PY 2015 VL 29 IS 2 BP 474 EP 482 DI 10.1038/leu.2014.202 PG 9 WC Oncology; Hematology SC Oncology; Hematology GA CB2GL UT WOS:000349445000025 PM 24962017 ER PT J AU Suzuki, R Hideshima, T Mimura, N Minami, J Ohguchi, H Kikuchi, S Yoshida, Y Gorgun, G Cirstea, D Cottini, F Jakubikova, J Tai, YT Chauhan, D Richardson, PG Munshi, NC Utsugi, T Anderson, KC AF Suzuki, R. Hideshima, T. Mimura, N. Minami, J. Ohguchi, H. Kikuchi, S. Yoshida, Y. Gorgun, G. Cirstea, D. Cottini, F. Jakubikova, J. Tai, Y-T Chauhan, D. Richardson, P. G. Munshi, N. C. Utsugi, T. Anderson, K. C. TI Anti-tumor activities of selective HSP90 alpha/beta inhibitor, TAS-116, in combination with bortezomib in multiple myeloma SO LEUKEMIA LA English DT Letter ID CELLS; APOPTOSIS; INDUCE AB Heat shock protein 90 (HSP90) is a highly conserved molecular chaperone that interacts with various client proteins in eukaryotic cells:(1) Akt (PI3K/Akt pathway), interleukin-6 R (JAK/STAT pathway), Bcr-Abl (RAS/ERK pathway), Cyclin-dependent kinase 4, 6, 9 (cell cycling) and I kappa B kinases (NF-kappa B pathway).(2) The expression of HSP90 is upregulated (2- to 10-fold) in tumor cells compared with normal cells, reflecting multiple oncogenic pathways and maintenance of homeostasis within tumor cells.(1,2) Because HSP90 inhibition triggers downregulation /degradation of client proteins and triggers apoptosis, it is considered a promising target for novel targeted therapies. Indeed HSP90 inhibitors (for example, geldanamycin analog 17-allylamino-17-demethoxy-geldanamycin (17-AAG), resorcinol derivatives, purine analogs) have shown early promising results in vitro and in vivo in solid tumors and some hematological malignancies, including multiple myeloma (MM).(3,4) However, some clinical studies have been discontinued due to adverse effects, including ocular toxicity.(3,5) Therefore, development of a next-generation less-toxic HSP90 inhibitor remains an important therapeutic goal. C1 [Suzuki, R.; Hideshima, T.; Mimura, N.; Minami, J.; Ohguchi, H.; Kikuchi, S.; Yoshida, Y.; Gorgun, G.; Cirstea, D.; Cottini, F.; Jakubikova, J.; Tai, Y-T; Chauhan, D.; Richardson, P. G.; Anderson, K. C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. [Utsugi, T.] TAIHO PHARMACEUT CO LTD, Tsukuba Res Ctr, Tsukuba, Ibaraki, Japan. [Munshi, N. C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,VA Boston Heal, Boston, MA 02115 USA. RP Suzuki, R (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM kenneth_anderson@dfci.harvard.edu FU NCI NIH HHS [P01 CA078378, P01 CA155258, R01-CA050947, P01-CA078378, P50 CA100707, R01 CA050947]; PHS HHS [R01 178264, SPOREP50100707, P01-155258] NR 15 TC 10 Z9 10 U1 3 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 EI 1476-5551 J9 LEUKEMIA JI Leukemia PD FEB PY 2015 VL 29 IS 2 BP 510 EP 514 DI 10.1038/leu.2014.300 PG 6 WC Oncology; Hematology SC Oncology; Hematology GA CB2GL UT WOS:000349445000033 PM 25306900 ER PT J AU Roberts, DA Wadleigh, M McDonnell, AM DeAngelo, DJ Stone, RM Steensma, DP AF Roberts, Daniel A. Wadleigh, Martha McDonnell, Anne M. DeAngelo, Daniel J. Stone, Richard M. Steensma, David P. TI Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes SO LEUKEMIA RESEARCH LA English DT Article DE Acute myeloid leukemia; Myelodysplastic syndromes; Clofarabine; Cytarabine ID STEM-CELL TRANSPLANTATION; INTERNATIONAL WORKING GROUP; ACUTE MYELOGENOUS LEUKEMIA; HIGH-DOSE CYTARABINE; NUCLEOSIDE ANALOG; RESPONSE CRITERIA; PLUS CYTARABINE; REFRACTORY AML; ADULT PATIENTS; CYTOREDUCTION AB Clofarabine, a second-generation nucleoside analog, has clinical activity in relapsed or refractory acute myelogenous leukemia (AML) and higher-risk myelodysplastic syndromes (MDS). However, there are few data evaluating performance of clofarabine in populations of patients not enrolled in clinical trials. We reviewed outcomes for 84 patients treated with clofarabine for relapsed or refractory AML or MDS, either with clofarabine as monotherapy (n= 19) or in combination with cytarabine (n= 65). Using International Working Group (IWG) response criteria, the overall response rate (ORR) of all treated patients was 21%, with a complete response rate with either complete or incomplete hematopoietic recovery (CRR = CR + CRi) of 14%. For combination therapy, ORR was 22% with CRR of 18%, and monotherapy patients had an ORR of 21% with CRR of 11%. Although limited by small numbers, subgroup analysis did not reveal variation in response rates when comparing different risk factors. The 30-day mortality was 21% and median survival was 3 months; a subset of 12 patients who were able to go to transplant had an 18-month median survival. Clofarabine's efficacy in a "real-world" setting appears to be less than has been reported in clinical trials, and treatment is associated with a high early mortality rate. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Roberts, Daniel A.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA. [Wadleigh, Martha; DeAngelo, Daniel J.; Stone, Richard M.; Steensma, David P.] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02115 USA. [McDonnell, Anne M.] Brigham & Womens Hosp, Dept Pharm, Boston, MA 02115 USA. RP Steensma, DP (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Adult Leukemia Program,Dept Med Oncol, 450 Brookline Ave,Dana 2037, Boston, MA 02215 USA. EM david_steensma@dfci.harvard.edu OI Steensma, David/0000-0001-5130-9284 NR 29 TC 4 Z9 4 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0145-2126 J9 LEUKEMIA RES JI Leuk. Res. PD FEB PY 2015 VL 39 IS 2 BP 204 EP 210 DI 10.1016/j.leukres.2014.11.031 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA AZ5WY UT WOS:000348290400015 PM 25554239 ER PT J AU Hopkin, RJ Cabrera, G Charrow, J Lemay, R Martins, AM Mauer, M Ortiz, A Patel, MR Sims, K Waldek, S Warnock, DG Wilcox, WR AF Hopkin, Robert J. Cabrera, Gustavo Charrow, Joel Lemay, Roberta Martins, Ana Maria Mauer, Michael Ortiz, Alberto Patel, Manesh R. Sims, Katherine Waldek, Stephen Warnock, David G. Wilcox, William R. TI Risk factors for severe clinical events and the incidence of these events in male and female patients with Fabry disease treated with agalsidase beta SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 11th Annual WORLD Symposium of the Lysosomal-Disease-Network CY FEB 09-13, 2015 CL Orlando, FL SP Lysosomal Dis Network C1 [Hopkin, Robert J.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Cabrera, Gustavo] Grp Med Viso, Buenos Aires, DF, Argentina. [Charrow, Joel] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA. [Lemay, Roberta] Genzyme, Cambridge, MA USA. [Martins, Ana Maria] Univ Fed Sao Paulo, Sao Paulo, Brazil. [Mauer, Michael] Univ Minnesota, Minneapolis, MN USA. [Ortiz, Alberto] IIS Fdn Jimenez Diaz UAM IRSIN REDINREN, Madrid, Spain. [Patel, Manesh R.] Duke Univ, Sch Med, Durham, NC USA. [Sims, Katherine] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Warnock, David G.] Univ Alabama Birmingham, Birmingham, AL USA. [Wilcox, William R.] Emory Univ, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 EI 1096-7206 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2015 VL 114 IS 2 MA 111 BP S55 EP S55 DI 10.1016/j.ymgme.2014.12.114 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA CA5UK UT WOS:000348973100110 ER PT J AU Karaa, A Simas, AM John, S Glykys, J Xin, W Cotman, SL Sims, KB AF Karaa, Amel Simas, Alexendra M. John, Staropoli Glykys, Joseph Xin, Winnie Cotman, Susan L. Sims, Katherine B. TI Expanding the clinical spectrum of the lysosomal disorders with whole exome sequencing SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 11th Annual WORLD Symposium of the Lysosomal-Disease-Network CY FEB 09-13, 2015 CL Orlando, FL SP Lysosomal Dis Network C1 [Karaa, Amel; Simas, Alexendra M.; Glykys, Joseph; Xin, Winnie; Cotman, Susan L.; Sims, Katherine B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [John, Staropoli] Biogen Idec Inc, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 EI 1096-7206 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2015 VL 114 IS 2 MA 122 BP S60 EP S60 DI 10.1016/j.ymgme.2014.12.125 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA CA5UK UT WOS:000348973100121 ER PT J AU Laney, DA White, AL Holida, M Clarke, V Lipinski, S Berry, L May, K Long, K AF Laney, Dawn A. White, Amy L. Holida, Myrl Clarke, Virginia Lipinski, Shawn Berry, Lisa May, Katie Long, Katie TI Comparison of clinical practice guidelines and actual clinical practice in Fabry disease diagnosis SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 11th Annual WORLD Symposium of the Lysosomal-Disease-Network CY FEB 09-13, 2015 CL Orlando, FL SP Lysosomal Dis Network C1 [Laney, Dawn A.] Emory, Decatur, GA USA. [White, Amy L.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA. [Holida, Myrl] Univ Iowa, Iowa City, IA USA. [Clarke, Virginia] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lipinski, Shawn] O&O Alpan LLC, Fairfax, VA USA. [Berry, Lisa] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [May, Katie] Infus Associates, Grand Rapids, MI USA. [Long, Katie] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 EI 1096-7206 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2015 VL 114 IS 2 MA 143 BP S68 EP S68 DI 10.1016/j.ymgme.2014.12.146 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA CA5UK UT WOS:000348973100142 ER PT J AU Weintraub, D David, AS Evans, AH Grant, JE Stacy, M AF Weintraub, Daniel David, Anthony S. Evans, Andrew H. Grant, Jon E. Stacy, Mark TI Clinical Spectrum of Impulse Control Disorders in Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Review DE Parkinson's disease; impulse control disorder; dopamine agonists ID DOPAMINE AGONIST USE; COMPULSIVE BEHAVIORS; DYSREGULATION SYNDROME; REPETITIVE BEHAVIORS; WITHDRAWAL SYNDROME; UNITED-STATES; RATING-SCALE; MDS-UPDRS; PREVALENCE; ASSOCIATION AB Impulse control disorders (ICDs), including compulsive gambling, buying, sexual behavior, and eating, are a serious and increasingly recognized psychiatric complication in Parkinson's disease (PD). Other impulsive-compulsive behaviors (ICBs) have been described in PD, including punding (stereotyped, repetitive, purposeless behaviors) and dopamine dysregulation syndrome (DDS; compulsive PD medication overuse). ICDs have been most closely related to the use of dopamine agonists (DAs), perhaps more so at higher doses; in contrast, DDS is primarily associated with shorter-acting, higher-potency dopaminergic medications, such as apomorphine and levodopa. Possible risk factors for ICDs include male sex, younger age and younger age at PD onset, a pre-PD history of ICDs, and a personal or family history of substance abuse, bipolar disorder, or gambling problems. Given the paucity of treatment options and potentially serious consequences, it is critical for PD patients to be monitored closely for development of ICDs as part of routine clinical care. (c) 2014 International Parkinson and Movement Disorder Society C1 [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [David, Anthony S.] Kings Coll London, Inst Psychiat, London WC2R 2LS, England. [Evans, Andrew H.] Royal Melbourne Hosp, Dept Neurol, Parkville, Vic 3050, Australia. [Grant, Jon E.] Univ Chicago, Sch Med, Dept Psychiat, Chicago, IL 60637 USA. [Stacy, Mark] Duke Univ, Sch Med, Dept Neurol, Durham, NC USA. RP Weintraub, D (reprint author), Univ Penn, Perelman Sch Med, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu RI David, Anthony/C-1315-2011 OI David, Anthony/0000-0003-0967-774X FU Parkinson's UK [J-0705] NR 77 TC 43 Z9 44 U1 2 U2 24 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB PY 2015 VL 30 IS 2 BP 121 EP 127 DI 10.1002/mds.26016 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA CB0IZ UT WOS:000349310600001 PM 25370355 ER PT J AU Rowland, NC Starr, PA Larson, PS Ostrem, JL Marks, WJ Lim, DA AF Rowland, Nathan C. Starr, Philip A. Larson, Paul S. Ostrem, Jill L. Marks, William J., Jr. Lim, Daniel A. TI Combining Cell Transplants or Gene Therapy With Deep Brain Stimulation for Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; stem cell technology; gene therapy; clinical trial design; deep brain stimulation ID RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; OPEN-LABEL; SUBTHALAMIC NUCLEUS; MEDICAL THERAPY; AAV2-NEURTURIN; DELIVERY; MOTOR AB Cell transplantation and gene therapy each show promise to enhance the treatment of Parkinson's disease (PD). However, because cell transplantation and gene therapy generally require direct delivery to the central nervous system, clinical trial design involves unique scientific, ethical, and financial concerns related to the invasive nature of the procedure. Typically, such biologics have been tested in PD patients who have not received any neurosurgical intervention. Here, we suggest that PD patients undergoing deep brain stimulation (DBS) device implantation are an ideal patient population for the clinical evaluation of cell transplantation and gene therapy. Randomizing subjects to an experimental group that receives the biologic concurrently with the DBS implantationor to a control group that receives the DBS treatment alonehas several compelling advantages. First, this study design enables the participation of patients likely to benefit from DBS, many of whom simultaneously meet the inclusion criteria of biologic studies. Second, the need for a sham neurosurgical procedure is eliminated, which may reduce ethical concerns, promote patient recruitment, and enhance the blinding of surgical trials. Third, testing the biologic by piggybacking onto an established, reimbursable procedure should reduce the cost of clinical trials, which may allow a greater number of biologics to reach this critical stage of research translation. Finally, this clinical trial design may lead to combinatorial treatment strategies that provide PD patients with more durable control over disabling motor symptoms. By combining neuromodulation with biologics, we may also reveal important treatment paradigms relevant to other diseases of the brain. (c) 2014 International Parkinson and Movement Disorder Society C1 [Rowland, Nathan C.; Starr, Philip A.; Larson, Paul S.; Lim, Daniel A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA. [Ostrem, Jill L.; Marks, William J., Jr.] Univ Calif San Francisco, Dept Neurol, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. [Starr, Philip A.; Larson, Paul S.; Ostrem, Jill L.; Marks, William J., Jr.; Lim, Daniel A.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA 94143 USA. RP Lim, DA (reprint author), 35 Med Ctr Way,RMB 1037, San Francisco, CA 94143 USA. EM LimD@neurosurg.ucsf.edu FU NIH [DP2OD006505-01]; CIRM [RT2-01975] FX DAL is supported by NIH DP2OD006505-01 and CIRM RT2-01975. NR 34 TC 6 Z9 6 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB PY 2015 VL 30 IS 2 BP 190 EP 195 DI 10.1002/mds.26083 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA CB0IZ UT WOS:000349310600010 PM 25521796 ER PT J AU Lo, RY Figueroa, KP Pulst, SM Lin, CY Perlman, S Wilmot, G Gomez, C Schmahmann, J Paulson, H Shakkottai, VG Ying, S Zesiewicz, T Bushara, K Geschwind, M Xia, GB Subramony, SH Ashizawa, T Kuo, SH AF Lo, Raymond Y. Figueroa, Karla P. Pulst, Stefan M. Lin, Chi-Ying Perlman, Susan Wilmot, George Gomez, Christopher Schmahmann, Jeremy Paulson, Henry Shakkottai, Vikram G. Ying, Sarah Zesiewicz, Theresa Bushara, Khalaf Geschwind, Michael Xia, Guangbin Subramony, S. H. Ashizawa, Tetsuo Kuo, Sheng-Han TI Coenzyme Q10 and Spinocerebellar Ataxias SO MOVEMENT DISORDERS LA English DT Article DE coenzyme Q10; statins; spinocerebellar ataxias; neurodegeneration ID MITOCHONDRIAL APOPTOTIC PATHWAY; UP-REGULATING BAX; CEREBELLAR-ATAXIA; FOLLOW-UP; POLYGLUTAMINE EXPANSIONS; STATINS; DISEASE; NEURONS; TRIAL; Q(10) AB The aim of this study was to investigate the association between drug exposure and disease severity in SCA types 1, 2, 3 and 6. The Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) enrolled 319 participants with SCA1, 2, 3, and 6 from 12 medical centers in the United States and repeatedly measured clinical severity by the Scale for Assessment and Rating of Ataxia (SARA), the Unified Huntington's Disease Rating Scale part IV (UHDRS-IV), and the 9-item Patient Health Questionnaire during July 2009 to May 2012. We employed generalized estimating equations in regression models to study the longitudinal effects of coenzyme Q10 (CoQ10), statin, and vitamin E on clinical severity of ataxia after adjusting for age, sex, and pathological CAG repeat number. Cross-sectionally, exposure to CoQ10 was associated with lower SARA and higher UHDRS-IV scores in SCA1 and 3. No association was found between statins, vitamin E, and clinical outcome. Longitudinally, CoQ10, statins, and vitamin E did not change the rates of clinical deterioration indexed by SARA and UHDRS-IV scores within 2 years. CoQ10 is associated with better clinical outcome in SCA1 and 3. These drug exposures did not appear to influence clinical progression within 2 years. Further studies are warranted to confirm the association. (c) 2014 International Parkinson and Movement Disorder Society C1 [Lo, Raymond Y.] Buddhist Tzu Chi Gen Hosp, Dept Neurol, Hualien, Taiwan. [Lo, Raymond Y.] Tzu Chi Univ, Hualien, Taiwan. [Figueroa, Karla P.; Pulst, Stefan M.] Univ Utah, Dept Neurol, Salt Lake City, UT USA. [Lin, Chi-Ying; Kuo, Sheng-Han] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA. [Perlman, Susan] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Wilmot, George] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA. [Gomez, Christopher] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA. [Schmahmann, Jeremy] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Paulson, Henry; Shakkottai, Vikram G.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA. [Ying, Sarah] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA. [Zesiewicz, Theresa] Univ S Florida, Dept Neurol, Tampa, FL 33620 USA. [Bushara, Khalaf] Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA. [Geschwind, Michael] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Xia, Guangbin; Subramony, S. H.; Ashizawa, Tetsuo] Univ Florida, Dept Neurol, Gainesville, FL USA. [Xia, Guangbin; Subramony, S. H.; Ashizawa, Tetsuo] Univ Florida, McKnight Brain Inst, Gainesville, FL USA. RP Kuo, SH (reprint author), Columbia Univ, Coll Phys & Surg, Dept Neurol, 710 West 168th St,3rd Floor, New York, NY 10032 USA. EM sk3295@columbia.edu FU American Academy of Neurology Clinical Research Training Fellowship; Parkinson Disease Foundation; National Institute of Neurological Disorders and Stroke [K08 NS083738]; Louis V. Gerstner Jr. Scholarship; American Parkinson's Disease Association; Rare Disease Clinical Research Network (RDCRN) [RC1NS068897] FX This work was supported by the American Academy of Neurology Clinical Research Training Fellowship, Parkinson Disease Foundation, the National Institute of Neurological Disorders and Stroke (K08 NS083738), the Louis V. Gerstner Jr. Scholarship, the American Parkinson's Disease Association, and the Rare Disease Clinical Research Network (RDCRN) (RC1NS068897). NR 28 TC 1 Z9 1 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB PY 2015 VL 30 IS 2 BP 214 EP 220 DI 10.1002/mds.26088 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA CB0IZ UT WOS:000349310600015 PM 25449974 ER PT J AU Scharf, JM Miller, LL Gauvin, CA Alabiso, J Mathews, CA Ben-Shlomo, Y AF Scharf, Jeremiah M. Miller, Laura L. Gauvin, Caitlin A. Alabiso, Janelle Mathews, Carol A. Ben-Shlomo, Yoav TI Population Prevalence of Tourette Syndrome: A Systematic Review and Meta-Analysis SO MOVEMENT DISORDERS LA English DT Review DE Tourette syndrome; tics; prevalence studies; meta-analysis; developmental disorders ID SINGLE SCHOOL-DISTRICT; TIC DISORDERS; SPECIAL-EDUCATION; EPIDEMIOLOGIC SURVEY; AGE-CHILDREN; SCHOOLCHILDREN; ADOLESCENTS; SAMPLE; PSYCHOPATHOLOGY; DIAGNOSES AB The aim of this study was to refine the population prevalence estimate of Tourette Syndrome (TS) in children and to investigate potential sources of heterogeneity in previously published studies. A systematic review was conducted and all qualifying published studies of TS prevalence were examined. Extracted data were subjected to a random-effects meta-analysis weighted by sample size; meta-regressions were performed to examine covariates that have previously been proposed as potential sources of heterogeneity. Twenty-six articles met study inclusion criteria. Studies derived from clinically referred cases had prevalence estimates that were significantly lower than those derived from population-based samples (P = 0.004). Among the 21 population-based prevalence studies, the pooled TS population prevalence estimate was 0.52% (95% confidence interval CI: 0.32-0.85). In univariable meta-regression analysis, study sample size (P = 0.002) and study date (P = 0.03) were significant predictors of TS prevalence. In the final multivariable model including sample size, study date, age, and diagnostic criteria, only sample size (P < 0.001) and diagnostic criteria (omnibus P = 0.003; Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision [DSM-IV-TR]: P = 0.005) were independently associated with variation in TS population prevalence across studies. This study refines the population prevalence estimate of TS in children to be 0.3% to 0.9%. Study sample size, which is likely a proxy for case assessment method, and the use of DSM-IV-TR diagnostic criteria are the major sources of heterogeneity across studies. The true TS population prevalence rate is likely at the higher end of these estimates, given the methodological limitations of most studies. Further studies in large, well-characterized samples will be helpful to determine the burden of disease in the general population. (c) 2014 International Parkinson and Movement Disorder Society C1 [Scharf, Jeremiah M.; Gauvin, Caitlin A.; Alabiso, Janelle] Massachusetts Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Dept Neurol, Boston, MA 02114 USA. [Scharf, Jeremiah M.; Gauvin, Caitlin A.; Alabiso, Janelle] Massachusetts Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Dept Psychiat, Boston, MA 02114 USA. [Scharf, Jeremiah M.] Brigham & Womens Hosp, Dept Neurol, Div Cognit & Behav Neurol, Boston, MA 02115 USA. [Miller, Laura L.; Ben-Shlomo, Yoav] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England. [Mathews, Carol A.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Scharf, JM (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, 185 Cambridge St,6th Floor, Boston, MA 02114 USA. EM jscharf@partners.org FU Tourette Syndrome Association; National Institutes of Mental Health [MH080857] FX This work was funded by the Tourette Syndrome Association and the National Institutes of Mental Health (MH080857). NR 52 TC 22 Z9 23 U1 6 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB PY 2015 VL 30 IS 2 BP 221 EP 228 DI 10.1002/mds.26089 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA CB0IZ UT WOS:000349310600016 PM 25487709 ER PT J AU Nabli, F Ben Sassi, S Amouri, R Duda, JE Farrer, MJ Hentati, F AF Nabli, Fatma Ben Sassi, Samia Amouri, Rim Duda, John E. Farrer, Matthew J. Hentati, Faycal TI Motor Phenotype of LRRK2-Associated Parkinson's Disease: A Tunisian Longitudinal Study SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; PARK8; LRRK2 gene; G2019S mutation; longitudinal study ID TREMOR-DOMINANT PARKINSONISM; LRRK2 G2019S MUTATION; PROGRESSION; PENETRANCE; IMPAIRMENT; ONSET AB Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) were found to be a significant cause of late-onset autosomal dominant forms of Parkinson's disease (PD). To determine the motor characteristics of LRRK2-related disease, we conducted a longitudinal study of 58 G2019S LRRK2-associated PD patients and compared them with genetically undefined (GU) PD patients. Fifty-eight patients diagnosed with PD-related LRRK2 G2019S mutation were included in the study and compared with 54 sporadic PD patients with negative tests for LRRK2 G2019S, PINK1, SNCA, PRKN, and DJ1 mutations. Patients were assessed at baseline and after a follow-up period of 6 years. The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), the Hoehn and Yahr, and the Schwab and England scores were determined. Logistic regression was used to examine associations of G2019S mutation status with motor phenotype and rate of motor decline. The LRRK2-associated PD patients had a mean age of onset of 56.25 +/- 12.05 years and in most cases (58.6%) a postural instability gait difficulty (PIGD) phenotype. The mean annual decline in the MDS-UDRS III motor score and the Hoehn and Yahr staging was of 1.3% and 2%, respectively. The PIGD phenotype predicted a more rapid progression of motor impairment. The PD motor phenotype and motor scores were similar in the LRRK2-associated PD group and in the GU PD group, with no significant differences in the progression rate of motor impairment. Motor phenotype seems to be similar in LRRK2-related PD and idiopathic PD. (c) 2014 International Parkinson and Movement Disorder Society C1 [Nabli, Fatma; Ben Sassi, Samia; Amouri, Rim; Hentati, Faycal] Univ Tunis El Manar, Natl Inst Mongi Ben Hmida Neurol, Fac Med Tunis, Dept Neurol, Tunis, Tunisia. [Duda, John E.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Farrer, Matthew J.] Univ British Columbia, Djavad Mowafhaghian Ctr Brain Hlth, Vancouver, BC V5Z 1M9, Canada. RP Nabli, F (reprint author), Inst Natl Mongi Ben Hmida Neurol, Tunis 1007, Tunisia. EM fatmafatnassi@yahoo.fr FU Department of Research and Development; GlaxoSmithKline; Michael. J. Fox Foundation FX This study was supported by the Department of Research and Development, GlaxoSmithKline, and by the Michael. J. Fox Foundation. NR 23 TC 6 Z9 6 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB PY 2015 VL 30 IS 2 BP 253 EP 258 DI 10.1002/mds.26097 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA CB0IZ UT WOS:000349310600020 PM 25487881 ER PT J AU Sharp, ME Caccappolo, E Mejia-Santana, H Tang, MX Rosado, L Reilly, MO Ruiz, D Louis, ED Comella, C Nance, M Bressman, S Scott, WK Tanner, C Waters, C Fahn, S Cote, L Ford, B Rezak, M Novak, K Friedman, JH Pfeiffer, R Payami, H Molho, E Factor, SA Nutt, J Serrano, C Arroyo, M Pauciulo, MW Nichols, WC Clark, LN Alcalay, RN Marder, KS AF Sharp, Madeleine E. Caccappolo, Elise Mejia-Santana, Helen Tang, Ming-X. Rosado, Llency Reilly, Martha Orbe Ruiz, Diana Louis, Elan D. Comella, Cynthia Nance, Martha Bressman, Susan Scott, William K. Tanner, Caroline Waters, Cheryl Fahn, Stanley Cote, Lucien Ford, Blair Rezak, Michael Novak, Kevin Friedman, Joseph H. Pfeiffer, Ronald Payami, Haydeh Molho, Eric Factor, Stuart A. Nutt, John Serrano, Carmen Arroyo, Maritza Pauciulo, Michael W. Nichols, William C. Clark, Lorraine N. Alcalay, Roy N. Marder, Karen S. TI The Relationship Between Obsessive-Compulsive Symptoms and PARKIN Genotype: The CORE-PD Study SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's; neuropsychological; obsessive-compulsive; parkin ID DISEASE; MUTATIONS; GENE; DISORDER; CARRIERS; VALIDATION; DEPRESSION AB BackgroundFew studies have systematically investigated the association between PARKIN genotype and psychiatric co-morbidities of Parkison's disease (PD). PARKIN-associated PD is characterized by severe nigral dopaminergic neuronal loss, a finding that may have implications for behaviors rooted in dopaminergic circuits such as obsessive-compulsive symptoms (OCS). MethodsThe Schedule of Compulsions and Obsessions Patient Inventory (SCOPI) was administered to 104 patients with early-onset PD and 257 asymptomatic first-degree relatives. Carriers of one and two PARKIN mutations were compared with noncarriers. ResultsAmong patients, carriers scored lower than noncarriers in adjusted models (one-mutation: 13.9 point difference, P=0.03; two-mutation: 24.1, P=0.001), where lower scores indicate less OCS. Among asymptomatic relatives, a trend toward the opposite was seen: mutation carriers scored higher than noncarriers (one mutation, P=0.05; two mutations, P=0.13). ConclusionsFirst, a significant association was found between PARKIN mutation status and obsessive-compulsive symptom level in both PD and asymptomatic patients, suggesting that OCS might represent an early non-motor dopamine-dependent feature. Second, irrespective of disease status, heterozygotes were significantly different from noncarriers, suggesting that PARKIN heterozygosity may contribute to phenotype. (c) 2014 International Parkinson and Movement Disorder Society C1 [Sharp, Madeleine E.; Caccappolo, Elise; Mejia-Santana, Helen; Tang, Ming-X.; Rosado, Llency; Reilly, Martha Orbe; Ruiz, Diana; Louis, Elan D.; Waters, Cheryl; Fahn, Stanley; Cote, Lucien; Ford, Blair; Alcalay, Roy N.; Marder, Karen S.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA. [Tang, Ming-X.; Louis, Elan D.; Clark, Lorraine N.; Alcalay, Roy N.; Marder, Karen S.] Columbia Univ, Coll Phys & Surg, Taub Inst Res Alzheimers & Aging Brain, New York, NY 10032 USA. [Louis, Elan D.; Cote, Lucien; Marder, Karen S.] Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY 10032 USA. [Louis, Elan D.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10032 USA. [Comella, Cynthia] Rush Univ, Dept Neurol Sci, Med Ctr, Chicago, IL 60612 USA. [Nance, Martha] Struthers Parkinsons Ctr, Pk Nicollet Clin, Golden Valley, MN USA. [Bressman, Susan] Beth Israel Deaconess Med Ctr, Alan & Barbara Mirken Dept Neurol, New York, NY 10003 USA. [Bressman, Susan] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA. [Scott, William K.] Univ Miami, Miller Sch Med, Miami Inst Human Genom, Dr John T Macdonald Fdn,Dept Human Genet, Miami, FL 33136 USA. [Tanner, Caroline] Parkinsons Inst, Sunnyvale, CA USA. [Tanner, Caroline] San Francisco VA Med Ctr, San Francisco, CA USA. [Tanner, Caroline] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Rezak, Michael] Cent DuPage Hosp, Movement Disorders Ctr, Neurosci Inst, Winfield, IL USA. [Novak, Kevin] NorthShore Univ Hlth Syst, Dept Neurol, Evanston, IL USA. [Novak, Kevin] Univ Chicago, Pritzker Sch Med, Dept Neurol, Chicago, IL 60637 USA. [Friedman, Joseph H.] Butler Hosp, Providence, RI 02906 USA. [Friedman, Joseph H.] Brown Univ, Dept Neurol, Alpert Med Sch, Providence, RI 02912 USA. [Pfeiffer, Ronald] Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Neurol, Memphis, TN 38163 USA. [Payami, Haydeh] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA. [Molho, Eric] Albany Med Ctr, Parkinsons Dis & Movement Disorders Ctr, Albany, NY USA. [Factor, Stuart A.] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA. [Nutt, John] Portland VA Med Ctr Parkinson Dis Res Educ & Clin, Portland, OR USA. [Nutt, John] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Serrano, Carmen; Arroyo, Maritza] Univ Puerto Rico, San Juan, PR 00936 USA. [Pauciulo, Michael W.; Nichols, William C.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA. [Pauciulo, Michael W.; Nichols, William C.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45221 USA. [Clark, Lorraine N.] Columbia Univ, Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY 10032 USA. [Clark, Lorraine N.] Columbia Univ, Coll Phys & Surg, Ctr Human Genet, New York, NY 10032 USA. [Marder, Karen S.] Columbia Univ, Dept Psychiat, Med Ctr, New York, NY 10032 USA. RP Marder, KS (reprint author), Columbia Univ, Coll Phys & Surg, Taub Inst Res Alzheimers & Aging Brain, 630 West 168th St,Unit 16, New York, NY 10032 USA. EM ksm1@cumc.columbia.edu FU NIH [NS036630, UL1 RR024156, NS050487, NS060113, K02NS080915]; Parkinson's Disease Foundation [P50 NS039764, P50 NS071674, NS36960]; University of British Columbia Clinician Investigator Program FX This study was supported by NIH NS036630, UL1 RR024156 (K.S.M.), NS050487, NS060113 (L.N.C.), K02NS080915 (R.N.A) the Parkinson's Disease Foundation (K.S.M., S.F., and L.N.C.), P50 NS039764 and P50 NS071674 (W.K.S), NS36960 (H.P) and the University of British Columbia Clinician Investigator Program (M.E.S). NR 30 TC 2 Z9 3 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB PY 2015 VL 30 IS 2 BP 278 EP 283 DI 10.1002/mds.26065 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA CB0IZ UT WOS:000349310600026 PM 25393808 ER PT J AU Frock, RL Hu, JZ Meyers, RM Ho, YJ Kii, E Alt, FW AF Frock, Richard L. Hu, Jiazhi Meyers, Robin M. Ho, Yu-Jui Kii, Erina Alt, Frederick W. TI Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases SO NATURE BIOTECHNOLOGY LA English DT Article ID RECURRENT CHROMOSOMAL TRANSLOCATIONS; SEQUENCING REVEALS; B-LYMPHOCYTES; CAS SYSTEMS; SPECIFICITY; INSTABILITY; MECHANISMS; CLEAVAGE; TALENS; CELLS AB Although great progress has been made in the characterization of the off-target effects of engineered nucleases, sensitive and unbiased genome-wide methods for the detection of off-target cleavage events and potential collateral damage are still lacking. Here we describe a linear amplification-mediated modification of a previously published high-throughput, genome-wide, translocation sequencing (HTGTS) method that robustly detects DNA double-stranded breaks (DSBs) generated by engineered nucleases across the human genome based on their translocation to other endogenous or ectopic DSBs. HTGTS with different Cas9:sgRNA or TALEN nucleases revealed off-target hotspot numbers for given nucleases that ranged from a few or none to dozens or more, and extended the number of known off-targets for certain previously characterized nucleases more than tenfold. We also identified translocations between bona fide nuclease targets on homologous chromosomes, an undesired collateral effect that has not been described previously. Finally, HTGTS confirmed that the, Cas9D10A paired nickase approach suppresses off-target cleavage genome-wide. C1 [Frock, Richard L.; Hu, Jiazhi; Meyers, Robin M.; Ho, Yu-Jui; Kii, Erina; Alt, Frederick W.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. [Frock, Richard L.; Hu, Jiazhi; Meyers, Robin M.; Ho, Yu-Jui; Kii, Erina; Alt, Frederick W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Frock, Richard L.; Hu, Jiazhi; Meyers, Robin M.; Ho, Yu-Jui; Kii, Erina; Alt, Frederick W.] Howard Hughes Med Inst, Boston, MA 02115 USA. RP Alt, FW (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. EM alt@enders.tch.harvard.edu OI Frock, Richard/0000-0001-6963-4931 FU National Institutes of Health [P01CA109901, P01AI076210, NRSA T32CA070083]; National Health Institutes of Health [NRSA T32AI007512]; Robertson Foundation/Cancer Research Institute Irvington Fellowship FX This work is supported by the National Institutes of Health Grants P01CA109901 and P01AI076210. R.L.F. was supported by the National Institutes of Health NRSA T32CA070083 and is supported by the National Health Institutes of Health NRSA T32AI007512. J.H. is supported by Robertson Foundation/Cancer Research Institute Irvington Fellowship. F.W.A. is an investigator of the Howard Hughes Medical Institute. A549 cells were provided by David Weinstock (Dana-Farber Cancer Institute). NR 43 TC 124 Z9 126 U1 6 U2 65 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1087-0156 EI 1546-1696 J9 NAT BIOTECHNOL JI Nat. Biotechnol. PD FEB PY 2015 VL 33 IS 2 BP 179 EP 186 DI 10.1038/nbt.3101 PG 8 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA CA8VK UT WOS:000349198800024 PM 25503383 ER PT J AU Tsai, SQ Zheng, Z Nguyen, NT Liebers, M Topkar, VV Thapar, V Wyvekens, N Khayter, C Iafrate, AJ Le, LP Aryee, MJ Joung, JK AF Tsai, Shengdar Q. Zheng, Zongli Nguyen, Nhu T. Liebers, Matthew Topkar, Ved V. Thapar, Vishal Wyvekens, Nicolas Khayter, Cyd Iafrate, A. John Le, Long P. Aryee, Martin J. Joung, J. Keith TI GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases SO NATURE BIOTECHNOLOGY LA English DT Article ID HUMAN-CELLS; DUAL-RNA; SPECIFICITY; DNA; SYSTEMS; REVEALS; ENDONUCLEASE; IDENTIFICATION; NICKASES; SITES AB CRISPR RNA-guided nucleases (RGNs) are widely used genome-editing reagents, but methods to delineate their genome-wide, off-target cleavage activities have been lacking. Here we describe an approach for global detection of DNA double-stranded breaks (DSBs) introduced by RGNs and potentially other nucleases. This method, called genome-wide, unbiased identification of DSBs enabled by sequencing (GUIDE-seq), relies on capture of double-stranded oligodeoxynucleotides into DSBs. Application of GUIDE-seq to 13 RGNs in two human cell lines revealed wide variability in RGN off-target activities and unappreciated characteristics of off-target sequences. The majority of identified sites were not detected by existing computational methods or chromatin immunoprecipitation sequencing (ChIP-seq). GUIDE-seq also identified RGN-independent genomic breakpoint 'hotspots'. Finally, GUIDE-seq revealed that truncated guide RNAs exhibit substantially reduced RGN-induced, off-target DSBs. Our experiments define the most rigorous framework for genome-wide identification of RGN off-target effects to date and provide a method for evaluating the safety of these nucleases before clinical use. C1 [Tsai, Shengdar Q.; Zheng, Zongli; Nguyen, Nhu T.; Liebers, Matthew; Topkar, Ved V.; Thapar, Vishal; Wyvekens, Nicolas; Khayter, Cyd; Iafrate, A. John; Le, Long P.; Aryee, Martin J.; Joung, J. Keith] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA. [Tsai, Shengdar Q.; Zheng, Zongli; Nguyen, Nhu T.; Liebers, Matthew; Topkar, Ved V.; Thapar, Vishal; Wyvekens, Nicolas; Khayter, Cyd; Iafrate, A. John; Le, Long P.; Aryee, Martin J.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA USA. [Tsai, Shengdar Q.; Zheng, Zongli; Iafrate, A. John; Le, Long P.; Aryee, Martin J.; Joung, J. Keith] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Tsai, Shengdar Q.; Zheng, Zongli] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. RP Joung, JK (reprint author), Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA. EM stsai4@mgh.harvard.edu; jjoung@mgh.harvard.edu RI Zheng, Zongli/B-2917-2011 OI Zheng, Zongli/0000-0003-4849-4903 FU National Institutes of Health (NIH) Director's Pioneer Award [DP1 GM105378]; NIH [R01 GM088040, R01 AR063070, F32 GM105189]; Jim and Ann Orr Massachusetts General Hospital (MGH) Research Scholar Award; US Army Research Laboratory; US Army Research Office [W911NF-11-2-0056] FX We thank J. Angstman, B. Kleinstiver, Y. Fu, J. Gehrke and R. Coltman for helpful comments on the manuscript and M. Maeder and J. Foden for technical assistance. This work was funded by a National Institutes of Health (NIH) Director's Pioneer Award (DP1 GM105378), NIH R01 GM088040, NIH R01 AR063070, and the Jim and Ann Orr Massachusetts General Hospital (MGH) Research Scholar Award. S.Q.T. was supported by NIH F32 GM105189. This material is based upon work supported by, or in part by, the US Army Research Laboratory and the US Army Research Office under grant number W911NF-11-2-0056. Links to software and resources for analyzing GUIDE-seq data will be made available at: http://www.jounglab.org/guideseq. NR 35 TC 235 Z9 243 U1 20 U2 99 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1087-0156 EI 1546-1696 J9 NAT BIOTECHNOL JI Nat. Biotechnol. PD FEB PY 2015 VL 33 IS 2 BP 187 EP 197 DI 10.1038/nbt.3117 PG 11 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA CA8VK UT WOS:000349198800025 PM 25513782 ER PT J AU Huynh, A DuPage, M Priyadharshini, B Sage, PT Quiros, J Borges, CM Townamchai, N Gerriets, VA Rathmell, JC Sharpe, AH Bluestone, JA Turka, LA AF Huynh, Alexandria DuPage, Michel Priyadharshini, Bhavana Sage, Peter T. Quiros, Jason Borges, Christopher M. Townamchai, Natavudh Gerriets, Valerie A. Rathmell, Jeffrey C. Sharpe, Arlene H. Bluestone, Jeffrey A. Turka, Laurence A. TI Control of PI(3) kinase in T-reg cells maintains homeostasis and lineage stability SO NATURE IMMUNOLOGY LA English DT Article ID TRANSCRIPTION FACTOR FOXP3; IN-VIVO; GLUCOSE-METABOLISM; PTEN; ACTIVATION; EXPRESSION; LEADS; MTOR; IL-2; DIFFERENTIATION AB Foxp3(+) regulatory T cells (T-reg cells) are required for immunological homeostasis. One notable distinction between conventional T cells (T-conv cells) and T-reg cells is differences in the activity of phosphatidylinositol-3-OH kinase (PI(3)K); only T-conv cells downregulate PTEN, the main negative regulator of PI(3)K, upon activation. Here we found that control of PI(3)K in T-reg cells was essential for lineage homeostasis and stability. Mice lacking Pten in T-reg cells developed an autoimmune-lymphoproliferative disease characterized by excessive T helper type 1 (T(H)1) responses and B cell activation. Diminished control of PI(3)K activity in T-reg cells led to reduced expression of the interleukin-2 (IL-2) receptor alpha subunit CD25, accumulation of Foxp3(+) CD25(-) cells and, ultimately, loss of expression of the transcription factor Foxp3 in these cells. Collectively, our data demonstrate that control of PI(3)K signaling by PTEN in T-reg cells is critical for maintaining their homeostasis, function and stability. C1 [Huynh, Alexandria; Borges, Christopher M.; Turka, Laurence A.] Harvard Univ, Sch Med, Div Med Sci, Boston, MA 02138 USA. [Huynh, Alexandria; Priyadharshini, Bhavana; Borges, Christopher M.; Turka, Laurence A.] Massachusetts Gen Hosp, Dept Surg, Ctr Transplantat Sci, Boston, MA 02114 USA. [DuPage, Michel; Quiros, Jason; Bluestone, Jeffrey A.] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA. [DuPage, Michel; Quiros, Jason; Bluestone, Jeffrey A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Sage, Peter T.; Sharpe, Arlene H.] Harvard Univ, Sch Med, Dept Microbiol, Div Immunol, Boston, MA USA. [Townamchai, Natavudh] Chulalongkorn Univ, Dept Med, Div Nephrol, Bangkok, Thailand. [Townamchai, Natavudh] King Chulalongkorn Mem Hosp, Bangkok, Thailand. [Gerriets, Valerie A.; Rathmell, Jeffrey C.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA. RP Turka, LA (reprint author), Harvard Univ, Sch Med, Div Med Sci, Boston, MA 02138 USA. EM lturka@partners.org FU US National Institutes of Health [R56AI083304, 01HL018646, R21AI105607, T32AI007529, P01AI56299]; Cancer Research Institute [1S10RR023440] FX We thank A. Rudensky (Memorial Sloan Kettering Cancer Center) for Foxp3-YFP-Cre mice and Foxp3eGFP-Cre-ERT2Rosa26-YFP mice. Supported by the US National Institutes of Health (R56AI083304 and 01HL018646 to L.A.T.; R21AI105607 to L.A.T. and J.A.B.; T32AI007529 to C.M.B.; and P01AI56299 to P.T.S., A.H.S. and L.A.T.), the Cancer Research Institute (A.H.) and (1S10RR023440). NR 50 TC 57 Z9 60 U1 4 U2 17 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1529-2908 EI 1529-2916 J9 NAT IMMUNOL JI Nat. Immunol. PD FEB PY 2015 VL 16 IS 2 BP 188 EP + DI 10.1038/ni.3077 PG 11 WC Immunology SC Immunology GA AZ3QZ UT WOS:000348143100011 PM 25559257 ER PT J AU Bilousova, T Taylor, K Emirzian, A Gylys, R Frautschy, SA Cole, GM Teng, E AF Bilousova, Tina Taylor, Karen Emirzian, Ana Gylys, Raymond Frautschy, Sally A. Cole, Gregory M. Teng, Edmond TI Parallel age-associated changes in brain and plasma neuronal pentraxin receptor levels in a transgenic APP/PS1 rat model of Alzheimer's disease SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Plasma; Cortex; Hippocampus; Biomarker; Neuronal pentraxin; Transgenic; Alzheimer's disease; Synaptic function ID LONG-TERM DEPRESSION; MILD COGNITIVE IMPAIRMENT; DEVELOPING VISUAL-SYSTEM; BINDING PROTEIN 49; CEREBROSPINAL-FLUID; AMYLOID-BETA; IN-VIVO; SYNAPTIC PLASTICITY; MOUSE MODEL; A-BETA AB Neuronal pentraxin receptor (NPR) is a synaptic protein implicated in AMPA receptor trafficking at excitatory synapses. Since glutamate neurotransmission is disrupted in Alzheimer's disease (AD), NPR levels measured from plasma represent a potential biomarker for synaptic dysfunction associated with AD. We sought to determine the relationship between AD pathology and brain and plasma NPR levels by examining age-associated NPR levels in these compartments in a transgenic APP/PS1 rat model of AD. NPR levels in cortical homogenate were similar in wild-type (Wt) and APP/PS1 rats at 3 months of age (prior to A beta plaque deposition), but significantly increased in APP/PS1 rats by 9 and 18-20 months of age (after the onset of plaque deposition). These age-dependent differences were driven by proportional increases in NPR in membrane-associated cortical fractions. Genotype-related differences in NPR expression were also seen in the hippocampus, which exhibits significant A beta pathology, but not in the cerebellum, which does not. Plasma analyses revealed increased levels of a 26 kDa NPR fragment in APP/PS1 rats relative to Wt rats by 18-20 months of age, which correlated with the levels of full-length NPR in cortex. Our findings indicate that cerebral accumulation of NPR and A beta occurs with similar temporal and regional patterns in the APP/PS1 model, and suggest that a 26 kDa plasma NPR fragment may represent a peripheral biomarker of this process. (C) 2014 Elsevier Inc. All rights reserved. C1 [Bilousova, Tina; Taylor, Karen; Emirzian, Ana; Gylys, Raymond; Frautschy, Sally A.; Cole, Gregory M.; Teng, Edmond] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Bilousova, Tina; Taylor, Karen; Frautschy, Sally A.; Cole, Gregory M.; Teng, Edmond] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Teng, E (reprint author), West Angeles VA Healthcare Ctr, Neurobehav Serv, 116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM eteng@ucla.edu FU National Institute on Aging [K08 AG34628]; NIA; AFAR; John A. Hartford Foundation; Atlantic Philanthropies; Starr Foundation; anonymous donor [RC1 AG035878]; National Center for Research Resources; National Center for Advancing Translational Sciences [UL1 TR000124]; UCLA Clinical and Translational Science Institute FX This work was supported by the National Institute on Aging (K08 AG34628 [to ET; jointly sponsored by NIA, AFAR, the John A. Hartford Foundation, the Atlantic Philanthropies, the Starr Foundation and an anonymous donor] and RC1 AG035878 [to GMC]), the National Center for Research Resources and the National Center for Advancing Translational Sciences (UL1 TR000124), and the UCLA Clinical and Translational Science Institute. NR 49 TC 1 Z9 1 U1 0 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 EI 1095-953X J9 NEUROBIOL DIS JI Neurobiol. Dis. PD FEB PY 2015 VL 74 BP 32 EP 40 DI 10.1016/j.nbd.2014.11.006 PG 9 WC Neurosciences SC Neurosciences & Neurology GA CB5GQ UT WOS:000349655900004 PM 25449907 ER PT J AU Cristofaro, V Yalla, SV Sullivan, MP AF Cristofaro, Vivian Yalla, Subbarao V. Sullivan, Maryrose P. TI ROLE OF P2X3 RECEPTOR IN MODULATING PURINERGIC NEUROTRANSMISSION SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Winter Meeting of the Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct ion CY FEB 24-28, 2015 CL Scottsdale, AZ SP Soc Urodynam, Female Pelv Med & Urogenital Reconstruct C1 [Cristofaro, Vivian; Yalla, Subbarao V.; Sullivan, Maryrose P.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 EI 1520-6777 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2015 VL 34 SU 1 MA BS23 BP S13 EP S13 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA CB0CT UT WOS:000349293400025 ER PT J AU Doyle, C Chung, YG Costa, K Cristofaro, V Sullivan, MP Adam, RM AF Doyle, Claire Chung, Yeun Goo Costa, Kyle Cristofaro, Vivian Sullivan, Maryrose P. Adam, Rosalyn M. TI INOSINE ALTERS MARKERS OF SENSORY NEUROTRANSMISSION AND IMPROVES DETRUSOR OVERACTIVITY FOLLOWING SPINAL CORD INJURY SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Winter Meeting of the Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct ion CY FEB 24-28, 2015 CL Scottsdale, AZ SP Soc Urodynam, Female Pelv Med & Urogenital Reconstruct C1 [Doyle, Claire; Chung, Yeun Goo; Costa, Kyle; Adam, Rosalyn M.] Boston Childrens Hosp, Boston, MA USA. [Doyle, Claire; Chung, Yeun Goo; Adam, Rosalyn M.] Harvard Univ, Sch Med, Boston, MA USA. [Cristofaro, Vivian; Sullivan, Maryrose P.] VA Boston Healthcare Syst, West Roxbury, MA USA. [Cristofaro, Vivian; Sullivan, Maryrose P.] Harvard Univ, Sch Med, West Roxbury, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 EI 1520-6777 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2015 VL 34 SU 1 MA 39 BP S93 EP S93 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA CB0CT UT WOS:000349293400213 ER PT J AU Kreydin, E Kim, M Ko, D AF Kreydin, Evgeniy Kim, Michelle Ko, Dicken TI HEALTH INSURANCE TYPE AND SELF-REPORTED URINARY INCONTINENCE RATES AMONG WOMEN BETWEEN 20 AND 65 YEARS OF AGE SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Winter Meeting of the Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct ion CY FEB 24-28, 2015 CL Scottsdale, AZ SP Soc Urodynam, Female Pelv Med & Urogenital Reconstruct C1 [Kreydin, Evgeniy; Kim, Michelle; Ko, Dicken] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 EI 1520-6777 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2015 VL 34 SU 1 MA M11 BP S22 EP S23 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA CB0CT UT WOS:000349293400048 ER PT J AU Liu, TX Wang, ZW Cristofaro, V Cao, HY Sullivan, MP Olumi, AF AF Liu, Tongxiang Wang, Zongwei Cristofaro, Vivian Cao, Hongying Sullivan, Maryrose P. Olumi, Aria F. TI EFFECT OF OBESITY ON THE DEVELOPMENT OF DIABETIC BLADDER DYSFUNCTION SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Winter Meeting of the Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct ion CY FEB 24-28, 2015 CL Scottsdale, AZ SP Soc Urodynam, Female Pelv Med & Urogenital Reconstruct C1 [Liu, Tongxiang; Cristofaro, Vivian; Cao, Hongying; Sullivan, Maryrose P.] Harvard Univ, VA Boston Healthcare, Sch Med, Cambridge, MA 02138 USA. [Wang, Zongwei; Olumi, Aria F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 EI 1520-6777 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2015 VL 34 SU 1 MA BS1 BP S3 EP S3 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA CB0CT UT WOS:000349293400003 ER PT J AU Seidman, MD Gurgel, RK Lin, SY Schwartz, SR Baroody, FM Bonner, JR Dawson, DE Dykewicz, MS Hackell, JM Han, JK Ishman, SL Krouse, HJ Malekzadeh, S Mims, JWW Omole, FS Reddy, WD Wallace, DV Walsh, SA Warren, BE Wilson, MN Nnacheta, LC AF Seidman, Michael D. Gurgel, Richard K. Lin, Sandra Y. Schwartz, Seth R. Baroody, Fuad M. Bonner, James R. Dawson, Douglas E. Dykewicz, Mark S. Hackell, Jesse M. Han, Joseph K. Ishman, Stacey L. Krouse, Helene J. Malekzadeh, Sonya Mims, James Whit W. Omole, Folashade S. Reddy, William D. Wallace, Dana V. Walsh, Sandra A. Warren, Barbara E. Wilson, Meghan N. Nnacheta, Lorraine C. TI Clinical Practice Guideline: Allergic Rhinitis SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE allergic rhinitis; allergic rhinitis immunotherapy; surgical management of allergic rhinitis; medical management of allergic rhinitis; allergic rhinitis and steroid use; antihistamine use; decongestant use; allergic rhinitis and complementary; alternative; integrative medicine; acupuncture; herbal therapies; diagnosis of allergic rhinitis; nasal allergies; hay fever; atopic rhinitis; atrophic rhinitis; pollinosis; catarrh ID AQUEOUS NASAL SPRAY; PLACEBO-CONTROLLED TRIAL; PITUITARY-ADRENAL AXIS; INTRANASAL FLUTICASONE PROPIONATE; ENVIRONMENTAL EXPOSURE UNIT; LONG-TERM SAFETY; LEUKOTRIENE RECEPTOR ANTAGONISTS; ONCE-DAILY TREATMENT; SKIN PRICK TESTS; QUALITY-OF-LIFE AB Objective Allergic rhinitis (AR) is one of the most common diseases affecting adults. It is the most common chronic disease in children in the United States today and the fifth most common chronic disease in the United States overall. AR is estimated to affect nearly 1 in every 6 Americans and generates $2 to $5 billion in direct health expenditures annually. It can impair quality of life and, through loss of work and school attendance, is responsible for as much as $2 to $4 billion in lost productivity annually. Not surprisingly, myriad diagnostic tests and treatments are used in managing this disorder, yet there is considerable variation in their use. This clinical practice guideline was undertaken to optimize the care of patients with AR by addressing quality improvement opportunities through an evaluation of the available evidence and an assessment of the harm-benefit balance of various diagnostic and management options. Purpose The primary purpose of this guideline is to address quality improvement opportunities for all clinicians, in any setting, who are likely to manage patients with AR as well as to optimize patient care, promote effective diagnosis and therapy, and reduce harmful or unnecessary variations in care. The guideline is intended to be applicable for both pediatric and adult patients with AR. Children under the age of 2 years were excluded from the clinical practice guideline because rhinitis in this population may be different than in older patients and is not informed by the same evidence base. The guideline is intended to focus on a limited number of quality improvement opportunities deemed most important by the working group and is not intended to be a comprehensive reference for diagnosing and managing AR. The recommendations outlined in the guideline are not intended to represent the standard of care for patient management, nor are the recommendations intended to limit treatment or care provided to individual patients. Action Statements The development group made a strong recommendation that clinicians recommend intranasal steroids for patients with a clinical diagnosis of AR whose symptoms affect their quality of life. The development group also made a strong recommendation that clinicians recommend oral second-generation/less sedating antihistamines for patients with AR and primary complaints of sneezing and itching. The panel made the following recommendations: (1) Clinicians should make the clinical diagnosis of AR when patients present with a history and physical examination consistent with an allergic cause and 1 or more of the following symptoms: nasal congestion, runny nose, itchy nose, or sneezing. Findings of AR consistent with an allergic cause include, but are not limited to, clear rhinorrhea, nasal congestion, pale discoloration of the nasal mucosa, and red and watery eyes. (2) Clinicians should perform and interpret, or refer to a clinician who can perform and interpret, specific IgE (skin or blood) allergy testing for patients with a clinical diagnosis of AR who do not respond to empiric treatment, or when the diagnosis is uncertain, or when knowledge of the specific causative allergen is needed to target therapy. (3) Clinicians should assess patients with a clinical diagnosis of AR for, and document in the medical record, the presence of associated conditions such as asthma, atopic dermatitis, sleep-disordered breathing, conjunctivitis, rhinosinusitis, and otitis media. (4) Clinicians should offer, or refer to a clinician who can offer, immunotherapy (sublingual or subcutaneous) for patients with AR who have inadequate response to symptoms with pharmacologic therapy with or without environmental controls. The panel recommended against (1) clinicians routinely performing sinonasal imaging in patients presenting with symptoms consistent with a diagnosis of AR and (2) clinicians offering oral leukotriene receptor antagonists as primary therapy for patients with AR. The panel group made the following options: (1) Clinicians may advise avoidance of known allergens or may advise environmental controls (ie, removal of pets; the use of air filtration systems, bed covers, and acaricides [chemical agents formulated to kill dust mites]) in patients with AR who have identified allergens that correlate with clinical symptoms. (2) Clinicians may offer intranasal antihistamines for patients with seasonal, perennial, or episodic AR. (3) Clinicians may offer combination pharmacologic therapy in patients with AR who have inadequate response to pharmacologic monotherapy. (4) Clinicians may offer, or refer to a surgeon who can offer, inferior turbinate reduction in patients with AR with nasal airway obstruction and enlarged inferior turbinates who have failed medical management. (5) Clinicians may offer acupuncture, or refer to a clinician who can offer acupuncture, for patients with AR who are interested in nonpharmacologic therapy. The development group provided no recommendation regarding the use of herbal therapy for patients with AR. C1 [Seidman, Michael D.] Henry Ford West Bloomfield Hosp, Dept Otolaryngol Head & Neck Surg, West Bloomfield, MI 48322 USA. [Gurgel, Richard K.] Univ Utah, Dept Surg Otolaryngol Head & Neck Surg, Salt Lake City, UT USA. [Lin, Sandra Y.] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA. [Schwartz, Seth R.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Baroody, Fuad M.] Univ Chicago, Med Ctr, Dept Otolaryngol, Chicago, IL 60637 USA. [Bonner, James R.] Birmingham VA Med Ctr, Birmingham, AL USA. [Dykewicz, Mark S.] St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO USA. [Hackell, Jesse M.] Pomona Pediat, Pomona, NY USA. [Han, Joseph K.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA. [Ishman, Stacey L.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Krouse, Helene J.] Wayne State Univ, Philadelphia, PA USA. [Malekzadeh, Sonya] Georgetown Univ Hosp, Washington, DC 20007 USA. [Mims, James Whit W.] Wake Forest Baptist Hlth, Winston Salem, NC USA. [Omole, Folashade S.] Morehouse Sch Med, East Point, GA USA. [Reddy, William D.] Acupuncture & Oriental Med AAAOM, Annandale, VA USA. [Wallace, Dana V.] Florida Atlantic Univ, Boca Raton, FL 33431 USA. [Wallace, Dana V.] Nova SE Univ, Davie, FL USA. [Walsh, Sandra A.; Warren, Barbara E.] Consumers United Evidence Based Healthcare, Fredericton, NB, Canada. [Wilson, Meghan N.] Louisiana State Univ, Sch Med, New Orleans, LA USA. [Nnacheta, Lorraine C.] Amer Acad Otolaryngol Head & Neck Surg Fdn, Dept Res & Qual, Alexandria, VA USA. RP Seidman, MD (reprint author), Henry Ford West Bloomfield Hosp, 6777 West Maple Rd, West Bloomfield, MI 48322 USA. EM mseidma1@hfhs.org FU American Academy of Otolaryngology-Head and Neck Surgery Foundation FX American Academy of Otolaryngology-Head and Neck Surgery Foundation. NR 365 TC 49 Z9 58 U1 14 U2 48 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2015 VL 152 SU 1 BP S1 EP S43 DI 10.1177/0194599814561600 PG 43 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CA9GP UT WOS:000349230300001 PM 25644617 ER PT J AU Sheridan, R AF Sheridan, Rob TI Pediatric Burn Injury in Iraq and Afghanistan SO PEDIATRIC CRITICAL CARE MEDICINE LA English DT Editorial Material DE burns; children; military ID MILITARY C1 [Sheridan, Rob] Boston Shriners Hosp Children, Boston, MA 02114 USA. [Sheridan, Rob] Massachusetts Gen Hosp, Div Burns, Boston, MA 02114 USA. [Sheridan, Rob] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. RP Sheridan, R (reprint author), Boston Shriners Hosp Children, Boston, MA 02114 USA. NR 4 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1529-7535 EI 1947-3893 J9 PEDIATR CRIT CARE ME JI Pediatr. Crit. Care Med. PD FEB PY 2015 VL 16 IS 2 BP 197 EP 197 DI 10.1097/PCC.0000000000000330 PG 1 WC Critical Care Medicine; Pediatrics SC General & Internal Medicine; Pediatrics GA CB1KZ UT WOS:000349387600025 PM 25647132 ER PT J AU Servaes, S Khanna, G Naranjo, A Geller, JI Ehrlich, PF Gow, KW Perlman, EJ Dome, JS Gratias, E Mullen, EA AF Servaes, Sabah Khanna, Geetika Naranjo, Arlene Geller, James I. Ehrlich, Peter F. Gow, Kenneth W. Perlman, Elizabeth J. Dome, Jeffrey S. Gratias, Eric Mullen, Elizabeth A. TI Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Children's Oncology Group SO PEDIATRIC RADIOLOGY LA English DT Article DE Renal tumors; Staging; Wilms tumor; Diagnosis; Magnetic resonance imaging; Computed tomography; Pediatric ID NATIONAL WILMS-TUMOR AB CT and MRI are both used for abdominal staging of pediatric renal tumors. The diagnostic performance of the two modalities for local and regional staging of renal tumors has not been systematically evaluated. To compare the diagnostic performance of CT and MRI for local staging of pediatric renal tumors. The study population was derived from the AREN03B2 study of the Children's Oncology Group. Baseline abdominal imaging performed with both CT and MRI within 30 days of nephrectomy was available for retrospective review in 82 renal tumor cases. Each case was evaluated for capsular penetration, lymph node metastasis, tumor thrombus, preoperative tumor rupture, and synchronous contralateral lesions. The surgical and pathological findings at central review were the reference standard. The sensitivity of CT and MRI for detecting capsular penetration was 68.6% and 62.9%, respectively (P = 0.73), while specificity was 86.5% and 83.8% (P = 1.0). The sensitivity of CT and MRI for detecting lymph node metastasis was 76.5% and 52.9% (P = 0.22), and specificity was 90.4% and 92.3% (P = 1.0). Synchronous contralateral lesions were identified by CT in 4/9 cases and by MRI in 7/9 cases. CT and MRI have similar diagnostic performance for detection of lymph node metastasis and capsular penetration. MR detected more contralateral synchronous lesions; however these were present in a very small number of cases. Either modality can be used for initial loco-regional staging of pediatric renal tumors. C1 [Servaes, Sabah] Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA. [Khanna, Geetika] Washington Univ, Sch Med, St Louis Childrens Hosp, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA. [Naranjo, Arlene] Univ Florida, Dept Biostat, Gainesville, FL USA. [Geller, James I.] Cincinnati Childrens Hosp Med Ctr, Div Oncol, Cincinnati, OH 45229 USA. [Ehrlich, Peter F.] Univ Michigan, Dept Surg, CS Mott Childrens Hosp, Ann Arbor, MI 48109 USA. [Gow, Kenneth W.] Seattle Childrens Hosp, Seattle, WA USA. [Perlman, Elizabeth J.] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pathol, Chicago, IL 60611 USA. [Dome, Jeffrey S.] Childrens Natl Med Ctr, Ctr Canc & Blood Disorders, Washington, DC 20010 USA. [Gratias, Eric; Mullen, Elizabeth A.] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA. [Gratias, Eric; Mullen, Elizabeth A.] Harvard Univ, Boston Childrens Hosp, Boston, MA 02115 USA. RP Khanna, G (reprint author), Washington Univ, Sch Med, St Louis Childrens Hosp, Mallinckrodt Inst Radiol, 510 S Kingshighway,Campus Box 8131-MIR, St Louis, MO 63110 USA. EM khannag@mir.wustl.edu FU National Institutes of Health to the Children's Oncology Group [U10 CA98543, U10 CA98413]; National Institutes of Health to the Quality Assurance Review Center (QARC) [CA29511] FX Research was supported by grants U10 CA98543 and U10 CA98413 from the National Institutes of Health to the Children's Oncology Group, and by grant CA29511 from the National Institutes of Health to the Quality Assurance Review Center (QARC). NR 14 TC 1 Z9 1 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0301-0449 EI 1432-1998 J9 PEDIATR RADIOL JI Pediatr. Radiol. PD FEB PY 2015 VL 45 IS 2 BP 166 EP 172 DI 10.1007/s00247-014-3138-2 PG 7 WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging GA CA6KE UT WOS:000349021100006 PM 25135711 ER PT J AU Sagar, P Nimkin, K AF Sagar, Pallavi Nimkin, Katherine TI Feasibility study to assess clinical applications of 3-T cine MRI coupled with synchronous audio recording during speech in evaluation of velopharyngeal insufficiency in children SO PEDIATRIC RADIOLOGY LA English DT Article DE Velopharyngeal insufficiency; Speech; Magnetic resonance imaging; Audio; Children ID VELI-PALATINI MUSCLE; CLEFT-PALATE; INJECTION PHARYNGOPLASTY; VIDEOFLUOROSCOPY; MANAGEMENT; CLOSURE AB In the past decade, there has been increased utilization of magnetic resonance imaging (MRI) in evaluating and understanding velopharyngeal insufficiency (VPI). To our knowledge, none of the prior studies with MRI has simultaneously linked the audio recordings of speech during cine MRI acquisition with the corresponding images and created a video for evaluating VPI. To develop an MRI protocol with static and cine sequences during phonation to evaluate for VPI in children and compare the findings to nasopharyngoscopy and videofluoroscopy. Five children, ages 8-16 years, with known VPI, who had previously undergone nasopharyngoscopy and videofluoroscopy, were included. MRI examination was performed on a 3-T Siemens scanner. Anatomical data was obtained using an isotropic T2-weighted 3-D SPACE sequence with multiplanar reformation capability. Dynamic data was obtained using 2-D FLASH cine sequences of the airway in three imaging planes during phonation. Audio recordings were captured by a MRI compatible optical microphone. All five cases had MRI and nasopharyngoscopy and four had videofluoroscopy performed. VPI was identified by MRI in all five patients. The location and severity of the velopharyngeal gap, closure pattern, velar size and shape and levator veli palatini (LVP) muscle were identified in all patients. MRI was superior in visualizing the integrity of the LVP muscle. MRI was unable to identify hemipalatal weakness in one case. In a case of stress-induced VPI, occurring only during clarinet playing, cine MRI demonstrated discordant findings of a velopharyngeal gap during phonatory tasks but not with instrument playing. Overall, there was satisfactory correlation among MRI, nasopharyngoscopy and videofluoroscopy findings. Cine MRI of the airway during speech is a noninvasive, well-tolerated diagnostic imaging tool that has the potential to serve as a guide prior to and after surgical correction of VPI. MRI provided superior anatomical detail of the levator musculature. The creation of a video with recorded phonation allowed correlation between palatal movements and specific phonatory tasks. C1 [Sagar, Pallavi; Nimkin, Katherine] Massachusetts Gen Hosp, Dept Radiol, Div Pediat Radiol, Boston, MA 02114 USA. RP Sagar, P (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Pediat Radiol, 34 Fruit St,Ellison 237, Boston, MA 02114 USA. EM psagar@mgh.harvard.edu NR 26 TC 4 Z9 4 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0301-0449 EI 1432-1998 J9 PEDIATR RADIOL JI Pediatr. Radiol. PD FEB PY 2015 VL 45 IS 2 BP 217 EP 227 DI 10.1007/s00247-014-3141-7 PG 11 WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging GA CA6KE UT WOS:000349021100013 PM 25124806 ER PT J AU Gfrerer, L Mattos, D Mastroianni, M Weng, QY Ricci, JA Heath, MP Lin, A Specht, MC Haynes, AB Austen, WG Liao, EC AF Gfrerer, Lisa Mattos, David Mastroianni, Melissa Weng, Qing Y. Ricci, Joseph A. Heath, Martha P. Lin, Alex Specht, Michelle C. Haynes, Alex B. Austen, William G., Jr. Liao, Eric C. TI Assessment of Patient Factors, Surgeons, and Surgeon Teams in Immediate Implant-Based Breast Reconstruction Outcomes SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID ACELLULAR DERMAL MATRIX; NIPPLE-SPARING MASTECTOMY; SURGICAL SAFETY CHECKLIST; OF-THE-LITERATURE; HOSPITAL VOLUME; CANCER SURGERY; SKIN FLAP; COMPLICATIONS; MORTALITY; RISK AB Background: Outcome studies of immediate implant-based breast reconstruction have focused largely on patient factors, whereas the relative impact of the surgeon as a contributing variable is not known. As the procedure requires collaboration of both a surgical oncologist and a plastic surgeon, the effect of the surgeon team interaction can have a significant impact on outcome. This study examines outcomes in implant-based breast reconstruction and the association with patient characteristics, surgeon, and surgeon team familiarity. Methods: A retrospective review of 3142 consecutive implant-based breast reconstruction mastectomy procedures at one institution was performed. Infection and skin necrosis rates were measured. Predictors of outcomes were identified by unadjusted logistic regression followed by multivariate logistic regression. Surgeon teams were grouped according to number of cases performed together. Results: Patient characteristics remain the most important predictors for outcomes in implant-based breast reconstruction, with odds ratios above those of surgeon variables. The authors observed significant differences in the rate of skin necrosis between surgical oncologists with an approximately twofold difference between surgeons with the highest and lowest rates. Surgeon teams that worked together on fewer than 150 procedures had higher rates of infection. Conclusions: Patient characteristics are the most important predictors for surgical outcomes in implant-based breast reconstruction, but surgeons and surgeon teams are also important variables. High-volume surgeon teams achieve lower rates of infection. This study highlights the need to examine modifiable risk factors associated with optimum implant-based breast reconstruction outcomes, which include patient and provider characteristics and the surgical team treating the patient. C1 Harvard Univ, Med Sch, Div Plast & Reconstruct Surg, Div Surg Oncol, Cambridge, MA 02138 USA. Harvard Univ, Med Sch, Codman Ctr Clin Effectiveness Surg, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. Harvard Stem Cell Inst, Ctr Regenerat Med, Cambridge, MA USA. RP Liao, EC (reprint author), Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, 15 Parkman St,WACC 435, Boston, MA 02114 USA. EM cliao@partners.org NR 43 TC 10 Z9 10 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0032-1052 EI 1529-4242 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD FEB PY 2015 VL 135 IS 2 BP 245E EP 252E DI 10.1097/PRS.0000000000000912 PG 8 WC Surgery SC Surgery GA CA2UQ UT WOS:000348763800001 PM 25626807 ER PT J AU Iskandar, ME Dayan, E Lucido, D Samson, W Sultan, M Dayan, JH Boolbol, SK Smith, ML AF Iskandar, Mazen E. Dayan, Erez Lucido, David Samson, William Sultan, Mark Dayan, Joseph H. Boolbol, Susan K. Smith, Mark L. TI Factors Influencing Incidence and Type of Postmastectomy Breast Reconstruction in an Urban Multidisciplinary Cancer Center SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID MASTECTOMY; SURGEONS; HEALTH; CARE; INSTITUTION; DISPARITIES; PATTERNS; RATES; WOMEN AB Background: On January 1, 2011, New York State amended the Public Health Law to ensure that patients receive "information and access to breast reconstruction surgery." The purposes of this study were to investigate the early impact of this legislation on reconstruction rates and to evaluate the influence of patient variables versus physician variables on the incidence and type of breast reconstruction performed. Methods: A retrospective study was conducted on all patients who underwent mastectomy between January 1, 2010, and December 31, 2011. Reconstruction rates were analyzed in relation to timing of legislation, breast surgeon variables, plastic surgeon faculty status, type of reconstruction, and patient variables. Results: Two hundred fifty-eight patients met inclusion criteria. The overall reconstruction rate was 56.59 percent. There was no statistically significant increase in reconstruction rate after the 2011 legislation (OR, 0.45; p = 0.057). Patients whose breast surgeon was female were more likely to undergo reconstruction (OR, 5.17; p = 0.001). Patients who were Asian (OR, 0.22; p = 0.002), older than 60 years (OR, 0.09; p = 0.001), or had stage 3 and 4 cancer (OR, 0.04; p = 0.03) were less likely to undergo reconstruction. Patients reconstructed by a hospital-employed plastic surgeon were significantly more likely to undergo autologous versus implant reconstruction (OR, 6.85; p = 0.001) and to undergo microsurgical versus nonmicrosurgical autologous reconstruction (78.2 percent versus 0 percent; p = 0.001). Conclusions: Breast surgeon sex and plastic surgeon faculty status were the factors that most affected the rate and type of reconstruction, respectively. Legislation mandating the discussion of breast reconstruction options had no impact on reconstruction rate. C1 Beth Israel Deaconess Med Ctr, Dept Surg, Div Gen Surg, New York, NY 10003 USA. Beth Israel Deaconess Med Ctr, Dept Surg, Div Biostat, New York, NY 10003 USA. Beth Israel Deaconess Med Ctr, Dept Surg, Div Plast Surg, New York, NY 10003 USA. Beth Israel Deaconess Med Ctr, Dept Surg, Div Breast Surg, New York, NY 10003 USA. RP Smith, ML (reprint author), 10 Union Sq East,Suite 2L, New York, NY 10003 USA. EM msmith@chpnet.org OI Iskandar, Mazen/0000-0001-8902-0419; Dayan, Joseph/0000-0002-6040-3595 NR 21 TC 5 Z9 5 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0032-1052 EI 1529-4242 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD FEB PY 2015 VL 135 IS 2 BP 270E EP 276E DI 10.1097/PRS.0000000000000888 PG 7 WC Surgery SC Surgery GA CA2UQ UT WOS:000348763800004 PM 25626810 ER PT J AU Adib-Samii, P Devan, W Traylor, M Lanfranconi, S Zhang, CR Cloonan, L Falcone, GJ Radmanesh, F Fitzpatrick, K Kanakis, A Rothwell, PM Sudlow, C Boncoraglio, GB Meschia, JF Levi, C Dichgans, M Bevan, S Rosand, J Rost, NS Markus, HS AF Adib-Samii, Poneh Devan, William Traylor, Matthew Lanfranconi, Silvia Zhang, Cathy R. Cloonan, Lisa Falcone, Guido J. Radmanesh, Farid Fitzpatrick, Kaitlin Kanakis, Allison Rothwell, Peter M. Sudlow, Cathie Boncoraglio, Giorgio B. Meschia, James F. Levi, Chris Dichgans, Martin Bevan, Steve Rosand, Jonathan Rost, Natalia S. Markus, Hugh S. TI Genetic Architecture of White Matter Hyperintensities Differs in Hypertensive and Nonhypertensive Ischemic Stroke SO STROKE LA English DT Article DE genetics; hypertension; leukoaraiosis; stroke ID MULTIPLE-SCLEROSIS; COMMON SNPS; VOLUME; HERITABILITY; DISEASE; CADASIL; COHORT AB Background and Purpose-Epidemiological studies suggest that white matter hyperintensities (WMH) are extremely heritable, but the underlying genetic variants are largely unknown. Pathophysiological heterogeneity is known to reduce the power of genome-wide association studies (GWAS). Hypertensive and nonhypertensive individuals with WMH might have different underlying pathologies. We used GWAS data to calculate the variance in WMH volume (WMHV) explained by common single nucleotide polymorphisms (SNPs) as a measure of heritability (SNP heritability [H-SNP]) and tested the hypothesis that WMH heritability differs between hypertensive and nonhypertensive individuals. Methods-WMHV was measured on MRI in the stroke-free cerebral hemisphere of 2336 ischemic stroke cases with GWAS data. After adjustment for age and intracranial volume, we determined which cardiovascular risk factors were independent predictors of WMHV. Using the genome-wide complex trait analysis tool to estimate H-SNP for WMHV overall and within subgroups stratified by risk factors found to be significant in multivariate analyses. Results-A significant proportion of the variance of WMHV was attributable to common SNPs after adjustment for significant risk factors (H-SNP =0.23; P=0.0026). H-SNP estimates were higher among hypertensive individuals (H-SNP =0.45; P=7.99x10-5); this increase was greater than expected by chance (P=0.012). In contrast, estimates were lower, and nonsignificant, in nonhypertensive individuals (H-SNP =0.13; P=0.13). Conclusions-A quarter of variance is attributable to common SNPs, but this estimate was greater in hypertensive individuals. These findings suggest that the genetic architecture of WMH in ischemic stroke differs between hypertensives and nonhypertensives. Future WMHV GWAS studies may gain power by accounting for this interaction. C1 [Adib-Samii, Poneh; Lanfranconi, Silvia] St Georges Univ London, Neurosci Res Ctr, London SW17 ORE, England. [Devan, William; Zhang, Cathy R.; Cloonan, Lisa; Falcone, Guido J.; Radmanesh, Farid; Fitzpatrick, Kaitlin; Kanakis, Allison; Rosand, Jonathan; Rost, Natalia S.] Massachusetts Gen Hosp, Dept Neurol, Ctr Human Genet Res, Boston, MA 02114 USA. [Traylor, Matthew; Bevan, Steve; Markus, Hugh S.] Univ Cambridge, Dept Clin Neurosci, Cambridge, England. [Radmanesh, Farid; Rosand, Jonathan] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Rothwell, Peter M.] Univ Oxford, Nuffield Dept Neurosci, Stroke Prevent Res Unit, Oxford, England. [Sudlow, Cathie] Univ Edinburgh, Inst Genet & Mol Med, Div Clin Neurosci, Edinburgh, Midlothian, Scotland. [Boncoraglio, Giorgio B.] Fdn IRCCS Ist Neurol Carlo Besta, Dept Cerebrovasc Dis, Milan, Italy. [Meschia, James F.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [Levi, Chris] Univ Newcastle, Hunter Med Res Inst, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia. [Levi, Chris] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia. [Dichgans, Martin] Univ Munich, Klinkum Univ Munchen, Inst Stroke & Dementia Res, Munich, Germany. [Dichgans, Martin] Ctr Stroke & Dementia Res, Munich Cluster Syst Neurol SyNergy, Munich, Germany. RP Adib-Samii, P (reprint author), St Georges Univ London, Stroke & Dementia Res Unit, London SW17 ORE, England. EM padibsam@sgul.ac.uk RI Boncoraglio, Giorgio/B-8647-2011; Falcone, Guido/L-2287-2016; OI Falcone, Guido/0000-0002-6407-0302; Traylor, Matthew/0000-0001-6624-8621; Bevan, Steve/0000-0003-0490-6830 FU Stroke Association; Medical Research Council (United Kingdom); National Institute of Health Research; National Institute of Health Research Comprehensive Biomedical Research Centre; National Institute of Neurological Disorders and Stroke; Wellcome Trust Case Control Consortium-2; National Institute of Ageing (Massachusetts General Hospital [MGH]); National Institute of Ageing (Ischemic Stroke Genetics Study [ISGS]); National Institute of Neurological Disorders and Stroke (Siblings With Ischemic Stroke Study); National Institute of Neurological Disorders and Stroke (ISGS); National Institute of Neurological Disorders and Stroke (MGH); American Heart Association/Bugher Foundation Centers for Stroke Prevention Research (MGH); Deane Institute for Integrative Study of Atrial Fibrillation and Stroke (MGH); National Health and Medical Research Council (Australian Stroke Genetics Collaborative); Italian Ministry of Health (Milan); Medical Research Council; Wellcome Trust FX The principal funding was provided by the Stroke Association and Medical Research Council (United Kingdom) training fellowship awarded to Dr Adib-Samii. Dr Markus was supported by a National Institute of Health Research Senior Investigator Award and National Institute of Health Research Comprehensive Biomedical Research Centre Award. Dr Rost was supported by National Institute of Neurological Disorders and Stroke grants. Funding for collection, genotyping, and analysis of stroke samples was provided by Wellcome Trust Case Control Consortium-2, the Intramural Research Program of National Institute of Ageing (Massachusetts General Hospital [MGH] and Ischemic Stroke Genetics Study [ISGS]), National Institute of Neurological Disorders and Stroke (Siblings With Ischemic Stroke Study, ISGS, and MGH), the American Heart Association/Bugher Foundation Centers for Stroke Prevention Research (MGH), Deane Institute for Integrative Study of Atrial Fibrillation and Stroke (MGH), National Health and Medical Research Council (Australian Stroke Genetics Collaborative), and Italian Ministry of Health (Milan). Additional support for sample collection came from the Medical Research Council, National Institute of Health Research Biomedical Research Centre and Acute Vascular Imaging Centre (Oxford), Binks Trust (Edinburgh), and Vascular Dementia Research Foundation (Munich). The British 1958 Birth Cohort was funded by the Medical Research Council and Wellcome Trust, and the UK National Blood Service population was funded by the Wellcome Trust. NR 26 TC 7 Z9 7 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD FEB PY 2015 VL 46 IS 2 BP 348 EP 353 DI 10.1161/STROKEAHA.114.006849 PG 6 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA AZ8AS UT WOS:000348437800023 PM 25550368 ER PT J AU Schaefer, PW Souza, L Kamalian, S Hirsch, JA Yoo, AJ Kamalian, S Gonzalez, RG Lev, MH AF Schaefer, Pamela W. Souza, Leticia Kamalian, Shervin Hirsch, Joshua A. Yoo, Albert J. Kamalian, Shahmir Gonzalez, R. Gilberto Lev, Michael H. TI Limited Reliability of Computed Tomographic Perfusion Acute Infarct Volume Measurements Compared With Diffusion-Weighted Imaging in Anterior Circulation Stroke SO STROKE LA English DT Article DE stroke ID ACUTE ISCHEMIC-STROKE; FOCAL CEREBRAL-ISCHEMIA; MEAN TRANSIT-TIME; PATIENT SELECTION; T2-WEIGHTED MRI; THRESHOLDS VARY; LESION VOLUME; BLOOD-FLOW; CT; THERAPY AB Background and Purpose-Diffusion-weighted imaging (DWI) can reliably identify critically ischemic tissue shortly after stroke onset. We tested whether thresholded computed tomographic cerebral blood flow (CT-CBF) and CT-cerebral blood volume (CT-CBV) maps are sufficiently accurate to substitute for DWI for estimating the critically ischemic tissue volume. Methods-Ischemic volumes of 55 patients with acute anterior circulation stroke were assessed on DWI by visual segmentation and on CT-CBF and CT-CBV with segmentation using 15% and 30% thresholds, respectively. The contrast: noise ratios of ischemic regions on the DWI and CT perfusion (CTP) images were measured. Correlation and Bland-Altman analyses were used to assess the reliability of CTP. Results-Mean contrast: noise ratios for DWI, CT-CBF, and CT-CBV were 4.3, 0.9, and 0.4, respectively. CTP and DWI lesion volumes were highly correlated (R-2=0.87 for CT-CBF; R-2=0.83 for CT-CBV; P<0.001). Bland-Altman analyses revealed little systemic bias (-2.6 mL) but high measurement variability (95% confidence interval, +/- 56.7 mL) between mean CT-CBF and DWI lesion volumes, and systemic bias (-26 mL) and high measurement variability (95% confidence interval, +/- 64.0 mL) between mean CT-CBV and DWI lesion volumes. A simulated treatment study demonstrated that using CTP-CBF instead of DWI for detecting a statistically significant effect would require at least twice as many patients. Conclusions-The poor contrast: noise ratios of CT-CBV and CT-CBF compared with those of DWI result in large measurement error, making it problematic to substitute CTP for DWI in selecting individual acute stroke patients for treatment. CTP could be used for treatment studies of patient groups, but the number of patients needed to identify a significant effect is much higher than the number needed if DWI is used. C1 [Schaefer, Pamela W.; Souza, Leticia; Kamalian, Shervin; Hirsch, Joshua A.; Yoo, Albert J.; Kamalian, Shahmir; Gonzalez, R. Gilberto; Lev, Michael H.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Schaefer, PW (reprint author), Massachusetts Gen Hosp, Dept Radiol, GRB 273A,55 Fruit St, Boston, MA 02114 USA. EM pschaefer@partners.org RI Kamalian, Shervin/D-7667-2013; OI Kamalian, Shervin/0000-0001-8962-4773; Kamalian, Shahmir/0000-0002-9640-8144 FU National Institutes of Health Special Program of Translational Research in Acute Stroke Network [P50 NS051343]; Agency for Healthcare Research and Quality [R01 HS11392]; Massachusetts General Hospital Clinical Research Center [1 UL1 RR025758-01] FX This work was supported by grants from the National Institutes of Health Special Program of Translational Research in Acute Stroke Network (P50 NS051343), Agency for Healthcare Research and Quality (R01 HS11392), and Massachusetts General Hospital Clinical Research Center (no. 1 UL1 RR025758-01). NR 31 TC 15 Z9 15 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD FEB PY 2015 VL 46 IS 2 BP 419 EP 424 DI 10.1161/STROKEAHA.114.007117 PG 6 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA AZ8AS UT WOS:000348437800034 PM 25550366 ER PT J AU Fisher, MB Belkin, NS Milby, AH Henning, EA Bostrom, M Kim, M Pfeifer, C Meloni, G Dodge, GR Burdick, JA Schaer, TP Steinberg, DR Mauck, RL AF Fisher, Matthew B. Belkin, Nicole S. Milby, Andrew H. Henning, Elizabeth A. Bostrom, Marc Kim, Minwook Pfeifer, Christian Meloni, Gregory Dodge, George R. Burdick, Jason A. Schaer, Thomas P. Steinberg, David R. Mauck, Robert L. TI Cartilage Repair and Subchondral Bone Remodeling in Response to Focal Lesions in a Mini-Pig Model: Implications for Tissue Engineering SO TISSUE ENGINEERING PART A LA English DT Article ID AUTOLOGOUS CHONDROCYTE IMPLANTATION; ARTICULAR-CARTILAGE; IN-VIVO; STEM-CELL; KNEE ARTHROSCOPIES; ANIMAL-MODELS; FOLLOW-UP; DEFECTS; MATRIX; TRANSPLANTATION AB Objective: Preclinical large animal models are essential for evaluating new tissue engineering (TE) technologies and refining surgical approaches for cartilage repair. Some preclinical animal studies, including the commonly used minipig model, have noted marked remodeling of the subchondral bone. However, the mechanisms underlying this response have not been well characterized. Thus, our objective was to compare in-vivo outcomes of chondral defects with varied injury depths and treatments. Design: Trochlear chondral defects were created in 11 Yucatan minipigs (6 months old). Groups included an untreated partial-thickness defect (PTD), an untreated full-thickness defect (FTD), and FTDs treated with microfracture, autologous cartilage transfer (FTD-ACT), or an acellular hyaluronic acid hydrogel. Six weeks after surgery, micro-computed tomography (mu CT) was used to quantitatively assess defect fill and subchondral bone remodeling. The quality of cartilage repair was assessed using the ICRS-II histological scoring system and immunohistochemistry for type II collagen. A finite element model (FEM) was developed to assess load transmission. Results: Using mu CT, substantial bone remodeling was observed for all FTDs, but not for the PTD group. The best overall histological scores and greatest type II collagen staining was found for the FTD-ACT and PTD groups. The FEM confirmed that only the FTD-ACT group could initially restore appropriate transfer of compressive loads to the underlying bone. Conclusions: The bony remodeling observed in this model system appears to be a biological phenomena and not a result of altered mechanical loading, with the depth of the focal chondral defect (partial vs. full thickness) dictating the bony remodeling response. The type of cartilage injury should be carefully controlled in studies utilizing this model to evaluate TE approaches for cartilage repair. C1 [Fisher, Matthew B.; Belkin, Nicole S.; Milby, Andrew H.; Henning, Elizabeth A.; Bostrom, Marc; Kim, Minwook; Pfeifer, Christian; Meloni, Gregory; Dodge, George R.; Steinberg, David R.; Mauck, Robert L.] Univ Penn, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. [Fisher, Matthew B.; Belkin, Nicole S.; Milby, Andrew H.; Henning, Elizabeth A.; Bostrom, Marc; Kim, Minwook; Pfeifer, Christian; Meloni, Gregory; Dodge, George R.; Burdick, Jason A.; Steinberg, David R.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA. [Burdick, Jason A.; Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. [Schaer, Thomas P.] Univ Penn, Sch Vet Med, Comparat Orthoped Res Lab, Philadelphia, PA 19104 USA. RP Mauck, RL (reprint author), Univ Penn, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Perelman Sch Med, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA. EM lemauck@mail.med.upenn.edu RI Fisher, Matthew/M-5809-2016 OI Fisher, Matthew/0000-0002-3212-0870 FU National Institutes of Health [R01 EB008722, F32 AR062971]; Department of Veterans Affairs [I01 RX000700]; AO Foundation; Orthopedic Research and Education Foundation (Resident Clinician Scientist Training Grant) FX The authors thank Nicole Soegaard for her technical assistance. This work was supported by the National Institutes of Health (R01 EB008722 and F32 AR062971), the Department of Veterans Affairs (I01 RX000700), the AO Foundation, and the Orthopedic Research and Education Foundation (Resident Clinician Scientist Training Grant). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs. No funding source had a role in the study design, collection, analysis and interpretation of data, writing of this article, or the decision to submit this article for publication. NR 54 TC 13 Z9 13 U1 4 U2 25 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3341 EI 1937-335X J9 TISSUE ENG PT A JI Tissue Eng. Part A PD FEB 1 PY 2015 VL 21 IS 3-4 BP 850 EP 860 DI 10.1089/ten.tea.2014.0384 PG 11 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA CB4PZ UT WOS:000349611600040 PM 25318414 ER PT J AU Levkovitz, Y Isserles, M Padberg, F Lisanby, SH Bystritsky, A Xia, GH Tendler, A Daskalakis, ZJ Winston, JL Dannon, P Hafez, HM Reti, IM Morales, OG Schlaepfer, TE Hollander, E Berman, JA Husain, MM Sofer, U Stein, A Adler, S Deutsch, L Deutsch, F Roth, Y George, MS Zangen, A AF Levkovitz, Yechiel Isserles, Moshe Padberg, Frank Lisanby, Sarah H. Bystritsky, Alexander Xia, Guohua Tendler, Aron Daskalakis, Zafiris J. Winston, Jaron L. Dannon, Pinhas Hafez, Hisham M. Reti, Irving M. Morales, Oscar G. Schlaepfer, Thomas E. Hollander, Eric Berman, Joshua A. Husain, Mustafa M. Sofer, Uzi Stein, Ahava Adler, Shmulik Deutsch, Lisa Deutsch, Frederic Roth, Yiftach George, Mark S. Zangen, Abraham TI Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial SO WORLD PSYCHIATRY LA English DT Article DE Deep transcranial magnetic stimulation; major depressive disorder; treatment resistance; response; remission; maintenance treatment ID FUNCTIONAL CONNECTIVITY; PREFRONTAL CORTEX; BRAIN-REGIONS; H-COIL; DISORDER; METAANALYSIS; FIGURE-8; THERAPY; TMS AB Major depressive disorder (MDD) is a prevalent and disabling condition, and many patients do not respond to available treatments. Deep transcranial magnetic stimulation (dTMS) is a new technology allowing non-surgical stimulation of relatively deep brain areas. This is the first double-blind randomized controlled multicenter study evaluating the efficacy and safety of dTMS in MDD. We recruited 212 MDD outpatients, aged 22-68 years, who had either failed one to four antidepressant trials or not tolerated at least two antidepressant treatments during the current episode. They were randomly assigned to monotherapy with active or sham dTMS. Twenty sessions of dTMS (18 Hz over the prefrontal cortex) were applied during 4 weeks acutely, and then biweekly for 12 weeks. Primary and secondary efficacy endpoints were the change in the Hamilton Depression Rating Scale (HDRS-21) score and response/remission rates at week 5, respectively. dTMS induced a 6.39 point improvement in HDRS-21 scores, while a 3.28 point improvement was observed in the sham group (p=0.008), resulting in a 0.76 effect size. Response and remission rates were higher in the dTMS than in the sham group (response: 38.4 vs. 21.4%, p=0.013; remission: 32.6 vs. 14.6%, p=0.005). These differences between active and sham treatment were stable during the 12-week maintenance phase. dTMS was associated with few and minor side effects apart from one seizure in a patient where a protocol violation occurred. These results suggest that dTMS constitutes a novel intervention in MDD, which is efficacious and safe in patients not responding to antidepressant medications, and whose effect remains stable over 3 months of maintenance treatment. C1 [Levkovitz, Yechiel] Tel Aviv Univ, Shalvata Mental Hlth Ctr, Hod Hasharon, Israel. [Isserles, Moshe] Hadassah Hebrew Univ Med Ctr, Dept Psychiat, Jerusalem, Israel. [Padberg, Frank] Univ Munich, Dept Psychiat & Psychotherapy, Munich, Germany. [Lisanby, Sarah H.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA. [Lisanby, Sarah H.] Duke Univ, Dept Psychol & Neurosci, Durham, NC USA. [Bystritsky, Alexander] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Xia, Guohua] Univ Calif Davis, UC Davis Ctr Mind & Brain, Davis, CA 95616 USA. [Xia, Guohua] Univ Calif Davis, Dept Psychiat & Behav Sci, Davis, CA 95616 USA. [Tendler, Aron] Adv Mental Hlth Care Inc, Royal Palm Beach, FL USA. [Daskalakis, Zafiris J.] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Winston, Jaron L.] Senior Adult Specialty Healthcare, Austin, TX USA. [Dannon, Pinhas] Tel Aviv Univ, Beer Yaakov Mental Hlth Ctr, Beer Yaagov, Israel. [Hafez, Hisham M.] Greater Nashua Mental Hlth Ctr, Nashua, NH USA. [Reti, Irving M.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Morales, Oscar G.] McLean Hosp, Belmont, MA 02178 USA. [Morales, Oscar G.] Harvard Univ, Sch Med, Belmont, MA 02178 USA. [Schlaepfer, Thomas E.] Univ Hosp, Dept Psychiat & Psychotherapy, Bonn, Germany. [Hollander, Eric] Spectrum Neurosci & Treatment Ctr, New York, NY USA. [Berman, Joshua A.] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Psychiat, New York, NY 10032 USA. [Husain, Mustafa M.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Sofer, Uzi] Brainsway Ltd, Jerusalem, Israel. [Stein, Ahava; Adler, Shmulik] A Stein Regulatory Affairs Consulting Ltd, Kefar Sava, Israel. [Roth, Yiftach; Zangen, Abraham] Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel. [George, Mark S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Levkovitz, Y (reprint author), Tel Aviv Univ, Shalvata Mental Hlth Ctr, Hod Hasharon, Israel. RI Tendler, Aron/L-9274-2016 OI Tendler, Aron/0000-0001-8587-7335 NR 29 TC 33 Z9 34 U1 5 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1723-8617 EI 2051-5545 J9 WORLD PSYCHIATRY JI World Psychiatry PD FEB PY 2015 VL 14 IS 1 BP 64 EP 73 DI 10.1002/wps.20199 PG 10 WC Psychiatry SC Psychiatry GA CB0FC UT WOS:000349300000019 PM 25655160 ER PT J AU Riess, H AF Riess, Helen TI Missed Moments: Slowing Down to Reclaim Empathy Reply SO ACADEMIC MEDICINE LA English DT Letter C1 [Riess, Helen] Harvard Univ, Sch Med, Boston, MA 02138 USA. [Riess, Helen] Massachusetts Gen Hosp, Empathy & Relat Sci Program, Boston, MA 02114 USA. RP Riess, H (reprint author), Harvard Univ, Sch Med, Boston, MA 02138 USA. EM hriess@mgh.harvard.edu NR 0 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD FEB PY 2015 VL 90 IS 2 BP 128 EP 128 PG 1 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA CA3LL UT WOS:000348808000007 PM 25628134 ER PT J AU Patel, N Brennan, PJ Metlay, J Bellini, L Shannon, RP Myers, JS AF Patel, Neha Brennan, P. J. Metlay, Joshua Bellini, Lisa Shannon, Richard P. Myers, Jennifer S. TI Building the Pipeline: The Creation of a Residency Training Pathway for Future Physician Leaders in Health Care Quality SO ACADEMIC MEDICINE LA English DT Editorial Material ID PATIENT SAFETY; IMPROVEMENT AB Problem Many health care organizations seek physicians to lead quality improvement (QI) efforts, yet struggle to find individuals with the necessary expertise. Although most residency programs incorporate QI and patient safety principles into their curricula, few provide a specialized training program for residents exploring careers as physician leaders in quality. Approach Recognizing this training void, the authors designed and implemented the Healthcare Leadership in Quality (HLQ) track for residents at the University of Pennsylvania Health System in 2010. This longitudinal, two-year graduate medical education (GME) track aligns with the quality goals of the University of Pennsylvania Health System and includes a core curriculum, integration into an interprofessional health care leadership team that is accountable for quality and safety outcomes on a hospital unit, a capstone QI project, and mentorship. Outcomes Early evaluation has demonstrated the feasibility and efficacy of the track diverse graduate medical education training programs. Using Yardley and Dornan's interpretation of the Kirkpatrick framework, the authors have demonstrated the track's impact on four levels of educational and organizational outcomes. Next Steps Building on their early experiences, the authors are integrating project and time management skills into the core curriculum, and they are focusing more effort on faculty development in QI mentorship. Additionally, the authors plan to follow HLQ track graduates to determine whether they seek leadership roles in quality and safety and to assess the influence of the program on their careers. C1 [Patel, Neha; Bellini, Lisa; Myers, Jennifer S.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Patel, Neha] Univ Penn, Perelman Sch Med, Sect Hosp Med, Philadelphia, PA 19104 USA. [Patel, Neha; Brennan, P. J.; Myers, Jennifer S.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Brennan, P. J.] Univ Penn Hlth Syst, Philadelphia, PA USA. [Metlay, Joshua] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Bellini, Lisa] Univ Penn, Perelman Sch Med, Fac Affairs, Philadelphia, PA 19104 USA. [Shannon, Richard P.] Univ Virginia Hlth Syst, Charlottesville, VA USA. RP Patel, N (reprint author), 3400 Spruce St,Penn Tower,Suite 2009, Philadelphia, PA 19104 USA. EM neha.patel@uphs.upenn.edu FU Office of the Chief Medical Officer of the University of Pennsylvania Health System; Department of Medicine at the Perelman School of Medicine at the University of Pennsylvania; Josiah Macy Jr. Foundation FX The Healthcare Leadership in Quality track is supported by the Office of the Chief Medical Officer of the University of Pennsylvania Health System and the Department of Medicine at the Perelman School of Medicine at the University of Pennsylvania. Dr. Myers is supported in part by a grant from the Josiah Macy Jr. Foundation. NR 10 TC 6 Z9 6 U1 4 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD FEB PY 2015 VL 90 IS 2 BP 185 EP 190 DI 10.1097/ACM.0000000000000546 PG 6 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA CA3LL UT WOS:000348808000023 PM 25354070 ER PT J AU Carnes, M Devine, PG Manwell, LB Byars-Winston, A Fine, E Ford, CE Forscher, P Isaac, C Kaatz, A Magua, W Palta, M Sheridan, J AF Carnes, Molly Devine, Patricia G. Manwell, Linda Baier Byars-Winston, Angela Fine, Eve Ford, Cecilia E. Forscher, Patrick Isaac, Carol Kaatz, Anna Magua, Wairimu Palta, Mari Sheridan, Jennifer TI The Effect of an Intervention to Break the Gender Bias Habit for Faculty at One Institution: A Cluster Randomized, Controlled Trial SO ACADEMIC MEDICINE LA English DT Article ID ACADEMIC MEDICINE; SEX-DISCRIMINATION; CONSORT STATEMENT; CAUTIONARY TALE; BASE-LINE; WOMEN; PREJUDICE; STEREOTYPES; LEADERSHIP; CULTURE AB Purpose Despite sincere commitment to egalitarian, meritocratic principles, subtle gender bias persists, constraining women's opportunities for academic advancement. The authors implemented a pair-matched, single-blind, cluster randomized, controlled study of a gender-bias-habit-changing intervention at a large public university. Method Participants were faculty in 92 departments or divisions at the University of Wisconsin Madison. Between September 2010 and March 2012, experimental departments were offered a gender-bias-habit-changing intervention as a 2.5-hour workshop. Surveys measured gender bias awareness; motivation, self-efficacy, and outcome expectations to reduce bias; and gender equity action. A timed word categorization task measured implicit gender/leadership bias. Faculty completed a work life survey before and after all experimental departments received the intervention. Control departments were offered workshops after data were collected. Results Linear mixed-effects models showed significantly greater changes post intervention for faculty in experimental versus control departments on several outcome measures, including self-efficacy to engage in gender-equity-promoting behaviors (P=.013). When 25% of a department's faculty attended the workshop (26 of 46 departments), significant increases in self-reported action to promote gender equity occurred at three months (P =.007). Post intervention, faculty in experimental departments expressed greater perceptions of fit (P=.024), valuing of their research (P=.019), and comfort in raising personal and professional conflicts (P =.025). Conclusions An intervention that facilitates intentional behavioral change can help faculty break the gender bias habit and change department climate in ways that should support the career advancement of women in academic medicine, science, and engineering. C1 [Carnes, Molly; Kaatz, Anna; Magua, Wairimu] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53715 USA. [Carnes, Molly; Manwell, Linda Baier; Byars-Winston, Angela] Univ Wisconsin, Dept Med, Madison, WI 53715 USA. [Carnes, Molly] Univ Wisconsin, Dept Psychiat, Madison, WI 53715 USA. [Carnes, Molly] Univ Wisconsin, Dept Ind & Syst Engn, Madison, WI 53715 USA. [Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Devine, Patricia G.; Forscher, Patrick] Univ Wisconsin, Dept Psychol, Madison, WI 53715 USA. [Manwell, Linda Baier] Vet Hlth Adm Cent Off, Womens Hlth Serv, Washington, DC USA. [Fine, Eve; Sheridan, Jennifer] Univ Wisconsin, Women Sci & Engn Leadership Inst, Madison, WI 53715 USA. [Ford, Cecilia E.] Univ Wisconsin, Dept English & Sociol, Madison, WI 53715 USA. [Isaac, Carol] Mercer Univ, Atlanta, GA USA. [Palta, Mari] Univ Wisconsin, Dept Biostat, Madison, WI 53715 USA. [Palta, Mari] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53715 USA. RP Carnes, M (reprint author), Univ Wisconsin, 700 Regent St,Suite 301, Madison, WI 53715 USA. EM mlcarnes@wisc.edu FU National Institutes of Health [R01 GM088477, DP4 GM096822, R25 GM083252] FX This work was supported by National Institutes of Health grants R01 GM088477, DP4 GM096822, and R25 GM083252. NR 76 TC 32 Z9 32 U1 6 U2 33 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD FEB PY 2015 VL 90 IS 2 BP 221 EP 230 DI 10.1097/ACM.0000000000000552 PG 10 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA CA3LL UT WOS:000348808000029 PM 25374039 ER PT J AU Iezzoni, LI Wint, AJ Smeltzer, SC Ecker, JL AF Iezzoni, Lisa I. Wint, Amy J. Smeltzer, Suzanne C. Ecker, Jeffrey L. TI Effects of disability on pregnancy experiences among women with impaired mobility SO ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA LA English DT Article DE Pregnancy; disability; functional impairment; wheelchair; falls; spasticity; respiratory support; pressure ulcers ID CHRONIC PHYSICAL-DISABILITIES; REPRODUCTIVE HEALTH-CARE; SPINAL-CORD INJURIES; CEREBRAL-PALSY; BREAST-CANCER; US WOMEN; BIFIDA; DIAGNOSIS; ISSUES; ADULTS AB ObjectiveLittle is known about how functional impairments might affect the pregnancies of women with mobility disability. We aimed to explore complications that arise during pregnancy that are specifically related to physical functional impairments of women with significant mobility disabilities. DesignQualitative descriptive analysis. SettingTelephone interviews with women from 17 USA states. Sample22 women with significant mobility difficulties who had delivered babies within the prior 10years; most participants were recruited through social networks. MethodsWe conducted 2-h, in-depth telephone interviews using a semi-structured, open-ended interview protocol. We used NVIVO software to sort interview transcript texts for conventional content analyses. Main outcome measuresFunctional impairment-related complications during pregnancy. ResultsThe women's mean (standard deviation) age was 34.8 (5.3)years. Most were white, well-educated, and higher income; eight women had spinal cord injuries, four cerebral palsy, and 10 had other conditions; 18 used wheeled mobility aids; and 14 had cesarean deliveries (eight elective). Impairment-related complications during pregnancy included: falls; urinary tract and bladder problems; wheelchair fit and stability problems that reduced mobility and compromised safety; significant shortness of breath, sometimes requiring respiratory support; increased spasticity; bowel management difficulties; and skin integrity problems (this was rare, but many women greatly increased skin monitoring during pregnancy to prevent pressure ulcers). ConclusionsIn addition to other pregnancy-associated health risks, women with mobility disabilities appear to experience problems relating to their functional impairments. Pre-conception planning and in-depth discussions during early pregnancy could potentially assist women with mobility disabilities to anticipate and address these difficulties. C1 [Iezzoni, Lisa I.; Wint, Amy J.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Iezzoni, Lisa I.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Smeltzer, Suzanne C.] Villanova Univ, Coll Nursing, Ctr Nursing Res, Philadelphia, PA USA. [Ecker, Jeffrey L.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Ecker, Jeffrey L.] Harvard Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA USA. RP Iezzoni, LI (reprint author), Massachusetts Gen Hosp, Mongan Inst Hlth Policy, 50 Staniford St,Room 901B, Boston, MA 02114 USA. EM liezzoni@mgh.harvard.edu FU Eunice Kennedy Shriver National Institute of Child Health and Human Development in the National Institutes of Health (USA) [1R21HD068756-02] FX The Eunice Kennedy Shriver National Institute of Child Health and Human Development in the National Institutes of Health (USA) funded this study (grant no. 1R21HD068756-02). NR 30 TC 7 Z9 7 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0001-6349 EI 1600-0412 J9 ACTA OBSTET GYN SCAN JI Acta Obstet. Gynecol. Scand. PD FEB PY 2015 VL 94 IS 2 BP 133 EP 140 DI 10.1111/aogs.12544 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CA2DJ UT WOS:000348718800003 PM 25417861 ER PT J AU Lowe, JR Raugi, G Reiber, GE Whitney, JD AF Lowe, Jeanne R. Raugi, Greg Reiber, Gayle E. Whitney, JoAnne D. TI Changes in Classifications of Chronic Lower-Limb Wound Codes in Patients with Diabetes: ICD-9-CM Versus ICD-10-CM SO ADVANCES IN SKIN & WOUND CARE LA English DT Article DE ICD-9; ICD-10; diabetes and foot ulcers; wound classification ID ADMINISTRATIVE DATA; AMPUTATION; VALIDITY AB OBJECTIVE: To determine the sensitivity and specificity of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) and ICD-10-CM codes for individuals with diabetes and foot ulcers. DESIGN AND METHODS: Wound care providers and researchers are concerned about the potential impacts when the United States transitions from ICD-9-CM to ICD-10-CM. To identify the impact on diabetic foot ulcers, health history and wound variables were prospectively assessed with criterion-standard data from a prospective study of 49 patients with 65 foot ulcer episodes representing 81 incident foot ulcers. The ICD-9-CM and ICD-10-CM code sets were mapped to correctly classify individuals with diabetes and foot ulcers. RESULTS: Frequencies for health history variables were similar in both systems. The ICD-9 code did not capture any data on laterality (left or right) or ulcer depth/severity. The ICD-9 captured 69 of 81 incident ulcers (85%) and 94% of heel and midfoot ulcers, whereas the ICD-10 code captured 78 of 81 incident ulcers (96%) and all incident heel or midfoot ulcers. Sensitivity and specificity for ulcer characteristics were consistently lower in ICD-9 than in ICD-10. CONCLUSIONS: The ICD-9 and ICD-10 are similar for data capture on health history variables, but wound variables are captured more accurately using ICD-10. The increased specificity of ICD-10 for ulcer location and severity improves identification and tracking ulcers during an episode of care. C1 [Lowe, Jeanne R.; Whitney, JoAnne D.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Lowe, Jeanne R.] UW Med Hlth Syst, Dept Finance, Pay For Performance, Seattle, WA USA. [Raugi, Greg] VA Puget Sound Med, Ctr, Teledermatol, Seattle, WA USA. [Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Lowe, JR (reprint author), Univ Washington, Sch Nursing, Seattle, WA 98195 USA. FU Biobehavioral Nursing Research Training Program, NIH/NINR University of Washington, Seattle [NR007106]; VA Health Services and Research Development Project [IBA 09061]; VA Senior Career Scientist Award [98-353] FX This study is funded in part by the Biobehavioral Nursing Research Training Program, NR007106 NIH/NINR University of Washington, Seattle. Funding was also provided by the VA Health Services and Research Development Project IBA 09061. Dr Reiber's salary is supported by VA Senior Career Scientist Award 98-353. NR 15 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1527-7941 EI 1538-8654 J9 ADV SKIN WOUND CARE JI Adv. Skin Wound Care PD FEB PY 2015 VL 28 IS 2 BP 84 EP 92 PG 9 WC Dermatology; Nursing; Surgery SC Dermatology; Nursing; Surgery GA CA0GS UT WOS:000348595600006 PM 25608014 ER PT J AU Mutumba, M Bauermeister, JA Musiime, V Byaruhanga, J Francis, K Snow, RC Tsai, AC AF Mutumba, Massy Bauermeister, Jose A. Musiime, Victor Byaruhanga, Judith Francis, Kiweewa Snow, Rachel C. Tsai, Alexander C. TI Psychosocial Challenges and Strategies for Coping with HIV Among Adolescents in Uganda: A Qualitative Study SO AIDS PATIENT CARE AND STDS LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED STIGMA; SUB-SAHARAN AFRICA; SOCIAL SUPPORT; SEROSTATUS DISCLOSURE; MEDICATION ADHERENCE; MENTAL-HEALTH; RURAL UGANDA; ANTIRETROVIRAL THERAPY; PSYCHOLOGICAL DISTRESS AB Although more than 90% of youth perinatally infected with HIV live in sub-Saharan Africa, little is known about the psychosocial factors that impact their wellbeing, or how these youth cope with these challenges. The purpose of this study was to identify the psychosocial challenges and coping strategies among perinatal HIV-infected adolescents in Uganda. In-depth interviews were conducted with a purposive sample of 38 HIV-infected adolescents aged 12-19 years at a large HIV treatment center in Kampala. Data were analyzed thematically to identify themes and domains related to stressors and specific coping strategies. Psychosocial challenges included stigma/discrimination, relationship challenges such as HIV status disclosure, and medication difficulties. Coping strategies included medication adherence, concealment or limited disclosure of HIV status, treatment optimism, social support, rationalizing, social comparison, spirituality/religiosity, avoidance, and distraction. Age and gender differences also emerged: younger participants generally lacked specific coping strategies; compared to females, male adolescents reported greater use of avoidance/distraction techniques. Findings underscore the need to address stigma within homes and schools, and to equip adolescents with the comprehensive knowledge and skills to address their varied challenges. C1 [Mutumba, Massy; Bauermeister, Jose A.; Snow, Rachel C.] Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48104 USA. [Mutumba, Massy; Musiime, Victor; Byaruhanga, Judith] Joint Clin Res Ctr, Kampala, Uganda. [Musiime, Victor] Makerere Univ, Coll Hlth Sci, Dept Pediat, Kampala, Uganda. [Francis, Kiweewa] Makerere Univ, Walter Reed Project, Kampala, Uganda. [Tsai, Alexander C.] Mbarara Univ Sci & Technol, Mbarara, Uganda. [Tsai, Alexander C.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Tsai, Alexander C.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA. [Tsai, Alexander C.] Massachusetts Gen Hosp, Chester M Pierce MD Div Global Psychiat, Boston, MA 02114 USA. RP Mutumba, M (reprint author), Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, 1415 Washington Hts, Ann Arbor, MI 48104 USA. EM massymutumba@umich.edu OI Musiime, Victor/0000-0001-7472-9054; Mutumba, Massy/0000-0002-0636-891X; Tsai, Alexander/0000-0001-6397-7917; Bauermeister, Jose/0000-0002-9276-2306 FU African Studies Center; Rackham School of Graduate Studies FX This study was facilitated through grants from various institutions at University of Michigan including the African Studies Center and Rackham School of Graduate Studies. We are especially grateful for the management and staff at the JCRC, particularly those in the Pediatric Clinic for their willingness to share their time and insights. A special thanks also to all the respondents, who so willingly labored through the interviews and focus group discussions to share their unique insights. NR 73 TC 6 Z9 6 U1 2 U2 8 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 EI 1557-7449 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD FEB 1 PY 2015 VL 29 IS 2 BP 86 EP 94 DI 10.1089/apc.2014.0222 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CB0MJ UT WOS:000349320000005 PM 25607900 ER PT J AU Sarma, A O'Donoghue, ML AF Sarma, Amy O'Donoghue, Michelle L. TI Surviving the gauntlet: Modern challenges in cardiovascular drug approval and implementation SO AMERICAN HEART JOURNAL LA English DT Editorial Material ID ACUTE CORONARY SYNDROMES; CLOPIDOGREL C1 [Sarma, Amy] Massachusetts Gen Hosp, Div Cardiovasc, Boston, MA 02114 USA. [O'Donoghue, Michelle L.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. RP O'Donoghue, ML (reprint author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 350 Longwood Ave,First Floor, Boston, MA 02115 USA. EM modonoghue@partners.org NR 17 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD FEB PY 2015 VL 169 IS 2 BP 191 EP 193 DI 10.1016/j.ahj.2014.10.016 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CA9AN UT WOS:000349212800001 PM 25641526 ER PT J AU Varraso, R Barr, RG Willett, WC Speizer, FE Camargo, CA AF Varraso, Raphaelle Barr, R. Graham Willett, Walter C. Speizer, Frank E. Camargo, Carlos A., Jr. TI Fish intake and risk of chronic obstructive pulmonary disease in 2 large US cohorts SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE diet; epidemiology; respiratory diseases; fish; dietary patterns ID POLYUNSATURATED FATTY-ACIDS; MIDDLE-AGED MEN; 3 EUROPEAN COUNTRIES; DIETARY PATTERNS; LUNG-FUNCTION; RESPIRATORY-DISEASE; NATIONAL-HEALTH; WOMEN; SMOKING; ASTHMA AB Background: Despite mechanistic data that linked fish and omega-3 (n-3) PUFAs with lower risk of chronic obstructive pulmonary disease (COPD), epidemiologic data remain scarce. Fish and n-3 PUFAs are an important component of the prudent dietary pattern that is thought to be protective in the onset of COPD. Objective: We examined the role of fish and PUPA intakes on risk of developing COPD while taking into account the overall dietary pattern. Design: We investigated the objective in 120,175 women and men from the Nurses' Health Study and Health Professionals Follow-Up Study. Over the study period (1984-2000), there were 889 cases of newly diagnosed COPD. Cumulative average intakes of fish, eicosapentaenoic acid, docosahexaenoic acid, n-3 PUFAs, n-6 PUFAs, and the n-3:n-6 ratio were calculated from repeated food-frequency questionnaires. Because fish is a food group included in the prudent pattern, we derived a new prudent pattern without the contribution from fish, and we termed this pattern the "modified prudent" pattern. We performed multivariable Cox proportional hazards models. Results: Before the dietary pattern was taken into account, and with 14 factors controlled for, we showed that more-frequent fish intake (>= 4 servings/wk) was inversely associated with risk of COPD [adjusted pooled HR for the highest intake compared with the lowest intake (<1 serving/wk): 0.71; 95% CI: 0.54, 0.94]. After additional adjustment for the dietary pattern (modified prudent and Western patterns), the association was NS (0.84; 95% CI: 0.63, 1.13). No Significant associations were shown between PUPA intakes and risk of COPD. Conclusion: Although COPD-prevention efforts should continue to focus on smoking cessation, these prospective findings support the importance of promoting a healthy diet in multi-interventional programs to prevent COPD instead of focusing on changes in an isolated food or nutrient. C1 [Varraso, Raphaelle] Ctr Res Epidemiol & Populat Hlth, U1018, Resp & Environm Epidemiol Team, Villejuif, France. [Varraso, Raphaelle] Univ Paris 11, UMRS 1018, Villejuif, France. [Barr, R. Graham] Columbia Univ, Med Ctr, Div Gen Med, Dept Med, New York, NY USA. [Barr, R. Graham] Columbia Univ, Med Ctr, Dept Epidemiol, New York, NY USA. [Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Willett, Walter C.; Camargo, Carlos A., Jr.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Willett, Walter C.; Speizer, Frank E.; Camargo, Carlos A., Jr.] Brigham & Womens Hosp, Channing Div, Med Network, Dept Med, Boston, MA 02115 USA. [Willett, Walter C.; Speizer, Frank E.; Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Boston, MA USA. [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Varraso, R (reprint author), INSERM, Ctr Res Epidemiol & Populat Hlth U1018, Resp & Environm Epidemiol Team, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France. EM raphaelle.varraso@inserm.fr RI Varraso, Raphaelle/R-8740-2016 OI Varraso, Raphaelle/0000-0002-3338-7825 FU NIH [CA-87969, CA-167552, HL-63841, AI-52338] FX Supported by the NIH (grants CA-87969, CA-167552, HL-63841, and AI-52338). NR 41 TC 2 Z9 2 U1 3 U2 12 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD FEB PY 2015 VL 101 IS 2 BP 354 EP 361 DI 10.3945/ajcn.114.094516 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CA5US UT WOS:000348973900015 PM 25646333 ER PT J AU Berhie, SH Molina, RL Davis, MR Anchan, RM Wang, KRC AF Berhie, Saba H. Molina, Rose L. Davis, Michelle R. Anchan, Raymond M. Wang, Karen C. TI Beware the scar Laparoscopic hysterectomy for 7-week cesarean delivery scar implantation pregnancy SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Editorial Material ID MANAGEMENT C1 [Berhie, Saba H.; Molina, Rose L.; Davis, Michelle R.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA. [Berhie, Saba H.; Molina, Rose L.; Davis, Michelle R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Anchan, Raymond M.] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. [Wang, Karen C.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Div Minimally Invas Gynecol, Boston, MA 02115 USA. RP Berhie, SH (reprint author), Brigham & Womens Hosp, Dept Obstet & Gynecol, 75 Francis St, Boston, MA 02115 USA. EM sberhie@partners.org NR 5 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD FEB PY 2015 VL 212 IS 2 AR 247.e1 DI 10.1016/j.ajog.2014.10.1096 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CA1IH UT WOS:000348665500037 PM 25448514 ER PT J AU Houston, KA Kaimal, AJ Nakagawa, S Gregorich, SE Yee, LM Kuppermann, M AF Houston, Kathryn A. Kaimal, Anjali J. Nakagawa, Sanae Gregorich, Steven E. Yee, Lynn M. Kuppermann, Miriam TI Mode of delivery and postpartum depression: the role of patient preferences SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE mode of delivery; patient preferences; postpartum depression ID HEALTH QUESTIONNAIRE; POSTNATAL DEPRESSION; CESAREAN-SECTION; PRIME-MD; COHORT; WOMEN; PREGNANCY; VALIDITY; UTILITY; PHQ-9 AB OBJECTIVE: The purpose of this study was to explore the relationship between strength of preference for vaginal delivery, delivery mode undergone, and postpartum depression. STUDY DESIGN: We conducted a secondary analysis of data from a longitudinal study of delivery-mode preferences. During an interview between 24-36 weeks of gestation, participants were asked whether they preferred vaginal or cesarean delivery; the strength of this preference was measured by the standard gamble metric. Depression was assessed antepartum and at 8-10 weeks and 6-8 months after delivery by using the Patient Health Questionnaire (PHQ-9). The primary outcome was PHQ-9 score at 8-10 weeks after delivery. We used multivariable regression analysis to assess the effect of strength of preference for vaginal delivery and delivery mode undergone on postpartum depression. RESULTS: Of 160 participants, 33.1% were nulliparous, and 30.6% had a previous cesarean delivery. Most of the participants (92.4%) preferred vaginal delivery, but the strength of preference varied substantially. The mean strength-of-preference score (0-1 scale; higher scores denote stronger vaginal delivery preference) was 0.658 (SD, +/- 0.352). A significant interaction emerged between the effects of delivery mode and vaginal delivery preference score on postpartum PHQ-9 score (P = .047). Specifically, a stronger preference for vaginal delivery was associated with higher PHQ-9 scores among women who underwent cesarean delivery (P = .027) but not among women who underwent vaginal delivery (P = .761). The interaction between delivery mode and vaginal delivery preference score was no longer significant at 6-8 months after delivery. CONCLUSION: Women who have a strong antepartum preference for vaginal delivery and deliver by cesarean may be at increased risk for depression in the early postpartum period. C1 [Houston, Kathryn A.; Nakagawa, Sanae; Kuppermann, Miriam] Univ Calif San Francisco, Sch Med, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Gregorich, Steven E.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA. [Kaimal, Anjali J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA USA. [Yee, Lynn M.] Northwestern Univ, Dept Obstet & Gynecol, Feinberg Sch Med, Chicago, IL 60611 USA. RP Houston, KA (reprint author), Univ Calif San Francisco, Sch Med, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. EM houstonk@obgyn.ucsf.edu FU National Center for Research Resources; National Center for Advancing Translational Sciences FX Supported in part by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through the University of California, San Francisco, Clinical & Translational Science Institute, grant number UL1 RR024131 and the University of California, San Francisco, Clinical & Translational Science Institute, grant number UL1 TR000004. NR 27 TC 0 Z9 0 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD FEB PY 2015 VL 212 IS 2 AR 229.e1 DI 10.1016/j.ajog.2014.09.002 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CA1IH UT WOS:000348665500030 PM 25218957 ER PT J AU Masia, R Krause, DS Yellen, G AF Masia, Ricard Krause, Daniela S. Yellen, Gary TI The inward rectifier potassium channel Kir2.1 is expressed in mouse neutrophils from bone marrow and liver SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE inward rectifier potassium channel; Kir2 channels; neutrophil; granulocyte colony-stimulating factor ID OXIDASE-RELATED PROTON; RECTIFYING WHOLE-CELL; FUNCTIONAL EXPRESSION; SINGLE-CHANNEL; ION CHANNELS; K+ CHANNEL; ELECTRON CURRENTS; MOLECULAR-CLONING; HEK-293 CELLS; MACROPHAGES AB Neutrophils are phagocytic cells that play a critical role in innate immunity by destroying bacterial pathogens. Channels belonging to the inward rectifier potassium channel subfamily 2 (Kir2 channels) have been described in other phagocytes (monocytes/macrophages and eosinophils) and in hematopoietic precursors of phagocytes. Their physiological function in these cells remains unclear, but some evidence suggests a role in growth factor-dependent proliferation and development. Expression of functional Kir2 channels has not been definitively demonstrated in mammalian neutrophils. Here, we show by RT-PCR that neutrophils from mouse bone marrow and liver express mRNA for the Kir2 subunit Kir2.1 but not for other subunits (Kir2.2, Kir2.3, and Kir2.4). In electrophysiological experiments, resting (unstimulated) neutrophils from mouse bone marrow and liver exhibit a constitutively active, external K+-dependent, strong inwardly rectifying current that constitutes the dominant current. The reversal potential is dependent on the external K+ concentration in a Nernstian fashion, as expected for a K+-selective current. The current is not altered by changes in external or internal pH, and it is blocked by Ba2+, Cs+, and the Kir2-selective inhibitor ML133. The single-channel conductance is in agreement with previously reported values for Kir2.1 channels. These properties are characteristic of homomeric Kir2.1 channels. Current density in short-term cultures of bone marrow neutrophils is decreased in the absence of growth factors that are important for neutrophil proliferation [granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF)]. These results demonstrate that mouse neutrophils express functional Kir2.1 channels and suggest that these channels may be important for neutrophil function, possibly in a growth factor-dependent manner. C1 [Masia, Ricard; Krause, Daniela S.] Massachusetts Gen Hosp, Dept Pathol & Lab Med, Boston, MA 02114 USA. [Masia, Ricard; Yellen, Gary] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA. RP Masia, R (reprint author), Massachusetts Gen Hosp, Dept Pathol & Lab Med, 55 Fruit St Warren 219, Boston, MA 02114 USA. EM rmasia@mgh.harvard.edu FU National Cancer Institute of the National Institutes of Health [T32 CA09216, K08 CA138916-02] FX This study was supported by the National Cancer Institute of the National Institutes of Health under award numbers T32 CA09216 (R.M.) and K08 CA138916-02 (D.S.K.). NR 64 TC 4 Z9 4 U1 2 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 EI 1522-1563 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD FEB 1 PY 2015 VL 308 IS 3 BP C264 EP C276 DI 10.1152/ajpcell.00176.2014 PG 13 WC Cell Biology; Physiology SC Cell Biology; Physiology GA CB0HR UT WOS:000349307100009 PM 25472961 ER PT J AU Eisenberg, JD Gervais, DA Singh, S Kalra, MK Sabir, SH Paul, AB Pandharipande, PV AF Eisenberg, Jonathan D. Gervais, Debra A. Singh, Sarabjeet Kalra, Mannudeep K. Sabir, Sharjeel H. Paul, Aaron B. Pandharipande, Pari V. TI Radiation Exposure From CTGuided Ablation of Renal Masses: Effects on Life Expectancy SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE CT; decision analysis; radiation risk; radiofrequency ablation; renal cancer ID COST-EFFECTIVENESS ANALYSIS; PERCUTANEOUS RADIOFREQUENCY ABLATION; CELL CARCINOMA; PATHOLOGICAL FEATURES; COMPUTED-TOMOGRAPHY; CANCER-RISK; 100 TUMORS; CT; SURVEILLANCE; MANAGEMENT AB OBJECTIVE. The purpose of this article is to project the effects of radiation exposure on life expectancy ( LE) in patients who opt for CT- guided radiofrequency ablation ( RFA) instead of surgery for renal cell carcinoma ( RCC). MATERIALS AND METHODS. We developed a decision- analytic Markov model to compare LE losses attributable to radiation exposure in hypothetical 65- year- old patients who undergo CT- guided RFA versus surgery for small (= 4 cm) RCC. We incorporated mortality risks from RCC, radiation- induced cancers ( for procedural and follow- up CT scans), and all other causes; institutional data informed the RFA procedural effective dose. Radiation- induced cancer risks were generated using an organ- specific approach. Effects of varying model parameters and of dose- reduction strategies were evaluated in sensitivity analysis. RESULTS. Cumulative RFA exposures ( up to 305.2 mSv for one session plus surveillance) exceeded those from surgery ( up to 87.2 mSv). In 65- year- old men, excess LE loss from radiation- induced cancers, comparing RFA to surgery, was 11.7 days ( 14.6 days for RFA vs 2.9 days for surgery). Results varied with sex and age; this difference increased to 14.6 days in 65- year- old women and to 21.5 days in 55- year- old men. Dose- reduction strategies that addressed follow- up rather than procedural exposure had a greater impact. In 65- year- old men, this difference decreased to 3.8 days if post- RFA follow- up scans were restricted to a single phase; even elimination of RFA procedural exposure could not achieve equivalent benefits. CONCLUSION. CT- guided RFA remains a safe alternative to surgery, but with decreasing age, the higher burden of radiation exposure merits explicit consideration. Dose- reduction strategies that target follow- up rather than procedural exposure will have a greater impact. C1 [Eisenberg, Jonathan D.; Pandharipande, Pari V.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Eisenberg, Jonathan D.; Gervais, Debra A.; Singh, Sarabjeet; Kalra, Mannudeep K.; Sabir, Sharjeel H.; Paul, Aaron B.; Pandharipande, Pari V.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Eisenberg, Jonathan D.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Gervais, Debra A.; Singh, Sarabjeet; Kalra, Mannudeep K.; Sabir, Sharjeel H.; Paul, Aaron B.; Pandharipande, Pari V.] Harvard Univ, Sch Med, Boston, MA USA. [Sabir, Sharjeel H.] Univ Texas MD Anderson Canc Ctr, Dept Radiol, Houston, TX 77030 USA. RP Pandharipande, PV (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St,10th Fl, Boston, MA 02114 USA. EM pari@mgh-ita.org FU NCI NIH HHS [K07CA133097] NR 52 TC 3 Z9 3 U1 0 U2 2 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD FEB PY 2015 VL 204 IS 2 BP 335 EP 342 DI 10.2214/AJR.14.13010 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CA1DD UT WOS:000348652300038 PM 25615756 ER PT J AU Baheti, AD Tirumani, SH Rosenthal, MH Howard, SA Shinagare, AB Ramaiya, NH Jagannathan, JP AF Baheti, Akshay D. Tirumani, Sree Harsha Rosenthal, Michael H. Howard, Stephanie A. Shinagare, Atul B. Ramaiya, Nikhil H. Jagannathan, Jyothi P. TI Myxoid Soft-Tissue Neoplasms: Comprehensive Update of the Taxonomy and MRI Features SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Review DE angiomyxoma; myxofibrosarcoma; myxoid; myxoid chondrosarcoma; myxoid liposarcoma; myxoinflammatory fibroblastic sarcoma; myxoma; ossifying fibromyxoid tumor ID OSSIFYING FIBROMYXOID TUMOR; MYXOINFLAMMATORY FIBROBLASTIC SARCOMA; INFILTRATIVE GROWTH-PATTERN; LOW-GRADE MYXOFIBROSARCOMA; ROUND-CELL LIPOSARCOMA; OF-THE-LITERATURE; TERM-FOLLOW-UP; AGGRESSIVE ANGIOMYXOMA; IMAGING FEATURES; CLINICOPATHOLOGICAL ANALYSIS AB OBJECTIVE. The purpose of this article is to review the classification, clinical presentation, and histopathologic and MRI features of myxoid soft-tissue neoplasms. CONCLUSION. MRI is the modality of choice for characterization of myxoid soft-tissue tumors. A combination of imaging features (including certain characteristic signs), clinical features, and patient demographics can help the radiologist in coming to a specific diagnosis or in narrowing down the differential diagnoses. C1 [Baheti, Akshay D.; Tirumani, Sree Harsha; Rosenthal, Michael H.; Howard, Stephanie A.; Shinagare, Atul B.; Ramaiya, Nikhil H.; Jagannathan, Jyothi P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, Boston, MA 02215 USA. [Baheti, Akshay D.; Tirumani, Sree Harsha; Rosenthal, Michael H.; Howard, Stephanie A.; Shinagare, Atul B.; Ramaiya, Nikhil H.; Jagannathan, Jyothi P.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02215 USA. RP Tirumani, SH (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02215 USA. EM stirumani@partners.org RI Rosenthal, Michael/D-4080-2015 FU RSNA Research Scholar Grant [2014-16] FX A. B. Shinagare has received support from RSNA Research Scholar Grant 2014-16 NR 75 TC 11 Z9 12 U1 0 U2 4 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD FEB PY 2015 VL 204 IS 2 BP 374 EP 385 DI 10.2214/AJR.14.12888 PG 12 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CA1DD UT WOS:000348652300043 PM 25615761 ER PT J AU Baheti, AD Tirumani, SH Giardino, A Rosenthal, MH Tirumani, H Krajewski, K Ramaiya, NH AF Baheti, Akshay D. Tirumani, Sree Harsha Giardino, Angela Rosenthal, Michael H. Tirumani, Harika Krajewski, Katherine Ramaiya, Nikhil H. TI Basal Cell Carcinoma: A Comprehensive Review for the Radiologist SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Review DE basal cell carcinoma; metastatic; radiology ID HEDGEHOG SIGNALING PATHWAY; LYMPH-NODE BIOPSY; SKIN-CANCER; RECURRENCE RATES; FOLLOW-UP; RISK; VISMODEGIB; UPDATE; ELECTRODESICCATION; TOMOGRAPHY AB OBJECTIVE. Basal cell carcinoma (BCC) is the most common malignancy in the United States. The purpose of this article is to provide a comprehensive description of the clinicopathologic features, diagnostic workup, staging, treatment, and follow-up of BCC. CONCLUSION. Radiology plays an important role in the evaluation and staging of locally advanced and metastatic BCC. MRI is the modality of choice for assessing perineural disease and is equivalent or superior to CT for evaluating bony involvement. CT and PET/CT are used to evaluate metastatic disease. C1 [Baheti, Akshay D.; Tirumani, Sree Harsha; Giardino, Angela; Rosenthal, Michael H.; Tirumani, Harika; Krajewski, Katherine; Ramaiya, Nikhil H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Baheti, Akshay D.; Tirumani, Sree Harsha; Giardino, Angela; Rosenthal, Michael H.; Krajewski, Katherine; Ramaiya, Nikhil H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA. RP Baheti, AD (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM akshaybaheti@gmail.com RI Rosenthal, Michael/D-4080-2015 NR 53 TC 0 Z9 0 U1 0 U2 3 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD FEB PY 2015 VL 204 IS 2 BP W132 EP W140 DI 10.2214/AJR.14.13160 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CA1DD UT WOS:000348652300003 PM 25615773 ER PT J AU Kulkarni, NM Hong, TS Kambadakone, A Arellano, RS AF Kulkarni, Naveen M. Hong, Theodore S. Kambadakone, Avinash Arellano, Ronald S. TI CT-Guided Implantation of Intrahepatic Fiducial Markers for Proton Beam Therapy of Liver Lesions: Assessment of Success Rate and Complications SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE gold fiducial marker; hepatocellular carcinoma proton beam therapy ID STEREOTACTIC BODY RADIOTHERAPY; RADIATION-THERAPY; HEPATOCELLULAR-CARCINOMA; ROBOTIC RADIOSURGERY; PHASE-I; FEASIBILITY; IRRADIATION; CYBERKNIFE; PLACEMENT; SAFETY AB OBJECTIVE. The purpose of this study is to evaluate the safety and complications of CTguided implantation of intrahepatic fiducial markers for proton beam therapy. MATERIALS AND METHODS. In this retrospective study, we reviewed 69 patients who underwent 149 percutaneous fiducial marker implantations for primary and metastatic hepatic tumors from April 2007 through July 2013. The implantations enabling satisfactory treatment planning and CT simulation were considered as technically successful. Major and minor procedurerelated complications during and after fiducial marker implantation were documented. RESULTS. The success rate of fiducial marker implantation was 99.3% (148/149). In one patient, a fiducial marker migrated into the vascular system, which was realized during the procedure and required reimplantation. None of the patients was required to return for additional implantations. The major and minor complication rates were 0% and 2.9% (2/69), respectively. Both minor complications included small pneumothorax not requiring hospital admission. CONCLUSION. CT-guided placement of gold fiducial markers is associated with a high technical success rate with few complications, which is an essential step in the overall treatment planning and performance of proton beam therapy for the management of hepatic tumors. C1 [Kulkarni, Naveen M.; Kambadakone, Avinash; Arellano, Ronald S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Intervent Radiol, Boston, MA 02114 USA. [Hong, Theodore S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA. RP Arellano, RS (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Intervent Radiol, 55 Fruit St, Boston, MA 02114 USA. EM rarellano@mgh.harvard.edu NR 26 TC 1 Z9 1 U1 1 U2 5 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD FEB PY 2015 VL 204 IS 2 BP W207 EP W213 DI 10.2214/AJR.14.12901 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CA1DD UT WOS:000348652300012 PM 25615782 ER PT J AU Misono, AS Oklu, R Prabhakar, AM AF Misono, Alexander S. Oklu, Rahmi Prabhakar, Anand M. TI Time-Driven Activity-Based Costing Trumps Traditional Cost Accounting for Radiologists SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Letter C1 [Misono, Alexander S.; Oklu, Rahmi; Prabhakar, Anand M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Prabhakar, Anand M.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. RP Misono, AS (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 3 TC 1 Z9 1 U1 0 U2 13 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD FEB PY 2015 VL 204 IS 2 BP W217 EP W217 DI 10.2214/AJR.14.13258 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CA1DD UT WOS:000348652300016 PM 25615786 ER PT J AU Patino, M Fuentes, JM Hayano, K Kambadakone, AR Uyeda, JW Sahani, DV AF Patino, Manuel Fuentes, Jorge M. Hayano, Koichi Kambadakone, Avinash R. Uyeda, Jennifer W. Sahani, Dushyant V. TI A Quantitative Comparison of Noise Reduction Across Five Commercial (Hybrid and ModelBased) Iterative Reconstruction Techniques: An Anthropomorphic Phantom Study SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE CT; filtered back projection; iterative reconstruction technique; phantom studies; radiation dose ID FILTERED BACK-PROJECTION; ABDOMINAL COMPUTED-TOMOGRAPHY; LOW-DOSE MDCT; IMAGE QUALITY; RADIATION-EXPOSURE; CT COLONOGRAPHY; CROHN DISEASE; PERFORMANCE; ALGORITHM; ENTEROGRAPHY AB OBJECTIVE. The objective of our study was to compare the performance of three hybrid iterative reconstruction techniques (IRTs) (ASiR, iDose4, SAFIRE) and their respective strengths for image noise reduction on low-dose CT examinations using filtered back projection (FBP) as the standard reference. Also, we compared the performance of these three hybrid IRTs with two model-based IRTs (Veo and IMR) for image noise reduction on low-dose examinations. MATERIALS AND METHODS. An anthropomorphic abdomen phantom was scanned at 100 and 120 kVp and different tube current-exposure time products (25-100 mAs) on three CT systems (for ASiR and Veo, Discovery CT750 HD; for iDose4 and IMR, Brilliance iCT; and for SAFIRE, Somatom Definition Flash). Images were reconstructed using FBP and using IRTs at various strengths. Nine noise measurements (mean ROI size, 423 mm2) on extracolonic fat for the different strengths of IRTs were recorded and compared with FBP using ANOVA. Radiation dose, which was measured as the volume CT dose index and dose-length product, was also compared. RESULTS. There were no significant differences in radiation dose and image noise among the scanners when FBP was used (p > 0.05). Gradual image noise reduction was observed with each increasing increment of hybrid IRT strength, with a maximum noise suppression of approximately 50% (48.2-53.9%). Similar noise reduction was achieved on the scanners by applying specific hybrid IRT strengths. Maximum noise reduction was higher on model-based IRTs (68.3-81.1%) than hybrid IRTs (48.2-53.9%) (p < 0.05). CONCLUSION. When constant scanning parameters are used, radiation dose and image noise on FBP are similar for CT scanners made by different manufacturers. Significant image noise reduction is achieved on low-dose CT examinations rendered with IRTs. The image noise on various scanners can be matched by applying specific hybrid IRT strengths. Model-based IRTs attain substantially higher noise reduction than hybrid IRTs irrespective of the radiation dose. C1 [Patino, Manuel; Fuentes, Jorge M.; Hayano, Koichi; Kambadakone, Avinash R.; Uyeda, Jennifer W.; Sahani, Dushyant V.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Div Abdominal Imaging & Intervent, Boston, MA 02114 USA. RP Sahani, DV (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Div Abdominal Imaging & Intervent, Boston, MA 02114 USA. EM dsahani@partners.org OI Fuentes-Orrego, Jorge/0000-0002-9254-0746 NR 34 TC 7 Z9 7 U1 0 U2 7 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD FEB PY 2015 VL 204 IS 2 BP W176 EP W183 DI 10.2214/AJR.14.12519 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CA1DD UT WOS:000348652300008 PM 25615778 ER PT J AU Brothers, TE AF Brothers, Thomas E. TI Failure of Patients with Peripheral Arterial Disease to Accept the Recommended Treatment Results in Worse Outcomes SO ANNALS OF VASCULAR SURGERY LA English DT Article ID QUALITY-OF-LIFE; PROSPECTIVE DECISION-ANALYSIS; VASCULAR-SURGERY; SEVERE ISCHEMIA; GRADING SYSTEM; LIMB ISCHEMIA; LEGS SCORE; BYPASS; QUESTIONNAIRE; AMPUTATION AB Background: Strategies available to facilitate decision making for patients with peripheral arterial disease (PAD) include a Markov-based decision analysis (DA) model and the Lower Extremity Grading System (LEGS) score. Both have suggested inferior outcomes when the actual treatment received (ATX) differs from that predicted. This study focuses on patient outcomes when such discordance exists. Methods: All patients referred for symptomatic lower extremity PAD over a 3-year period were evaluated using the DA model and the LEGS score. Calculated quality of life (cQOL) values were assigned before treatment based on patient symptom, perfusion, and amputation status and at follow-up (range 1.000 [perfect health] to .000 [death]). The primary outcome of cQOL was compared according to whether the ATX matched that proposed by the surgeon or predicted by the DA model or LEGS score. Secondary outcomes for revascularized patients included major adverse limb event with perioperative death (MALE + POD) and amputation-free survival (AFS). Results: Among 375 procedures in 345 consecutive patients, the greatest improvement in cQOL at last follow-up (median 16 months) was observed with endovascular (0.23 +/- 0.16, n=93) or open (0.21 +/- 0.17, n=137) revascularization compared with primary amputation (0.10 +/- 0.07, n=23) or medical therapy (0.04 +/- 0.09, n = 122). Multivariate regression showed discordance with the surgeon's recommendation (P<0.05) and/or the DA model (P<0.05) to be independent predictors of improvement failure. ATX did not always agree with that proposed by the surgeon (89% agree, kappa = 0.84), the DA model (68% agree, kappa = 0.53), or the LEGS score (53% agree, kappa = 0.32). Improvement in cQOL was greatest when ATX was concordant with treatment proposed by the surgeon (0.18 vs. 0.08, P < 0.01), the DA model (0.19 vs. 0.13, P < 0.01), or the LEGS score (0.23 vs. 0.10, P < 0.01). Patient refusal to follow the surgeon's recommendations and continued smoking were associated with minimal improvement (cQOL ranges 0.05-0.07 and 0.00-0.02, respectively), while pursuing a less morbid procedure was associated with greater improvement (cQOL range 0.28-0.38). Among revascularized patients, MALE + POD was lower at 36 months after endovascular than open surgery (21% +/- 5% vs. 36% +/- 4%, P < 0.05), while AFS was not significantly different. Only discordance with the surgeon's recommendation was an independent predictor of MALE + POD, possibly because of limitations in sample subset size. Conclusions: Mean cQOL improved most with direct revascularization, especially when the treatment received matched that predicted by the models or proposed by the surgeon. Type of treatment received was an independent predictor of agreement of treatment with recommendations. Patient refusal to follow the recommended treatment as well as the strategy not to revascularize claudicants who persist in smoking were associated with much less patient benefit from treatment. C1 Med Univ S Carolina, Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Brothers, TE (reprint author), Med Univ S Carolina, Ralph H Johnson Dept Vet Affairs Med Ctr, 25 Courtenay Dr, Charleston, SC 29425 USA. EM brothete@musc.edu OI Brothers, Thomas/0000-0001-9780-9559 NR 22 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0890-5096 EI 1615-5947 J9 ANN VASC SURG JI Ann. Vasc. Surg. PD FEB PY 2015 VL 29 IS 2 BP 244 EP 259 DI 10.1016/j.avsg.2014.08.006 PG 16 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CA8VY UT WOS:000349200200011 PM 25305420 ER PT J AU Lepak, AJ Marchillo, K Craig, WA Andes, DR AF Lepak, Alexander J. Marchillo, Karen Craig, William A. Andes, David R. TI In Vivo Pharmacokinetics and Pharmacodynamics of the Lantibiotic NAI-107 in a Neutropenic Murine Thigh Infection Model SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; PRECURSOR LIPID II; DISEASES-SOCIETY; BAD BUGS; STREPTOCOCCUS-PNEUMONIAE; HEALTH-CARE; ANTIBIOTICS; VANCOMYCIN; AMERICA; NISIN AB NAI-107 is a novel lantibiotic compound with potent in vitro activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The purpose of this study was to examine the activity of NAI-107 against S. aureus strains, including MRSA, in the neutropenic murine thigh infection model. Serum pharmacokinetics were determined and timekill studies were performed following administration of single subcutaneous doses of 5, 20, and 80 mg/kg body weight. The dose fractionation included total doses ranging from 1.56 to 400 mg/kg/72 h, divided into 1, 2, 3, or 6 doses. Studies of treatment effects against 9 S. aureus strains (4 methicillin-susceptible Staphylococcus aureus [MSSA] and 5 MRSA) using a 12-h dosing interval and total dose range of 1.56 to 400 mg/kg/72 h were also performed. A maximum effect (E-max) model was used to determine the pharmacokinetic/pharmacodynamic (PK/PD) index that best described the dose-response data and to estimate the doses required to achieve a net bacteriostatic dose (SD) and a 1-log reduction in CFU/thigh. The pharmacokinetic studies demonstrated an area under the concentration-time curve (AUC) range of 26.8 to 276 mg.h/liter and half-lives of 4.2 to 8.2 h. MICs ranged from 0.125 to 0.5 mu g/ml. The 2 highest single doses produced more than a 2-log kill and prolonged postantibiotic effects (PAEs) ranging from 36 to > 72 h. The dose fractionation-response curves were similar, and the AUC/MIC ratio was the most predictive PD index (AUC/MIC, coefficient of determination [R-2] = 0.89; maximum concentration of drug in serum [C-max]/MIC, R-2 = 0.79; time [T] > MIC, R-2 = 0.63). A >= 2-log kill was observed against all 9 S. aureus strains. The total drug 24-h AUC/MIC values associated with stasis and a 1-log kill for the 9 S. aureus strains were 371 +/- 130 and 510 +/- 227, respectively. NAI-107 demonstrated concentration-dependent killing and prolonged PAEs. The AUC/MIC ratio was the predictive PD index. Extensive killing was observed for S. aureus organisms, independent of the MRSA status. The AUC/MIC target should be useful for the design of clinical dosing regimens. C1 [Lepak, Alexander J.; Craig, William A.; Andes, David R.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA. [Andes, David R.] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI USA. [Marchillo, Karen; Andes, David R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Andes, DR (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA. EM dra@medicine.wisc.edu FU Sentinella Pharmaceuticals, Inc. FX This study was funded by Sentinella Pharmaceuticals, Inc. NR 47 TC 13 Z9 13 U1 0 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD FEB PY 2015 VL 59 IS 2 BP 1258 EP 1264 DI 10.1128/AAC.04444-14 PG 7 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA CA0LT UT WOS:000348610000062 PM 25512404 ER PT J AU Wiederhold, NP Najvar, LK Fothergill, AW Bocanegra, R Olivo, M McCarthy, DI Kirkpatrick, WR Fukuda, Y Mitsuyama, J Patterson, TF AF Wiederhold, Nathan P. Najvar, Laura K. Fothergill, Annette W. Bocanegra, Rosie Olivo, Marcos McCarthy, Dora I. Kirkpatrick, William R. Fukuda, Yoshiko Mitsuyama, Junichi Patterson, Thomas F. TI The Novel Arylamidine T-2307 Maintains In Vitro and In Vivo Activity against Echinocandin-Resistant Candida albicans SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID BLOOD-STREAM INFECTIONS; SURVEILLANCE; EFFICACY AB We evaluated the in vitro and in vivo activities of the investigational arylamidine T-2307 against echinocandin-resistant Candida albicans. T-2307 demonstrated potent in vitro activity, and daily subcutaneous doses between 0.75 and 6 mg/kg of body weight significantly improved survival and reduced fungal burden compared to placebo control and caspofungin (10 mg/kg/day) in mice with invasive candidiasis caused by an echinocandin-resistant strain. Thus, T-2307 may have potential use in the treatment of echinocandin-resistant C. albicans infections. C1 [Wiederhold, Nathan P.; Najvar, Laura K.; Fothergill, Annette W.; Bocanegra, Rosie; Olivo, Marcos; McCarthy, Dora I.; Kirkpatrick, William R.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Najvar, Laura K.; Bocanegra, Rosie; Olivo, Marcos; Kirkpatrick, William R.; Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Fukuda, Yoshiko; Mitsuyama, Junichi] Toyama Chem Co Ltd, Toyama, Japan. RP Wiederhold, NP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. EM wiederholdn@uthscsa.edu OI Wiederhold, Nathan/0000-0002-2225-5122 FU National Institute of Allergy and Infectious Diseases, National Institutes of Health; Department of Health and Human Services [HHS272201000018I, HHSN272201000038I]; Astellas; Dow; F2G; Merck; Merz; Viamet FX This project utilized preclinical services funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and Department of Health and Human Services under contract no. HHS272201000018I and HHSN272201000038I, Task Orders A03 and A13, respectively.; N.P.W. has received research support from Astellas, Dow, F2G, Merck, Merz, and Viamet and has served on advisory boards for Merck, Astellas, Toyama, and Viamet. T.F.P. has received research grants to UT Health Science Center San Antonio from Astellas and Merck and has served as a consultant for Astellas, Merck, Toyama, Viamet, and SCYN-EXIS. L.K.N. has received travel support from Viamet. Y.F. and J.M. are employees of Toyama Chemical Co., Ltd. NR 13 TC 3 Z9 3 U1 1 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD FEB PY 2015 VL 59 IS 2 BP 1341 EP 1343 DI 10.1128/AAC.04228-14 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA CA0LT UT WOS:000348610000074 PM 25451054 ER PT J AU Stein, J Bettger, JP Sicklick, A Hedeman, R Magdon-Ismail, Z Schwamm, LH AF Stein, Joel Bettger, Janet Prvu Sicklick, Alyse Hedeman, Robin Magdon-Ismail, Zainab Schwamm, Lee H. TI Use of a Standardized Assessment to Predict Rehabilitation Care After Acute Stroke SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Outcomes; Rehabilitation; Stroke ID POSTACUTE CARE; INPATIENT REHABILITATION; NORTHERN CALIFORNIA; FUNCTIONAL OUTCOMES; MORTALITY FINDINGS; GUIDELINES-STROKE; HIP FRACTURE; SYSTEMS; RECOMMENDATIONS; AGE AB Objective: To pilot a program of formal assessment of rehabilitation needs and predictors of referral to rehabilitation. Design: A prospective pilot project to collect standardized measures of stroke severity and function: National Institutes of Health Stroke Scale, premorbid modified Rankin scale, Short Portable Mental Status Questionnaire, and Barthel Index (BI). These were collected in addition to routine data in the Get With The Guidelines-Stroke registry. Logistic regression was used to examine predictors of referral to any institution-based rehabilitation versus discharge home and referral to an inpatient rehabilitation facility (IRF) versus a skilled nursing facility (SNF). Setting: Twenty-two hospitals within the Northeast Cerebrovascular Consortium (located in the northeastern United States). Participants: Data were collected on individuals with acute ischemic and hemorrhagic stroke (N=736). Interventions: Not applicable. Main Outcome Measures: Discharge disposition location. Results: The BI score was recorded in 736 (81%) patients. In multivariable analyses, a higher BI score (85-100) was the only factor associated with return home versus need for institution-based rehabilitation (P<.001). Among patients discharged to IRF versus SNF, discharge to IRF was less likely in older patients (odds ratio [OR], .96; confidence interval [CI], .94-.98; P<.001) and in those with prestroke disability (modified Rankin scale score, 2-5) (OR, .47; CI, .28-.78; P=.004) and more likely in those with moderate-severe (BI score, 25-40; OR, 3.26; CI, 1.45-7.30; P=.004) or moderate (BI score, 45-60; OR, 2.47; CI, 1.17-5.21; P=.018) activities of daily living (ADL) impairment. Conclusions: Formal standardized assessment of rehabilitation needs was feasible in this pilot project. Patients' sociodemographic characteristics, premorbid function, and ADL impairment discriminated better between discharge home and institution-based rehabilitation than between IRF and SNF. Selection of MP versus SNF appears to be influenced either by unmeasured clinical characteristics of individuals with stroke or by nonclinical factors, such as cost, geography, referral relationships, or IRF availability. (C) 2015 by the American Congress of Rehabilitation Medicine C1 [Stein, Joel] Columbia Univ, Coll Phys & Surg, Dept Rehabil & Regenerat Med, New York, NY USA. [Stein, Joel] Weill Cornell Med Coll, Div Rehabil Med, New York, NY USA. [Stein, Joel] New York Presbyterian Hosp, New York, NY USA. [Bettger, Janet Prvu] Duke Univ, Sch Nursing, Durham, NC USA. [Sicklick, Alyse] Gaylord Specialty Healthcare, Wallingford, CT USA. [Hedeman, Robin] Kessler Inst Rehabil, W Orange, NJ USA. [Magdon-Ismail, Zainab] Amer Stroke Assoc Founders Affiliate, Amer Heart Assoc, Albany, NY USA. [Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Schwamm, Lee H.] Harvard Univ, Sch Med, Boston, MA USA. RP Stein, J (reprint author), Columbia Univ, Med Ctr, Dept Rehabil & Regenerat Med, Harkness Pavil,Rm HP-1-165,180 Ft Washington Ave, New York, NY 10027 USA. EM JS1165@columbia.edu OI Stein, Joel/0000-0001-5527-025X FU Northeast Cerebrovascular Consortium; American Heart Association/American Stroke Association FX Supported by the Northeast Cerebrovascular Consortium and the American Heart Association/American Stroke Association through staff and information system support. NR 33 TC 5 Z9 5 U1 1 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD FEB PY 2015 VL 96 IS 2 BP 210 EP 217 DI 10.1016/j.apmr.2014.07.403 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CA2QF UT WOS:000348751800005 PM 25102387 ER PT J AU Losina, E Paltiel, AD Weinstein, AM Yelin, E Hunter, DJ Chen, SP Klara, K Suter, LG Solomon, DH Burbine, SA Walensky, RP Katz, JN AF Losina, Elena Paltiel, A. David Weinstein, Alexander M. Yelin, Edward Hunter, David J. Chen, Stephanie P. Klara, Kristina Suter, Lisa G. Solomon, Daniel H. Burbine, Sara A. Walensky, Rochelle P. Katz, Jeffrey N. TI Lifetime Medical Costs of Knee Osteoarthritis Management in the United States: Impact of Extending Indications for Total Knee Arthroplasty SO ARTHRITIS CARE & RESEARCH LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PLACEBO-CONTROLLED TRIAL; SURGEON PROCEDURE VOLUME; RHEUMATOID-ARTHRITIS; JOINT REPLACEMENT; OARSI RECOMMENDATIONS; DOUBLE-BLIND; TOTAL HIP; RISK; OUTCOMES AB ObjectiveThe impact of increasing utilization of total knee arthroplasty (TKA) on lifetime costs in persons with knee osteoarthritis (OA) is understudied. MethodsWe used the Osteoarthritis Policy Model to estimate total lifetime costs and TKA utilization under a range of TKA eligibility criteria among US persons with symptomatic knee OA. Current TKA utilization was estimated from the Multicenter Osteoarthritis Study and calibrated to Health Care Cost and Utilization Project data. OA treatment efficacy and toxicity were drawn from published literature. Costs in 2013 dollars were derived from Medicare reimbursement schedules and Red Book Online. Time costs were derived from published literature and the US Bureau of Labor Statistics. ResultsEstimated average discounted (3% per year) lifetime costs for persons diagnosed with knee OA were $140,300. Direct medical costs were $129,600, with $12,400 (10%) attributable to knee OA over 28 years. OA patients spent a mean SD of 13 +/- 10 years waiting for TKA after failing nonsurgical regimens. Under current TKA eligibility criteria, 54% of knee OA patients underwent TKA over their lifetimes. Estimated OA-related discounted lifetime direct medical costs ranged from $12,400 (54% TKA uptake) when TKA eligibility was limited to Kellgren/Lawrence grades 3 or 4 to $16,000 (70% TKA uptake) when eligibility was expanded to include symptomatic OA with a lesser degree of structural damage. ConclusionBecause of low efficacy of nonsurgical regimens, knee OA treatment-attributable costs are low, representing a small portion of all costs for OA patients. Expanding TKA eligibility increases OA-related costs substantially for the population, underscoring the need for more effective nonoperative therapies. C1 [Losina, Elena; Walensky, Rochelle P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Losina, Elena] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Paltiel, A. David; Suter, Lisa G.] Yale Univ, Sch Med, New Haven, CT USA. [Weinstein, Alexander M.; Chen, Stephanie P.; Klara, Kristina; Solomon, Daniel H.; Burbine, Sara A.; Katz, Jeffrey N.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Yelin, Edward] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hunter, David J.] Univ Sydney, Kolling Inst, Sydney, NSW 2006, Australia. [Hunter, David J.] Univ Sydney, Royal N Shore Hosp, Sydney, NSW 2006, Australia. [Suter, Lisa G.] Vet Affairs Med Ctr, West Haven, CT USA. [Solomon, Daniel H.; Katz, Jeffrey N.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Walensky, Rochelle P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Losina, E (reprint author), Brigham & Womens Hosp, Orthopaed & Arthrit Ctr Outcomes Res, 75 Francis St,BC 4-016, Boston, MA 02115 USA. EM elosina@partners.org FU National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01-AR-064320, K24-AR-057827]; Pfizer; Lilly; Amgen FX Supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grants R01-AR-064320 and K24-AR-057827).; Dr. Solomon has received royalties from UptoDate for articles on the cardiovascular effects of nonsteroidal antiinflammatory drugs and Cox-2 inhibitors, and research support from Pfizer, Lilly, and Amgen. Dr. Walensky has served as an expert witness on behalf of LeClair Ryan. NR 78 TC 28 Z9 28 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD FEB PY 2015 VL 67 IS 2 BP 203 EP 215 DI 10.1002/acr.22412 PG 13 WC Rheumatology SC Rheumatology GA CA6DD UT WOS:000348998000007 PM 25048053 ER PT J AU Leahy, AA Esfahani, SA Foote, AT Hui, CK Rainbow, RS Nakamura, DS Tracey, BH Mahmood, U Zeng, L AF Leahy, Averi A. Esfahani, Shadi A. Foote, Andrea T. Hui, Carrie K. Rainbow, Roshni S. Nakamura, Daisy S. Tracey, Brian H. Mahmood, Umar Zeng, Li TI Analysis of the Trajectory of Osteoarthritis Development in a Mouse Model by Serial Near-Infrared Fluorescence Imaging of Matrix Metalloproteinase Activities SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID SURGICALLY INDUCED OSTEOARTHRITIS; HUMAN ARTICULAR-CARTILAGE; IN-VIVO; INDUCED ARTHRITIS; EARLY-DIAGNOSIS; MICE; PROBE; PROGRESSION; EXPRESSION; BIOMARKERS AB Objective. A major hurdle in osteoarthritis (OA) research is the lack of sensitive detection and monitoring methods. It is hypothesized that proteases, such as matrix metalloproteinases (MMPs), are up-regulated in the early stages of OA development. This study was undertaken to investigate if a near-infrared (NIR) fluorescent probe activated by MMPs could visualize in vivo OA progression beginning in the early stages of the disease. Methods. Using an MMP-activatable NIR fluorescent probe (MMPSense 680), we assessed the upregulation of MMP activity in vitro by incubating human chondrocytes with the proinflammatory cytokine interleukin-1 beta (IL-1 beta). MMP activity was then evaluated in vivo serially in a mouse model of chronic, injury-induced OA. To track MMP activity over time, mice were imaged 1-8 weeks after OA-inducing surgery. Imaging results were correlated with histologic findings. Results. In vitro studies confirmed that NIR fluorescence imaging identified enhanced MMP activity in IL-1 beta-treated human chondrocytes. In vivo imaging showed significantly higher fluorescence intensity in OA knees compared to sham-operated (control) knees of the same mice. Additionally, the total emitted fluorescence intensity steadily increased over the entire course of OA progression that was examined. NIR fluorescence imaging results correlated with histologic findings, which showed an increase in articular cartilage structural damage over time. Conclusion. Imaging of MMP activity in a mouse model of OA provides sensitive and consistent visualization of OA progression, beginning in the early stages of OA. In addition to facilitating the preclinical study of OA modulators, this approach has the potential for future translation to humans. C1 [Leahy, Averi A.; Foote, Andrea T.; Hui, Carrie K.; Rainbow, Roshni S.; Nakamura, Daisy S.; Zeng, Li] Tufts Univ, Boston, MA 02111 USA. [Esfahani, Shadi A.; Mahmood, Umar] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Esfahani, Shadi A.; Mahmood, Umar] Harvard Univ, Sch Med, Boston, MA USA. [Tracey, Brian H.] Tufts Univ, Medford, MA 02155 USA. [Zeng, Li] Tufts Med Ctr, Boston, MA USA. RP Zeng, L (reprint author), Tufts Univ, Sch Med, Dept Integrat Physiol & Pathobiol, 136 Harrison Ave, Boston, MA 02111 USA. EM Li.Zeng@tufts.edu FU National Science Foundation [CBET-0966920]; NIH [1R01-AR-059106-01A1, 1F30-AR-065866-01A1, K12-GM-074869]; Tufts Clinical and Translational Science Institute [UL1-TR-001064]; Tufts University FX Supported by grants to Dr. Zeng from the National Science Foundation (grant CBET-0966920), the NIH (grant 1R01-AR-059106-01A1), Tufts Clinical and Translational Science Institute (through NIH/National Center for Advancing Translational Sciences award UL1-TR-001064), and Tufts University (Tufts Collaborates grant). Ms Leahy's work was supported by the NIH (Fellowship 1F30-AR-065866-01A1). Dr. Rainbow's work was supported by the NIH (National Institute of General Medical Sciences Postdoctoral Fellowship K12-GM-074869). NR 50 TC 12 Z9 12 U1 4 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD FEB PY 2015 VL 67 IS 2 BP 442 EP 453 DI 10.1002/art.38957 PG 12 WC Rheumatology SC Rheumatology GA CA9CR UT WOS:000349218500016 PM 25385707 ER PT J AU Unizony, S Lim, N Phippard, DJ Carey, VJ Miloslavsky, EM Tchao, NK Ikle, D Asare, AL Merkel, PA Monach, PA Seo, P St Clair, EW Langford, CA Spiera, R Hoffman, GS Kallenberg, CGM Specks, U Stone, JH AF Unizony, Sebastian Lim, Noha Phippard, Deborah J. Carey, Vincent J. Miloslavsky, Eli M. Tchao, Nadia K. Ikle, David Asare, Adam L. Merkel, Peter A. Monach, Paul A. Seo, Philip St Clair, E. William Langford, Carol A. Spiera, Robert Hoffman, Gary S. Kallenberg, Cees G. M. Specks, Ulrich Stone, John H. TI Peripheral CD5+B Cells in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID REGULATORY B-CELLS; ANCA-ASSOCIATED VASCULITIS; WEGENERS-GRANULOMATOSIS; AUTOIMMUNE-DISEASE; B10 CELLS; RITUXIMAB; SUBSET; INDUCTION; REMISSION; ARTHRITIS AB Objective. CD5(+) B cells have been conceptualized as a possible surrogate for Breg cells. The aim of the present study was to determine the utility of CD5(+) B cells as biomarkers in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Methods. The absolute and relative numbers (percentages) of CD5(+) B cells (explanatory variables) were measured longitudinally during 18 months in 197 patients randomized to receive either rituximab (RTX) or cyclophosphamide (CYC) followed by azathioprine (AZA) for the treatment of AAV (Rituximab in ANCA-Associated Vasculitis [RAVE] trial). Outcome variables included disease activity (status of active disease versus complete remission), responsiveness to induction therapy, disease relapse, disease severity, and, in RTX-treated patients, relapse-free survival according to the percentage of CD5(+) B cells detected upon B cell repopulation. Results. CD5(+) B cell numbers were comparable between the treatment groups at baseline. After an initial decline, absolute CD5(+) B cell numbers progressively increased in patients in the RTX treatment arm, but remained low in CYC/AZA-treated patients. In both groups, the percentage of CD5(+) B cells increased during remission induction and slowly declined thereafter. During relapse, the percentage of CD5(+) B cells correlated inversely with disease activity in RTX-treated patients, but not in patients who received CYC/AZA. No significant association was observed between the numbers of CD5(+) B cells and induction treatment failure or disease severity. The dynamics of the CD5(+) B cell compartment did not anticipate disease relapse. Following B cell repopulation, the percentage of CD5(+) B cells was not predictive of time to flare in RTX-treated patients. Conclusion. The percentage of peripheral CD5(+) B cells might reflect disease activity in RTX-treated patients. However, sole staining for CD5 as a putative surrogate marker for Breg cells did not identify a subpopulation of B cells with clear potential for meaningful clinical use. Adequate phenotyping of Breg cells is required to further explore the value of these cells as biomarkers in AAV. C1 [Unizony, Sebastian; Miloslavsky, Eli M.; Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lim, Noha; Phippard, Deborah J.; Tchao, Nadia K.; Asare, Adam L.] Immune Tolerance Network, San Francisco, CA USA. [Carey, Vincent J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Merkel, Peter A.] Univ Penn, Philadelphia, PA 19104 USA. [Monach, Paul A.] Boston Univ, Boston, MA 02215 USA. [Seo, Philip] Johns Hopkins Univ, Baltimore, MD USA. [St Clair, E. William] Duke Univ, Med Ctr, Durham, NC USA. [Langford, Carol A.; Hoffman, Gary S.] Cleveland Clin, Cleveland, OH 44106 USA. [Spiera, Robert] Hosp Special Surg, New York, NY 10021 USA. [Kallenberg, Cees G. M.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [Specks, Ulrich] Mayo Clin, Rochester, MN USA. RP Stone, JH (reprint author), Massachusetts Gen Hosp, Rheumatol Unit, Yawkey 2C,55 Fruit St, Boston, MA 02114 USA. EM jhstone@partners.org FU Genentech; Roche; Novo Nordisk; Eli Lilly; MedImmune; ChemoCentyx FX Dr. Miloslavsky has received honoraria for Advisory Board service from Genentech (less than $10,000). Dr. Langford has participated in clinical trials at the Cleveland Clinic that were funded by Genentech. Dr. Spiera has served as an investigator in clinical trials funded by Roche and Genentech. Dr. Kallenberg has received consulting fees from Novo Nordisk, Eli Lilly, MedImmune, and ChemoCentyx (less than $10,000 each). Dr. Stone has received consulting fees, speaking fees, and/or honoraria from Genentech and Roche (less than $10,000 each). NR 28 TC 8 Z9 8 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD FEB PY 2015 VL 67 IS 2 BP 535 EP 544 DI 10.1002/art.38916 PG 10 WC Rheumatology SC Rheumatology GA CA9CR UT WOS:000349218500026 PM 25332071 ER PT J AU Choi, HK Niu, JB Neogi, T Chen, CA Chaisson, C Hunter, D Zhang, YQ AF Choi, Hyon K. Niu, Jingbo Neogi, Tuhina Chen, Clara A. Chaisson, Christine Hunter, David Zhang, Yuqing TI Nocturnal Risk of Gout Attacks SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID POSITIVE AIRWAY PRESSURE; NUTRITION EXAMINATION SURVEY; AMBULATORY BLOOD-PRESSURE; OBSTRUCTIVE SLEEP-APNEA; CASE-CROSSOVER DESIGN; URINARY URIC-ACID; NATIONAL-HEALTH; DOUBLE-BLIND; PREVALENCE; ARTHRITIS AB Objective. Several plausible mechanisms and anecdotal descriptions suggest that gout attacks often occur at night, although there are no scientific data supporting this. We undertook this study to evaluate the hypothesis that gout attacks occur more frequently at night. Methods. We conducted a case-crossover study to examine the risk of acute gout attacks in relation to the time of the day. Gout patients were prospectively recruited and followed up via the internet for 1 year. Participants were asked about the following information concerning their gout attacks:the date and hour of attack onset, symptoms and signs, medication use, and purported risk factors during the 24- and 48-hour periods prior to the gout attack. We calculated the odds ratios (ORs) of gout attacks (with 95% confidence intervals [95% CIs]) according to three 8-hour time blocks of the day (i.e., 12:00 AM to 7:59 AM, 8:00 AM to 3:59 PM [reference], and 4:00 PM to 11:59 PM) using conditional logistic regression. Results. Our study included 724 gout patients who experienced a total of 1,433 attacks (733, 310, and 390 attacks during the first, second, and third 8-hour time blocks, respectively) over 1 year. The risk of gout flares in the 8-hour overnight time block (12:00 AM to 7:59 AM) was 2.36 times higher than in the daytime (8:00 AM to 3:59 PM) (OR 2.36 [95% CI 2.05-2.73]). The corresponding OR in the evening (4:00 PM to 11:59 PM) was 1.26 (95% CI 1.07-1.48). These associations persisted among those with no alcohol use and in the lowest quintile of purine intake in the 24 hours prior to attack onset. Furthermore, these associations persisted in subgroups according to sex, age group, obesity status, diuretic use, and use of allopurinol, colchicine, and nonsteroidal antiinflammatory drugs. Conclusion. These findings provide the first prospective evidence that the risk of gout attacks during the night and early morning is 2.4 times higher than in the daytime. Further, these data support the purported mechanisms and historical descriptions of the nocturnal onset of gout attacks and may have implications for antigout prophylactic measures. C1 [Choi, Hyon K.; Niu, Jingbo; Neogi, Tuhina; Chen, Clara A.; Chaisson, Christine; Zhang, Yuqing] Boston Univ, Boston, MA 02215 USA. [Hunter, David] Univ Sydney, Sydney, NSW 2006, Australia. [Hunter, David] Royal N Shore Hosp, St Leonards, NSW 2065, Australia. RP Choi, HK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol, 55 Fruit St,Bulfinch 165, Boston, MA 02114 USA. EM HCHOI@PARTNERS.ORG OI Neogi, Tuhina/0000-0002-9515-1711 FU Arthritis Foundation; Rheumatology Research Foundation; NIH [AR-47785] FX Supported by the Arthritis Foundation, the Rheumatology Research Foundation, and the NIH (grant AR-47785). NR 31 TC 7 Z9 7 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD FEB PY 2015 VL 67 IS 2 BP 555 EP 562 DI 10.1002/art.38917 PG 8 WC Rheumatology SC Rheumatology GA CA9CR UT WOS:000349218500028 PM 25504842 ER PT J AU Rines, AK Verdeguer, F Puigserver, P AF Rines, Amy K. Verdeguer, Francisco Puigserver, Pere TI Adenosine activates thermogenic adipocytes SO CELL RESEARCH LA English DT Editorial Material ID BROWN ADIPOSE-TISSUE; ADAPTIVE THERMOGENESIS; RECEPTORS C1 [Rines, Amy K.; Verdeguer, Francisco; Puigserver, Pere] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. [Rines, Amy K.; Verdeguer, Francisco; Puigserver, Pere] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA. RP Puigserver, P (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. EM pere_puigserver@dfci.harvard.edu NR 11 TC 0 Z9 0 U1 2 U2 6 PU INST BIOCHEMISTRY & CELL BIOLOGY PI SHANGHAI PA SIBS, CAS, 319 YUEYANG ROAD, SHANGHAI, 200031, PEOPLES R CHINA SN 1001-0602 EI 1748-7838 J9 CELL RES JI Cell Res. PD FEB PY 2015 VL 25 IS 2 BP 155 EP 156 DI 10.1038/cr.2014.157 PG 2 WC Cell Biology SC Cell Biology GA CB0RJ UT WOS:000349334100004 PM 25449131 ER PT J AU Mawet, J Kurth, T Ayata, C AF Mawet, Jerome Kurth, Tobias Ayata, Cenk TI Migraine and stroke: In search of shared mechanisms SO CEPHALALGIA LA English DT Review DE Migraine; ischemic stroke; cerebrovascular disease; spreading depression; migrainous infarct ID CORTICAL SPREADING DEPRESSION; CERVICAL ARTERY DISSECTION; PATENT FORAMEN OVALE; HEREDITARY HEMORRHAGIC TELANGIECTASIA; SMALL-VESSEL DISEASE; CEREBRAL VASOCONSTRICTION SYNDROME; POSTERIOR CIRCULATION TERRITORY; ENDOTHELIAL PROGENITOR CELLS; NEAR-INFRARED SPECTROSCOPY; INFARCT-LIKE LESIONS AB Background Migraine, particularly with aura, increases the risk for ischemic stroke, at least in a subset of patients. The underlying mechanisms are poorly understood and probably multifactorial. Methods We carried out an extended literature review of experimental and clinical evidence supporting the association between migraine and ischemic stroke to identify potential mechanisms that can explain the association. Results Observational, imaging and genetic evidence support a link between migraine and ischemic stroke. Based on clinical and experimental data, we propose mechanistic hypotheses to explain the link, such as microembolic triggers of migraine and enhanced sensitivity to ischemic injury in migraineurs. Discussion We discuss the possible practical implications of clinical and experimental data, such as aggressive risk factor screening and management, stroke prophylaxis and specific acute stroke management in migraineurs. However, evidence from prospective clinical trials is required before modifying the practice in this patient population. C1 [Mawet, Jerome; Ayata, Cenk] Harvard Univ, Massachusetts Gen Hosp, Neurovasc Res Lab, Dept Radiol,Med Sch, Cambridge, MA 02138 USA. [Mawet, Jerome] Lariboisiere Hosp, AP HP, Emergency Headache Ctr, Paris, France. [Mawet, Jerome] DHU NeuroVasc, Paris, France. [Kurth, Tobias] INSERM, Res Ctr Epidemiol & Biostat, U897, Team Neuroepidemiol, Paris, France. [Kurth, Tobias] Univ Bordeaux, Coll Hlth Sci, Talence, France. [Kurth, Tobias] Harvard Univ, Brigham & Womens Hosp, Div Prevent Med, Dept Med,Med Sch, Cambridge, MA 02138 USA. [Ayata, Cenk] Harvard Univ, Massachusetts Gen Hosp, Stroke Serv & Neurosci Intens Care Unit, Dept Med,Med Sch, Cambridge, MA 02138 USA. RP Ayata, C (reprint author), MGH Neurosci Ctr, Neurovasc Res Lab, 149 13th St,Room 6408, Charlestown, MA 02129 USA. EM cayata@partners.org RI Kurth, Tobias/A-9243-2012 OI Kurth, Tobias/0000-0001-7169-2620 FU US National Institutes of Health (NIH) [NS055104, NS061505]; American Heart Association (AHA) [11SDG7600037]; Fondation Leducq; Heitman Foundation; Ellison Foundation; Institut Servier; Philippe Foundation; Therese and Rene Planiol Foundation for the Study of the Brain; Association CADASIL France FX This work was indirectly supported by grants from the US National Institutes of Health (NIH) (NS055104, NS061505); the American Heart Association (AHA) (11SDG7600037); Fondation Leducq; the Heitman Foundation; the Ellison Foundation; Institut Servier; Philippe Foundation, Therese and Rene Planiol Foundation for the Study of the Brain; and the Association CADASIL France. NR 177 TC 16 Z9 16 U1 5 U2 17 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0333-1024 EI 1468-2982 J9 CEPHALALGIA JI Cephalalgia PD FEB PY 2015 VL 35 IS 2 SI SI BP 165 EP 181 DI 10.1177/0333102414550106 PG 17 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CA0ZI UT WOS:000348641600009 PM 25228681 ER PT J AU Taveras, EM Blaine, RE Davison, KK Gortmaker, S Anand, S Falbe, J Kwass, JA Perkins, M Giles, C Criss, S Colchamiro, R Baidal, JW Land, T Smith, L AF Taveras, Elsie M. Blaine, Rachel E. Davison, Kirsten K. Gortmaker, Steven Anand, Shikha Falbe, Jennifer Kwass, Jo-Ann Perkins, Meghan Giles, Catherine Criss, Shaniece Colchamiro, Rachel Baidal, Jennifer Woo Land, Thomas Smith, Lauren CA MA-CORD Study Grp TI Design of the Massachusetts Childhood Obesity Research Demonstration (MA-CORD) Study SO CHILDHOOD OBESITY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; PHYSICAL-ACTIVITY; SLEEP DURATION; INTERDISCIPLINARY INTERVENTION; PRIMARY-CARE; ENERGY-GAP; AGES 9; CHILDREN; OVERWEIGHT; HEALTH AB Background: Childhood obesity is highly prevalent, is associated with both short- and long-term adverse outcomes, disproportionately affects racial/ethnic minority and economically deprived children, and represents a major threat to public health. Among the most promising approaches for its prevention and management are multilevel, multisector strategies. Methods/Design: The Massachusetts Childhood Obesity Research Demonstration (MA-CORD) Study was a comprehensive, systematic intervention to prevent and reduce childhood obesity among low-income children ages 2-12 years in two selected cities in Massachusetts. Building on the Obesity Chronic Care Model, MA-CORD expanded a state public health department community-level obesity prevention initiative that incorporated evidence-based interventions in primary healthcare, the Women, Infants, and Children program, early care and education, schools/afterschool programs, as well as community-wide programs to improve food, beverage, physical activity (PA), and messaging environments. The study used a combination of pre- and post-time series and quasi-experimental designs to examine the extent to which the intervention resulted in changes in BMI, individual-level lifestyle behaviors, satisfaction with healthcare services, and quality of life among children, as well as changes in health policies, programs, and environments in the two intervention cities, compared to a comparison city. The intervention period was 2 years. Conclusions: MA-CORD will determine the extent to which a multisetting, multilevel intervention that integrates activities in primary care with broader public health interventions in schools, early care and education, and the community at large can improve children's dietary and PA behaviors and ultimately reduce obesity in low-income children. C1 [Taveras, Elsie M.; Perkins, Meghan; Baidal, Jennifer Woo] MassGen Hosp Children, Dept Pediat, Div Gen Acad Pediat, Boston, MA 02114 USA. [Taveras, Elsie M.; Blaine, Rachel E.; Davison, Kirsten K.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Davison, Kirsten K.; Gortmaker, Steven; Giles, Catherine; Criss, Shaniece] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA. [Anand, Shikha; Smith, Lauren] Natl Initiat Childrens Healthcare Qual, Boston, MA USA. [Falbe, Jennifer] Univ Calif Berkeley, Sch Publ Hlth, Div Community Hlth & Human Dev, Berkeley, CA 94720 USA. [Kwass, Jo-Ann; Colchamiro, Rachel] Massachusetts Dept Publ Hlth, Bur Community Hlth & Prevent, Boston, MA USA. [Baidal, Jennifer Woo] Childrens Hosp Boston, Div Gastroenterol & Nutr, Boston, MA USA. [Land, Thomas] Massachusetts Dept Publ Hlth, Off Commissioner, Boston, MA USA. RP Taveras, EM (reprint author), MassGen Hosp Children, Dept Pediat, Div Gen Acad Pediat, 100 Cambridge St 15th Floor, Boston, MA 02114 USA. EM etaveras@partners.org FU CDC, National Center for Chronic Disease Prevention and Health Promotion [U18DP003370]; Initiative to Maximize Student Diversity Award [GM055353-13]; Maternal and Child Health Bureau [T03MC07648]; National Institutes of Health [3R25CA057711] FX This study was supported by the CDC, National Center for Chronic Disease Prevention and Health Promotion (award no.: U18DP003370). This work is solely the responsibility of the authors and does not represent official views of the CDC. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the listed funding sources. Funding support for S.C. was also provided by predoctoral training grants from the Initiative to Maximize Student Diversity Award (grant no.: GM055353-13), the Maternal and Child Health Bureau (grant no.: T03MC07648), and the National Institutes of Health (grant no.: 3R25CA057711). NR 47 TC 15 Z9 15 U1 3 U2 25 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2153-2168 EI 2153-2176 J9 CHILD OBES JI Child Obes. PD FEB 1 PY 2015 VL 11 IS 1 BP 11 EP 22 DI 10.1089/chi.2014.0031 PG 12 WC Pediatrics SC Pediatrics GA CB0LH UT WOS:000349317000003 PM 25469676 ER PT J AU Brandon, TH Goniewicz, ML Hanna, NH Hatsukami, DK Herbst, RS Hobin, JA Ostroff, JS Shields, PG Toll, BA Tyne, CA Viswanath, K Warren, GW AF Brandon, Thomas H. Goniewicz, Maciej L. Hanna, Nasser H. Hatsukami, Dorothy K. Herbst, Roy S. Hobin, Jennifer A. Ostroff, Jamie S. Shields, Peter G. Toll, Benjamin A. Tyne, Courtney A. Viswanath, Kasisomayajula Warren, Graham W. TI Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology SO CLINICAL CANCER RESEARCH LA English DT Article ID TOBACCO PRODUCT USE; DEVICE E-CIGARETTE; SMOKING REDUCTION; UNITED-STATES; DOUBLE-BLIND; THIRDHAND-SMOKE; SALIVA COTININE; CESSATION; TRIAL; ADULTS AB Combustible tobacco use remains the number one preventable cause of disease, disability, and death in the United States. Electronic nicotine delivery systems (ENDS), which include e-cigarettes, are devices capable of delivering nicotine in an aerosolized form. ENDS use by both adults and youth has increased rapidly, and some have advocated these products could serve as harm-reduction devices and smoking cessation aids. ENDS may be beneficial if they reduce smoking rates or prevent or reduce the known adverse health effects of smoking. However, ENDS may also be harmful, particularly to youth, if they increase the likelihood that nonsmokers or formers smokers will use combustible tobacco products or if they discourage smokers from quitting. The American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) recognize the potential ENDS have to alter patterns of tobacco use and affect the public's health; however, definitive data are lacking. AACR and ASCO recommend additional research on these devices, including assessing the health impacts of ENDS, understanding patterns of ENDS use, and determining what role ENDS have in cessation. Key policy recommendations include supporting federal, state, and local regulation of ENDS; requiring manufacturers to register with the FDA and report all product ingredients, requiring childproof caps on ENDS liquids, and including warning labels on products and their advertisements; prohibiting youth-oriented marketing and sales; prohibiting child-friendly ENDS flavors; and prohibiting ENDS use in places where cigarette smoking is prohibited. C1 [Brandon, Thomas H.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Goniewicz, Maciej L.] Roswell Pk Canc Inst, Buffalo, NY USA. [Hanna, Nasser H.] Indiana Univ, Hlth Simon Canc Ctr, Indianapolis, IN USA. [Hatsukami, Dorothy K.] Mason Canc Ctr, Minneapolis, MN USA. [Hobin, Jennifer A.] Amer Assoc Canc Res, Philadelphia, PA USA. [Herbst, Roy S.; Toll, Benjamin A.] Yale Univ, Sch Med, Ctr Comprehens Canc, New Haven, CT 06510 USA. [Ostroff, Jamie S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Shields, Peter G.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Tyne, Courtney A.] Amer Soc Clin Oncol, Alexandria, VA USA. [Viswanath, Kasisomayajula] Dana Farber Canc Inst, Boston, MA 02115 USA. [Warren, Graham W.] Med Univ S Carolina, Charleston, SC 29425 USA. RP Brandon, TH (reprint author), Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. OI Ostroff, Jamie/0000-0003-2671-5680 FU Pfizer; Genentech/Roche FX T.H. Brandon reports receiving research funding from Pfizer and is a consultant/advisory board member for Voxiva, Inc.. R. S. Herbst reports receiving honoraria from Boehringer Ingelheim, Celgene, Eli Lilly, Merck, NovaRX, and Pfizer; research funding from Genentech/Roche; and is a consultant/advisory board member for Biothera, DiaTech Oncology, Kolltan Pharmaceuticals, and N-of-Ones. J.S. Ostroff reports receiving research funding from Pfizer. No potential conflicts of interest were disclosed by the other authors. NR 80 TC 26 Z9 26 U1 2 U2 28 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD FEB 1 PY 2015 VL 21 IS 3 BP 514 EP 525 DI 10.1158/1078-0432.CCR-14-2544 PG 12 WC Oncology SC Oncology GA CA4WR UT WOS:000348908500005 PM 25573384 ER PT J AU McDermott, DF Cheng, SC Signoretti, S Margolin, KA Clark, JI Sosman, JA Dutcher, JP Logan, TF Curti, BD Ernstoff, MS Appleman, L Wong, MKK Khushalani, NI Oleksowicz, L Vaishampayan, UN Mier, JW Panka, DJ Bhatt, RS Bailey, AS Leibovich, BC Kwon, ED Kabbinavar, FF Belldegrun, AS Figlin, RA Pantuck, AJ Regan, MM Atkins, MB AF McDermott, David F. Cheng, Su-Chun Signoretti, Sabina Margolin, Kim A. Clark, Joseph I. Sosman, Jeffrey A. Dutcher, Janice P. Logan, Theodore F. Curti, Brendan D. Ernstoff, Marc S. Appleman, Leonard Wong, Michael K. K. Khushalani, Nikhil I. Oleksowicz, Leslie Vaishampayan, Ulka N. Mier, James W. Panka, David J. Bhatt, Rupal S. Bailey, Alexandra S. Leibovich, Bradley C. Kwon, Eugene D. Kabbinavar, Fairooz F. Belldegrun, Arie S. Figlin, Robert A. Pantuck, Allan J. Regan, Meredith M. Atkins, Michael B. TI The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma SO CLINICAL CANCER RESEARCH LA English DT Article ID CARBONIC-ANHYDRASE-IX; PHASE-III TRIAL; INTERLEUKIN-2 THERAPY; INTERFERON-ALPHA; SUBCUTANEOUS INTERLEUKIN-2; CLINICAL-TRIALS; CANCER; IMMUNOTHERAPY; NEPHRECTOMY; PROGNOSIS AB Purpose: High-dose aldesleukin (HD IL2) received FDA approval for the treatment of metastatic renal cell carcinoma (MRCC) in 1992, producing a 14% objective response rate (ORR) and durable remissions. Retrospective studies suggested that clinical and pathologic features could predict for benefit. The Cytokine Working Group conducted this prospective trial to validate proposed predictive markers of response to HD IL2. Experimental Design: Standard HD IL2 was administered to prospectively evaluate whether the ORR of patients with mRCC with "good" predictive pathologic features based on an "integrated selection" model [ISM (e.g., clear-cell histology subclassification and carbonic anhydrase-9 (CA-9) IHC staining] was significantly higher than the ORR of a historical, unselected population. Archived tumor was collected for pathologic analysis including tumor programmed death-ligand 1 (PD-L1) expression. Results: One hundred and twenty eligible patients were enrolled between June 11 and September 7; 70% were Memorial Sloan Kettering Cancer Center (New York, NY) intermediate risk, 96% had clear cell RCC, and 99% had prior nephrectomy. The independently assessed ORR was 25% (30/120, 95% CI, 17.5%-33.7%, P = 0.0014; 3 complete responses, 27 partial responses) and was higher than a historical ORR. Thirteen patients (11%) remained progression free at 3 years and the median overall survival was 42.8 months. ORR was not statistically different by ISM classification ("good-risk" 23% vs. "poor-risk" 30%; P = 0.39). ORR was positively associated with tumor PD-L1 expression (P = 0.01) by IHC. Conclusions: In this prospective, biomarker validation study, HD IL2 produced durable remissions and prolonged survival in both "good" and "poor-risk" patients. The proposed ISM was unable to improve the selection criteria. Novel markers (e.g., tumor PD L1 expression) appeared useful, but require independent validation. (C) 2014 AACR. C1 [McDermott, David F.; Mier, James W.; Panka, David J.; Bhatt, Rupal S.; Bailey, Alexandra S.] Beth Israel Deaconess Med Ctr, Dana Farber Harvard Canc Ctr, Boston, MA 02215 USA. [Cheng, Su-Chun; Regan, Meredith M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Signoretti, Sabina] Brigham & Womens Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02115 USA. [Margolin, Kim A.] Univ Washington, Seattle, WA 98195 USA. [Clark, Joseph I.] Loyola Univ, Stritch Sch Med, Chicago, IL 60611 USA. [Sosman, Jeffrey A.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37235 USA. [Dutcher, Janice P.] Our Lady Mercy Med Ctr, Newark, NY USA. [Logan, Theodore F.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA. [Curti, Brendan D.] Earle A Chiles Res Inst, Providence Canc Ctr, Portland, OR USA. [Ernstoff, Marc S.] Norris Cotton Canc Ctr, Dartmouth Hitchcock Med Ctr, Dartmouth, NS, Canada. [Appleman, Leonard] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA. [Wong, Michael K. K.; Khushalani, Nikhil I.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Oleksowicz, Leslie] Lawrence Mem Hosp, Waterford, CT USA. [Vaishampayan, Ulka N.] Karmanos Canc Inst, Detroit, MI USA. [Leibovich, Bradley C.; Kwon, Eugene D.] Mayo Clin, Dept Urol, Rochester, MN USA. [Kabbinavar, Fairooz F.; Belldegrun, Arie S.; Pantuck, Allan J.] Univ Calif Los Angeles, Med Ctr, Santa Monica, CA USA. [Figlin, Robert A.] Cedars Sinais Samuel Oschin Comprehens Canc Ins, West Hollywood, CA USA. [Atkins, Michael B.] Georgetown Lombardi Canc Ctr, Washington, DC USA. RP McDermott, DF (reprint author), Beth Israel Deaconess Med Ctr, 375 Longwood Ave,Masco 4th Floor, Boston, MA 02215 USA. EM dmcdermo@bidmc.harvard.edu FU Prometheus Laboratories Inc.; Novartis International AG; National Cancer Institute of the NIH; SPORE in Kidney Cancer [P50CA101942] FX Research reported in this article was supported by Prometheus Laboratories Inc., Novartis International AG, the National Cancer Institute of the NIH, and SPORE in Kidney Cancer under award number P50CA101942. NR 42 TC 27 Z9 27 U1 3 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD FEB 1 PY 2015 VL 21 IS 3 BP 561 EP 568 DI 10.1158/1078-0432.CCR-14-1520 PG 8 WC Oncology SC Oncology GA CA4WR UT WOS:000348908500010 PM 25424850 ER PT J AU Shou, Y Robinson, DM Amakye, DD Rose, KL Cho, YJ Ligon, KL Sharp, T Haider, AS Bandaru, R Ando, Y Geoerger, B Doz, F Ashley, DM Hargrave, DR Casanova, M Tawbi, HA Rodon, J Thomas, AL Mita, AC MacDonald, TJ Kieran, MW AF Shou, Yaping Robinson, Douglas M. Amakye, Dereck D. Rose, Kristine L. Cho, Yoon-Jae Ligon, Keith L. Sharp, Thad Haider, Asifa S. Bandaru, Raj Ando, Yuichi Geoerger, Birgit Doz, Francois Ashley, David M. Hargrave, Darren R. Casanova, Michela Tawbi, Hussein A. Rodon, Jordi Thomas, Anne L. Mita, Alain C. MacDonald, Tobey J. Kieran, Mark W. TI A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma SO CLINICAL CANCER RESEARCH LA English DT Article ID SOLID TUMORS; EXPRESSION; PATHWAY; ACTIVATION; REGRESSION; SUBGROUPS; CANCER; LASSO AB Purpose: Distinct molecular subgroups of medulloblastoma, including hedgehog (Hh) pathway-activated disease, have been reported. We identified and clinically validated a five-gene Hh signature assay that can be used to preselect patients with Hh pathway-activated medulloblastoma. Experimental Design: Gene characteristics of the Hh medulloblastoma subgroup were identified through published bioinformatic analyses. Thirty-two genes shown to be differentially expressed in fresh-frozen and formalin-fixed paraffin-embedded tumor samples and reproducibly analyzed by RT-PCR were measured in matched samples. These data formed the basis for building a multi-gene logistic regression model derived through elastic net methods from which the five-gene Hh signature emerged after multiple iterations. On the basis of signature gene expression levels, the model computed a propensity score to determine Hh activation using a threshold set a priori. The asso-ciation between Hh activation status and tumor response to the Hh pathway inhibitor sonidegib (LDE225) was analyzed. Results: Five differentially expressed genes in medulloblastoma (GLI1, SPHK1, SHROOM2, PDLIM3, and OTX2) were found to associate with Hh pathway activation status. In an independent validation study, Hh activation status of 25 medulloblastoma samples showed 100% concordance between the five-gene signature and Affymetrix profiling. Further, in medulloblastoma samples from 50 patients treated with sonidegib, all 6 patients who responded were found to have Hh-activated tumors. Three patients with Hh-activated tumors had stable or progressive disease. No patients with Hh-nonactivated tumors responded. Conclusions: This five-gene Hh signature can robustly identify Hh-activated medulloblastoma and may be used to preselect patients who might benefit from sonidegib treatment. (C) 2014 AACR. C1 [Shou, Yaping; Robinson, Douglas M.; Sharp, Thad; Bandaru, Raj] Novartis Inst BioMed Res Inc, Cambridge, MA USA. [Amakye, Dereck D.; Rose, Kristine L.; Haider, Asifa S.] Novartis Pharmaceut, E Hanover, NJ USA. [Cho, Yoon-Jae] Stanford Univ, Sch Med, Dept Neurol, Stanford, CA 94305 USA. [Cho, Yoon-Jae] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA. [Ligon, Keith L.; Kieran, Mark W.] Dana Farber Canc Inst, Boston, MA 02215 USA. [Ligon, Keith L.; Kieran, Mark W.] Boston Childrens Hosp, Boston, MA 02115 USA. [Ligon, Keith L.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Ligon, Keith L.] Brigham & Womens Hosp, Childrens Hosp Boston, Dept Pathol, Boston, MA 02115 USA. [Ligon, Keith L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ligon, Keith L.] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA. [Ando, Yuichi] Nagoya Univ Hosp, Nagoya, Aichi, Japan. [Geoerger, Birgit] Univ Paris 11, Inst Gustave Roussy, Villejuif, France. [Doz, Francois] Inst Curie, F-75231 Paris, France. [Doz, Francois] Univ Paris 05, Sorbonne Paris Cite, Paris, France. [Ashley, David M.] Deakin Univ, Barwon Hlth, Melbourne, Vic 3217, Australia. [Hargrave, Darren R.] Great Ormond St Hosp Sick Children, London, England. [Casanova, Michela] Fdn IRCCS Ist Nazl Tumori, Milan, Italy. [Tawbi, Hussein A.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. [Tawbi, Hussein A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Rodon, Jordi] Vall Hebron Inst Oncol, Barcelona, Spain. [Rodon, Jordi] Univ Autonoma Barcelona, E-08193 Barcelona, Spain. [Thomas, Anne L.] Univ Leicester, Leicester, Leics, England. [Mita, Alain C.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. [MacDonald, Tobey J.] Emory Univ, Sch Med, Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA 30322 USA. RP Kieran, MW (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,D 3154, Boston, MA 02215 USA. EM mark_kieran@dfci.harvard.edu RI Casanova, Michela/K-8436-2016; OI Casanova, Michela/0000-0003-0368-7883; Hargrave, Darren/0000-0001-8219-9807 FU Novartis Pharmaceuticals Corporation FX This study was supported by Novartis Pharmaceuticals Corporation for clinical studies and medical editorial support. NR 35 TC 16 Z9 16 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD FEB 1 PY 2015 VL 21 IS 3 BP 585 EP 593 DI 10.1158/1078-0432.CCR-13-1711 PG 9 WC Oncology SC Oncology GA CA4WR UT WOS:000348908500013 PM 25473003 ER PT J AU Seiwert, TY Zuo, ZX Keck, MK Khattri, A Pedamallu, CS Stricker, T Brown, C Pugh, TJ Stojanov, P Cho, J Lawrence, MS Getz, G Bragelmann, J DeBoer, R Weichselbaum, RR Langerman, A Portugal, L Blair, E Stenson, K Lingen, MW Cohen, EEW Vokes, EE White, KP Hammerman, PS AF Seiwert, Tanguy Y. Zuo, Zhixiang Keck, Michaela K. Khattri, Arun Pedamallu, Chandra S. Stricker, Thomas Brown, Christopher Pugh, Trevor J. Stojanov, Petar Cho, Juok Lawrence, Michael S. Getz, Gad Braegelmann, Johannes DeBoer, Rebecca Weichselbaum, Ralph R. Langerman, Alexander Portugal, Louis Blair, Elizabeth Stenson, Kerstin Lingen, Mark W. Cohen, Ezra E. W. Vokes, Everett E. White, Kevin P. Hammerman, Peter S. TI Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas SO CLINICAL CANCER RESEARCH LA English DT Article ID HUMAN-PAPILLOMAVIRUS; COPY-NUMBER; MUTATIONAL LANDSCAPE; OROPHARYNGEAL CANCER; SOMATIC MUTATIONS; FREQUENT MUTATION; GENE-EXPRESSION; SAMPLES; TUMORS; FGFR3 AB Purpose: The genetic differences between human papilloma virus (HPV)-positive and -negative head and neck squamous cell carcinomas (HNSCC) remain largely unknown. To identify differential biology and novel therapeutic targets for both entities, we determined mutations and copy-number aberrations in a large cohort of locoregionally advanced HNSCC. Experimental Design: We performed massively parallel sequencing of 617 cancer-associated genes in 120 matched tumor/normal samples (42.5% HPV-positive). Mutations and copy-number aberrations were determined and results validated with a secondary method. Results: The overall mutational burden in HPV-negative and HPV-positive HNSCC was similar with an average of 15.2 versus 14.4 somatic exonic mutations in the targeted cancer-associated genes. HPV-negative tumors showed a mutational spectrum concordant with published lung squamous cell carcinoma analyses with enrichment for mutations in TP53, CDKN2A, MLL2, CUL3, NSD1, PIK3CA, and NOTCH genes. HPV-positive tumors showed unique mutations in DDX3X, FGFR2/3 and aberrations in PIK3CA, KRAS, MLL2/3, and NOTCH1 were enriched in HPV-positive tumors. Currently targetable genomic alterations were identified in FGFR1, DDR2, EGFR, FGFR2/3, EPHA2, and PIK3CA. EGFR, CCND1, and FGFR1 amplifications occurred in HPV-negative tumors, whereas 17.6% of HPV-positive tumors harbored mutations in fibroblast growth factor receptor genes (FGFR2/3), including six recurrent FGFR3 S249C mutations. HPV-positive tumors showed a 5.8% incidence of KRAS mutations, and DNA-repair gene aberrations, including 7.8% BRCA1/2 mutations, were identified. Conclusions: The mutational makeup of HPV-positive and HPV-negative HNSCC differs significantly, including targetable genes. HNSCC harbors multiple therapeutically important genetic aberrations, including frequent aberrations in the FGFR and PI3K pathway genes. (C) 2014 AACR. C1 [Seiwert, Tanguy Y.; Zuo, Zhixiang; Keck, Michaela K.; Khattri, Arun; Braegelmann, Johannes; DeBoer, Rebecca; Cohen, Ezra E. W.; Vokes, Everett E.] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA. [Seiwert, Tanguy Y.; Weichselbaum, Ralph R.; Langerman, Alexander; Portugal, Louis; Blair, Elizabeth; Stenson, Kerstin; Lingen, Mark W.; Cohen, Ezra E. W.; Vokes, Everett E.; White, Kevin P.] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA. [Seiwert, Tanguy Y.; White, Kevin P.] Univ Chicago, Inst Genom & Syst Biol, Chicago, IL 60637 USA. [Pedamallu, Chandra S.; Pugh, Trevor J.; Stojanov, Petar; Cho, Juok; Lawrence, Michael S.; Getz, Gad; Hammerman, Peter S.] Broad Inst Harvard & MIT, Cambridge, MA USA. [Pedamallu, Chandra S.; Pugh, Trevor J.; Hammerman, Peter S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Stricker, Thomas] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Nashville, TN 37235 USA. [Brown, Christopher] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA. [Weichselbaum, Ralph R.] Univ Chicago, Dept Radiat Oncol, Chicago, IL 60637 USA. [Langerman, Alexander; Portugal, Louis; Blair, Elizabeth; Stenson, Kerstin] Univ Chicago, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA. [Lingen, Mark W.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA. RP Seiwert, TY (reprint author), Univ Chicago, Dept Med, Hematol Oncol Sect, 5841 South Maryland Ave,MC2115, Chicago, IL 60637 USA. EM tseiwert@medicine.bsd.uchicago.edu RI Zuo, Zhixiang/M-4441-2016; OI Zuo, Zhixiang/0000-0002-2492-2689; Brown, Christopher/0000-0002-3785-5008 FU ASCO Translational Professorship award; Grant Achatz and Nick Kokonas/Alinea Head and Neck Cancer Research Fund; Flight Attending Medical Research Institute Young Clinical Scientist Award (FAMRI, YCSA); NCI K08 Award [1K08CA163677] FX This work was supported by an ASCO Translational Professorship award (to E.E. Vokes), the Grant Achatz and Nick Kokonas/Alinea Head and Neck Cancer Research Fund (to E.E. Vokes and T.Y. Seiwert), a Flight Attending Medical Research Institute Young Clinical Scientist Award (FAMRI, YCSA; to T.Y. Seiwert), and a NCI K08 Award 1K08CA163677 (to P.S. Hammerman). NR 50 TC 93 Z9 95 U1 5 U2 22 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD FEB 1 PY 2015 VL 21 IS 3 BP 632 EP 641 DI 10.1158/1078-0432.CCR-13-3310 PG 10 WC Oncology SC Oncology GA CA4WR UT WOS:000348908500018 PM 25056374 ER PT J AU Trimboli, P Treglia, G Guidobaldi, L Romanelli, F Nigri, G Valabrega, S Sadeghi, R Crescenzi, A Faquin, WC Bongiovanni, M Giovanella, L AF Trimboli, Pierpaolo Treglia, Giorgio Guidobaldi, Leo Romanelli, Francesco Nigri, Giuseppe Valabrega, Stefano Sadeghi, Ramin Crescenzi, Anna Faquin, William C. Bongiovanni, Massimo Giovanella, Luca TI Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis SO CLINICAL ENDOCRINOLOGY LA English DT Article ID FINE-NEEDLE-ASPIRATION; WASH-OUT FLUID; CALCITONIN MEASUREMENT; SERUM CALCITONIN; ROUTINE MEASUREMENT; DIAGNOSIS; CANCER; SENSITIVITY; EXPERIENCE; DISORDERS AB BackgroundThe early detection of medullary thyroid carcinoma (MTC) can improve patient prognosis, because histological stage and patient age at diagnosis are highly relevant prognostic factors. As a consequence, delay in the diagnosis and/or incomplete surgical treatment should correlate with a poorer prognosis for patients. Few papers have evaluated the specific capability of fine-needle aspiration cytology (FNAC) to detect MTC, and small series have been reported. This study conducts a meta-analysis of published data on the diagnostic performance of FNAC in MTC to provide more robust estimates. Research Design and MethodsA comprehensive computer literature search of the PubMed/MEDLINE, Embase and Scopus databases was conducted by searching for the terms medullary thyroid' AND cytology', FNA', FNAB', FNAC', fine needle' or fine-needle'. The search was updated until 21 March 2014, and no language restrictions were used. ResultsFifteen relevant studies and 641 MTC lesions that had undergone FNAC were included. The detection rate (DR) of FNAC in patients with MTC (diagnosed as MTC' or suspicious for MTC') on a per lesion-based analysis ranged from 125% to 882%, with a pooled estimate of 564% (95% CI: 526-601%). The included studies were statistically heterogeneous in their estimates of DR (I-square >50%). Egger's regression intercept for DR pooling was 003 (95% CI: -31 to 32, P=09). The study that reported the largest MTC series had a DR of 45%. Data on immunohistochemistry for calcitonin in diagnosing MTC were inconsistent for the meta-analysis. ConclusionsThe presented meta-analysis demonstrates that FNAC is able to detect approximately one-half of MTC lesions. These findings suggest that other techniques may be needed in combination with FNAC to diagnose MTC and avoid false negative results. C1 [Trimboli, Pierpaolo] Osped Israelit, Sect Endocrinol & Diabetol, I-00148 Rome, Italy. [Trimboli, Pierpaolo; Treglia, Giorgio; Giovanella, Luca] Oncol Inst Southern Switzerland, Dept Nucl Med, Bellinzona, Switzerland. [Trimboli, Pierpaolo; Treglia, Giorgio; Giovanella, Luca] Oncol Inst Southern Switzerland, Thyroid Ctr, Bellinzona, Switzerland. [Guidobaldi, Leo] Osped Israelit, Sect Pathol, I-00148 Rome, Italy. [Romanelli, Francesco] Univ Roma La Sapienza, Dept Expt Med, Rome, Italy. [Nigri, Giuseppe; Valabrega, Stefano] Univ Roma La Sapienza, Osped S Andrea, Dept Med & Surg Sci, Rome, Italy. [Sadeghi, Ramin] Mashhad Univ Med Sci, Nucl Med Res Ctr, Mashhad, Iran. [Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Bongiovanni, Massimo] Univ Lausanne Hosp, Inst Pathol, Lausanne, Switzerland. [Crescenzi, Anna] Univ Hosp Campus Bio Med, Sect Pathol, Rome, Italy. RP Trimboli, P (reprint author), Osped Israelit, Sect Endocrinol & Diabetol, Via Fulda 14, I-00148 Rome, Italy. EM pierpaolo.trimboli@gmail.com RI Sadeghi, Ramin/F-5629-2011; Bongiovanni, Massimo/C-3144-2017 OI Sadeghi, Ramin/0000-0002-1666-5440; Bongiovanni, Massimo/0000-0001-9846-6682 NR 31 TC 23 Z9 24 U1 0 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0300-0664 EI 1365-2265 J9 CLIN ENDOCRINOL JI Clin. Endocrinol. PD FEB PY 2015 VL 82 IS 2 BP 280 EP 285 DI 10.1111/cen.12563 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AZ9ZZ UT WOS:000348575000018 PM 25047365 ER PT J AU Ananthakrishnan, AN Cagan, A Cai, TX Gainer, VS Shaw, SY Churchill, S Karlson, EW Murphy, SN Kohane, I Liao, KP AF Ananthakrishnan, Ashwin N. Cagan, Andrew Cai, Tianxi Gainer, Vivian S. Shaw, Stanley Y. Churchill, Susanne Karlson, Elizabeth W. Murphy, Shawn N. Kohane, Isaac Liao, Katherine P. TI Colonoscopy Is Associated With a Reduced Risk for Colon Cancer and Mortality in Patients With Inflammatory Bowel Diseases SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE CD; UC; Colon Cancer; Screening; Risk Factor; Early Detection ID POPULATION-BASED COHORT; LONG-TERM RISK; COLORECTAL-CANCER; ULCERATIVE-COLITIS; SURVEILLANCE COLONOSCOPY; CROHNS-DISEASE; NEGATIVE COLONOSCOPY; GUIDELINES; MANAGEMENT; ENDOSCOPY AB BACKGROUND & AIMS: Crohn's disease and ulcerative colitis are associated with an increased risk of colorectal cancer (CRC). Surveillance colonoscopy is recommended at 2- to 3-year intervals beginning 8 years after diagnosis of inflammatory bowel disease (IBD). However, there have been no reports of whether colonoscopy examination reduces the risk for CRC in patients with IBD. METHODS: In a retrospective study, we analyzed data from 6823 patients with IBD (2764 with a recent colonoscopy, 4059 without a recent colonoscopy) seen and followed up for at least 3 years at 2 tertiary referral hospitals in Boston, Massachusetts. The primary outcome was diagnosis of CRC. We examined the proportion of patients undergoing a colonoscopy within 36 months before a diagnosis of CRC or at the end of the follow-up period, excluding colonoscopies performed within 6 months before a diagnosis of CRC, to avoid inclusion of prevalent cancers. Multivariate logistic regression was performed, adjusting for plausible confounders. RESULTS: A total of 154 patients developed CRC. The incidence of CRC among patients without a recent colonoscopy (2.7%) was significantly higher than among patients with a recent colonoscopy (1.6%) (odds ratio [OR], 0.56; 95% confidence interval [CI], 0.39-0.80). This difference persisted in multivariate analysis (OR, 0.65; 95% CI, 0.45-0.93) and was robust when adjusted for a range of assumptions in sensitivity analyses. Among patients with CRC, a colonoscopy within 6 to 36 months before diagnosis was associated with a reduced mortality rate (OR, 0.34; 95% CI, 0.12-0.95). CONCLUSIONS: Recent colonoscopy (within 36 months) is associated with a reduced incidence of CRC in patients with IBD, and lower mortality rates in those diagnosed with CRC. C1 [Ananthakrishnan, Ashwin N.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Ananthakrishnan, Ashwin N.; Shaw, Stanley Y.; Murphy, Shawn N.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Shaw, Stanley Y.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Murphy, Shawn N.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Ananthakrishnan, Ashwin N.; Shaw, Stanley Y.; Karlson, Elizabeth W.; Murphy, Shawn N.; Kohane, Isaac; Liao, Katherine P.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Cagan, Andrew; Gainer, Vivian S.] Partners HealthCare, Res IS & Comp, Charlestown, MA USA. [Cai, Tianxi] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Churchill, Susanne; Murphy, Shawn N.; Kohane, Isaac] Brigham & Womens Hosp, Natl Ctr Biomed Comp i2b2, Boston, MA 02115 USA. [Karlson, Elizabeth W.; Liao, Katherine P.] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA. [Kohane, Isaac] Childrens Hosp, Boston, MA 02115 USA. RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. EM aananthakrishnan@mgh.harvard.edu FU National Institutes of Health [U54-LM008748, K23 DK097142, K08 AR060257, K24 AR052403, P60 AR047782, R01 AR049880]; American Gastroenterological Association; Harold and Duval Bowen Fund FX Supported by National Institutes of Health grants U54-LM008748 (I.K.), and K23 DK097142 (A.N.A.), K08 AR060257 (K.P.L.), and K24 AR052403, P60 AR047782, and R01 AR049880 (E.W.K.); by the American Gastroenterological Association (A.N.A.); and by the Harold and Duval Bowen Fund (K.P.L.). NR 38 TC 23 Z9 23 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD FEB PY 2015 VL 13 IS 2 BP 322 EP U163 DI 10.1016/j.cgh.2014.07.018 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AZ9BB UT WOS:000348505100021 PM 25041865 ER PT J AU Yaffe, RB Borger, P Megevand, P Groppe, DM Kramer, MA Chu, CJ Santaniello, S Meisel, C Mehta, AD Sarma, SV AF Yaffe, Robert B. Borger, Philip Megevand, Pierre Groppe, David M. Kramer, Mark A. Chu, Catherine J. Santaniello, Sabato Meisel, Christian Mehta, Ashesh D. Sarma, Sridevi V. TI Physiology of functional and effective networks in epilepsy SO CLINICAL NEUROPHYSIOLOGY LA English DT Review DE Effective connectivity; Functional connectivity; Networks; Brain; Epilepsy ID TEMPORAL-LOBE EPILEPSY; CORTICOCORTICAL EVOKED-POTENTIALS; SMALL-WORLD NETWORKS; GRAPH-THEORETICAL ANALYSIS; DEFAULT-MODE NETWORK; HUMAN BRAIN; NEURONAL AVALANCHES; SEIZURE-ONSET; NEOCORTICAL EPILEPSY; COMPLEX NETWORKS AB Epilepsy is a network phenomenon characterized by atypical activity during seizure both at the level of single neurons and neural populations. The etiology of epilepsy is not completely understood but a common theme among proposed mechanisms is abnormal synchronization between neuronal populations. Recent advances in novel imaging and recording technologies have enabled the inference of comprehensive maps of both the anatomical and physiological inter-relationships between brain regions. Clinical protocols established for diagnosis and treatment of epilepsy utilize both advanced neuroimaging techniques and neurophysiological data. These growing clinical datasets can be further exploited to better understand the complex connectivity patterns in the epileptic brain. In this article, we review results and insights gained from the growing body of research focused on epilepsy from a network perspective. In particular, we put an emphasis on two different notions of network connectivity: functional and effective; and studies investigating these notions in epilepsy are highlighted. We also discuss limitations and opportunities in data collection and analyses that will further our understanding of epileptic networks and the mechanisms of seizures. (C) 2014 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved. C1 [Yaffe, Robert B.; Santaniello, Sabato; Sarma, Sridevi V.] Johns Hopkins Univ, Inst Computat Med, Dept Biomed Engn, Baltimore, MD 21218 USA. [Borger, Philip; Megevand, Pierre; Groppe, David M.; Mehta, Ashesh D.] Feinstein Inst Med Res, Manhasset, NY 11030 USA. [Borger, Philip; Megevand, Pierre; Groppe, David M.; Mehta, Ashesh D.] Hofstra North Shore LIJ Sch Med, Dept Neurosurg, Manhasset, NY 11030 USA. [Kramer, Mark A.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA. [Chu, Catherine J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Chu, Catherine J.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Meisel, Christian] NIMH, Bethesda, MD 20892 USA. RP Yaffe, RB (reprint author), Johns Hopkins Univ, Inst Computat Med, Dept Biomed Engn, Hackerman Hall,Room 318,3400 North Charles St, Baltimore, MD 21218 USA. EM yaffer@jhu.edu OI Santaniello, Sabato/0000-0002-2133-9471; Megevand, Pierre/0000-0002-0427-547X FU Epilepsy Foundation Predoctoral Research Training Fellowship; Swiss National Science Foundation [P3SMP3_148388]; Career Award at the Scientific Interface from the Burroughs Wellcome Fund; Page and Otto Marx Jr. Foundation; US NSF Grant [ECCS 1346888]; US NSF Career Award [1055560]; Burroughs Wellcome Fund CASI Award [1007274] FX R.B. Yaffe was supported by the Epilepsy Foundation Predoctoral Research Training Fellowship. P. Megevand was supported by the Swiss National Science Foundation (Grant P3SMP3_148388). M. A. Kramer was supported by a Career Award at the Scientific Interface from the Burroughs Wellcome Fund. A. D. Mehta and D. M. Groppe are supported by the Page and Otto Marx Jr. Foundation. S. Santaniello was supported by the US NSF Grant ECCS 1346888. S. V. Sarma was supported by the US NSF Career Award 1055560 and the Burroughs Wellcome Fund CASI Award 1007274. NR 110 TC 14 Z9 14 U1 9 U2 30 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1388-2457 EI 1872-8952 J9 CLIN NEUROPHYSIOL JI Clin. Neurophysiol. PD FEB PY 2015 VL 126 IS 2 BP 227 EP 236 DI 10.1016/j.clinph.2014.09.009 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AZ9UL UT WOS:000348562000004 PM 25283711 ER PT J AU Borrero, S Nikolajski, C Steinberg, JR Freedman, L Akers, AY Ibrahim, S Schwarz, EB AF Borrero, Sonya Nikolajski, Cara Steinberg, Julia R. Freedman, Lori Akers, Aletha Y. Ibrahim, Said Schwarz, Eleanor Bimla TI "It just happens": a qualitative study exploring low-income women's perspectives on pregnancy intention and planning SO CONTRACEPTION LA English DT Article DE Pregnancy intention; Race; Pregnancy planning; Reproductive coercion ID UNINTENDED PREGNANCY; CONTRACEPTIVE USE; UNPROTECTED INTERCOURSE; PARTNER VIOLENCE; AVOID PREGNANCY; UNITED-STATES; YOUNG-ADULTS; ATTITUDES; AMBIVALENCE; ADOLESCENTS AB Objective: Unintended pregnancy is common and disproportionately occurs among low-income women. We conducted a qualitative study with low-income women to better typologize pregnancy intention, understand the relationship between pregnancy intention and contraceptive use, and identify the contextual factors that shape pregnancy intention and contraceptive behavior. Study design: Semistructured interviews were conducted with low-income, African American and white women aged 18-45 recruited from reproductive health clinics in Pittsburgh, PA, to explore factors that influence women's pregnancy-related behaviors. Narratives were analyzed using content analysis and the constant comparison method. Results: Among the 66 participants (36 African American and 30 white), we identified several factors that may impede our public health goal of increasing the proportion of pregnancies that are consciously desired and planned. First, women do not always perceive that they have reproductive control and therefore do not necessarily formulate clear pregnancy intentions. Second, the benefits of a planned pregnancy may not be evident. Third, because preconception intention and planning do not necessarily occur, decisions about the acceptability of a pregnancy are often determined after the pregnancy has already occurred. Finally, even when women express a desire to avoid pregnancy, their contraceptive behaviors are not necessarily congruent with their desires. We also identified several clinically relevant and potentially modifiable factors that help to explain this intention behavior discrepancy, including women's perceptions of low fecundity and their experiences with male partner contraceptive sabotage. Conclusion: Our findings suggest that the current conceptual framework that views pregnancy-related behaviors from a strict planned behavior perspective may be limited, particularly among low-income populations. Implications: This study identified several cognitive and interpersonal pathways to unintended pregnancy among low-income women in Pittsburgh, PA, including perceptions of low reproductive control, perceptions of low fecundity and male partner reproductive coercion. Published by Elsevier Inc. C1 [Borrero, Sonya; Nikolajski, Cara] Univ Pittsburgh, Dept Med, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. [Borrero, Sonya] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Steinberg, Julia R.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Freedman, Lori] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Akers, Aletha Y.] Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA. [Akers, Aletha Y.] Univ Pittsburgh, Pittsburgh, PA 15213 USA. [Ibrahim, Said] Philadelphia VA Med Ctr, VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Ibrahim, Said] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Schwarz, Eleanor Bimla] Univ Calif Davis, Davis Sch Med, Dept Med, Sacramento, CA USA. RP Borrero, S (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM borrerosp@upmc.edu OI Freedman, Lori/0000-0002-7919-9520; Schwarz, Eleanor Bimla/0000-0002-9912-8236 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [1 R21 HD068736-01]; a component of the National Institutes of Health (NIH); K01 [K01HD075834] FX This study was funded by Dr. Borrero's grant (1 R21 HD068736-01) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a component of the National Institutes of Health (NIH). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of NICHD or NIH. Dr. Steinberg's effort on this study was supported by her K01 grant (K01HD075834). NR 39 TC 27 Z9 27 U1 1 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 EI 1879-0518 J9 CONTRACEPTION JI Contraception PD FEB PY 2015 VL 91 IS 2 BP 150 EP 156 DI 10.1016/j.contraception.2014.09.014 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CA4TD UT WOS:000348896300009 PM 25477272 ER PT J AU Stanford, KI Lee, MY Getchell, KM So, KW Hirshman, MF Goodyear, LJ AF Stanford, Kristin I. Lee, Min-Young Getchell, Kristen M. So, Kawai Hirshman, Michael F. Goodyear, Laurie J. TI Exercise Before and During Pregnancy Prevents the Deleterious Effects of Maternal High-Fat Feeding on Metabolic Health of Male Offspring SO DIABETES LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; EXPOSURE IN-UTERO; ADIPOSE-TISSUE; SKELETAL-MUSCLE; DIET EXPOSURE; HEART-DISEASE; FETAL; OBESITY; LIFE; RAT AB The intrauterine environment during pregnancy is a critical factor in the development of diabetes and obesity in offspring. To determine the effects of maternal exercise during pregnancy on the metabolic health of offspring, 6-week-old C57BL/6 virgin female mice were fed a chow (21%) or high-fat (60%) diet and divided into four subgroups: trained (housed with running wheels for 2 weeks preconception and during gestation), prepregnancy trained (housed with running wheels for 2 weeks preconception), gestation trained (housed with running wheels during gestation), or sedentary (static cages). Male offspring were chow fed, sedentary, and studied at 8, 12, 24, 36, and 52 weeks of age. Offspring from chow-fed dams that trained both before and during gestation had improved glucose tolerance beginning at 8 weeks of age and continuing throughout the 1st year of life, and at 52 weeks of age had significantly lower serum insulin concentrations and percent body fat compared with all other groups. High-fat feeding of sedentary dams resulted in impaired glucose tolerance, increased serum insulin concentrations, and increased percent body fat in offspring. Remarkably, maternal exercise before and during gestation ameliorated the detrimental effect of a maternal high-fat diet on the metabolic profile of offspring. Exercise before and during pregnancy may be a critical component for combating the increasing rates of diabetes and obesity. C1 [Stanford, Kristin I.; Lee, Min-Young; Getchell, Kristen M.; So, Kawai; Hirshman, Michael F.; Goodyear, Laurie J.] Joslin Diabet Ctr, Sect Integrat Physiol & Metab, Boston, MA 02215 USA. [Stanford, Kristin I.; Lee, Min-Young; Goodyear, Laurie J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. RP Goodyear, LJ (reprint author), Joslin Diabet Ctr, Sect Integrat Physiol & Metab, Boston, MA 02215 USA. EM laurie.goodyear@joslin.harvard.edu FU National Institutes of Health [R01-DK-101043, R01-AR-42238, 5P30-DK-36836]; American College of Sports Medicine Research Endowment grant; Mary K. Iacocca Fellowship; American Diabetes Association FX This work was supported by National Institutes of Health grants R01-DK-101043 and R01-AR-42238 (to L.J.G.) and 5P30-DK-36836 (Joslin Diabetes Center DERC), an American College of Sports Medicine Research Endowment grant (to K.I.S.), and a Mary K. Iacocca Fellowship (to K.I.S.). M.-Y.L. was supported by a mentor-based fellowship awarded to L.J.G. from the American Diabetes Association. NR 30 TC 19 Z9 19 U1 1 U2 15 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD FEB PY 2015 VL 64 IS 2 BP 427 EP 433 DI 10.2337/db13-1848 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CA3ST UT WOS:000348827100014 PM 25204976 ER PT J AU Ross, SA Caballero, AE Del Prato, S Gallwitz, B Lewis-D'Agostino, D Bailes, Z Thiemann, S Patel, S Woerle, HJ von Eynatten, M AF Ross, S. A. Caballero, A. E. Del Prato, S. Gallwitz, B. Lewis-D'Agostino, D. Bailes, Z. Thiemann, S. Patel, S. Woerle, H. -J. von Eynatten, M. TI Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial SO DIABETES OBESITY & METABOLISM LA English DT Article DE antidiabetes drug; clinical trial; metformin; DPP-4 inhibitor; type 2 diabetes ID FIXED-DOSE COMBINATION; IMPROVES GLYCEMIC CONTROL; PLUS METFORMIN; NAIVE PATIENTS; THERAPY; MELLITUS; EFFICACY; SAFETY; VILDAGLIPTIN; SITAGLIPTIN AB AimsTo evaluate glucose-lowering treatment strategies with linagliptin and metformin in people with newly diagnosed type 2 diabetes and marked hyperglycaemia, a prevalent population for which few dedicated studies of oral antidiabetes drugs have been conducted. MethodsA total of 316 patients, with type 2 diabetes diagnosed for 12months and with glycated haemoglobin (HbA1c) concentration in the range 8.5-12.0%, were randomized 1:1 to double-blind, free-combination treatment with linagliptin 5mg once daily and metformin twice daily (uptitrated to 2000mg/day maximum) or to linagliptin monotherapy. The primary endpoint was change in HbA1c concentration from baseline at week 24 (per-protocol completers' cohort: n=245). ResultsThe mean (standard deviation) age and HbA1c at baseline were 48.8 (11.0) years and 9.8 (1.1)%, respectively. At week 24, the meanstandard error (s.e.) HbA1c decreased from baseline by -2.8 +/- 0.1% with linagliptin/metformin and -2.0 +/- 0.1% with linagliptin; a treatment difference of -0.8% (95% confidence interval -1.1 to -0.5; p <0.0001). Similar results were observed in a sensitivity analysis based on intent-to-treat principles: adjusted mean +/- s.e. changes in HbA1c of -2.7 +/- 0.1% and -1.8 +/- 0.1%, respectively; treatment difference of -0.9% (95% CI -1.3 to -0.6; p <0.0001). A treatment response of HbA1c <7.0% was achieved by 61 and 40% of patients in the linagliptin/metformin and linagliptin groups, respectively. Few patients experienced drug-related adverse events (8.8 and 5.7% of patients in the linagliptin/metformin and linagliptin groups, respectively). Hypoglycaemia occurred in 1.9 and 3.2% of patients in the linagliptin/metformin and linagliptin groups, respectively (no severe episodes). Body weight decreased significantly with the combination therapy (-1.3kg between-group difference; p =0.0033). ConclusionsLinagliptin in initial combination with metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia, an understudied group, elicited significant improvements in glycaemic control with a low incidence of hypoglycaemia, weight gain or other adverse effects. These results support early combination treatment strategies and suggest that newly diagnosed patients with marked hyperglycaemia may be effectively managed with oral, non-insulin therapy. C1 [Ross, S. A.] Univ Calgary, LMC Endocrinol Ctr, Calgary, AB T2H 2G4, Canada. [Caballero, A. E.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. [Del Prato, S.] Univ Pisa, Sect Diabet, Dept Endocrinol & Metab, Pisa, Italy. [Gallwitz, B.] Univ Klinikum Tubingen, Dept Med 4, Tubingen, Germany. [Lewis-D'Agostino, D.] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA. [Bailes, Z.; Patel, S.] Boehringer Ingelheim Ltd, Bracknell, Berks, England. [Thiemann, S.; Woerle, H. -J.; von Eynatten, M.] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany. RP Ross, SA (reprint author), Univ Calgary, LMC Endocrinol Ctr, 102-5940 MacLeod Trail SW, Calgary, AB T2H 2G4, Canada. EM drross@telus.net RI Del Prato, Stefano/K-3405-2016 OI Del Prato, Stefano/0000-0002-5388-0270 FU Boehringer Ingelheim FX This study was sponsored by Boehringer Ingelheim, the manufacturer of linagliptin. The authors thank the patients and staff involved in this study. Data from this study have previously been presented at the 22nd World Diabetes Congress, Melbourne, Australia, 2-6 December 2013 (Abstract ME-2726). Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Giles Brooke, PhD, CMPP, of Envision Scientific Solutions during the preparation of this manuscript. NR 38 TC 8 Z9 8 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1462-8902 EI 1463-1326 J9 DIABETES OBES METAB JI Diabetes Obes. Metab. PD FEB PY 2015 VL 17 IS 2 BP 136 EP 144 DI 10.1111/dom.12399 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CA4AW UT WOS:000348847600006 PM 25298165 ER PT J AU Bell, K Toschi, E Wolpert, H Steil, G AF Bell, K. Toschi, E. Wolpert, H. Steil, G. TI USE OF MODEL PREDICTED BOLUS ESTIMATION (MPB) TO OPTIMIZE INSULIN DOSING STRATEGIES COVERING HIGH FAT MEALS SO DIABETES TECHNOLOGY & THERAPEUTICS LA English DT Meeting Abstract C1 [Bell, K.] Univ Sydney, Sch Mol Biosci, Sydney, NSW 2006, Australia. [Bell, K.] Univ Sydney, Charles Perkins Ctr, Sydney, NSW 2006, Australia. [Toschi, E.; Wolpert, H.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Steil, G.] Boston Childrens Hosp, Div Med Crit Care, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1520-9156 EI 1557-8593 J9 DIABETES TECHNOL THE JI Diabetes Technol. Ther. PD FEB 1 PY 2015 VL 17 SU 1 MA 50 BP A23 EP A23 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CB0LL UT WOS:000349317500051 ER PT J AU DuBose, S Weinstock, R Hirsch, I Bergenstal, R Chaytor, N Peterson, C Olson, B Munshi, M Perrin, A Beck, R AF DuBose, S. Weinstock, R. Hirsch, I. Bergenstal, R. Chaytor, N. Peterson, C. Olson, B. Munshi, M. Perrin, A. Beck, R. TI FACTORS ASSOCIATED WITH SEVERE HYPOGLYCEMIA IN OLDER ADULTS WITH TYPE 1 DIABETES SO DIABETES TECHNOLOGY & THERAPEUTICS LA English DT Meeting Abstract C1 [Weinstock, R.; Perrin, A.; Beck, R.] Jaeb Ctr Hlth Res, TID Exchange Clin Network, Tampa, FL USA. [Weinstock, R.] SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA. [Hirsch, I.; Peterson, C.] Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Bergenstal, R.; Olson, B.] Pk Nicollet, Int Diabet Ctr, Minneapolis, MN USA. [Chaytor, N.] Univ Washington, Seattle, WA 98195 USA. [Munshi, M.] Beth Israel Deaconess Med Ctr, Joslin Diabet Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1520-9156 EI 1557-8593 J9 DIABETES TECHNOL THE JI Diabetes Technol. Ther. PD FEB 1 PY 2015 VL 17 SU 1 MA 68 BP A32 EP A32 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CB0LL UT WOS:000349317500069 ER PT J AU Laffel, L Bailey, T Liljenquist, L Tsalikian, E Chase, P AF Laffel, L. Bailey, T. Liljenquist, L. Tsalikian, E. Chase, P. TI PERFORMANCE OF A NEW CONTINUOUS GLUCOSE MONITORING SYSTEM (CGM) IN YOUTH SO DIABETES TECHNOLOGY & THERAPEUTICS LA English DT Meeting Abstract C1 [Laffel, L.] Harvard Univ, Joslin Diabet Ctr, Boston, MA 02115 USA. [Bailey, T.] AMCR Inst Inc, Clin Res, Escondido, CA USA. [Liljenquist, L.] Rocky Mt Diabet & Osteoporosis Ctr, Idaho Falls, ID USA. [Tsalikian, E.] Univ Iowa, Dept Pediat, UIHC, Iowa City, IA 52242 USA. [Chase, P.] Barbara Davis Ctr Diabet, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1520-9156 EI 1557-8593 J9 DIABETES TECHNOL THE JI Diabetes Technol. Ther. PD FEB 1 PY 2015 VL 17 SU 1 MA 222 BP A98 EP A99 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CB0LL UT WOS:000349317500223 ER PT J AU Laffel, L AF Laffel, L. TI APPROACHES TO BEHAVIORAL INTERVENTIONS TO ENCOURAGE CGM USE IN PEDIATRIC PATIENTS SO DIABETES TECHNOLOGY & THERAPEUTICS LA English DT Meeting Abstract C1 [Laffel, L.] Joslin Diabet Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1520-9156 EI 1557-8593 J9 DIABETES TECHNOL THE JI Diabetes Technol. Ther. PD FEB 1 PY 2015 VL 17 SU 1 MA 12 BP A5 EP A5 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CB0LL UT WOS:000349317500013 ER PT J AU Scaramuzza, A Iafusco, D La Loggia, A Maffeis, C Rabbone, I Toni, S Laffel, L Domenger, C Tumini, S AF Scaramuzza, A. Iafusco, D. La Loggia, A. Maffeis, C. Rabbone, I. Toni, S. Laffel, L. Domenger, C. Tumini, S. CA ISPED TI DIABETES MANAGEMENT IN ITALIAN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH TYPE 1 DIABETES (T1D) IN TEENS: ADVANCED VS CONVENTIONAL THERAPIES SO DIABETES TECHNOLOGY & THERAPEUTICS LA English DT Meeting Abstract C1 [Scaramuzza, A.; Iafusco, D.; La Loggia, A.; Maffeis, C.; Rabbone, I.; Toni, S.; Tumini, S.; ISPED] ISPED SIEDP, Italian Soc Pediat Endocrinol & Diabetol, Turin, Italy. [Laffel, L.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. [Domenger, C.] Sanofi, Global Diabet Div, Paris, France. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1520-9156 EI 1557-8593 J9 DIABETES TECHNOL THE JI Diabetes Technol. Ther. PD FEB 1 PY 2015 VL 17 SU 1 MA 73 BP A34 EP A34 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CB0LL UT WOS:000349317500074 ER PT J AU Steil, G Kavanagh, M Atakov-Castillo, A Wolpert, H AF Steil, G. Kavanagh, M. Atakov-Castillo, A. Wolpert, H. TI THE ARTIFICIAL PANCREAS: USE OF CONTROLLED IN-PATIENT STUDIES TO ASSESS PERFORMANCE DURING PUTATIVE HIGH-RISK CONDITIONS ANTICIPATED TO OCCUR WITH PROLONGED AT-HOME USE SO DIABETES TECHNOLOGY & THERAPEUTICS LA English DT Meeting Abstract C1 [Steil, G.] Boston Childrens Hosp, Div Med Crit Care, Boston, MA USA. [Kavanagh, M.; Atakov-Castillo, A.; Wolpert, H.] Joslin Diabet Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1520-9156 EI 1557-8593 J9 DIABETES TECHNOL THE JI Diabetes Technol. Ther. PD FEB 1 PY 2015 VL 17 SU 1 MA 225 BP A100 EP A100 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CB0LL UT WOS:000349317500226 ER PT J AU Huang, T Brown, FM Curran, A James-Todd, T AF Huang, T. Brown, F. M. Curran, A. James-Todd, T. TI Association of pre-pregnancy BMI and postpartum weight retention with postpartum HbA(1c) among women with Type 1 diabetes SO DIABETIC MEDICINE LA English DT Article ID GLYCEMIC CONTROL; OBESITY; PREGNANCY; IMPACT; COMPLICATIONS; EPIDEMIOLOGY; OVERWEIGHT; GAIN AB AimTo examine the association of pre-pregnancy BMI and postpartum weight retention with postpartum HbA(1c) levels in women with Type 1 diabetes. MethodsWe longitudinally evaluated 136 women with Type 1 diabetes who received prenatal, pregnancy, and postpartum care through Joslin Diabetes Center's Diabetes and Pregnancy Program between 2004 and 2009. Weight, BMI and HbA(1c) concentrations were assessed before the index pregnancy and repeatedly monitored after delivery until 12months postpartum. We used linear mixed models to assess the association of postpartum HbA(1c) with pre-pregnancy BMI and postpartum weight retention. ResultsThe mean HbA(1c) concentration increased from 49mmol/mol (6.6%) at 6weeks postpartum to 58mmol/mol (7.5%) by 10months postpartum, a level similar to the mean pre-pregnancy HbA(1c) concentration. Postpartum weight retention showed a linearly decreasing trend of 0.06kg/week (P<0.0001), with -0.1kg average postpartum weight retention by 1year postpartum. Compared with women with a pre-pregnancy BMI25kg/m(2), women with a lower pre-pregnancy BMI maintained a 3.4mmol/mol (0.31%) lower HbA(1c) concentration, after adjusting for several sociodemographic, reproductive and diabetes-related factors (P=0.03). There was a suggestion of a time-varying positive association between HbA(1c) and postpartum weight retention, with the most significant difference of 3.7mmol/mol (0.34%; P=0.05) at 30weeks postpartum among women with postpartum weight retention 5kg vs those with postpartum weight retention <5kg. ConclusionsPre-pregnancy BMI and postpartum weight retention were positively associated with HbA(1c) during the first postpartum year in women with Type 1 diabetes. Interventions to modify the behaviours associated with these body weight factors before pregnancy and after delivery may help women with Type 1 diabetes maintain good glycaemic control after pregnancy. C1 [Huang, T.; James-Todd, T.] Brigham & Womens Hosp, Dept Med, Connors Ctr Womens Hlth & Gender Biol, Div Womens Hlth, Boston, MA 02115 USA. [Huang, T.; Brown, F. M.; Curran, A.; James-Todd, T.] Harvard Univ, Sch Med, Boston, MA USA. [Huang, T.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Brown, F. M.; Curran, A.] Joslin Diabet Ctr, Dept Adult Diabet, Boston, MA 02215 USA. RP James-Todd, T (reprint author), Brigham & Womens Hosp, Dept Med, Connors Ctr Womens Hlth & Gender Biol, Div Womens Hlth, 75 Francis St, Boston, MA 02115 USA. EM tjames-todd@bics.bwh.harvard.edu OI Huang, Tianyi/0000-0001-8420-9167 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [K12HD051959] FX This research was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD051959). NR 25 TC 1 Z9 4 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0742-3071 EI 1464-5491 J9 DIABETIC MED JI Diabetic Med. PD FEB PY 2015 VL 32 IS 2 BP 181 EP 188 DI 10.1111/dme.12617 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AZ9EN UT WOS:000348515500007 PM 25346003 ER PT J AU Gilman, JM Calderon, V Curran, MT Evins, AE AF Gilman, Jodi M. Calderon, Vanessa Curran, Max T. Evins, A. Eden TI Young adult cannabis users report greater propensity for risk-taking only in non-monetary domains SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Risk-taking; Substance use; Marijuana; Cannabis; Decision-making ID ANTERIOR CINGULATE CORTEX; DECISION-MAKING; PREFRONTAL CORTEX; MARIJUANA USERS; GAMBLING TASK; HYPOTHETICAL REWARDS; SUBSTANCE USERS; HISTORY; ABUSERS; CHOICE AB Background: Though substance use is often associated with elevated risk-taking in real-world scenarios, many risk-taking tasks in experimental psychology using financial gambles fail to find significant differences between individuals with substance use disorders and healthy controls. We assessed whether participants using marijuana would show a greater propensity for risk-taking in distinct domains including, but not limited to, financial risk-taking. Methods: In the current study, we assessed risk-taking in young adult (age 18-25) regular marijuana users and in non-using control participants using a domain-specific risk-taking self-report scale (DOSPERT) encompassing five domains of risk-taking (social, financial, recreational, health/safety, and ethical). We also measured behavioral risk-taking using a laboratory monetary risk-taking task. Results: Marijuana users and controls reported significant differences on the social, health/safety, and ethical risk-taking scales, but no differences in the propensity to take recreational or financial risks. Complementing the self-report finding, there were no differences between marijuana users and controls in their performance on the laboratory risk-taking task. Conclusions: These findings suggest that financial risk-taking may be less sensitive than other domains of risk-taking in assessing differences in risky behavior between those who use marijuana and those who do not. In order to more consistently determine whether increased risk-taking is a factor in substance use, it may be necessary to use both monetary risk-taking tasks and complementary assessments of non-monetary-based risk-taking measures. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Gilman, Jodi M.; Calderon, Vanessa; Curran, Max T.; Evins, A. Eden] Harvard Univ, Ctr Addict Med, Dept Psychiat, Massachusetts Gen Hosp,Med Sch, Cambridge, MA 02138 USA. RP Gilman, JM (reprint author), MGH Ctr Addict Med, 60 Staniford St, Boston, MA 02114 USA. EM jgilman1@partners.org RI Roberts, James/A-1082-2009 OI Roberts, James/0000-0002-8485-8172 FU Harvard Medical School Norman E. Zinberg Fellowship in Addiction Psychiatry Research; NIDA [K01 DA034093, K24 DA030443] FX This work was supported by the Harvard Medical School Norman E. Zinberg Fellowship in Addiction Psychiatry Research (JMG), NIDA K01 DA034093 (JMG), and NIDA K24 DA030443 (AEE). These funding sources had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the manuscript for publication. NR 54 TC 5 Z9 5 U1 9 U2 22 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD FEB 1 PY 2015 VL 147 BP 26 EP 31 DI 10.1016/j.drugalcdep.2014.12.020 PG 6 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CA4RU UT WOS:000348893000003 PM 25577478 ER PT J AU Bernstein, J Derrington, TM Belanoff, C Cabral, HJ Babakhanlou-Chase, H Diop, H Evans, SR Jacobs, H Kotelchuck, M AF Bernstein, Judith Derrington, Taletha M. Belanoff, Candice Cabral, Howard J. Babakhanlou-Chase, Hermik Diop, Hafsatou Evans, Stephen R. Jacobs, Hilary Kotelchuck, Milton TI Treatment outcomes for substance use disorder among women of reproductive age in Massachusetts: A population-based approach SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Substance use disorder; Substance abuse treatment utilization; Detoxification; Gender; Women's health ID ABUSE TREATMENT; GENDER-DIFFERENCES; ALCOHOL; RETENTION; COCAINE AB Introduction: Longitudinal patterns of treatment utilization and relapse among women of reproductive age with substance use disorder (SUD) are not well known. In this statewide report spanning seven years we describe SUD prevalence, SUD treatment utilization, and differences in subsequent emergency department (ED) use and post-treatment relapse rates by type of treatment: none, 'acute only' (detoxification/stabilization), or 'ongoing' services. Methods: We linked a statewide dataset of hospital discharge, observation stay and ED records with SUD treatment admission records from hospitals and freestanding facilities, and birth/fetal death certificates, in Massachusetts, 2002-2008. We aggregated episodes into individual woman records, identified evidence of SUD and treatment, and tested post-treatment outcomes. Results: Nearly 150,000 (8.5%) of 1.7 million Massachusetts women aged 15-49 were identified as SUD-positive. Nearly half of SUD-positive women (71,533 or 48.3%) had evidence of hospital or facility-based SUD treatment; among these, 12% received acute care/detoxification only while 88% obtained 'ongoing' treatment. Treatment varied by substance type; women with dual diagnosis and those with opiate use were least likely to receive 'ongoing' treatment. Treated women were older and less likely to have a psychiatric history or chronic illness. Women who received 'acute only' services were more likely to relapse (12.4% vs. 9.6%) and had a 10% higher rate of ED visits post-treatment than women receiving 'ongoing' treatment. Conclusions: Many Massachusetts women of reproductive age need but do not receive adequate SUD treatment. 'Ongoing' services beyond detoxification/stabilization may reduce the likelihood of post-treatment relapse and/or reliance on the ED for subsequent medical care. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Bernstein, Judith; Derrington, Taletha M.; Belanoff, Candice; Cabral, Howard J.; Evans, Stephen R.] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA. [Babakhanlou-Chase, Hermik; Diop, Hafsatou; Jacobs, Hilary] Massachusetts Dept Publ Hlth, Bur Subst Abuse Serv, Boston, MA USA. [Kotelchuck, Milton] MassGen Hosp Children, Ctr Child & Adolescent Hlth Res & Policy, Boston, MA USA. RP Bernstein, J (reprint author), Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, 801 Massachusetts Ave 431B, Boston, MA 02118 USA. EM jbernste@bu.edu; taletha.derrington@sri.com; cbelanof@bu.edu; hjcab@bu.edu; Hermik.Babkhanlou-Chase@state.ma.us; Hafsatou.Diop@state.ma.us; deeny@bu.edu; Hilary.Jacobs@state.ma.us; mkotelchuck@mgh.harvard.edu FU NIH NIAAA [R21AA018395]; NIH NIDA [R21DA027181]; Massachusetts Department of Public Health [RFR703015] FX Supported in part by NIH NIAAA R21AA018395, NIH NIDA R21DA027181, and supplemental funding from the Massachusetts Department of Public Health RFR703015. NR 35 TC 1 Z9 1 U1 3 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD FEB 1 PY 2015 VL 147 BP 151 EP 159 DI 10.1016/j.drugalcdep.2014.11.025 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CA4RU UT WOS:000348893000021 PM 25496707 ER PT J AU Arnason, JE Brown, JR AF Arnason, Jon E. Brown, Jennifer R. TI Targeted Therapy for Chronic Lymphocytic Leukemia: Current Status and Future Directions SO DRUGS LA English DT Article ID PREVIOUSLY UNTREATED PATIENTS; CELL-MEDIATED CYTOTOXICITY; KINASE BTK FUNCTION; PHASE-II TRIAL; TERM-FOLLOW-UP; TYROSINE KINASE; B-CELLS; SUBCUTANEOUS ALEMTUZUMAB; ANTIGEN RECEPTOR; DOSE-ESCALATION AB The majority of patients with chronic lymphocytic leukemia (CLL) respond to chemo-immunotherapy. However, long-term remission remains elusive and the majority of patients will die of complications related to CLL. In this review we discuss the recent developments in targeted therapy for CLL. Targeted therapy has evolved beyond the cell surface targeting of CD20 with rituximab. Our review focuses on the evolution of antibody therapy in CLL, strategies to target effector T cells to the tumor, inhibition of the B-cell receptor signaling pathway, and finally targeting the mediators of apoptosis. With our improved understanding of the biology of CLL, the evolution of targeted therapy has resulted in significant clinical responses in patients who are refractory to traditional treatment options and holds the potential for a future where we can manage this disease without chemotherapy. C1 [Arnason, Jon E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Brown, Jennifer R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Brown, JR (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM jarnason@bidmc.harvard.edu; jbrown2@partners.org NR 113 TC 4 Z9 4 U1 1 U2 8 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 0012-6667 EI 1179-1950 J9 DRUGS JI Drugs PD FEB PY 2015 VL 75 IS 2 BP 143 EP 155 DI 10.1007/s40265-014-0338-x PG 13 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA CA6HC UT WOS:000349010600001 PM 25619739 ER PT J AU Furlong, M Tanner, CM Goldman, SM Bhudhikanok, GS Blair, A Chade, A Comyns, K Hoppin, JA Kasten, M Korell, M Langston, JW Marras, C Meng, C Richards, M Ross, GW Umbach, DM Sandler, DP Kamel, F AF Furlong, Melissa Tanner, Caroline M. Goldman, Samuel M. Bhudhikanok, Grace S. Blair, Aaron Chade, Anabel Comyns, Kathleen Hoppin, Jane A. Kasten, Meike Korell, Monica Langston, J. William Marras, Connie Meng, Cheryl Richards, Marie Ross, G. Webster Umbach, David M. Sandler, Dale P. Kamel, Freya TI Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's disease SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Personal protective equipment; Parkinson's disease; Pesticides; Neurodegenerative diseases; Movement disorders ID AGRICULTURAL HEALTH; INCOMPLETE REMOVAL; EXPOSURE; RISK; DETERMINANTS; APPLICATORS; FARMWORKERS; CALIFORNIA; CAPTAN; SKIN AB Pesticides have been associated with Parkinson's disease (PD), and protective gloves and workplace hygiene can reduce pesticide exposure. We assessed whether use of gloves and workplace hygiene modified associations between pesticides and PD. The Farming and Movement Evaluation (FAME) study is a nested case-control study within the Agricultural Health Study. Use of protective gloves, other PPE, and hygiene practices were determined by questionnaire (69 cases and 237 controls were included). We considered interactions of gloves and hygiene with ever-use of pesticides for all pesticides with >= 5 exposed and unexposed cases and controls in each glove-use stratum (paraquat, permethrin, rotenone, and trifluralin). 61% of respondents consistently used protective gloves and 87% consistently used >= 2 hygiene practices. Protective glove use modified the associations of paraquat and permethrin with PD: neither pesticide was associated with PD among protective glove users, while both pesticides were associated with PD among non-users (paraquat OR 3.9 [95% CI 13, 11.7], interaction p = 0.15; permethrin OR 4.3 [95% CI 1.2, 15.6] interaction p = 0.05). Rotenone was associated with PD regardless of glove use. Trifluralin was associated with PD among participants who used <2 hygiene practices (OR 5.5 [95% CI 1.1, 27.1]) but was not associated with PD among participants who used 2 or more practices (interaction p = 0.02). Although sample size was limited in the FAME study, protective glove use and hygiene practices appeared to be important modifiers of the association between pesticides and PD and may reduce risk of PD associated with certain pesticides. Published by Elsevier Ltd C1 [Furlong, Melissa] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Tanner, Caroline M.; Meng, Cheryl] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA. [Tanner, Caroline M.; Goldman, Samuel M.; Comyns, Kathleen; Korell, Monica; Meng, Cheryl] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA. [Bhudhikanok, Grace S.; Langston, J. William] Parkinsons Inst & Clin Ctr, Sunnyvale, CA USA. [Blair, Aaron] NCI, Occupat & Environm Epidemiol Branch, Bethesda, MD 20892 USA. [Chade, Anabel] Favaloro Univ, Inst Neurosci, Buenos Aires, DF, Argentina. [Hoppin, Jane A.] N Carolina State Univ, Dept Biol Sci, Raleigh, NC 27695 USA. [Kasten, Meike] Univ Lubeck, Dept Psychiat, Lubeck, Germany. [Marras, Connie] Univ Toronto, Toronto, ON, Canada. [Richards, Marie] Westat Corp, Durham, NC USA. [Ross, G. Webster] VA Pacific Isl Hlth Care Syst, Honolulu, HI USA. [Umbach, David M.] NIEHS, Biostat Branch, Res Triangle Pk, NC 27709 USA. [Sandler, Dale P.; Kamel, Freya] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA. RP Furlong, M (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Box 7435, Chapel Hill, NC 27599 USA. EM furlongm@med.unc.edu OI Kamel, Freya/0000-0001-5052-6615; Sandler, Dale/0000-0002-6776-0018 FU NIEHS [R01-ES10803, ES07018]; National Institutes of Health [National Institute of Environmental Health Sciences (NIEHS)] [Z01-ES044007, Z01-ES049030]; National Institutes of Health [National Cancer Institute] [Z01-CP010119] FX This study was supported by the NIEHS grant R01-ES10803, the James and Sharron Clark, and the Intramural Research Program of the National Institutes of Health [National Institute of Environmental Health Sciences (NIEHS) grants Z01-ES044007 and Z01-ES049030, and the National Cancer Institute grant Z01-CP010119]. M Furlong was partly supported by the NIEHS institutional training grant ES07018. The authors would also like to thank the participants and the research team. We are indebted to Kent Thomas at the US EPA for valuable discussions about PPE and hygiene. NR 36 TC 7 Z9 7 U1 0 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 EI 1873-6750 J9 ENVIRON INT JI Environ. Int. PD FEB PY 2015 VL 75 BP 144 EP 150 DI 10.1016/j.envint.2014.11.002 PG 7 WC Environmental Sciences SC Environmental Sciences & Ecology GA CA2OD UT WOS:000348746600014 PM 25461423 ER PT J AU Fay, AP Albiges, L Bellmunt, J AF Fay, Andre P. Albiges, Laurence Bellmunt, Joaquim TI Current role of cabozantinib in metastatic castration-resistant prostate cancer SO EXPERT REVIEW OF ANTICANCER THERAPY LA English DT Review DE bone metastasis; cabozantinib; castration-resistant prostate cancer; MET; VEGF; XL-184 ID HEPATOCYTE GROWTH-FACTOR; MEDULLARY-THYROID CANCER; PHASE-III TRIAL; C-MET; DOUBLE-BLIND; INCREASED SURVIVAL; SIGNALING PATHWAY; PLUS PREDNISONE; CHEMOTHERAPY; DOCETAXEL AB Over 80% of men with castration-resistant prostate cancer have bone metastases. This condition can dramatically impact quality of life and is associated with short-term survival. Consequently, the development of bone-targeted therapies is a relevant topic on prostate cancer management. Hepatocyte growth factor receptor and vascular endothelial growth factor signaling pathways have been identified to play a role in prostate cancer progression and bone metastasis and are potential targets for therapeutic intervention. Early-phase studies have shown encouraging responses in bone metastases and pain control with cabozantinib, a multi-tyrosine kinase inhibitor targeting hepatocyte growth factor receptor and vascular endothelial growth factor receptor. Despite striking responses seen in some patients, preliminary results from a pivotal Phase III study have failed to produce survival benefit. This review encompasses preclinical and clinical data of cabozantinib in metastatic castration-resistant prostate cancer highlighting future research options for this agent. C1 [Fay, Andre P.; Albiges, Laurence; Bellmunt, Joaquim] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA. [Fay, Andre P.] Pontificia Univ Catolica Rio Grande do Sul, Fac Med, Programa Posgrad Med & Ciencias Saude, Porto Alegre, RS, Brazil. [Albiges, Laurence] Inst Gustave Roussy, Villejuif, France. [Bellmunt, Joaquim] Univ Hosp del Mar IMIM, GU Res Lab, Barcelona, Spain. RP Fay, AP (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave DANA 1230, Boston, MA 02215 USA. EM andre_fay@dfci.harvard.edu; joaquim_bellmunt@dfci.harvard.edu NR 44 TC 8 Z9 9 U1 0 U2 2 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1473-7140 EI 1744-8328 J9 EXPERT REV ANTICANC JI Expert Rev. Anticancer Ther PD FEB PY 2015 VL 15 IS 2 BP 151 EP 156 DI 10.1586/14737140.2015.1003047 PG 6 WC Oncology SC Oncology GA CA2IY UT WOS:000348733300003 PM 25586337 ER PT J AU Forghani, R Yu, E Levental, M Som, PM Curtin, HD AF Forghani, Reza Yu, Eugene Levental, Mark Som, Peter M. Curtin, Hugh D. TI Imaging evaluation of lymphadenopathy and patterns of lymph node spread in head and neck cancer SO EXPERT REVIEW OF ANTICANCER THERAPY LA English DT Review DE cervical lymph nodes; head and neck cancer; imaging-based lymph node classification; lymphadenopathy; squamous cell carcinoma; TNM ID SQUAMOUS-CELL-CARCINOMA; EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; DUAL-ENERGY CT; COMPUTED-TOMOGRAPHY; NORMAL ANATOMY; EXTRACAPSULAR SPREAD; EXTRANODAL SPREAD; NASOPHARYNGEAL CARCINOMA; F-18-FDG PET/CT; METASTATIC HEAD AB Accurate and consistent characterization of metastatic cervical adenopathy is essential for the initial staging, treatment planning and surveillance of head and neck cancer patients. While enlarged superficial nodes may be clinically palpated, imaging allows identification of deeper adenopathy as well as clinically unsuspected pathology and thus imaging has become an integral part of the evaluation of most head and neck cancers patients. This review will focus on the evaluation of cervical adenopathy, summarizing the currently used nomenclature and imaging approach for determining cervical lymph node metastases in head and neck malignancies. The imaging-based classification, which has also been adopted by the American Joint Committee on Cancer, will be presented, the morphologic characteristics used to identify metastatic nodes will be reviewed and the typical nodal spread patterns of the major mucosal cancers of the head and neck will be examined. C1 [Forghani, Reza; Levental, Mark] Jewish Gen Hosp, Montreal, PQ, Canada. [Forghani, Reza; Levental, Mark] McGill Univ, Montreal, PQ H3A 2T5, Canada. [Yu, Eugene] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Joint Dept Med Imaging, Toronto, ON, Canada. [Som, Peter M.] NYU, Dept Radiol, Mt Sinai Med Ctr, Mt Sinai Sch Med, New York, NY 10016 USA. [Curtin, Hugh D.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. RP Forghani, R (reprint author), Jewish Gen Hosp, Room C-212-1,3755 Cote Ste Catherine Rd, Montreal, PQ, Canada. EM rforghani@jgh.mcgill.ca NR 81 TC 4 Z9 4 U1 0 U2 9 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7140 EI 1744-8328 J9 EXPERT REV ANTICANC JI Expert Rev. Anticancer Ther PD FEB PY 2015 VL 15 IS 2 BP 207 EP 224 DI 10.1586/14737140.2015.978862 PG 18 WC Oncology SC Oncology GA CA2IY UT WOS:000348733300008 PM 25385488 ER PT J AU Russell, S Duquette, M Liu, J Drapkin, R Lawler, J Petrik, J AF Russell, Samantha Duquette, Mark Liu, Joyce Drapkin, Ronny Lawler, Jack Petrik, Jim TI Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer SO FASEB JOURNAL LA English DT Article DE antiangiogenic; metronomic; vessel normalization ID GROWTH-FACTOR-BETA; ENDOTHELIAL-CELLS; PHASE-1 TRIAL; TUMOR-GROWTH; MOUSE MODEL; METRONOMIC CHEMOTHERAPY; PANCREATIC-CANCER; UP-REGULATION; ABT-510; ANGIOGENESIS AB Most women are diagnosed with epithelial ovarian cancer ( EOC) at advanced stage, where therapies have limited effectiveness and the long- term survival rate is low. We evaluated the effects of combined antiangiogenic and chemotherapy treatments on advanced stage EOC. Treatment of EOC cells with a recombinant version of the thrombospondin- 1 type I repeats ( 3TSR) induced more apoptotic cell death ( 36.5 6 9.6%) in vitro compared to untreated controls ( 4.1 6 1.4). In vivo, tumors were induced in an orthotopic, syngeneic mouse model of advanced stage EOC. Mice were treated with 3TSR ( 4 mg/ kg per day) alone or in combination with chemotherapy drugs delivered with maximum tolerated dose or metronomic scheduling. Pretreatment with 3TSR induced tumor regression, normalized tumor vasculature, and improved uptake of chemotherapy drugs. Combination 3TSR and metronomic chemotherapy induced the greatest tumor regression ( 6.2- fold reduction in size compared to PBS- treated controls) and highest survival when treatment was initiated at advanced stage. 3TSR binding to its receptor, CD36 ( cluster of differentiation 36), increased binding of CD36 and SHP- 1, which significantly inhibited phosphorylation of the VEGF receptor. In this study, we describe a novel treatment approach and mechanism of action with 3TSR and chemotherapy that induces regression of advanced stage EOC and significantly improves survival.- C1 [Russell, Samantha; Petrik, Jim] Univ Guelph, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada. [Duquette, Mark; Lawler, Jack] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA. [Liu, Joyce; Drapkin, Ronny] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Petrik, J (reprint author), Univ Guelph, 50 Stone Rd, Guelph, ON N1G 2W1, Canada. EM jpetrik@uoguelph.ca RI Drapkin, Ronny/E-9944-2016 OI Drapkin, Ronny/0000-0002-6912-6977 FU Canadian Institutes of Health Research [450084]; NCI NIH HHS [CA130895, R01 CA130895]; NINDS NIH HHS [NS077797] NR 55 TC 13 Z9 13 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD FEB PY 2015 VL 29 IS 2 BP 576 EP 588 DI 10.1096/fj.14-261636 PG 13 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CB1ET UT WOS:000349370400020 PM 25395453 ER PT J AU Lu, A Wu, H AF Lu, Alvin Wu, Hao TI Structural mechanisms of inflammasome assembly SO FEBS JOURNAL LA English DT Review DE ASC; CARD; death-domain superfamily; filaments; helical assembly; inflammasomes; polymerization; prion-like; PYD; structures ID CASPASE RECRUITMENT DOMAIN; NLRP3 INFLAMMASOME; CRYSTAL-STRUCTURE; INTERLEUKIN-1-BETA GENERATION; SIGNAL-TRANSDUCTION; ADAPTIVE IMMUNITY; DANGER SIGNAL; PYRIN DOMAIN; KAPPA-B; ACTIVATION AB Inflammasomes are supramolecular signaling complexes that activate a subset of caspases known as the inflammatory caspases, an example of which is caspase1. Upon stimulation by microbial and damage-associated signals, inflammasomes assemble to elicit the first line of host defense via the proteolytic maturation of cytokines interleukin-1 and interleukin-18, and by induction of pyroptotic cell death. Inflammasome assembly requires activation of an upstream sensor, a downstream effector and, in most cases, an adaptor molecule such as apoptosis-associate speck-like protein containing a caspase recruitment domain (ASC). Depending on whether ASC is required, inflammasomes can be categorized into ASC-dependent and ASC-independent inflammasomes. Here, we review current understandings of the structures of inflammasomes, as probed using traditional structural methods, as well as biochemical, biophysical and single-molecule methods. The key structural scaffold for inflammasome assembly is composed of filaments of Pyrin domains and caspase recruitment domains (CARD) in the sensor, adaptor and effector components. Nucleated polymerization appears to govern the ordered assembly process from activation of a Pyrin domain-containing sensor such as AIM2 by dsDNA or NLRP3 by extracellular particulates, to recruitment of the Pyrin domain and CARD-containing adaptor ASC, and finally to activation of CARD-containing caspase1. The underlying filamentous architecture of inflammasomes and the cooperativity in the assembly may explain the all-or-none' response in inflammasome activation. Inflammasomes are tightly regulated by a number of cytosolic inhibitors, which may change the morphology and assembly kinetics of inflammasomes. Biochemical and cellular studies suggest that Pyrin domain and CARD filaments possess prion-like properties in propagating inflammasome activation within and between cells. C1 [Lu, Alvin; Wu, Hao] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Cambridge, MA 02138 USA. [Lu, Alvin; Wu, Hao] Harvard Univ, Chem Biol PhD Program, Cambridge, MA 02138 USA. [Lu, Alvin; Wu, Hao] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. RP Wu, H (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. EM wu@crystal.harvard.edu OI Lu, Alvin/0000-0003-2353-848X NR 62 TC 23 Z9 26 U1 7 U2 36 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1742-464X EI 1742-4658 J9 FEBS J JI FEBS J. PD FEB PY 2015 VL 282 IS 3 BP 435 EP 444 DI 10.1111/febs.13133 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CA4US UT WOS:000348901600002 PM 25354325 ER PT J AU Fuchs, BC Hoshida, Y Tanabe, KK AF Fuchs, Bryan C. Hoshida, Yujin Tanabe, Kenneth K. TI Erlotinib Might Be a Double-Edged Sword in HCC SO HEPATOLOGY LA English DT Letter ID FACTOR RECEPTOR INHIBITION; HEPATOCELLULAR-CARCINOMA; MUTATION; CANCER C1 [Fuchs, Bryan C.; Tanabe, Kenneth K.] Massachusetts Gen Hosp Canc Ctr & Harvard Med Sch, Div Surg Oncol, Boston, MA USA. [Hoshida, Yujin] Tisch Canc Inst, Icahn Sch Med, Div Liver Dis, Dept Med, New York, NY USA. RP Fuchs, BC (reprint author), Massachusetts Gen Hosp Canc Ctr & Harvard Med Sch, Div Surg Oncol, Boston, MA 02114 USA. FU NCI NIH HHS [K01 CA140861, R01 CA076183]; NIDDK NIH HHS [R01 DK099558] NR 8 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD FEB PY 2015 VL 61 IS 2 BP 729 EP 730 DI 10.1002/hep.27205 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AZ9UX UT WOS:000348563200037 PM 24799327 ER PT J AU Kunisaki, KM Akgun, KM Fiellin, DA Gibert, CL Kim, JW Rimland, D Rodriguez-Barradas, MC Yaggi, HK Crothers, K AF Kunisaki, K. M. Akguen, K. M. Fiellin, D. A. Gibert, C. L. Kim, J. W. Rimland, D. Rodriguez-Barradas, M. C. Yaggi, H. K. Crothers, K. TI Prevalence and correlates of obstructive sleep apnoea among patients with and without HIV infection SO HIV MEDICINE LA English DT Article DE fatigue; HIV; obesity; obstructive; sleep apnoea; sleep apnoea syndromes ID POSITIVE AIRWAY PRESSURE; RISK-FACTOR; HYPERTENSION; ASSOCIATION; DISEASE; MEN; VETERANS; PATTERNS; OUTCOMES; COHORT AB ObjectivesIn HIV-uninfected populations, obstructive sleep apnoea (OSA) is commonly associated with cardiovascular disease, metabolic syndrome, and cognitive impairment. These comorbidities are common in HIV-infected patients, but there are scarce data regarding OSA in HIV-infected patients. Therefore, we examined the prevalence and correlates of OSA in a cohort of HIV-infected and uninfected patients. MethodsAn observational cohort study was carried out. Electronic medical record and self-report data were examined in patients enrolled in the Veterans Aging Cohort Study (VACS) between 2002 and 2008 and followed until 2010. The primary outcome was OSA diagnosis, determined using International Classification of Diseases, 9th edition (ICD-9) codes, in HIV-infected compared with uninfected individuals. We used regression analyses to determine the association between OSA diagnosis, symptoms and comorbidities in adjusted models. ResultsOf 3683 HIV-infected and 3641 uninfected patients, 143 (3.9%) and 453 (12.4%) had a diagnosis of OSA (p<0.0001), respectively. HIV-infected patients were more likely to report symptoms associated with OSA such as tiredness and fatigue. Compared with uninfected patients with OSA, HIV-infected patients with OSA were younger, had lower body mass indexes (BMIs), and were less likely to have hypertension. In models adjusting for these traditional OSA risk factors, HIV infection was associated with markedly reduced odds of OSA diagnosis (odds ratio 0.48; 95% confidence interval 0.39-0.60). ConclusionsHIV-infected patients are less likely to receive a diagnosis of OSA. Future studies are needed to determine whether the lower prevalence of OSA diagnoses in HIV-infected patients is attributable to decreased screening and detection or to a truly decreased likelihood of OSA in the setting of HIV infection. C1 [Kunisaki, K. M.] Minneapolis VA Hlth Care Syst, Minneapolis, MN 55417 USA. [Kunisaki, K. M.] Univ Minnesota, Minneapolis, MN USA. [Akguen, K. M.; Yaggi, H. K.] VA Connecticut Hlth Care Syst, West Haven, CT USA. [Akguen, K. M.; Fiellin, D. A.; Yaggi, H. K.] Yale Univ, Sch Med, New Haven, CT USA. [Gibert, C. L.] Washington DC VA Med Ctr, Washington, DC USA. [Gibert, C. L.] George Washington Univ, Washington, DC USA. [Kim, J. W.] James J Peters VA Med Ctr, Bronx, NY USA. [Rimland, D.] Atlanta VA Med Ctr, Atlanta, GA USA. [Rimland, D.] Emory Univ, Atlanta, GA 30322 USA. [Rodriguez-Barradas, M. C.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, M. C.] Baylor Coll Med, Houston, TX 77030 USA. [Crothers, K.] Univ Washington, Seattle, WA 98195 USA. RP Kunisaki, KM (reprint author), Minneapolis VA Hlth Care Syst, Pulm Crit Care & Sleep Apnea 111N, One Vet Dr, Minneapolis, MN 55417 USA. EM kunis001@umn.edu OI Kunisaki, Ken/0000-0001-8644-2827; Fiellin, David/0000-0002-4006-010X FU Department of Veterans Affairs, Veterans Health Administration, VISN 1 Career Development Award [VA HSRD V1CDA2012-20]; National Heart Lung and Blood Institute [R01-HL090342]; National Institute on Alcohol Abuse and Alcoholism [U10-AA13566, U24-AA020794, U01-AA020790] FX The research reported/outlined here was supported by the Department of Veterans Affairs, Veterans Health Administration, VISN 1 Career Development Award (VA HSR&D V1CDA2012-20), the National Heart Lung and Blood Institute (R01-HL090342), and the National Institute on Alcohol Abuse and Alcoholism (U10-AA13566, U24-AA020794 and U01-AA020790). NR 26 TC 4 Z9 4 U1 3 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-2662 EI 1468-1293 J9 HIV MED JI HIV Med. PD FEB PY 2015 VL 16 IS 2 BP 105 EP 113 DI 10.1111/hiv.12182 PG 9 WC Infectious Diseases SC Infectious Diseases GA CA2AW UT WOS:000348712300005 PM 25230851 ER PT J AU Osborn, MJ Gabriel, R Webber, BR DeFeo, AP McElroy, AN Jarjour, J Starker, CG Wagner, JE Joung, JK Voytas, DF von Kalle, C Schmidt, M Blazar, BR Tolar, J AF Osborn, Mark J. Gabriel, Richard Webber, Beau R. DeFeo, Anthony P. McElroy, Amber N. Jarjour, Jordan Starker, Colby G. Wagner, John E. Joung, J. Keith Voytas, Daniel F. von Kalle, Christof Schmidt, Manfred Blazar, Bruce R. Tolar, Jakub TI Fanconi Anemia Gene Editing by the CRISPR/Cas9 System SO HUMAN GENE THERAPY LA English DT Article ID ZINC-FINGER NUCLEASES; HOMOLOGY-DIRECTED REPAIR; HEMATOPOIETIC STEM-CELLS; DOUBLE-STRAND BREAKS; DONOR BONE-MARROW; VECTOR INTEGRATION; HUMAN GENOME; DNA-REPAIR; CORD BLOOD; IN-VIVO AB Genome engineering with designer nucleases is a rapidly progressing field, and the ability to correct human gene mutations in situ is highly desirable. We employed fibroblasts derived from a patient with Fanconi anemia as a model to test the ability of the clustered regularly interspaced short palindromic repeats/Cas9 nuclease system to mediate gene correction. We show that the Cas9 nuclease and nickase each resulted in gene correction, but the nickase, because of its ability to preferentially mediate homology-directed repair, resulted in a higher frequency of corrected clonal isolates. To assess the off-target effects, we used both a predictive software platform to identify intragenic sequences of homology as well as a genome-wide screen utilizing linear amplification-mediated PCR. We observed no off-target activity and show RNA-guided endonuclease candidate sites that do not possess low sequence complexity function in a highly specific manner. Collectively, we provide proof of principle for precision genome editing in Fanconi anemia, a DNA repair-deficient human disorder. C1 [Osborn, Mark J.; Webber, Beau R.; DeFeo, Anthony P.; McElroy, Amber N.; Wagner, John E.; Blazar, Bruce R.; Tolar, Jakub] Univ Minnesota, Dept Pediat, Div Blood & Marrow Transplantat, Minneapolis, MN 55455 USA. [Osborn, Mark J.; Starker, Colby G.; Voytas, Daniel F.] Univ Minnesota, Ctr Genome Engn, Minneapolis, MN 55455 USA. [Osborn, Mark J.; Starker, Colby G.; Wagner, John E.; Blazar, Bruce R.; Tolar, Jakub] Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA. [Voytas, Daniel F.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA. [Gabriel, Richard; von Kalle, Christof; Schmidt, Manfred] Natl Ctr Tumor Dis, Dept Translat Oncol, D-69120 Heidelberg, Germany. [Gabriel, Richard; von Kalle, Christof; Schmidt, Manfred] German Canc Res Ctr, D-69120 Heidelberg, Germany. [Jarjour, Jordan] Pregenen Inc, Seattle, WA 98103 USA. [Joung, J. Keith] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Mol Pathol Unit, Boston, MA 02114 USA. [Joung, J. Keith] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA. [Joung, J. Keith] Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA. RP Tolar, J (reprint author), Univ Minnesota, Stem Cell Inst, 420 Delaware St SE,MMC 366, Minneapolis, MN 55455 USA. EM tolar003@umn.edu OI Tolar, Jakub/0000-0002-0957-4380 FU National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000114]; [8UL1TR000114-02]; [R01 AR063070]; [P01 CA065493] FX We are grateful to Nancy Griggs Morgan for expert assistance in article preparation and editing. We are also thankful for the generosity of the Kidz 1st Fund, the Fanconi Anemia Research Fund, the Children's Cancer Research Fund, the Lindahl Family & the Corrigan Family. MJO is supported by 8UL1TR000114-02. JT is supported in part by R01 AR063070 and P01 CA065493. Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114 (MJO). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 59 TC 24 Z9 28 U1 1 U2 19 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1043-0342 EI 1557-7422 J9 HUM GENE THER JI Hum. Gene Ther. PD FEB 1 PY 2015 VL 26 IS 2 BP 114 EP 126 DI 10.1089/hum.2014.111 PG 13 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA CB0KX UT WOS:000349315900005 PM 25545896 ER PT J AU Khalili, H Ananthakrishnan, AN Konijeti, GG Higuchi, LM Fuchs, CS Richter, JM Chan, AT AF Khalili, Hamed Ananthakrishnan, Ashwin N. Konijeti, Gauree G. Higuchi, Leslie M. Fuchs, Charles S. Richter, James M. Chan, Andrew T. TI Measures of Obesity and Risk of Crohn's Disease and Ulcerative Colitis SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE inflammatory bowel disease; Crohn's Disease; ulcerative colitis; obesity; body mass index; waist to hip ratio; nurses' health study II ID INFLAMMATORY-BOWEL-DISEASE; CORE GUT MICROBIOME; LIFE-STYLE FACTORS; LONG-TERM INTAKE; BODY-MASS INDEX; ADIPOSE-TISSUE; OLMSTED COUNTY; PROSPECTIVE COHORT; CLINICAL-COURSE; US WOMEN AB Background:Obesity is associated with intestinal-specific inflammation. Nonetheless, a specific role of obesity in the etiology of inflammatory bowel disease is unclear.Methods:We conducted a prospective cohort study of U.S. women enrolled in 1989 in the Nurses' Health Study II. At baseline, we collected information on height, weight, waist and hip circumference, weight at age 18, and body shape at age 20. We used Cox proportional hazard models to calculate hazard ratios and 95% confidence intervals (CIs).Results:Among 111,498 women (median age, 35 yr), we documented 153 cases of Crohn's disease (CD) and 229 cases of ulcerative colitis (UC) more than 18 years of follow-up, encompassing 2,028,769 person-years. Compared with women with normal BMI, the multivariate-adjusted hazard ratios of CD were 2.33 (95% CI, 1.15-4.69) for obese women at age 18 and 1.58 (95% CI, 1.01-2.47) for obese women at baseline. Increasing weight gain between age 18 and baseline was associated with increased risk of CD (P-trend = 0.04). Adolescent body habitus was also associated with risk of CD with a multivariate-adjusted hazard ratio of CD of 1.63 (95% CI, 1.07-2.50) for women with overweight/obese body shape compared with women with a thin/slender body shape. We did not observe a significant association between any of these anthropometric measures and risk of UC.Conclusions:In a large prospective cohort of U.S. women, measures of adiposity were associated with an increased risk of CD but not UC. Additional studies are needed to elucidate the biological mechanisms by which excess adiposity may increase the risk of CD. C1 [Khalili, Hamed; Ananthakrishnan, Ashwin N.; Konijeti, Gauree G.; Richter, James M.; Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Khalili, Hamed; Ananthakrishnan, Ashwin N.; Konijeti, Gauree G.; Higuchi, Leslie M.; Fuchs, Charles S.; Richter, James M.; Chan, Andrew T.] Harvard Univ, Sch Med, Boston, MA USA. [Higuchi, Leslie M.] Childrens Hosp Boston, Div Gastroenterol & Nutr, Boston, MA USA. [Fuchs, Charles S.; Chan, Andrew T.] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA. [Fuchs, Charles S.; Chan, Andrew T.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA. RP Khalili, H (reprint author), Massachusetts Gen Hosp, Digest Healthcare Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. EM hkhalili@partners.org FU Crohn's and Colitis Foundation of America (CCFA); American Gastroenterological Association (AGA); National Institute of Diabetes and Digestive and Kidney Diseases [K23 DK099681, K08 DK064256]; [R01 CA137178]; [R01 CA050385]; [P01 CA87969]; [P30 DK043351]; [098311]; [K23 DK091742] FX Supported by R01 CA137178, R01 CA050385, P01 CA87969, P30 DK043351, K23 DK099681, K08 DK064256, K24 098311, and K23 DK091742. A. T. Chan is supported by a senior investigator grant from the Crohn's and Colitis Foundation of America (CCFA). H. Khalili is supported by a career development award from the American Gastroenterological Association (AGA) and by National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK099681). L. M. Higuchi is supported by National Institute of Diabetes and Digestive and Kidney Diseases (K08 DK064256). NR 35 TC 22 Z9 22 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-0998 EI 1536-4844 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD FEB PY 2015 VL 21 IS 2 BP 361 EP 368 DI 10.1097/MIB.0000000000000283 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CA4WA UT WOS:000348906200015 PM 25563694 ER PT J AU Nota, SPFT Bot, AGJ Ring, D Kloen, P AF Nota, Sjoerd P. F. T. Bot, Arjan G. J. Ring, David Kloen, Peter TI Disability and depression after orthopaedic trauma SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED LA English DT Article DE Orthopaedic trauma; Depression; PTSD; Injury; Psychosocial ID MUSCULOSKELETAL FUNCTION ASSESSMENT; INJURY SEVERITY SCORE; IDIOPATHIC ARM PAIN; MAJOR DEPRESSION; HEALTH-STATUS; EVENT SCALE; PREVALENCE; VALIDATION; DISORDERS; VALIDITY AB Introduction: Musculoskeletal injury is a common cause of impairment (pathophysiology), but the correlation of impairment with pain intensity and magnitude of disability is limited. Psychosocial factors explain a large proportion of the variance in disability for various orthopaedic pathologies. The aim of this study is to prospectively assess the relationship between psychological factors and magnitude of disability in a sample of orthopaedic trauma patients in The Netherlands. Material and methods: One hundred and one adult patients between 1 and 2 months after one or more fractures, tendon or ligament injuries were enrolled. Four eligible patients refused to participate. Thirty-five women and 30 men with an average age of 50 years (range, 22-92 years) completed the follow-up evaluation between 5 and 8 months after their injury and their data was analyzed. The patients completed a measure of disability (the Short Musculoskeletal Function Assessment-Netherlands, SMFA-NL), the Dutch Centre for Epidemiologic Study of Depression-scale (CES-D), the Dutch Impact of Event Scale (SVL), and the Dutch Pain Catastrophizing Scale (PCS) at the time of enrollment and again 5-8 months after injury. Results: There were moderate correlations between symptoms of depression (CES-D, r = 0.48, p < 0.001) and symptoms of PTSD (SVL, r = 0.35, p = 0.004) at enrollment and magnitude of disability 5-8 months after trauma. Catastrophic thinking (PCS) at enrollment and magnitude of disability 5-8 months after trauma showed a small correlation (PCS, r = 0.26, p = 0.034). The Pain Catastrophizing Scale (Beta = 0.29; p = 0.049), surgery (Beta = 026; p = 0.034), additional surgery (Beta = 0.26; p = 0.019) and other pain conditions (Beta = 0.31; p = 0.009) were the significant predictors in the final model (adjusted R-squared = 0.35; p < 0.001) for greater disability 5-8 months after trauma. Discussion and conclusions: In The Netherlands, symptoms of depression measured 1-2 months after musculoskeletal trauma correlate with disability 5-8 months after this trauma. The psychological aspects of recovery from musculoskeletal injury merit greater attention. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Nota, Sjoerd P. F. T.; Ring, David] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv,Yawkey Ctr, Boston, MA 02114 USA. [Bot, Arjan G. J.; Kloen, Peter] Acad Med Ctr, Dept Orthopaed Surg, NL-1100 DD Amsterdam, Netherlands. RP Nota, SPFT (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv,Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM spnota@hotmail.com; a.g.j.bot@gmail.com; dring@partners.org; p.kloen@amc.uva.nl NR 29 TC 11 Z9 11 U1 1 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-1383 EI 1879-0267 J9 INJURY JI Injury-Int. J. Care Inj. PD FEB PY 2015 VL 46 IS 2 BP 207 EP 212 DI 10.1016/j.injury.2014.06.012 PG 6 WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery GA CB1FE UT WOS:000349371600008 PM 25015790 ER PT J AU Kozanek, M Menendez, ME Ring, D AF Kozanek, Michal Menendez, Mariano E. Ring, David TI Association of perioperative blood transfusion and adverse events after operative treatment of proximal humerus fractures SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED LA English DT Article DE Transfusion; Proximal humerus fracture; Adverse events; Mortality; Shoulder ID POSTOPERATIVE BACTERIAL-INFECTION; HIP FRACTURE; ADMINISTRATIVE DATA; CELL TRANSFUSION; SURGERY; IMMUNOMODULATION; RISK; MORTALITY; TRIM AB Background: The purpose of this study was to assess the relationship between perioperative blood transfusion for proximal humerus fracture and inpatient mortality, adverse events, prolonged hospital stay, and nonroutine disposition. Methods: Among the >55,000 patients with an operatively treated proximal humerus fracture identified in the Nationwide Inpatient Sample between 2008 and 2011, 17% received a perioperative blood transfusion. Multivariable logistic regression analyses addressed the association of blood transfusion with inpatient mortality, adverse events, hospital stay, and nonroutine discharge, accounting for comorbidities and other known confounders. Results: Perioperative blood transfusion for fracture of the proximal humerus was not associated with inhospital death, but it was independently associated with inpatient adverse events (odds ratio (OR) 4.4, 95% confidence interval (CI) 4.2-4.6), prolonged hospital stay (OR 2.8, 95% CI 2.7-2.9), and increased nonroutine discharge (OR 1.8, 95% CI 1.7-1.9). Conclusions: Inpatients with fracture of the proximal humerus who receive transfusion are not more likely to die in hospital, but they do stay longer, experience more adverse events, and are less likely to be discharged home. Additional study is merited to determine if the judicious use of blood transfusion in the perioperative period can decrease inpatient morbidity and health-care resource utilisation. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Kozanek, Michal; Menendez, Mariano E.; Ring, David] Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Yawkey Ctr, Boston, MA 02114 USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM kozanek.michael@mhg.harvard.edu; memenendez@partners.org; dring@mgh.harvard.edu FU Orthopaedic Research and Education Foundation FX This work was aided by a grant from the Orthopaedic Research and Education Foundation. NR 32 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-1383 EI 1879-0267 J9 INJURY JI Injury-Int. J. Care Inj. PD FEB PY 2015 VL 46 IS 2 BP 270 EP 274 DI 10.1016/j.injury.2014.11.032 PG 5 WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery GA CB1FE UT WOS:000349371600018 PM 25528399 ER PT J AU Jin, JO Yu, Q AF Jin, Jun-O Yu, Qing TI Fucoidan delays apoptosis and induces pro-inflammatory cytokine production in human neutrophils SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES LA English DT Article DE Fucoidan; Neutrophils; Apoptosis ID SIGNAL-REGULATED KINASE; A SCAVENGER RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; ADAPTIVE IMMUNITY; SPONTANEOUS DEATH; DENDRITIC CELLS; C-DELTA; ACTIVATION; MACROPHAGES; MODULATION AB Although some immune modulatory effects of fucoidan have been elucidated, the effects of fucoidan on the apoptosis and activation of human neutrophils have not been investigated. In this study, we demonstrated that fucoidan purified from the brown seaweed Undaria pinnarifilda delays spontaneous apoptosis of human neutrophils and induces their activation. Fucoidan treatment inhibited apoptotic nuclei changes and phosphatidyl serine (PS) exposure on neutrophils cultured in vitro for 24h. The delay in neutrophil apoptosis mediated by fucoidan was associated with increased levels of the anti-apoptotic protein Mcl-1 and decreased levels of activated caspase-3. Screening of the signaling pathways by specific inhibitors indicated that fucoidan-induced delay in neutrophil apoptosis was dependent on the activation of PI3K/AKT signaling pathway, whereas MAPK signaling pathway was not critical. In addition, fucoidan enhanced the production of IL-6, IL-8 and TNF-alpha from neutrophils in an AKT-dependent manner. Taken together, these results demonstrated that fucoidan delays human neutrophil apoptosis and induces their production of pro-inflammatory cytokines. This knowledge could facilitate the development of novel therapeutic strategies for infectious diseases and neutropenia by controlling neutrophil homeostasis and function with fucoidan. (C) 2014 Elsevier B.V. All rights reserved. C1 [Jin, Jun-O] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai Med Coll, Shanghai 200433, Peoples R China. [Yu, Qing] Forsyth Inst, Dept Immunol & Infectios Dis, Cambridge, MA USA. RP Jin, JO (reprint author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai Med Coll, Shanghai 200433, Peoples R China. EM Junojin1@gmail.com FU National Natural Science Foundation of China [81450110090]; National Institutes of Health [R01 DE023838] FX This study was supported by Research Fund for International Young Scientists from National Natural Science Foundation of China (81450110090). Qing Yu was supported by grant R01 DE023838 from the National Institutes of Health. The authors have no competing financial interests. NR 51 TC 7 Z9 10 U1 3 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0141-8130 EI 1879-0003 J9 INT J BIOL MACROMOL JI Int. J. Biol. Macromol. PD FEB PY 2015 VL 73 BP 65 EP 71 DI 10.1016/j.ijbiomac.2014.10.059 PG 7 WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science SC Biochemistry & Molecular Biology; Chemistry; Polymer Science GA CA8TR UT WOS:000349194300010 PM 25445688 ER PT J AU Sinha, N Cifter, G Sajo, E Kumar, R Sridhar, S Nguyen, PL Cormack, RA Makrigiorgos, GM Ngwa, W AF Sinha, Neeharika Cifter, Gizem Sajo, Erno Kumar, Rajiv Sridhar, Srinivas Nguyen, Paul L. Cormack, Robert A. Makrigiorgos, G. Mike Ngwa, Wilfred TI Brachytherapy Application With In Situ Dose Painting Administered by Gold Nanoparticle Eluters SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID PROSTATE-SPECIFIC ANTIGEN; SOLID TUMORS; CANCER; DELIVERY; THERAPY; CELLS; NANOMEDICINE; RADIOTHERAPY; ENHANCEMENT; AGENTS AB Purpose: Recent studies show promise that administering gold nanoparticles (GNP) to tumor cells during brachytherapy could significantly enhance radiation damage to the tumor. A new strategy proposed for sustained administration of the GNP in prostate tumors is to load them into routinely used brachytherapy spacers for customizable in situ release after implantation. This in silico study investigated the intratumor bio-distribution and corresponding dose enhancement over time due to GNP released from such GNP-loaded brachytherapy spacers (GBS). Method and Materials: An experimentally determined intratumoral diffusion coefficient (D) for 10-nm nanoparticles was used to estimate D for other sizes by using the Stokes-Einstein equation. GNP concentration profiles, obtained using D, were then used to calculate the corresponding dose enhancement factor (DEF) for each tumor voxel, using dose painting-by-numbers approach, for times relevant to the considered brachytherapy sources' lifetimes. The investigation was carried out as a function of GNP size for the clinically applicable low-dose-rate brachytherapy sources iodine-125 (I-125), palladium-103 (Pd-103), and cesium-131 (Cs-131). Results: Results showed that dose enhancement to tumor voxels and subvolumes during brachytherapy can be customized by varying the size of GNP released or eluted from the GBS. For example, using a concentration of 7 mg/g GNP, significant DEF (> 20%) could be achieved 5 mm from a GBS after 5, 12, 25, 46, 72, 120, and 195 days, respectively, for GNP sizes of 2, 5, 10, 20, 30, and 50 nm and for 80 nm when treating with I-125. Conclusions: Analyses showed that using Cs-131 provides the highest dose enhancement to tumor voxels. However, given its relatively longer half-life, I-125 presents the most flexibility for customizing the dose enhancement as a function of GNP size. These findings provide a useful reference for further work toward development of potential new brachytherapy application with in situ dose painting administered via gold nanoparticle eluters for prostate cancer. (C) 2015 Elsevier Inc. C1 [Sinha, Neeharika] Wentworth Inst Technol, Dept Sci, Boston, MA USA. [Cifter, Gizem; Sajo, Erno; Ngwa, Wilfred] Univ Massachusetts, Dept Phys & Appl Phys, Lowell, MA USA. [Cifter, Gizem; Kumar, Rajiv; Sridhar, Srinivas; Nguyen, Paul L.; Cormack, Robert A.; Makrigiorgos, G. Mike; Ngwa, Wilfred] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Cifter, Gizem; Kumar, Rajiv; Sridhar, Srinivas; Nguyen, Paul L.; Cormack, Robert A.; Makrigiorgos, G. Mike; Ngwa, Wilfred] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Kumar, Rajiv; Sridhar, Srinivas] Northeastern Univ, Elect Mat Res Inst, Boston, MA 02115 USA. [Kumar, Rajiv; Sridhar, Srinivas] Northeastern Univ, Dept Phys, Boston, MA 02115 USA. RP Ngwa, W (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St,ASB1,L2, Boston, MA 02115 USA. EM wngwa@lroc.harvard.edu FU National Institutes of Health National Cancer Institute [1 K01 CA172478-01] FX This study was supported by National Institutes of Health National Cancer Institute grant 1 K01 CA172478-01. NR 30 TC 13 Z9 13 U1 1 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD FEB 1 PY 2015 VL 91 IS 2 BP 385 EP 392 DI 10.1016/j.ijrobp.2014.10.001 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AZ2DR UT WOS:000348045400020 PM 25482302 ER PT J AU Kumar, R Belz, J Markovic, S Jadhav, T Fowle, W Niedre, M Cormack, R Makrigiorgos, MG Sridhar, S AF Kumar, Rajiv Belz, Jodi Markovic, Stacey Jadhav, Tej Fowle, William Niedre, Mark Cormack, Robert Makrigiorgos, Mike G. Sridhar, Srinivas TI Nanoparticle-Based Brachytherapy Spacers for Delivery of Localized Combined Chemoradiation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID MODIFIED SILICA NANOPARTICLES; CONFORMAL RADIATION-THERAPY; RISK PROSTATE-CANCER; DRUG-DELIVERY; IN-VITRO; PLGA NANOPARTICLES; TRIAL; VIVO; PHARMACOKINETICS; NANOTECHNOLOGY AB Purpose: In radiation therapy (RT), brachytherapy-inert source spacers are commonly used in clinical practice to achieve high spatial accuracy. These implanted devices are critical technical components of precise radiation delivery but provide no direct therapeutic benefits. Methods and Materials: Here we have fabricated implantable nanoplatforms or chemoradiation therapy (INCeRT) spacers loaded with silica nanoparticles (SNPs) conjugated containing a drug, to act as a slow-release drug depot for simultaneous localized chemoradiation therapy. The spacers are made of poly(lactic-co-glycolic) acid (PLGA) as matrix and are physically identical in size to the commercially available brachytherapy spacers (5 mm x 0.8 mm). The silica nanoparticles, 250 nm in diameter, were conjugated with near infrared fluorophore Cy7.5 as a model drug, and the INCeRT spacers were characterized in terms of size, morphology, and composition using different instrumentation techniques. The spacers were further doped with an anticancer drug, docetaxel. We evaluated the in vivo stability, biocompatibility, and biodegradation of these spacers in live mouse tissues. Results: The electron microscopy studies showed that nanoparticles were distributed throughout the spacers. These INCeRT spacers remained stable and can be tracked by the use of optical fluorescence. In vivo optical imaging studies showed a slow diffusion of nanoparticles from the spacer to the adjacent tissue in contrast to the control Cy7.5-PLGA spacer, which showed rapid disintegration in a few days with a burst release of Cy7.5. The docetaxel spacers showed suppression of tumor growth in contrast to control mice over 16 days. Conclusions: The imaging with the Cy7.5 spacer and therapeutic efficacy with docetaxel spacers supports the hypothesis that INCeRT spacers can be used for delivering the drugs in a slow, sustained manner in conjunction with brachytherapy, in contrast to the rapid clearance of the drugs when administered systemically. The results demonstrate that these spacers with tailored release profiles have potential in improving the combined therapeutic efficacy of chemoradiation therapy. (C) 2015 Elsevier Inc. C1 [Kumar, Rajiv; Belz, Jodi; Jadhav, Tej; Fowle, William; Sridhar, Srinivas] Northeastern Univ, Nanomed Sci & Technol Ctr, Boston, MA 02115 USA. [Markovic, Stacey; Niedre, Mark] Northeastern Univ, Dept Elect & Comp Engn, Boston, MA 02115 USA. [Kumar, Rajiv; Cormack, Robert; Makrigiorgos, Mike G.; Sridhar, Srinivas] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Kumar, Rajiv; Cormack, Robert; Makrigiorgos, Mike G.; Sridhar, Srinivas] Harvard Univ, Sch Med, Boston, MA USA. RP Kumar, R (reprint author), Northeastern Univ, Nanomed Sci & Technol Ctr, 110 Forsyth St,111 Dana, Boston, MA 02115 USA. EM r.kumar@neu.edu OI Markovic, Stacey/0000-0001-8846-3832 FU NSF [DGE 0965843]; Electronics Materials Research Institute at Northeastern University; Brigham and Women's Hospital; [ARMY/ W81XWH-12-1-0154]; [HHS/5U54CA151881-02] FX Supported in part by ARMY/ W81XWH-12-1-0154, NSF DGE 0965843, HHS/5U54CA151881-02, the Electronics Materials Research Institute at Northeastern University, and Brigham and Women's Hospital. NR 42 TC 2 Z9 2 U1 4 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD FEB 1 PY 2015 VL 91 IS 2 BP 393 EP 400 DI 10.1016/j.ijrobp.2014.10.041 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AZ2DR UT WOS:000348045400021 PM 25636762 ER PT J AU Depauw, N Batin, E Daartz, J Rosenfeld, A Adams, J Kooy, H MacDonald, S Lu, HM AF Depauw, Nicolas Batin, Estelle Daartz, Julianne Rosenfeld, Anatoly Adams, Judith Kooy, Hanne MacDonald, Shannon Lu, Hsiao-Ming TI A Novel Approach to Postmastectomy Radiation Therapy Using Scanned Proton Beams SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID BREAST-CANCER; REGIONAL NODES; CHEST-WALL; RADIOTHERAPY; HEART; TRIAL; IRRADIATION; DELIVERY; PHOTONS; SURFACE AB Purpose: Postmastectomy radiation therapy (PMRT), currently offered at Massachusetts General Hospital, uses proton pencil beam scanning (PBS) with intensity modulation, achieving complete target coverage of the chest wall and all nodal regions and reduced dose to the cardiac structures. This work presents the current methodology for such treatment and the ongoing effort for its improvements. Methods and Materials: A single PBS field is optimized to ensure appropriate target coverage and heart/lung sparing, using an inehouse-developed proton planning system with the capability of multicriteria optimization. The dose to the chest wall skin is controlled as a separate objective in the optimization. Surface imaging is used for setup because it is a suitable surrogate for superficial target volumes. In order to minimize the effect of beam range uncertainties, the relative proton stopping power ratio of the material in breast implants was determined through separate measurements. Phantom measurements were also made to validate the accuracy of skin dose calculation in the treatment planning system. Additionally, the treatment planning robustness was evaluated relative to setup perturbations and patient breathing motion. Results: PBS PMRT planning resulted in appropriate target coverage and organ sparing, comparable to treatments by passive scattering (PS) beams but much improved in nodal coverage and cardiac sparing compared to conventional treatments by photon/electron beams. The overall treatment time was much shorter than PS and also shorter than conventional photon/electron treatment. The accuracy of the skin dose calculation by the planning system was within +/- 2%. The treatment was shown to be adequately robust relative to both setup uncertainties and patient breathing motion, resulting in clinically satisfying dose distributions. Conclusions: More than 25 PMRT patients have been successfully treated at Massachusetts General Hospital by using single-PBS fields. The methodology and robustness of both the setup and the treatment have been discussed. (C) 2015 Elsevier Inc. C1 [Depauw, Nicolas; Batin, Estelle; Daartz, Julianne; Adams, Judith; Kooy, Hanne; MacDonald, Shannon; Lu, Hsiao-Ming] Massachusetts Gen Hosp, Dept Radiat Oncol, Francis H Burr Proton Therapy Ctr, Boston, MA 02114 USA. [Depauw, Nicolas; Rosenfeld, Anatoly] Univ Wollongong, Ctr Med Radiat Phys, Wollongong, NSW 2522, Australia. RP Depauw, N (reprint author), MS 55 Fruit St, Boston, MA 02114 USA. EM ndepauw@partners.org NR 26 TC 5 Z9 5 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD FEB 1 PY 2015 VL 91 IS 2 BP 427 EP 434 DI 10.1016/j.ijrobp.2014.10.039 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AZ2DR UT WOS:000348045400025 PM 25636765 ER PT J AU Ngwa, W Sajo, E Ngoma, T Bortfeld, T Gierga, D White, KB Akinwande, B Enwerem-Bromson, MM Forbang, RT Winningham, TA Court, LE Odedina, FT Wu, R Makrigiorgos, M Nguyen, PL AF Ngwa, Wilfred Sajo, Erno Ngoma, Twalib Bortfeld, Thomas Gierga, David White, Karen Burns Akinwande, Babatope Enwerem-Bromson, Maria Manuella Forbang, Roland Teboh Winningham, Thomas Andrew Court, Laurence Edward Odedina, Folakemi T. Wu, Raymond Makrigiorgos, Mike Nguyen, Paul L. TI Potential for Information and Communication Technologies to Catalyze Global Collaborations in Radiation Oncology SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID THERAPY; RESPONSIBILITY; RESOURCES C1 [Ngwa, Wilfred; Makrigiorgos, Mike; Nguyen, Paul L.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Ngwa, Wilfred; Makrigiorgos, Mike; Nguyen, Paul L.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Ngwa, Wilfred; Sajo, Erno] Univ Massachusetts, Lowell, MA USA. [Ngoma, Twalib] Ocean Rd Canc Inst, Dar Es Salaam, Tanzania. [Bortfeld, Thomas; Gierga, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. [White, Karen Burns] Dana Farber Canc Inst, Boston, MA 02115 USA. [Akinwande, Babatope; Enwerem-Bromson, Maria Manuella] IAEA, A-1400 Vienna, Austria. [Forbang, Roland Teboh] Johns Hopkins Univ, Baltimore, MD USA. [Winningham, Thomas Andrew] Space Coast Canc Ctr, Titusville, FL USA. [Winningham, Thomas Andrew] African Renaissance Ambassador Corp, Orlando, FL USA. [Court, Laurence Edward] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Odedina, Folakemi T.] African Org Res & Training Canc, Rondebosch, South Africa. [Odedina, Folakemi T.] Univ Florida, Gainesville, FL USA. [Wu, Raymond] Univ Arizona, Ctr Canc, Int Org Med Phys, Phoenix, AZ USA. RP Ngwa, W (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiat Oncol, 75 Francis St,ASB L2, Boston, MA 02115 USA. EM wngwa@lroc.harvard.edu FU NCI NIH HHS [K01 CA172478] NR 11 TC 5 Z9 5 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD FEB 1 PY 2015 VL 91 IS 2 BP 444 EP 447 DI 10.1016/j.ijrobp.2014.10.031 PG 4 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AZ2DR UT WOS:000348045400027 PM 25636767 ER PT J AU Teo, AR Fetters, MD Stufflebam, K Tateno, M Balhara, Y Choi, TY Kanba, S Mathews, CA Kato, TA AF Teo, Alan R. Fetters, Michael D. Stufflebam, Kyle Tateno, Masaru Balhara, Yatan Choi, Tae Young Kanba, Shigenobu Mathews, Carol A. Kato, Takahiro A. TI Identification of the hikikomori syndrome of social withdrawal: Psychosocial features and treatment preferences in four countries SO INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY LA English DT Article DE Social isolation; cross-national; culture ID CULTURE-BOUND SYNDROME; COMMUNITY POPULATION; PRIMARY-CARE; MECHANISMS; DISORDERS; VERSION; SCALE; JAPAN; RISK AB Background: Hikikomori, a form of social withdrawal first reported in Japan, may exist globally but cross-national studies of cases of hikikomori are lacking. Aims: To identify individuals with hikikomori in multiple countries and describe features of the condition. Method: Participants were recruited from sites in India, Japan, Korea and the United States. Hikikomori was defined as a 6-month or longer period of spending almost all time at home and avoiding social situations and social relationships, associated with significant distress/impairment. Additional measures included the University of California, Los Angeles (UCLA) Loneliness Scale, Lubben Social Network Scale (LSNS-6), Sheehan Disability Scale (SDS) and modified Cornell Treatment Preferences Index. Results: A total of 36 participants with hikikomori were identified, with cases detected in all four countries. These individuals had high levels of loneliness (UCLA Loneliness Scale M = 55.4, SD = 10.5), limited social networks (LSNS-6 M = 9.7, SD = 5.5) and moderate functional impairment (SDS M = 16.5, SD = 7.9). Of them 28 (78%) desired treatment for their social withdrawal, with a significantly higher preference for psychotherapy over pharmacotherapy, in-person over telepsychiatry treatment and mental health specialists over primary care providers. Across countries, participants with hikikomori had similar generally treatment preferences and psychosocial features. Conclusion: Hikikomori exists cross-nationally and can be assessed with a standardized assessment tool. Individuals with hikikomori have substantial psychosocial impairment and disability, and some may desire treatment. C1 [Teo, Alan R.] Portland VA Med Ctr, Portland, OR 97239 USA. [Fetters, Michael D.] Univ Michigan, Dept Family Med, Japanese Family Hlth Program, Ann Arbor, MI 48109 USA. [Stufflebam, Kyle] Univ Michigan, Robert Wood Johnson Fdn, Clin Scholars Program, Ann Arbor, MI 48109 USA. [Tateno, Masaru] Sapporo Med Univ, Dept Neuropsychiat, Sapporo Hana Dev Psychiat Clin, Sapporo, Hokkaido, Japan. [Balhara, Yatan] All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, New Delhi, India. [Choi, Tae Young] Catholic Univ Daegu, Sch Med, Dept Psychiat, Taegu, South Korea. [Kanba, Shigenobu; Kato, Takahiro A.] Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Fukuoka 812, Japan. [Mathews, Carol A.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Kato, Takahiro A.] Kyushu Univ, Innovat Ctr Med Redox Nav, Fukuoka 812, Japan. RP Teo, AR (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd R&D 66, Portland, OR 97239 USA. EM teoa@ohsu.edu; takahiro@npsych.med.kyushu-u.ac.jp NR 35 TC 11 Z9 11 U1 5 U2 18 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0020-7640 EI 1741-2854 J9 INT J SOC PSYCHIATR JI Int. J. Soc. Psychiatr. PD FEB PY 2015 VL 61 IS 1 BP 64 EP 72 DI 10.1177/0020764014535758 PG 9 WC Psychiatry SC Psychiatry GA CA8CD UT WOS:000349143200009 PM 24869848 ER PT J AU Caqueo-Urizar, A Breslau, J Gilman, SE AF Caqueo-Urizar, Alejandra Breslau, Joshua Gilman, Stephen E. TI Beliefs about the causes of schizophrenia among Aymara and non-Aymara patients and their primary caregivers in the Central-Southern Andes SO INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY LA English DT Article DE Beliefs; Aymara; schizophrenia; Latin America ID FAMILY-MEMBERS; EXPLANATIONS; PERCEPTIONS; ATTITUDES; CHILE; INDIA; HELP AB Aim: The aim of this study is to investigate differences in the beliefs about the causes of schizophrenia between Aymara and non-Aymara patients with schizophrenia and their primary caregivers. Ethnic background plays an important role in the formation of beliefs regarding the causes of schizophrenia, and there have been no prior studies on such beliefs among the Aymara, an indigenous community with a population of about 2million people living in the Andes. We focused on three systems of beliefs distinguished in the literature: biological, psychosocial and magical-religious. Methods: The sample comprised 253 patients (n=117 Aymara, and n=136 non-Aymara) of public mental health centers in Chile (33.6%), Peru (33.6%) and Bolivia (32.8%) with a diagnosis of schizophrenia, and each patient's primary caregiver. We administered to patients and caregivers a questionnaire with scales assessing the perceived causes of schizophrenia. Linear regression models were fitted to compare differences in the levels of causal beliefs between Aymara and non-Aymara patients and caregivers, and to identify socio-demographic and clinical predictors of different types of beliefs about the causes of schizophrenia. Results: Adjusted for socio-demographic and clinical covariates, levels of psychosocial beliefs were significantly higher for Aymara caregivers (0.33, 95% confidence interval (CI)=0.05, 0.62) than non-Aymara caregivers. Conclusions: Contrary to expectations, beliefs about the causes of schizophrenia among Aymara are not more magical-religious than those of their non-Aymara counterparts. It may be necessary for mental health staff members to evaluate beliefs about the disorder, especially in ethnic minorities, before applying a standard model of treatment. C1 [Caqueo-Urizar, Alejandra] Univ Tarapaca, Dept Filosofia & Psicol, Arica, Chile. [Breslau, Joshua] RAND Corp, Hlth Div, Pittsburgh, PA USA. [Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA. [Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Gilman, Stephen E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Caqueo-Urizar, A (reprint author), Univ Tarapaca, Dept Filosofia & Psicol, Ave 18 Septiembre 2222, Arica, Chile. EM acaqueo@uta.cl RI Gilman, Stephen/E-7632-2010 OI Gilman, Stephen/0000-0002-8331-6419 NR 41 TC 6 Z9 7 U1 1 U2 7 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0020-7640 EI 1741-2854 J9 INT J SOC PSYCHIATR JI Int. J. Soc. Psychiatr. PD FEB PY 2015 VL 61 IS 1 BP 82 EP 91 DI 10.1177/0020764014544768 PG 10 WC Psychiatry SC Psychiatry GA CA8CD UT WOS:000349143200011 PM 25085414 ER PT J AU Teo, AR Kato, TA AF Teo, Alan R. Kato, Takahiro A. TI The prevalence and correlates of severe social withdrawal in Hong Kong SO INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY LA English DT Letter C1 [Teo, Alan R.] Portland VA Med Ctr, Portland, OR 97239 USA. [Teo, Alan R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kato, Takahiro A.] Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Fukuoka 812, Japan. [Kato, Takahiro A.] Kyushu Univ, Innovat Ctr Med Redox Nav, Fukuoka 812, Japan. RP Teo, AR (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd R&D 66, Portland, OR 97239 USA. EM teoa@ohsu.edu NR 3 TC 1 Z9 1 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0020-7640 EI 1741-2854 J9 INT J SOC PSYCHIATR JI Int. J. Soc. Psychiatr. PD FEB PY 2015 VL 61 IS 1 BP 102 EP 102 DI 10.1177/0020764014554923 PG 1 WC Psychiatry SC Psychiatry GA CA8CD UT WOS:000349143200013 PM 25323493 ER PT J AU Lochhead, P Chan, AT AF Lochhead, Paul Chan, Andrew T. TI Screening and Surveillance for Barrett Esophagus SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID ENDOSCOPIC SURVEILLANCE; COST-EFFECTIVENESS; ADENOCARCINOMA; MORTALITY C1 [Lochhead, Paul] Univ Aberdeen, Inst Med Sci, Div Appl Med, Gastrointestinal Res Grp, Aberdeen, Scotland. [Chan, Andrew T.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Chan, Andrew T.] Harvard Univ, Sch Med, Boston, MA USA. [Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. RP Chan, AT (reprint author), Massachusetts Gen Hosp, Div Gastroenterol, 55 Fruit St,GRJ-825C, Boston, MA 02114 USA. EM achan@mgh.harvard.edu FU NCI NIH HHS [P50 CA127003]; NIDDK NIH HHS [K24 DK098311] NR 9 TC 1 Z9 1 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2015 VL 175 IS 2 BP 159 EP 160 DI 10.1001/jamainternmed.2014.6983 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CA7TL UT WOS:000349120100004 PM 25546002 ER PT J AU Butt, AA Yan, P Lo Re, V Rimland, D Goetz, MB Leaf, D Freiberg, MS Klein, MB Justice, AC Sherman, KE AF Butt, Adeel A. Yan, Peng Lo Re, Vincent, III Rimland, David Goetz, Matthew B. Leaf, David Freiberg, Matthew S. Klein, Marina B. Justice, Amy C. Sherman, Kenneth E. CA ERCHIVES Elect Retrieved Cohort HC TI Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion SO JAMA INTERNAL MEDICINE LA English DT Article ID NON-B-HEPATITIS; TERM-FOLLOW-UP; NON-A; POSTTRANSFUSION HEPATITIS; NATURAL-HISTORY; HCV; COINFECTION; VETERANS; SURVIVAL; COHORT AB IMPORTANCE Knowing the rate of liver fibrosis progression in hepatitis C virus (HCV)-infected persons can help inform patients and providers (clinicians, medical institutions or organizations, and third-party payers) in making treatment decisions. OBJECTIVE To determine the rate and factors associated with liver fibrosis progression and hepatic decompensation in persons after acquiring HCV infection. DESIGN, SETTING, AND PARTICIPANTS Secondary data analysis of persons in the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES), a national Veterans Affairs (VA) database, between 2002 and 2012. Among 610 514 persons in ERCHIVES (half were HCV positive), we identified those with an initial negative and subsequent positive test result for HCV antibody and positive HCV RNA test result (HCV+). Controls had 2 negative HCV antibody test results (HCV-) in a comparable time frame and were matched 1: 1 on age (in 5-year blocks), race, and sex. We excluded persons with human immunodeficiency virus, hepatitis B, less than 24 months of follow-up, hepatocellular carcinoma, and cirrhosis at baseline. MAIN OUTCOMES AND MEASURES Progression of liver fibrosis as estimated by the Fibrosis-4 (FIB-4) index; development of cirrhosis, defined by a FIB-4 score greater than 3.5; and development of hepatic decompensation. RESULTS The evaluable data set consisted of 1840 persons who were HCV+ and 1840 HCV-controls. The HCV+ persons were younger and had a lower mean (SD) body mass index (27.39 [5.51] vs 29.49 [6.16]; P <.001), a higher prevalence of alcohol and drug abuse and dependence diagnoses, and higher serum aminotransferase levels, but had a lower prevalence of diabetes and hypertension. Fibrosis progression started early after infection among HCV+ persons and tapered off after 5 years. A total of 452 cirrhosis and 85 hepatic decompensation events were recorded. After 10 years of follow-up, HCV+ persons were more likely to have a diagnosis of cirrhosis compared with HCV-controls (18.4% vs 6.1%). Nine years after diagnosis of cirrhosis, hepatic decompensation events were uncommon but had a higher rate in the HCV+ group (1.79% vs 0.33%). CONCLUSIONS AND RELEVANCE Persons who seroconverted for HCV have a more rapid progression of liver fibrosis and accelerated time to development of cirrhosis after seroconversion compared with HCV-controls. Fibrosis progression occurs early after infection; however, hepatic decompensation is uncommon after diagnosis of cirrhosis. C1 [Butt, Adeel A.; Freiberg, Matthew S.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Butt, Adeel A.; Yan, Peng; Freiberg, Matthew S.] Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Lo Re, Vincent, III] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Rimland, David] Atlanta VA Med Ctr, Dept Med, Decatur, GA USA. [Goetz, Matthew B.; Leaf, David] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Klein, Marina B.] McGill Univ, Dept Med, Ctr Hlth, Montreal, PQ, Canada. [Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Justice, Amy C.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA. [Sherman, Kenneth E.] Univ Cincinnati, Med Ctr, Dept Med, Cincinnati, OH 45267 USA. RP Butt, AA (reprint author), Univ Pittsburgh, Sch Med, Div Infect Dis, 3601 Fifth Ave,Ste 3A, Pittsburgh, PA 15213 USA. EM aabutt@pitt.edu RI Lo Re, Vincent/N-7817-2015; OI Butt, Adeel/0000-0002-1118-1826; Goetz, Matthew/0000-0003-4542-992X; Justice, Amy/0000-0003-0139-5502 FU National Institutes of Health (NIH) [U24 AA020794, U01 AA020790] FX Dr Justice's time was supported by grants U24 AA020794 and U01 AA020790 from the National Institutes of Health (NIH). This material is the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System and the central data repositories maintained by the VA Information Resource Center, including the National Patient Care Database, Decisions Support System Database and Pharmacy Benefits Management Database. NR 30 TC 27 Z9 27 U1 1 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2015 VL 175 IS 2 BP 178 EP 185 DI 10.1001/jamainternmed.2014.6502 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CA7TL UT WOS:000349120100012 PM 25485735 ER PT J AU Sanghavi, P Jena, AB Newhouse, JP Zaslavsky, AM AF Sanghavi, Prachi Jena, Anupam B. Newhouse, Joseph P. Zaslavsky, Alan M. TI Outcomes After Out-of-Hospital Cardiac Arrest Treated by Basic vs Advanced Life Support SO JAMA INTERNAL MEDICINE LA English DT Article ID ADVANCED AIRWAY MANAGEMENT; CARDIOPULMONARY-RESUSCITATION; VENTRICULAR-FIBRILLATION; INDUCED HYPOTHERMIA; COMATOSE SURVIVORS; ASSOCIATION; DEFIBRILLATION; EPINEPHRINE; IMPROVE; CPR AB IMPORTANCE Most out-of-hospital cardiac arrests receiving emergency medical services in the United States are treated by ambulance service providers trained in advanced life support (ALS), but supporting evidence for the use of ALS over basic life support (BLS) is limited. OBJECTIVE To compare the effects of BLS and ALS on outcomes after out-of-hospital cardiac arrest. DESIGN, SETTING, AND PARTICIPANTS Observational cohort study of a nationally representative sample of traditional Medicare beneficiaries from nonrural counties who experienced out-of-hospital cardiac arrest between January 1, 2009, and October 2, 2011, and for whom ALS or BLS ambulance services were billed to Medicare (31 292 ALS cases and 1643 BLS cases). Propensity score methods were used to compare the effects of ALS and BLS on patient survival, neurological performance, and medical spending after cardiac arrest. MAIN OUTCOMES AND MEASURES Survival to hospital discharge, to 30 days, and to 90 days; neurological performance; and incremental medical spending per additional survivor to 1 year. RESULTS Survival to hospital discharge was greater among patients receiving BLS (13.1% vs 9.2% for ALS; 4.0 [95% CI, 2.3-5.7] percentage point difference), as was survival to 90 days (8.0% vs 5.4% for ALS; 2.6 [95% CI, 1.2-4.0] percentage point difference). Basic life support was associated with better neurological functioning among hospitalized patients (21.8% vs 44.8% with poor neurological functioning for ALS; 23.0 [95% CI, 18.6-27.4] percentage point difference). Incremental medical spending per additional survivor to 1 year for BLS relative to ALS was $ 154 333. CONCLUSIONS AND RELEVANCE Patients with out-of-hospital cardiac arrest who received BLS had higher survival at hospital discharge and at 90 days compared with those who received ALS and were less likely to experience poor neurological functioning. C1 [Sanghavi, Prachi] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA. [Jena, Anupam B.; Newhouse, Joseph P.; Zaslavsky, Alan M.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Jena, Anupam B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Jena, Anupam B.; Newhouse, Joseph P.] Natl Bur Econ Res, Cambridge, MA 02138 USA. [Newhouse, Joseph P.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Newhouse, Joseph P.] Harvard Univ, Kennedy Sch, Cambridge, MA 02138 USA. RP Sanghavi, P (reprint author), Harvard Univ, Interfac Initiat Hlth Policy, 1737 Cambridge St,Room K311, Cambridge, MA 02138 USA. EM sanghav@fas.harvard.edu FU National Science Foundation; Agency for Healthcare Research and Quality [R36]; National Institutes of Health [1DP5OD017897-01] FX Ms Sanghavi was supported by a National Science Foundation Graduate Research Fellowship and a Health Services Research Dissertation Award (R36) from the Agency for Healthcare Research and Quality. Dr Jena was supported by Early Independence Award 1DP5OD017897-01 from the National Institutes of Health. NR 32 TC 20 Z9 20 U1 3 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2015 VL 175 IS 2 BP 196 EP 204 DI 10.1001/jamainternmed.2014.5420 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CA7TL UT WOS:000349120100015 PM 25419698 ER PT J AU Vora, AN Holmes, DN Rokos, I Roe, MT Granger, CB French, WJ Antman, E Henry, TD Thomas, L Bates, ER Wang, TY AF Vora, Amit N. Holmes, DaJuanicia N. Rokos, Ivan Roe, Matthew T. Granger, Christopher B. French, William J. Antman, Elliott Henry, Timothy D. Thomas, Laine Bates, Eric R. Wang, Tracy Y. TI Fibrinolysis Use Among Patients Requiring Interhospital Transfer for ST-Segment Elevation Myocardial Infarction Care A Report From the US National Cardiovascular Data Registry SO JAMA INTERNAL MEDICINE LA English DT Article ID PERCUTANEOUS CORONARY INTERVENTION; IN-HOSPITAL MORTALITY; REPERFUSION THERAPY; PRIMARY PCI; RISK SCORE; THROMBOLYSIS; ANGIOPLASTY; GUIDELINES; EFFICACY; LONG AB IMPORTANCE Guidelines for patients with ST-segment elevation myocardial infarction (STEMI) recommend timely reperfusion with primary percutaneous coronary intervention (pPCI) or fibrinolysis. Among patients with STEMI who require interhospital transfer, it is unclear how reperfusion strategy selection and outcomes vary with interhospital drive times. OBJECTIVE To assess the association of estimated interhospital drive times with reperfusion strategy selection among transferred patients with STEMI in the United States. DESIGN, SETTING, AND PARTICIPANTS We identified 22 481 patients eligible for pPCI or fibrinolysis who were transferred from 1771 STEMI referring centers to 366 STEMI receiving centers in the Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines database between July 1, 2008, and March 31, 2012. MAIN OUTCOMES AND MEASURES In-hospital mortality and major bleeding. RESULTS The median estimated interhospital drive time was 57 minutes (interquartile range [IQR], 36-88 minutes). When the estimated drive time exceeded 30 minutes, only 42.6% of transfer patients treated with pPCI achieved the first door-to-balloon time within 120 minutes. Only 52.7% of eligible patients with a drive time exceeding 60 minutes received fibrinolysis. Among 15 437 patients with estimated drive times of 30 to 120 minutes who were eligible for fibrinolysis or pPCI, 5296 (34.3%) received pretransfer fibrinolysis, with a median door-to-needle time of 34 minutes (IQR, 23-53 minutes). After fibrinolysis, the median time to transfer to the STEMI receiving center was 49 minutes (IQR, 34-69 minutes), and 97.1% underwent follow-up angiography. Patients treated with fibrinolysis vs pPCI had no significant mortality difference (3.7% vs 3.9%; adjusted odds ratio, 1.13; 95% CI, 0.94-1.36) but had higher bleeding risk (10.7% vs 9.5%; adjusted odds ratio, 1.17; 95% CI, 1.02-1.33). CONCLUSIONS AND RELEVANCE In the United States, neither fibrinolysis nor pPCI is being optimally used to achieve guideline-recommended reperfusion targets. For patients who are unlikely to receive timely pPCI, pretransfer fibrinolysis, followed by early transfer for angiography, may be a reperfusion option when potential benefits of timely reperfusion outweigh bleeding risk. C1 [Vora, Amit N.; Holmes, DaJuanicia N.; Roe, Matthew T.; Granger, Christopher B.; Thomas, Laine; Wang, Tracy Y.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA. [Rokos, Ivan] Olive View Univ Calif Los Angeles, Med Ctr, Dept Emergency Med, Sylmar, CA USA. [French, William J.] Harbor Univ Calif Los Angeles, Dept Med, Div Cardiol, Med Ctr, Torrance, CA 90509 USA. [Antman, Elliott] Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiovasc Div,TIMI Study Grp, Boston, MA 02115 USA. [Henry, Timothy D.] Abbott NW Hosp, Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA. [Bates, Eric R.] Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiovasc Dis, Ann Arbor, MI 48109 USA. RP Vora, AN (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA. EM a.vora@duke.edu FU American College of Cardiology Foundation's National Cardiovascular Data Registry; American Heart Association'sMission: Lifeline program; Society of Chest Pain Centers; American College of Emergency Physicians; Society of Hospital Medicine FX This research was supported by the American College of Cardiology Foundation's National Cardiovascular Data Registry and by the American Heart Association'sMission: Lifeline program. The ACTION Registry-GWTG is an initiative of the American College of Cardiology Foundation and the American Heart Association, with partnering support from the Society of Chest Pain Centers, the American College of Emergency Physicians, and the Society of Hospital Medicine. NR 29 TC 17 Z9 17 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2015 VL 175 IS 2 BP 207 EP 215 DI 10.1001/jamainternmed.2014.6573 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CA7TL UT WOS:000349120100017 PM 25485876 ER PT J AU Haas, JS Linder, JA Park, ER Gonzalez, I Rigotti, NA Klinger, EV Kontos, EZ Zaslavsky, AM Brawarsky, P Marinacci, LX St Hubert, S Fleegler, EW Williams, DR AF Haas, Jennifer S. Linder, Jeffrey A. Park, Elyse R. Gonzalez, Irina Rigotti, Nancy A. Klinger, Elissa V. Kontos, Emily Z. Zaslavsky, Alan M. Brawarsky, Phyllis Marinacci, Lucas X. St Hubert, Stella Fleegler, Eric W. Williams, David R. TI Proactive Tobacco Cessation Outreach to Smokers of Low Socioeconomic Status A Randomized Clinical Trial SO JAMA INTERNAL MEDICINE LA English DT Article ID SMOKING-CESSATION; CIGARETTE-SMOKING; AFRICAN-AMERICAN; SOCIAL-PROBLEMS; DISPARITIES; DEPENDENCE; CARE; TECHNOLOGY; RECORDS; ADULTS AB IMPORTANCE Widening socioeconomic disparities in mortality in the United States are largely explained by slower declines in tobacco use among smokers of low socioeconomic status (SES) than among those of higher SES, which points to the need for targeted tobacco cessation interventions. Documentation of smoking status in electronic health records (EHRs) provides the tools for health systems to proactively offer tobacco treatment to socioeconomically disadvantaged smokers. OBJECTIVE To evaluate a proactive tobacco cessation strategy that addresses sociocontextual mediators of tobacco use for low-SES smokers. DESIGN, SETTING, AND PARTICIPANTS This prospective, randomized clinical trial included low-SES adult smokers who described their race and/or ethnicity as black, Hispanic, or white and received primary care at 1 of 13 practices in the greater Boston area (intervention group, n = 399; control group, n = 308). INTERVENTIONS We analyzed EHRs to identify potentially eligible participants and then used interactive voice response (IVR) techniques to reach out to them. Consenting patients were randomized to either receive usual care from their own health care team or enter an intervention program that included (1) telephone-based motivational counseling, (2) free nicotine replacement therapy (NRT) for 6 weeks, (3) access to community-based referrals to address sociocontextual mediators of tobacco use, and (4) integration of all these components into their normal health care through the EHR system. MAIN OUTCOMES AND MEASURES Self-reported past-7-day tobacco abstinence 9 months after randomization ("quitting"), assessed by automated caller or blinded study staff. RESULTS The intervention group had a higher quit rate than the usual care group (17.8% vs 8.1%; odds ratio, 2.5; 95% CI, 1.5-4.0; number needed to treat, 10). We examined whether use of intervention components was associated with quitting among individuals in the intervention group: individuals who participated in the telephone counseling were more likely to quit than those who did not (21.2% vs 10.4%; P < .001). There was no difference in quitting by use of NRT. Quitting did not differ by a request for a community referral, but individuals who used their referral were more likely to quit than those who did not (43.6% vs 15.3%; P < .001). CONCLUSIONS AND RELEVANCE Proactive, IVR-facilitated outreach enables engagement with low-SES smokers. Providing counseling, NRT, and access to community-based resources to address sociocontextual mediators among smokers reached in this setting is effective. C1 [Haas, Jennifer S.; Linder, Jeffrey A.; Gonzalez, Irina; Klinger, Elissa V.; Brawarsky, Phyllis; Marinacci, Lucas X.; St Hubert, Stella] Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02120 USA. [Haas, Jennifer S.; Kontos, Emily Z.; Williams, David R.] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA. [Haas, Jennifer S.; Linder, Jeffrey A.; Park, Elyse R.; Rigotti, Nancy A.; Zaslavsky, Alan M.; Fleegler, Eric W.] Harvard Univ, Sch Med, Boston, MA USA. [Park, Elyse R.; Rigotti, Nancy A.] Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA. [Park, Elyse R.; Rigotti, Nancy A.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA. [Fleegler, Eric W.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA. RP Haas, JS (reprint author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St, Boston, MA 02120 USA. EM jhaas@partners.org FU Lung Cancer Disparities Center at the Harvard School of Public Health (National Cancer Institute) [P50 CA148596]; Harvard Catalyst; Harvard Clinical and Translational Science Center (National Institutes of Health [NIH]) [1 UL1 RR 025758-01]; NIH; Home for Little Wanderers Service Grant; Aerosmith Endowment Fund for Prevention and Treatment of AIDS and HIV Infections; Verizon Foundation; Thrive in 5/Boston Mayor's Office Ready Families Program; Highland Street Foundation; Boston Foundation FX This work was conducted with support from the Lung Cancer Disparities Center at the Harvard School of Public Health (funded by National Cancer Institute grant P50 CA148596) and the Harvard Catalyst and from the Harvard Clinical and Translational Science Center (funded by National Institutes of Health [NIH] grant 1 UL1 RR 025758-01 and financial contributions from participating institutions). In addition, Drs Haas and Rigotti and Mss Klinger and St Hubert report receiving grants from the NIH during the conduct of this study. Dr Fleegler reports receipt of a Home for Little Wanderers Service Grant and grants from the Aerosmith Endowment Fund for Prevention and Treatment of AIDS and HIV Infections, the Verizon Foundation, Thrive in 5/Boston Mayor's Office Ready Families Program, the Highland Street Foundation, and the Boston Foundation to fund the initial development of HelpSteps.com, for which Dr Fleegler serves as project director. Dr Fleegler also receives ongoing support from Boston Children's Hospital and the Boston Public Health Commission. NR 41 TC 16 Z9 16 U1 5 U2 16 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2015 VL 175 IS 2 BP 218 EP 226 DI 10.1001/jamainternmed.2014.6674 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CA7TL UT WOS:000349120100019 PM 25506771 ER PT J AU Jena, AB Prasad, V Goldman, DP Romley, J AF Jena, Anupam B. Prasad, Vinay Goldman, Dana P. Romley, John TI Mortality and Treatment Patterns Among Patients Hospitalized With Acute Cardiovascular Conditions During Dates of National Cardiology Meetings SO JAMA INTERNAL MEDICINE LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; DUTY HOUR REFORM; MEDICARE BENEFICIARIES; OUTCOMES; RISK; CARE; ADMISSION; TRENDS; VOLUME AB IMPORTANCE Thousands of physicians attend scientific meetings annually. Although hospital physician staffing and composition may be affected by meetings, patient outcomes and treatment patterns during meeting dates are unknown. OBJECTIVE To analyze mortality and treatment differences among patients admitted with acute cardiovascular conditions during dates of national cardiology meetings compared with nonmeeting dates. DESIGN, SETTING, AND PARTICIPANTS Retrospective analysis of 30-day mortality among Medicare beneficiaries hospitalized with acutemyocardial infarction (AMI), heart failure, or cardiac arrest from 2002 through 2011 during dates of 2 national cardiology meetings compared with identical nonmeeting days in the 3 weeks before and after conferences (AMI, 8570 hospitalizations during 82 meeting days and 57 471 during 492 nonmeeting days; heart failure, 19 282 during meeting days and 11 4591 during nonmeeting days; cardiac arrest, 1564 during meeting days and 9580 during nonmeeting days). Multivariable analyses were conducted separately for major teaching hospitals and nonteaching hospitals and for low- and high-risk patients. Differences in treatment utilization were assessed. EXPOSURES Hospitalization during cardiology meeting dates. MAIN OUTCOMES AND MEASURES Thirty-day mortality, procedure rates, charges, length of stay. RESULTS Patient characteristics were similar between meeting and nonmeeting dates. In teaching hospitals, adjusted 30-day mortality was lower among high-risk patients with heart failure or cardiac arrest admitted during meeting vs nonmeeting dates (heart failure, 17.5% [95% CI, 13.7%-21.2%] vs 24.8%[95% CI, 22.9%-26.6%]; P <.001; cardiac arrest, 59.1% [95% CI, 51.4%-66.8%] vs 69.4%[95% CI, 66.2%-72.6%]; P=.01). Adjusted mortality for high-risk AMI in teaching hospitals was similar between meeting and nonmeeting dates (39.2%[95% CI, 31.8%-46.6%] vs 38.5%[95% CI, 35.0%-42.0%]; P=.86), although adjusted percutaneous coronary intervention (PCI) rates were lower during meetings (20.8% vs 28.2%; P = .02). No mortality or utilization differences existed for low-risk patients in teaching hospitals or high- or low-risk patients in nonteaching hospitals. In sensitivity analyses, cardiac mortality was not affected by hospitalization during oncology, gastroenterology, and orthopedics meetings, nor was gastrointestinal hemorrhage or hip fracture mortality affected by hospitalization during cardiology meetings. CONCLUSIONS AND RELEVANCE High-risk patients with heart failure and cardiac arrest hospitalized in teaching hospitals had lower 30-day mortality when admitted during dates of national cardiology meetings. High-risk patients with AMI admitted to teaching hospitals during meetings were less likely to receive PCI, without any mortality effect. C1 [Jena, Anupam B.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Jena, Anupam B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Jena, Anupam B.; Goldman, Dana P.] Natl Bur Econ Res, Cambridge, MA 02138 USA. [Prasad, Vinay] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA. [Goldman, Dana P.; Romley, John] Univ So Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA. [Goldman, Dana P.; Romley, John] RAND Corp, Santa Monica, CA USA. RP Jena, AB (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA. EM jena@hcp.med.harvard.edu OI Prasad, Vinay/0000-0002-6110-8221 FU Office of the Director, National Institutes of Health (NIH Early Independence Award) [1DP50D017897-01]; National Institute of Aging [5P01AG033559] FX Dr Jena has received funding from the Office of the Director, National Institutes of Health (NIH Early Independence Award, grant 1DP50D017897-01). Drs Goldman and Romley have received funding from the National Institute of Aging (grant 5P01AG033559). NR 31 TC 16 Z9 16 U1 1 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2015 VL 175 IS 2 BP 237 EP 244 DI 10.1001/jamainternmed.2014.6781 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CA7TL UT WOS:000349120100022 PM 25531231 ER PT J AU Rigotti, NA AF Rigotti, Nancy A. TI Improving the Success of Treating Tobacco Smokers SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID VARENICLINE; DEPENDENCE; SMOKING; TRIAL C1 [Rigotti, Nancy A.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA. [Rigotti, Nancy A.] Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA. [Rigotti, Nancy A.] Harvard Univ, Sch Med, Boston, MA USA. RP Rigotti, NA (reprint author), Massachusetts Gen Hosp, Div Gen Internal Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM nrigotti@partners.org NR 7 TC 0 Z9 0 U1 2 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2015 VL 175 IS 2 BP 272 EP 273 DI 10.1001/jamainternmed.2014.6921 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CA7TL UT WOS:000349120100028 PM 25545347 ER PT J AU Burke, RE Juarez-Colunga, E Levy, C Prochazka, AV Coleman, EA Ginde, AA AF Burke, Robert E. Juarez-Colunga, Elizabeth Levy, Cari Prochazka, Allan V. Coleman, Eric A. Ginde, Adit A. TI Rise of Post-Acute Care Facilities as a Discharge Destination of US Hospitalizations SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Burke, Robert E.; Prochazka, Allan V.] Eastern Colorado Hlth Care Syst, Dept Vet Affairs Med Ctr, Denver, CO USA. [Burke, Robert E.; Prochazka, Allan V.] Univ Colorado, Sch Med, Dept Med, Div Gen Internal Med, Aurora, CO USA. [Juarez-Colunga, Elizabeth] Univ Colorado, Sch Med, Dept Biostat & Informat, Aurora, CO USA. [Levy, Cari; Coleman, Eric A.] Univ Colorado, Sch Med, Div Hlth Care Policy & Res, Aurora, CO USA. [Ginde, Adit A.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA. RP Burke, RE (reprint author), Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM robert.burke5@va.gov RI bebarta, vikhyat/K-3476-2015 FU NCATS NIH HHS [UL1 TR001082]; NIA NIH HHS [K23AG040708] NR 6 TC 14 Z9 14 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2015 VL 175 IS 2 BP 295 EP 296 DI 10.1001/jamainternmed.2014.6383 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA CA7TL UT WOS:000349120100034 PM 25437642 ER PT J AU Shtasel-Gottlieb, Z Palakshappa, D Yang, FY Goodman, E AF Shtasel-Gottlieb, Zoe Palakshappa, Deepak Yang, Fanyu Goodman, Elizabeth TI The Relationship Between Developmental Assets and Food Security in Adolescents From a Low-Income Community SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Food insecurity; Developmental assets; Adolescents; Poverty ID YOUTH DEVELOPMENT; INSECURITY; CHILDREN; HEALTH; HUNGER; SCHOOL; INSUFFICIENCY; NUTRITION; BEHAVIOR; IMPACT AB Purpose: To explore the association between developmental assets (characteristics, experiences, and relationships that shape healthy development) and food insecurity among adolescents from a low-income urban community. Methods: This mixed-methods study occurred in two phases. In phase 1, using a census approach, 2,350 6th to 12th graders from the public school district completed an anonymous survey that included the developmental assets profile (DAP), the youth self-report form of the Core Food Security Module, and demographic questions. Logistic and multinomial regression analyses determined independent associations between developmental assets and food security adjusting for demographics. In phase 2, 20 adult key informant interviews and four semistructured student focus groups were performed to explain findings from phase 1. Results: On average, DAP scores were consistent with national norms. Food insecurity was prevalent; 14.9% reported low food security and 8.6% very low food security (VLFS). Logistic regression revealed that higher DAP was associated with lower odds of food insecurity (odds ratio [OR], .96; 95% confidence interval [CI], .95-.97); family assets drove this association (OR, .93; 95% CI, .91-.95). In multinomial regression modeling, these associations persisted, and paradoxically, higher community assets were also associated with VLFS (ORVLFS, 1.08; 95% CI, 1.04-1.13). Qualitative analyses suggested that greater need among VLFS youth led to increased connections to community resources despite barriers to access such as stigma, home instability, and cultural differences. Conclusion: Food insecurity is a pervasive problem among adolescents from low-income communities and is associated with lower developmental assets, particularly family assets. The fact that community assets were higher among VLFS youth underscores the importance of community-level resources in struggling areas. (C) 2015 Society for Adolescent Health and Medicine. All rights reserved. C1 [Shtasel-Gottlieb, Zoe; Goodman, Elizabeth] Harvard Univ, Sch Med, Boston, MA USA. [Palakshappa, Deepak; Goodman, Elizabeth] MassGen Hosp Children, Div Gen Acad Pediat, Boston, MA 02114 USA. [Yang, Fanyu] Univ Toronto, Fac Med, Toronto, ON, Canada. RP Goodman, E (reprint author), MassGen Hosp Children, Div Gen Acad Pediat, 100 Cambridge St,15th Floor, Boston, MA 02114 USA. EM PalakshappaD@email.chop.edu; egoodman3@mgh.harvard.edu OI Goodman, Elizabeth/0000-0002-9640-9884; Palakshappa, Deepak/0000-0003-1467-4965 FU National Institutes of Health [P30DK046200, T35-HD07446]; Foster Scholars Program of the John D. Stoeckle Center for Primary Care Innovation at Massachusetts General Hospital FX Funded, in part, by National Institutes of Health grant P30DK046200, the Foster Scholars Program of the John D. Stoeckle Center for Primary Care Innovation at Massachusetts General Hospital, and the T35-HD07446 (National Institutes of Health). NR 37 TC 4 Z9 4 U1 4 U2 25 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2015 VL 56 IS 2 BP 215 EP 222 DI 10.1016/j.jadohealth.2014.10.001 PG 8 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA AZ8YQ UT WOS:000348498100014 PM 25620305 ER PT J AU Keller, AC Knaub, LA Miller, MW Birdsey, N Klemm, DJ Reusch, JEB AF Keller, Amy C. Knaub, Leslie A. Miller, Matthew W. Birdsey, Nicholas Klemm, Dwight J. Reusch, Jane E. B. TI Saxagliptin Restores Vascular Mitochondrial Exercise Response in the Goto-Kakizaki Rat SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article DE mitochondria; exercise; saxagliptin; type 2 diabetes; GLP-1; eNOS ID GLUCAGON-LIKE PEPTIDE-1; NITRIC-OXIDE SYNTHASE; CHRONIC HEART-FAILURE; PHYSICAL-ACTIVITY; SKELETAL-MUSCLE; SMOOTH-MUSCLE; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; DIABETES-MELLITUS; ENDOTHELIAL-CELLS AB Cardiovascular disease risk and all-cause mortality are largely predicted by physical fitness. Exercise stimulates vascular mitochondrial biogenesis through endothelial nitric oxide synthase (eNOS), sirtuins, and PPAR gamma coactivator 1 alpha (PGC-1 alpha), a response absent in diabetes and hypertension. We hypothesized that an agent regulating eNOS in the context of diabetes could reconstitute exercise-mediated signaling to mitochondrial biogenesis. Glucagon-like peptide 1 (GLP-1) stimulates eNOS and blood flow; we used saxagliptin, an inhibitor of GLP-1 degradation, to test whether vascular mitochondrial adaptation to exercise in diabetes could be restored. Goto-Kakizaki (GK) rats, a nonobese, type 2 diabetes model, and Wistar controls were exposed to an 8-day exercise intervention with or without saxagliptin (10 mg.kg(-1).d(-1)). We evaluated the impact of exercise and saxagliptin on mitochondrial proteins and signaling pathways in aorta. Mitochondrial protein expression increased with exercise in the Wistar aorta and decreased or remained unchanged in the GK animals. GK rats treated with saxagliptin plus exercise showed increased expression of mitochondrial complexes, cytochrome c, eNOS, nNOS, PGC-1 alpha, and UCP3 proteins. Notably, a 3-week saxagliptin plus exercise intervention significantly increased running time in the GK rats. These data suggest that saxagliptin restores vascular mitochondrial adaptation to exercise in a diabetic rodent model and may augment the impact of exercise on the vasculature. C1 [Keller, Amy C.; Knaub, Leslie A.; Miller, Matthew W.; Birdsey, Nicholas; Reusch, Jane E. B.] Univ Colorado Denver, Div Endocrinol Metab & Diabet, Aurora, CO 80045 USA. [Keller, Amy C.; Knaub, Leslie A.; Miller, Matthew W.; Birdsey, Nicholas; Reusch, Jane E. B.] Denver VA Med Ctr, Dept Med, Denver, CO USA. [Klemm, Dwight J.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO 80045 USA. RP Reusch, JEB (reprint author), Univ Colorado Denver, Div Endocrinol Metab & Diabet, Anschutz Med Campus,12801 E 17th Ave,MS8106, Aurora, CO 80045 USA. EM jane.reusch@ucdenver.edu FU VA Merit; Denver Research Institue; Bristol-Myers Squibb; CCTSI [UL1RR025780]; Center for Women's Health Research; [NIH-5T32HL007171]; [NIH-5P01HL014985] FX Funded by VA Merit, Denver Research Institute, Bristol-Myers Squibb, NIH-5T32HL007171, NIH-5P01HL014985, CCTSI (UL1RR025780), and the Center for Women's Health Research. NR 54 TC 4 Z9 4 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0160-2446 EI 1533-4023 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PD FEB PY 2015 VL 65 IS 2 BP 137 EP 147 PG 11 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA CB0KE UT WOS:000349313800007 PM 25264749 ER PT J AU Elad, N De Strooper, B Lismont, S Hagen, W Veugelen, S Arimon, M Horre, K Berezovska, O Sachse, C Chavez-Gutierrez, L AF Elad, Nadav De Strooper, Bart Lismont, Sam Hagen, Wim Veugelen, Sarah Arimon, Muriel Horre, Katrien Berezovska, Oksana Sachse, Carsten Chavez-Gutierrez, Lucia TI The dynamic conformational landscape of gamma-secretase SO JOURNAL OF CELL SCIENCE LA English DT Article DE gamma-secretase; Alzheimer disease; Conformational landscape; Regulated intramembrane proteolysis; Single particle electron microscopy ID AMYLOID PRECURSOR PROTEIN; SPORADIC ALZHEIMERS-DISEASE; EM STRUCTURE DETERMINATION; ELECTRON-MICROSCOPY; SUBSTRATE DOCKING; PRESENILIN-1; COMPLEX; NICASTRIN; INHIBITORS; SUBUNIT AB The structure and function of the gamma-secretase proteases are of great interest because of their crucial roles in cellular and disease processes. We established a novel purification protocol for the gamma-secretase complex that involves a conformation-and complexspecific nanobody, yielding highly pure and active enzyme. Using single particle electron microscopy, we analyzed the gamma-secretase structure and its conformational variability. Under steady-state conditions, the complex adopts three major conformations, which differ in overall compactness and relative position of the nicastrin ectodomain. Occupancy of the active or substrate-binding sites by inhibitors differentially stabilizes subpopulations of particles with compact conformations, whereas a mutation linked to familial Alzheimer disease results in enrichment of extended-conformation complexes with increased flexibility. Our study presents the gamma-secretase complex as a dynamic population of interconverting conformations, involving rearrangements at the nanometer scale and a high level of structural interdependence between subunits. The fact that protease inhibition or clinical mutations, which affect amyloid beta (A beta) generation, enrich for particular subpopulations of conformers indicates the functional relevance of the observed dynamic changes, which are likely to be instrumental for highly allosteric behavior of the enzyme. C1 [Elad, Nadav; De Strooper, Bart; Lismont, Sam; Veugelen, Sarah; Horre, Katrien; Chavez-Gutierrez, Lucia] VIB Ctr Biol Dis, B-3000 Louvain, Belgium. [Elad, Nadav; De Strooper, Bart; Lismont, Sam; Veugelen, Sarah; Horre, Katrien; Chavez-Gutierrez, Lucia] Katholieke Univ Leuven, Univ Hosp Leuven, Ctr Human Genet, B-3000 Louvain, Belgium. [Elad, Nadav; De Strooper, Bart; Lismont, Sam; Veugelen, Sarah; Horre, Katrien; Chavez-Gutierrez, Lucia] Katholieke Univ Leuven, Dept Human Genet, B-3000 Louvain, Belgium. [Elad, Nadav; De Strooper, Bart; Lismont, Sam; Veugelen, Sarah; Horre, Katrien; Chavez-Gutierrez, Lucia] Leuven Res Inst Neurosci & Dis LIND, B-3000 Louvain, Belgium. [De Strooper, Bart] UCL Inst Neurol, London WC1N 3BG, England. [Hagen, Wim; Berezovska, Oksana; Sachse, Carsten] European Mol Biol Lab, Struct & Computat Biol Unit, D-69117 Heidelberg, Germany. [Arimon, Muriel] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA. RP De Strooper, B (reprint author), VIB Ctr Biol Dis, B-3000 Louvain, Belgium. EM Bart.DeStrooper@cme.vib-kuleuven.be; carsten.sachse@embl.de; Lucia.ChavezGutierrez@cme.vib-kuleuven.be RI Chavez-Gutierrez, Lucia/E-2657-2017 FU Fund for Scientific Research Flanders (FWO); research fund KU Leuven; Hercules Foundation; Federal Office for Scientific Affairs [IAP P7/16]; Flemish Government; Flanders Institute for Biotechnology (VIB); Agency for Innovation by Science and Technology (IWT); European Research Council (AdG); Marie Curie fellowship; European Molecular Biology Organization (EMBO); Foundation for Alzheimer Research (SAO-FRA); National Institutes of Health [AG15379] FX This work was supported by the Fund for Scientific Research Flanders (FWO); research fund KU Leuven; the Hercules Foundation; Federal Office for Scientific Affairs [grant number IAP P7/16]; a Methusalem grant of the Flemish Government; Flanders Institute for Biotechnology (VIB); Agency for Innovation by Science and Technology (IWT); the European Research Council (AdG to B.D.S.). B.D.S. is the Arthur Bax and Anna Vanluffelen chair for Alzheimer disease. N.E. was supported by Marie Curie and European Molecular Biology Organization (EMBO) fellowships, and by the Foundation for Alzheimer Research (SAO-FRA). O.B. was supported by the National Institutes of Health [grant number AG15379]. We also acknowledge an anonymous foundation. Deposited in PMC for immediate release. NR 57 TC 7 Z9 7 U1 0 U2 10 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0021-9533 EI 1477-9137 J9 J CELL SCI JI J. Cell Sci. PD FEB 1 PY 2015 VL 128 IS 3 BP 589 EP 598 DI 10.1242/jcs.164384 PG 10 WC Cell Biology SC Cell Biology GA CA6JF UT WOS:000349017900015 PM 25501811 ER PT J AU Brent, BK AF Brent, Benjamin K. TI A Mentalization-Based Approach to the Development of the Therapeutic Alliance in the Treatment of Schizophrenia SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE schizophrenia; psychosis; mentalization-based treatment; mentalization; attachment ID PSYCHOTHERAPY; PSYCHOSIS; METACOGNITION; ASSOCIATIONS; ILLNESS; NEUROCOGNITION; DISTURBANCES; NARRATIVES; INSIGHT; RISK AB This article presents a clinical illustration of a mentalization-based approach to the development of a therapeutic alliance in the treatment of schizophrenia. A clinically focused overview of the attachment-based understanding of mentalization central to the mentalization-based treatment model is first provided. This is followed by a brief summary of the theory and evidence supporting the possible link between attachment disturbances and deficits of mental state understanding in schizophrenia. A case presentation then illustrates the application of core mentalization-based principles and interventions to enhance the therapeutic alliance by addressing disruptions of mentalization and reducing paranoia in the treatment of a patient with early course schizophrenia. C1 [Brent, Benjamin K.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Psychiat, Cambridge, MA 02138 USA. [Brent, Benjamin K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA. RP Brent, BK (reprint author), Massachusetts Mental Hlth Ctr, 75 Fenwood Rd,Room 618, Boston, MA 02115 USA. EM bbrent@bidmc.harvard.edu NR 24 TC 3 Z9 3 U1 2 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9762 EI 1097-4679 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD FEB PY 2015 VL 71 IS 2 BP 146 EP 156 DI 10.1002/jclp.22150 PG 11 WC Psychology, Clinical SC Psychology GA CA1NF UT WOS:000348678500004 PM 25557537 ER PT J AU Badano, A Revie, C Casertano, A Cheng, WC Green, P Kimpe, T Krupinski, E Sisson, C Skrovseth, S Treanor, D Boynton, P Clunie, D Flynn, MJ Heki, T Hewitt, S Homma, H Masia, A Matsui, T Nagy, B Nishibori, M Penczek, J Schopf, T Yagi, Y Yokoi, H AF Badano, Aldo Revie, Craig Casertano, Andrew Cheng, Wei-Chung Green, Phil Kimpe, Tom Krupinski, Elizabeth Sisson, Christye Skrovseth, Stein Treanor, Darren Boynton, Paul Clunie, David Flynn, Michael J. Heki, Tatsuo Hewitt, Stephen Homma, Hiroyuki Masia, Andy Matsui, Takashi Nagy, Balazs Nishibori, Masahiro Penczek, John Schopf, Thomas Yagi, Yukako Yokoi, Hideto TI Consistency and Standardization of Color in Medical Imaging: a Consensus Report SO JOURNAL OF DIGITAL IMAGING LA English DT Article DE Color imaging; Medical imaging; Color calibration; Color management ID PERFORMANCE; LESIONS; IMAGES; CAMERA AB This article summarizes the consensus reached at the Summit on Color in Medical Imaging held at the Food and Drug Administration (FDA) on May 8-9, 2013, co-sponsored by the FDA and ICC (International Color Consortium). The purpose of the meeting was to gather information on how color is currently handled by medical imaging systems to identify areas where there is a need for improvement, to define objective requirements, and to facilitate consensus development of best practices. Participants were asked to identify areas of concern and unmet needs. This summary documents the topics that were discussed at the meeting and recommendations that were made by the participants. Key areas identified where improvements in color would provide immediate tangible benefits were those of digital microscopy, telemedicine, medical photography (particularly ophthalmic and dental photography), and display calibration. Work in these and other related areas has been started within several professional groups, including the creation of the ICC Medical Imaging Working Group. C1 [Badano, Aldo; Cheng, Wei-Chung] US FDA, Div Imaging & Appl Math, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA. [Revie, Craig] FFEI Ltd, London, England. [Revie, Craig] Int Color Consortium, London, England. [Casertano, Andrew] SAN Business Consultants LLP, New York, NY USA. [Green, Phil] Gjovik Univ Coll, Tromso, Norway. [Kimpe, Tom] Barco NV, Healthcare Div, Brussels, Belgium. [Krupinski, Elizabeth] Univ Arizona, Dept Med Imaging, Tucson, AZ USA. [Krupinski, Elizabeth] Univ Arizona, Arizona Telemed Program, Tucson, AZ USA. [Sisson, Christye] Rochester Inst Technol, Sch Photog Arts & Sci, Rochester, NY 14623 USA. [Skrovseth, Stein] Univ Hosp North Norway, Norwegian Ctr Integrated Care & Telemed, Tromso, Norway. [Treanor, Darren] Leeds Teaching Hosp NHS Trust, London, England. [Treanor, Darren] Univ Leeds, London, England. [Boynton, Paul] NIST, Gaithersburg, MD 20899 USA. [Clunie, David] PixelMed Publishing, Philadelphia, PA USA. [Flynn, Michael J.] Henry Ford Hlth Syst, New York, NY USA. [Heki, Tatsuo] Fujifilm Corp, Healthcare Business Dev Off, Tokyo, Japan. [Hewitt, Stephen] NCI, Ctr Canc Res, Bethesda, MD 20892 USA. [Homma, Hiroyuki] Olympus Med Syst Corp, Tokyo, Japan. [Masia, Andy] X Rite, Boston, MA USA. [Matsui, Takashi] Eizo Corp, Tokyo, Japan. [Nagy, Balazs] Inst Psychol, Dept Expt Psychol, Sao Paulo, Brazil. [Nishibori, Masahiro] Int Univ Hlth & Welf, Dept Social Serv & Healthcare Management, Tokyo, Japan. [Penczek, John] NIST, Boulder, CO USA. [Penczek, John] Univ Colorado, Boulder, CO 80309 USA. [Schopf, Thomas] Univ Hosp North Norway, Norwegian Ctr Integrated Care & Telemed, Tromso, Norway. [Yokoi, Hideto] Kagawa Univ Hosp, Dept Med Informat, Tokyo, Japan. [Yagi, Yukako] Harvard Univ, Sch Med, Boston, MA USA. [Yagi, Yukako] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nagy, Balazs] Budapest Univ Technol & Econ, Ctr Neurosci & Behav, Budapest, Hungary. [Nagy, Balazs] Budapest Univ Technol & Econ, Dept Mechatron Opt & Engn Informat, Budapest, Hungary. RP Badano, A (reprint author), US FDA, Div Imaging & Appl Math, Ctr Devices & Radiol Hlth, 10993 New Hampshire Ave, Silver Spring, MD 20993 USA. EM aldo.badano@fda.hhs.gov RI NAGY, Balazs Vince/K-6546-2015; Clunie, David/Q-2777-2015; OI NAGY, Balazs Vince/0000-0002-8489-7200; Clunie, David/0000-0002-2406-1145; Skrovseth, Stein Olav/0000-0003-3568-867X; Hewitt, Stephen/0000-0001-8283-1788; badano, aldo/0000-0003-3712-6670 FU Research Council of Norway [174,934] FX SS and TS were funded by the Research Council of Norway grant no. 174,934, Tromso Telemedicine Laboratory. The mention of commercial products, their sources, or their use in connection with material reported herein is not to be construed as either an actual or implied endorsement of such products by the Department of Health and Human Services. NR 30 TC 11 Z9 11 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0897-1889 EI 1618-727X J9 J DIGIT IMAGING JI J. Digit. Imaging PD FEB PY 2015 VL 28 IS 1 BP 41 EP 52 DI 10.1007/s10278-014-9721-0 PG 12 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AZ7KO UT WOS:000348398200007 PM 25005868 ER PT J AU Herbst, MK Camargo, CA Perez, A Moore, CL AF Herbst, Meghan Kelly Camargo, Carlos A., Jr. Perez, Alberto Moore, Christopher L. TI USE OF POINT-OF-CARE ULTRASOUND IN CONNECTICUT EMERGENCY DEPARTMENTS SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE ultrasound; survey; emergency department ID PHYSICIANS; ULTRASONOGRAPHY; ACCESS AB Background: Point-of-care ultrasound (PoC US) is now taught and used in nearly all academic emergency departments (EDs), but prior surveys have shown that adoption in the community ED setting is much lower. Objective: Our aim was to characterize the current practice of emergency physician (EP)-performed PoC US in Connecticut. Methods: We conducted a 20-question online survey of all ED directors in Connecticut to determine how PoC US is utilized. The questions addressed ED demo-graphics, ownership of ultrasound (US) equipment, frequency of PoC US performance in general and by examination type, credentialing patterns, quality assurance methods, and billing patterns. Results: The response rate was 83% (25 of 30). Almost all (96%) respondent EDs owned at least one US machine, and 24% used US regularly for diverse applications according to 2008 American College of Emergency Physicians (ACEP) guidelines. PoC US was most commonly used for Focused Assessment with Sonography in Trauma examinations, procedural guidance, and assessing the aorta for an abdominal aortic aneurysm. Although 64% reported hospital ultrasonography privileges, 40% did not keep any record of PoC US performed in the ED. More than half (56%) required an over-read by radiology, and 36% required an over-read by another EP (e. g., ED Ultrasound Director). Only 8% of EDs billed for PoC US. Conclusions: Most Connecticut EDs own an US machine and have hospital privileges for PoC US. However, a minority use or bill for PoC US regularly for diffuse applications, and most do not have a quality assurance program as described by ACEP guidelines. (C) 2015 Elsevier Inc. C1 [Herbst, Meghan Kelly] Univ Connecticut, Sch Med, Hartford Hosp, Dept Emergency Med, Hartford, CT 06112 USA. [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. [Perez, Alberto] Univ Connecticut, Sch Med, Dept Emergency Med, John Dempsey Hosp, Farmington, CT USA. [Moore, Christopher L.] Yale Univ, Yale New Haven Hosp, Dept Emergency Med, New Haven, CT USA. RP Herbst, MK (reprint author), Hartford Hosp, 80 Seymour St, Ishikari, Hokkaido 06102, Japan. NR 22 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 EI 1090-1280 J9 J EMERG MED JI J. Emerg. Med. PD FEB PY 2015 VL 48 IS 2 BP 191 EP U194 DI 10.1016/j.jemermed.2014.09.017 PG 8 WC Emergency Medicine SC Emergency Medicine GA AZ9AO UT WOS:000348503900018 PM 25440859 ER PT J AU Song, ZR McMahon, LF AF Song, Zirui McMahon, Laurence F., Jr. TI Rethinking Physician Payment SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE Payment; Reform; Innovation; Global budget; Value ID INCENTIVES C1 [Song, Zirui] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Song, Zirui] Harvard Univ, Sch Med, Boston, MA USA. [Song, Zirui] Natl Bur Econ Res, Cambridge, MA 02138 USA. [McMahon, Laurence F., Jr.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. [McMahon, Laurence F., Jr.] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA. RP Song, ZR (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. EM zirui_song@post.harvard.edu FU NIA NIH HHS [F30 AG039175] NR 5 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2015 VL 30 IS 2 BP 152 EP 154 DI 10.1007/s11606-014-3035-2 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CA9HX UT WOS:000349234300005 PM 25245886 ER PT J AU Gerber, MR King, MW Pineles, SL Wiltsey-Stirman, S Bean-Mayberry, B Japuntich, SJ Haskell, SG AF Gerber, Megan R. King, Matthew W. Pineles, Suzanne L. Wiltsey-Stirman, Shannon Bean-Mayberry, Bevanne Japuntich, Sandra J. Haskell, Sally G. TI Hormone Therapy Use in Women Veterans Accessing Veterans Health Administration Care: A National Cross-Sectional Study SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE women Veterans; hormone therapy; mental health ID RANDOMIZED CONTROLLED-TRIAL; POSTTRAUMATIC-STRESS-DISORDER; MILITARY SEXUAL TRAUMA; CHRONIC PELVIC PAIN; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; VASOMOTOR SYMPTOMS; PHYSICAL SYMPTOMS; FEMALE VETERANS; MENTAL-HEALTH AB The majority of women Veterans using VA (Veterans Administration) care fall in the 45-65 year-old age range. Understanding how menopause is managed in this group is of importance to optimizing their health. National population estimates showed a prevalence of hormone therapy (HT) use by women over 45 years of 4.7 % (2009-2010). Our study described the frequency of HT use among women Veterans in VA, and examined whether mental health (MH) was predictive of HT use. This was a cross-sectional analysis of national VA administrative data for fiscal year 2009. Women Veterans over the age of 45 (N = 157,195) accessing VA outpatient care were included in the analysis. Logistic regression analyses using HT use as the dependent variable. Mean age was 59.4 years (SD =12.2, range =46-110), and 16,227 (10.3 %) of all women used HT. Hysterectomy (OR 3.99 [3.53, 4.49]) and osteoporosis (1.34 [1.27, 1.42]) were the strongest medical indicators of HT use. A total of 49,557 (31.5 %) women in the sample received at least one primary diagnosis of a MH disorder and were more likely to use HT than women with no MH diagnoses (unadjusted OR 1.56, 95 % CI [1.50, 1.61]). Women Veterans with a mood disorder (depression/bipolar) or anxiety disorder [post-traumatic stress disorder (PTSD), other anxiety diagnoses] were more likely to use HT after controlling for demographics and medical comorbidity. The prevalence of HT use among women Veterans using VA is more than twice that of the general population. Prior work suggested that women Veterans were discontinuing HT at comparable rates, but these data demonstrate that decline in VA HT use has not kept pace with that of civilian medical care. The association of MH diagnosis with HT use suggests that MH plays an important role in VA rates. Further study is needed to understand contributing patient and provider factors. C1 [Gerber, Megan R.] VA Boston Healthcare Syst, Women Vet Program, Boston, MA 02130 USA. [Gerber, Megan R.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [King, Matthew W.; Pineles, Suzanne L.; Wiltsey-Stirman, Shannon; Japuntich, Sandra J.] VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr PTSD, Boston, MA 02130 USA. [King, Matthew W.; Pineles, Suzanne L.; Wiltsey-Stirman, Shannon; Japuntich, Sandra J.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Bean-Mayberry, Bevanne] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bean-Mayberry, Bevanne] UCLA David Geffen Sch Med, Dept Med, Los Angeles, CA USA. [Haskell, Sally G.] VA Connecticut Healthcare Syst, Gen Internal Med Sect, Dept Med, West Haven, CT USA. [Haskell, Sally G.] Yale Univ, Sch Med, Dept Med, Gen Internal Med Sect, New Haven, CT 06510 USA. RP Gerber, MR (reprint author), VA Boston Healthcare Syst, Women Vet Program, 150 S Huntington Ave PC11 WHC, Boston, MA 02130 USA. EM Megan.gerber@va.gov OI Gerber, Megan/0000-0002-8444-5554; Wiltsey Stirman, Shannon/0000-0001-9917-5078 FU National Center for PTSD (NCPTSD), U.S. Department of Veterans Affairs, Executive Division, White River Junction, VT; United States Department of Veterans Affairs Clinical Sciences Research and Development Service [1IK2CX000918-01A1] FX Funding to support database creation was provided by National Center for PTSD (NCPTSD), U.S. Department of Veterans Affairs, Executive Division, White River Junction, VT.; This work was supported in part by Career Development Award (Japuntich) #1IK2CX000918-01A1 from the United States Department of Veterans Affairs Clinical Sciences Research and Development Service. NR 48 TC 3 Z9 3 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2015 VL 30 IS 2 BP 169 EP 175 DI 10.1007/s11606-014-3073-9 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CA9HX UT WOS:000349234300008 PM 25373833 ER PT J AU Jones, J Nowels, CT Sudore, R Ahluwalia, S Bekelman, DB AF Jones, Jacqueline Nowels, Carolyn T. Sudore, Rebecca Ahluwalia, Sangeeta Bekelman, David B. TI The Future as a Series of Transitions: Qualitative Study of Heart Failure Patients and Their Informal Caregivers SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE advance care planning; transitions; palliative care; decision making; patient-centered care ID ADVANCE DIRECTIVES; LIFE; CARE; END; COMMUNICATION; ADJUSTMENT; PEOPLE; HOPE AB Advance care planning often only focuses on written advance directives rather than on future goals important to patients and families. Heart failure has a particularly uncertain future with variable clinical trajectories. A better understanding of patient and family concerns about and perceptions of the future could improve advance care planning. We aimed to identify how patients with heart failure and their informal (family) caregivers perceive their future. This was a cross-sectional study using qualitative methods. Thirty-three patients from an academic health care system with New York Heart Association class II-IV heart failure and 20 of their informal caregivers participated in the study. We used a purposive sampling strategy to include patients within a range of ages and health statuses. Participants were asked in individual, semi-structured interviews: "When you think about what lies ahead, what comes to mind?" Qualitative analysis used an inductive approach. Early in the analysis, it became clear that participants' narratives about the future were described in terms of past transitions. This led us to use transition theory to further guide analysis. Transition theory describes how people restructure their reality and resolve uncertainty during change. Patients and their caregivers talked about past and present transitions when asked about the future: "The present gets in the way of talking about the future." We identified four common pivotal transitions, including the shock of first being diagnosed with heart failure; learning to adjust to life with heart failure; reframing and taking back control of one's life; and understanding and accepting that death is inevitable. Concerns about the future were framed based on the most recent transition. Heart failure is a series of transitions according to patients and caregivers. By recognizing and educating patients about transitions, identifying transition-specific concerns, and supporting patients and caregivers through transitions, the process of planning for the future as part of advance care planning may be improved. C1 [Jones, Jacqueline] Univ Colorado, Coll Nursing, Aurora, CO 80045 USA. [Nowels, Carolyn T.; Bekelman, David B.] Univ Colorado, Sch Med, Aurora, CO 80045 USA. [Nowels, Carolyn T.; Bekelman, David B.] Eastern Colorado Hlth Care Syst, Dept Vet Affairs, Denver, CO USA. [Sudore, Rebecca] Univ Calif San Francisco, Sch Med, Div Geriatr, San Francisco, CA USA. [Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA. [Ahluwalia, Sangeeta] Oregon State Univ, Coll Publ Hlth & Human Sci, Corvallis, OR 97331 USA. RP Jones, J (reprint author), Univ Colorado, Coll Nursing, Campus Box C-288-19,13120 E 19th Ave, Aurora, CO 80045 USA. EM jacqueline.jones@ucdenver.edu FU University of Colorado Hartford/Jahnigen Center for Excellence in Geriatric Medicine; Mordecai Palliative Care Grants Fund; Department of Veterans Affairs [HSRD CDA 08-022] FX Funders: This research was funded by the University of Colorado Hartford/Jahnigen Center for Excellence in Geriatric Medicine and the Mordecai Palliative Care Grants Fund. Dr. Bekelman is funded by a Department of Veterans Affairs Career Development Award (HSR&D CDA 08-022). The funding organizations had no role in any part of the study. The views expressed in this paper are those of the authors and do not necessarily reflect the views of the Department of Veterans Affairs. NR 31 TC 5 Z9 5 U1 2 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2015 VL 30 IS 2 BP 176 EP 182 DI 10.1007/s11606-014-3085-5 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CA9HX UT WOS:000349234300009 PM 25385209 ER PT J AU Chiovaro, J AF Chiovaro, Joseph TI Capsule Commentary on Turner et al., Chronic Opioid Therapy Urine Drug Testing in Primary Care: Prevalence and Predictors of Aberrant Results SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA. RP Chiovaro, J (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA. EM jchiovaro@gmail.com NR 4 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2015 VL 30 IS 2 BP 241 EP 241 DI 10.1007/s11606-014-3091-7 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CA9HX UT WOS:000349234300022 PM 25387440 ER PT J AU Zeidman, J Baggett, M Hunt, DP AF Zeidman, Jessica Baggett, Meridale Hunt, Daniel P. TI Can One-Minute Preceptor and SNAPPS Improve Your Inpatient Teaching? SO JOURNAL OF HOSPITAL MEDICINE LA English DT Editorial Material ID PATIENT C1 [Zeidman, Jessica; Baggett, Meridale; Hunt, Daniel P.] Massachusetts Gen Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02114 USA. RP Hunt, DP (reprint author), Massachusetts Gen Hosp, Dept Med, Inpatient Clinician Educ Serv, 50 Staniford St,Suite 503B, Boston, MA 02114 USA. EM dphunt@partners.org NR 10 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD FEB PY 2015 VL 10 IS 2 BP 131 EP 132 DI 10.1002/jhm.2307 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CA7AE UT WOS:000349068600012 PM 25627349 ER PT J AU Ozieh, MN Bishu, KG Dismuke, CE Egede, LE AF Ozieh, M. N. Bishu, K. G. Dismuke, C. E. Egede, L. E. TI TREND OF HEALTH CARE EXPENDITURE IN UNITED STATES ADULTS WITH CHRONIC KIDNEY DISEASE: 2002-2011 SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 26-28, 2015 CL New Orleans, LA SP Amer Federat Med Res C1 [Ozieh, M. N.; Bishu, K. G.; Dismuke, C. E.; Egede, L. E.] MUSC, Charleston, SC USA. [Dismuke, C. E.; Egede, L. E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2015 VL 63 IS 2 MA 447 BP 453 EP 454 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA CA0GM UT WOS:000348595000454 ER PT J AU Swenson, C Sadikot, R AF Swenson, C. Sadikot, R. TI DIFFERENTIAL INDUCTION OF HOST GENES BY ACHROMOBACTER SPECIES SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 26-28, 2015 CL New Orleans, LA SP Amer Federat Med Res C1 [Swenson, C.] Univ Florida, Gainesville, FL USA. [Sadikot, R.] Emory Univ, Atlanta, GA 30322 USA. [Sadikot, R.] US Dept Vet Affairs, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2015 VL 63 IS 2 MA 517 BP 474 EP 474 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA CA0GM UT WOS:000348595000524 ER PT J AU Xu, YX Ashline, D Liu, L Tassa, C Shaw, SY Ravid, K Layne, MD Reinhold, V Robbins, PW AF Xu, Yu-Xin Ashline, David Liu, Li Tassa, Carlos Shaw, Stanley Y. Ravid, Katya Layne, Matthew D. Reinhold, Vernon Robbins, Phillips W. TI The glycosylation-dependent interaction of perlecan core protein with LDL: implications for atherosclerosis SO JOURNAL OF LIPID RESEARCH LA English DT Article DE low density lipoprotein receptor; sialic acid; low density lipoprotein ID LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; RETENTION; RECEPTOR; PROTEOGLYCANS; BINDING; ATHEROGENESIS; ACCUMULATION; MUTANTS; PH AB Perlecan is a major heparan sulfate (HS) proteoglycan in the arterial wall. Previous studies have linked it to atherosclerosis. Perlecan contains a core protein and three HS side chains. Its core protein has five domains (DI-DV) with disparate structures and DII is highly homologous to the ligand-binding portion of LDL receptor (LDLR). The functional significance of this domain has been unknown. Here, we show that perlecan DII interacts with LDL. Importantly, the interaction largely relies on O-linked glycans that are only present in the secreted DII. Among the five repeat units of DII, most of the glycosylation sites are from the second unit, which is highly divergent and rich in serine and threonine, but has no cysteine residues. Interestingly, most of the glycans are capped by the negatively charged sialic acids, which are critical for LDL binding. We further demonstrate an additive effect of HS and DII on LDL binding. Unlike LDLR, which directs LDL uptake through endocytosis, this study uncovers a novel feature of the perlecan LDLR-like DII in receptor-mediated lipoprotein retention, which depends on its glycosylation. Thus, perlecan glycosylation may play a role in the early LDL retention during the development of atherosclerosis. C1 [Xu, Yu-Xin] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Xu, Yu-Xin] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Tassa, Carlos; Shaw, Stanley Y.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Ashline, David; Reinhold, Vernon] Univ New Hampshire, Glyc Ctr, Durham, NH 03824 USA. [Liu, Li; Robbins, Phillips W.] Boston Univ, Henry M Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA. [Ravid, Katya] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Ravid, Katya; Layne, Matthew D.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA. RP Xu, YX (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. EM yxu17@mgh.harvard.edu FU SDG from the American Heart Association [11SDG7670007]; National Institutes of Health/National Heart, Lung, and Blood Institute [HHSN268201000044C] FX This work was supported by SDG Grant 11SDG7670007 from the American Heart Association to Y-X.X., and contract HHSN268201000044C (National Institutes of Health/National Heart, Lung, and Blood Institute) to S.Y.S. NR 47 TC 8 Z9 9 U1 0 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 EI 1539-7262 J9 J LIPID RES JI J. Lipid Res. PD FEB PY 2015 VL 56 IS 2 BP 266 EP 276 DI 10.1194/jlr.M053017 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CA4VR UT WOS:000348905000007 PM 25528754 ER PT J AU Ioannou, GN Van Rooyen, DM Savard, C Haigh, WG Yeh, MM Teoh, NC Farrell, GC AF Ioannou, George N. Van Rooyen, Derrick M. Savard, Christopher Haigh, W. Geoffrey Yeh, Matthew M. Teoh, Narci C. Farrell, Geoffrey C. TI Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH SO JOURNAL OF LIPID RESEARCH LA English DT Article DE crown-like structure; caspase 1; lipotoxicity; nonalcoholic steatohepatitis ID FATTY LIVER-DISEASE; RECEPTOR-DEFICIENT MICE; NONALCOHOLIC STEATOHEPATITIS; NALP3 INFLAMMASOME; DIETARY-CHOLESTEROL; METABOLIC SYNDROME; CONTROLLED-TRIAL; ADIPOCYTE DEATH; ADIPOSE-TISSUE; DIABETIC MICE AB Cholesterol crystals form within hepatocyte lipid droplets in human and experimental nonalcoholic steatohepatitis (NASH) and are the focus of crown-like structures (CLSs) of activated Kupffer cells (KCs). Obese, diabetic Alms1 mutant (foz/foz) mice were a fed high-fat (23%) diet containing 0.2% cholesterol for 16 weeks and then assigned to four intervention groups for 8 weeks: a) vehicle control, b) ezetimibe (5 mg/kg/day), c) atorvastatin (20 mg/kg/day), or d) ezetimibe and atorvastatin. Livers of vehicle-treated mice developed fibrosing NASH with abundant cholesterol crystallization within lipid droplets calculated to extend over 3.3% (SD, 2.2%) of liver surface area. Hepatocyte lipid droplets with prominent cholesterol crystallization were surrounded by TNF-positive (activated) KCs forming CLSs (3 per high-power field). KCs that formed CLSs stained positive for NLRP3, implicating activation of the NLRP3 inflammasome in response to cholesterol crystals. In contrast, foz/foz mice treated with ezetimibe and atorvastatin showed near-complete resolution of cholesterol crystals [0.01% (SD, 0.02%) of surface area] and CLSs (0 per high-power field), with amelioration of fibrotic NASH. Ezetimibe or atorvastatin alone had intermediate effects on cholesterol crystallization, CLSs, and NASH. These findings are consistent with a causative link between exposure of hepatocytes and KCs to cholesterol crystals and with the development of NASH possibly mediated by NLRP3 activation. C1 [Ioannou, George N.; Savard, Christopher; Haigh, W. Geoffrey] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98195 USA. [Van Rooyen, Derrick M.; Teoh, Narci C.; Farrell, Geoffrey C.] Australian Natl Univ, Sch Med, Canberra Hosp, Liver Res Grp, Garran, ACT, Australia. [Yeh, Matthew M.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU Diabetes Research Center, University of Washington FX This work was supported by a grant from the Diabetes Research Center, University of Washington (G.N.I.) and by resources from VAPSHCS Research and Development. NR 41 TC 13 Z9 13 U1 2 U2 8 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 EI 1539-7262 J9 J LIPID RES JI J. Lipid Res. PD FEB PY 2015 VL 56 IS 2 BP 277 EP 285 DI 10.1194/jlr.M053785 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CA4VR UT WOS:000348905000008 PM 25520429 ER PT J AU Burhans, MS Flowers, MT Harrington, KR Bond, LM Guo, CA Anderson, RM Ntambi, JM AF Burhans, Maggie S. Flowers, Matthew T. Harrington, Kristin R. Bond, Laura M. Guo, Chang-An Anderson, Rozalyn M. Ntambi, James M. TI Hepatic oleate regulates adipose tissue lipogenesis and fatty acid oxidation SO JOURNAL OF LIPID RESEARCH LA English DT Article DE -oxidation; de novo lipogenesis; fatty acid; desaturases; fatty acid; metabolism; lipids; liver; triglycerides; white adipose tissue ID STEAROYL-COA DESATURASE-1; DE-NOVO LIPOGENESIS; LIVER-DISEASE; INSULIN-RESISTANCE; PROTECTS MICE; DIACYLGLYCEROL ACYLTRANSFERASE; OBESITY; DEFICIENCY; HUMANS; GENE AB Hepatic steatosis is associated with detrimental metabolic phenotypes including enhanced risk for diabetes. Stearoyl-CoA desaturases (SCDs) catalyze the synthesis of MUFAs. In mice, genetic ablation of SCDs reduces hepatic de novo lipogenesis (DNL) and protects against diet-induced hepatic steatosis and adiposity. To understand the mechanism by which hepatic MUFA production influences adipose tissue stores, we created two liver-specific transgenic mouse models in the SCD1 knockout that express either human SCD5 or mouse SCD3, that synthesize oleate and palmitoleate, respectively. We demonstrate that hepatic de novo synthesized oleate, but not palmitoleate, stimulate hepatic lipid accumulation and adiposity, reversing the protective effect of the global SCD1 knockout under lipogenic conditions. Unexpectedly, the accumulation of hepatic lipid occurred without induction of the hepatic DNL program. Changes in hepatic lipid composition were reflected in plasma and in adipose tissue. Importantly, endogenously synthesized hepatic oleate was associated with suppressed DNL and fatty acid oxidation in white adipose tissue. Regression analysis revealed a strong correlation between adipose tissue lipid fuel utilization and hepatic and adipose tissue lipid storage. These data suggest an extrahepatic mechanism where endogenous hepatic oleate regulates lipid homeostasis in adipose tissues. C1 [Burhans, Maggie S.; Ntambi, James M.] Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA. [Flowers, Matthew T.; Harrington, Kristin R.; Bond, Laura M.; Guo, Chang-An; Ntambi, James M.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA. [Anderson, Rozalyn M.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. [Anderson, Rozalyn M.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. RP Ntambi, JM (reprint author), Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA. EM jmntambi@wisc.edu FU National Institutes of Health (NIH) [R01 DK062388]; ADA [7-13-BS-118]; USDA Hatch [W2005]; NIH [RO1 AG037000, T32 DK007665, T32 GM07215]; American Heart Association FX This work was supported by National Institutes of Health (NIH) Grant R01 DK062388, ADA 7-13-BS-118, and USDA Hatch W2005 (to J.M.N.), and NIH Grant RO1 AG037000 (to R.M.A.). M.S.B was supported by NIH Predoctoral Training Grant T32 DK007665, M.T.F was supported by NIH Postdoctoral Training Grant T32 DK007665 and an American Heart Association postdoctoral fellowship, L.M.B. was supported by NIH National Research Service Award T32 GM07215. NR 47 TC 7 Z9 7 U1 2 U2 15 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 EI 1539-7262 J9 J LIPID RES JI J. Lipid Res. PD FEB PY 2015 VL 56 IS 2 BP 304 EP 318 DI 10.1194/jlr.M054429 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CA4VR UT WOS:000348905000011 PM 25555387 ER PT J AU Bohr, S Patel, SJ Vasko, R Shen, K Iracheta-Vellve, A Lee, J Bale, SS Chakraborty, N Brines, M Cerami, A Berthiaume, F Yarmush, ML AF Bohr, Stefan Patel, Suraj J. Vasko, Radovan Shen, Keyue Iracheta-Vellve, Arvin Lee, Jungwoo Bale, Shyam Sundhar Chakraborty, Nilay Brines, Michael Cerami, Anthony Berthiaume, Francois Yarmush, Martin L. TI Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells SO JOURNAL OF MOLECULAR MEDICINE-JMM LA English DT Article DE ARA290; Oxidative stress; Heat shock; Apoptosis; TNF alpha; Homeostasis; Mesenchymal stem cells ID HEAT-SHOCK RESPONSE; KAPPA-B ACTIVATION; STEM-CELLS; TNF-ALPHA; NITRIC-OXIDE; RECEPTOR; TISSUE; EXPRESSION; ENDOTOXIN; INJURY AB Tissue-protective properties of erythropoietin (EPO) have let to the discovery of an alternative EPO signaling via an EPO-R/CD131 receptor complex which can now be specifically targeted through pharmaceutically designed short sequence peptides such as ARA290. However, little is still known about specific functions of alternative EPO signaling in defined cell populations. In this study, we investigated effects of signaling through EPO-R/CD131 complex on cellular stress responses and pro-inflammatory activation in different mesenchymal-derived phenotypes. We show that anti-apoptotic, anti-inflammatory effects of ARA290 and EPO coincide with the externalization of CD131 receptor component as an immediate response to cellular stress. In addition, alternative EPO signaling strongly modulated transcriptional, translational, or metabolic responses after stressor removal. Specifically, we saw that ARA290 was able to overcome a TNF alpha-mediated inhibition of transcription factor activation related to cell stress responses, most notably of serum response factor (SRF), heat shock transcription factor protein 1 (HSF1), and activator protein 1 (AP1). We conclude that alternative EPO signaling acts as a modulator of pro-inflammatory signaling pathways and likely plays a role in restoring tissue homeostasis. Erythropoietin (EPO) triggers an alternative pathway via heteroreceptor EPO/CD131. ARA290 peptide specifically binds EPO/CD131 but not the canonical EPO/EPO receptor. Oxidative stress and inflammation promote cell surface expression of CD131. ARA290 prevents tumor necrosis factor-mediated inhibition of stress-related genes. Alternative EPO signaling modulates inflammation and promotes tissue homeostasis. C1 [Bohr, Stefan; Patel, Suraj J.; Shen, Keyue; Iracheta-Vellve, Arvin; Lee, Jungwoo; Bale, Shyam Sundhar; Chakraborty, Nilay; Yarmush, Martin L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med,Surg Serv, Boston, MA 02114 USA. [Bohr, Stefan; Patel, Suraj J.; Shen, Keyue; Iracheta-Vellve, Arvin; Lee, Jungwoo; Bale, Shyam Sundhar; Chakraborty, Nilay; Yarmush, Martin L.] Shriners Hosp Children, Boston, MA 02114 USA. [Vasko, Radovan] New York Med Coll, Dept Med, Valhalla, NY 10595 USA. [Brines, Michael; Cerami, Anthony] Araim Pharmaceut, Ossining, NY 10562 USA. [Berthiaume, Francois; Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA. [Bohr, Stefan] UKA Univ Clin RWTH, Burn Ctr, Dept Plast & Hand Surg, D-52074 Aachen, Germany. [Vasko, Radovan] UMG Univ Clin, Dept Nephrol & Rheumatol, D-37075 Gottingen, Germany. RP Yarmush, ML (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med,Surg Serv, 51 Blossom St,4th Floor, Boston, MA 02114 USA. EM fberthia@rci.rutgers.edu; ireis@sbi.org RI Iracheta-Vellve, Arvin/K-6140-2014 OI Iracheta-Vellve, Arvin/0000-0002-6635-3904 FU Shriners Hospitals for Children; National Institutes of Health [P41EB002503, R21AR056446]; Deutsche Forschungs Gemeinschaft [GZ:BO3468/2-1]; Shriners Hospitals for Children postdoctoral fellowship FX The peptides ARA290 and ARA297 were kindly provided by Araim Pharmaceuticals, Inc. (Ossining, NY). This work was partially funded by the Shriners Hospitals for Children and grants from the National Institutes of Health (P41EB002503, R21AR056446). S. Bohr is a receipt of a Deutsche Forschungs Gemeinschaft (GZ:BO3468/2-1). S. J. Patel was supported by a Shriners Hospitals for Children postdoctoral fellowship. NR 34 TC 5 Z9 5 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0946-2716 EI 1432-1440 J9 J MOL MED JI J. Mol. Med. PD FEB PY 2015 VL 93 IS 2 BP 199 EP 210 DI 10.1007/s00109-014-1218-2 PG 12 WC Genetics & Heredity; Medicine, Research & Experimental SC Genetics & Heredity; Research & Experimental Medicine GA CB0BD UT WOS:000349288800009 PM 25373867 ER PT J AU Edds-Walton, PL Arruda, J Fay, RR Ketten, DR AF Edds-Walton, Peggy L. Arruda, Julie Fay, Richard R. Ketten, Darlene R. TI Computerized Tomography of the Otic Capsule and Otoliths in the Oyster Toadfish, Opsanus tau SO JOURNAL OF MORPHOLOGY LA English DT Article DE lagena; neurocranium; saccule; teleost skull; utricle ID SOUND-SOURCE LOCALIZATION; SWIM BLADDER; FISH; PROJECTIONS; AFFERENTS; AUDITION; HEARING; SACCULE; CELLS AB The neurocranium of the toadfish (Opsanus tau) exhibits a distinct translucent region in the otic capsule (OC) that may have functional significance for the auditory pathway. This study used ultrahigh resolution computerized tomography (100 mu m voxels) to compare the relative density of three sites along the OC (dorsolateral, midlateral, and ventromedial) and two reference sites (dorsal: supraoccipital crest; ventral: parasphenoid bone) in the neurocranium. Higher attenuation occurs where structural density is greater; thus, we compared the X-ray attenuations measured, which provided a measure of relative density. The maximum attenuation value was recorded for each of the five sites (x and y) on consecutive sections throughout the OC and for each of the three calcareous otoliths associated with the sensory maculae (lagena, saccule, and utricle) in the OC. All three otoliths had higher attenuations than any sites in the neurocranium. Both dorsal and ventral reference sites (supraoccipital crest and parasphenoid bone, respectively) had attenuation levels consistent with calcified bone and had relatively small, irregular variations along the length of the OC in all individuals. The lowest relative attenuations (lowest densities) occurred consistently at the three sites along the OC. In addition, the lowest attenuations measured along the OC occurred at the ventromedial site around the saccular otolith for all seven fish. The decrease in bone density along the OC is consistent with the hypothesis that there is a low-density channel in the skull to facilitate transmission of acoustic stimuli to the auditory endorgans of the ear. J. Morphol. 276:228-240, 2015. (c) 2014 Wiley Periodicals, Inc. C1 [Edds-Walton, Peggy L.; Arruda, Julie; Ketten, Darlene R.] Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA. [Edds-Walton, Peggy L.; Fay, Richard R.] Marine Biol Lab, Whitman Ctr, Woods Hole, MA 02543 USA. [Arruda, Julie] Massachusetts Eye & Ear Infirm, Dept Radiol, Boston, MA 02114 USA. [Ketten, Darlene R.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Edds-Walton, PL (reprint author), 6864 Rycroft Dr, Riverside, CA 92506 USA. EM seewalton@gmail.com FU Office of Naval Research [N000140811231]; Mellon Foundation; Ocean Life Institute; Summer Research Fellowship: Marine Biological Laboratory FX Grant sponsors: Office of Naval Research (N000140811231), Mellon Foundation, and a Fellowship from the Ocean Life Institute (to D.K.); Summer Research Fellowship: Marine Biological Laboratory (to R.F.). NR 38 TC 2 Z9 2 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0362-2525 EI 1097-4687 J9 J MORPHOL JI J. Morphol. PD FEB PY 2015 VL 276 IS 2 BP 228 EP 240 DI 10.1002/jmor.20336 PG 13 WC Anatomy & Morphology SC Anatomy & Morphology GA AZ9EJ UT WOS:000348514800008 PM 25502869 ER PT J AU Mocco, J Fiorella, D Fargen, KM Albuquerque, F Chen, M Gupta, R Hirsch, JA Linfante, I Mack, W Rai, AT Tarr, RW AF Mocco, J. Fiorella, David Fargen, Kyle M. Albuquerque, Felipe Chen, Michael Gupta, Rishi Hirsch, Joshua A. Linfante, Italo Mack, William Rai, Ansaar T. Tarr, Robert W. TI Endovascular therapy for acute ischemic stroke is indicated and evidence based: a position statement SO JOURNAL OF NEUROINTERVENTIONAL SURGERY LA English DT Editorial Material ID TISSUE-PLASMINOGEN ACTIVATOR; RANDOMIZED CONTROLLED-TRIAL; INTRAVENOUS THROMBOLYSIS; ALTEPLASE; STREPTOKINASE C1 [Mocco, J.] Mt Sinai Med Ctr, Dept Neurosurg, New York, NY 10029 USA. [Fargen, Kyle M.] Univ Florida, Dept Neurosurg, Gainesville, FL USA. [Fiorella, David] SUNY Stony Brook, Dept Neurosurg, Stony Brook, NY 11794 USA. [Albuquerque, Felipe] Barrow Neurol Inst, Div Neurol Surg, Phoenix, AZ 85013 USA. [Chen, Michael] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Gupta, Rishi] Emory Univ, Sch Med, Dept Neurol Sci, Atlanta, GA 30322 USA. [Linfante, Italo] Baptist Cardiac & Vasc Inst, Dept Neurol Sci, Miami, FL USA. [Mack, William] Univ So Calif, Dept Neurosurg, Los Angeles, CA USA. [Rai, Ansaar T.] West Virginia Univ Hosp, Dept Intervent Neuroradiol, Morgantown, WV USA. [Tarr, Robert W.] Univ Hosp Case Med Ctr, Dept Radiol, Cleveland, OH USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, Neuroendovasc Program, Boston, MA 02114 USA. RP Fargen, KM (reprint author), Box 100265, Gainesville, FL 32610 USA. EM kyle.fargen@neurosurgery.ufl.edu NR 22 TC 9 Z9 9 U1 0 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1759-8478 EI 1759-8486 J9 J NEUROINTERV SURG JI J. NeuroInterventional Surg. PD FEB PY 2015 VL 7 IS 2 BP 79 EP 81 DI 10.1136/neurintsurg-2014-011591 PG 3 WC Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA CA1WN UT WOS:000348699800005 PM 25523788 ER PT J AU Gupta, R Rai, AT Hirsch, JA Linfante, I Mack, W Mocco, J Albuquerque, F Chen, M Fiorella, D Tarr, RW AF Gupta, Rishi Rai, Ansaar T. Hirsch, Joshua A. Linfante, Italo Mack, William Mocco, J. Albuquerque, Felipe Chen, Michael Fiorella, David Tarr, Robert W. TI A research roadmap of future endovascular stroke trials SO JOURNAL OF NEUROINTERVENTIONAL SURGERY LA English DT Editorial Material ID ACUTE ISCHEMIC-STROKE; THERAPY; REPERFUSION; OUTCOMES; SCORE AB The recent completion of the MR CLEAN trial(1) and news of early stoppage of other stroke trials demonstrates the ability for the neurointerventional community to address a crucial question that has hindered the ability of intra-arterial therapy (IAT) to be offered more widely. The focus of future studies will now shift towards improving clinical outcomes in patients undergoing IAT. C1 [Gupta, Rishi] Wellstar Med Grp, Dept Neurosurg, Marietta, GA 30060 USA. [Rai, Ansaar T.] West Virginia Univ Hosp, Morgantown, WV USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, NeuroEndovasc Program, Boston, MA 02114 USA. [Linfante, Italo] Baptist Cardiac & Vasc Inst, NeuroEndovasc Program, Miami, FL USA. [Mack, William] Univ So Calif, Dept Neurosurg, Los Angeles, CA USA. [Mocco, J.] Vanderbilt Univ, Dept Neurosurg, Nashville, TN 37235 USA. [Albuquerque, Felipe] Barrow Neurol Inst, Div Neurol Surg, Phoenix, AZ 85013 USA. [Chen, Michael] Rush Univ, Med Ctr, Neurol Sci 8Dept, Chicago, IL 60612 USA. [Fiorella, David] SUNY Stony Brook, Dept Neurosurg, Stony Brook, NY 11794 USA. [Tarr, Robert W.] Univ Hosp Case Med Ctr, Dept Radiol, Cleveland, OH USA. RP Gupta, R (reprint author), Wellstar Med Grp, Neurosurg 61 Whitcher St,Suite 3110, Marietta, GA 30060 USA. EM rishi.gupta@wellstar.org NR 14 TC 1 Z9 1 U1 0 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1759-8478 EI 1759-8486 J9 J NEUROINTERV SURG JI J. NeuroInterventional Surg. PD FEB PY 2015 VL 7 IS 2 BP 82 EP 83 DI 10.1136/neurintsurg-2014-011592 PG 2 WC Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA CA1WN UT WOS:000348699800006 PM 25523787 ER PT J AU Walling, AM Weeks, JC Kahn, KL Tisnado, D Keating, NL Dy, SM Arora, NK Mack, JW Pantoja, PM Malin, JL AF Walling, Anne M. Weeks, Jane C. Kahn, Katherine L. Tisnado, Diana Keating, Nancy L. Dy, Sydney M. Arora, Neeraj K. Mack, Jennifer W. Pantoja, Philip M. Malin, Jennifer L. TI Symptom Prevalence in Lung and Colorectal Cancer Patients SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Cancer; symptoms; prevalence; colorectal neoplasms; lung neoplasms ID LONGITUDINAL FOLLOW-UP; CARE OUTCOMES RESEARCH; PERFORMANCE STATUS; REPORTED OUTCOMES; PALLIATIVE CARE; ONCOLOGY; PAIN; MANAGEMENT; LIFE; INTERVENTIONS AB Context.. Relatively few data are available about symptoms among cancer patients. Objectives. To describe the prevalence and severity of symptoms among a large, representative cohort of newly diagnosed cancer patients. Methods. We collected survey data about symptoms (pain, fatigue, depression, nausea/vomiting, cough, dyspnea, and diarrhea) from 5422 patients with incident lung and colorectal cancer from the diverse, nationally representative Cancer Care Outcomes Research and Surveillance Consortium cohort. We described the prevalence of any symptoms and moderate/severe symptoms approximately four to six months after diagnosis. We used logistic regression to identify patient and clinical characteristics associated with symptoms, and calculated adjusted proportions of patients with symptoms. Results. In total, 5067 (93.5%) patients reported at least one symptom in the four weeks before their survey, with 51% reporting at least one moderate/severe symptom. Lung cancer patients reported more symptoms than colorectal cancer patients. Patients who received treatment or had more comorbidities were more likely to report symptoms. For example, after adjustment, patients who received chemotherapy during the six weeks before the survey were more likely than others to report at least one symptom (97.3% vs. 90.8%, P < 0.001), and at least one moderate/severe symptom (56.8% vs. 46.2%, P < 0.001). After adjustment, early-vs. late-stage patients did not differ in reports of at least one symptom (93.6% vs. 93.4%, P = 0.853) and differed only slightly in reports of at least one moderate/severe symptom (53.3% vs. 49.6%, P = 0.009). Conclusion. Most recently diagnosed lung and colorectal cancer patients have cancer-related symptoms regardless of stage, and more than half have at least one moderate/severe symptom. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine. C1 [Walling, Anne M.; Kahn, Katherine L.; Tisnado, Diana] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90024 USA. [Walling, Anne M.; Kahn, Katherine L.; Tisnado, Diana] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Walling, Anne M.; Tisnado, Diana; Pantoja, Philip M.; Malin, Jennifer L.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Walling, Anne M.; Kahn, Katherine L.] RAND Hlth, Santa Monica, CA USA. [Keating, Nancy L.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA. [Keating, Nancy L.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Weeks, Jane C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Weeks, Jane C.] Harvard Univ, Sch Med, Dept Hlth Policy & Management, Boston, MA USA. [Weeks, Jane C.; Mack, Jennifer W.] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA. [Dy, Sydney M.] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA. [Arora, Neeraj K.] NCI, Div Canc Control & Populat Sci, Rockville, MD USA. RP Walling, AM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, 911 Broxton Plaza, Los Angeles, CA 90024 USA. EM awalling@mednet.ucla.edu FU NCATS NIH HHS [U54 TR000123, UL1 TR000124, UL1TR000123]; NCI NIH HHS [U01 CA093348, R01 CA164021, R011CA164021-01A1, U01 CA093324, U01 CA093326, U01 CA093329, U01 CA093332, U01 CA093339, U01 CA093344]; NIA NIH HHS [L30 AG030993] NR 50 TC 11 Z9 11 U1 2 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 BP 192 EP 202 DI 10.1016/j.jpainsymman.2014.06.003 PG 11 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200004 PM 24973624 ER PT J AU Kamal, AH Nipp, RD Bull, JH Stinson, CS Lowery, AW Nicolla, JM Abernethy, AP AF Kamal, Arif H. Nipp, Ryan D. Bull, Janet H. Stinson, Charles S. Lowery, Ashlei W. Nicolla, Jonathan M. Abernethy, Amy P. TI Quality of Palliative Care for Patients With Advanced Cancer in a Community Consortium SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Oncology; quality; symptoms; performance status; palliative care ID HOSPICE; IMPROVEMENT AB Background. Measuring quality of care delivery is essential to palliative care program growth and sustainability. We formed the Carolinas Consortium for Palliative Care and collected a quality data registry to monitor our practice and inform quality improvement efforts. Measures. We analyzed all palliative care consultations in patients with cancer in our quality registry from March 2008 through October 2011 using 18 palliative care quality measures. Descriptive metric adherence was calculated after analyzing the relevant population for measurement. Intervention. We used a paper-based, prospective method to monitor adherence for quality measures in a community-based palliative care consortium. Outcomes. We demonstrate that measures evaluating process assessment (range 63%-100%), as opposed to interventions (range 3%-17%), are better documented. Conclusions/Lessons Learned. Analyzing data on quality is feasible and valuable in community-based palliative care. Overall, processes to collect data on quality using nontechnology methods may underestimate true adherence to quality measures. (C) 2015 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Kamal, Arif H.; Nicolla, Jonathan M.; Abernethy, Amy P.] Duke Univ, Med Ctr, Duke Ctr Learning Hlth Care, Durham, NC 27710 USA. [Kamal, Arif H.; Abernethy, Amy P.] Duke Univ, Med Ctr, Div Med Oncol, Durham, NC 27710 USA. [Kamal, Arif H.; Abernethy, Amy P.] Duke Univ, Med Ctr, Ctr Palliat Care, Durham, NC 27710 USA. [Kamal, Arif H.; Abernethy, Amy P.] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC 27710 USA. [Nipp, Ryan D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bull, Janet H.] Four Seasons, Flat Rock, NC USA. [Stinson, Charles S.] Forsyth Med Ctr Palliat Care Serv, Winston Salem, NC USA. [Lowery, Ashlei W.] Capital Caring, Falls Church, VA USA. RP Kamal, AH (reprint author), Duke Univ, Med Ctr, Box 3436, Durham, NC 27710 USA. EM Arif.kamal@duke.edu FU AHRQ HHS [R18 HS022763]; NINR NIH HHS [U24 NR 014637-02, U24 NR014637] NR 10 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 BP 289 EP 292 DI 10.1016/j.jpainsymman.2014.05.024 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200014 PM 25220048 ER PT J AU Kvale, E Bailey, AA Dionne-Odom, J Redden, D Burgio, A AF Kvale, Elizabeth Bailey, Al F. Amos Dionne-Odom, James Redden, David Burgio, Al Kathryn TI Predictors of Physical Restraint Use in Hospitalized Veterans at End of Life in the Acute Care Setting: An Analysis of Data from the BEACON Trial SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Kvale, Elizabeth; Burgio, Al Kathryn] Birmingham VAMC, Birmingham, AL USA. [Bailey, Al F. Amos] Birmingham VAMC, Denver, CO USA. [Dionne-Odom, James; Redden, David] Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA TH318-C BP 341 EP 342 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200031 ER PT J AU Ullrich, C Rodday, AM Parsons, S AF Ullrich, Christina Rodday, Angie Mae Parsons, Susan TI Parent Outlook Regarding Their Child's Potential Health Outcomes During the Hematopoietic Stem Cell Transplant (HSCT) Course SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Ullrich, Christina] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rodday, Angie Mae] Tufts Med Ctr, Boston, MA USA. [Parsons, Susan] Tufts Univ, Sch Med, Boston, MA 02111 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA TH346-D BP 350 EP 351 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200050 ER PT J AU Kapo, J Carey, E Periyakoil, V Thomas, JD Morrison, L AF Kapo, Jennifer Carey, Elise Periyakoil, Vyjeyanthi Thomas, Jane deLima Morrison, Laura TI Training Fellows to Be Leaders: Ensuring the Future of Palliative Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Kapo, Jennifer] Yale Univ, Bethany, CT USA. [Carey, Elise] Mayo Clin, Rochester, MN USA. [Periyakoil, Vyjeyanthi] Stanford Univ, Palo Alto, CA 94304 USA. [Thomas, Jane deLima] Dana Farber Canc Inst, Boston, MA 02115 USA. [Morrison, Laura] Yale Univ, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA FR401 BP 354 EP 354 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200057 ER PT J AU Claxton, R Kamal, A Bernacki, R O'Donnell, A Stahl, D AF Claxton, Rene Kamal, Arif Bernacki, Rachelle O'Donnell, Arden Stahl, Denise TI Putting the "I'' back in "QI'' - Teaching Lifelong Skills in Clinician-Directed Quality Improvement SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Claxton, Rene] Univ Pittsburgh, Pittsburgh, PA USA. [Kamal, Arif] Duke Canc Inst, Durham, NC USA. [Bernacki, Rachelle] Dana Farber Canc Inst, Boston, MA 02115 USA. [O'Donnell, Arden] Boston Childrens Hosp, Boston, MA USA. [Stahl, Denise] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA FR432 BP 364 EP 365 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200078 ER PT J AU Walling, A Mack, J Malin, J Dy, S Tisnado, D AF Walling, Anne Mack, Jennifer Malin, Jennifer Dy, Sydney Tisnado, Diana TI Lower Patient Ratings of Physician Communication Are Associated with Greater Unmet Need for Symptom Management in Lung and Colorectal Cancer Patients SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Walling, Anne] Univ Calif Los Angeles, Studio City, CA USA. [Mack, Jennifer] Dana Farber Canc Inst, Boston, MA 02115 USA. [Malin, Jennifer] WellPoint Inc, Santa Monica, CA USA. [Dy, Sydney] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA. [Tisnado, Diana] Calif State Univ Fullerton, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA FR435-C BP 367 EP 367 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200083 ER PT J AU Cooke, K Franklin, J AF Cooke, Kelly Franklin, John TI Paying Homage to Unsung Heroes: Understanding and Honoring Military Service at the End of Life SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Cooke, Kelly] Prohlth Care, Eagle, WI USA. [Franklin, John] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA FR453 BP 373 EP 373 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200094 ER PT J AU Gafford, EF Schaefer, K O'Donnell, A Cooper, S Wissman, S AF Gafford, Ellin Frair Schaefer, Kristen O'Donnell, Arden Cooper, Stephanie Wissman, Sherri TI The LVADs Are Coming, the LVADs Are Coming! The Anticipated Growth of LVAD Use and the Role of the Hospice and Palliative Medicine Specialist in LVAD Patient Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Gafford, Ellin Frair; Wissman, Sherri] Ohio State Univ, Columbus, OH 43210 USA. [Schaefer, Kristen] Dana Farber Canc Inst, Boston, MA 02115 USA. [O'Donnell, Arden] Brigham & Womens Hosp, Boston, MA 02115 USA. [Cooper, Stephanie] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA FR461 BP 378 EP 378 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200104 ER PT J AU Vig, E Wocial, L AF Vig, Elizabeth Wocial, Lucia TI Recognizing and Responding to Moral Distress SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Vig, Elizabeth] Univ Washington, Mercer Isl, WA USA. [Vig, Elizabeth] VA Puget Sound Hlth Care Syst, Mercer Isl, WA USA. [Wocial, Lucia] Indiana Univ, Indianapolis, IN 46204 USA. [Wocial, Lucia] Fairbanks Ctr Med Eth, Indianapolis, IN USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA FR463 BP 378 EP 379 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200106 ER PT J AU Jacobsen, J Thomas, JD Jackson, V AF Jacobsen, Juliet Thomas, Jane deLima Jackson, Vicki TI Pilot to Design an Observed Structured Clinical Examination (OSCE) for the Communication Skill of Cultivating Prognostic Awareness SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Jacobsen, Juliet] Harvard Palliat Med Fellowship, Boston, MA USA. [Thomas, Jane deLima; Jackson, Vicki] Dana Farber Canc Inst, Boston, MA 02115 USA. [Thomas, Jane deLima; Jackson, Vicki] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA FR469-D BP 386 EP 386 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200119 ER PT J AU Marks, A Nabati, L Blinderman, C AF Marks, Adam Nabati, Lida Blinderman, Craig TI Policies and Procedures of Pacemaker Deactivation: Opportunities and Pitfalls SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Marks, Adam] Univ Michigan, Ann Arbor, MI 48109 USA. [Nabati, Lida] Dana Farber Canc Inst, Boston, MA 02115 USA. [Blinderman, Craig] Columbia Univ, New York Presbyterian Hosp, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA SA515 BP 392 EP 393 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200134 ER PT J AU Jacobsen, J Greer, J Jackson, V AF Jacobsen, Juliet Greer, Joseph Jackson, Vicki TI How to Help Patients Make Value-Based Medical Decisions: Promoting Adaptive Coing and Prognostic Awareness SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Jacobsen, Juliet; Greer, Joseph] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Jackson, Vicki] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA SA543 BP 403 EP 403 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200154 ER PT J AU Bernacki, R Paladino, J Neville, B Block, S AF Bernacki, Rachelle Paladino, Joanna Neville, Bridget Block, Susan TI Novel Tool Reveals Varied Life Priorities of Advanced Cancer Patients: "Living as Long as Possible" Generally Not a Top Priority SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Bernacki, Rachelle; Paladino, Joanna] Dana Farber Canc Inst, Boston, MA USA. [Bernacki, Rachelle] Brigham & Womens Hosp, Boston, MA 02115 USA. [Bernacki, Rachelle] Ariadne Labs, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S708 BP 411 EP 411 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200168 ER PT J AU Gilbert, A Dubeansky, D Garrido, M Howe, J Chang, V AF Gilbert, Amanda Dubeansky, Debbie Garrido, Melissa Howe, Judith Chang, Victor TI Palliative Social Work Services for Hepatocellular Cancer Patients at a VA Medical Center SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Gilbert, Amanda] James J Peters VAMC, New York, NY USA. [Dubeansky, Debbie; Garrido, Melissa; Howe, Judith] James J Peters VAMC, Bronx, NY USA. [Garrido, Melissa; Howe, Judith] Icahn Sch Med, Bronx, NY USA. [Chang, Victor] New Jersey Hlth Care Syst, E Orange, NJ USA. [Chang, Victor] Rutgers NJMS, E Orange, NJ USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S717 BP 415 EP 416 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200177 ER PT J AU Goebel, J Guo, W Chong, K AF Goebel, Joy Guo, William Chong, Kelly TI A Team of Experts or an Expert Team: Interdisciplinary Teamwork and Perceptions of Palliative Care Quality SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Goebel, Joy] Calif State Univ Long Beach, Long Beach, CA 90840 USA. [Guo, William] Master Quick Bridge Funding, Walnut, CA USA. [Chong, Kelly] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S742 BP 429 EP 429 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200201 ER PT J AU Hagiwara, Y Ross, J Aagaard, H Lee, S Sanchez-Reilly, S AF Hagiwara, Yuya Ross, Jeanette Aagaard, Hannah Lee, Shuko Sanchez-Reilly, Sandra TI As Real as It Gets: Enhancing Medical Student's Palliative Communication Skills Through Standardized Family Meetings with Onsite-Feedback SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Hagiwara, Yuya; Ross, Jeanette; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Ross, Jeanette; Sanchez-Reilly, Sandra] GEC GRECC South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Aagaard, Hannah; Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. High Sch Student South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S743 BP 429 EP 430 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200202 ER PT J AU Azuero, C Huang, CH Bae, S Kvale, E Ritchie, C AF Azuero, Casey Huang, Chao-Hui Bae, Sejong Kvale, Elizabeth Ritchie, Christine TI Concordance Between Structured and Unstructured Debriefing on Symptom Burden in Breast Cancer: A Mixed Methods Analysis SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Azuero, Casey; Bae, Sejong] Univ Alabama Birmingham, Birmingham, AL USA. [Huang, Chao-Hui] Univ Alabama, Tuscaloosa, AL USA. [Kvale, Elizabeth] Birmingham VAMC, Birmingham, AL USA. [Ritchie, Christine] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S755 BP 436 EP 436 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200214 ER PT J AU Mireles, C Ross, J Lee, S Noble, S Healy, A AF Mireles, Christina Ross, Jeanette Lee, Shuko Noble, Sara Healy, Amanda TI Facebook as a Resource for Caregivers of Hospice Patients SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Mireles, Christina; Ross, Jeanette; Noble, Sara] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S769 BP 443 EP 443 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200227 ER PT J AU Paladino, J Bernacki, R Billings, J Block, S AF Paladino, Joanna Bernacki, Rachelle Billings, J. Block, Susan TI Triggering Advance Care Planning Conversations in Oncology and Identifying Barriers to These Discussions SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Paladino, Joanna] Dana Farber Canc Inst, Brookline, MA USA. [Paladino, Joanna] Ariadne Labs, Brookline, MA USA. [Bernacki, Rachelle; Block, Susan] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bernacki, Rachelle; Block, Susan] Ariadne Labs, Boston, MA USA. [Bernacki, Rachelle; Block, Susan] Brigham & Womens Hosp, Boston, MA 02115 USA. [Billings, J.] Ariadne Labs, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S774 BP 445 EP 446 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200232 ER PT J AU Rodin, D Balboni, M Smith, P Vanderweele, T Balboni, T AF Rodin, Danielle Balboni, Michael Smith, Patrick Vanderweele, Tyler Balboni, Tracy TI Whose Role? Oncology Practitioners' Perceptions of Their Role in Providing Spiritual Care to Advanced Cancer Patients SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Rodin, Danielle] Univ Toronto, Toronto, ON, Canada. [Balboni, Michael] Dana Farber Canc Inst, Boston, MA 02115 USA. [Smith, Patrick] Harvard Univ, Sch Med, South Hamilton, MA USA. [Vanderweele, Tyler] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Balboni, Tracy] Dept Radiat Oncol, Roxbury Crossing, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S784 BP 451 EP 451 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200242 ER PT J AU Espada, M Schaefer, K Bernacki, R AF Espada, Maya Schaefer, Kristen Bernacki, Rachelle TI Experience is the Teacher of All Things: Educational Outcomes of Home Hospice Visits SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Espada, Maya; Bernacki, Rachelle] Dana Farber Canc Inst, Boston, MA 02115 USA. [Schaefer, Kristen] DFCI Brigham & Womens Hosp, Brookline, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S787 BP 452 EP 453 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200245 ER PT J AU Singer, A Kim, Y Goebel, J Ahluwalia, S Lapham, C AF Singer, Adam Kim, Yan Goebel, Joy Ahluwalia, Sangeeta Lapham, Carrie TI A Systematic Review of Palliative Interventions: Populations, Intervention Components, and Healthcare Use and Cost SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Singer, Adam] RAND Corp, Santa Monica, CA USA. [Kim, Yan] Kaiser Permanente No Calif, Millbrae, CA USA. [Goebel, Joy] Calif State Univ Long Beach, Long Beach, CA 90840 USA. [Ahluwalia, Sangeeta] Oregon State Univ, Corvallis, OR 97331 USA. [Lapham, Carrie] VA Greater Los Angeles Healthcare Syst, La Crosse, WI USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S790 BP 454 EP 455 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200248 ER PT J AU Wachterman, M Ersek, M Gilbert, D Keating, N AF Wachterman, Melissa Ersek, Mary Gilbert, Dawn Keating, Nancy TI Quality of End-of-Life Care Provided to Patients with Different Life-Limiting Conditions in the Veterans Health Administration SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Wachterman, Melissa] VA Boston Healthcare Syst, Brookline, MA USA. [Ersek, Mary] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Gilbert, Dawn] Philadelphia VA Med Ctr, Bellmawr, NJ USA. [Keating, Nancy] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S797 BP 458 EP 458 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200255 ER PT J AU Delgado-Borrego, A Gonzalez-Peralta, RP Raza, R Negre, B Goodman, ZD Jonas, MM Chung, RT Ludwig, DA AF Delgado-Borrego, Aymin Gonzalez-Peralta, Regino P. Raza, Roshan Negre, Betania Goodman, Zachary D. Jonas, Maureen M. Chung, Raymond T. Ludwig, David A. CA PEDS-C Clinical Res Network TI Correlates of Adiponectin in Hepatitis C-Infected Children: The Importance of Body Mass Index SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION LA English DT Article DE adiponectin; body mass index; hepatitis C; pediatric ID INSULIN-RESISTANCE; VIRUS-INFECTION; CARDIOVASCULAR-DISEASE; INDEPENDENT PREDICTOR; VIRAL-INFECTION; HEART-DISEASE; UNITED-STATES; LIVER; STEATOSIS; PROGRESSION AB Objectives: Adiponectin is a regulator of cytokines that, in turn, play a vital role in inflammatory and immune responses. Adiponectin is therefore likely to have a contributory role in hepatitis C virus (HCV) infection. We sought to characterize adiponectin levels and examine correlates in a pediatric HCV-infected cohort. Methods: We performed a cross-sectional study in children (5-17 years of age, n = 86) in the Pediatric Study of Hepatitis C (PEDS-C) trial. Adiponectin levels were univariately correlated with patient demographics, anthropometrics, and viral and histological measures. Multivariate regression models were used to identify the unique (ie, nonconfounded) associations with adiponectin concentrations. Results: Body mass index (BMI) had the highest univariate inverse correlation with log(e) adiponectin (r = -0.5, P < 0.0001). In multivariate analysis, BMI remained inversely correlated with loge adiponectin after accounting for age and route of HCV transmission (r = -0.38, P = 0.0003). Steatosis and fibrosis were inversely related to loge adiponectin in univariate analysis, but these associations were not statistically significant after multivariate adjustments (P >= 0.1827). Conclusions: High BMI among HCV-infected children is associated with lower adiponectin levels. Practitioners should be cognizant of the possible risks of low adiponectin when managing HCV-infected children who are overweight. Further studies are indicated to determine the impact of having low adiponectin on HCV infection in youth. C1 [Delgado-Borrego, Aymin; Negre, Betania; Ludwig, David A.] Univ Miami, Miller Sch Med, Batchelor Childrens Res Inst, Dept Pediat, Miami, FL 33136 USA. [Raza, Roshan; Jonas, Maureen M.] Harvard Univ, Boston Childrens Hosp, Div Gastroenterol, Boston, MA USA. [Chung, Raymond T.] Harvard Univ, Massachusetts Gen Hosp, Dept Med, Gastrointestinal Unit,Med Sch, Boston, MA USA. [Gonzalez-Peralta, Regino P.] Univ Florida, Coll Med, Div Pediat Gastroenterol Hepatol & Nutr, Gainesville, FL USA. [Goodman, Zachary D.] Armed Forces Inst Pathol, Washington, DC 20306 USA. RP Delgado-Borrego, A (reprint author), Univ Miami, Miller Sch Med, Batchelor Childrens Res Inst, 1580 NW 10th Ave,Room 523, Miami, FL 33136 USA. EM adelgado@kidzmedical.com FU Robert Wood Johnson Foundation; NIH [K08 DK070022]; NIH DK [078772]; National Institute of Diabetes and Digestive and Kidney Diseases [1UO1DK067767-01.CRC]; Food and Drug Administration [1UO1DK067767-01.CRC]; National Institutes of Health/National Center for Research Resources, Colorado CTSI [UL1 RR025780]; Children's Hospital, Aurora, CO [M01-RR-00069]; Children's Hospital Boston, Boston, MA [M01-RR-02172]; University of California, San Francisco [M01-RR-01271]; Children's National Medical Center, Washington, DC [5-M01-RR-020359-01]; Columbia University Medical Center, New York, NY [M01-RR-00645]; University of Florida, Gainesville [M01-RR-00082]; University of Washington, Seattle, WA [M01-RR-00037]; Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia [5-M01-RR-000240]; Johns Hopkins Medical Center, Baltimore, MD [U01-DK-067767-02]; University of Cincinnati, Cincinnati, OH [M01-RR-08084]; Indiana University, Indianapolis [M01-RR-00750] FX The present work was supported by the Robert Wood Johnson Foundation (A.D.B.), NIH K08 DK070022 (A.D.B.), and NIH DK 078772 (R.T.C.). It was also supported by a cooperative agreement between the National Institute of Diabetes and Digestive and Kidney Diseases and the Food and Drug Administration (contract no. 1UO1DK067767-01.CRC) and in part by National Institutes of Health/National Center for Research Resources, Colorado CTSI grant no. UL1 RR025780 and the following study sites: M01-RR-00069, Children's Hospital, Aurora, CO; M01-RR-02172, Children's Hospital Boston, Boston, MA; M01-RR-01271, University of California, San Francisco; 5-M01-RR-020359-01, Children's National Medical Center, Washington, DC; M01-RR-00645, Columbia University Medical Center, New York, NY; M01-RR-00082, University of Florida, Gainesville; M01-RR-00037, University of Washington, Seattle, WA; 5-M01-RR-000240, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia; U01-DK-067767-02, Johns Hopkins Medical Center, Baltimore, MD; M01-RR-08084, University of Cincinnati, Cincinnati, OH; and M01-RR-00750, Indiana University, Indianapolis. NR 50 TC 1 Z9 1 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0277-2116 EI 1536-4801 J9 J PEDIATR GASTR NUTR JI J. Pediatr. Gastroenterol. Nutr. PD FEB PY 2015 VL 60 IS 2 BP 165 EP 170 DI 10.1097/MPG.0000000000000604 PG 6 WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics GA CB0MW UT WOS:000349321400007 PM 25313851 ER PT J AU Cheng, ER Cohen, A Goodman, E AF Cheng, Erika R. Cohen, Alyssa Goodman, Elizabeth TI The Role of Perceived Discrimination during Childhood and Adolescence in Understanding Racial and Socioeconomic Influences on Depression in Young Adulthood SO JOURNAL OF PEDIATRICS LA English DT Article ID AFRICAN-AMERICAN ADOLESCENTS; PSYCHIATRIC-DISORDER; HEALTH RESEARCH; SYMPTOMS; POPULATION; PREVALENCE; ASSOCIATIONS; DISPARITIES; CHILDREN; EPIDEMIOLOGY AB Objective To describe levels of perceived lifetime discrimination among young adults and determine its role in understanding this racial/ethnic disparity. Study design Data were from the Princeton School District study, a 10-year cohort study in which investigators followed 545 non-Hispanic black (46%) and white initial 5-12 graders. Perceived lifetime racial discrimination was assessed with the General Ethnic Discrimination Scale and depressive symptoms with the Center for Epidemiological Studies Depression Scale. Stepped linear and logistic regression analyses assessed the relationships of race/ethnicity, parental education, and quintiles of discrimination to depressive symptoms. Stratification by race/ethnicity explored differences in the role of discrimination in explaining the relationship between parental education and depressive symptoms. Results Black students from professionally educated families had the greatest discrimination scores, 1.8 times greater than among their white peers (mean(black) = 42.1 vs mean(white) = 22.8; P < .0001). Greater parental education was associated with lower depressive symptoms in all regression models. Race/ethnicity became predictive of depressive symptoms only after adjusting for discrimination, which was strongly associated with depressive symptoms. Stratified analysis suggested discrimination accounted for the relationship of parental education to depressive symptoms among whites. Among black subjects, accounting for discrimination unmasked a buffering effect of parental education. Conclusions Greater levels of parent education are protective against depression for white youth. However, for black youth, greater parent education confers both risk and protective effects. The high discrimination among black youth from families with college or professionally educated parents overwhelms the protective effect of greater levels of parent education. C1 [Cheng, Erika R.; Goodman, Elizabeth] MassGen Hosp Children, Ctr Child & Adolescent Hlth Res & Policy, Div Gen Acad Pediat, Boston, MA 02114 USA. [Cheng, Erika R.; Goodman, Elizabeth] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Cohen, Alyssa] Univ Rochester, Sch Med & Dent, Rochester, NY USA. RP Goodman, E (reprint author), MassGen Hosp Children, Ctr Child & Adolescent Hlth Res & Policy, Div Gen Acad Pediat, 100 Cambridge St, Boston, MA 02114 USA. EM egoodman3@mgh.harvard.edu FU National Institutes of Health [HD041527, DK59183, T35-HD07446]; National Research Services Award [T32-HD075727]; William T. Grant Foundation [2151] FX Supported by the National Institutes of Health (HD041527, DK59183, and T35-HD07446), a National Research Services Award (T32-HD075727), and the William T. Grant Foundation (2151). The authors declare no conflicts of interest. NR 44 TC 2 Z9 2 U1 3 U2 21 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD FEB PY 2015 VL 166 IS 2 BP 370 EP + DI 10.1016/j.jpeds.2014.10.010 PG 9 WC Pediatrics SC Pediatrics GA AZ8XY UT WOS:000348496200036 PM 25454941 ER PT J AU Loke, W Girvan, T Ingmundson, P Verrett, R Schoolfield, J Mealey, BL AF Loke, Weiqiang Girvan, Thomas Ingmundson, Paul Verrett, Ronald Schoolfield, John Mealey, Brian L. TI Investigating the Association Between Obstructive Sleep Apnea and Periodontitis SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE Chronic periodontitis; sleep apnea; obstructive ID C-REACTIVE PROTEIN; BREATHING DISORDERS; ADULTS; INFLAMMATION; PREVALENCE; MECHANISMS; DISEASE; STATES; CARE AB Background: Obstructive sleep apnea (OSA) is a sleep disorder characterized by disruptions of normal sleep architecture. Chronic periodontitis is a chronic disease of the periodontium that elicits a general inflammatory response to local dental plaque. It has been suggested that periodontal disease may increase in severity with increasingly severe OSA because both disease entities share common inflammatory pathways, acting synergistically to alter the host response. The aim of this study is to analyze the association between severity of OSA and the prevalence/severity of periodontitis. Methods: One hundred patients from a large veterans administration sleep study center (n = 26 normal, n = 21 mild, n = 19 moderate, n = 34 severe) diagnosed with an overnight polysomnogram underwent a comprehensive periodontal examination. Periodontal parameters measured included the following: 1) mean periodontal probing depth (PD); 2) clinical attachment level (CAL); 3) gingival recession; and 4) percentage of sites with bleeding on probing, plaque, PD >= 5 mm, and CAL >= 3 mm. Results: Seventy-three percent of the sampled population had moderate/severe periodontal disease. chi(2) analyses revealed no significant differences in the prevalence of periodontal disease between the apnea-hypopnea index (AHI) groups, with a negligible Spearman correlation coefficient of 0.246 between AHI severity and periodontal disease severity categories. Analysis of covariance indicated a significant association between AHI severity categories and percentage of sites with plaque, after adjusting for age. Multivariable logistic regression analysis predicting moderate/severe periodontitis with AHI score, age, and smoking status indicated a significant association with age (P = 0.028) but no significant association with the other two predictors. Conclusion: OSA was not significantly associated with the prevalence of moderate/severe periodontitis and the periodontal parameters examined, except percentage plaque. C1 [Loke, Weiqiang; Schoolfield, John; Mealey, Brian L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA. [Girvan, Thomas] Vet Adm Facil, South Texas Vet Hlth Care Syst, Sleep Clin, San Antonio, TX USA. [Ingmundson, Paul] Vet Adm Facil, South Texas Vet Hlth Care Syst, Dent Clin, San Antonio, TX USA. [Verrett, Ronald] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. RP Mealey, BL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, MSC 7894,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM mealey@uthscsa.edu NR 33 TC 3 Z9 4 U1 0 U2 2 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 EI 1943-3670 J9 J PERIODONTOL JI J. Periodont. PD FEB PY 2015 VL 86 IS 2 BP 232 EP 243 DI 10.1902/jop.2014.140229 PG 12 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA CB1IK UT WOS:000349380500009 PM 25299385 ER PT J AU Traverso, G Schoellhammer, CM Schroeder, A Maa, R Lauwers, GY Polat, BE Anderson, DG Blankschtein, D Langer, R AF Traverso, Giovanni Schoellhammer, Carl M. Schroeder, Avi Maa, Ruby Lauwers, Gregory Y. Polat, Baris E. Anderson, Daniel G. Blankschtein, Daniel Langer, Robert TI Microneedles for Drug Delivery via the Gastrointestinal Tract SO JOURNAL OF PHARMACEUTICAL SCIENCES LA English DT Article DE mucosal drug delivery; gastrointestinal; macromolecular drug delivery; oral drug delivery; membrane transport; microneedles; pill; drug delivery systems ID INGESTED FOREIGN-BODIES; TRANSDERMAL DELIVERY; IN-VIVO; INSULIN; MANAGEMENT; TRANSIT; PIGS AB Both patients and physicians prefer the oral route of drug delivery. The gastrointestinal (GI) tract, though, limits the bioavailability of certain therapeutics because of its protease and bacteria-rich environment as well as general pH variability from pH 1 to 7. These extreme environments make oral delivery particularly challenging for the biologic class of therapeutics. Here, we demonstrate proof-of-concept experiments in swine that microneedle-based delivery has the capacity for improved bioavailability of a biologically active macromolecule. Moreover, we show that microneedle-containing devices can be passed and excreted from the GI tract safely. These findings strongly support the success of implementation of microneedle technology for use in the GI tract. (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:362-367, 2015 C1 [Traverso, Giovanni] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gastroenterol, Boston, MA USA. [Traverso, Giovanni; Schoellhammer, Carl M.; Maa, Ruby; Polat, Baris E.; Anderson, Daniel G.; Blankschtein, Daniel; Langer, Robert] MIT, Dept Chem Engn, Cambridge, MA 02139 USA. [Traverso, Giovanni; Schoellhammer, Carl M.; Schroeder, Avi; Polat, Baris E.; Anderson, Daniel G.; Langer, Robert] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Schroeder, Avi] Technion Israel Inst Technol, Dept Chem Engn, IL-32000 Haifa, Israel. [Lauwers, Gregory Y.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Anderson, Daniel G.; Langer, Robert] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA. [Anderson, Daniel G.; Langer, Robert] MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Anderson, DG (reprint author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA. EM dgander@mit.edu; dblank@mit.edu; rlanger@mit.edu OI Schoellhammer, Carl/0000-0001-6694-6761; Schroeder, Avi/0000-0003-2571-5937 FU NIH [EB000244, T32DK7191-38-S1, CA014051] FX This work was funded in part by NIH grant EB000244 (to R.L.), NIH grant T32DK7191-38-S1 (to G.T.), and NIH grant CA014051 for the Hope Babette Tang (1983) Histology Facility. We would like to thank Pentax for providing the endoscopic equipment used for this research, and in particular Mr. Mike Fina for facilitating access to the equipment. We also thank Monica Siddalls and Robert Marini for their excellent veterinary support as well as Andrew Ryan from the MIT Central Machine Shop for his assistance in assembling prototypes. We dedicate this paper to the memory of Officer Sean Collier, for his caring service to the MIT community and for his sacrifice. NR 20 TC 11 Z9 12 U1 8 U2 59 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3549 EI 1520-6017 J9 J PHARM SCI-US JI J. Pharm. Sci. PD FEB PY 2015 VL 104 IS 2 SI SI BP 362 EP 367 DI 10.1002/jps.24182 PG 6 WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy SC Pharmacology & Pharmacy; Chemistry GA CA7HX UT WOS:000349089500008 PM 25250829 ER PT J AU Akiba, Y Inoue, T Kaji, I Higashiyama, M Narimatsu, K Iwamoto, K Watanabe, M Guth, PH Engel, E Kuwahara, A Kaunitz, JD AF Akiba, Yasutada Inoue, Takuya Kaji, Izumi Higashiyama, Masaaki Narimatsu, Kazuyuki Iwamoto, Ken-ichi Watanabe, Masahiko Guth, Paul H. Engel, Eli Kuwahara, Atsukazu Kaunitz, Jonathan D. TI Short-chain fatty acid sensing in rat duodenum SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID GLUCAGON-LIKE PEPTIDE-2; ENTEROENDOCRINE CELLS; FUNCTIONAL DYSPEPSIA; BICARBONATE SECRETION; HEALTHY-SUBJECTS; GASTROINTESTINAL-TRACT; BACTERIAL OVERGROWTH; MOUSE INTESTINE; ENTERIC NEURONS; RECEPTOR GPR40 AB Key points Luminal lipid in the duodenum modulates gastroduodenal functions via the release of gut hormones and mediators such as cholecystokinin and 5-HT. The effects of luminal short-chain fatty acids (SCFAs) in the foregut are unknown. Free fatty acid receptors (FFARs) for long-chain fatty acids (LCFAs) and SCFAs are expressed in enteroendocrine cells. SCFA receptors, termed FFA2 and FFA3, are expressed in duodenal enterochromaffin cells and L cells, respectively. Activation of LCFA receptor (FFA1) and presumed FFA3 stimulates duodenal HCO3- secretion via a glucagon-like peptide (GLP)-2 pathway, whereas FFA2 activation induces HCO3- secretion via muscarinic and 5-HT4 receptor activation. The presence of SCFA sensing in the duodenum with GLP-2 and 5-HT signals further supports the hypothesis that luminal SCFA in the foregut may contribute towards the generation of functional symptoms. Intraduodenal fatty acids (FA) and bacterial overgrowth, which generate short-chain FAs (SCFAs), have been implicated in the generation of functional dyspepsia symptoms. We studied the mechanisms by which luminal SCFA perfusion affects duodenal HCO3- secretion (DBS), a measure of mucosal neurohumoral activation. Free fatty acid receptor (FFAR) 1 (FFA1), which binds long-chain FA (LCFA), and SCFA receptors FFA2 and FFA3 were immunolocalised to duodenal enteroendocrine cells. FFA3 colocalised with glucagon-like peptide (GLP)-1, whereas FFA2 colocalised with 5-HT. Luminal perfusion of the SCFA acetate or propionate increased DBS, enhanced by dipeptidyl peptidase-IV (DPPIV) inhibition, at the same time as increasing GLP-2 portal blood concentrations. Acetate-induced DBS was partially inhibited by monocarboxylate/HCO3- exchanger inhibition without affecting GLP-2 release, implicating acetate absorption in the partial mediation of DBS. A selective FFA2 agonist dose-dependently increased DBS, unaffected by DPPIV inhibition or by cholecystokinin or 5-HT3 receptor antagonists, but was inhibited by atropine and a 5-HT4 antagonist. By contrast, a selective FFA1 agonist increased DBS accompanied by GLP-2 release, enhanced by DPPIV inhibition and inhibited by a GLP-2 receptor antagonist. Activation of FFA1 by LCFA and presumably FFA3 by SCFA increased DBS via GLP-2 release, whereas FFA2 activation stimulated DBS via muscarinic and 5-HT4 receptor activation. SCFA/HCO3- exchange also appears to be present in the duodenum. The presence of duodenal fatty acid sensing receptors that signal hormone release and possibly signal neural activation may be implicated in the pathogenesis of functional dyspepsia. C1 [Akiba, Yasutada; Guth, Paul H.; Kaunitz, Jonathan D.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA. [Akiba, Yasutada; Inoue, Takuya; Kaji, Izumi; Higashiyama, Masaaki; Narimatsu, Kazuyuki; Kaunitz, Jonathan D.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Akiba, Yasutada; Kaji, Izumi; Kaunitz, Jonathan D.] Brentwood Biomed Res Inst, Los Angeles, CA 90073 USA. [Kaji, Izumi; Watanabe, Masahiko] Hokkaido Univ, Dept Anat, Grad Sch Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan. [Iwamoto, Ken-ichi] Sch Pharmaceut Sci, Organ Chem Lab, Suruga Ku, Shizuoka 4228526, Japan. [Engel, Eli; Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Kuwahara, Atsukazu] Univ Shizuoka, Inst Environm Sci, Physiol Lab, Suruga Ku, Shizuoka 4228526, Japan. RP Kaunitz, JD (reprint author), West Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu RI WATANABE, Masahiko/A-4055-2012 FU Department of Veterans Affairs; NIH-NIDDK [R01 DK54221, P30 DK0413]; [24-5317] FX This work was supported by a Department of Veterans Affairs Merit Review Award, NIH-NIDDK R01 DK54221 (J. Kaunitz), a Grant-in-aid for Japanese Society for the Promotion of Science Fellow (I. Kaji, 24-5317) and the animal core of NIH-NIDDK P30 DK0413 (J. E. Rozengurt). NR 54 TC 8 Z9 8 U1 1 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3751 EI 1469-7793 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD FEB 1 PY 2015 VL 593 IS 3 BP 585 EP 599 DI 10.1113/jphysiol.2014.280792 PG 15 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA CB0CP UT WOS:000349292900011 PM 25433076 ER PT J AU Huckans, M Fuller, B Wheaton, V Jaehnert, S Ellis, C Kolessar, M Kriz, D Anderson, JR Berggren, K Olavarria, H Sasaki, AW Chang, M Flora, KD Loftis, JM AF Huckans, Marilyn Fuller, Bret Wheaton, Viva Jaehnert, Sarah Ellis, Carilyn Kolessar, Michael Kriz, Daniel Anderson, Jeanne Renee Berggren, Kristin Olavarria, Hannah Sasaki, Anna W. Chang, Michael Flora, Kenneth D. Loftis, Jennifer M. TI A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C SO JOURNAL OF PSYCHOSOMATIC RESEARCH LA English DT Article DE Anxiety; Cognition; Depression; Fatigue; Interferon; Hepatitis C; Pain ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; CHRONIC VIRAL-HEPATITIS; FATIGUE SEVERITY SCALE; GENOTYPE 1 INFECTION; VIRUS-INFECTION; INDUCED DEPRESSION; PEGYLATED INTERFERON; ANTIVIRAL TREATMENT; RANDOMIZED-TRIAL; SOMATIC SYMPTOMS AB Objective: To prospectively evaluate for changes in objective cognitive performance (attention, memory, and executive function) and psychiatric symptom severity (depression, anxiety, fatigue, and pain) in patients before, during and after interferon-alpha based therapy (IFN) for chronic hepatitis C virus infection (HCV). Methods: 33 HCV+ adults were evaluated two months before IFN initiation (baseline), three months into IFN, and six months following IFN termination (IFN+ Group). 31 HCV+ adults who did not undergo IFN therapy were evaluated at baseline and six months later (IFN - Group). At each evaluation, participants completed the Neuropsychological Assessment Battery (NAB) Attention, Memory and Executive Functions Modules, the Beck Depression Inventory, Second Edition (BDI), Generalized Anxiety Disorder Inventory (GADO, Fatigue Severity Scale (FSS), and Brief Pain Inventory (BPI). Results: Compared with the IFN - Group, the IFN + Group experienced significantly (p < 0.050) increased symptoms of depression, anxiety, fatigue and pain during IFN therapy relative to baseline. In the IFN + Group, psychiatric symptoms generally returned to baseline levels following IFN termination. Sustained viral response was associated with significantly lower depression and fatigue. No significant changes in cognitive performance were observed. Conclusions: During IFN, patients with HCV evidence significantly increased psychiatric symptoms, including symptoms of depression, anxiety, fatigue and pain. These psychiatric symptoms are generally short-term and remit following IFN termination, with increased benefit if viral clearance is achieved. However, IFN is not associated with significant declines in objective cognitive performance during or following IFN. (c) 2014 Published by Elsevier Inc. C1 [Huckans, Marilyn; Wheaton, Viva; Jaehnert, Sarah; Ellis, Carilyn; Kolessar, Michael; Kriz, Daniel; Anderson, Jeanne Renee; Berggren, Kristin; Olavarria, Hannah; Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. [Huckans, Marilyn; Fuller, Bret] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Huckans, Marilyn; Fuller, Bret; Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Wheaton, Viva; Jaehnert, Sarah; Kolessar, Michael; Kriz, Daniel; Anderson, Jeanne Renee] Univ Pacific, Sch Profess Psychol, Hillsboro, OR 97123 USA. [Ellis, Carilyn; Berggren, Kristin] George Fox Univ, Grad Dept Clin Psychol, Newberg, OR 97132 USA. [Sasaki, Anna W.; Chang, Michael] Portland VA Med Ctr, Gastroenterol Serv, Portland, OR 97239 USA. [Sasaki, Anna W.; Chang, Michael] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97239 USA. [Flora, Kenneth D.] Oregon Clin, Portland Gastroenterol Div, Clackamas, OR 97015 USA. RP Huckans, M (reprint author), Portland VA Med Ctr, P3MHN,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM marilyn.huckans@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development Clinical Sciences Research and Development FX This work was supported by career development awards to M.H. (Staff Psychologist and Neuropsychologist) and J.M.L (Research Scientist) from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development Clinical Sciences Research and Development This material is the result of work supported with resources and the use of facilities at the Portland Veterans Affairs Medical Center, Portland, Oregon. The authors thank the study participants and staff at each of the recruitment sites, especially Betsy Zucker and Janice Voukidis. The authors also acknowledge Arthur Vandenbark, Peter Hauser, William Hoffman, Diane Howieson, Daniel Storzbach, and Alexander Stevens for consultation regarding study design and implementation. All authors read and approved the final contents of the manuscript. The authors have no competing interests to report. NR 69 TC 9 Z9 9 U1 3 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3999 EI 1879-1360 J9 J PSYCHOSOM RES JI J. Psychosomat. Res. PD FEB PY 2015 VL 78 IS 2 BP 184 EP 192 DI 10.1016/j.jpsychores.2014.07.020 PG 9 WC Psychiatry SC Psychiatry GA CA0US UT WOS:000348632400014 PM 25219976 ER PT J AU Ibrahim, AMS Vargas, CR Colakoglu, S Nguyen, JT Lin, SJ Lee, BT AF Ibrahim, Ahmed M. S. Vargas, Christina R. Colakoglu, Salih Nguyen, John T. Lin, Samuel J. Lee, Bernard T. TI Properties of Meshes used in Hernia Repair: A Comprehensive Review of Synthetic and Biologic Meshes SO JOURNAL OF RECONSTRUCTIVE MICROSURGERY LA English DT Review DE biomechanical properties; synthetic mesh; biologic mesh; hernia repair ID ACELLULAR DERMAL MATRIX; ABDOMINAL-WALL DEFECTS; XENOGENEIC EXTRACELLULAR-MATRIX; BREAST RECONSTRUCTION; MECHANICAL-PROPERTIES; INCISIONAL HERNIA; PORCINE MODEL; SUTURE REPAIR; IN-VIVO; ALLODERM AB Background Data on the mechanical properties of the adult human abdominal wall have been difficult to obtain rendering manufacture of the ideal mesh for ventral hernia repair a challenge. An ideal mesh would need to exhibit greater biomechanical strength and elasticity than that of the abdominal wall. The aim of this study is to quantitatively compare the biomechanical properties of the most commonly used synthetic and biologic meshes in ventral hernia repair and presents a comprehensive literature review. Methods A narrative review of the literature was performed using the PubMed database spanning articles from 1982 to 2012 including a review of company Web sites to identify all available information relating to the biomechanical properties of various synthetic and biologic meshes used in ventral hernia repair. Results There exist differences in the mechanical properties and the chemical nature of different meshes. In general, most synthetic materials have greater stiffness and elasticity than what is required for abdominal wall reconstruction; however, each exhibits unique properties that may be beneficial for clinical use. On the contrary, biologic meshes are more elastic but less stiff and with a lower tensile strength than their synthetic counterparts. Conclusions The current standard of practice for the treatment of ventral hernias is the use of permanent synthetic mesh material. Recently, biologic meshes have become more frequently used. Most meshes exhibit biomechanical properties over the known abdominal wall thresholds. Augmenting strength requires increasing amounts of material contributing to more stiffness and foreign body reaction, which is not necessarily an advantage. C1 [Ibrahim, Ahmed M. S.; Nguyen, John T.; Lin, Samuel J.; Lee, Bernard T.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Plast & Reconstruct Surg, Boston, MA 02215 USA. [Vargas, Christina R.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA. [Colakoglu, Salih] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02215 USA. RP Lee, BT (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Plast & Reconstruct Surg, 110 Francis St,Lowry Suite 5A, Boston, MA 02215 USA. EM blee3@bidmc.harvard.edu RI Lee, Bernard/K-1106-2016; OI Lee, Bernard/0000-0002-5533-3166; Colakoglu, Salih/0000-0002-8747-0616 NR 55 TC 2 Z9 2 U1 3 U2 15 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0743-684X EI 1098-8947 J9 J RECONSTR MICROSURG JI J. Reconstr. Microsurg. PD FEB PY 2015 VL 31 IS 2 BP 83 EP 94 DI 10.1055/s-0034-1376886 PG 12 WC Surgery SC Surgery GA CA2QJ UT WOS:000348752200001 PM 25192272 ER PT J AU Wu, F Xing, DM Ren, D Feng, W Eberlin, KR Yan, C Kan, WS AF Wu Fei Xing Danmou Ren Dong Feng Wei Eberlin, Kyle R. Chen Yan Kan Wusheng TI Free Vascularized Medial Femoral Condyle Corticocancellous Flap for Treatment of Challenging Upper Extremity Nonunions SO JOURNAL OF RECONSTRUCTIVE MICROSURGERY LA English DT Article DE upper extremity; nonunion; free vascularized corticocancellous flap ID BONE-GRAFT; CORTICOPERIOSTEAL GRAFTS; PROXIMAL POLE; UPPER-LIMB; RECONSTRUCTION; DEFECTS; FOREARM; AUTOGRAFT; FIBULA AB Background Nonunions in the upper extremity are challenging for the reconstructive surgeon. The evolution of microsurgical techniques has allowed for the reliable use of free vascularized bone flaps. Methods In a retrospective study, patients with challenging upper limb nonunions who underwent free vascularized corticocancellous flaps from the medial femoral condyle (MFC) were included. Patient demographics, surgical technique, and outcomes were evaluated. Results Fifteen patients with nonunions of the upper extremity underwent free MFC corticocancellous flap reconstruction. The length of preoperative bone defects ranged from 0.8 to 3 cm, and the mean number of procedure prior to free MFC reconstruction was 1.5. Thirteen patients healed completely in an average of 15 weeks (range, 8-22 weeks). Two patients were lost to follow-up. Only one patient required additional surgery. Functional outcome measures such as Mayo, Disability of Arm, Shoulder, and Hand, and Constant Murley scores all demonstrated improvement. Conclusion The free vascularized MFC corticocancellous flap can be successfully used for challenging upper extremity nonunions and small bone defects. C1 [Wu Fei; Xing Danmou; Ren Dong; Feng Wei; Chen Yan; Kan Wusheng] Huazhong Univ Sci & Technol, Tongji Med Coll, Affiliated Pu Ai Hosp, Dept Hand Surg & Microsurg, Wuhan 430033, Hu Bei Province, Peoples R China. [Eberlin, Kyle R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Plast Surg, Boston, MA USA. RP Xing, DM (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Affiliated Pu Ai Hosp, Dept Hand Surg & Microsurg, Wuhan 430033, Hu Bei Province, Peoples R China. EM xingdanmou@hotmail.com NR 36 TC 0 Z9 0 U1 1 U2 3 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0743-684X EI 1098-8947 J9 J RECONSTR MICROSURG JI J. Reconstr. Microsurg. PD FEB PY 2015 VL 31 IS 2 BP 124 EP 131 DI 10.1055/s-0034-1390045 PG 8 WC Surgery SC Surgery GA CA2QJ UT WOS:000348752200007 ER PT J AU Offodile, AC Prigerson, H Craft, RO Liu, A Guo, LF AF Offodile, Anaeze C., II Prigerson, Holly Craft, Randall O. Liu, Allen Guo, Lifei TI Impact of Personality Traits on Choice and Perceptions of Autologous Breast Reconstruction SO JOURNAL OF RECONSTRUCTIVE MICROSURGERY LA English DT Article DE personality; perforator flaps; quality of life; outcomes ID EPIGASTRIC PERFORATOR FLAP; DONOR-SITE COMPLICATIONS; RECTUS-ABDOMINIS MUSCLE; DIEP FLAP; PATIENT SATISFACTION; FREE TRAM; COSMETIC SURGERY; MASTECTOMY; MORTALITY; OUTCOMES AB Background There is little data examining the psychosocial characteristics of women who choose a type of autologous postmastectomy reconstruction. This study sought to investigate the role of personality on decision making and postoperative satisfaction in autologous breast reconstruction. Patients and Methods A retrospective survey of 120 consecutive patients who had undergone transverse rectus abdominis myocutaneous (TRAM) or perforator flap (PF) reconstruction over a 4-year period by a single surgeon at a single academic institution. All patients underwent similar preoperative consultations and were categorized into one of four groups based on surgical procedure they chose and their PF candidacy as determined by body mass index, age, and laterality. The survey packet included three validated measures of personality indices and a quality-of-life questionnaire. Intergroup analysis was performed using the Wilcoxon rank sum test. Results The overall survey response rate was 52.5%. PF patients were younger (p = 0.007) and more likely to undergo bilateral reconstruction (p = 0.0009) relative to TRAM patients. Comparisons between the two most clinically extreme groups showed significant results with regard to personality testing. Patients who were deemed not ideal PF candidates but nevertheless chose PF reconstruction were shown to be more narcissistic (p = 0.033), extroverted (p = 0.024), and having a higher postoperative quality of life (p = 0.021) than those who were deemed ideal PF candidates but ended up choosing pedicled TRAM reconstruction. Conclusion Specific personality traits play a role in the patients' choice of a reconstructive option and their overall postoperative satisfaction. Clinicians should be aware of the possible influence of personality type on surgery selection. C1 [Offodile, Anaeze C., II; Guo, Lifei] Lahey Hosp & Med Ctr, Dept Plast Surg, Burlington, MA 01805 USA. [Prigerson, Holly] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA 02115 USA. [Craft, Randall O.] Banner MD Anderson Canc Ctr, Div Surg Oncol, Gilbert, AZ USA. [Liu, Allen] Arizona Ctr Hand Surg, Phoenix, AZ USA. RP Guo, LF (reprint author), Lahey Hosp & Med Ctr, Dept Plast Surg, 41 Mall Rd, Burlington, MA 01805 USA. EM Lifei.guo@lahey.org NR 48 TC 2 Z9 2 U1 1 U2 1 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0743-684X EI 1098-8947 J9 J RECONSTR MICROSURG JI J. Reconstr. Microsurg. PD FEB PY 2015 VL 31 IS 2 BP 139 EP 144 DI 10.1055/s-0034-1390246 PG 6 WC Surgery SC Surgery GA CA2QJ UT WOS:000348752200009 PM 25360861 ER PT J AU Walch, G Vezeridis, PS Boileau, P Deransart, P Chaoui, J AF Walch, Gilles Vezeridis, Peter S. Boileau, Pascal Deransart, Pierric Chaoui, Jean TI Three-dimensional planning and use of patient-specific guides improve glenoid component position: an in vitro study SO JOURNAL OF SHOULDER AND ELBOW SURGERY LA English DT Article DE Total shoulder arthroplasty; patient-specific guides; glenoid component position; computed tomography; 3D; preoperative planning ID TOTAL SHOULDER ARTHROPLASTY; COMPUTED-TOMOGRAPHY SCANS; VERSION; OSTEOARTHRITIS; RETROVERSION AB Background: Glenoid component positioning is a key factor for success in total shoulder arthroplasty. Three-dimensional (3D) measurements of glenoid retroversion, inclination, and humeral head subluxation are helpful tools for preoperative planning. The purpose of this study was to assess the reliability and precision of a novel surgical method for placing the glenoid component with use of patient-specific templates created by preoperative surgical planning and 3D modeling. Methods: A preoperative computed tomography examination of cadaveric scapulae (N = 18) was performed. The glenoid implants were virtually placed, and patient-specific guides were created to direct the guide pin into the desired orientation and position in the glenoid. The 3D orientation and position of the guide pin were evaluated by performing a postoperative computed tomography scan for each scapula. The differences between the preoperative planning and the achieved result were analyzed. Results: The mean error in 3D orientation of the guide pin was 2.39 degrees, the mean entry point position error was 1.05 mm, and the mean inclination angle error was 1.42 degrees. The average error in the version angle was 1.64 degrees. There were no technical difficulties or complications related to use of patient-specific guides for guide pin placement. Quantitative analysis of guide pin positioning demonstrated a good correlation between preoperative planning and the achieved position of the guide pin. Conclusion: This study demonstrates the reliability and precision of preoperative planning software and patient-specific guides for glenoid component placement in total shoulder arthroplasty. (C) C1 [Walch, Gilles] Hop Prive Jean Mermoz, Ctr Orthoped Santy, Lyon, France. [Vezeridis, Peter S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Boileau, Pascal] Hop LArchet 2, Nice, France. [Deransart, Pierric] Tornier, Grenoble, France. [Chaoui, Jean] Telecom Bretagne, Brest, France. [Chaoui, Jean] Imascap, Brest, France. RP Walch, G (reprint author), Ctr Orthoped Santy, 24 Ave P Santy, F-69008 Lyon, France. EM walch.gilles@wanadoo.fr NR 25 TC 22 Z9 23 U1 1 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1058-2746 J9 J SHOULDER ELB SURG JI J. Shoulder Elbow Surg. PD FEB PY 2015 VL 24 IS 2 BP 302 EP 309 DI 10.1016/j.jse.2014.05.029 PG 8 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA AY7DJ UT WOS:000347721200027 PM 25183662 ER PT J AU Anthony, SG McCormick, F Gross, DJ Golijanin, P Provencher, MT AF Anthony, Shawn G. McCormick, Frank Gross, Daniel J. Golijanin, Petar Provencher, Matthew T. TI Biceps tenodesis for long head of the biceps after auto-rupture or failed surgical tenotomy: results in an active population SO JOURNAL OF SHOULDER AND ELBOW SURGERY LA English DT Article DE SLAP; biceps tenotomy; long head of biceps; tenodesis; tenotomy; superior labrum; Popeye deformity ID CLINICAL-OUTCOMES; TENDON; MANAGEMENT AB Background: Long head of the biceps (LHB) deformity after surgical tenotomy or auto-rupture may result from attrition or injury. The purpose of this study was to describe the surgical outcomes of biceps tenodesis after failed surgical tenotomy or auto-rupture of the LHB tendon in a population of active patients. Methods: During a 5-year period, 11 patients with a mean age of 43.3 years (range, 33-56 years) presented with symptoms of biceps cramping with activity (100%), deformity (100%), or pain (36%) at a mean of 8 months (range, 0.5-22 months) from a tenotomy (6 of 11) or an auto-rupture (5 of 11). All patients underwent a mini-open subpectoral biceps tenodesis with interference screw fixation. Patients were independently evaluated by patient-reported outcome measures (Single Assessment Numeric Evaluation [SANE] and Western Ontario Rotator Cuff Index [WORC]) and a biceps position examination. Results: Of the 11 patients, 10 (91%) completed the study requirements at a mean of 2.6 years (range, 1.6-4.2 years). A total of 9 of the 10 patients (90%) returned to full activity. The mean preoperative SANE score was 61.1 (standard deviation [SD], 8.8), and the mean preoperative WORC score was 53.2 (SD, 9.2), which improved postoperatively to a SANE score of 84.2 (SD, 7.1) and a WORC score of 86 (SD, 8.2). There were no differences in LHB muscle position relative to the antecubital fossa (3.17 cm preoperatively to 3.25 cm postoperatively; P = .35). Deformity was resolved in all patients; 9 of 10 patients reported full resolution of cramping, and pain was resolved in 8 of 10. Conclusions: LHB tenodesis after auto-rupture or surgical tenotomy improved symptoms and allowed predictable return to activity and patient satisfaction. Additional work is necessary to determine the optimal treatment of primary biceps lesions. Published by Elsevier Inc. on behalf of Journal of Shoulder and Elbow Surgery Board of Trustees. C1 [Anthony, Shawn G.; Gross, Daniel J.; Golijanin, Petar; Provencher, Matthew T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Sports Med Serv,Dept Orthoped Surg, Boston, MA USA. [McCormick, Frank] Holy Cross Hosp, Holy Cross Orthoped Inst, Ft Lauderdale, FL USA. [McCormick, Frank; Provencher, Matthew T.] Naval Med Ctr San Diego, Dept Orthoped Surg, Sports Med Div, San Diego, CA USA. RP Provencher, MT (reprint author), Massachusetts Gen Hosp, Dept Orthoped Surg, Sports Med Serv, 175 Cambridge St,Ste 400, Boston, MA 02114 USA. EM mtprovencher@partners.org NR 15 TC 1 Z9 1 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1058-2746 J9 J SHOULDER ELB SURG JI J. Shoulder Elbow Surg. PD FEB PY 2015 VL 24 IS 2 BP E36 EP E40 DI 10.1016/j.jse.2014.06.031 PG 5 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA AY7DJ UT WOS:000347721200002 PM 25174939 ER PT J AU Agnew-Blais, JC Wassertheil-Smoller, S Kang, JH Hogan, PE Coker, LH Snetselaar, LG Smoller, JW AF Agnew-Blais, Jessica C. Wassertheil-Smoller, Sylvia Kang, Jae H. Hogan, Patricia E. Coker, Laura H. Snetselaar, Linda G. Smoller, Jordan W. TI Folate, Vitamin B-6, and Vitamin B-12 Intake and Mild Cognitive Impairment and Probable Dementia in the Women's Health Initiative Memory Study SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS LA English DT Article DE Folic acid; Vitamin B-6; Vitamin B-12; Dementia; Cognitive impairment ID RANDOMIZED CONTROLLED-TRIAL; FOLIC-ACID SUPPLEMENTATION; ESTROGEN PLUS PROGESTIN; PLACEBO-CONTROLLED TRIAL; ALZHEIMERS-DISEASE; POSTMENOPAUSAL WOMEN; CARDIOVASCULAR-DISEASE; B-VITAMINS; DIETARY-FOLATE; OLDER PERSONS AB Background Whether higher B vitamin intake (ie, B-6, B-12, and folate) is protective against cognitive decline in later life remains uncertain. Several prospective, observational studies find higher B vitamin intake to be associated with lower risk of dementia; other studies, including most trials of B vitamin supplementation, have observed no effect on cognition. We examined this question in a large population of older women carefully monitored for development of mild cognitive impairment (MCI) and probable dementia. Objective To determine whether baseline folate, vitamin B-6, and/or vitamin B-12 intake, alone or in combination, are associated with incident MCI/probable dementia among older women. Design Prospective, longitudinal cohort study. Participants were enrolled between 1993 and 1998, and B vitamin intake was self-reported using a food frequency questionnaire administered at baseline. Participants/setting Postmenopausal women (N = 7,030) free of MCI/probable dementia at baseline in the Women's Health Initiative Memory Study. Main outcome measures Over a mean follow-up of 5.0 years, 238 cases of incident MCI and 69 cases of probable dementia were identified through rigorous screening and expert adjudication. Statistical analyses Cox proportional hazard models adjusting for sociodemographic and lifestyle factors examined the association of B vitamin intake above and below the Recommended Daily Allowance and incident MCI/probable dementia. Results Folate intake below the Recommended Daily Allowance at study baseline was associated with increased risk of incident MCI/probable dementia (hazard ratio 2.0, 95% CI 1.3 to 2.9), after controlling for multiple confounders. There were no significant associations between vitamins B-6 or B-12 and MCI/probable dementia, nor any evidence of an interaction between these vitamins and folate intake. Conclusions Folate intake below the Recommended Daily Allowance may increase risk for MCI/probable dementia in later life. Future research should include long-term trials of folic acid supplementation to examine whether folate may impart a protective effect on cognition in later life. C1 [Agnew-Blais, Jessica C.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA. [Wassertheil-Smoller, Sylvia] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, New York, NY USA. [Kang, Jae H.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Hogan, Patricia E.] Wake Forest Univ, Sch Med, Dept Biostat Sci, Winston Salem, NC 27109 USA. [Coker, Laura H.] Wake Forest Univ, Sch Med, Div Publ Hlth Sci, Winston Salem, NC 27109 USA. [Snetselaar, Linda G.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA. [Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. RP Agnew-Blais, JC (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, Allan Rosenfield Bldg,722 168th St, New York, NY 10032 USA. EM jcb370@mail.harvard.edu RI Agnew-Blais, Jessica/L-9236-2015; OI Agnew-Blais, Jessica/0000-0002-0755-6867; Smoller, Jordan/0000-0002-0381-6334 FU National Heart, Lung and Blood Institute; National Institutes of Health, US Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; National Institute on Aging [N01-AG-9-2115, HHSN-271-2011-00004C]; Women's Health Initiative Memory Study (WHIMS) by National Heart, Lung and Blood Institute [HHSN268200464221C]; National Institute of Mental Health [NIH T32MH017119]; [N01-WH-4-4221] FX The Women's Health Initiative (WHI) program is funded by the National Heart, Lung and Blood Institute; National Institutes of Health, US Department of Health and Human Services, through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. The Women's Health Initiative Study of Cognitive Aging (WHISCA) is funded by National Institute on Aging contract number N01-AG-9-2115 and the Women's Health Initiative Memory Study (WHIMS) by National Heart, Lung and Blood Institute contract number HHSN268200464221C, Administrative Data Base number contract N01-WH-4-4221, National Institute on Aging contract HHSN-271-2011-00004C. J. C. Agnew-Blais was supported by a training grant from National Institute of Mental Health (grant no. NIH T32MH017119) while completing the manuscript. NR 61 TC 9 Z9 10 U1 7 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 EI 2212-2680 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD FEB PY 2015 VL 115 IS 2 BP 231 EP 241 DI 10.1016/j.jand.2014.07.006 PG 11 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CA1YC UT WOS:000348703900009 PM 25201007 ER PT J AU Saxena, RC Lehmann, AE Hight, AE Darrow, K Remenschneider, A Kozin, ED Lee, DJ AF Saxena, Rajeev C. Lehmann, Ashton E. Hight, A. Ed Darrow, Keith Remenschneider, Aaron Kozin, Elliott D. Lee, Daniel J. TI Social Media Utilization in the Cochlear Implant Community SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Article DE Cochlear implant; social media; Facebook; blog; otolaryngology ID NETWORKING SITES; CARE AB Background: More than 200,000 individuals worldwide have received a cochlear implant (CI). Social media Websites may provide a paramedical community for those who possess or are interested in a CI. The utilization patterns of social media by the CI community, however, have not been thoroughly investigated. Purpose: The purpose of this study was to investigate participation of the CI community in social media Websites. Research Design: We conducted a systematic survey of online CI-related social media sources. Using standard search engines, the search terms cochlear implant, auditory implant, forum, and blog identified relevant social media platforms and Websites. Social media participation was quantified by indices of membership and posts. Study Sample: Social media sources included Facebook, Twitter, YouTube, blogs, and online forums. Each source was assigned one of six functional categories based on its description. Intervention: No intervention was performed. Data Collection and Analysis: We conducted all online searches in February 2014. Total counts of each CI-related social media source were summed, and descriptive statistics were calculated. Results: More than 350 sources were identified, including 60 Facebook groups, 36 Facebook pages, 48 Twitter accounts, 121 YouTube videos, 13 forums, and 95 blogs. The most active online communities were Twitter accounts, which totaled 35,577 members, and Facebook groups, which totaled 17,971 members. CI users participated in Facebook groups primarily for general information/support (68%). Online forums were the next most active online communities by membership. The largest forum contained approximately 9,500 topics with roughly 127,000 posts. CI users primarily shared personal stories through blogs (92%), Twitter (71%), and YouTube (62%). Conclusions: The CI community engages in the use of a wide range of online social media sources. The CI community uses social media for support, advocacy, rehabilitation information, research endeavors, and sharing of personal experiences. Future studies are needed to investigate how social media Websites may be harnessed to improve patient-provider relationships and potentially used to augment patient education. C1 [Saxena, Rajeev C.] Tufts Univ, Sch Med, Dept Otolaryngol, Boston, MA 02111 USA. [Lehmann, Ashton E.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Hight, A. Ed; Darrow, Keith; Remenschneider, Aaron; Kozin, Elliott D.; Lee, Daniel J.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. [Darrow, Keith] Worcester State Univ, Dept Commun Sci & Disorders, Worcester, MA USA. RP Kozin, ED (reprint author), 243 Charles St, Boston, MA 02114 USA. EM Elliott_kozin@meei.harvard.edu RI Kozin, Elliott/J-1225-2014 OI Kozin, Elliott/0000-0002-0305-0682 FU NIDCD NIH HHS [T32 DC000020] NR 16 TC 1 Z9 2 U1 0 U2 2 PU AMER ACAD AUDIOLOGY PI RESTON PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA SN 1050-0545 EI 2157-3107 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD FEB PY 2015 VL 26 IS 2 BP 197 EP 204 DI 10.3766/jaaa.26.2.8 PG 8 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA CA9UA UT WOS:000349269100008 PM 25690778 ER PT J AU Rosman, DA Farinhas, J Kassing, P Pattie, LN McGinty, G AF Rosman, David A. Farinhas, Joaquim Kassing, Pam Pattie, Laura N. McGinty, Geraldine TI Radiology in Pioneer Accountable Care Organizations: Much Ado About Nothing? SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material C1 [Rosman, David A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rosman, David A.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Farinhas, Joaquim] Montefiore Med Ctr, Bronx, NY 10467 USA. [Kassing, Pam; Pattie, Laura N.] Amer Coll Radiol, Reston, VA USA. [McGinty, Geraldine] Weill Cornell Med Coll, New York, NY USA. RP Rosman, DA (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. EM darosman@gmail.com OI McGinty, Geraldine/0000-0001-6111-2514 NR 7 TC 3 Z9 3 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD FEB PY 2015 VL 12 IS 2 BP 124 EP 126 DI 10.1016/j.jacr.2014.03.012 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CA4PR UT WOS:000348887700003 PM 24726445 ER PT J AU Pannu, HK Javitt, MC Glanc, P Bhosale, PR Harisinghani, MG Khati, NJ Mitchell, DG Nyberg, DA Pandharipande, PV Shipp, TD Siegel, CL Simpson, L Wall, DJ Wong-You-Cheong, JJ AF Pannu, Harpreet K. Javitt, Marcia C. Glanc, Phyllis Bhosale, Priyadarshani R. Harisinghani, Mukesh G. Khati, Nadia J. Mitchell, Donald G. Nyberg, David A. Pandharipande, Pari V. Shipp, Thomas D. Siegel, Cary Lynn Simpson, Lynn Wall, Darci J. Wong-You-Cheong, Jade J. TI ACR Appropriateness Criteria Pelvic Floor Dysfunction SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Appropriateness criteria; pelvic floor dysfunction; fluoroscopy; ultrasound; MRI ID STRESS URINARY-INCONTINENCE; EXTERNAL ANAL-SPHINCTER; POSTERIOR COMPARTMENT PROLAPSE; LEVATOR ANI MUSCLE; TAPE TVT PROCEDURE; ORGAN PROLAPSE; FECAL INCONTINENCE; ENDOANAL US; OBSTRUCTED DEFECATION; MR DEFECOGRAPHY AB Pelvic floor dysfunction is a common and potentially complex condition. Imaging can complement physical examination by revealing clinically occult abnormalities and clarifying the nature of the pelvic floor defects present. Imaging can add value in preoperative management for patients with a complex clinical presentation, and in postoperative management of patients suspected to have recurrent pelvic floor dysfunction or a surgical complication. Imaging findings are only clinically relevant if the patient is symptomatic. Several imaging modalities have a potential role in evaluating patients; the choice of modality depends on the patient's symptoms, the clinical information desired, and the usefulness of the test. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions; they are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals, and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. C1 [Pannu, Harpreet K.] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA. [Javitt, Marcia C.] Rambam Healthcare Campus, Haifa, Israel. [Glanc, Phyllis] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada. [Bhosale, Priyadarshani R.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Harisinghani, Mukesh G.; Pandharipande, Pari V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Khati, Nadia J.] George Washington Univ Hosp, Washington, DC USA. [Mitchell, Donald G.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. [Shipp, Thomas D.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Siegel, Cary Lynn] Edward Mallinckrodt Inst Radiol, St Louis, MO 63110 USA. [Simpson, Lynn] Columbia Univ, New York, NY USA. [Wall, Darci J.] Mayo Clin, Rochester, MN USA. [Wong-You-Cheong, Jade J.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. RP Pannu, HK (reprint author), Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10065 USA. EM pannuh@mskcc.org NR 109 TC 0 Z9 0 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD FEB PY 2015 VL 12 IS 2 BP 134 EP 142 DI 10.1016/j.jacr.2014.10.021 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CA4PR UT WOS:000348887700008 PM 25652300 ER PT J AU Hoang, JK Langer, JE Middleton, WD Wu, CC Hammers, LW Cronan, JJ Tessler, FN Grant, EG Berland, LL AF Hoang, Jenny K. Langer, Jill E. Middleton, William D. Wu, Carol C. Hammers, Lynwood W. Cronan, John J. Tessler, Franklin N. Grant, Edward G. Berland, Lincoln L. TI Managing Incidental Thyroid Nodules Detected on Imaging: White Paper of the ACR Incidental Thyroid Findings Committee SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Incidental findings; thyroid nodule; thyroid cancer; imaging; incidentaloma ID OF-THE-LITERATURE; US FEATURES; F-18-FDG PET; WORK-UP; CT; RADIOLOGISTS; PREVALENCE; ULTRASOUND; MANAGEMENT; RISK AB The incidental thyroid nodule (ITN) is one of the most common incidental findings on imaging studies that include the neck. An ITN is defined as a nodule not previously detected or suspected clinically, but identified by an imaging study. The workup of ITNs has led to increased costs from additional procedures, and in some cases, to increased risk to the patient because physicians are naturally concerned about the risk of malignancy and a delayed cancer diagnosis. However, the majority of ITNs are benign, and small, incidental thyroid malignancies typically have indolent behavior. The ACR formed the Incidental Thyroid Findings Committee to derive a practical approach to managing ITNs on CT, MRI, nuclear medicine, and ultrasound studies. This white paper describes consensus recommendations representing this committee's review of the literature and their practice experience. C1 [Hoang, Jenny K.] Duke Univ, Med Ctr, Durham, NC 27710 USA. [Langer, Jill E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Middleton, William D.] Washington Univ, Sch Med, St Louis, MO USA. [Wu, Carol C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hammers, Lynwood W.] Hammers Healthcare Imaging LLC, New Haven, CT USA. [Hammers, Lynwood W.] Yale Univ, Sch Med, New Haven, CT USA. [Cronan, John J.] Brown Univ, Providence, RI 02912 USA. [Tessler, Franklin N.; Berland, Lincoln L.] Univ Alabama Birmingham, Birmingham, AL USA. [Grant, Edward G.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. RP Hoang, JK (reprint author), Duke Univ, Dept Radiol, Med Ctr, Box 3808,Erwin Rd, Durham, NC 27710 USA. EM jennykh@gmail.com RI Hoang, Jenny/B-7779-2016 OI Hoang, Jenny/0000-0002-6715-0922 NR 45 TC 37 Z9 37 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD FEB PY 2015 VL 12 IS 2 BP 143 EP 150 DI 10.1016/j.jacr.2014.09.038 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CA4PR UT WOS:000348887700009 PM 25456025 ER PT J AU Ranschaert, ER Boland, GW Duerinckx, AJ Binkhuysen, FHB AF Ranschaert, Erik R. Boland, Giles W. Duerinckx, Andre J. Binkhuysen, Frits H. Barneveld TI Comparison of European (ESR) and American (ACR) White Papers on Teleradiology: Patient Primacy Is Paramount SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Teleradiology; teleradiologic services; regulatory issues; legal issues; patient primacy; Europe; United States; white paper ID RADIOLOGY AB The ACR and European Society of Radiology white papers on teleradiology propose best practice guidelines for teleradiology, with each body focusing on its respective local situation, market, and legal regulations. The organizations have common viewpoints, the most important being patient primacy, maintenance of quality, and the "supplementary" position of teleradiology to local services. The major differences between the white papers are related mainly to the market situation, the use of teleradiology, teleradiologist credentialing and certification, the principles of "international" teleradiology, and the need to obtain "informed consent" from patients. The authors describe these similarities and differences by highlighting the background and context of teleradiology in Europe and the United States. C1 [Ranschaert, Erik R.] Jeroen Bosch Ziekenhuis, NL-5223 GZ Shertogenbosch, Netherlands. [Boland, Giles W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Duerinckx, Andre J.] Howard Univ Hosp, Washington, DC USA. [Binkhuysen, Frits H. Barneveld] Diagnosdek U, Eindhoven, Netherlands. RP Ranschaert, ER (reprint author), Jeroen Bosch Ziekenhuis, Henri Dunantstr 1, NL-5223 GZ Shertogenbosch, Netherlands. EM e.ranschaert@jbz.nl RI Ranschaert, Erik R./Q-4577-2016 OI Ranschaert, Erik R./0000-0001-9375-9750 NR 24 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD FEB PY 2015 VL 12 IS 2 BP 174 EP 182 DI 10.1016/j.jacr.2014.09.027 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CA4PR UT WOS:000348887700014 PM 25652303 ER PT J AU Unroe, KT Ersek, M Cagle, J AF Unroe, Kathleen T. Ersek, Mary Cagle, John TI The IOM Report on Dying in America: A Call to Action for Nursing Homes SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Editorial Material ID OF-LIFE CARE; PALLIATIVE CARE; HOSPICE ENROLLMENT; DEMENTIA; PROGRAM; INTERVENTION; PERSPECTIVES; SETTINGS; PLACE; DEATH C1 [Unroe, Kathleen T.] Indiana Univ, Sch Med, Indianapolis, IN 46202 USA. [Unroe, Kathleen T.] Indiana Univ, Ctr Aging Res, Indianapolis, IN 46202 USA. [Unroe, Kathleen T.] Regenstrief Inst Hlth Care, Indianapolis, IN USA. [Ersek, Mary] Philadelphia Vet Affairs Med Ctr, Natl PROMISE Ctr, Philadelphia, PA USA. [Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Cagle, John] Univ Maryland, Sch Social Work, Baltimore, MD 21201 USA. RP Unroe, KT (reprint author), Indiana Univ, Ctr Aging Res, 410 West 10th St,Suite 2000, Indianapolis, IN 46202 USA. EM kunroe@iupui.edu NR 31 TC 6 Z9 6 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 EI 1538-9375 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD FEB 1 PY 2015 VL 16 IS 2 BP 90 EP 92 DI 10.1016/j.jamda.2014.11.010 PG 3 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA CA2KR UT WOS:000348738000002 PM 25512213 ER PT J AU Kim, GE Seidler, E Kimball, AB AF Kim, G. E. Seidler, E. Kimball, A. B. TI A measure of chronic quality of life predicts socioeconomic and medical outcomes in psoriasis patients SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY LA English DT Article ID INDEX; DEPRESSION; IMPAIRMENT; PERCEPTION; MORBIDITY; IMPACT AB BackgroundPsoriasis is a chronic skin disorder that detracts from quality of life, including elements of physical, psychological and social functioning. ObjectiveThis study investigated whether retrospective questions about chronic quality of life (CQoL) were better predictors of poor socioeconomic and medical outcomes than the current Dermatology Life Quality Index (DLQI). MethodsOne hundred fourteen participants answered the 10 questions used in the standard DLQI for over the last week', over the last year' and over your lifetime with psoriasis'. Subjects were examined and completed a self-administered questionnaire regarding disabilities, relationships, education and medical and economic outcomes (a smaller subset of 58 subjects also answered questions regarding religion and discrimination). ResultsGreater lifetime DLQI (LT DLQI) correlated with lower satisfaction with treatment (P=0.007), greater concern that psoriasis will worsen (P=0.012), worse perceived general health (P=0.003), younger age at which weight became problematic (P=0.002), greater likelihood of believing psoriasis had caused weight gain (P<0.001), shorter retention of current job (P=0.001), more experiences of discrimination at work (P=0.002) and in social settings (P<0.001) over one's lifetime and more severe discrimination in social settings over one's lifetime (P=0.002). Greater LT DLQI predicted more packs smoked per day (P=0.005), greater likelihood of believing psoriasis caused smoking (P=0.012), greater likelihood of recreational drug use (P=0.004), greater likelihood of a depression diagnosis (P<0.001), greater likelihood of having felt depressed (P=0.011) and greater likelihood of believing psoriasis caused depression (P<0.001). ConclusionCompared to the standard LW DLQI, LT DLQI was a better predictor of patient outcomes related to weight, discrimination and depression. C1 [Kim, G. E.; Kimball, A. B.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Seidler, E.] Emory Univ, Sch Med, Atlanta, GA USA. [Kimball, A. B.] Massachusetts Gen Hosp, Clin Unit Res Trials & Outcomes Skin CURTIS, Boston, MA 02114 USA. RP Kimball, AB (reprint author), Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. EM harvardskinstudies@partners.org FU Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship FX This study was supported in part by an Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship. The funder was not involved in any aspect of the study. NR 19 TC 5 Z9 5 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0926-9959 EI 1468-3083 J9 J EUR ACAD DERMATOL JI J. Eur. Acad. Dermatol. Venereol. PD FEB PY 2015 VL 29 IS 2 BP 249 EP 254 DI 10.1111/jdv.12503 PG 6 WC Dermatology SC Dermatology GA CA2CY UT WOS:000348717700008 PM 24684416 ER PT J AU Gainor, JF Sherman, CA Willoughby, K Logan, J Kennedy, E Brastianos, PK Chi, AS Shaw, AT AF Gainor, Justin F. Sherman, Carol A. Willoughby, Kathryn Logan, Jennifer Kennedy, Elizabeth Brastianos, Priscilla K. Chi, Andrew S. Shaw, Alice T. TI Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE ALK; Anaplastic lymphoma kinase; Leptomeningeal metastases; Alectinib ID HIGH-DOSE CRIZOTINIB; LEPTOMENINGEAL METASTASIS; INHIBITOR CRIZOTINIB; BRAIN METASTASES; CSF; CHEMOTHERAPY; CYTOLOGY; ERA AB Background: Leptomeningeal metastases (LM) are an increasingly frequent and devastating complication of anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). Currently, the optimal management of LM in ALK-positive patients remains poorly understood as these patients have been routinely excluded from clinical trials. Methods: We describe four ALK-positive patients with LM who were treated with the next-generation ALK inhibitor alectinib through single-patient, compassionate use protocols at two institutions. All patients had previously been treated with both FDA-approved ALK inhibitors-crizotinib and ceritinib. Patients received alectinib at a starting dose of 600 mg twice daily. Results: Four ALK-positive NSCLC patients with symptomatic leptomeningeal disease were identified. Three of four patients experienced significant clinical and radiographic improvements in LM upon treatment with alectinib. A fourth patient had stable intracranial disease for 4 months before eventual systemic disease progression. Overall, alectinib was well tolerated. One patient required dose reduction due to grade 2 hyperbilirubinemia. Conclusions: Alectinib is active in ALK-rearranged NSCLC patients with LM, including in patients previously treated with crizotinib and ceritinib. Additional prospective studies of alectinib in ALK-positive patients with LM are warranted. C1 [Gainor, Justin F.; Logan, Jennifer; Kennedy, Elizabeth; Brastianos, Priscilla K.; Shaw, Alice T.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Sherman, Carol A.; Willoughby, Kathryn] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Brastianos, Priscilla K.; Chi, Andrew S.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Shaw, AT (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM ashaw1@partners.org OI Brastianos, Priscilla/0000-0003-4470-8425 FU US National Institutes of Health [5R01CA164273, C06CA059267] FX This study was supported by grants from the US National Institutes of Health 5R01CA164273 and C06CA059267. F Hoffmann La-Roche supplied alectinib on a compassionate use basis. NR 24 TC 46 Z9 48 U1 1 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD FEB PY 2015 VL 10 IS 2 BP 232 EP 236 DI 10.1097/JTO.0000000000000455 PG 5 WC Oncology; Respiratory System SC Oncology; Respiratory System GA CA3TM UT WOS:000348829400007 PM 25526238 ER PT J AU Kaafarani, HMA Lee, J Cropano, C Chang, YC Raybould, T Klein, E Gervasini, A Petrovick, L DePesa, C Camargo, CA Velmahos, GC Masiakos, P AF Kaafarani, Haytham M. A. Lee, Jarone Cropano, Catrina Chang, Yuchiao Raybould, Toby Klein, Eric Gervasini, Alice Petrovick, Laurie DePesa, Chris Camargo, Carlos A., Jr. Velmahos, George C. Masiakos, Peter TI The impact and sustainability of the graduated driver licensing program in preventing motor vehicle crashes in Massachusetts SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY LA English DT Article; Proceedings Paper CT 73rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery CY SEP 09-13, 2014 CL Philadelphia, PA SP Amer Assoc Surg Trauma DE Injury prevention; motor vehicle crashes; graduated driver license law ID ANALYSIS REPORTING SYSTEM; YOUNG DRIVERS; TRAUMA SYSTEM; UNITED-STATES; FATALITY; NIGHTTIME; RATES AB BACKGROUND: Graduated driving licensing (GDL) programs phase in driving privileges for teenagers. We aimed to evaluate the effect of the 2007 GDL law on the incidence of total motor vehicle crashes (tMVCs) and fatal motor vehicle crashes (fMVCs) among teenagers in Massachusetts. METHODS: The Fatality Analysis and Reporting System, the Missouri Census Data Center, and the Massachusetts Department of Transportation databases were all used to create and compare the incidence of tMVCs and fMVCs before (2002-2006) and after (2007-2011) the law enactment. The following three driver age groups were studied: 16 years to 17 years (evaluating the law effect), 18 years to 20 years (evaluating the sustainability of the effect), and 25 years to 29 years (control group). As a sensitivity analysis, we compared the incidence rates per population and per licenses issued. RESULTS: tMVCs decreased following the law for all three age groups (16-17 years, from 7.6 to 4.8 per 1,000 people, p < 0.0001; 18-20 years, from 8.5 to 6.4 per 1,000 people, p < 0.0001; 25-29 years, from 6.2 to 5.2 per 1,000 people, p < 0.0001), but the percentage decrease in tMVC rates was less in the control group (37%, 25%, and 15%, respectively; both p's < 0.0001). The rates of fMVC also decreased in the age groups of 16 years to 17 years (from 14.0 to 8.6 per 100,000 people, p = 0.0006), 18 years to 20 years (from 21.2 to 13.7 per 100,000 people, p < 0.0001), and 25 years to 29 years (from 14.4 to 11.0 per 100,000 people, p < 0.0001). All of these results were confirmed in the sensitivity analyses. CONCLUSION: The 2007 Massachusetts GDL was associated with a decreased incidence of teenager tMVCs and fMVCs, and the effect was sustainable. This study provides further support to develop, implement, enforce, and maintain GDL programs aimed at preventing MVCs and their related mortality in the young novice driver population. (Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.) LEVEL OF EVIDENCE: Epidemiologic/prognostic study, level III. C1 [Kaafarani, Haytham M. A.; Lee, Jarone; Cropano, Catrina; Raybould, Toby; Klein, Eric; Gervasini, Alice; Petrovick, Laurie; DePesa, Chris; Velmahos, George C.] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. [Chang, Yuchiao] Massachusetts Gen Hosp, Dept Surg, Dept Med, Boston, MA 02114 USA. [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Masiakos, Peter] Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA. RP Kaafarani, HMA (reprint author), Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02114 USA. EM hkaafarani@mgh.harvard.edu NR 29 TC 3 Z9 3 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0755 EI 2163-0763 J9 J TRAUMA ACUTE CARE JI J. Trauma Acute Care Surg. PD FEB PY 2015 VL 78 IS 2 BP 265 EP 270 DI 10.1097/TA.0000000000000512 PG 6 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA CA3TF UT WOS:000348828300007 PM 25757110 ER PT J AU Rago, AP Larentzakis, A Marini, J Picard, A Duggan, MJ Busold, R Helmick, M Zugates, G Beagle, J Sharma, U King, DR AF Rago, Adam P. Larentzakis, Andreas Marini, John Picard, Abby Duggan, Michael J. Busold, Rany Helmick, Marc Zugates, Greg Beagle, John Sharma, Upma King, David R. TI Efficacy of a prehospital self-expanding polyurethane foam for noncompressible hemorrhage under extreme operational conditions SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY LA English DT Article DE Battlefield; exsanguination; tourniquet; prehospital; swine ID COMBAT CASUALTY CARE; ABDOMINAL HEMORRHAGE; IMPROVES SURVIVAL; TORSO HEMORRHAGE; CLOSED-ABDOMEN; BATTLEFIELD; INJURY; LETHAL; DEATH; MODEL AB BACKGROUND: Noncompressible abdominal hemorrhage is a significant cause of battlefield and civilian mortality. We developed a self-expanding polyurethane foam intended to provide temporary hemorrhage control and enable evacuation to a definitive surgical capability, for casualties who would otherwise die. We hypothesized that foam treatment would be efficacious over a wide range of out-of-hospital operational conditions. METHODS: The foam was tested in an established lethal, closed-cavity hepatoportal injury model in four groups as follows. Group 1 involved baseline conditions, wherein foam was deployed from a pneumatically driven, first-generation delivery device at room temperature (n = 6). Group 2 involved foam deployment from a field-relevant, handheld delivery prototype (n = 12). Group 3 involved foam components that were conditioned to simulate 1-year shelf-life (n = 6). Group 4 involved foam that was conditioned to a range of temperatures (10 degrees C and 50 degrees C; n = 6 per group). In all studies, survival was monitored for up to 180 minutes and compared with an ongoing and accumulating control group with no intervention (n = 14). RESULTS: In Group 1 with a first-generation delivery system, foam treatment resulted in a significant survival advantage relative to the control group (p < 0.001), confirming previous results. In Group 2 with a handheld delivery system, survival was also improved, 83% at 3 hours, compared with 7% in the control group (p < 0.001). In Group 3, survival was 83% at 3 hours (p = 0.002). In Group 4 at temperature extremes, 3-hour survival was 83% (p = 0.002) and 67% (p = 0.014) in the low-and high-temperature groups, respectively. Temperature extremes did not result in hypothermia, hyperthermia, or thermal injury. In all studies, the bleeding rate in foam groups was significantly lower than in the control group (p < 0.05). CONCLUSION: Under a range of military operational conditions, foam treatment resulted in a survival advantage relative to the control group. This supports the feasibility of foam treatment as a prehospital hemostatic bridge to surgery for severely bleeding causalities. (Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.) C1 [Larentzakis, Andreas; Duggan, Michael J.; Beagle, John; King, David R.] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Dept Surg, Boston, MA 02141 USA. Harvard Univ, Sch Med, Boston, MA USA. [Rago, Adam P.; Marini, John; Picard, Abby; Busold, Rany; Helmick, Marc; Zugates, Greg; Sharma, Upma] Arsenal Med Inc, Watertown, MA USA. RP King, DR (reprint author), Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02141 USA. EM dking3@partners.org OI King, David/0000-0003-1028-1478 FU DARPA; ARO [W911NF-10-C-0089, W911NF-12-C-0066] FX This study was supported by DARPA and ARO contracts W911NF-10-C-0089 and W911NF-12-C-0066. A.P.R., J.M., A.P., R.B., M.H., G.Z., and U.S. are employees of and receive compensation from Arsenal Medical, Inc. The remaining authors declare no conflicts. NR 19 TC 6 Z9 6 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0755 EI 2163-0763 J9 J TRAUMA ACUTE CARE JI J. Trauma Acute Care Surg. PD FEB PY 2015 VL 78 IS 2 BP 324 EP 329 DI 10.1097/TA.0000000000000507 PG 6 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA CA3TF UT WOS:000348828300016 PM 25757118 ER PT J AU Li, YQ Zhao, T Liu, BL Halaweish, I Mazitschek, R Duan, XZ Alam, HB AF Li, Yongqing Zhao, Ting Liu, Baoling Halaweish, Ihab Mazitschek, Ralph Duan, Xiuzhen Alam, Hasan B. TI Inhibition of histone deacetylase 6 improves long-term survival in a lethal septic model SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY LA English DT Article; Proceedings Paper CT 73rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery CY SEP 09-13, 2014 CL Philadelphia, PA SP Amer Assoc Surg Trauma DE Septic shock; HDAC6; acute liver injury; bacteria clearance; mice ID SEPSIS; HEAT-SHOCK-PROTEIN-90; INFLAMMATION; MACROPHAGES; LIPOPOLYSACCHARIDE; APOPTOSIS; CHAPERONE; CELLS; HDAC6; SHOCK AB BACKGROUND: We recently demonstrated that suberoylanilide hydroxamic acid, a broad-spectrum histone deacetylase (HDAC) inhibitor that inhibits HDACs 1, 2, 3, and 6, improves survival in a mouse model of cecal ligation and puncture (CLP)-induced lethal sepsis. The current study was undertaken to determine the effect of selective inhibition of HDAC isoform on survival, key cytokine production, organ injury, bacteria clearance, and cell apoptosis. METHODS: In Experiment 1, C57BL/6J mice were subjected to CLP and, 1 hour later, given intraperitoneal injections of (1) Tubastatin A (inhibitor of HDAC6) dissolved in dimethyl sulfoxide (DMSO), (2) MS-275 (inhibitor of HDACs 1, 2, and 3) in DMSO, and (3) DMSO only. Survival was monitored for 10 days. In Experiment 2, 1 hour after CLP, animals were treated with DMSO vehicle or Tubastatin A. Sham-operated animals served as control. Peritoneal fluid and blood samples were collected for measurement of cytokines at 24 hours or 48 hours. Blood at 48 hours was also used to determine bacteria load. Liver was harvested to evaluate acute liver injury. In Experiment 3, Primary splenocytes were used to assess cytokine responses and phagocytosis. Macrophages were cultured and harvested 3 hours and 6 hours after lipopolysaccharide stimulation in the absence or presence of Tubastatin A to analyze cell apoptosis. RESULTS: Animals treated with Tubastatin A, but not MS-275, displayed a significant improvement in survival. Moreover, Tubastatin A significantly inhibited cytokine production in peritoneal fluid and plasma as well as in supernatant from splenocytes stimulated with lipopolysaccharide. Tubastatin A significantly attenuated acute liver injury, increased blood bacteria clearance and splenocyte phagocytosis, and decreased macrophage apoptosis. CONCLUSION: HDAC6 inhibition significantly improves survival, reduces "cytokine storm," attenuates acute livery injury, increases bacteria clearance and immune cell phagocytosis, and inhibits macrophage apoptosis in a lethal mouse CLP model. (Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.) C1 [Li, Yongqing; Zhao, Ting; Liu, Baoling; Halaweish, Ihab; Alam, Hasan B.] Univ Michigan Hosp, Dept Surg, Ann Arbor, MI 48109 USA. [Mazitschek, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Mazitschek, Ralph] Broad Inst Harvard & MIT, Chem Biol Program, Cambridge, MA USA. [Duan, Xiuzhen] Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA. RP Li, YQ (reprint author), Univ Michigan Hlth Syst, Univ Michigan Med Sch, NCRC, Rm 363 N,Bldg 26,2800 Plymouth Rd, Ann Arbor, MI 48109 USA. EM yqli@med.umich.edu FU NIH [RO1 GM084127] FX R.M. has financial interests in SHAPE Pharmaceuticals and Acetylon Pharmaceuticals. R.M.'s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict-of-interest policies. This work was funded by a grant from NIH RO1 GM084127 (to H.B.A.). NR 31 TC 11 Z9 12 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0755 EI 2163-0763 J9 J TRAUMA ACUTE CARE JI J. Trauma Acute Care Surg. PD FEB PY 2015 VL 78 IS 2 BP 378 EP 385 DI 10.1097/TA.0000000000000510 PG 8 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA CA3TF UT WOS:000348828300023 PM 25757125 ER PT J AU Obedin-Maliver, J AF Obedin-Maliver, Juno TI Time for OBGYNs to Care for People of All Genders SO JOURNAL OF WOMENS HEALTH LA English DT Editorial Material ID TRANSGENDER; GAY C1 [Obedin-Maliver, Juno] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Obedin-Maliver, Juno] San Francisco VA Med Ctr, Dept Internal Med, San Francisco, CA USA. [Obedin-Maliver, Juno] Stanford Univ, Sch Med, Lesbian Gay Bisexual & Transgender Med Educ Res G, Stanford, CA 94305 USA. RP Obedin-Maliver, J (reprint author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, 505 Parnassus Ave, San Francisco, CA 94143 USA. EM ObedinMaliverJ@obgyn.ucsf.edu NR 16 TC 1 Z9 1 U1 0 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD FEB 1 PY 2015 VL 24 IS 2 BP 109 EP 111 DI 10.1089/jwh.2015.1518 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA CB0NI UT WOS:000349322700001 PM 25682814 ER PT J AU Percac-Lima, S Ashburner, JM McCarthy, AM Piawah, S Atlas, SJ AF Percac-Lima, Sanja Ashburner, Jeffrey M. McCarthy, Anne Marie Piawah, Sorbarikor Atlas, Steven J. TI Patient Navigation to Improve Follow-Up of Abnormal Mammograms Among Disadvantaged Women SO JOURNAL OF WOMENS HEALTH LA English DT Article ID BREAST-CANCER DIAGNOSIS; RESEARCH-PROGRAM; PRIMARY-CARE; RESOLUTION; POPULATION; SURVIVAL; SCIENCE; SYSTEM; TRIAL; STATE AB Background: Patient navigation (PN) can improve breast cancer care among disadvantaged women. We evaluated the impact of a PN program on follow-up after an abnormal mammogram. Methods: Between 2007 and 2010, disadvantaged women with an abnormal mammogram (Breast Imaging-Reporting and Data System [BI-RADS] codes 0, 3, 4, 5) cared for in a community health center (CHC) with PN were compared to those receiving care in 11 network practices without PN. Multivariable logistic regression and Cox proportional hazards modeling were used to compare the percentages receiving appropriate follow-up and time to follow-up between the groups. Results: Abnormal mammography findings were reported for 132 women in the CHC with PN and 168 from practices without PN. The percentage of women with appropriate follow-up care was higher in the practice with PN than in non-PN practices (90.4% vs. 75.3%, adjusted p=0.006). Results varied by BI-RADS score for women in PN and non-PN practices (BI-RADS 0, 93.7% vs. 90.2%, p=0.24; BI-RADS 3, 85.7% vs. 49.2%, p=0.003; BI-RADS 4/5, 95.1% vs. 82.8%, p=0.26). Time to follow-up was similar for BI-RADS 0 and occurred sooner for women in the PN practice than in non-PN practices for BI-RADS 3 and 4/5 (BI-RADS 3, adjusted hazard ratio [aHR], 95% confidence interval [CI]: 2.41 [1.36-4.27], BI-RADS 4/5, aHR [95% CI]: 1.41 [0.88-2.24]). Conclusions: Disadvantaged women from a CHC with PN were more likely to receive appropriate follow-up after an abnormal mammogram than were those from practices without PN. Expanding PN to include all disadvantaged women within primary care networks could improve equity in cancer care. C1 [Percac-Lima, Sanja] Massachusetts Gen Hosp, Chelsea HealthCare Ctr, Chelsea, MA 02150 USA. [Percac-Lima, Sanja; Ashburner, Jeffrey M.; McCarthy, Anne Marie; Atlas, Steven J.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA. [Percac-Lima, Sanja] Massachusetts Gen Hosp, Ctr Community Hlth Improvement, Boston, MA 02114 USA. [Percac-Lima, Sanja; Piawah, Sorbarikor; Atlas, Steven J.] Harvard Univ, Sch Med, Dept Internal Med, Boston, MA USA. RP Percac-Lima, S (reprint author), Massachusetts Gen Hosp, Chelsea HealthCare Ctr, 151 Everett Ave, Chelsea, MA 02150 USA. EM Spercaclima@mgh.harvard.edu FU Avon Foundation; Control Career Development Award for Primary Care Physicians, from the American Cancer Society [CCCDAA-14-012-01-CCCDA]; Lazarex Cancer Foundation; National Institutes of Health, National Cancer Institute [NCI U54 CA163313] FX This program was funded by a grant from Avon Foundation. Sanja Percac-Lima, MD, is supported in part by the Control Career Development Award for Primary Care Physicians, CCCDAA-14-012-01-CCCDA, from the American Cancer Society and Lazarex Cancer Foundation. Anne Marie McCarthy, MD, is supported by a grant from the National Institutes of Health, National Cancer Institute: NCI U54 CA163313. NR 25 TC 2 Z9 2 U1 2 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD FEB 1 PY 2015 VL 24 IS 2 BP 138 EP 143 DI 10.1089/jwh.2014.4954 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA CB0NI UT WOS:000349322700007 PM 25522246 ER PT J AU Zhong, F Chen, HB Wei, CG Zhang, WJ Li, ZZ Jain, MK Chuang, PY Chen, HY Wang, YJ Mallipattu, SK He, JC AF Zhong, Fang Chen, Habing Wei, Chengguo Zhang, Weijia Li, Zhengzhe Jain, Mukesh K. Chuang, Peter Y. Chen, Hongyu Wang, Yongjun Mallipattu, Sandeep K. He, John C. TI Reduced Kruppel-like factor 2 expression may aggravate the endothelial injury of diabetic nephropathy SO KIDNEY INTERNATIONAL LA English DT Article DE diabetic nephropathy; endothelium; podocyte ID PROTEASE-ACTIVATED RECEPTOR-1; TRANSCRIPTIONAL REGULATOR; GENE-EXPRESSION; PROINFLAMMATORY ACTIVATION; GLOMERULAR ENDOTHELIUM; UP-REGULATION; KLF2; MICE; PERMEABILITY; DEFICIENCY AB Kruppel-like factor 2 (KLF2), a shear stress-inducible transcription factor, has endoprotective effects. In streptozotocin-induced diabetic rats, we found that glomerular Klf2 expression was reduced in comparison with nondiabetic rats. However, normalization of hyperglycemia by insulin treatment increased Klf2 expression to a level higher than that of nondiabetic rats. Consistent with this, we found that Klf2 expression was suppressed by high glucose but increased by insulin in cultured endothelial cells. To determine the role of KLF2 in streptozotocin-induced diabetic nephropathy, we used endothelial cell-specific Klf2 heterozygous knockout mice and found that diabetic knockout mice developed more kidney/glomerular hypertrophy and proteinuria than diabetic wild-type mice. Glomerular expression of Vegfa, Flk1, and angiopoietin 2 increased, but expression of Flt1, Tie2, and angiopoietin 1 decreased, in diabetic knockout mice compared with diabetic wild-type mice. Glomerular expression of ZO-1, glycocalyx, and eNOS was also decreased in diabetic knockout compared with diabetic wild-type mice. These data suggest knockdown of Klf2 expression in the endothelial cells induced more endothelial cell injury. Interestingly, podocyte injury was also more prominent in diabetic knockout compared with diabetic wild-type mice, indicating a cross talk between these two cell types. Thus, KLF2 may play a role in glomerular endothelial cell injury in early diabetic nephropathy. C1 [Zhong, Fang; Chen, Habing; Wei, Chengguo; Zhang, Weijia; Li, Zhengzhe; Chuang, Peter Y.; He, John C.] Icahn Sch Med Mt Sinai, Dept Med Nephrol, New York, NY 10029 USA. [Zhong, Fang; Chen, Hongyu; Wang, Yongjun] Zhejiang Chinese Med Univ, Hang Zhou Hosp Tradit Chinese Med, Dept Nephrol, Zhejiang, Peoples R China. [Chen, Habing] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai Clin Ctr Diabet, Shanghai Diabet Inst,Dept Endocrinol & Metab,Shan, Shanghai, Peoples R China. [Jain, Mukesh K.] Case Western Reserve Univ, Case Cardiovasc Res Inst, Dept Med, Cleveland, OH 44106 USA. [Mallipattu, Sandeep K.] SUNY Stony Brook, Dept Med, Div Nephrol, Stony Brook, NY 11794 USA. [He, John C.] James J Peters VAMC, Renal Sect, Bronx, NY USA. RP He, JC (reprint author), Mt Sinai Sch Med, Div Nephrol, Box 1243,1 Gustave L Levy Pl, New York, NY 10029 USA. EM cijiang.he@mssm.edu FU Chinese 973 fund [2012CB517601]; VA Merit Award [NIH 1R01DK078897, NIH1R01DK088541, NIH P01-DK-56492] FX JCH is supported by Chinese 973 fund 2012CB517601, VA Merit Award, NIH 1R01DK078897, NIH1R01DK088541, NIH P01-DK-56492. JCH is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 56 TC 9 Z9 10 U1 1 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD FEB PY 2015 VL 87 IS 2 BP 382 EP 395 DI 10.1038/ki.2014.286 PG 14 WC Urology & Nephrology SC Urology & Nephrology GA CA5UH UT WOS:000348972800019 PM 25185079 ER PT J AU Powell, RA Mwangi-Powell, FN Radbruch, L Yamey, G Krakauer, EL Spence, D Ali, Z Baxter, S De Lima, L Xhixha, A Rajagopal, MR Knaul, F AF Powell, Richard A. Mwangi-Powell, Faith N. Radbruch, Lukas Yamey, Gavin Krakauer, Eric L. Spence, Dingle Ali, Zipporah Baxter, Sharon De Lima, Liliana Xhixha, Ali Rajagopal, M. R. Knaul, Felicia TI Putting palliative care on the global health agenda SO LANCET ONCOLOGY LA English DT Editorial Material C1 [Mwangi-Powell, Faith N.] Univ Res Co, Nairobi, Kenya. [Radbruch, Lukas] Univ Hosp Bonn, Dept Palliat Med, Bonn, Germany. [Yamey, Gavin] Univ Calif San Francisco, Global Hlth Grp, Evidence Policy Initiat, San Francisco, CA USA. [Krakauer, Eric L.] Harvard Univ, Sch Med, Boston, MA USA. [Krakauer, Eric L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Krakauer, Eric L.] Partners Hlth, Boston, MA USA. [Spence, Dingle] Hope Inst Hosp, Kingston, Jamaica. [Ali, Zipporah] Kenya Hosp & Palliat Care Assoc, Nairobi, Kenya. [Baxter, Sharon] Canadian Hosp Palliat Care Assoc, Ottawa, ON, Canada. [De Lima, Liliana] Int Assoc Hosp & Palliat Care, Houston, TX USA. [Xhixha, Ali] Ryder Albania Assoc, Tirana, Albania. [Rajagopal, M. R.] WHO, Collaborating Ctr Training & Policy Access Pain R, Trivandrum, Kerala, India. [Knaul, Felicia] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Harvard Global Equity Initiat, Boston, MA USA. RP Powell, RA (reprint author), POB 459-00621, Nairobi, Kenya. EM richard2powell@yahoo.co.uk NR 8 TC 4 Z9 4 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 EI 1474-5488 J9 LANCET ONCOL JI Lancet Oncol. PD FEB PY 2015 VL 16 IS 2 BP 131 EP 133 PG 3 WC Oncology SC Oncology GA CA3YR UT WOS:000348841700026 PM 25638676 ER PT J AU Yang, JCH Wu, YL Schuler, M Sebastian, M Popat, S Yamamoto, N Zhou, CC Hu, CP O'Byrne, K Feng, JF Lu, S Huang, YC Geater, SL Lee, KY Tsai, CM Gorbunova, V Hirsh, V Bennouna, J Orlov, S Mok, T Boyer, M Su, WC Lee, KH Kato, T Massey, D Shahidi, M Zazulina, V Sequist, LV AF Yang, James Chih-Hsin Wu, Yi-Long Schuler, Martin Sebastian, Martin Popat, Sanjay Yamamoto, Nobuyuki Zhou, Caicun Hu, Cheng-Ping O'Byrne, Kenneth Feng, Jifeng Lu, Shun Huang, Yunchao Geater, Sarayut L. Lee, Kye Young Tsai, Chun-Ming Gorbunova, Vera Hirsh, Vera Bennouna, Jaafar Orlov, Sergey Mok, Tony Boyer, Michael Su, Wu-Chou Lee, Ki Hyeong Kato, Terufumi Massey, Dan Shahidi, Mehdi Zazulina, Victoria Sequist, Lecia V. TI Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials SO LANCET ONCOLOGY LA English DT Article ID GROWTH-FACTOR RECEPTOR; OPEN-LABEL; 1ST-LINE TREATMENT; CANCER PATIENTS; CARBOPLATIN-PACLITAXEL; EXON-21 MUTATIONS; CLINICAL-TRIALS; GEFITINIB; ERLOTINIB; MULTICENTER AB Background We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Methods Previously untreated patients with EGFR mutation-positive stage IIIB or IV lung adenocarcinoma were enrolled in LUX-Lung 3 (n=345) and LUX-Lung 6 (n=364). These patients were randomly assigned in a 2:1 ratio to receive afatinib or chemotherapy (pemetrexed-cisplatin [LUX-Lung 3] or gemcitabine-cisplatin [LUX-Lung 6]), stratified by EGFR mutation (exon 19 deletion [del19], Leu858Arg, or other) and ethnic origin (LUX-Lung 3 only). We planned analyses of mature overall survival data in the intention-to-treat population after 209 (LUX-Lung 3) and 237 (LUX-Lung 6) deaths. These ongoing studies are registered with ClinicalTrials.gov, numbers NCT00949650 and NCT01121393. Findings Median follow-up in LUX-Lung 3 was 41 months (IQR 35-44); 213 (62%) of 345 patients had died. Median follow-up in LUX-Lung 6 was 33 months (IQR 31-37); 246 (68%) of 364 patients had died. In LUX-Lung 3, median overall survival was 28.2 months (95% CI 24.6-33.6) in the afatinib group and 28.2 months (20.7-33.2) in the pemetrexed-cisplatin group (HR 0.88, 95% CI 0.66-1.17, p=0.39). In LUX-Lung 6, median overall survival was 23.1 months (95% CI 20.4-27.3) in the afatinib group and 23.5 months (18.0-25.6) in the gemcitabine-cisplatin group (HR 0.93, 95% CI 0.72-1.22, p=0.61). However, in preplanned analyses, overall survival was significantly longer for patients with del19-positive tumours in the afatinib group than in the chemotherapy group in both trials: in LUX-Lung 3, median overall survival was 33.3 months (95% CI 26.8-41.5) in the afatinib group versus 21.1 months (16.3-30.7) in the chemotherapy group (HR 0.54, 95% CI 0.36-0.79, p=0.0015); in LUX-Lung 6, it was 31.4 months (95% CI 24.2-35.3) versus 18.4 months (14.6-25.6), respectively (HR 0.64, 95% CI 0.44-0.94, p=0.023). By contrast, there were no significant differences by treatment group for patients with EGFR Leu858Arg-positive tumours in either trial: in LUX-Lung 3, median overall survival was 27.6 months (19.8-41.7) in the afatinib group versus 40.3 months (24.3-not estimable) in the chemotherapy group (HR 1.30, 95% CI 0.80-2.11, p=0.29); in LUX-Lung 6, it was 19.6 months (95% CI 17.0-22.1) versus 24.3 months (19.0-27.0), respectively (HR 1.22, 95% CI 0.81-1.83, p=0.34). In both trials, the most common afatinib-related grade 3-4 adverse events were rash or acne (37 [16%] of 229 patients in LUX-Lung 3 and 35 [15%] of 239 patients in LUX-Lung 6), diarrhoea (33 [14%] and 13 [5%]), paronychia (26 [11%] in LUX-Lung 3 only), and stomatitis or mucositis (13 [5%] in LUX-Lung 6 only). In LUX-Lung 3, neutropenia (20 [18%] of 111 patients), fatigue (14 [13%]) and leucopenia (nine [8%]) were the most common chemotherapy-related grade 3-4 adverse events, while in LUX-Lung 6, the most common chemotherapy-related grade 3-4 adverse events were neutropenia (30 [27%] of 113 patients), vomiting (22 [19%]), and leucopenia (17 [15%]). Interpretation Although afatinib did not improve overall survival in the whole population of either trial, overall survival was improved with the drug for patients with del19 EGFR mutations. The absence of an effect in patients with Leu858Arg EGFR mutations suggests that EGFR del19-positive disease might be distinct from Leu858Arg-positive disease and that these subgroups should be analysed separately in future trials. C1 [Yang, James Chih-Hsin] Natl Taiwan Univ Hosp, Taipei 100, Taiwan. [Yang, James Chih-Hsin] Natl Taiwan Univ, Taipei 10764, Taiwan. [Wu, Yi-Long] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China. [Wu, Yi-Long] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China. [Schuler, Martin] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany. [Sebastian, Martin] Goethe Univ Frankfurt, Med Ctr, D-60054 Frankfurt, Germany. [Sebastian, Martin] Johannes Gutenberg Univ Mainz, Univ Med Ctr, D-55122 Mainz, Germany. [Popat, Sanjay] Royal Marsden Hosp, London SW3 6JJ, England. [Yamamoto, Nobuyuki] Wakayama Med Univ, Wakayama, Japan. [Zhou, Caicun] Tongji Univ, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China. [Hu, Cheng-Ping] Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China. [O'Byrne, Kenneth] Princess Alexandra Hosp, Brisbane, Qld, Australia. [O'Byrne, Kenneth] Queensland Univ Technol, Brisbane, Qld 4001, Australia. [Feng, Jifeng] Jiangsu Prov Canc Hosp, Nanjing, Jiangsu, Peoples R China. [Lu, Shun] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Tumor Clin Med Ctr, Shanghai 200030, Peoples R China. [Huang, Yunchao] Kunming Med Univ, Affiliated Hosp 3, Yunnan Tumor Hosp, Kunming, Yunnan Province, Peoples R China. [Geater, Sarayut L.] Prince Songkla Univ, Hat Yai, Thailand. [Lee, Kye Young] Konkuk Univ, Med Ctr, Dept Internal Med, Seoul, South Korea. [Tsai, Chun-Ming] Taipei Vet Gen Hosp, Taipei, Taiwan. [Gorbunova, Vera] Russian Acad Med Sci, FSBI N N Blokhin Russian Canc Res Ctr, Moscow, Russia. [Hirsh, Vera] McGill Univ, Montreal, PQ, Canada. [Bennouna, Jaafar] Inst Cancerol Ouest, Nantes, France. [Orlov, Sergey] Pavlov State Med Univ, St Petersburg, Russia. [Mok, Tony] Chinese Univ Hong Kong, Hong Kong Canc Inst, State Key Lab South China, Hong Kong, Hong Kong, Peoples R China. [Boyer, Michael] Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia. [Su, Wu-Chou] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan. [Lee, Ki Hyeong] Chungbuk Natl Univ Hosp, Cheongju, South Korea. [Kato, Terufumi] Kanagawa Cardiovasc & Resp Ctr, Yokohama, Kanagawa, Japan. [Massey, Dan; Shahidi, Mehdi; Zazulina, Victoria] Boehringer Ingelheim Ltd UK, Bracknell, Berks, England. [Sequist, Lecia V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sequist, Lecia V.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Yang, JCH (reprint author), Natl Taiwan Univ Hosp, Taipei 100, Taiwan. EM chihyang@ntu.edu.tw RI bennouna, jaafar/K-9350-2015; OI Yang, James Chih-Hsin/0000-0002-5586-5138 FU Boehringer Ingelheim FX Boehringer Ingelheim. NR 30 TC 280 Z9 287 U1 12 U2 50 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 EI 1474-5488 J9 LANCET ONCOL JI Lancet Oncol. PD FEB PY 2015 VL 16 IS 2 BP 141 EP 151 DI 10.1016/S1470-2045(14)71173-8 PG 11 WC Oncology SC Oncology GA CA3YR UT WOS:000348841700030 PM 25589191 ER PT J AU Ryan, CJ Smith, MR Fizazi, K Saad, F Mulders, PFA Sternberg, CN Miller, K Logothetis, CJ Shore, ND Small, EJ Carles, J Flaig, TW Taplin, ME Higano, CS de Souza, P de Bono, JS Griffin, TW De Porre, P Yu, MK Park, YC Li, J Kheoh, T Naini, V Molina, A Rathkopf, DE AF Ryan, Charles J. Smith, Matthew R. Fizazi, Karim Saad, Fred Mulders, Peter F. A. Sternberg, Cora N. Miller, Kurt Logothetis, Christopher J. Shore, Neal D. Small, Eric J. Carles, Joan Flaig, Thomas W. Taplin, Mary-Ellen Higano, Celestia S. de Souza, Paul de Bono, Johann S. s Griffin, Thomas W. De Porre, Peter Yu, Margaret K. Park, Youn C. Li, Jinhui Kheoh, Thian Naini, Vahid Molina, Arturo Rathkopf, Dana E. CA COU-AA-302 Investigators TI Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study SO LANCET ONCOLOGY LA English DT Article ID DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; CABAZITAXEL; TRIAL AB Background Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim analyses of the COU-AA-302 trial. Here, we present the prespecified final analysis of the trial, assessing the effect of abiraterone acetate plus prednisone on overall survival, time to opiate use, and use of other subsequent therapies. Methods In this placebo-controlled, double-blind, randomised phase 3 study, 1088 asymptomatic or mildly symptomatic patients with chemotherapy-naive prostate cancer stratified by Eastern Cooperative Oncology performance status (0 vs 1) were randomly assigned with a permuted block allocation scheme via a web response system in a 1:1 ratio to receive either abiraterone acetate (1000 mg once daily) plus prednisone (5 mg twice daily; abiraterone acetate group) or placebo plus prednisone (placebo group). Coprimary endpoints were radiographic progression-free survival and overall survival analysed in the intention-to-treat population. The study is registered with ClinicalTrials.gov, number NCT00887198. Findings At a median follow-up of 49 . 2 months (IQR 47.0-51.8), 741 (96%) of the prespecifi ed 773 death events for the final analysis had been observed: 354 (65%) of 546 patients in the abiraterone acetate group and 387 (71%) of 542 in the placebo group. 238 (44%) patients initially receiving prednisone alone subsequently received abiraterone acetate plus prednisone as crossover per protocol (93 patients) or as subsequent therapy (145 patients). Overall, 365 (67%) patients in the abiraterone acetate group and 435 (80%) in the placebo group received subsequent treatment with one or more approved agents. Median overall survival was significantly longer in the abiraterone acetate group than in the placebo group (34.7 months [95% CI 32.7-36.8] vs 30.3 months [28.7-33.3]; hazard ratio 0.81 [95% CI 0.70-0.93]; p = 0.0033). The most common grade 3-4 adverse events of special interest were cardiac disorders (41 [8%] of 542 patients in the abiraterone acetate group vs 20 [4%] of 540 patients in the placebo group), increased alanine aminotransferase (32 [6%] vs four [<1%]), and hypertension (25 [5%] vs 17 [3%]). Interpretation In this randomised phase 3 trial with a median follow-up of more than 4 years, treatment with abiraterone acetate prolonged overall survival compared with prednisone alone by a margin that was both clinically and statistically significant. These results further support the favourable safety profile of abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. C1 [Ryan, Charles J.; Small, Eric J.] UCSF, Helen Diller Family Comprehens Canc Ctr, Genitourinary Med Oncol Program, San Francisco, CA 94115 USA. [Smith, Matthew R.] Harvard Univ, Sch Med, Boston, MA USA. [Smith, Matthew R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Fizazi, Karim] Univ Paris Sud, Inst Gustave Roussy, Villejuif, France. [Saad, Fred] Univ Montreal, Montreal, PQ, Canada. [Mulders, Peter F. A.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands. [Sternberg, Cora N.] San Camillo & Forlanini Hosp, Rome, Italy. [Miller, Kurt] Charite, Berlin, Germany. [Logothetis, Christopher J.] Anderson Canc Ctr, Houston, TX USA. [Shore, Neal D.] Atlant Urol Clin, Carolina Urol Res Ctr, Myrtle Beach, SC USA. [Carles, Joan] Vall Hebron Univ Hosp, Barcelona, Spain. [Carles, Joan] Vall Hebron Inst Oncol, Barcelona, Spain. [Flaig, Thomas W.] Univ Colorado, Ctr Canc, Aurora, CO USA. [Flaig, Thomas W.] Univ Colorado, Sch Med, Aurora, CO USA. [Taplin, Mary-Ellen] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Higano, Celestia S.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [de Souza, Paul] Univ Western Sydney, Sch Med, Liverpool, Merseyside, Australia. [de Souza, Paul] Ingham Inst, Liverpool, Merseyside, Australia. [de Bono, Johann S. s] Inst Canc Res, Sutton, Surrey, England. [de Bono, Johann S. s] Royal Marsden Hosp, Sutton, Surrey, England. [Griffin, Thomas W.; Kheoh, Thian; Naini, Vahid] Janssen Res & Dev, Los Angeles, CA USA. [Park, Youn C.; Li, Jinhui] Janssen Res & Dev, Raritan, NJ USA. [Molina, Arturo] Janssen Res & Dev, Menlo Pk, CA USA. [Rathkopf, Dana E.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. RP Ryan, CJ (reprint author), UCSF, Helen Diller Family Comprehens Canc Ctr, Genitourinary Med Oncol Program, 1600 Div St, San Francisco, CA 94115 USA. EM ryanc@medicine.ucsf.edu RI Mulders, Peter/H-8076-2014; Gerritsen, W.R./H-8031-2014 FU Janssen Research Development; Janssen Global Services FX This study was funded by Janssen Research & Development (formerly Ortho Biotech Oncology Research & Development unit of Cougar Biotechnology). We thank the patients who volunteered to participate in this study and the study site staff who cared for them, and Ira Mills (PAREXEL, Hackensack, NJ, USA) for editorial assistance funded by Janssen Global Services. NR 23 TC 179 Z9 180 U1 2 U2 25 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 EI 1474-5488 J9 LANCET ONCOL JI Lancet Oncol. PD FEB PY 2015 VL 16 IS 2 BP 152 EP 160 DI 10.1016/S1470-2045(14)71205-7 PG 9 WC Oncology SC Oncology GA CA3YR UT WOS:000348841700031 PM 25601341 ER PT J AU Singh, JP Yang, S Mulvey, EP AF Singh, Jay P. Yang, Suzanne Mulvey, Edward P. CA RAGEE Grp TI Reporting Guidance for Violence Risk Assessment Predictive Validity Studies: The RAGEE Statement SO LAW AND HUMAN BEHAVIOR LA English DT Article DE reporting guidance; risk assessment; violence; checklist; RAGEE ID RANDOMIZED CONTROLLED-TRIALS; DIAGNOSTIC-ACCURACY; QUALITY; CONSORT; GUIDELINES; RECOMMENDATIONS; RELIABILITY; INDICATORS; EXTENSION; STANDARDS AB Available reporting guidelines for prognostic and diagnostic accuracy studies apply primarily to biological assessment and outcomes, overlooking behavioral issues with major public health and safety implications such as violence. The present study aimed to develop the first set of reporting guidance for predictive validity studies of violence risk assessments: the Risk Assessment Guidelines for the Evaluation of Efficacy (RAGEE) Statement. A systematic search of 8 electronic databases prior to September 2012 identified 279 reporting guidelines for prognostic and diagnostic accuracy studies. Unique items were extracted and modified to make them relevant to risk assessment. A 4-wave Delphi process involving a multidisciplinary team of 37 international experts resulted in a 50-item reporting checklist. The panelists endorsed the RAGEE Statement checklist as being highly satisfactory and as indicating study features that should be reported routinely in manuscripts. Use of these proposed standards has the potential to improve the quality of the risk assessment literature. C1 [Singh, Jay P.] Singh Inst Forens Res LLC, Reston, VA 20190 USA. [Singh, Jay P.] Univ Konstanz, Dept Psychol, Constance, Germany. [Yang, Suzanne] Vet Affairs Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr VISN4, Pittsburgh, PA USA. [Yang, Suzanne; Mulvey, Edward P.] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA 15260 USA. RP Singh, JP (reprint author), Singh Inst Forens Res LLC, 11700 Plaza Amer Dr,Suite 810, Reston, VA 20190 USA. EM jaysingh@sifrllc.com NR 32 TC 7 Z9 7 U1 0 U2 4 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0147-7307 EI 1573-661X J9 LAW HUMAN BEHAV JI Law Hum. Behav. PD FEB PY 2015 VL 39 IS 1 BP 15 EP 22 DI 10.1037/lhb0000090 PG 8 WC Law; Psychology, Social SC Government & Law; Psychology GA CA6KN UT WOS:000349022200002 PM 25133921 ER PT J AU Fontana, RJ Ellerbe, C Durkalski, VE Rangnekar, A Reddy, RK Stravitz, T McGuire, B Davern, T Reuben, A Liou, I Fix, O Ganger, DR Chung, RT Schilsky, M Han, S Hynan, LS Sanders, C Lee, WM AF Fontana, Robert J. Ellerbe, Caitlyn Durkalski, Valerie E. Rangnekar, Amol Reddy, Rajender K. Stravitz, Todd McGuire, Brendan Davern, Timothy Reuben, Adrian Liou, Iris Fix, Oren Ganger, Daniel R. Chung, Raymond T. Schilsky, Mike Han, Steven Hynan, Linda S. Sanders, Corron Lee, William M. CA US Acute Liver Failure Study Grp TI Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study SO LIVER INTERNATIONAL LA English DT Article DE age; cerebral oedema; liver transplantation; prognosis; regeneration ID FULMINANT HEPATIC-FAILURE; QUALITY-OF-LIFE; LONG-TERM OUTCOMES; UNITED-STATES; SERUM PHOSPHATE; EARLY PREDICTOR; BLOOD LACTATE; TRANSPLANTATION; DISEASE; DYSFUNCTION AB Background & AimsThe long-term clinical outcomes in initial survivors with acute liver failure (ALF) are not well known. The aim of this study was to provide an overview of the 2-year clinical outcomes among initial survivors and liver transplant (LT) recipients that were alive 3weeks after enrolment in the Acute Liver Failure Study Group (ALFSG). MethodsOutcomes in adult ALFSG patients that were enrolled between 1998 and 2010 were reviewed. ResultsTwo-year patient survival was significantly higher in the 262 LT recipients (92.4%) compared to the 306 acetaminophen (APAP) spontaneous survivors (SS) (89.5%) and 200 non-APAP SS (75.5%) (P<0.0001). The causes of death were similar in the three groups but the time to death was significantly longer in the LT recipients (P<0.0001). Independent predictors of 2-year mortality in the APAP group were a high serum phosphate level and patient age (c-statistic=0.65 (0.54, 0.76)), patient age and days from jaundice to ALF onset in the non-APAP group (c-statistic=0.69 (0.60, 0.78)), and patient age, days from jaundice, and higher coma grade in the LT recipients (c-statistic=0.74 (0.61, 0.87)). The LT recipients were significantly more likely to be employed and have a higher educational level (P<0.05). ConclusionsTwo-year outcomes in initial survivors of ALF are generally good but non-APAP patients have a significantly lower survival which may relate to pre-existing medical comorbidities. Spontaneous survivors with APAP overdose experience substantial morbidity during follow-up from ongoing psychiatric and substance abuse issues. C1 [Fontana, Robert J.; Rangnekar, Amol] Univ Michigan, Div Gastroenterol, Dept Internal Med, Med Ctr, Ann Arbor, MI 48109 USA. [Ellerbe, Caitlyn; Durkalski, Valerie E.] Med Univ S Carolina, Dept Publ Hlth Sci, Div Biostat, Charleston, SC 29425 USA. [Reddy, Rajender K.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Stravitz, Todd] Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA. [McGuire, Brendan] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Davern, Timothy] Calif Pacific Med Ctr, San Francisco, CA USA. [Reuben, Adrian] Med Univ S Carolina, Dept Internal Med, Charleston, SC 29425 USA. [Liou, Iris] Univ Washington, Dept Internal Med, Seattle, WA 98195 USA. [Fix, Oren] Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA. [Ganger, Daniel R.] Northwestern Univ, Div Gastroenterol, Chicago, IL 60611 USA. [Chung, Raymond T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Schilsky, Mike] Yale Univ, Sect Transplantat & Immunol, New Haven, CT USA. [Han, Steven] Univ Calif Los Angeles, Dept Internal Med, Los Angeles, CA USA. [Hynan, Linda S.; Sanders, Corron; Lee, William M.] Univ Texas Southwestern, Dept Internal Med, Div Digest & Liver Dis, Dallas, TX USA. RP Fontana, RJ (reprint author), 3912 Taubman Ctr, Ann Arbor, MI 48109 USA. EM rfontana@med.umich.edu OI Ellerbe, Caitlyn/0000-0002-9905-4329 FU National Institute of Diabetes, Digestive and Kidney Diseases [DK U-01-58369]; Northwestern Medical Foundation; Southwestern Medical Foundation; NIDDK [T32 DK62708-01]; Michigan Institute for Clinical and Health Research FX We gratefully acknowledge the support provided by the members of The Acute Liver Failure Study Group. This study was funded by the National Institute of Diabetes, Digestive and Kidney Diseases (DK U-01-58369). Additional funding provided by the Tips Fund of Northwestern Medical Foundation and the Jeanne Roberts and Rollin and Mary Ella King Funds of the Southwestern Medical Foundation. In addition, Dr. Rangnekar is supported by the T32 DK62708-01, NIDDK Training Grant in Gastrointestinal Epidemiology, and a Clinical and Translational Science Award from the Michigan Institute for Clinical and Health Research. NR 36 TC 7 Z9 7 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1478-3223 EI 1478-3231 J9 LIVER INT JI Liver Int. PD FEB PY 2015 VL 35 IS 2 BP 370 EP 380 DI 10.1111/liv.12632 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CA2BR UT WOS:000348714500013 PM 25039930 ER PT J AU Norman, GL Yang, CY Ostendorff, HP Shums, Z Lim, MJ Wang, JJ Awad, A Hirschfield, GM Milkiewicz, P Bloch, DB Rothschild, KJ Bowlus, CL Adamopoulos, IE Leung, PSC Janssen, HJ Cheung, AC Coltescu, C Gershwin, ME AF Norman, Gary L. Yang, Chen-Yen Ostendorff, Heather P. Shums, Zakera Lim, Mark J. Wang, Jinjun Awad, Amany Hirschfield, Gideon M. Milkiewicz, Piotr Bloch, Donald B. Rothschild, Kenneth J. Bowlus, Christopher L. Adamopoulos, Iannis E. Leung, Patrick S. C. Janssen, Harry J. Cheung, Angela C. Coltescu, Catalina Gershwin, M. Eric TI Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis SO LIVER INTERNATIONAL LA English DT Article DE diagnostics; liver; serology ID DEPENDENT ANION CHANNEL; APOPTOTIC CELL-DEATH; ANTIMITOCHONDRIAL ANTIBODIES; CLINICAL-SIGNIFICANCE; INCREASED EXPRESSION; SJOGRENS-SYNDROME; NUCLEAR; PROTEIN; IDENTIFICATION; AUTOANTIGENS AB Background & AimsUsing high-density human recombinant protein microarrays, we identified two potential biomarkers, kelch-like 12 (KLHL12) and hexokinase-1 (HK1), in primary biliary cirrhosis (PBC). The objective of this study was to determine the diagnostic value of anti-KLHL12/HK1 autoantibodies in PBC. Initial discovery used sera from 22 patients with PBC and 62 non-PBC controls. KLHL12 and HK1 proteins were then analysed for immunoglobulin reactivity by immunoblot and enzyme-linked immunosorbent assay (ELISA) in two independent cohorts of PBC and disease/healthy control patients. MethodsSerum samples from 100 patients with PBC and 165 non-PBC disease controls were analysed by immunoblot and samples from 366 patients with PBC, 174 disease controls, and 80 healthy donors were tested by ELISA. ResultsAnti-KLHL12 and anti-HK1 antibodies were each detected more frequently in PBC compared with non-PBC disease controls (P<0.001). Not only are both markers highly specific for PBC (95%) but they also yielded higher sensitivity than anti-gp210 and anti-sp100 antibodies. Combining anti-HK1 and anti-KLHL12 with available markers (MIT3, gp210 and sp100), increased the diagnostic sensitivity for PBC. Most importantly, anti-KLHL12 and anti-HK1 antibodies were present in 10-35% of anti-mitochondrial antibody (AMA)-negative PBC patients and adding these two biomarkers to conventional PBC assays dramatically improved the serological sensitivity in AMA-negative PBC from 55% to 75% in immunoblot and 48.3% to 68.5% in ELISA. ConclusionsThe addition of tests for highly specific anti-KLHL12 and anti-HK1 antibodies to AMA and ANA serological assays significantly improves efficacy in the clinical detection and diagnosis of PBC, especially for AMA-negative subjects. C1 [Norman, Gary L.; Shums, Zakera] Inova Diagnost, San Diego, CA USA. [Yang, Chen-Yen; Wang, Jinjun; Leung, Patrick S. C.; Gershwin, M. Eric] Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA. [Ostendorff, Heather P.; Lim, Mark J.; Awad, Amany; Rothschild, Kenneth J.] AmberGen Inc, Watertown, MA USA. [Hirschfield, Gideon M.] Univ Birmingham, Liver Res Ctr, Inst Biomed Res, Birmingham, W Midlands, England. [Milkiewicz, Piotr] Med Univ Warsaw, Dept Gen Transplant & Liver Surg, Liver & Internal Med Unit, Warsaw, Poland. [Bloch, Donald B.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Harvard, MA USA. [Bloch, Donald B.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Gen Med Serv, Harvard, MA USA. [Bloch, Donald B.] Massachusetts Gen Hosp, Anesthesia Ctr Crit Care Res, Dept Anesthesia Crit Care & Pain Med, Harvard, MA USA. [Bowlus, Christopher L.] Harvard Univ, Sch Med, Harvard, MA USA. [Bowlus, Christopher L.] Univ Calif Davis, Div Gastroenterol & Hepatol, Davis, CA 95616 USA. [Adamopoulos, Iannis E.] Shriners Hosp Northern Calif, Inst Pediat & Regenerat Med, Sacramento, CA USA. [Janssen, Harry J.; Cheung, Angela C.] Univ Toronto, Div Gastroenterol, Toronto, ON, Canada. [Janssen, Harry J.] Erasmus MC Univ Med Ctr Rotterdam, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands. [Coltescu, Catalina] Univ Hlth Network, Toronto Western Hosp, Toronto Ctr Liver Dis, Toronto, ON, Canada. RP Gershwin, ME (reprint author), Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, 451 Hlth Sci Dr,Suite 6510, Davis, CA 95616 USA. EM megershwin@ucdavis.edu RI Hirschfield, Gideon/M-2143-2015; Bowlus, Christopher/N-9276-2016 OI Hirschfield, Gideon/0000-0002-6736-2255; Bowlus, Christopher/0000-0002-3906-6811 FU SBIR from the National Institute of Allergy and Infectious Diseases (NIAID) [R44 AI052525] FX Financial Support: The portions of the work performed by AmberGen and MGH were funded in part by SBIR grant number R44 AI052525 from the National Institute of Allergy and Infectious Diseases (NIAID) to AmberGen. NR 50 TC 11 Z9 12 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1478-3223 EI 1478-3231 J9 LIVER INT JI Liver Int. PD FEB PY 2015 VL 35 IS 2 BP 642 EP 651 DI 10.1111/liv.12690 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CA2BR UT WOS:000348714500044 PM 25243383 ER PT J AU Saidi, RF Razavi, M Cosimi, AB Ko, DSC AF Saidi, Reza F. Razavi, Moaven Cosimi, A. Benedict Ko, Dicken S. C. TI Competition in Liver Transplantation: Helpful or Harmful? SO LIVER TRANSPLANTATION LA English DT Article ID ORGAN PROCUREMENT ORGANIZATIONS; RENAL-TRANSPLANTATION; RESOURCE UTILIZATION; SURVIVAL BENEFIT; CARDIAC DEATH; UNITED-STATES; ALLOCATION; MELD; CENTERS; DONORS AB Improved outcomes of liver transplantation have led to increases in the numbers of US transplant centers and candidates on the list. The resultant and ever-expanding organ shortage has created competition among centers, especially in regions with multiple liver transplant programs. Multiple reports now document that competition among the country's transplant centers has led to the listing of increasingly high-risk patients and the utilization of more marginal liver allografts. The transplant and medical communities at large should carefully re-evaluate these practices and promote innovative approaches to restoring trust in the allocation of donor organs and confirming that there is nationwide conformity in the guidelines used for evaluating and listing potential candidates for this scarce resource. Liver Transpl 21:145-150, 2015. (c) 2014 AASLD. C1 [Saidi, Reza F.] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Div Organ Transplantat,Dept Surg, Providence, RI 02903 USA. [Razavi, Moaven] Brandeis Univ, Heller Sch, Schneider Inst Hlth Policy, Waltham, MA 02254 USA. [Cosimi, A. Benedict; Ko, Dicken S. C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplant Ctr, Boston, MA USA. RP Saidi, RF (reprint author), Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Div Organ Transplantat,Dept Surg, 593 Eddy St, Providence, RI 02903 USA. EM reza_saidi@brown.edu NR 35 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD FEB PY 2015 VL 21 IS 2 BP 145 EP 150 DI 10.1002/lt.24039 PG 6 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA CA0AC UT WOS:000348575400002 PM 25370903 ER PT J AU Vagefi, PA Dodge, JL Yao, FY Roberts, JP AF Vagefi, Parsia A. Dodge, Jennifer L. Yao, Francis Y. Roberts, John P. TI Potential Role of the Donor in Hepatocellular Carcinoma Recurrence After Liver Transplantation SO LIVER TRANSPLANTATION LA English DT Article ID ALLOCATION SYSTEM; HEPATITIS-C; MICROMETASTASES; RECIPIENTS; OUTGROWTH; SURVIVAL; PATIENT; MODEL; TIME; RISK AB A subset of liver transplantation (LT) recipients who undergo transplantation for hepatocellular carcinoma (HCC) will develop postoperative recurrence. There has yet to be a thorough investigation of donor factors influencing recurrence. Data regarding adult, primary LT recipients with HCC (n=5002) who underwent transplantation between January 1, 2006 and September 30, 2010 were extracted from the United Network for Organ Sharing database, and the cumulative incidence of post-LT recurrence by donor factors was subsequently estimated. Among the HCC LT recipients, 324 (6.5%) developed recurrence. An analysis of donor characteristics demonstrated a higher cumulative incidence of recurrence within 4 years of transplantation among recipients with donors60 years old (11.8% versus 7.3% with donors<60 years old, P<0.001) and with donors from a nonlocal share distribution (10.6% versus 7.4% with donors with a local share distribution, P=0.004). The latter 2 findings held true in a multivariate analysis: the risk of HCC recurrence increased by 70% for recipients of livers from donors60 years old [subhazard ratio (SHR)=1.70, 95% confidence interval (CI)=1.31-2.20, P<0.001] and by 42% for recipients of nonlocal share distribution livers (SHR=1.42, 95% CI=1.09-1.84, P=0.009) after adjustments for clinical characteristics. In conclusion, the consideration of certain donor factors may reduce the cumulative incidence of posttransplant HCC recurrence and thus improve long-term survival after LT. Liver Transpl 21:187-194, 2015. (c) 2014 AASLD. C1 [Vagefi, Parsia A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Transplant Surg,Dept Surg, Boston, MA 02114 USA. [Dodge, Jennifer L.; Roberts, John P.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. [Yao, Francis Y.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Vagefi, PA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Transplant Surg,Dept Surg, 55 Fruit St,White 521c, Boston, MA 02114 USA. EM pvagefi@mgh.harvard.edu FU Biostatistics Core of the University of California San Francisco Liver Center [P30 DK026743] FX This work was supported by the Biostatistics Core of the University of California San Francisco Liver Center (P30 DK026743). NR 19 TC 8 Z9 8 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD FEB PY 2015 VL 21 IS 2 BP 187 EP 194 DI 10.1002/lt.24042 PG 8 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA CA0AC UT WOS:000348575400007 PM 25371243 ER PT J AU Quinzanos, I Davis, L Keniston, A Nash, A Yazdany, J Fransen, R Hirsh, JM Zell, J AF Quinzanos, I. Davis, L. Keniston, A. Nash, A. Yazdany, J. Fransen, R. Hirsh, J. M. Zell, J. TI Application and feasibility of systemic lupus erythematosus reproductive health care quality indicators at a public urban rheumatology clinic SO LUPUS LA English DT Article DE Systemic lupus erythematous; quality indicators health care; reproductive health; teratogens; contraception ID PREGNANT-WOMEN; ARTHRITIS; CLASSIFICATION; PRESCRIPTION; MEDICATIONS; MOTHERS; SET; AGE AB Objectives Quality indicators (QIs) are evidence-based processes of care designed to represent the current standard of care. Reproductive health QIs for the care of patients with systemic lupus erythematosus (SLE) have recently been developed, and examine areas such as pregnancy screening for autoantibodies, treatment of pregnancy-associated antiphospholipid syndrome, and contraceptive counseling. This study was designed to investigate our performance on these QIs and to explore potential gaps in care and demographic predictors of adherence to the QIs in a safety-net hospital. Methods We performed a record review of patients with a diagnosis of SLE at Denver Health Medical Center (DH) through an electronic query of existing medical records and via chart review. Data were limited to female patients between the ages of 18 and 50 who were seen between July 2006 and August 2011. Results A total of 137 female patients between the ages of 18 and 50 were identified by ICD-9 code and confirmed by chart review to have SLE. Of these, 122 patients met the updated 1997 American College of Rheumatology SLE criteria and had intact reproductive systems. Only 15 pregnancies were documented during this five-year period, and adherence to autoantibody screening was 100 percent. We did not have any patients who were pregnant and met criteria for pregnancy-associated antiphospholipid syndrome. Sixty-five patients (53%) received potentially teratogenic medications, and 30 (46%) had documented discussions about these medications' potential risk upon their initiation. Predictors of whether patients received appropriate counseling included younger age (OR 0.92, CI 0.87-0.98) and those who did not describe English as their primary language (OR 0.24, CI 0.07-0.87) in the multivariate analysis. Conclusions We were able to detect an important gap in care regarding teratogenic medication education to SLE patients of childbearing potential in our public health academic clinic, as only one in two eligible patients had documented appropriate counseling at the initiation of a teratogenic medication. C1 [Quinzanos, I.; Davis, L.; Hirsh, J. M.; Zell, J.] Univ Colorado, Sch Med, Dept Med, Div Rheumatol, Aurora, CO USA. [Quinzanos, I.; Davis, L.] Denver Vet Affairs Med Ctr, Dept Med, Div Rheumatol, Denver, CO 80220 USA. [Quinzanos, I.; Davis, L.; Keniston, A.; Hirsh, J. M.; Zell, J.] Denver Hlth Med Ctr, Div Rheumatol, Dept Med, Denver, CO USA. [Nash, A.] Univ Colorado, Div Gen Internal Med, Sch Med, Aurora, CO USA. [Yazdany, J.] Univ Calif San Francisco, Div Rheumatol, Dept Med, San Francisco, CA USA. [Fransen, R.] Exempla St Joseph Hosp, Denver, CO USA. [Zell, J.] Natl Jewish Hlth, Div Rheumatol, Dept Med, Denver, CO USA. RP Quinzanos, I (reprint author), Denver Vet Affairs Med Ctr, Dept Med, 1055 Clermont St, Denver, CO 80220 USA. EM itziar.quinzanos@ucdenver.edu FU NIAMS NIH HHS [K23 AR060259] NR 15 TC 3 Z9 3 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 EI 1477-0962 J9 LUPUS JI Lupus PD FEB PY 2015 VL 24 IS 2 BP 203 EP 209 DI 10.1177/0961203314552832 PG 7 WC Rheumatology SC Rheumatology GA CA0YX UT WOS:000348640500013 PM 25267076 ER PT J AU Whitman, GT Yates, BJ AF Whitman, Gregory T. Yates, Bill J. TI Orthostatic Intolerance in Acute Vestibular Neuritis SO MAYO CLINIC PROCEEDINGS LA English DT Letter ID SYMPATHETIC RESPONSES C1 [Whitman, Gregory T.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02138 USA. [Yates, Bill J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Whitman, GT (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02138 USA. NR 6 TC 2 Z9 3 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD FEB PY 2015 VL 90 IS 2 BP 308 EP 309 DI 10.1016/j.mayocp.2014.11.015 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CA9LO UT WOS:000349245300019 PM 25659247 ER PT J AU Kyle, RA Steensma, DP Shampo, MA AF Kyle, Robert A. Steensma, David P. Shampo, Marc A. TI Oscar (Oskar) Minkowski: Discovery of the Pancreatic Origin of Diabetes SO MAYO CLINIC PROCEEDINGS LA English DT Editorial Material C1 [Kyle, Robert A.; Shampo, Marc A.] Mayo Clin, Rochester, MN 55902 USA. [Steensma, David P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Kyle, RA (reprint author), Mayo Clin, Rochester, MN 55902 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD FEB PY 2015 VL 90 IS 2 BP E17 EP E18 DI 10.1016/j.mayocp.2014.06.026 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CA9LO UT WOS:000349245300002 PM 25659250 ER PT J AU Huang, C Petibon, Y Ouyang, J Reese, TG Ahlman, MA Bluemke, DA El Fakhri, G AF Huang, Chuan Petibon, Yoann Ouyang, Jinsong Reese, Timothy G. Ahlman, Mark A. Bluemke, David A. El Fakhri, Georges TI Accelerated acquisition of tagged MRI for cardiac motion correction in simultaneous PET-MR: Phantom and patient studies SO MEDICAL PHYSICS LA English DT Article DE simultaneous PET-MR; motion correction; cardiac PET; cardiac motion; tagged MR ID RESPIRATORY MOTION; MYOCARDIAL-PERFUSION; GATED PET; COMPENSATION; RECONSTRUCTION; FOCUSS; SENSE; ARRAY; CT AB Purpose: Degradation of image quality caused by cardiac and respiratory motions hampers the diagnostic quality of cardiac PET. It has been shown that improved diagnostic accuracy of myocardial defect can be achieved by tagged MR (tMR) based PET motion correction using simultaneous PET-MR. However, one major hurdle for the adoption of tMR-based PET motion correction in the PET-MR routine is the long acquisition time needed for the collection of fully sampled tMR data. In this work, the authors propose an accelerated tMR acquisition strategy using parallel imaging and/or compressed sensing and assess the impact on the tMR-based motion corrected PET using phantom and patient data. Methods: Fully sampled tMR data were acquired simultaneously with PET list-mode data on two simultaneous PET-MR scanners for a cardiac phantom and a patient. Parallel imaging and compressed sensing were retrospectively performed by GRAPPA and kt-FOCUSS algorithms with various acceleration factors. Motion fields were estimated using nonrigid B-spline image registration from both the accelerated and fully sampled tMR images. The motion fields were incorporated into a motion corrected ordered subset expectation maximization reconstruction algorithm with motion-dependent attenuation correction. Results: Although tMR acceleration introduced image artifacts into the tMR images for both phantom and patient data, motion corrected PET images yielded similar image quality as those obtained using the fully sampled tMR images for low to moderate acceleration factors (< 4). Quantitative analysis of myocardial defect contrast over ten independent noise realizations showed similar results. It was further observed that although the image quality of the motion corrected PET images deteriorates for high acceleration factors, the images were still superior to the images reconstructed without motion correction. Conclusions: Accelerated tMR images obtained with more than 4 times acceleration can still provide relatively accurate motion fields and yield tMR-based motion corrected PET images with similar image quality as those reconstructed using fully sampled tMR data. The reduction of tMR acquisition time makes it more compatible with routine clinical cardiac PET-MR studies. (C) 2015 American Association of Physicists in Medicine. C1 [Huang, Chuan; Petibon, Yoann; Ouyang, Jinsong; El Fakhri, Georges] Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Dept Imaging, Ctr Adv Med Imaging Sci, Boston, MA 02114 USA. [Huang, Chuan; Ouyang, Jinsong; Reese, Timothy G.; El Fakhri, Georges] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Huang, Chuan] Stony Brook Med, Dept Radiol, Stony Brook, NY 11794 USA. [Reese, Timothy G.] Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Ahlman, Mark A.; Bluemke, David A.] NIH, Ctr Clin, Bethesda, MD 20892 USA. RP Huang, C (reprint author), Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Dept Imaging, Ctr Adv Med Imaging Sci, Boston, MA 02114 USA. EM chuan.huang@stonybrookmedicine.edu OI Bluemke, David/0000-0002-8323-8086 FU NIH [R21-EB012326, R01-CA165221, R01-HL110241, R01-HL118261]; NIH intramural research program; Athinoula A. Martinos Center for Biomedical Imaging; Imaging Sciences Training Program at the National Institutes of Health; Center for Functional Neuroimaging Technologies - NIH [P41-EB015896] FX This research was supported in part by NIH Grant No. R21-EB012326, R01-CA165221, R01-HL110241, R01-HL118261, NIH intramural research program, the Athinoula A. Martinos Center for Biomedical Imaging, the Imaging Sciences Training Program at the National Institutes of Health, and the Center for Functional Neuroimaging Technologies (funded by NIH Grant No. P41-EB015896). The authors would like to thank Wen-TungWang for the help with patient acquisition. NR 46 TC 5 Z9 5 U1 1 U2 8 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD FEB PY 2015 VL 42 IS 2 BP 1087 EP 1097 DI 10.1118/1.4906247 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CA9GJ UT WOS:000349229600055 PM 25652521 ER PT J AU Ghodbane, M Kulesa, A Yu, HH Maguire, TJ Schloss, RS Ramachandran, R Zahn, JD Yarmush, ML AF Ghodbane, Mehdi Kulesa, Anthony Yu, Henry H. Maguire, Tim J. Schloss, Rene S. Ramachandran, Rohit Zahn, Jeffrey D. Yarmush, Martin L. TI Development of a low-volume, highly sensitive microimmunoassay using computational fluid dynamics-driven multiobjective optimization SO MICROFLUIDICS AND NANOFLUIDICS LA English DT Article DE Immunoassay; Microfluidic; Computational fluid dynamics; Multiobjective optimization ID INFLAMMATORY CYTOKINES; PROTEIN ADSORPTION; SOFT LITHOGRAPHY; CONTINUOUS-FLOW; MICROFLUIDICS; MEMBRANE; SURFACE; SYSTEM; VALVES; BEADS AB Immunoassays are one of the most versatile and widely performed biochemical assays and, given their selectivity and specificity, are used in both clinical and research settings. However, the high cost of reagents and relatively large sample volumes constrain the integration of immunoassays into many applications. Scaling the assay down within microfluidic devices can alleviate issues associated with reagent and sample consumption. However, in many cases, a new device is designed and empirically optimized for each specific analyte, a costly and time-consuming approach. In this paper, we report the development of a microfluidic bead-based immunoassay that, using antibody-coated microbeads, can potentially detect any analyte or combination of analytes for which antibody-coated microbeads can be generated. We also developed a computational reaction model and optimization algorithm that can be used to optimize the device for any analyte. We applied this technique to develop a low-volume IL-6 immunoassay with high sensitivity (358 fM, 10 pg/mL) and a large dynamic range (four orders of magnitude). This device design and optimization technique can be used to design assays for any protein with an available antibody and can be used with a large number of applications including biomarker discovery, temporal in vitro studies using a reduced number of cells and reagents, and analysis of scarce biological samples in animal studies and clinical research settings. C1 [Ghodbane, Mehdi; Kulesa, Anthony; Yu, Henry H.; Maguire, Tim J.; Schloss, Rene S.; Zahn, Jeffrey D.; Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA. [Ramachandran, Rohit] Rutgers State Univ, Dept Chem & Biochem Engn, Piscataway, NJ 08854 USA. [Yarmush, Martin L.] Massachusetts Gen Hosp, Ctr Engn Med Surg Serv, Boston, MA 02114 USA. RP Yarmush, ML (reprint author), Massachusetts Gen Hosp, Ctr Engn Med Surg Serv, 51 Blossom St, Boston, MA 02114 USA. EM yarmush@rci.rutgers.edu FU National Institute of Health [P41EB002503, UH2TR000503]; National Institute of Health Rutgers Biotechnology Training Program [T32GM008339]; National Science Foundation Integrated Science and Engineering of Stem Cells Program [DGE0801620] FX This work was partially funded by the National Institute of Health Grants P41EB002503 and UH2TR000503, the National Institute of Health Rutgers Biotechnology Training Program (T32GM008339), and the National Science Foundation Integrated Science and Engineering of Stem Cells Program (DGE0801620). The authors would like to thank Dr. Sara Salahi, Dr. Kellie Anderson, and Anwesha Chaudhury for productive conversations regarding computational and optimization issues, Dana Barrasso for guidance pertaining to statistical analysis, Dr. Bhaskar Mitra for support in developing the fabrication protocols, and modeFrontier customer support for extensive troubleshooting of the optimization platform. NR 55 TC 1 Z9 1 U1 6 U2 16 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1613-4982 EI 1613-4990 J9 MICROFLUID NANOFLUID JI Microfluid. Nanofluid. PD FEB PY 2015 VL 18 IS 2 BP 199 EP 214 DI 10.1007/s10404-014-1416-9 PG 16 WC Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics, Fluids & Plasmas SC Science & Technology - Other Topics; Instruments & Instrumentation; Physics GA CA5WO UT WOS:000348978800005 PM 25691853 ER PT J AU Belanger, HG Barwick, F Silva, MA Kretzmer, T Kip, KE Vanderploeg, RD AF Belanger, Heather G. Barwick, Fiona Silva, Marc A. Kretzmer, Tracy Kip, Kevin E. Vanderploeg, Rodney D. TI Web-Based Psychoeducational Intervention for Postconcussion Symptoms: A Randomized Trial SO MILITARY MEDICINE LA English DT Article ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIOR THERAPY; PSYCHOLOGICAL TREATMENTS; HEAD-INJURY; METAANALYSIS; PAPER; CONCUSSION; DEPRESSION; COMPLAINTS AB The objective of this study was to investigate the effectiveness of a web-based educational intervention for reducing postconcussion symptoms. 158 participants with self-reported symptomatic mild traumatic brain injury were randomized to intervention versus control. There was no effect of intervention on symptom severity or attributions. Subgroup analyses suggested benefit of the web-based intervention in those receiving concurrent mental health treatment and in those participants with the greatest time since injury (>1 year after mild traumatic brain injury). Web-based educational intervention was not effective overall in this sample. However, there is some suggestion of promise in those receiving concurrent mental health treatment and with more chronic symptoms. Findings also suggest potential benefit of interventions targeting self-efficacy. C1 [Belanger, Heather G.; Silva, Marc A.; Kretzmer, Tracy; Vanderploeg, Rodney D.] James A Haley VA, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA. [Belanger, Heather G.; Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33612 USA. [Belanger, Heather G.; Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL 33612 USA. [Belanger, Heather G.; Vanderploeg, Rodney D.] Def & Vet Brain Injury Ctr, Tampa, FL 33612 USA. [Barwick, Fiona] VA Greater Los Angeles Healthcare Syst, Dept Mental Behav Hlth, Los Angeles, CA 90073 USA. [Kip, Kevin E.] Univ S Florida, Coll Nursing, Tampa, FL USA. RP Belanger, HG (reprint author), James A Haley VA, Dept Mental Hlth & Behav Sci, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA. FU Department of Defense [W81XWH-10-1-0719]; Department of Veterans Affairs; Defense and Veterans Brain Injury Center (DVBIC); James A. Haley Veterans' Hospital; Veterans Health Administration (VHA) FX The research reported here was supported by the Department of Defense (W81XWH-10-1-0719), Department of Veterans Affairs, Veterans Health Administration (VHA), and the Defense and Veterans Brain Injury Center (DVBIC). Further support was provided by the James A. Haley Veterans' Hospital. NR 53 TC 1 Z9 1 U1 1 U2 8 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD FEB PY 2015 VL 180 IS 2 BP 192 EP 200 DI 10.7205/MILMED-D-14-00388 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CA7MR UT WOS:000349101900012 PM 25643387 ER PT J AU Teng, SZ Stegner, D Chen, Q Hongu, T Hasegawa, H Chen, L Kanaho, Y Nieswandt, B Frohman, MA Huang, P AF Teng, Shuzhi Stegner, David Chen, Qin Hongu, Tsunaki Hasegawa, Hiroshi Chen, Li Kanaho, Yasunori Nieswandt, Bernhard Frohman, Michael A. Huang, Ping TI Phospholipase D1 facilitates second-phase myoblast fusion and skeletal muscle regeneration SO MOLECULAR BIOLOGY OF THE CELL LA English DT Article ID AUSTRALIAN TIGER SNAKE; PANCREATIC BETA-CELLS; MEMBRANE-FUSION; MUSCULAR-DYSTROPHY; MYOGENIC DIFFERENTIATION; PHOSPHATIDIC-ACID; GENE-EXPRESSION; ACTIVATION; MICE; LYSOPHOSPHATIDYLCHOLINE AB Myoblast differentiation and fusion is a well-orchestrated multistep process that is essential for skeletal muscle development and regeneration. Phospholipase D1 (PLD1) has been implicated in the initiation of myoblast differentiation in vitro. However, whether PLD1 plays additional roles in myoblast fusion and exerts a function in myogenesis in vivo remains unknown. Here we show that PLD1 expression is up-regulated in myogenic cells during muscle regeneration after cardiotoxin injury and that genetic ablation of PLD1 results in delayed myofiber regeneration. Myoblasts derived from PLD1-null mice or treated with PLD1-specific inhibitor are unable to form mature myotubes, indicating defects in second-phase myoblast fusion. Concomitantly, the PLD1 product phosphatidic acid is transiently detected on the plasma membrane of differentiating myocytes, and its production is inhibited by PLD1 knockdown. Exogenous lysophosphatidylcholine, a key membrane lipid for fusion pore formation, partially rescues fusion defect resulting from PLD1 inhibition. Thus these studies demonstrate a role for PLD1 in myoblast fusion during myogenesis in which PLD1 facilitates the fusion of mononuclear myocytes with nascent myotubes. C1 [Teng, Shuzhi] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Teng, Shuzhi; Huang, Ping] Jilin Univ, Coll Basic Med Sci, Minist Educ, Key Lab Pathobiol, Changchun 130021, Peoples R China. [Stegner, David; Nieswandt, Bernhard] Univ Wurzburg, Univ Hosp, D-97080 Wurzburg, Germany. [Stegner, David; Nieswandt, Bernhard] Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97080 Wurzburg, Germany. [Chen, Qin; Frohman, Michael A.] SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA. [Hongu, Tsunaki; Hasegawa, Hiroshi; Kanaho, Yasunori] Univ Tsukuba, Dept Phys Chem, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan. [Hongu, Tsunaki; Hasegawa, Hiroshi; Kanaho, Yasunori] Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan. [Chen, Li] Jilin Univ, Coll Basic Med Sci, Dept Pharmacol, Changchun 130021, Peoples R China. [Huang, Ping] Boston Childrens Hosp, Div Genet & Genom, Boston, MA 02115 USA. RP Huang, P (reprint author), Jilin Univ, Coll Basic Med Sci, Minist Educ, Key Lab Pathobiol, Changchun 130021, Peoples R China. EM szteng@yahoo.com; phuang@enders.tch.harvard.edu OI Stegner, David/0000-0003-1059-9865 FU American Heart Association [SDG 0730285N]; Key Technology Project of Jilin Province [20076023]; Deutsche Forschungsgemeinschaft [Ni556/8-1]; National Institute of Child Health and Human Development FX We thank Emanuela Gussoni for helpful discussion and Melissa Wu for critical reading of the manuscript. Funding for this work was generously provided by the American Heart Association (Grant SDG 0730285N to P.H.), The Key Technology Project of Jilin Province (20076023), and the Deutsche Forschungsgemeinschaft (Grant Ni556/8-1 to B.N.). The myosin heavy chain antibody (MF20, developed by Donald Fischman) was obtained from the Development Studies Hybridoma Bank developed under the auspices of the National Institute of Child Health and Human Development and maintained by the Department of Biology, University of Iowa, Iowa City, IA. NR 61 TC 4 Z9 4 U1 0 U2 4 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 EI 1939-4586 J9 MOL BIOL CELL JI Mol. Biol. Cell PD FEB 1 PY 2015 VL 26 IS 3 BP 506 EP 517 DI 10.1091/mbc.E14-03-0802 PG 12 WC Cell Biology SC Cell Biology GA CA4EP UT WOS:000348857300011 PM 25428992 ER PT J AU Knight, EM Williams, HN Stevens, AC Kim, SH Kottwitz, JC Morant, AD Steele, JW Klein, WL Yanagisawa, K Boyd, RE Lockhart, DJ Sjoberg, ER Ehrlich, ME Wustman, BA Gandy, S AF Knight, E. M. Williams, H. N. Stevens, A. C. Kim, S. H. Kottwitz, J. C. Morant, A. D. Steele, J. W. Klein, W. L. Yanagisawa, K. Boyd, R. E. Lockhart, D. J. Sjoberg, E. R. Ehrlich, M. E. Wustman, B. A. Gandy, S. TI Evidence that small molecule enhancement of beta-hexosaminidase activity corrects the behavioral phenotype in Dutch APP(E693Q) mice through reduction of ganglioside-bound A beta SO MOLECULAR PSYCHIATRY LA English DT Article ID ALZHEIMERS-DISEASE; GM1 GANGLIOSIDE; PHARMACOLOGICAL CHAPERONE; SANDHOFF-DISEASE; TAY-SACHS; PROTEIN; BRAIN; CHOLESTEROL; GLUCOCEREBROSIDASE; MUTATIONS AB Certain mutant Alzheimer's amyloid-beta (A beta) peptides (that is, Dutch mutant APP(E693Q)) form complexes with gangliosides (GA beta). These mutant A beta peptides may also undergo accelerated aggregation and accumulation upon exposure to GM2 and GM3. We hypothesized that increasing beta-hexosaminidase (beta-hex) activity would lead to a reduction in GM2 levels, which in turn, would cause a reduction in A beta aggregation and accumulation. The small molecule OT1001 is a beta-hex-targeted pharmacological chaperone with good bioavailability, blood-brain barrier penetration, high selectivity for beta-hex and low cytotoxicity. Dutch APP(E693Q) transgenic mice accumulate oligomeric A beta as they age, as well as A beta oligomer-dose-dependent anxiety and impaired novel object recognition (NOR). Treatment of Dutch APP(E693Q) mice with OT1001 caused a dose-dependent increase in brain beta-hex levels up to threefold over those observed at baseline. OT1001 treatment was associated with reduced anxiety, improved learning behavior in the NOR task and dramatically reduced GA beta accumulation in the subiculum and perirhinal cortex, both of which are brain regions required for normal NOR. Pharmacological chaperones that increase beta-hex activity may be useful in reducing accumulation of certain mutant species of A beta and in preventing the associated behavioral pathology. C1 [Knight, E. M.; Kim, S. H.; Kottwitz, J. C.; Morant, A. D.; Ehrlich, M. E.; Gandy, S.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Knight, E. M.; Kim, S. H.; Kottwitz, J. C.; Morant, A. D.; Ehrlich, M. E.; Gandy, S.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Knight, E. M.; Kim, S. H.; Gandy, S.] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Williams, H. N.; Boyd, R. E.] Amicus Therapeut, Cranbury, NJ USA. [Stevens, A. C.; Steele, J. W.; Lockhart, D. J.; Sjoberg, E. R.; Wustman, B. A.] OrPhi Therapeut, Carlsbad, CA USA. [Klein, W. L.] Northwestern Univ, Dept Neurobiol, Evanston, IL USA. [Klein, W. L.] Northwestern Univ, Dept Cognit Neurol, Evanston, IL USA. [Klein, W. L.] Northwestern Univ, Alzheimers Dis Ctr, Evanston, IL USA. [Yanagisawa, K.] Natl Ctr Geriatr Gerontol, Res Inst, Obu City, Aichi, Japan. [Gandy, S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Gandy, S (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave L Levy Pl, New York, NY 10029 USA. EM samuel.gandy@mssm.edu FU Alzheimer's Drug Discovery Foundation [291003]; BrightFocus Foundation FX This work was supported by Alzheimer's Drug Discovery Foundation grant 291003. SHK is supported by BrightFocus Foundation. The beta-hex targeted pharmacological chaperone OT1001 was supplied by Amicus Therapeutics. We thank Drs Richie Khanna, Anadina Garcia and Michelle Frascella for their assistance in animal handling and dosing, and Drs Elfrida Benjamin and Rick Hamler for their assistance in measuring OT1001 levels in the PK and PD studies conducted in C57BL/J6 mice. NR 48 TC 8 Z9 8 U1 0 U2 16 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD FEB PY 2015 VL 20 IS 1 BP 109 EP 117 DI 10.1038/mp.2014.135 PG 9 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA CB1QR UT WOS:000349403400011 PM 25349165 ER PT J AU Maillard, AM Ruef, A Pizzagalli, F Migliavacca, E Hippolyte, L Adaszewski, S Dukart, J Ferrari, C Conus, P Mannik, K Zazhytska, M Siffredi, V Maeder, P Kutalik, Z Kherif, F Hadjikhani, N Beckmann, JS Reymond, A Draganski, B Jacquemont, S AF Maillard, A. M. Ruef, A. Pizzagalli, F. Migliavacca, E. Hippolyte, L. Adaszewski, S. Dukart, J. Ferrari, C. Conus, P. Maennik, K. Zazhytska, M. Siffredi, V. Maeder, P. Kutalik, Z. Kherif, F. Hadjikhani, N. Beckmann, J. S. Reymond, A. Draganski, B. Jacquemont, S. CA 16p11 2 European Consortium TI The 16p11.2 locus modulates brain structures common to autism, schizophrenia and obesity SO MOLECULAR PSYCHIATRY LA English DT Article ID CORTICAL SURFACE-AREA; DIAGNOSTIC INTERVIEW; CHROMOSOME 16P11.2; DELETION SYNDROME; DISORDERS; SPECTRUM; ABNORMALITIES; PHENOTYPES; DOSAGE; ASSOCIATION AB Anatomical structures and mechanisms linking genes to neuropsychiatric disorders are not deciphered. Reciprocal copy number variants at the 16p11.2 BP4-BP5 locus offer a unique opportunity to study the intermediate phenotypes in carriers at high risk for autism spectrum disorder (ASD) or schizophrenia (SZ). We investigated the variation in brain anatomy in 16p11.2 deletion and duplication carriers. Beyond gene dosage effects on global brain metrics, we show that the number of genomic copies negatively correlated to the gray matter volume and white matter tissue properties in cortico-subcortical regions implicated in reward, language and social cognition. Despite the near absence of ASD or SZ diagnoses in our 16p11.2 cohort, the pattern of brain anatomy changes in carriers spatially overlaps with the well-established structural abnormalities in ASD and SZ. Using measures of peripheral mRNA levels, we confirm our genomic copy number findings. This combined molecular, neuroimaging and clinical approach, applied to larger datasets, will help interpret the relative contributions of genes to neuropsychiatric conditions by measuring their effect on local brain anatomy. C1 [Maillard, A. M.; Pizzagalli, F.; Hippolyte, L.; Siffredi, V.; Beckmann, J. S.; Jacquemont, S.] CHU Vaudois, Serv Med Genet, CH-1011 Lausanne, Switzerland. [Maillard, A. M.; Ruef, A.; Pizzagalli, F.; Hippolyte, L.; Adaszewski, S.; Dukart, J.; Ferrari, C.; Conus, P.; Siffredi, V.; Maeder, P.; Kutalik, Z.; Kherif, F.; Beckmann, J. S.; Draganski, B.; Jacquemont, S.] Univ Lausanne, CH-1011 Lausanne, Switzerland. [Ruef, A.; Pizzagalli, F.; Adaszewski, S.; Dukart, J.; Kherif, F.; Draganski, B.] CHU Vaudois, LREN Dept Neurosci Clin, CH-1011 Lausanne, Switzerland. [Migliavacca, E.; Maennik, K.; Zazhytska, M.; Reymond, A.] Univ Lausanne, Ctr Integrat Genom, CH-1011 Lausanne, Switzerland. [Migliavacca, E.; Kutalik, Z.; Beckmann, J. S.] Univ Lausanne, Swiss Inst Bioinformat, CH-1011 Lausanne, Switzerland. [Dukart, J.; Draganski, B.] Max Planck Inst Human Cognit & Brain Sci, Dept Neurol, Leipzig, Germany. [Ferrari, C.; Conus, P.] CHU Vaudois, CERY Hosp, Dept Psychiat, CH-1011 Lausanne, Switzerland. [Maeder, P.] CHU Vaudois, Dept Radiol, CH-1011 Lausanne, Switzerland. [Kutalik, Z.; Beckmann, J. S.] Univ Lausanne, Dept Med Genet, CH-1011 Lausanne, Switzerland. [Kutalik, Z.] CHU Vaudois, Inst Social & Prevent Med IUMSP, CH-1011 Lausanne, Switzerland. [Hadjikhani, N.] Ecole Polytech Fed Lausanne, Sch Life Sci, Brain Mind Inst, Lausanne, Switzerland. [Hadjikhani, N.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Hadjikhani, N.] Univ Gothenburg, Sahlgrenska Acad, Gillberg Neuropsychiat Ctr, Gothenburg, Sweden. RP Draganski, B (reprint author), Univ Lausanne, CHUV, LREN, Dept Clin Neurosci, Mont Paisible 16, CH-1011 Lausanne, Switzerland. EM bogdan.draganski@chuv.ch; sebastien.jacquemont@chuv.ch RI Centre d'imagerie Biomedicale, CIBM/B-5740-2012; Le Caignec, Cedric/K-8467-2015; Isidor, Bertrand/L-2435-2015; Draganski, Bogdan/C-3096-2016; Brusco, Alfredo/A-1811-2013; Beckmann, Jacques S /A-9772-2008; OI Le Caignec, Cedric/0000-0002-0598-653X; Isidor, Bertrand/0000-0001-6480-126X; Draganski, Bogdan/0000-0002-5159-5919; Brusco, Alfredo/0000-0002-8318-7231; Beckmann, Jacques S /0000-0002-9741-1900; Hadjikhani, Nouchine/0000-0003-4075-3106 FU Leenaards Foundation Prize; Swiss National Science Foundation (SNSF) Sinergia grant [CRIS FN CRSII33-133044]; Simons Foundation Autism Research Initiative [SFARI274424]; European Union [604102]; SNSF (NCCR Synapsy) [320030_135679, SPUM 33CM30_140332/1]; Foundation Parkinson Switzerland; Foundation Synapsis; Novartis Foundation for medical-biological research; Deutsche Forschungsgemeinschaft [Kfo 247]; Roger de Spoelberch; Partridge Foundations; SNSF [PP00P3_144902/2]; Swiss Scientific Exchange NMS Program; doctoral school of the Faculty of Biology and Medicine, University of Lausanne FX We thank the participants, families and referring providers (see Supplementary Table 1) for their contribution. We are very grateful to Richard S. Frackowiak for his valuable comments and edits on the manuscript. We acknowledge Stephanie Selmoni, Nathalie Isidor and Ana Machado for their contribution in the recruitment of the participants as well as Guillaume Sierro and Melody Laser for their help scanning the participants. This work was supported by the Leenaards Foundation Prize (SJ, AR and NH), a Swiss National Science Foundation (SNSF) Sinergia grant CRIS FN CRSII33-133044 (AR, SJ), and the Simons Foundation Autism Research Initiative SFARI274424 (AR) the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 604102. BD was supported by the SNSF (NCCR Synapsy, project grant Nr 320030_135679 and SPUM 33CM30_140332/1), Foundation Parkinson Switzerland, Foundation Synapsis, Novartis Foundation for medical-biological research and Deutsche Forschungsgemeinschaft (Kfo 247). LREN is supported by the Roger de Spoelberch and the Partridge Foundations. SJ was supported by a professorship grant from the SNSF PP00P3_144902/2. KM is a grantee of a scholarship from the Swiss Scientific Exchange NMS Program and MZ by a fellowship from the doctoral school of the Faculty of Biology and Medicine, University of Lausanne. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Participants were scanned at the 'Centre d'Imagerie BioMedicale' (CIBM) which is a research initiative of the following partners: University of Lausanne, Swiss Federal Institute of Technology Lausanne, University of Geneva, Centre Hospitalier Universitaire Vaudois, Hopitaux Universitaires de Geneve and the Leenaards and the Jeantet Foundations. We thank the participants and their families for their contribution. 16p11.2 European Consortium contributing members: M-C Addor, Service of Medical Genetics, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne. J Andrieux, Institut de Genetique Medicale, Hopital Jeanne de Flandre, Lille. B Arveiler, Univ. Bordeaux, Maladies Rares: Genetique et Metabolisme, Service de Genetique Medicale, CHU-Bordeaux, Bordeaux. G Baujat, Centre de Reference Departement de Genetique, Hopital Necker-Enfants malades, Paris. F Bena, Service of Genetic Medicine, University Hospitals of Geneva, Geneva. D Bonneau, Service de genetique medicale, CHU-Angers, Angers. S Bouquillon, Institut de Genetique Medicale, Hopital Jeanne de Flandre, Lille. O Boute, Hopital Jeanne de Flandre, CHRU de Lille, Lille. A Brusco, University of Torino, Department of Medical Sciences, Turin. D Campion, Service de psychiatrie, Centre hospitalier de Rouvray, Sotteville les Rouen. A David, Service de Genetique Medicale, CHU-Nantes, Nantes. M-A Delrue, Univ. Bordeaux, Maladies Rares: Genetique et Metabolisme, Service de Genetique Medicale, CHU-Bordeaux, Bordeaux. M Doco-Fenzy, Service de Genetique, CHU, EA3801 SFR-CAP Sante Reims. C Fagerberg, Department of Clinical Genetics, Odense University Hospital, Odense. L Faivre, Hopital d'Enfants, CHU Dijon. F Forzano, SSD Genetica Medica, EO Ospedali Galliera, Genova. D Giachino, Genetica Medica, Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano, Torino. A Guichet, Service de genetique medicale, CHU-Angers. O Guillin, Service de psychiatrie, Centre hospitalier de Rouvray, Sotteville les Rouen. D Heron, Departement de Genetique, Hopital Pitie-Salptriere, Universite Pierre et Marie Curie, Paris.; B Isidor, Service de Genetique Medicale, CHU-Nantes, Nantes. A Jacquette, Departement de Genetique, groupe hospitalier Pitie-Salpetriere, Paris. H Journel, Genetique medicale, Centre Hospitalier Bretagne Atlantique, Vannes. B Keren, Departement de Genetique Cytogenetique et Embryologie AP-HP, Hopital Pitie-Salpetriere, Universite Pierre et Marie Curie, Paris. D Lacombe, Univ. Bordeaux, Maladies Rares: Genetique et Metabolisme, Service de Genetique Medicale, CHU-Bordeaux, Bordeaux. C Le Caignec, Service de Genetique Medicale, CHU Nantes, Nantes. M-P Lemaitre, Service de Neuropediatrie, Centre Hospitalier Regional Universitaire, Lille. J Lespinasse, Service genetique medicale, CH Chambery. G Mandrile, Genetica Medica, Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano, Torino. M Mathieu-Dramard, Service de Genetique Clinique, CHU Amiens, Amiens. C Mignot, Service de Genetique Clinique, CHU La Pitie Salpetriere, France; Service de Neuropediatrie, APHP, Hopital Armand Trousseau. F Petit, Hopital Jeanne de Flandre, CHRU de Lille, Lille. G Plessis, Service de Genetique, CHU Clemenceau, Caen. F Prieur, Service de genetique medicale, CHU St Etienne C Rooryck, Univ. Bordeaux, Maladies Rares: Genetique et Metabolisme, Service de Genetique Medicale, CHU-Bordeaux, Bordeaux. D Sanlaville, Service de Cytogenetique Constitutionnelle, Hospices Civils de Lyon, CHU de Lyon and Centre de Recherche en Neuroscience de Lyon, Lyon. MM Van Haelst, Department of Medical Genetics, University Medical Center, Utrecht. L Van Maldergem, Centre de Genetique humaine, CHU-Besancon. NR 61 TC 25 Z9 26 U1 2 U2 17 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD FEB PY 2015 VL 20 IS 1 BP 140 EP 147 DI 10.1038/mp.2014.145 PG 8 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA CB1QR UT WOS:000349403400015 PM 25421402 ER PT J AU Choi, SH Tamura, K Khajuria, RK Bhere, D Nesterenko, I Lawler, J Shah, K AF Choi, Sung Hugh Tamura, Kaoru Khajuria, Rajiv Kumar Bhere, Deepak Nesterenko, Irina Lawler, Jack Shah, Khalid TI Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas SO MOLECULAR THERAPY LA English DT Article ID TRAIL-INDUCED APOPTOSIS; MESENCHYMAL STEM-CELLS; COLON-CANCER CELLS; GROWTH-FACTOR-BETA; IN-VIVO; BRAIN-TUMORS; CHEMOTHERAPEUTIC DRUGS; GLIOMA THERAPY; ANGIOGENESIS; THROMBOSPONDIN-1 AB Three type-1 repeat (3TSR) domain of thrombospondin-1 is known to have anti-angiogenic effects by targeting tumor-associated endothelial cells, but its effect on tumor cells is unknown. This study explored the potential of 3TSR to target glioblastoma (GBM) cells in vitro and in vivo. We show that 3TSR upregulates death receptor (DR) 4/5 expression in a CD36-dependent manner and primes resistant GBMs to tumor necrosis factor related apoptosis-inducing ligand (TRAIL)-induced caspase-8/3/7 mediated apoptosis. We engineered human mesenchymal stem cells (MSC) for on-site delivery of 3TSR and a potent and secretable variant of TRAIL (S-TRAIL) in an effort to simultaneously target tumor cells and associated endothelial cells and circumvent issues of systemic delivery of drugs across the blood brain barrier. We show that MSC-3TSR/S-TRAIL inhibits tumor growth in an expanded spectrum of GBMs. In vivo, a single administration of MSC-3TSR/S-TRAIL significantly targets both tumor cells and vascular component of GBMs, inhibits tumor progression, and extends survival of mice bearing highly vascularized GBM. The ability of 3TSR/S-TRAIL to simultaneously act on tumor cells and tumor-associated endothelial cells offers a great potential to target a broad spectrum of cancers and translate 3TSR/TRAIL therapies into clinics. C1 [Choi, Sung Hugh; Tamura, Kaoru; Khajuria, Rajiv Kumar; Bhere, Deepak; Nesterenko, Irina; Shah, Khalid] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Neurotherapy & Imaging Lab,Dept Radiol, Boston, MA 02114 USA. [Lawler, Jack] Beth Israel Deaconess Med Ctr, Dept Pathol, Div Expt Pathol, Boston, MA 02215 USA. [Lawler, Jack] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Shah, Khalid] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Shah, Khalid] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. RP Shah, K (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol & Radiol, Boston, MA 02114 USA. EM kshah@mgh.harvard.edu FU James McDonnell Foundation; [RO1 CA138922]; [RO1 NS071197]; [RO1 CA130895] FX The authors would like to acknowledge the technical assistance of Mark Duquette. No potential conflicts of interest were disclosed. This work was supported by RO1 CA138922 (KS), RO1 NS071197 (KS), RO1 CA130895 (JL) and James McDonnell Foundation (KS). NR 49 TC 8 Z9 8 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1525-0016 EI 1525-0024 J9 MOL THER JI Mol. Ther. PD FEB PY 2015 VL 23 IS 2 BP 235 EP 243 DI 10.1038/mt.2014.214 PG 9 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA CA2PT UT WOS:000348750700005 PM 25358253 ER PT J AU Jiang, P Liu, XS AF Jiang, Peng Liu, X. Shirley TI Big data mining yields novel insights on cancer SO NATURE GENETICS LA English DT Editorial Material ID GENOMICS DATA; PLATFORM; MAP AB Recent years have seen the rapid growth of large-scale biological data, but the effective mining and modeling of `big data' for new biological discoveries remains a significant challenge. A new study reanalyzes expression profiles from the Gene Expression Omnibus to make novel discoveries about genes involved in DNA damage repair and genome instability in cancer. C1 [Jiang, Peng; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. RP Jiang, P (reprint author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. EM xsliu@jimmy.harvard.edu NR 15 TC 6 Z9 6 U1 3 U2 32 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD FEB PY 2015 VL 47 IS 2 BP 103 EP 104 PG 2 WC Genetics & Heredity SC Genetics & Heredity GA CA1TQ UT WOS:000348694700004 PM 25627899 ER PT J AU Leiserson, MDM Vandin, F Wu, HT Dobson, JR Eldridge, JV Thomas, JL Papoutsaki, A Kim, Y Niu, BF McLellan, M Lawrence, MS Gonzalez-Perez, A Tamborero, D Cheng, YW Ryslik, GA Lopez-Bigas, N Getz, G Ding, L Raphael, BJ AF Leiserson, Mark D. M. Vandin, Fabio Wu, Hsin-Ta Dobson, Jason R. Eldridge, Jonathan V. Thomas, Jacob L. Papoutsaki, Alexandra Kim, Younhun Niu, Beifang McLellan, Michael Lawrence, Michael S. Gonzalez-Perez, Abel Tamborero, David Cheng, Yuwei Ryslik, Gregory A. Lopez-Bigas, Nuria Getz, Gad Ding, Li Raphael, Benjamin J. TI Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes SO NATURE GENETICS LA English DT Article ID COPY-NUMBER ALTERATION; CELL LUNG CANCERS; GENOMIC CHARACTERIZATION; PROSTATE-CANCER; NEXT-GENERATION; CARCINOMA; LANDSCAPE; CHROMATIN; COHESIN; GENES AB Cancers exhibit extensive mutational heterogeneity, and the resulting long-tail phenomenon complicates the discovery of genes and pathways that are significantly mutated in cancer. We perform a pan-cancer analysis of mutated networks in 3,281 samples from 12 cancer types from The Cancer Genome Atlas (TCGA) using HotNet2, a new algorithm to find mutated subnetworks that overcomes the limitations of existing single-gene, pathway and network approaches. We identify 16 significantly mutated subnetworks that comprise well-known cancer signaling pathways as well as subnetworks with less characterized roles in cancer, including cohesin, condensin and others. Many of these subnetworks exhibit co-occurring mutations across samples. These subnetworks contain dozens of genes with rare somatic mutations across multiple cancers; many of these genes have additional evidence supporting a role in cancer. By illuminating these rare combinations of mutations, pan-cancer network analyses provide a roadmap to investigate new diagnostic and therapeutic opportunities across cancer types. C1 [Leiserson, Mark D. M.; Vandin, Fabio; Wu, Hsin-Ta; Dobson, Jason R.; Eldridge, Jonathan V.; Thomas, Jacob L.; Papoutsaki, Alexandra; Kim, Younhun; Raphael, Benjamin J.] Brown Univ, Dept Comp Sci, Providence, RI 02912 USA. [Leiserson, Mark D. M.; Vandin, Fabio; Wu, Hsin-Ta; Dobson, Jason R.; Raphael, Benjamin J.] Brown Univ, Ctr Computat Mol Biol, Providence, RI 02912 USA. [Dobson, Jason R.] Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA. [Niu, Beifang; Ding, Li] Washington Univ, Genome Inst, St Louis, MO USA. [Lawrence, Michael S.; Getz, Gad] Broad Inst MIT & Harvard, Cambridge, MA USA. [Gonzalez-Perez, Abel; Tamborero, David; Lopez-Bigas, Nuria] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Res Unit Biomed Informat, Barcelona, Spain. [Cheng, Yuwei] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT USA. [Ryslik, Gregory A.] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA. [Lopez-Bigas, Nuria] ICREA, Barcelona, Spain. [Getz, Gad] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Ding, Li] Washington Univ, Dept Med, St Louis, MO USA. [Ding, Li] Washington Univ, Siteman Canc Ctr, St Louis, MO USA. RP Raphael, BJ (reprint author), Brown Univ, Dept Comp Sci, Providence, RI 02912 USA. EM braphael@brown.edu RI Gasull, Martina/A-6630-2013; Lopez-Bigas, Nuria/F-6193-2011; tamborero, david/M-5283-2015 OI Gonzalez-Perez, Abel/0000-0002-8582-4660; Lopez-Bigas, Nuria/0000-0003-4925-8988; tamborero, david/0000-0002-7218-2806 FU US National Science Foundation (NSF) [IIS-1016648]; US National Institutes of Health (NIH) [R01HG005690, R01HG007069, R01CA180776]; National Human Genome Research Institute (NHGRI) grant [U01HG006517]; Career Award at the Scientific Interface from the Burroughs Wellcome Fund; Alfred P. Sloan Research Fellowship; NSF CAREER Award [CCF-1053753]; NSF fellowship GRFP [DGE 0228243]; NHGRI of the US NIH; Ellison Foundation; Dana-Farber Cancer Institute Strategic Initiative FX The authors thank F. Roth for his assistance in constructing the HINT+HI2012 interaction network. We gratefully acknowledge the contributions of the TCGA Research Network and its TCGA Pan-Cancer Analysis Working Group. This work is supported by US National Science Foundation (NSF) grant IIS-1016648 and US National Institutes of Health (NIH) grants R01HG005690, R01HG007069 and R01CA180776 to B.J.R. and by National Human Genome Research Institute (NHGRI) grant U01HG006517 to L.D. B.J.R. is supported by a Career Award at the Scientific Interface from the Burroughs Wellcome Fund, an Alfred P. Sloan Research Fellowship and an NSF CAREER Award (CCF-1053753). M.D.M.L. is supported by NSF fellowship GRFP DGE 0228243. The hinders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Data for HI2012, created by the Center for Cancer Systems Biology (CCSB) at the Dana-Farber Cancer Institute, are supported by the NHGRI of the US NIH, the Ellison Foundation and the Dana-Farber Cancer Institute Strategic Initiative. NR 57 TC 97 Z9 98 U1 5 U2 36 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD FEB PY 2015 VL 47 IS 2 BP 106 EP 114 DI 10.1038/ng.3168 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA CA1TQ UT WOS:000348694700005 PM 25501392 ER PT J AU Kuchenbaecker, KB Ramus, SJ Tyrer, J Lee, A Shen, HC Beesley, J Lawrenson, K McGuffog, L Healey, S Lee, JM Spindler, TJ Lin, YG Pejovic, T Bean, Y Li, Q Coetzee, S Hazelett, D Miron, A Southey, M Terry, MB Goldgar, DE Buys, SS Janavicius, R Dorfling, CM van Rensburg, EJ Neuhausen, SL Ding, YC Hansen, TVO Jonson, L Gerdes, AM Ejlertsen, B Barrowdale, D Dennis, J Benitez, J Osorio, A Garcia, MJ Komenaka, I Weitzel, JN Ganschow, P Peterlongo, P Bernard, L Viel, A Bonanni, B Peissel, B Manoukian, S Radice, P Papi, L Ottini, L Fostira, F Konstantopoulou, I Garber, J Frost, D Perkins, J Platte, R Ellis, S Godwin, AK Schmutzler, RK Meindl, A Engel, C Sutter, C Sinilnikova, OM Damiola, F Mazoyer, S Stoppa-Lyonnet, D Claes, K De Leeneer, K Kirk, J Rodriguez, GC Piedmonte, M O'Malley, DM de la Hoya, M Caldes, T Aittomaki, K Nevanlinna, H Collee, JM Rookus, MA Oosterwijk, JC Tihomirova, L Tung, N Hamann, U Isaccs, C Tischkowitz, M Imyanitov, EN Caligo, MA Campbe, IG Hogervorst, FBL Olah, E Diez, O Blanco, I Brunet, J Lazaroso, C Pujana, MA Jakubowska, A Gronwald, J Lubinski, J Sukiennicki, G Barkardottir, RB Plante, M Simard, J Soucy, P Montagna, M Tognazzo, S Teixeira, MR Pankratz, VS Wang, XS Lindor, N Szabo, CI Kauff, N Vijai, J Aghajanian, CA Pfeiler, G Berger, A Singer, CF Tea, MK Phelan, CM Greene, MH Mai, PL Rennert, G Mulligan, AM Tchatchou, S Andrulis, IL Glendon, G Toland, AE Jensen, UB Kruse, TA Thomassen, M Bojesen, A Zidan, J Friedman, E Laitman, Y Soller, M Liljegren, A Arver, B Einbeigi, Z Stenmark-Askmalm, M Olopade, OI Nussbaum, RL Rebbeck, TR Nathanson, KL Domchek, SM Lu, KH Karlan, BY Walsh, C Lester, J Hein, A Ekici, AB Beckmann, MW Fasching, PA Lambrechts, D Van Nieuwenhuysen, E Vergote, I Lambrechts, S Dicks, E Doherty, JA Wicklund, KG Rossing, MA Rudolph, A Chang-Claude, J Wang-Gohrke, S Eilber, U Moysich, KB Odunsi, K Sucheston, L Lele, S Wilkens, LR Goodman, MT Thompson, PJ Shvetsov, YB Runnebaum, IB Durst, M Hillemanns, P Dork, T Antonenkova, N Bogdanova, N Leminen, A Pelttari, LM Butzow, R Modugno, F Kelley, JL Edwards, RP Ness, RB du Bois, A Heitz, F Schwaab, I Harter, P Matsuo, K Hosono, S Orsulic, S Jensen, A Kjaer, SK Hogdall, E Hasmad, HN Azmi, MAN Teo, SH Woo, YL Fridley, BL Goode, EL Cunningham, JM Vierkant, RA Bruinsma, F Giles, GG Liang, D Hildebrandt, MAT Wu, XF Levine, DA Bisogna, M Berchuck, A Iversen, ES Schildkraut, JM Concannon, P Weber, RP Cramer, DW Terry, KL Poole, EM Tworoger, SS Bandera, EV Orlow, I Olson, SH Krakstad, C Salvesen, HB Tangen, IL Bjorge, L van Altena, AM Aben, KKH Kiemeney, LA Massuger, LFAG Kellar, M Brooks-Wilson, A Kelemen, LE Cook, LS Le, ND Cybulski, C Yang, H Lissowska, J Brinton, LA Wentzensen, N Hogdall, C Lundvall, L Nedergaard, L Baker, H Song, HL Eccles, D McNeish, I Paul, J Carty, K Siddiqui, N Glasspool, R Whittemore, AS Rothstein, JH McGuire, V Sieh, W Ji, BT Zheng, W Shu, XO Gao, YT Rosen, B Risch, HA McLaughlin, JR Narod, SA Monteiro, AN Chen, A Lin, HY Permuth-Wey, J Sellers, TA Tsai, YY Chen, Z Ziogas, A Anton-Culver, H Gentry-Maharaj, A Menon, U Harrington, P Lee, AW Wu, AH Pearce, CL Coetzee, G Pike, MC Dansonka-Mieszkowska, A Timorek, A Rzepecka, IK Kupryjanczyk, J Freedman, M Noushmehr, H Easton, DF Offit, K Couch, FJ Gayther, S Pharoah, PP Antoniou, AC Chenevix-Trench, G AF Kuchenbaecker, Karoline B. Ramus, Susan J. Tyrer, Jonathan Lee, Andrew Shen, Howard C. Beesley, Jonathan Lawrenson, Kate McGuffog, Lesley Healey, Sue Lee, Janet M. Spindler, Tassja J. Lin, Yvonne G. Pejovic, Tanja Bean, Yukie Li, Qiyuan Coetzee, Simon Hazelett, Dennis Miron, Alexander Southey, Melissa Terry, Mary Beth Goldgar, David E. Buys, Saundra S. Janavicius, Ramunas Dorfling, Cecilia M. van Rensburg, Elizabeth J. Neuhausen, Susan L. Ding, Yuan Chun Hansen, Thomas V. O. Jonson, Lars Gerdes, Anne-Marie Ejlertsen, Bent Barrowdale, Daniel Dennis, Joe Benitez, Javier Osorio, Ana Garcia, Maria Jose Komenaka, Ian Weitzel, Jeffrey N. Ganschow, Pamela Peterlongo, Paolo Bernard, Loris Viel, Alessandra Bonanni, Bernardo Peissel, Bernard Manoukian, Siranoush Radice, Paolo Papi, Laura Ottini, Laura Fostira, Florentia Konstantopoulou, Irene Garber, Judy Frost, Debra Perkins, Jo Platte, Radka Ellis, Steve Godwin, Andrew K. Schmutzler, Rita Katharina Meindl, Alfons Engel, Christoph Sutter, Christian Sinilnikova, Olga M. Damiola, Francesca Mazoyer, Sylvie Stoppa-Lyonnet, Dominique Claes, Kathleen De Leeneer, Kim Kirk, Judy Rodriguez, Gustavo C. Piedmonte, Marion O'Malley, David M. de la Hoya, Miguel Caldes, Trinidad Aittomaeki, Kristiina Nevanlinna, Heli Collee, J. Margriet Rookus, Matti A. Oosterwijk, Jan C. Tihomirova, Laima Tung, Nadine Hamann, Ute Isaccs, Claudine Tischkowitz, Marc Imyanitov, Evgeny N. Caligo, Maria A. Campbell, Ian G. Hogervorst, Frans B. L. Olah, Edith Diez, Orland Blanco, Ignacio Brunet, Joan Lazaroso, Conxi Angel Pujana, Miguel Jakubowska, Anna Gronwald, Jacek Lubinski, Jan Sukiennicki, Grzegorz Barkardottir, Rosa B. Plante, Marie Simard, Jacques Soucy, Penny Montagna, Marco Tognazzo, Silvia Teixeira, Manuel R. Pankratz, Vernon S. Wang, Xianshu Lindor, Noralane Szabo, Csilla I. Kauff, Noah Vijai, Joseph Aghajanian, Carol A. Pfeiler, Georg Berger, Andreas Singer, Christian F. Tea, Muy-Kheng Phelan, Catherine M. Greene, Mark H. Mai, Phuong L. Rennert, Gad Mulligan, Anna Marie Tchatchou, Sandrine Andrulis, Irene L. Glendon, Gord Toland, Amanda Ewart Jensen, Uffe Birk Kruse, Torben A. Thomassen, Mads Bojesen, Anders Zidan, Jamal Friedman, Eitan Laitman, Yael Soller, Maria Liljegren, Annelie Arver, Brita Einbeigi, Zakaria Stenmark-Askmalm, Marie Olopade, Olufunmilayo I. Nussbaum, Robert L. Rebbeck, Timothy R. Nathanson, Katherine L. Domchek, Susan M. Lu, Karen H. Karlan, Beth Y. Walsh, Christine Lester, Jenny Hein, Alexander Ekici, Arif B. Beckmann, Matthias W. Fasching, Peter A. Lambrechts, Diether Van Nieuwenhuysen, Els Vergote, Ignace Lambrechts, Sandrina Dicks, Ed Doherty, Jennifer A. Wicklund, Kristine G. Rossing, Mary Anne Rudolph, Anja Chang-Claude, Jenny Wang-Gohrke, Shan Eilber, Ursula Moysich, Kirsten B. Odunsi, Kunle Sucheston, Lara Lele, Shashi Wilkens, Lynne R. Goodman, Marc T. Thompson, Pamela J. Shvetsov, Yurii B. Runnebaum, Ingo B. Duerst, Matthias Hillemanns, Peter Doerk, Thilo Antonenkova, Natalia Bogdanova, Natalia Leminen, Arto Pelttari, Liisa M. Butzow, Ralf Modugno, Francesmary Kelley, Joseph L. Edwards, Robert P. Ness, Roberta B. du Bois, Andreas Heitz, Florian Schwaab, Ira Harter, Philipp Matsuo, Keitaro Hosono, Satoyo Orsulic, Sandra Jensen, Allan Kjaer, Susanne Kruger Hogdall, Estrid Hasmad, Hanis Nazihah Azmi, Mat Adenan Noor Teo, Soo-Hwang Woo, Yin-Ling Fridley, Brooke L. Goode, Ellen L. Cunningham, Julie M. Vierkant, Robert A. Bruinsma, Fiona Giles, Graham G. Liang, Dong Hildebrandt, Michelle A. T. Wu, Xifeng Levine, Douglas A. Bisogna, Maria Berchuck, Andrew Iversen, Edwin S. Schildkraut, Joellen M. Concannon, Patrick Weber, Rachel Palmieri Cramer, Daniel W. Terry, Kathryn L. Poole, Elizabeth M. Tworoger, Shelley S. Bandera, Elisa V. Orlow, Irene Olson, Sara H. Krakstad, Camilla Salvesen, Helga B. Tangen, Ingvild L. Bjorge, Line van Altena, Anne M. Aben, Katja K. H. Kiemeney, Lambertus A. Massuger, Leon F. A. G. Kellar, Melissa Brooks-Wilson, Angela Kelemen, Linda E. Cook, Linda S. Le, Nhu D. Cybulski, Cezary Yang, Hannah Lissowska, Jolanta Brinton, Louise A. Wentzensen, Nicolas Hogdall, Claus Lundvall, Lene Nedergaard, Lotte Baker, Helen Song, Honglin Eccles, Diana McNeish, Ian Paul, James Carty, Karen Siddiqui, Nadeem Glasspool, Rosalind Whittemore, Alice S. Rothstein, Joseph H. McGuire, Valerie Sieh, Weiva Ji, Bu-Tian Zheng, Wei Shu, Xiao-Ou Gao, Yu-Tang Rosen, Barry Risch, Harvey A. McLaughlin, John R. Narod, Steven A. Monteiro, Alvaro N. Chen, Ann Lin, Hui-Yi Permuth-Wey, Jenny Sellers, Thomas A. Tsai, Ya-Yu Chen, Zhihua Ziogas, Argyrios Anton-Culver, Hoda Gentry-Maharaj, Aleksandra Menon, Usha Harrington, Patricia Lee, Alice W. Wu, Anna H. Pearce, Celeste L. Coetzee, Gerry Pike, Malcolm C. Dansonka-Mieszkowska, Agnieszka Timorek, Agnieszka Rzepecka, Iwona K. Kupryjanczyk, Jolanta Freedman, Matt Noushmehr, Houtan Easton, Douglas F. Offit, Kenneth Couch, Fergus J. Gayther, Simon Pharoah, Paul P. Antoniou, Antonis C. Chenevix-Trench, Georgia CA EMBRACE GEMO Study Collaborators Breast Cancer Family Registry HEBON KConFab Investigators Australian Canc Study Ovarian Canc Australian Ovarian Canc Study Grp Consortium Invest Modifiers BRCA1 TI Identification of six new susceptibility loci for invasive epithelial ovarian cancer SO NATURE GENETICS LA English DT Article ID BRCA2 MUTATION CARRIERS; GENOME-WIDE ASSOCIATION; ABO BLOOD-GROUP; BREAST-CANCER; GENETIC-VARIATION; COMMON VARIANTS; HUMAN ELG1; RISK; MYOPODIN; METAANALYSIS AB Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibility alleles. The pattern of association at these loci is consistent in BRCA1 and BRCA2 mutation carriers who are at high risk of EOC. After imputation to 1000 Genomes Project data, we assessed associations of 11 million genetic variants with EOC risk from 15,437 cases unselected for family history and 30,845 controls and from 15,252 BRCA1 mutation carriers and 8,211 BRCA2 mutation carriers (3,096 with ovarian cancer), and we combined the results in a meta-analysis. This new study design yielded increased statistical power, leading to the discovery of six new EOC susceptibility loci. Variants at 1p36 (nearest gene, WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with EOC risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) variants were specifically associated with the serous EOC subtype, all with P < 5 x 10(-8). Incorporating these variants into risk assessment tools will improve clinical risk predictions for BRCA1 and BRCA2 mutation carriers. C1 [Kuchenbaecker, Karoline B.; Lee, Andrew; McGuffog, Lesley; Barrowdale, Daniel; Dennis, Joe; Frost, Debra; Perkins, Jo; Platte, Radka; Ellis, Steve; Easton, Douglas F.; Antoniou, Antonis C.] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Publ Hlth & Primary Care, Cambridge, England. [Ramus, Susan J.; Shen, Howard C.; Lawrenson, Kate; Lee, Janet M.; Spindler, Tassja J.; Hazelett, Dennis; Lee, Alice W.; Wu, Anna H.; Pearce, Celeste L.; Coetzee, Gerry; Pike, Malcolm C.; Gayther, Simon] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA. [Tyrer, Jonathan; Dennis, Joe; Dicks, Ed; Baker, Helen; Song, Honglin; Harrington, Patricia; Pharoah, Paul P.] Univ Cambridge, Dept Oncol, Strangeways Res Lab, Cambridge, England. [Beesley, Jonathan; Healey, Sue; Chenevix-Trench, Georgia] QIMR Berghofer Med Res Inst, Cancer Div, Brisbane, Qld, Australia. [Lin, Yvonne G.] Univ So Calif, Dept Obstet & Gynaecol, Los Angeles, CA USA. [Pejovic, Tanja; Bean, Yukie; Kellar, Melissa] Oregon Hlth & Sci Univ, Dept Obstet & Gynaecol, Portland, OR 97201 USA. [Pejovic, Tanja; Bean, Yukie; Kellar, Melissa] Knight Canc Inst, Portland, OR USA. [Li, Qiyuan; Freedman, Matt] Ctr Funct Canc Epigenet, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [Coetzee, Simon; Noushmehr, Houtan] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Genet, BR-14049 Ribeirao Preto, Brazil. Ctr Cell Based Therapy, Ribeirao Preto, Brazil. [Coetzee, Simon] Ctr Integrat Syst Biol, Ribeirao Preto, Brazil. [Hazelett, Dennis; Coetzee, Gerry] Univ So Calif, Dept Urol, Los Angeles, CA USA. [Miron, Alexander] Case Western Reserve Univ, Sch Med, Dept Genom & Genome Sci, Cleveland, OH 44106 USA. [Southey, Melissa] Univ Melbourne, Dept Pathol, Genet Epidemiol Lab, Parkville, Vic 3052, Australia. [Terry, Mary Beth] Columbia Univ, Dept Epidemiol, New York, NY USA. [Goldgar, David E.] Univ Utah, Sch Med, Dept Dermatol, Salt Lake City, UT USA. [Buys, Saundra S.] Univ Utah, Sch Med, Huntsman Canc Inst, Dept Med, Salt Lake City, UT USA. [Janavicius, Ramunas] Vilnius Univ Hosp Santariskiu Clin, Hematol Oncol & Transfus Med Ctr, Dept Mol & Regenerat Med, Vilnius, Lithuania. [Janavicius, Ramunas] State Res Inst Ctr Innovat Med, Vilnius, Lithuania. [Dorfling, Cecilia M.; van Rensburg, Elizabeth J.] Univ Pretoria, Dept Genet, ZA-0002 Pretoria, South Africa. [Neuhausen, Susan L.; Ding, Yuan Chun] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Duarte, CA 91010 USA. [Hansen, Thomas V. O.; Jonson, Lars] Univ Copenhagen Hosp, Ctr Genet Med, DK-2100 Copenhagen, Denmark. [Gerdes, Anne-Marie] Univ Copenhagen Hosp, Dept Clin Genet, DK-2100 Copenhagen, Denmark. [Ejlertsen, Bent] Univ Copenhagen Hosp, Dept Oncol, DK-2100 Copenhagen, Denmark. [Benitez, Javier; Osorio, Ana; Garcia, Maria Jose] Spanish Natl Canc Ctr CNIO, Human Canc Genet Program, Human Genet Grp, Madrid, Spain. Spanish Natl Canc Ctr CNIO, Human Canc Genet Program, Human Genotyping Unit CEGEN, Madrid, Spain. [Benitez, Javier; Osorio, Ana; Garcia, Maria Jose] CIBERER, Biomed Network Rare Dis, Madrid, Spain. [Komenaka, Ian] Maricopa Cty Gen Hosp, Clin Canc Genet Community Res Network, Duarte, CA USA. [Weitzel, Jeffrey N.] Clin Canc Genet, Clin Canc Genet Community Res Network, Duarte, CA USA. [Ganschow, Pamela] Cook Cty Hlth & Hosp Syst, Clin Canc Genet Community Res Network, Duarte, CA USA. [Peterlongo, Paolo] Italian Fdn Canc Research, Fdn Ist FIRC Oncol Molecolare IFOM, Milan, Italy. [Bernard, Loris] Ist Europeo Oncol, Dept Expt Oncol, Milan, Italy. [Bernard, Loris] Cogentech Canc Genet Test Lab, Milan, Italy. [Viel, Alessandra] CRO, Aviano Natl Canc Inst, Aviano, Italy. [Bonanni, Bernardo] Ist Europeo Oncol, Div Canc Prevent & Genet, Milan, Italy. [Peissel, Bernard; Manoukian, Siranoush] Italian Res Hospital, Fdn IRCCS, INT, Dept Prevent & Predict Med,Unit Med Genet, Milan, Italy. [Radice, Paolo] Fdn IRCCS, INT, Dept Prevent & Predict Med, Unit Mol Bases Genet Risk & Genet Testing, Milan, Italy. [Papi, Laura] Univ Florence, Dept Biomed Expt & Clin Sci, Unit Med Genet, Florence, Italy. [Ottini, Laura] Univ Roma La Sapienza, Dept Mol Med, Rome, Italy. [Fostira, Florentia; Konstantopoulou, Irene] Natl Ctr Sci Res Demokritos, INRASTES Inst Nucl & Radiol Sci & Technology, Mol Diag Lab, Athens, Greece. [Garber, Judy] Childrens Hosp, Dana Farber Canc Inst, Canc Risk & Prevent Clin, Boston, MA 02115 USA. [Godwin, Andrew K.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA. [Schmutzler, Rita Katharina] Univ Hosp Cologne, Fac Med, Center Hereditary Breast & Ovarian Canc, Cologne, Germany. Univ Hosp Cologne, Fac Med, CIO, Cologne, Germany. Univ Hosp Cologne, CMMC, Cologne, Germany. [Meindl, Alfons] Tech Univ Munich, Klinikum Rechts Isar, Dept Gynecol & Obstet, Div Tumor Genet, D-80290 Munich, Germany. [Engel, Christoph] Univ Leipzig, Inst Med Informat Stat & Epidemiol, D-04109 Leipzig, Germany. [Sutter, Christian] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany. [Sinilnikova, Olga M.; Damiola, Francesca; Mazoyer, Sylvie] Univ Lyon, Ctr Rech Cancerol Lyon, CNRS UMR 5286, INSERM U1052, Lyon, France. [Sinilnikova, Olga M.] Hosp Civils Lyon, Ctr Leon Berard, Unite Mixte Genet Constitutionnelle Canc Frequent, Lyon, France. [Stoppa-Lyonnet, Dominique] Inst Curie, Dept Tumor Biol, Paris, France. Inst Curie, INSERM, U830, Paris, France. [Stoppa-Lyonnet, Dominique] Univ Paris 05, Paris, France. [Claes, Kathleen; De Leeneer, Kim] Univ Ghent, Ctr Med Genet, B-9000 Ghent, Belgium. [Kirk, Judy] Westmead Hosp, ANZGOG, Sydney, NSW, Australia. [Kirk, Judy] Westmead Hosp, Familial Canc Serv, Sydney, NSW, Australia. [Rodriguez, Gustavo C.] NorthShore Univ HealthSystem, Div Gynecol Oncol, Evanston, IL USA. [Piedmonte, Marion] Roswell Pk Canc Inst, Stat & Data Ctr, Gynecol Oncol Grp, Buffalo, NY 14263 USA. [O'Malley, David M.] Ohio State Univ, James Canc Ctr, Columbus, OH 43210 USA. [de la Hoya, Miguel; Caldes, Trinidad] Hosp Clin San Carlos, IdISSC Inst Invest Sanit Hosp Clin San Carlos, Mol Oncol Lab, Madrid, Spain. [Aittomaeki, Kristiina] Univ Helsinki, Cent Hosp, Dept Clin Genet, Helsinki, Finland. [Nevanlinna, Heli; Leminen, Arto; Pelttari, Liisa M.; Butzow, Ralf] Univ Helsinki, Dept Obstet & Gynaecol, Helsinki, Finland. [Nevanlinna, Heli; Leminen, Arto; Pelttari, Liisa M.; Butzow, Ralf] Univ Helsinki, Cent Hosp, Helsinki, Finland. [Collee, J. Margriet] Erasmus Univ, Med Ctr, Family Canc Clin, Dept Clin Genet, Rotterdam, Netherlands. [Rookus, Matti A.] Netherlands Canc Inst, Dept Epidemiol, Amsterdam, Netherlands. [Oosterwijk, Jan C.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands. [Tihomirova, Laima] Latvian Biomed Res & Study Ctr, Riga, Latvia. [Tung, Nadine] Beth Israel Deaconess Med Ctr, Dept Med Oncol, Boston, MA 02215 USA. [Hamann, Ute] DKFZ, Mol Genet Breast Canc, Heidelberg, Germany. [Isaccs, Claudine] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA. [Tischkowitz, Marc] McGill Univ, Program Canc Genet, Montreal, PQ, Canada. [Imyanitov, Evgeny N.] NN Petrov Inst Oncol, St Petersburg, Russia. [Caligo, Maria A.] Univ Pisa, Dept Lab Med, Sect Genet Oncol, Pisa, Italy. [Caligo, Maria A.] Univ Hosp Pisa, Pisa, Italy. [Campbell, Ian G.] Peter MacCallum Canc Ctr, VBCRC Canc Genet Lab, Melbourne, Vic, Australia. [Hogervorst, Frans B. L.] Netherlands Canc Inst, Family Canc Clin, Amsterdam, Netherlands. [Olah, Edith] Natl Inst Oncol, Dept Mol Genet, Budapest, Hungary. [Diez, Orland] Univ Hosp Vall Hebron, VHIO, Oncogenet Grp, Barcelona, Spain. [Diez, Orland] Univ Autonoma Barcelona, E-08193 Barcelona, Spain. [Blanco, Ignacio] Catalan Inst Oncol, IDIBELL Bellvitge Biomed Res Inst, Hereditary Canc Program, Genet Counseling Unit, Barcelona, Spain. [Brunet, Joan] Catalan Inst Oncol, IDIBGI Institut dInvestigacie Biomed Girona, Hereditary Canc Program, Genet Counseling Unit, Girona, Spain. [Lazaroso, Conxi; Angel Pujana, Miguel] Catalan Inst Oncol, IDIBELL, Hereditary Canc Program, Molecular Diagnost Unit, Barcelona, Spain. [Jakubowska, Anna; Gronwald, Jacek; Lubinski, Jan; Sukiennicki, Grzegorz] Pomeranian Med Univ, Dept Genet & Pathol, Szczecin, Poland. [Barkardottir, Rosa B.] Landspitali Univ Hosp, Dept Pathol, Reykjavik, Iceland. [Barkardottir, Rosa B.] Univ Iceland, Fac Med, Biomed Ctr, Reykjavik, Iceland. [Plante, Marie] CHUQ, Gynaecol Oncol Serv, Quebec City, PQ, Canada. [Simard, Jacques; Soucy, Penny] Univ Laval, CHUQ, Res Ctr, Quebec City, PQ, Canada. [Montagna, Marco; Tognazzo, Silvia] IRCCS, IOV, Immunol & Mol Oncol Unit, Padua, Italy. [Teixeira, Manuel R.; McNeish, Ian] Univ Porto, Inst Biomed Sci ICBAS, P-4100 Oporto, Portugal. [Teixeira, Manuel R.] Portuguese Oncol Inst, Dept Genet, Oporto, Portugal. [Pankratz, Vernon S.; Lindor, Noralane; Goode, Ellen L.; Couch, Fergus J.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA. [Wang, Xianshu; Cunningham, Julie M.; Couch, Fergus J.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA. [Szabo, Csilla I.] NHGRI, NIH, Bethesda, MD 20892 USA. [Kauff, Noah; Vijai, Joseph; Aghajanian, Carol A.; Offit, Kenneth] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. [Pfeiler, Georg; Berger, Andreas; Singer, Christian F.; Tea, Muy-Kheng] Med Univ Vienna, Ctr Comprehens Canc, Dept Obstet & Ginecol, Vienna, Austria. [Phelan, Catherine M.; Monteiro, Alvaro N.; Permuth-Wey, Jenny; Sellers, Thomas A.; Tsai, Ya-Yu] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA. [Greene, Mark H.; Mai, Phuong L.] NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA. [Rennert, Gad] Carmel Hosp, Dept Community Med & Epidemiol, Haifa, Israel. [Mulligan, Anna Marie; Andrulis, Irene L.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada. [Mulligan, Anna Marie] Univ Hlth Network, Lab Med Program, Toronto, ON, Canada. [Tchatchou, Sandrine; Glendon, Gord] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada. [Andrulis, Irene L.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada. [Toland, Amanda Ewart] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA. [Jensen, Uffe Birk] Aarhus Univ Hosp, Dept Clin Genet, DK-8000 Aarhus, Denmark. [Kruse, Torben A.; Thomassen, Mads] Odense Univ Hosp, Dept Clin Genet, DK-5000 Odense, Denmark. [Bojesen, Anders] Vejle Hosp, Dept Clin Genet, Vejle, Denmark. [Zidan, Jamal] Rivka Ziv Med Ctr, Inst Oncol, Safed, Israel. [Friedman, Eitan; Laitman, Yael] Sheba Med Ctr, Susanne Levy Gertner Oncogenet Unit, Tel Aviv, Israel. [Soller, Maria] Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden. [Liljegren, Annelie; Arver, Brita] Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden. [Einbeigi, Zakaria] Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden. [Stenmark-Askmalm, Marie] Linkoping Univ, Dept Clin & Expt Med, Div Clin Genet, Linkoping, Sweden. [Olopade, Olufunmilayo I.] Univ Chicago, Med Ctr, Ctr Clin Canc Genet & Global Hlth, Chicago, IL 60637 USA. [Nussbaum, Robert L.] Univ Calif San Francisco, Dept Med Genet, San Francisco, CA 94143 USA. [Rebbeck, Timothy R.; Nathanson, Katherine L.; Domchek, Susan M.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Lu, Karen H.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA. [Karlan, Beth Y.; Walsh, Christine; Lester, Jenny; Orsulic, Sandra] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA. [Hein, Alexander; Beckmann, Matthias W.; Fasching, Peter A.] Univ Erlangen Nurnberg, Erlangen Univ Hosp, Dept Obstet & Gynecol, D-91054 Erlangen, Germany. [Ekici, Arif B.] Univ Erlangen Nurnberg, Inst Human Genet, D-91054 Erlangen, Germany. [Fasching, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA. [Lambrechts, Diether] Vesalius Res Ctr, VIB, Leuven, Belgium. [Lambrechts, Diether] Univ Leuven, Dept Oncol, Lab Translat Genet, Leuven, Belgium. [Van Nieuwenhuysen, Els; Vergote, Ignace; Lambrechts, Sandrina] Univ Leuven, Dept Oncol, Div Gynecol Oncol, Leuven, Belgium. [Doherty, Jennifer A.] Geisel Sch Med, Dept Community & Family Med, Epidemiol & Biostat Sect, Lebanon, NH USA. [Wicklund, Kristine G.; Rossing, Mary Anne] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, Seattle, WA 98104 USA. [Rossing, Mary Anne] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Rudolph, Anja; Chang-Claude, Jenny; Eilber, Ursula] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany. [Wang-Gohrke, Shan] Univ Ulm, Dept Obstet & Gynaecol, D-89069 Ulm, Germany. [Moysich, Kirsten B.; Sucheston, Lara; Lele, Shashi] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA. [Odunsi, Kunle] Roswell Pk Canc Inst, Dept Gynecol Oncol, Buffalo, NY 14263 USA. [Wilkens, Lynne R.; Shvetsov, Yurii B.] Univ Hawaii Canc Ctr, Canc Epidemiol Program, Honolulu, HI USA. [Goodman, Marc T.; Thompson, Pamela J.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA. [Goodman, Marc T.; Thompson, Pamela J.] Cedars Sinai Med Ctr, Commun & Populat Hlth Res Inst, Dept Biomed Sci, Los Angeles, CA 90048 USA. [Runnebaum, Ingo B.; Duerst, Matthias] Univ Jena, Jena Univ Hosp, Dept Gynecol, Jena, Germany. [Hillemanns, Peter] Hannover Med Sch, Clin Obstet & Gynaecol, Hannover, Germany. [Doerk, Thilo; Bogdanova, Natalia] Hannover Med Sch, Gynaecol Res Unit, Hannover, Germany. [Antonenkova, Natalia] Byelorussian Inst Oncol & Med Radiol Aleksandrov, Minsk, Byelarus. [Butzow, Ralf] Univ Helsinki, Cent Hosp, Dept Pathol, Helsinki, Finland. [Modugno, Francesmary] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Kelley, Joseph L.; Edwards, Robert P.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA. [Edwards, Robert P.] Univ Pittsburgh, Ovarian Canc Ctr Excellence, Pittsburgh, PA USA. [Modugno, Francesmary] Magee Womens Res Inst, Womens Canc Res ProgramInst Canc, Pittsburgh, PA USA. [Modugno, Francesmary] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. [Ness, Roberta B.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. [du Bois, Andreas; Heitz, Florian; Harter, Philipp] Dr Horst Schmidt Klin Wiesbaden, Dept Gynecol & Gynecol Oncol, Wiesbaden, Germany. [du Bois, Andreas; Heitz, Florian; Harter, Philipp] Klin Essen Mitte, Dept Gynecol & Gynecol Oncol, Essen, Germany. [Schwaab, Ira] Inst Humangenetik Wiesbaden, Wiesbaden, Germany. [Matsuo, Keitaro] Kyushu Univ, Fac Med Sci, Dept Prevent Med, Fukuoka 812, Japan. [Hosono, Satoyo] Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi 464, Japan. [Jensen, Allan; Kjaer, Susanne Kruger; Hogdall, Estrid] Danish Canc Soc, Res Ctr, Dept Virus Lifestyle & Genes, Copenhagen, Denmark. [Kjaer, Susanne Kruger; Hogdall, Claus; Lundvall, Lene] Univ Copenhagen, Dept Gynaecol, Copenhagen, Denmark. [Hogdall, Estrid] Univ Copenhagen, Herlev Hosp, Dept Pathol, Mol Unit, Copenhagen, Denmark. [Hasmad, Hanis Nazihah; Teo, Soo-Hwang] Canc Res Initiat Fdn, Sime Darby Med Ctr, Subang Jaya, Malaysia. [Azmi, Mat Adenan Noor; Woo, Yin-Ling] Univ Malaya, Med Ctr, Dept Obstet & Gynaecol, Kuala Lumpur, Malaysia. [Teo, Soo-Hwang; Woo, Yin-Ling] Univ Malaya, Fac Med, Med Ctr, Canc Res Inst, Kuala Lumpur, Malaysia. [Fridley, Brooke L.] Univ Kansas, Med Ctr, Biostat & Informat Shared Resource, Kansas City, KS 66103 USA. [Vierkant, Robert A.] Mayo Clin, Dept Hlth Sci Res, Div Biomed Stat & Informat, Rochester, MN USA. [Bruinsma, Fiona; Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia. [Liang, Dong] Texas So Univ, Coll Pharm & Hlth Sci, Houston, TX 77004 USA. [Hildebrandt, Michelle A. T.; Wu, Xifeng] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA. [Levine, Douglas A.; Bisogna, Maria] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10021 USA. [Berchuck, Andrew] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA. [Iversen, Edwin S.] Duke Univ, Dept Stat Sci, Durham, NC USA. [Schildkraut, Joellen M.] Duke Canc Inst, Canc Control & Populat Sci, Durham, NC USA. [Schildkraut, Joellen M.; Weber, Rachel Palmieri] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA. [Concannon, Patrick] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL USA. [Concannon, Patrick] Univ Florida, Genet Inst, Gainesville, FL USA. [Cramer, Daniel W.; Terry, Kathryn L.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Cramer, Daniel W.; Terry, Kathryn L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Obstetr & Gynecol Epidemiol Ctr, Boston, MA 02115 USA. [Poole, Elizabeth M.; Tworoger, Shelley S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA. [Poole, Elizabeth M.; Tworoger, Shelley S.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Bandera, Elisa V.] Rutgers Canc Inst New Jersey, Cancer Prevent & Control, New Brunswick, NJ USA. [Orlow, Irene; Olson, Sara H.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Epidemiol Serv, New York, NY 10021 USA. [Krakstad, Camilla; Salvesen, Helga B.; Tangen, Ingvild L.; Bjorge, Line] Univ Bergen, Dept Clin Med, Ctr Canc Biomarkers, Bergen, Norway. [Krakstad, Camilla; Salvesen, Helga B.; Tangen, Ingvild L.; Bjorge, Line] Haukeland Hosp, Dept Gynecol & Obstet, N-5021 Bergen, Norway. [van Altena, Anne M.; Massuger, Leon F. A. G.] Radboud Univ Nijmegen, Med Ctr, Dept Gynaecol, Nijmegen, Netherlands. [Aben, Katja K. H.] Ctr Comprehens Canc, Utrecht, Netherlands. [Aben, Katja K. H.; Kiemeney, Lambertus A.] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, Nijmegen, Netherlands. [Kiemeney, Lambertus A.] Radboud Univ Nijmegen, Med Ctr, Dept Urol, Nijmegen, Netherlands. [Brooks-Wilson, Angela] British Columbia Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada. [Brooks-Wilson, Angela] Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Burnaby, BC V5A 1S6, Canada. [Kelemen, Linda E.] Med Univ S Carolina, Coll Med, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Cook, Linda S.] Univ New Mexico, Dept Internal Med, Div Epidemiol & Biostat, Albuquerque, NM 87131 USA. [Le, Nhu D.] British Columbia Canc Agcy, Canc Control Res, Vancouver, BC V5Z 4E6, Canada. [Cybulski, Cezary] Pomeranian Med Univ, Internat Hereditary Canc Ctr, Dept Genet & Pathol, Clin Opthalmol, Szczecin, Poland. [Yang, Hannah; Brinton, Louise A.; Wentzensen, Nicolas; Ji, Bu-Tian] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Lissowska, Jolanta] Maria Sklodowska Curie Mem Canc Ctr, Inst Oncol, Dept Canc Epidemiol & Prevent, Warsaw, Poland. [Nedergaard, Lotte; Paul, James; Carty, Karen] Univ Copenhagen, Dept Pathol, Copenhagen, Denmark. [Eccles, Diana] Princess Anne Hosp, Wessex Clin Genet Serv, Southampton, Hants, England. [McNeish, Ian] Univ Glasgow, Wolfson Wohl Canc Res Ctr, Beatson Inst Canc Res, Inst Canc Sci, Glasgow, Lanark, Scotland. [Glasspool, Rosalind] Beatson West Scotland, Ctr Canc, Canc Res UK Clin, Trials Unit, Glasgow, Lanark, Scotland. [Siddiqui, Nadeem] Glasgow Royal Infirm, Dept Gynecol Oncol, Glasgow G4 0SF, Lanark, Scotland. [Whittemore, Alice S.; Rothstein, Joseph H.; McGuire, Valerie; Sieh, Weiva] Stanford Univ, Sch Med, Dept Hlth Res & Policy Epidemiol, Stanford, CA 94305 USA. [Zheng, Wei; Shu, Xiao-Ou] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Gao, Yu-Tang] Shanghai Canc Inst, Shanghai, Peoples R China. [Rosen, Barry] Univ Toronto, Fac Med, Dept Obstet & Gynaecol, Toronto, ON, Canada. [Rosen, Barry] Princess Margaret Hosp, Dept Gynecol Oncol, Toronto, ON M4X 1K9, Canada. [Risch, Harvey A.] Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT USA. [McLaughlin, John R.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Prosserman Ctr Hlth Res, Toronto, ON M5G 1X5, Canada. [Narod, Steven A.] Univ Toronto, Womens Coll Res Inst, Toronto, ON, Canada. [Chen, Ann; Lin, Hui-Yi; Chen, Zhihua] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat, Tampa, FL USA. [Ziogas, Argyrios; Anton-Culver, Hoda] Univ Calif Irvine, Dept Epidemiol, Irvine, CA USA. [Gentry-Maharaj, Aleksandra; Menon, Usha] UCL, Elizabeth Garrett Anderson EGA Inst Womens Hlth, London, England. [Pike, Malcolm C.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Dansonka-Mieszkowska, Agnieszka; Rzepecka, Iwona K.; Kupryjanczyk, Jolanta] Maria Sklodowska Curie Mem Canc Ctr, Inst Oncol, Dept Pathol, Warsaw, Poland. [Timorek, Agnieszka] Med Univ Warsaw, Fac Med 2, Dept Obstet Gynecol & Oncol, Warsaw, Poland. [Timorek, Agnieszka] Brodnowski Hosp, Warsaw, Poland. RP Chenevix-Trench, G (reprint author), QIMR Berghofer Med Res Inst, Cancer Div, Brisbane, Qld, Australia. EM georgia.trench@qimrberghofer.edu.au RI Gronwald, Jacek/A-4576-2017; Bjorge, Line/C-1307-2017; salvesen, Helga/C-1187-2017; manoukian, siranoush/E-7132-2017; Coetzee, Simon/C-1218-2014; Peissel, Bernard/E-8187-2017; Ligtenberg, Marjolijn/N-9666-2013; Mensenkamp, A.R./L-4520-2015; Osorio, Ana/I-4324-2014; van Altena, Anne/B-9824-2016; Dork, Thilo/J-8620-2012; Arnold, Norbert/E-3012-2010; Teixeira, Manuel/E-4885-2011; Garcia, Maria/G-1361-2016; Aben, Katja/G-9686-2016; Bowtell, David/H-1007-2016; Andrulis, Irene/E-7267-2013; OMalley, David/E-3789-2011; Menkiszak, Janusz/I-4036-2014; Hein, Alexander/F-6999-2010; Woo, Yin Ling/B-5198-2010; Massuger, Leon/H-8072-2014; Jansen van Rensburg, Elizabeth (Lizette)/B-9104-2011; Kiemeney, Lambertus/D-3357-2009; Teo, Soo-hwang/H-2353-2014; Fridley, Brooke/D-8315-2015; BYRSKI, Tomasz/I-2844-2014; Ehrencrona, Hans/M-5619-2014; Brinton, Louise/G-7486-2015; Brooks-Wilson, Angela/E-9399-2012; Bandera, Elisa/M-4169-2014; montagna, marco/E-2225-2012 OI Eeles, Rosalind/0000-0002-3698-6241; Blanco, Ignacio/0000-0002-7414-7481; Kjaer, Susanne/0000-0002-8347-1398; Ramus, Susan/0000-0003-0005-7798; Sunde, Lone/0000-0002-8479-165X; Khan, Sofia/0000-0003-4185-8882; Brunet, Joan/0000-0003-1945-3512; Kauff, Noah/0000-0001-7242-6156; Joseph, Vijai/0000-0002-7933-151X; Tommasi, Stefania/0000-0002-2157-2978; McNeish, Iain/0000-0002-9387-7586; Gronwald, Jacek/0000-0002-3643-2871; Bjorge, Line/0000-0002-0240-2770; salvesen, Helga/0000-0002-4438-8831; manoukian, siranoush/0000-0002-6034-7562; Coetzee, Simon/0000-0003-4267-5930; Peissel, Bernard/0000-0001-9233-3571; Peixoto, Ana/0000-0002-1404-5897; Glasspool, Rosalind/0000-0002-5000-1680; Barrowdale, Daniel/0000-0003-1661-3939; Dolcetti, Riccardo/0000-0003-1625-9853; Orlow, Irene/0000-0001-6234-6961; Dunning, Alison Margaret/0000-0001-6651-7166; Krakstad, Camilla/0000-0002-0174-8139; ROMERO, ATOCHA/0000-0002-1634-7397; Giles, Graham/0000-0003-4946-9099; Matsuo, Keitaro/0000-0003-1761-6314; Dobrovic, Alexander/0000-0003-3414-112X; Evans, Gareth/0000-0002-8482-5784; Ligtenberg, Marjolijn/0000-0003-1290-1474; Osorio, Ana/0000-0001-8124-3984; Arnold, Norbert/0000-0003-4523-8808; Teixeira, Manuel/0000-0002-4896-5982; Garcia, Maria/0000-0002-2236-9912; Aben, Katja/0000-0002-0214-2147; Bowtell, David/0000-0001-9089-7525; Hein, Alexander/0000-0003-2601-3398; Woo, Yin Ling/0000-0003-1742-1066; Kiemeney, Lambertus/0000-0002-2368-1326; Fridley, Brooke/0000-0001-7739-7956; Ehrencrona, Hans/0000-0002-5589-3622; Brinton, Louise/0000-0003-3853-8562; Brooks-Wilson, Angela/0000-0003-1009-6408; Bandera, Elisa/0000-0002-8789-2755; montagna, marco/0000-0002-4929-2150 FU European Commission Seventh Framework Programme [223175-HEALTH-F2-2009-223175]; Cancer Research UK [C12292/A11174, C1287/A10118]; Ovarian Cancer Research Fund; US National Cancer Institute GAME-ON Post-GWAS Initiative [U19-CA148112]; Wellcome Trust [076113]; National Health and Medical Research Council of Australia Program Grant; Associazione Italiana per la Ricerca sul Cancro FX We thank all the individuals who took part in this study and all the researchers, clinicians, and technical and administrative staff who made possible the many studies contributing to this work (a full list is provided in the Supplementary Note), including X.Q. Chen for iPLEX genotyping. The COGS project is funded through a European Commission Seventh Framework Programme grant (agreement number 223175-HEALTH-F2-2009-223175). CIMBA data management and data analysis were supported by Cancer Research UK grants C12292/A11174 and C1287/A10118. The Ovarian Cancer Association Consortium (OCAC) is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). Scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control Consortium. Funding for the project was provided by the Wellcome Trust under award 076113. The results published here are in part based on data generated by The Cancer Genome Atlas (TCGA) Pilot Project established by the US National Cancer Institute and US National Human Genome Research Institute (database of Genotypes and Phenotypes (dbGaP) accession phs000178.v8.p7). The cBio Portal is developed and maintained by the Computational Biology Center at the Memorial Sloan-Kettering Cancer Center. S. Healey is supported by a National Health and Medical Research Council of Australia Program Grant to G.C.-T. Details of the funding of individual investigators and studies are provided in the Supplementary Note. A full list of the investigators who contributed to the generation of the data is available on the CIMBA website (see URLs). NR 38 TC 51 Z9 52 U1 6 U2 53 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD FEB PY 2015 VL 47 IS 2 BP 164 EP 171 DI 10.1038/ng.3185 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA CA1TQ UT WOS:000348694700012 PM 25581431 ER PT J AU Goyette, P Boucher, G Mallon, D Ellinghaust, E Jostins, L Huang, HL Ripke, S Gusareva, ES Annese, V Hauser, SL Oksenberg, JR Thomsent, I Leslie, S Daly, MJ Van Steen, K Duerr, RH Barrett, JC McGovern, DPB Schumm, LP Traherne, JA Carrington, MN Kosmoliaptsis, V Karsen, TH Franke, A Rioux, JD AF Goyette, Philippe Boucher, Gabrielle Mallon, Dermot Ellinghaust, Eva Jostins, Luke Huang, Hailiang Ripke, Stephan Gusareva, Elena S. Annese, Vito Hauser, Stephen L. Oksenberg, Jorge R. Thomsent, Ingo Leslie, Stephen Daly, Mark J. Van Steen, Kristel Duerr, Richard H. Barrett, Jeffrey C. McGovern, Dermot P. B. Schumm, L. Philip Traherne, James A. Carrington, Mary N. Kosmoliaptsis, Vasilis Karsen, Tom H. Franke, Andre Rioux, John D. CA Int Inflammatory Bowel Dis Genetic TI High-density mapping of the MHC identifies a shared role for HLA-DRB1(star)01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis SO NATURE GENETICS LA English DT Article ID PRIMARY SCLEROSING CHOLANGITIS; MAJOR HISTOCOMPATIBILITY COMPLEX; HLA-DR; SUSCEPTIBILITY; ALLELES; HAPLOTYPES; REGION AB Genome-wide association studies of the related chronic inflammatory bowel diseases (IBD) known as Crohn's disease and ulcerative colitis have shown strong evidence of association to the major histocompatibility complex (MHC). This region encodes a large number of immunological candidates, including the antigen-presenting classical human leukocyte antigen (HLA) molecules(1). Studies in IBD have indicated that multiple independent associations exist at HLA and non-HLA genes, but they have lacked the statistical power to define the architecture of association and causal alleles2,3. To address this, we performed high-density SNP typing of the MHC in >32,000 individuals with IBD, implicating multiple HLA alleles, with a primary role for HLA-DRB1*01:03 in both Crohn's disease and ulcerative colitis. Noteworthy differences were observed between these diseases, including a predominant role for class II HLA variants and heterozygous advantage observed in ulcerative colitis, suggesting an important role of the adaptive immune response in the colonic environment in the pathogenesis of IBD. C1 [Goyette, Philippe; Boucher, Gabrielle; Rioux, John D.] Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada. [Mallon, Dermot; Kosmoliaptsis, Vasilis] Univ Cambridge, Dept Surg, Cambridge, England. [Mallon, Dermot; Kosmoliaptsis, Vasilis] Cambridge Biomed Res Ctr, NIHR, Cambridge, England. [Ellinghaust, Eva; Thomsent, Ingo; Franke, Andre] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany. [Huang, Hailiang; Ripke, Stephan; Daly, Mark J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Analyt & Translat Genet Unit, Boston, MA 02115 USA. [Huang, Hailiang; Ripke, Stephan; Daly, Mark J.] Broad Inst MIT & Harvard, Cambridge, MA USA. [Gusareva, Elena S.; Van Steen, Kristel] Univ Liege, Inst Montefiore, Syst & Modeling Unit, B-4000 Liege, Belgium. [Gusareva, Elena S.; Van Steen, Kristel] Univ Liege, GIGA R Grp Interdisciplinaire Genoproteom Appl Re, Liege, Belgium. [Annese, Vito] IRCCS CSS Hosp, Gastroenterol Unit, San Giovanni Rotondo, Italy. [Annese, Vito] Azienda Osped Univ AOU Careggi, Strut Org Dipartimentali, Unit Gastroenterol SOD2, Florence, Italy. [Hauser, Stephen L.; Oksenberg, Jorge R.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Thomsent, Ingo; Leslie, Stephen] Murdoch Childrens Res Inst, Parkville, Vic, Australia. [Leslie, Stephen] Univ Melbourne, Dept Math & Stat, Melbourne, Vic, Australia. [Duerr, Richard H.] Univ Pittsburgh, Sch Med, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. [Duerr, Richard H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. [McGovern, Dermot P. B.] Cedars Sinai Med Ctr, F Widjaja Fdn Inflammatory Bowel & Immunobiol Res, Los Angeles, CA 90048 USA. [Schumm, L. Philip] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA. [Traherne, James A.] Cambridge Inst Med Res, Cambridge, England. [Traherne, James A.] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England. [Carrington, Mary N.] Frederick Natl Lab Canc Res, Leidos Biomed Res Inc, Expt Immunol Lab, Canc & Inflammat Program, Frederick, MD USA. [Carrington, Mary N.] Massachusetts Gen Hosp, Ragon Inst, Cambridge, MA USA. [Karsen, Tom H.] Oslo Univ Hosp, Rikshosp, Res Inst Internal Med, Dept Transplantat Med,Div Canc Surg & Transplanta, N-0450 Oslo, Norway. [Karsen, Tom H.] Oslo Univ Hosp, Rikshosp, Norwegian Primary Sclerosing Cholangitis Res Ctr, Dept Transplantat Med,Div Canc Surg & Transplanta, N-0450 Oslo, Norway. [Karsen, Tom H.] Univ Oslo, Inst Clin Med, KG Jebsen Inflammat Res Ctr, Oslo, Norway. [Rioux, John D.] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada. RP Rioux, JD (reprint author), Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada. EM john.david.rioux@umontreal.ca RI Franke, Andre/B-2151-2010; Prescott, Natalie/F-6490-2011; Zeissig, Sebastian/B-6297-2012; Rioux, John/A-9599-2015; Ellinghaus, Eva/E-6490-2012; Palmieri, Orazio/J-7697-2012; Silverberg, Mark/B-4183-2008; Whiteman, David/P-2728-2014; OI Franke, Andre/0000-0003-1530-5811; Prescott, Natalie/0000-0002-5901-7371; Duerr, Richard/0000-0001-6586-3905; Potocnik, Uros/0000-0003-1624-9428; Mallon, Dermot/0000-0001-7434-1201; Rioux, John/0000-0001-7560-8326; Ellinghaus, Eva/0000-0003-2914-3382; Palmieri, Orazio/0000-0002-0019-7929; Whiteman, David/0000-0003-2563-9559; Laukens, Debby/0000-0002-1984-5850; Winkelmann, Juliane/0000-0003-2667-9691; Kennedy, Nicholas/0000-0003-4368-1961; Barrett, Jeffrey/0000-0002-1152-370X; D'Amato, Mauro/0000-0003-2743-5197; Nothen, Markus/0000-0002-8770-2464; Kosmoliaptsis, Vasilis/0000-0001-7298-1387; Andersen, Vibeke/0000-0002-0127-2863; Newman, William/0000-0002-6382-4678 FU Canada Research Chair; US National Institute of Diabetes and Digestive and Kidney Diseases grant (NIDDK) [R01 DK064869, U01 DK062432]; German Ministry of Education and Research (BMBF) grant programe: Med (sysINFLAME); Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence 'Inflammation at Interfaces'; Foundation for Experimental Biomedicine (Zurich, Switzerland); European Union Seventh Framework Programme (FP7) [262055]; Intramural Research Program of the US National Institutes of Health (NIH); Frederick National Laboratory; Center for Cancer Research; Frederick National Laboratory for Cancer Research [HHSN261200800001E]; Wellcome Trust [WT098051]; NIHR Cambridge Biomedical Research Centre; NIDDK [U01 DK062429-14, U01 DK062413, P01 DK046763-19, U54 DE023789-01, U01 DK062420]; UK Medical Research Council; Leona M. and Harry B. Helmsley Charitable Trust; European Union [305479]; National Institute of Allergy and Infectious Diseases (NIAID) [U01 AI067068]; Agency for Healthcare Research and Quality (AHRQ) [HS021747]; Inflammatory Bowel Disease Genetic Research endowed chair at the University of Pittsburgh; US National Cancer Institute grant [CA141743]; US NIH [R01 NSO49477, 1U19 A1067152]; National Multiple Sclerosis Society [RG 2899-D11]; Australian National Health and Medical Research Council (R.D. Wright Career Development Fellowship) [APP1053756] FX We would like to thank the International PSC study group (http://www.ipscsg.org/) for sharing data. We are grateful to B.A. Lie and K. Holm for helpful discussions. J.D.R. holds a Canada Research Chair, and this work was supported by a US National Institute of Diabetes and Digestive and Kidney Diseases grant (NIDDK; R01 DK064869 and U01 DK062432). The laboratory of A.F. is supported by the German Ministry of Education and Research (BMBF) grant programe: Med (sysINFLAME). A.F. receives infrastructure support from the Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence 'Inflammation at Interfaces' and holds an endowment professorship (Peter Hans Hofschneider Professorship) of the Foundation for Experimental Biomedicine (Zurich, Switzerland). Grant support for T.H.K. and A.F. was received from the European Union Seventh Framework Programme (FP7/2007-2013, grant number 262055, ESGI). M.N.C. is supported by the Intramural Research Program of the US National Institutes of Health (NIH), Frederick National Laboratory, Center for Cancer Research. This project has been funded in whole or in part with federal funds from the Frederick National Laboratory for Cancer Research, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the US Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US government. J.C.B. was supported by a Wellcome Trust grant (WT098051). D.M. and V.K. are supported by the NIHR Cambridge Biomedical Research Centre. L.P.S. is supported by an NIDDK grant (U01 DK062429-14). J.A.T. is supported by the UK Medical Research Council. D.P.B.M. is supported by the Leona M. and Harry B. Helmsley Charitable Trust, the European Union (305479) and by grants from the NIDDK (U01 DK062413, P01 DK046763-19, U54 DE023789-01), the National Institute of Allergy and Infectious Diseases (NIAID; U01 AI067068) and the Agency for Healthcare Research and Quality (AHRQ; HS021747). R.H.D. holds the Inflammatory Bowel Disease Genetic Research endowed chair at the University of Pittsburgh and was supported by an NIDDK grant (U01 DK062420) and a US National Cancer Institute grant (CA141743). S.L.H. and J.R.O. would like to also acknowledge the support of the US NIH (R01 NSO49477 and 1U19 A1067152) and the National Multiple Sclerosis Society (RG 2899-D11). S.L. wishes to acknowledge support from the Australian National Health and Medical Research Council (R.D. Wright Career Development Fellowship, APP1053756). NR 16 TC 49 Z9 50 U1 1 U2 14 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD FEB PY 2015 VL 47 IS 2 BP 172 EP 179 DI 10.1038/ng.3176 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA CA1TQ UT WOS:000348694700013 PM 25559196 ER PT J AU Zhang, MY Churpek, JE Kee, SB Walsh, T Lee, MK Loeb, KR Gulsuner, S Pritchard, CC Sanchez-Bonilla, M Delrow, JJ Basom, RS Forouhar, M Gyurkocza, B Schwartz, BS Neistadt, B Marquez, R Mariani, CJ Coats, SA Hofmann, I Lindsley, RC Williams, DA Abkowitz, JL Horwitz, MS King, MC Godley, LA Shimamura, A AF Zhang, Michael Y. Churpek, Jane E. Kee, Sioban B. Walsh, Tom Lee, Ming K. Loeb, Keith R. Gulsuner, Suleyman Pritchard, Colin C. Sanchez-Bonilla, Marilyn Delrow, Jeffrey J. Basom, Ryan S. Forouhar, Melissa Gyurkocza, Boglarka Schwartz, Bradford S. Neistadt, Barbara Marquez, Rafael Mariani, Christopher J. Coats, Scott A. Hofmann, Inga Lindsley, R. Coleman Williams, David A. Abkowitz, Janis L. Horwitz, Marshall S. King, Mary-Claire Godley, Lucy A. Shimamura, Akiko TI Germ line ETV6 mutations in familial thrombocytopenia and hematologic malignancy SO NATURE GENETICS LA English DT Article ID ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; MYELODYSPLASTIC SYNDROMES; INHERITED THROMBOCYTOPENIA; GENOMIC LANDSCAPE; GATA2 MUTATIONS; DNA-BINDING; TEL; GENE; PROTEIN AB We report germline missense mutations in ETV6 segregating with the dominant transmission of thrombocytopenia and hematologic malignancy in three unrelated kindreds, defining a new hereditary syndrome featuring thrombocytopenia with susceptibility to diverse hematologic neoplasms. Two variants, p.Arg369Gln and p.Arg399Cys, reside in the highly conserved ETS DNA-binding domain. The third variant, p.Pro214Leu, lies within the internal linker domain, which regulates DNA binding. These three amino acid sites correspond to hotspots for recurrent somatic mutation in malignancies. Functional studies show that the mutations abrogate DNA binding, alter subcellular localization, decrease transcriptional repression in a dominant-negative fashion and impair hematopoiesis. These familial genetic studies identify a central role for ETV6 in hematopoiesis and malignant transformation. The identification of germline predisposition to cytopenias and cancer informs the diagnosis and medical management of at-risk individuals. C1 [Zhang, Michael Y.; Loeb, Keith R.; Sanchez-Bonilla, Marilyn; Gyurkocza, Boglarka; Coats, Scott A.; Shimamura, Akiko] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Churpek, Jane E.; Neistadt, Barbara; Marquez, Rafael; Mariani, Christopher J.; Godley, Lucy A.] Univ Chicago, Ctr Clin Canc Genet, Sect Hematol Oncol, Chicago, IL 60637 USA. [Churpek, Jane E.; Neistadt, Barbara; Marquez, Rafael; Mariani, Christopher J.] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA. [Kee, Sioban B.; Abkowitz, Janis L.] Univ Washington, Div Hematol, Dept Med, Seattle, WA 98195 USA. [Walsh, Tom; Lee, Ming K.; Gulsuner, Suleyman; King, Mary-Claire] Univ Washington, Div Med Genet, Dept Med, Seattle, WA 98195 USA. [Walsh, Tom; Lee, Ming K.; Gulsuner, Suleyman; King, Mary-Claire] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Loeb, Keith R.; Horwitz, Marshall S.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Pritchard, Colin C.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Delrow, Jeffrey J.; Basom, Ryan S.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Forouhar, Melissa] Madigan Army Med Ctr, Tacoma, WA 98431 USA. [Schwartz, Bradford S.] Univ Wisconsin, Morgridge Inst Res, Madison, WI 53706 USA. [Schwartz, Bradford S.] Univ Wisconsin, Dept Med, Madison, WI USA. [Schwartz, Bradford S.] Univ Wisconsin, Dept Biomol Chem, Madison, WI USA. [Hofmann, Inga; Williams, David A.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Hofmann, Inga; Williams, David A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Hofmann, Inga; Williams, David A.] Harvard Stem Cell Inst, Boston, MA USA. [Lindsley, R. Coleman] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Lindsley, R. Coleman] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Shimamura, Akiko] Seattle Childrens Hosp, Seattle, WA USA. [Shimamura, Akiko] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. RP Shimamura, A (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA. EM ashimamu@fhcrc.org OI Walsh, Tom/0000-0002-8875-0310 FU US National Institutes of Health [R24DK093425, R24DK099808-01, K12CA139160]; Ghiglione Aplastic Anemia Fund; Julian's Dinosaur Guild from Seattle Children's Hospital; Medical Scientist Training Program [T32GM007266]; Genetic Approaches to Aging Training grant [T32AG000057]; Cancer Research Foundation FX We thank all patients and their families for participation in this research study. We thank M. Chin (University of Washington), B. Turok-Storb (Fred Hutchinson Cancer Research Center) and S. Tapscott (Fred Hutchinson Cancer Research Center) for luciferase plasmids and reagents. We thank H. Hock, B. Stoddard, S. Meshinchi, G. Smith, A. Kumar, C. Toledo, S. Yu, A. Fong and K. MacQuarrie for helpful discussions. We thank S. Castro for clinical sample processing. This work was supported by US National Institutes of Health grants R24DK093425 and R24DK099808-01 to A.S., M.-C.K. and J.L.A.; by the Ghiglione Aplastic Anemia Fund and Julian's Dinosaur Guild from Seattle Children's Hospital to A.S.; by Medical Scientist Training Program Training grant T32GM007266 and Genetic Approaches to Aging Training grant T32AG000057 to M.Y.Z.; and by grants from the US National Institutes of Health (K12CA139160) and the Cancer Research Foundation to J.E.C. M.-C.K. is an American Cancer Society professor. NR 45 TC 62 Z9 64 U1 3 U2 16 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD FEB PY 2015 VL 47 IS 2 BP 180 EP 185 DI 10.1038/ng.3177 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA CA1TQ UT WOS:000348694700014 PM 25581430 ER PT J AU Huber, W Carey, VJ Gentleman, R Anders, S Carlson, M Carvalho, BS Bravo, HC Davis, S Gatto, L Girke, T Gottardo, R Hahne, F Hansen, KD Irizarry, RA Lawrence, M Love, MI MacDonald, J Obenchain, V Oles, AK Pages, H Reyes, A Shannon, P Smyth, GK Tenenbaum, D Waldron, L Morgan, M AF Huber, Wolfgang Carey, Vincent J. Gentleman, Robert Anders, Simon Carlson, Marc Carvalho, Benilton S. Bravo, Hector Corrada Davis, Sean Gatto, Laurent Girke, Thomas Gottardo, Raphael Hahne, Florian Hansen, Kasper D. Irizarry, Rafael A. Lawrence, Michael Love, Michael I. MacDonald, James Obenchain, Valerie Oles, Andrzej K. Pages, Herve Reyes, Alejandro Shannon, Paul Smyth, Gordon K. Tenenbaum, Dan Waldron, Levi Morgan, Martin TI Orchestrating high-throughput genomic analysis with Bioconductor SO NATURE METHODS LA English DT Article ID COMPUTATIONAL BIOLOGY; BIOINFORMATICS; SOFTWARE AB Bioconductor is an open-source, open-development software project for the analysis and comprehension of high-throughput data in genomics and molecular biology. The project aims to enable interdisciplinary research, collaboration and rapid development of scientific software. Based on the statistical programming language R, Bioconductor comprises 934 interoperable packages contributed by a large, diverse community of scientists. Packages cover a range of bioinformatic and statistical applications. They undergo formal initial review and continuous automated testing. We present an overview for prospective users and contributors. C1 [Huber, Wolfgang; Anders, Simon; Oles, Andrzej K.] European Mol Biol Lab, Heidelberg, Germany. [Carey, Vincent J.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA. [Carey, Vincent J.] Harvard Univ, Sch Med, Boston, MA USA. [Carey, Vincent J.; Irizarry, Rafael A.; Love, Michael I.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Gentleman, Robert; Lawrence, Michael] Genentech Inc, San Francisco, CA USA. [Carlson, Marc; Obenchain, Valerie; Pages, Herve; Shannon, Paul; Tenenbaum, Dan; Morgan, Martin] Fred Hutchinson Canc Res Ctr, Computat Biol Program, Seattle, WA 98104 USA. [Carvalho, Benilton S.] Univ Estadual Campinas, Sch Med Sci, Dept Med Genet, Campinas, Brazil. [Bravo, Hector Corrada] Univ Maryland, Ctr Bioinformat & Computat Biol, College Pk, MD 20742 USA. [Davis, Sean] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Gatto, Laurent] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England. [Girke, Thomas] Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA. [Gottardo, Raphael] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA. [Hahne, Florian] Novartis Inst Biomed Res, Basel, Switzerland. [Hansen, Kasper D.] Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD USA. [Hansen, Kasper D.] Johns Hopkins Univ, Dept Biostat, Baltimore, MD USA. [Irizarry, Rafael A.; Love, Michael I.] Dana Farber Canc Inst, Boston, MA 02115 USA. [MacDonald, James] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA. [Smyth, Gordon K.] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia. [Smyth, Gordon K.] Univ Melbourne, Dept Math & Stat, Parkville, Vic 3052, Australia. [Waldron, Levi] CUNY, Hunter Coll, Sch Urban Publ Hlth, New York, NY 10021 USA. RP Huber, W (reprint author), European Mol Biol Lab, Heidelberg, Germany. EM whuber@embl.de RI Carvalho, Benilton/G-1868-2012; Anders, Simon/D-4087-2011; Smyth, Gordon/B-5276-2008; Reyes, Alejandro/D-8258-2017; OI Hansen, Kasper/0000-0003-0086-0687; Waldron, Levi/0000-0003-2725-0694; Carvalho, Benilton/0000-0001-5122-5646; Anders, Simon/0000-0003-4868-1805; Smyth, Gordon/0000-0001-9221-2892; Reyes, Alejandro/0000-0001-8717-6612; Gatto, Laurent/0000-0002-1520-2268; Huber, Wolfgang/0000-0002-0474-2218; Corrada Bravo, Hector/0000-0002-1255-4444; Davis, Sean/0000-0002-8991-6458; Love, Michael/0000-0001-8401-0545 FU National Human Genome Research Institute of the US National Institutes of Health [U41HG004059]; US National Science Foundation [1247813]; European Commission FP7 project RADIANT FX We thank all contributors to the Bioconductor and R projects. Bioconductor is supported by the National Human Genome Research Institute of the US National Institutes of Health (U41HG004059 to M.M.). Additional support is from the US National Science Foundation (1247813 to M.M.) and the European Commission FP7 project RADIANT (to W.H.). A. Bruce provided graphics support for Figure 2. NR 24 TC 188 Z9 189 U1 11 U2 53 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1548-7091 EI 1548-7105 J9 NAT METHODS JI Nat. Methods PD FEB PY 2015 VL 12 IS 2 BP 115 EP 121 DI 10.1038/NMETH.3252 PG 7 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA CA4GL UT WOS:000348862500011 PM 25633503 ER PT J AU Koussa, MA Halvorsen, K Ward, A Wong, WP AF Koussa, Mounir A. Halvorsen, Ken Ward, Andrew Wong, Wesley P. TI DNA nanoswitches: a quantitative platform for gel-based biomolecular interaction analysis SO NATURE METHODS LA English DT Article ID ELECTROPHORETIC SEPARATION; STREPTAVIDIN; EVOLUTION; PROTEINS AB We introduce a nanoscale experimental platform that enables kinetic and equilibrium measurements of a wide range of molecular interactions using a gel electrophoresis readout. Programmable, self-assembled DNA nanoswitches serve both as templates for positioning molecules and as sensitive, quantitative reporters of molecular association and dissociation. We demonstrated this low-cost, versatile, 'lab-on-a-molecule' system by characterizing ten different interactions, including a complex four-body interaction with five discernible states. C1 [Koussa, Mounir A.] Harvard Univ, Sch Med, Dept Neurobiol, Program Neurosci, Boston, MA USA. [Halvorsen, Ken] SUNY Albany, RNA Inst, Albany, NY 12222 USA. [Halvorsen, Ken; Ward, Andrew; Wong, Wesley P.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA. [Wong, Wesley P.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Wong, Wesley P.] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA USA. RP Halvorsen, K (reprint author), SUNY Albany, RNA Inst, Albany, NY 12222 USA. EM khalvorsen@albany.edu; wesley.wong@childrens.harvard.edu OI Halvorsen, Ken/0000-0002-2578-1339 FU US National Institutes of Health [R01 DC02281]; National Science Foundation [USA GRFP 2012147612]; Boston Children's Hospital startup funds; Takeda New Frontier Science FX The authors gratefully acknowledge D. Corey, G. Yellen, R. Wilson, J. Holt, H. Ploegh, G. Wong, A. Badran, Z. Tsun, A. Golden and members of the Wong and Corey Labs for critical discussions and T. Kao for her early work on the project. Funding for this project was provided by US National Institutes of Health R01 DC02281 to D. Corey; M.A.K. was supported by National Science Foundation USA GRFP 2012147612; W.P.W. was supported by Boston Children's Hospital startup funds and Takeda New Frontier Science. NR 16 TC 10 Z9 10 U1 6 U2 48 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1548-7091 EI 1548-7105 J9 NAT METHODS JI Nat. Methods PD FEB PY 2015 VL 12 IS 2 BP 123 EP U148 DI 10.1038/nmeth.3209 PG 8 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA CA4GL UT WOS:000348862500012 PM 25486062 ER PT J AU Tasan, M Musso, G Hao, T Vidal, M MacRae, CA Roth, FP AF Tasan, Murat Musso, Gabriel Hao, Tong Vidal, Marc MacRae, Calum A. Roth, Frederick P. TI Selecting causal genes from genome-wide association studies via functionally coherent subnetworks SO NATURE METHODS LA English DT Article ID PROTEIN-INTERACTION NETWORKS; PROSTATE-CANCER; ANDROGEN RECEPTOR; HUMAN-DISEASES; MUS-MUSCULUS; PREDICTION; EXPRESSION; INTEGRATION; ANNOTATION; PHENOTYPE AB Genome-wide association (GWA) studies have linked thousands of loci to human diseases, but the causal genes and variants at these loci generally remain unknown. Although investigators typically focus on genes closest to the associated polymorphisms, the causal gene is often more distal. Reliance on published work to prioritize candidates is biased toward well-characterized genes. We describe a 'prix fixe' strategy and software that uses genome-scale shared-function networks to identify sets of mutually functionally related genes spanning multiple GWA loci. Using associations from similar to 100 GWA studies covering ten cancer types, our approach outperformed the common alternative strategy in ranking known cancer genes. As more GWA loci are discovered, the strategy will have increased power to elucidate the causes of human disease. C1 [Tasan, Murat; Roth, Frederick P.] Univ Toronto, Donnelly Ctr, Toronto, ON, Canada. [Tasan, Murat; Roth, Frederick P.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada. [Tasan, Murat; Roth, Frederick P.] Univ Toronto, Dept Comp Sci, Toronto, ON, Canada. [Tasan, Murat; Hao, Tong; Vidal, Marc; Roth, Frederick P.] Dana Farber Canc Inst, CCSB, Dept Canc Biol, Boston, MA 02115 USA. [Tasan, Murat; Roth, Frederick P.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada. [Musso, Gabriel; MacRae, Calum A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Musso, Gabriel; MacRae, Calum A.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. [Hao, Tong; Vidal, Marc] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Roth, Frederick P.] Canadian Inst Adv Res, Toronto, ON, Canada. RP Tasan, M (reprint author), Univ Toronto, Donnelly Ctr, Toronto, ON, Canada. EM murat@tasanlab.org; fritz.roth@utoronto.ca RI Roth, Frederick/H-6308-2011; OI Roth, Frederick/0000-0002-6628-649X FU Center of Excellence in Genomic Science (CEGS) from the NHGRI [P50 (HG004233)]; US National Institutes of Health (NIH) [HG003224, HL107440]; Krembil Foundation; Avon Foundation; Canadian Ontario Research Fund Research Excellence Award; Canada Excellence Research Chairs Program; NIH [HL098938, HG004098]; Leducq Foundation; Harvard Stem Cell Institute FX We thank members of the Roth lab and the Center for Cancer Systems Biology (CCSB) at the Dana-Farber Cancer Institute (DFCI) for helpful comments and discussion; the lab of Q. Morris for assistance with GeneMANIA data; and M. Cokol and J. Mellor for useful conversations and advice during manuscript preparation. This work was primarily supported by Center of Excellence in Genomic Science (CEGS) grant P50 (HG004233) from the NHGRI awarded to M.V. and F.P.R. F.P.R. is additionally supported by US National Institutes of Health (NIH) grants (HG003224 and HL107440), the Krembil and Avon Foundations, a Canadian Ontario Research Fund Research Excellence Award and the Canada Excellence Research Chairs Program. C.A.M. was supported in this work by an NIH grant (HL098938), the Leducq Foundation and the Harvard Stem Cell Institute. M.T. was supported by an NIH grant (HG004098). NR 70 TC 10 Z9 10 U1 0 U2 22 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1548-7091 EI 1548-7105 J9 NAT METHODS JI Nat. Methods PD FEB PY 2015 VL 12 IS 2 BP 154 EP U106 DI 10.1038/nmnmeth.3215 PG 10 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA CA4GL UT WOS:000348862500019 PM 25532137 ER PT J AU Ghetti, B Oblak, AL Boeve, BF Johnson, KA Dickerson, BC Goedert, M AF Ghetti, B. Oblak, A. L. Boeve, B. F. Johnson, K. A. Dickerson, B. C. Goedert, M. TI Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging SO NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY LA English DT Review DE FTDP-17 MAPT; tau aggregation; neurofibrillary tangle; Pick body; tau; [F18]-T807 ID PROGRESSIVE SUPRANUCLEAR PALSY; FAMILIAL PRESENILE-DEMENTIA; PONTO-NIGRAL DEGENERATION; MULTIPLE-SYSTEM TAUOPATHY; PAIRED HELICAL FILAMENT; AUTOSOMAL-DOMINANT PARKINSONISM; INTRONIC TAU-10(+16) MUTATION; HEREDITARY PICKS-DISEASE; MOTOR-NEURON DISEASE; ALZHEIMERS-DISEASE AB Hereditary frontotemporal dementia associated with mutations in the microtubule-associated protein tau gene (MAPT) is a protean disorder. Three neuropathologic subtypes can be recognized, based on the presence of inclusions made of tau isoforms with three and four repeats, predominantly three repeats and mostly four repeats. This is relevant for establishing a correlation between structural magnetic resonance imaging and positron emission tomography using tracers specific for aggregated tau. Longitudinal studies will be essential to determine the evolution of anatomical alterations from the asymptomatic stage to the various phases of disease following the onset of symptoms. C1 [Ghetti, B.; Oblak, A. L.] Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA. [Boeve, B. F.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Johnson, K. A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Johnson, K. A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. [Goedert, M.] MRC, Mol Biol Lab, Cambridge CB2 2QH, England. RP Ghetti, B (reprint author), Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA. EM bghetti@iupui.edu FU UK Medical Research Council [U105184291]; [P30 AG010133]; [R21 NS084156]; [P50 AG016574]; [R01 AG011378] FX We extend our appreciation to Clifford R. Jack, Jr. M.D. for providing some of the MR images and to Jill Murrell Ph.D., Matthew Baker B.S., Rosa Rademakers Ph.D. and Michael Hutton Ph.D. for performing some of the genetic analyses. We would like to thank Urs Kuederli, Rose Richardson, Brenda Dupree and Brad Glazier for their technical expertise and Diane Lucente for her genetic counselling contributions. We would like to thank the Department of Pathology and Laboratory Medicine at Indiana University School of Medicine, as well as the following grants, P30 AG010133 (BG), R21 NS084156 (BD), P50 AG016574 (BB) and R01 AG011378 (BB). The work of MG is supported by the UK Medical Research Council (U105184291). NR 162 TC 35 Z9 36 U1 3 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0305-1846 EI 1365-2990 J9 NEUROPATH APPL NEURO JI Neuropathol. Appl. Neurobiol. PD FEB PY 2015 VL 41 IS 1 BP 24 EP 46 DI 10.1111/nan.12213 PG 23 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA CA7PI UT WOS:000349109100003 PM 25556536 ER PT J AU Stanford, FC Kyle, TK Claridy, MD Nadglowski, JF Apovian, CM AF Stanford, Fatima Cody Kyle, Theodore K. Claridy, Mechelle D. Nadglowski, Joseph F. Apovian, Caroline M. TI The Influence of an Individual's Weight Perception on the Acceptance of Bariatric Surgery SO OBESITY LA English DT Article ID PRIMARY-CARE PATIENTS; OBESE-PATIENTS; US ADULTS; ATTITUDES; OVERWEIGHT AB ObjectiveThis study assessed the proportion of US adults with excess weight and obesity who consider bariatric surgery to be appropriate for themselves and how their own weight perception influences this consideration. MethodsA stratified sample of 920 US adults in June 2014 was obtained through an online survey. The respondents were queried about bariatric surgery acceptability and personal weight perception. Average body mass index (BMI) was determined for each demographic variable, and responses were characterized according to BMI and concordance with perceived weight status. Chi-square analyses served to assess perceived weight concordance in relation to bariatric acceptance. ResultsOnly 32% of respondents with Class III obesity indicated that bariatric surgery would be an acceptable option for them, most often because they considered it to be too risky. Respondents with Class III obesity and concordant perception of weight status were more likely (P < 0.03) than discordant Class III respondents to accept bariatric surgery. Likewise, concordant respondents with excess weight, but not obesity, were more likely (P < 0.001) to correctly consider bariatric surgery to be inappropriate for them. ConclusionsDespite good safety and efficacy, many persons still believe bariatric surgery is too risky. Weight perception concordance or discordance influences one's decision to consider this treatment option. C1 [Stanford, Fatima Cody] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Weight Ctr, Boston, MA 02138 USA. [Kyle, Theodore K.] ConscienHealth, Pittsburgh, PA USA. [Kyle, Theodore K.; Nadglowski, Joseph F.] Obes Act Coalit, Tampa, FL USA. [Claridy, Mechelle D.] Morehouse Sch Med, Dept Community Hlth & Prevent Med, Atlanta, GA 30310 USA. [Apovian, Caroline M.] Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02118 USA. RP Stanford, FC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Weight Ctr, Boston, MA 02138 USA. EM fstanford@mgh.harvard.edu OI Stanford, Fatima/0000-0003-4616-533X FU ConscienHealth FX Financial support was provided by ConscienHealth. NR 20 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD FEB PY 2015 VL 23 IS 2 BP 277 EP 281 DI 10.1002/oby.20968 PG 5 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA CA6QN UT WOS:000349040400005 PM 25546377 ER PT J AU Oliveira, AL Azevedo, DC Bredella, MA Stanley, TL Torriani, M AF Oliveira, Adriana L. Azevedo, Debora C. Bredella, Miriam A. Stanley, Takara L. Torriani, Martin TI Visceral and Subcutaneous Adipose Tissue FDG Uptake by PET/CT in Metabolically Healthy Obese Subjects SO OBESITY LA English DT Article ID CARDIOVASCULAR-DISEASE; GLUCOSE-UPTAKE; RISK; INDIVIDUALS; MORTALITY; INSULIN; HUMANS AB ObjectiveTo measure FDG uptake in visceral (VAT) and subcutaneous (SAT) adipose tissue of metabolically healthy obese (MHO) and metabolically abnormal obese (MAO) compared to metabolically healthy lean (MHL) subjects. Given that MHO has increased metabolic risk, it was hypothesized that MHO and MAO display similar VAT FDG uptake. MethodsThe 18F-FDG-PET/CT studies of 141 adults (n = 60 MHL, n = 20 MHO, n = 61 MAO) were examined to determine VAT and SAT volumes and FDG uptake. Data on CVD risk factors (BMI, abdominal circumference, blood pressure, serum lipids, and fasting plasma glucose) were collected. ResultsMHO and MAO had similar VAT FDG uptake (P = 0.74), both significantly lower than MHL (P < 0.01) independent of age and gender. SAT FDG uptake was similar across all groups (P > 0.2) independent of age and gender. In all groups, VAT FDG uptake was higher than SAT (P < 0.0001). In separate sub-analyses of obese groups, VAT FDG uptake was more broadly negatively associated with whole-body adiposity than SAT FDG uptake, and FDG uptake in abdominal adipose depots was positively associated with liver density (P < 0.05). ConclusionsFDG uptake in VAT of MHO is similar to MAO and lower than MHL, suggesting these subjects may present similar VAT dysfunction. C1 [Oliveira, Adriana L.; Azevedo, Debora C.; Bredella, Miriam A.; Torriani, Martin] Massachusetts Gen Hosp, Dept Radiol, Div Musculoskeletal Imaging & Intervent, Boston, MA 02114 USA. [Oliveira, Adriana L.; Azevedo, Debora C.; Bredella, Miriam A.; Stanley, Takara L.; Torriani, Martin] Harvard Univ, Sch Med, Boston, MA USA. [Stanley, Takara L.] Massachusetts Gen Hosp, Dept Med, Neuroendocrine Unit, Boston, MA 02114 USA. RP Torriani, M (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Musculoskeletal Imaging & Intervent, Boston, MA 02114 USA. EM mtorriani@mgh.harvard.edu FU NIH/NIDDK Pilot and Feasibility Grant, Nutrition and Obesity Research Center at Harvard [P30DK040561] FX Supported in part by NIH/NIDDK P30DK040561 Pilot and Feasibility Grant, Nutrition and Obesity Research Center at Harvard. NR 20 TC 5 Z9 5 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD FEB PY 2015 VL 23 IS 2 BP 286 EP 289 DI 10.1002/oby.20957 PG 4 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA CA6QN UT WOS:000349040400007 PM 25522219 ER PT J AU Yu, EW Putman, MS Derrico, N Abrishamanian-Garcia, G Finkelstein, JS Bouxsein, ML AF Yu, E. W. Putman, M. S. Derrico, N. Abrishamanian-Garcia, G. Finkelstein, J. S. Bouxsein, M. L. TI Defects in cortical microarchitecture among African-American women with type 2 diabetes SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE African-American; Bone microarchitecture; Diabetes mellitus type 2; HR-pQCT; Microfinite element analysis ID POSTMENOPAUSAL WOMEN; TRABECULAR BONE; DISTAL RADIUS; HR-PQCT; FRACTURE; RISK; MELLITUS; HEALTH; POROSITY; IMAGES AB Patients with type 2 diabetes mellitus (DM2) have increased fracture risk. We found that African-American women with DM2 have increased cortical porosity and lower cortical bone density at the radius than non-diabetic controls. These cortical deficits are associated with hyperglycemia and may contribute to skeletal fragility associated with DM2. Fracture risk is increased in patients with type 2 diabetes mellitus (DM2) despite normal areal bone mineral density (aBMD). DM2 is more common in African-Americans than in Caucasians. It is not known whether African-American women with DM2 have deficits in bone microstructure. We measured aBMD at the spine and hip by DXA, and volumetric BMD (vBMD) and microarchitecture at the distal radius and tibia by HR-pQCT in 22 DM2 and 78 non-diabetic African-American women participating in the Study of Women Across the Nation (SWAN). We also measured fasting glucose and HOMA-IR. Age, weight, and aBMD at all sites were similar in both groups. At the radius, cortical porosity was 26 % greater, while cortical vBMD and tissue mineral density were lower in women with DM2 than in controls. There were no differences in radius total vBMD or trabecular vBMD between groups. Despite inferior cortical bone properties at the radius, FEA-estimated failure load was similar between groups. Tibia vBMD and microarchitecture were also similar between groups. There were no significant associations between cortical parameters and duration of DM2 or HOMA-IR. However, among women with DM2, higher fasting glucose levels were associated with lower cortical vBMD (r = -0.54, p = 0.018). DM2 and higher fasting glucose are associated with unfavorable cortical bone microarchitecture at the distal radius in African-American women. These structural deficits may contribute to the increased fracture risk among women with DM2. Further, our results suggest that hyperglycemia may be involved in mechanisms of skeletal fragility associated with DM2. C1 [Yu, E. W.; Putman, M. S.; Derrico, N.; Abrishamanian-Garcia, G.; Finkelstein, J. S.; Bouxsein, M. L.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Putman, M. S.] Childrens Hosp Boston, Div Endocrine, Boston, MA 02115 USA. RP Yu, EW (reprint author), Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St,THR-1051, Boston, MA 02114 USA. EM ewyu@partners.org FU National Institutes of Health (NIH), DHHS, through the National Institute on Aging (NIA); National Institute of Nursing Research (NINR); NIH Office of Research on Women's Health (ORWH) [U01NR004061, U01AG012505, U01AG012535, U01AG012531, U01AG012539, U01AG012546, U01AG012553, U01AG012554, U01AG012495]; NIH [1S10RR023405, DK093713] FX The Study of Women's Health Across the Nation (SWAN) has grant support from the National Institutes of Health (NIH), DHHS, through the National Institute on Aging (NIA), the National Institute of Nursing Research (NINR), and the NIH Office of Research on Women's Health (ORWH) (Grants U01NR004061; U01AG012505, U01AG012535, U01AG012531, U01AG012539, U01AG012546, U01AG012553, U01AG012554, U01AG012495). We would like to thank the Massachusetts General Hospital (MGH) Bone Density Center and the MGH HR-pQCT Core Facility, which is supported by NIH grant 1S10RR023405. EWY was also supported by NIH grant DK093713. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIA, NINR, ORWH or the NIH. NR 25 TC 21 Z9 22 U1 1 U2 4 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD FEB PY 2015 VL 26 IS 2 BP 673 EP 679 DI 10.1007/s00198-014-2927-7 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CA6JM UT WOS:000349018700028 PM 25398431 ER PT J AU Buehring, B Krueger, D Fidler, E Gangnon, R Heiderscheit, B Binkley, N AF Buehring, B. Krueger, D. Fidler, E. Gangnon, R. Heiderscheit, B. Binkley, N. TI Reproducibility of jumping mechanography and traditional measures of physical and muscle function in older adults SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE DXA leanmass; Jumpingmechanography; Muscle function; Reproducibility; Sarcopenia ID LOWER-EXTREMITY FUNCTION; PERFORMANCE BATTERY; BODY-COMPOSITION; SUBSEQUENT DISABILITY; GRIP STRENGTH; SARCOPENIA; MASS; AGE; POWER; HEALTH AB A Summary Improved approaches to assess functional change over time are needed to optimally reduce fall/fracture risk; jumping mechanography (JM) may be one such methodology. In this study, JM parameters were more reproducible than traditional functional tests. JM may be better able to demonstrate efficacy of interventions to mitigate sarcopenia. Introduction Jumping mechanography (JM), a tool using maximal countermovement jumps performed on a force plate, may more reliably assess muscle function than traditional methods. The purpose of this study was to examine JM retest reliability in older adults compared with commonly used muscle and physical function assessments. Methods Community-dwelling individuals age >= 70 years performed physical and muscle function assessments including the short physical performance battery (SPPB), grip strength, and JM on multiple occasions over 3 months. JM parameters included body weight-corrected peak power and jump height. Appendicular lean mass was measured by dual energy x-ray (DXA). Mixed effects linear regression models were used to estimate between- and within-person variability summarized as intra-class correlation coefficients (ICC). Results Ninety-seven individuals (49 females, 48 males, mean age 80.7 years) participated. All testing was well tolerated; no participant sustained injury. Jump power, height, and grip strength were greater (p < 0.0001) in men than women. Grip strength, jump power, and height had excellent ICCs (0.95, 0.93, and 0.88, respectively); chair rise, SPPB score, and gait speed had lower ICCs (0.81, 0.77, and 0.76, respectively). Conclusion In older adults, JM has excellent retest reliability, is stable over time, and can be performed safely. JM retest reliability was comparable to grip strength and possibly better than SPPB and gait speed. JM is a promising tool for muscle function assessment in older adults. Comparison of this approach with traditional assessment tools in longitudinal interventional studies is needed. C1 [Buehring, B.; Krueger, D.; Fidler, E.; Binkley, N.] Univ Wisconsin, Osteoporosis Clin Res Program, Madison, WI 53705 USA. [Buehring, B.; Binkley, N.] Univ Wisconsin, William S Middleton Mem Vet Adm Hosp, GRECC, Madison, WI 53705 USA. [Gangnon, R.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53705 USA. [Gangnon, R.] Univ Wisconsin, Dept Populat Hlth, Madison, WI 53705 USA. [Heiderscheit, B.] Univ Wisconsin, Dept Orthopaed & Rehabil, Madison, WI 53705 USA. [Heiderscheit, B.] Univ Wisconsin, Dept Intercollegiate Athlet, Madison, WI 53705 USA. RP Buehring, B (reprint author), Univ Wisconsin, Osteoporosis Clin Res Program, 2870 Univ Ave,Suite 100, Madison, WI 53705 USA. EM bbuehring@medicine.wisc.edu OI Buehring, Bjoern/0000-0003-3841-624X FU Merck Co., Inc.; John A. Hartford Foundation FX All authors contributed to the study concept and design, acquisition of subjects and data, analysis and interpretation of data, and preparation of manuscript. This work was sponsored by an investigator initiated research grant from Merck & Co., Inc. Merck & Co., Inc and did not have any role in the design, methods, subject recruitment, data collection, analysis, or preparation of paper. Dr. Buehring receives research funding from the John A. Hartford Foundation as a Centers of Excellence in Geriatric Medicine and Geriatric Psychiatry scholar. Dr. Binkley is participating in a multicenter trial with Lilly in functional outcomes in older adults. He also consults on the same project. NR 41 TC 4 Z9 4 U1 2 U2 16 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD FEB PY 2015 VL 26 IS 2 BP 819 EP 825 DI 10.1007/s00198-014-2983-z PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CA6JM UT WOS:000349018700043 PM 25488806 ER PT J AU Karaa, A Goldstein, A AF Karaa, Amel Goldstein, Amy TI The spectrum of clinical presentation, diagnosis, and management of mitochondrial forms of diabetes SO PEDIATRIC DIABETES LA English DT Review DE diabetes; Kearns Sayre syndrome; MELAS; mitochondria; mtDNA ID DNA MUTATION; 3243A-GREATER-THAN-G MUTATION; MTDNA MUTATION; MELAS SYNDROME; GENE MUTATION; DEAFNESS; MANIFESTATIONS; HETEROPLASMY; RESISTANCE; DISORDERS AB Primary mitochondrial diseases refer to a group of heterogeneous and complex genetic disorders affecting 1:5000 people. The true prevalence is anticipated to be even higher because of the complexity of achieving a diagnosis in many patients who present with multisystemic complaints ranging from infancy to adulthood. Diabetes is a prominent feature of several of these disorders which might be overlooked by the endocrinologist. We here review mitochondrial disorders and describe the phenotypic and pathogenetic differences between mitochondrial diabetes mellitus (mDM) and other more common forms of diabetes mellitus. C1 [Karaa, Amel] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurogenet Clin, Boston, MA USA. [Goldstein, Amy] Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, UPMC,Div Child Neurol, Pittsburgh, PA USA. RP Goldstein, A (reprint author), UPMC, Childrens Hosp Pittsburgh, Div Child Neurol, 4401 Penn Ave, Pittsburgh, PA 15224 USA. EM amy.goldstein@chp.edu NR 35 TC 4 Z9 5 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1399-543X EI 1399-5448 J9 PEDIATR DIABETES JI Pediatr. Diabetes PD FEB PY 2015 VL 16 IS 1 BP 1 EP 9 DI 10.1111/pedi.12223 PG 9 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA CA2XG UT WOS:000348768500001 PM 25330715 ER PT J AU Plummer, L Sridhar, S Beninato, M Parlman, K AF Plummer, Laura Sridhar, Sowmya Beninato, Marianne Parlman, Kristin TI Physical Therapist Practice in the Emergency Department Observation Unit: Descriptive Study SO PHYSICAL THERAPY LA English DT Article ID LOW-BACK-PAIN; PATIENT SATISFACTION; TRIAL; INJURIES; SERVICES; DOCTORS; STATES; CARE AB Background. An upward trend in the number of hospital emergency department (ED) visits frequently results in ED overcrowding: The concept of the emergency department observation unit (EDOU) was introduced to allow patients to transfer out of the ED and remain under observation for up to 24 hours before making a decision regarding the appropriate disposition. No study has yet been completed to describe physical therapist practice in the EDOU. Objective. The objectives of this study were: (1) to describe patient demographics, physical therapist management and utilization, and discharge dispositions of patients receiving physical therapy in the EDOU and (2) to describe these variables according to the most frequently occurring diagnostic groups. Design. This was a descriptive study of patients who received physical therapist services in the EDOU of Massachusetts General Hospital during the months of March, May, and August 2010. Methods. Data from 151 medical records of patients who received physical therapist services in the EDOU were extracted. Variables consisted of patient characteristics, medical and physical therapist diagnoses, and physical therapist management and utilization derived from billing data. Descriptive statistics were used to analyze data. Results. The leading EDOU medical diagnoses of individuals receiving physical therapist services included people with falls without fracture (n=30), back pain (n=27), falls with fracture (n=22), and dizziness (n=22). There were significant differences in discharge disposition, age, and total physical therapy time among groups. Limitations. This was a retrospective study, so there was no ability to control how data were recorded. Conclusions. This study provides information on common patient groups seen in the EDOU, physical therapist service utilization, and discharge disposition that may guide facilities in anticipated staffing needs associated with providing physical therapist services in the EDOU. C1 [Plummer, Laura; Beninato, Marianne] MGH Inst Hlth Profess, Boston, MA 02129 USA. [Sridhar, Sowmya] Highland Care Ctr, Jamaica, NY USA. [Parlman, Kristin] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Plummer, L (reprint author), MGH Inst Hlth Profess, 36 First St, Boston, MA 02129 USA. EM lplummer@mghihp.edu NR 30 TC 0 Z9 0 U1 0 U2 0 PU AMER PHYSICAL THERAPY ASSOC PI ALEXANDRIA PA 1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA SN 0031-9023 EI 1538-6724 J9 PHYS THER JI Phys. Ther. PD FEB PY 2015 VL 95 IS 2 BP 249 EP 256 DI 10.2522/ptj.20140017 PG 8 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA AZ8UX UT WOS:000348490900010 PM 25278339 ER EF